Clustering O 0 3.814488081843592e-05
of O 0 8.001685500858002e-07
missense O 0 0.01588822528719902
mutations O 0 0.0006926565547473729
in O 0 2.194360320117994e-07
the O 0 1.0944496580123086e-06
ataxia B-Disease 1 0.9999622106552124
- I-Disease 1 0.9002912640571594
telangiectasia I-Disease 1 0.9995477795600891
gene O 0 4.172919943812303e-06
in O 0 1.8744918506286012e-08
a O 0 2.6929436103273474e-07
sporadic B-Disease 0 0.0006435306859202683
T I-Disease 1 0.9974386692047119
- I-Disease 0 0.14951899647712708
cell I-Disease 0 0.05730079859495163
leukaemia I-Disease 1 0.9878568649291992
. O 0 2.0253617094567744e-06

Ataxia B-Disease 1 0.9998770952224731
- I-Disease 1 0.9993071556091309
telangiectasia I-Disease 1 0.9999349117279053
( O 0 0.00017673637194093317
A B-Disease 1 0.9546321034431458
- I-Disease 1 0.9956610798835754
T I-Disease 1 0.997719943523407
) O 0 7.837015481015897e-09
is O 0 3.5699299072433632e-09
a O 0 8.365871195792352e-08
recessive B-Disease 0 0.0007358749280683696
multi I-Disease 1 0.6897715330123901
- I-Disease 1 0.9726868271827698
system I-Disease 0 0.04055429622530937
disorder I-Disease 1 0.960181474685669
caused O 0 9.973093256121501e-06
by O 0 1.966137475051255e-08
mutations O 0 1.1929932952625677e-06
in O 0 7.4610750910864e-10
the O 0 8.769088788440627e-10
ATM O 0 3.6201768125465605e-06
gene O 0 1.8612284691243985e-07
at O 0 6.797850460316113e-08
11q22 O 0 6.087187648518011e-05
- O 0 7.126159471226856e-05
q23 O 0 3.232011658838019e-05
( O 0 2.72983644578062e-08
ref O 0 8.301990601466969e-05
. O 0 2.919193109462981e-09
3 O 0 2.7765613808128364e-08
) O 0 2.7971163163442725e-08
. O 0 1.4380130153313075e-07

The O 0 7.928541890578344e-06
risk O 0 0.0006385675515048206
of O 0 3.848372671200195e-06
cancer B-Disease 1 0.985316812992096
, O 0 8.041052979024244e-08
especially O 0 7.983287275692419e-08
lymphoid B-Disease 0 0.000384769169613719
neoplasias I-Disease 0 0.009090026840567589
, O 0 5.556505300319259e-08
is O 0 1.7323225520726737e-08
substantially O 0 4.449094831215916e-06
elevated O 0 0.00046644368558190763
in O 0 8.946031471168681e-07
A B-Disease 1 0.865925669670105
- I-Disease 1 0.9999340772628784
T I-Disease 1 0.9999918937683105
patients O 0 0.00019465252989903092
and O 0 6.808618557840873e-09
has O 0 1.6885209674910584e-08
long O 0 2.993990619870601e-07
been O 0 1.150588690990162e-08
associated O 0 1.674825682584924e-07
with O 0 1.6242348692685482e-06
chromosomal O 1 0.9997381567955017
instability O 1 0.9256721138954163
. O 0 4.610531050275313e-06

By O 0 1.2876041637355229e-06
analysing O 0 0.00023824146774131805
tumour B-Disease 1 0.9998430013656616
DNA O 0 0.0005641798488795757
from O 0 1.9989712995993614e-07
patients O 0 5.330575277184835e-06
with O 0 4.175528189875877e-08
sporadic B-Disease 0 0.00016749295173212886
T I-Disease 1 0.9820832014083862
- I-Disease 0 0.020716054365038872
cell I-Disease 0 0.013385013677179813
prolymphocytic I-Disease 1 0.686268150806427
leukaemia I-Disease 1 0.9996591806411743
( O 0 7.075808298395714e-06
T B-Disease 1 0.6429238319396973
- I-Disease 0 7.223767170216888e-05
PLL I-Disease 0 0.00010823827324202284
) O 0 6.7635235190266485e-09
, O 0 1.995187348668992e-09
a O 0 1.6482051279353982e-08
rare O 0 4.988482373846637e-07
clonal B-Disease 0 0.0011532283388078213
malignancy I-Disease 0 0.20046120882034302
with O 0 8.651107386015155e-09
similarities O 0 1.850901476529998e-08
to O 0 7.274018054559406e-10
a O 0 8.556571629014798e-08
mature B-Disease 0 1.4196507436281536e-05
T I-Disease 0 0.4676537811756134
- I-Disease 0 0.00044658451224677265
cell I-Disease 0 0.00017798478074837476
leukaemia I-Disease 0 0.08235650509595871
seen O 0 2.383314523513036e-07
in O 0 1.1243754016732055e-07
A B-Disease 0 0.039938755333423615
- I-Disease 1 0.9401329755783081
T I-Disease 1 0.9955800175666809
, O 0 1.7344772285099452e-09
we O 0 8.898719955352519e-11
demonstrate O 0 5.62193347430906e-10
a O 0 7.492105824624673e-10
high O 0 1.442753583269507e-09
frequency O 0 1.6824955872962732e-09
of O 0 1.613580713488716e-09
ATM O 0 0.00015551171964034438
mutations O 0 0.00015388251631520689
in O 0 2.687791720745736e-06
T B-Disease 1 0.9579713344573975
- I-Disease 0 0.002669615438207984
PLL I-Disease 0 0.0019995244219899178
. O 0 8.211306408156815e-07

In O 0 4.239682311890647e-07
marked O 0 6.939241075087921e-07
contrast O 0 1.1148404865934936e-07
to O 0 1.8400450052524775e-09
the O 0 3.4438649709755964e-09
ATM O 0 2.6626603357726708e-05
mutation O 0 3.532410119078122e-05
pattern O 0 3.1723836855235277e-06
in O 0 1.9409517904023232e-07
A B-Disease 0 0.09894977509975433
- I-Disease 1 0.8471767902374268
T I-Disease 1 0.9903705716133118
, O 0 9.341735163204135e-10
the O 0 1.3833489909131913e-10
most O 0 1.0724082732949114e-10
frequent O 0 3.0229201364306846e-09
nucleotide O 0 2.9075478025220036e-08
changes O 0 4.41973346809732e-09
in O 0 1.8329132656091929e-09
this O 0 4.726232738505587e-09
leukaemia B-Disease 0 0.21111007034778595
were O 0 3.9730215917188616e-07
missense O 0 0.07129350304603577
mutations O 0 0.0012705303961411119
. O 0 8.462804430564574e-07

These O 0 2.389582220985176e-07
clustered O 0 4.333434389991453e-06
in O 0 2.4418296717954036e-08
the O 0 2.561030720826807e-09
region O 0 8.234249726513099e-09
corresponding O 0 1.7872330282386883e-09
to O 0 9.352997543121688e-11
the O 0 2.231431844856857e-10
kinase O 0 2.9596847639368207e-08
domain O 0 8.038994359083063e-09
, O 0 6.772569727253597e-10
which O 0 8.651395572156773e-11
is O 0 8.721062760841392e-11
highly O 0 4.5277187554759735e-10
conserved O 0 2.965424128476002e-09
in O 0 8.629711389929184e-10
ATM O 0 8.60166983329691e-06
- O 0 5.214627435634611e-06
related O 0 4.836623546111696e-09
proteins O 0 9.520535471096991e-10
in O 0 4.651182494708195e-10
mouse O 0 7.361650489201566e-08
, O 0 5.682119774697014e-10
yeast O 0 1.9365820946859458e-08
and O 0 2.738429261128772e-09
Drosophila O 0 2.0058766381225723e-07
. O 0 1.1499321317387512e-07

The O 0 3.02501575788483e-07
resulting O 0 1.0906715033343062e-06
amino O 0 1.2052499869241728e-06
- O 0 2.8310434572631493e-05
acid O 0 5.309032076183939e-07
substitutions O 0 2.2938559496310518e-08
are O 0 4.996399960432996e-10
predicted O 0 6.2298757264045435e-09
to O 0 4.9967783383175757e-11
interfere O 0 3.1122757704338255e-09
with O 0 2.1108776948608465e-09
ATP O 0 1.7155229215859435e-05
binding O 0 1.6143518166700233e-07
or O 0 1.2216876399406829e-08
substrate O 0 2.5620029191486537e-06
recognition O 0 1.5666977333239629e-06
. O 0 5.47043214282894e-07

Two O 0 2.864770749511081e-07
of O 0 4.667155906190601e-08
seventeen O 0 1.9928586425521644e-06
mutated O 0 0.0010103253880515695
T B-Disease 0 0.24971790611743927
- I-Disease 0 2.3378475816571154e-05
PLL I-Disease 0 1.997847357415594e-05
samples O 0 2.544749300170679e-08
had O 0 3.6653180490731074e-09
a O 0 8.77786199282582e-09
previously O 0 9.736245232261354e-08
reported O 0 3.370877266206662e-06
A B-Disease 0 0.001048491569235921
- I-Disease 1 0.7057039141654968
T I-Disease 1 0.9961264729499817
allele O 0 5.286359737510793e-06
. O 0 5.277416335047747e-07

In O 0 2.2946539957047207e-06
contrast O 0 6.191041393321939e-06
, O 0 6.001554453405333e-08
no O 0 2.6044306267181128e-08
mutations O 0 7.344315235968679e-07
were O 0 1.0335565736596664e-09
detected O 0 3.1824328061702545e-08
in O 0 2.0541625345149583e-10
the O 0 3.582936725088359e-10
p53 O 0 8.182275479384771e-08
gene O 0 1.9054931854611823e-08
, O 0 1.001251193066821e-09
suggesting O 0 1.2639397084512893e-08
that O 0 4.0942155221657117e-10
this O 0 1.10367324168692e-08
tumour B-Disease 1 0.9962393045425415
suppressor O 0 7.662423013243824e-05
is O 0 4.429641098369075e-09
not O 0 6.175522315743365e-10
frequently O 0 1.0614651380080886e-08
altered O 0 1.6942577474310383e-07
in O 0 1.1726378090770595e-08
this O 0 6.281231179627866e-08
leukaemia B-Disease 1 0.7729263305664062
. O 0 1.842423785092251e-06

Occasional O 0 4.5039781980449334e-05
missense O 0 0.03906761854887009
mutations O 0 0.00026394802262075245
in O 0 7.336404905800009e-08
ATM O 0 1.1074647773057222e-05
were O 0 6.582695721846221e-09
also O 0 2.304942015030065e-09
found O 0 2.3411603322642804e-08
in O 0 2.0006400802685675e-07
tumour B-Disease 1 0.9995036125183105
DNA O 0 3.0388182494789362e-05
from O 0 4.703187173049628e-08
patients O 0 1.4699612620461266e-06
with O 0 2.2333415117259392e-08
B B-Disease 0 1.0627641131577548e-05
- I-Disease 0 0.00024345165002159774
cell I-Disease 0 0.0002810996084008366
non I-Disease 0 1.4985566849645693e-05
- I-Disease 1 0.6154041886329651
Hodgkins I-Disease 1 0.9997778534889221
lymphomas I-Disease 1 0.9740506410598755
( O 0 5.069455966122405e-08
B B-Disease 0 7.160458608268527e-07
- I-Disease 0 1.2391499240038684e-06
NHL I-Disease 0 8.550910024496261e-08
) O 0 3.29695548639819e-10
and O 0 2.776007756999377e-10
a O 0 1.5563635713533586e-08
B B-Disease 0 3.7247061754897004e-06
- I-Disease 0 3.2312778785126284e-05
NHL I-Disease 0 1.4488629858533386e-05
cell O 0 4.790716411662288e-05
line O 0 2.160194753741962e-06
. O 0 3.62550395038852e-07

The O 0 1.7695657561489497e-07
evidence O 0 2.5953855953275706e-08
of O 0 3.2414007034020642e-09
a O 0 1.3793982844845232e-08
significant O 0 9.752504581683752e-09
proportion O 0 5.9069321878268966e-08
of O 0 7.989498840288434e-09
loss O 0 1.4222878235159442e-05
- O 0 2.1796511191496393e-06
of O 0 2.9752027508322954e-09
- O 0 1.1093230568803847e-05
function O 0 4.430623690154789e-08
mutations O 0 3.6491718446995947e-07
and O 0 3.2485350520694567e-10
a O 0 2.9443343319002224e-09
complete O 0 1.304464536389105e-08
absence O 0 4.877291903682135e-09
of O 0 1.510562230855328e-10
the O 0 2.6588165003005315e-10
normal O 0 2.275882371449711e-09
copy O 0 1.1389915677284534e-09
of O 0 1.480181671675851e-10
ATM O 0 1.8203166973762563e-07
in O 0 5.354570675741854e-10
the O 0 4.935628572511064e-10
majority O 0 4.307299406036691e-09
of O 0 3.472504506163432e-09
mutated O 0 3.163286601193249e-05
tumours B-Disease 1 0.8399487733840942
establishes O 0 2.8513409233710263e-06
somatic O 0 2.698022854019655e-06
inactivation O 0 0.001033819979056716
of O 0 1.942777938523932e-09
this O 0 3.9763639603229706e-10
gene O 0 8.066780132764961e-09
in O 0 4.998916280918309e-10
the O 0 9.096660091856279e-10
pathogenesis O 0 2.0748555016325554e-06
of O 0 5.850863793455119e-09
sporadic B-Disease 0 0.00011096539674326777
T I-Disease 1 0.8758826851844788
- I-Disease 0 5.4095253290142864e-05
PLL I-Disease 0 3.2290725357597694e-05
and O 0 2.2570172397706756e-09
suggests O 0 1.8356561826138318e-09
that O 0 1.001798990984959e-10
ATM O 0 7.280576141965867e-08
acts O 0 4.28020019427322e-09
as O 0 8.301634046858908e-09
a O 0 1.0098448910866864e-05
tumour B-Disease 1 0.999761164188385
suppressor O 0 0.004202271346002817
. O 0 7.189005373220425e-07

As O 0 2.1303384301063488e-07
constitutional O 0 1.2443487094060401e-06
DNA O 0 6.361467058013659e-06
was O 0 2.5633484668219353e-08
not O 0 3.0550417751129544e-10
available O 0 2.5747237675233237e-10
, O 0 4.743452297617523e-10
a O 0 1.9929441208432763e-08
putative O 0 5.56521954422351e-05
hereditary O 0 0.28331783413887024
predisposition O 0 0.006292806006968021
to O 0 2.009863351304375e-07
T B-Disease 1 0.9181439876556396
- I-Disease 0 0.0002694832510314882
PLL I-Disease 0 0.0002742132928688079
will O 0 5.131783886724861e-09
require O 0 1.4547469007197833e-08
further O 0 1.0406287387354496e-08
investigation O 0 6.044681413186481e-07
. O 0 2.82898131587217e-08
. O 0 2.1257802984564478e-07

Myotonic B-Disease 1 0.9998462200164795
dystrophy I-Disease 1 0.9999104738235474
protein O 0 0.000604152912274003
kinase O 0 0.00033282567164860666
is O 0 3.114391589065235e-08
involved O 0 4.401746966919973e-09
in O 0 4.1991327082158136e-10
the O 0 1.2717443764742598e-10
modulation O 0 2.911047847220516e-09
of O 0 1.5679285647607344e-10
the O 0 6.577471900470755e-10
Ca2 O 0 1.1720361499101273e-06
+ O 0 2.517017946956912e-06
homeostasis O 0 0.0013320581056177616
in O 0 6.624325123993913e-07
skeletal O 1 0.5626387000083923
muscle O 0 0.30089032649993896
cells O 0 0.0001609065948287025
. O 0 4.884938107352355e-07

Myotonic B-Disease 1 0.9998632669448853
dystrophy I-Disease 1 0.9999641180038452
( O 0 0.0010119485668838024
DM B-Disease 1 0.9998192191123962
) O 0 1.5598874369970872e-07
, O 0 6.439683453152156e-09
the O 0 3.5058060898762733e-09
most O 0 2.292762601996401e-08
prevalent O 0 5.7977485994342715e-05
muscular B-Disease 1 0.99835604429245
disorder I-Disease 1 0.9840703010559082
in O 0 2.800725496854284e-06
adults O 0 3.4375589166302234e-05
, O 0 1.5776112149978871e-07
is O 0 3.610766086126205e-08
caused O 0 2.639825140704488e-07
by O 0 2.0265722433521205e-09
( O 0 2.334711091123154e-09
CTG O 0 1.1666114005493e-05
) O 0 2.278910171682469e-09
n O 0 2.944971413398889e-07
- O 0 1.0349281183152925e-06
repeat O 0 2.47334792646825e-08
expansion O 0 6.1016578456474235e-09
in O 0 1.5253569241036047e-10
a O 0 1.961962120544669e-10
gene O 0 5.254169876955928e-10
encoding O 0 9.49137990424731e-10
a O 0 4.701067979340223e-09
protein O 0 3.146832128209098e-08
kinase O 0 1.1133885209346772e-06
( O 0 2.1818102879933576e-08
DM B-Disease 1 0.7873149514198303
protein O 0 9.567989991410286e-07
kinase O 0 1.1342301149852574e-05
; O 0 3.2897098378725786e-08
DMPK O 0 4.212692510918714e-05
) O 0 1.0876857192698708e-09
and O 0 4.974642364707904e-10
involves O 0 2.410009614095543e-08
changes O 0 1.4153562766239247e-08
in O 0 5.1428270531062026e-09
cytoarchitecture O 0 1.941777372849174e-05
and O 0 6.290031251410255e-08
ion O 0 0.001209635753184557
homeostasis O 0 0.3456229567527771
. O 0 3.843864760710858e-06

To O 0 9.91026425367636e-08
obtain O 0 1.0174385778327633e-07
clues O 0 1.199094157300351e-07
to O 0 1.1725275195217932e-09
the O 0 1.3012232402687118e-09
normal O 0 8.602338397167841e-09
biological O 0 7.144808300552086e-09
role O 0 1.5451113721809406e-09
of O 0 6.643818828422354e-10
DMPK O 0 5.895445156056667e-06
in O 0 5.9337250668534125e-09
cellular O 0 7.783524779370055e-06
ion O 0 6.34232274023816e-05
homeostasis O 0 0.007322046905755997
, O 0 6.7956444915751035e-09
we O 0 1.476882227624543e-10
have O 0 1.1323778026373077e-10
compared O 0 1.6930060686703996e-09
the O 0 3.140599447171155e-10
resting O 0 1.422013440333103e-07
[ O 0 9.122484101453665e-09
Ca2 O 0 4.601657224156952e-07
+ O 0 5.095756705486565e-07
] O 0 3.07502681096139e-08
i O 0 7.242924038308729e-10
, O 0 3.8197656843097505e-11
the O 0 2.6465961366906043e-11
amplitude O 0 1.145230577037637e-09
and O 0 1.8105979215921053e-10
shape O 0 6.7407026627108735e-09
of O 0 9.02469876606915e-10
depolarization O 0 5.381152277550427e-06
- O 0 1.5420495401485823e-05
induced O 0 5.215303644945379e-06
Ca2 O 0 2.162911641789833e-06
+ O 0 4.3723454723476607e-07
transients O 0 1.3847569562130957e-06
, O 0 3.246001800683018e-10
and O 0 4.8987675027589717e-11
the O 0 4.2333563737839697e-11
content O 0 1.0973958547433327e-10
of O 0 1.5409490350393185e-10
ATP O 0 1.4045583611732582e-06
- O 0 4.376913977921504e-07
driven O 0 1.4423360283899456e-08
ion O 0 6.256062761167414e-07
pumps O 0 2.0173833092940185e-07
in O 0 3.501482437329173e-09
cultured O 0 3.217135144950589e-07
skeletal O 0 0.0002569733769632876
muscle O 0 1.2173180039098952e-05
cells O 0 7.787890154986599e-08
of O 0 6.953664311026841e-10
wild O 0 5.688382742619069e-08
- O 0 3.515240223350702e-06
type O 0 7.79936613071186e-08
and O 0 4.460332103661813e-09
DMPK O 0 0.0003665949625428766
[ O 0 1.117643932957435e-06
- O 0 6.770320032956079e-05
/ O 0 4.8776408220874146e-05
- O 0 0.00015592644922435284
] O 0 3.1553543067275314e-06
knockout O 0 0.00028951343847438693
mice O 0 6.137630407465622e-05
. O 0 2.777515817342646e-07

In O 0 1.481747403886402e-06
vitro O 0 5.99479244556278e-05
- O 0 3.585781087167561e-05
differentiated O 0 6.514242159028072e-06
DMPK O 0 0.0025447006337344646
[ O 0 4.363274911156623e-06
- O 0 5.497240636032075e-05
/ O 0 9.911454071698245e-06
- O 0 3.8096327443781774e-06
] O 0 3.4737912102400514e-08
myotubes O 0 7.462845701411425e-07
exhibit O 0 1.3414184429905163e-08
a O 0 7.875721408368008e-09
higher O 0 1.6144342751545082e-08
resting O 0 3.459193180788134e-07
[ O 0 2.1878610922954067e-08
Ca2 O 0 6.166407047203393e-07
+ O 0 3.961852712563996e-07
] O 0 3.694490047223553e-08
i O 0 2.047416236550248e-09
than O 0 3.4862265851920426e-10
do O 0 3.6249708790236923e-10
wild O 0 1.5503550443440872e-08
- O 0 1.9879669252986787e-06
type O 0 1.9531400141659105e-07
myotubes O 0 5.595074071607087e-06
because O 0 9.840526171700503e-10
of O 0 1.1549806944177732e-10
an O 0 3.067174569881814e-10
altered O 0 1.5987206225531736e-08
open O 0 8.143535623617026e-09
probability O 0 9.260377464848091e-10
of O 0 2.2669131849450963e-10
voltage O 0 2.949834367882431e-07
- O 0 1.5303204463634756e-06
dependent O 0 3.1227010310885817e-08
l O 0 7.55016299081035e-06
- O 0 5.5065902415663e-07
type O 0 3.61259857584173e-08
Ca2 O 0 3.2725131404731655e-07
+ O 0 1.4157214422994002e-07
and O 0 4.365110495285762e-09
Na O 0 1.0159033990930766e-05
+ O 0 1.0954521485473379e-06
channels O 0 4.482149620343989e-07
. O 0 4.854426265410439e-07

The O 0 6.937851821930963e-07
mutant O 0 2.4315446353284642e-05
myotubes O 0 0.00012264943507034332
exhibit O 0 2.577995132924116e-07
smaller O 0 4.0017578584183866e-08
and O 0 1.1791817522421866e-09
slower O 0 2.995395220750652e-08
Ca2 O 0 8.15020257505239e-07
+ O 0 1.1349352035949778e-07
responses O 0 5.067365194122431e-09
upon O 0 1.809252525575289e-09
triggering O 0 1.8627876841037505e-07
by O 0 1.4932149960955599e-09
acetylcholine O 0 3.963983090216061e-06
or O 0 1.3651543895321083e-08
high O 0 4.403479181291914e-07
external O 0 6.087326710257912e-06
K O 0 0.00016850518295541406
+ O 0 8.105307642836124e-05
. O 0 1.0682161928343703e-06

In O 0 6.034118200659577e-07
addition O 0 1.1349525408377303e-07
, O 0 8.918218163955771e-09
we O 0 7.497394927113987e-10
observed O 0 3.042355034565958e-09
that O 0 9.727080946264621e-11
these O 0 9.610292422967959e-11
Ca2 O 0 2.9159627956687473e-07
+ O 0 1.384183860864141e-06
transients O 0 3.535227006068453e-05
partially O 0 3.30403349835251e-06
result O 0 6.174089239863179e-09
from O 0 1.243068981082729e-10
an O 0 3.684505825440887e-11
influx O 0 4.1220632462923845e-10
of O 0 3.214455437938746e-11
extracellular O 0 2.731975756731231e-09
Ca2 O 0 1.3153606914784177e-07
+ O 0 2.151625544399849e-08
through O 0 5.764569932509289e-10
the O 0 1.6085994758441302e-09
l O 0 3.3102624001912773e-06
- O 0 5.031635737395845e-06
type O 0 3.1129189892453724e-07
Ca2 O 0 5.994912498863414e-06
+ O 0 2.0805421172553906e-06
channel O 0 1.8916474573416053e-06
. O 0 3.040147191768483e-07

Neither O 0 2.870781599995098e-06
the O 0 4.573307421651407e-08
content O 0 1.4081399157817032e-08
nor O 0 1.3097848139409507e-08
the O 0 5.315850537535027e-10
activity O 0 1.5854315638108574e-09
of O 0 8.504659199104481e-10
Na O 0 1.0619100066833198e-05
+ O 0 1.241032691723376e-06
/ O 0 4.0615995544612815e-07
K O 0 1.8866160189645598e-07
+ O 0 6.404945906979265e-08
ATPase O 0 4.929057695335359e-07
and O 0 2.093300421890376e-09
sarcoplasmic O 0 2.2539383280673064e-05
reticulum O 0 2.6200557840638794e-05
Ca2 O 0 3.311876071165898e-06
+ O 0 2.034902536252048e-06
- O 0 3.578273435778101e-06
ATPase O 0 3.382541081009549e-06
are O 0 1.6482735176737151e-09
affected O 0 2.829985135122115e-08
by O 0 2.213971761477751e-08
DMPK O 0 0.0010998474899679422
absence O 0 6.63138780510053e-06
. O 0 6.053646188775019e-07

In O 0 3.3532191423546465e-07
conclusion O 0 7.423182069032919e-08
, O 0 4.464706826468046e-09
our O 0 2.898133955042681e-09
data O 0 6.530173735086464e-09
suggest O 0 6.695917598165124e-09
that O 0 3.9772288240591536e-10
DMPK O 0 5.848579348821659e-06
is O 0 6.298597199361211e-10
involved O 0 6.022740639544111e-10
in O 0 2.380249330968809e-10
modulating O 0 2.8292403086993545e-08
the O 0 4.760601357567396e-10
initial O 0 2.8610391833439053e-09
events O 0 2.2496410290173685e-10
of O 0 3.823025784832623e-10
excitation O 0 5.53285758542188e-07
- O 0 3.3076477848226205e-05
contraction O 0 3.5718501294468297e-06
coupling O 0 1.9105500541627407e-06
in O 0 1.5637674266599788e-07
skeletal O 0 0.04278620705008507
muscle O 0 0.0009477657731622458
. O 0 5.684586312781903e-08
. O 0 2.677752490853891e-07

Constitutional O 0 0.0009579180041328073
RB1 O 1 0.9749246835708618
- O 0 0.020635347813367844
gene O 0 0.00034808649797923863
mutations O 0 0.002904861466959119
in O 0 1.53256962676096e-06
patients O 0 4.9850070354295895e-05
with O 0 2.3603017496043321e-07
isolated O 0 0.00011046043800888583
unilateral B-Disease 0 0.00040241293027065694
retinoblastoma I-Disease 0 0.3178170323371887
. O 0 3.948683570342837e-06

In O 0 2.8852266495960066e-06
most O 0 2.7174525030204677e-07
patients O 0 2.3353561118710786e-05
with O 0 5.4501970936371436e-08
isolated O 0 7.177658972068457e-06
unilateral B-Disease 0 4.025717134936713e-05
retinoblastoma I-Disease 0 0.09500911831855774
, O 0 1.1161281463500927e-06
tumor B-Disease 0 0.037161801010370255
development O 0 1.3796613629324384e-08
is O 0 8.833971887334258e-10
initiated O 0 1.5661964170021747e-08
by O 0 6.705141997187525e-10
somatic O 0 2.093238293809918e-07
inactivation O 0 9.418468835065141e-05
of O 0 5.955980153515839e-10
both O 0 5.698866933911972e-10
alleles O 0 1.2524303372174472e-08
of O 0 3.077642141136039e-09
the O 0 1.8558263548129617e-07
RB1 O 0 0.10939206182956696
gene O 0 1.342590076092165e-05
. O 0 6.484834784714621e-07

However O 0 1.2197200476293801e-06
, O 0 1.2268903226697603e-08
some O 0 6.486127746008208e-10
of O 0 1.6275985004199356e-09
these O 0 7.076426999930163e-09
patients O 0 3.4160934774263296e-06
can O 0 4.8696695564842685e-09
transmit O 0 2.675858240763773e-06
retinoblastoma B-Disease 0 0.03432091325521469
predisposition O 0 9.441596921533346e-05
to O 0 2.7530615565041217e-09
their O 0 3.53540734465696e-08
offspring O 0 1.0749839020718355e-05
. O 0 4.681983796217537e-07

To O 0 7.340702268265886e-08
determine O 0 7.671172852496966e-08
the O 0 5.600435226682521e-09
frequency O 0 2.0145797918758035e-08
and O 0 1.2124016235404156e-09
nature O 0 6.0961786729762935e-09
of O 0 1.769402069307091e-09
constitutional O 0 6.650520390394377e-06
RB1 O 1 0.7202038764953613
- O 0 0.012304934673011303
gene O 0 2.2484935470856726e-05
mutations O 0 3.226732587791048e-05
in O 0 7.41727959052696e-08
patients O 0 4.568256372294854e-06
with O 0 3.440098339524411e-08
isolated O 0 4.190227173239691e-06
unilateral B-Disease 0 7.280594672920415e-06
retinoblastoma I-Disease 0 0.0019410185050219297
, O 0 5.341058262331444e-09
we O 0 2.7287819226451404e-10
analyzed O 0 5.364919175576688e-09
DNA O 0 4.3053550058402834e-08
from O 0 9.387854937870088e-10
peripheral O 0 1.6961054143393994e-06
blood O 0 3.3880426144605735e-06
and O 0 1.9762058656169756e-08
from O 0 7.77927766648645e-07
tumor B-Disease 1 0.9039682149887085
tissue O 0 0.0015510699013248086
. O 0 1.0350287311666762e-06

The O 0 3.909501344878663e-07
analysis O 0 5.65932509744016e-07
of O 0 2.6302205924366717e-07
tumors B-Disease 1 0.9785284399986267
from O 0 2.0982424686621926e-08
54 O 0 3.161436836762732e-07
( O 0 4.080597637567962e-09
71 O 0 6.683581688093909e-08
% O 0 7.353503916895932e-10
) O 0 1.6853789197579516e-10
of O 0 4.3567069396566183e-10
76 O 0 2.6170545197601314e-07
informative O 0 3.169197668739798e-07
patients O 0 6.998940807534382e-05
showed O 0 3.232831431887462e-06
loss O 0 3.098440856774687e-06
of O 0 9.912037413073449e-09
constitutional O 0 3.149329131701961e-05
heterozygosity O 1 0.6875410079956055
( O 0 2.333260226805578e-06
LOH O 1 0.9993973970413208
) O 0 3.4340672527832794e-08
at O 0 1.4822121841007174e-07
intragenic O 0 0.00032446676050312817
loci O 0 3.6057484976481646e-05
. O 0 9.867737844615476e-07

Three O 0 2.6604482172842836e-07
of O 0 9.32860260149937e-08
13 O 0 4.9060963647207245e-06
uninformative O 0 0.10185332596302032
patients O 0 0.0013556159101426601
had O 0 3.098642480381386e-07
constitutional O 0 4.130885372433113e-06
deletions O 0 0.0001040148563333787
. O 0 7.638000738552364e-07

For O 0 2.55003158144973e-07
39 O 0 7.340799470512138e-07
randomly O 0 3.306203666397778e-07
selected O 0 5.080879077468126e-07
tumors B-Disease 1 0.9870129227638245
, O 0 1.9238402870769278e-08
SSCP O 0 0.0001329336519120261
, O 0 2.60062353873991e-08
hetero O 0 0.0008651380776427686
- O 0 1.6189002053579316e-05
duplex O 0 4.4121017708675936e-05
analysis O 0 1.1839737190655342e-08
, O 0 4.86911011510216e-10
sequencing O 0 7.407281898963447e-09
, O 0 2.9994740025074407e-10
and O 0 1.780179476051913e-10
Southern O 0 8.960691744164251e-09
blot O 0 3.7361792237788904e-07
analysis O 0 1.6521009005288079e-09
were O 0 3.2525090953861024e-10
used O 0 5.550821469135769e-10
to O 0 1.7782425532075763e-09
identify O 0 4.1968792174884584e-07
mutations O 0 4.522545714280568e-05
. O 0 3.5853781810146756e-07

Mutations O 0 0.011346112936735153
were O 0 5.787866257378482e-07
detected O 0 5.4343736337614246e-06
in O 0 1.1965417101578169e-08
21 O 0 3.5382814900231097e-08
( O 0 4.75895101104129e-09
91 O 0 6.780059180755416e-08
% O 0 4.934689989966046e-09
) O 0 1.7460782819611609e-09
of O 0 8.376229487794262e-09
23 O 0 6.644098175456747e-05
tumors B-Disease 1 0.9998481273651123
with O 0 2.1806301447213627e-05
LOH O 1 0.9998737573623657
. O 0 5.9209119172010105e-06

In O 0 1.286147380596958e-06
6 O 0 4.2269769551239733e-07
( O 0 9.46829370462865e-09
38 O 0 3.044969076881898e-08
% O 0 3.0017992536102156e-09
) O 0 1.2158383189131428e-09
of O 0 5.775875777658257e-09
16 O 0 2.2836749849375337e-05
tumors B-Disease 1 0.9998998641967773
without O 0 3.1926092560752295e-06
LOH O 1 0.9997096657752991
, O 0 2.224418160778896e-08
one O 0 8.273323359730966e-09
mutation O 0 2.7473984118842054e-06
was O 0 2.675821697550873e-08
detected O 0 1.605765476142551e-07
, O 0 2.1737663058463141e-10
and O 0 1.5908102612982589e-10
in O 0 7.641856036855188e-10
9 O 0 1.5202640923916988e-08
( O 0 6.756016301956436e-10
56 O 0 1.0422397167531017e-08
% O 0 7.214314146075651e-10
) O 0 3.3313937719547937e-10
of O 0 1.6373660205459828e-09
the O 0 3.722408337125671e-07
tumors B-Disease 1 0.9997444748878479
without O 0 3.5185200886189705e-06
LOH O 1 0.9997318387031555
, O 0 1.6021333593130294e-08
both O 0 8.308810528490085e-09
mutations O 0 4.162553977948846e-06
were O 0 1.0682570383835355e-08
found O 0 1.2088894152384455e-07
. O 0 1.6433936878001987e-07

Thus O 0 1.0678759281290695e-06
, O 0 1.609861932649892e-08
a O 0 3.4601541631928967e-09
total O 0 9.257763999848123e-10
of O 0 6.916138217682999e-10
45 O 0 1.4604237819071386e-08
mutations O 0 2.6781250994645234e-07
were O 0 1.1925629372910862e-09
identified O 0 7.494113418715642e-08
in O 0 1.6789516621429357e-07
tumors B-Disease 1 0.9939197301864624
of O 0 5.730012730964518e-08
36 O 0 4.021880522486754e-05
patients O 0 0.00019886867085006088
. O 0 8.439076850663696e-07

Thirty O 0 9.999969734053593e-06
- O 0 4.620373601937899e-06
nine O 0 1.5338923020635775e-08
of O 0 1.7335545221541793e-09
the O 0 4.704655776066602e-09
mutations O 0 1.4517720501316944e-06
- O 0 5.649790750794637e-07
including O 0 2.194366910401868e-09
34 O 0 3.161548178809426e-08
small O 0 3.258013592244424e-08
mutations O 0 2.307636805198854e-06
, O 0 1.9634380787891814e-09
2 O 0 6.642960848068924e-09
large O 0 2.307947788438014e-08
structural O 0 6.251259492273675e-06
alterations O 0 2.0070947357453406e-06
, O 0 1.4412683269071636e-09
and O 0 1.6540809832932268e-09
hypermethylation O 0 0.00020937218505423516
in O 0 1.0511099901577836e-07
3 O 0 1.2641909052035771e-05
tumors O 1 0.9998138546943665
- O 0 6.391429633367807e-05
were O 0 1.4267829140379718e-09
not O 0 3.539371018490556e-10
detected O 0 2.2864913518105823e-08
in O 0 2.300153956191764e-10
the O 0 5.437710282052421e-10
corresponding O 0 6.266177621228053e-08
peripheral O 0 7.903992081992328e-05
blood O 0 0.0005398541106842458
DNA O 0 0.0001267342595383525
. O 0 6.972355777179473e-07

In O 0 1.2749171673931414e-06
6 O 0 8.882976771928952e-07
( O 0 2.552449451798111e-08
17 O 0 4.354451732524467e-08
% O 0 2.315817759779293e-09
) O 0 2.335235615991138e-10
of O 0 1.3176312818607983e-10
the O 0 3.3003548782772896e-09
36 O 0 5.111853624839569e-07
patients O 0 2.826061063387897e-06
, O 0 3.3755414019509544e-09
a O 0 4.750800641772912e-08
mutation O 0 4.247227479936555e-06
was O 0 1.1289888135479487e-08
detected O 0 1.295238405418786e-07
in O 0 8.704863496689086e-10
constitutional O 0 2.4795969721935762e-08
DNA O 0 1.4040318774277694e-07
, O 0 2.686137978713532e-10
and O 0 1.8607682061855257e-10
1 O 0 1.0165629449332414e-09
of O 0 5.483537512951386e-10
these O 0 2.0247563625730436e-09
mutations O 0 3.098192564721103e-06
is O 0 1.5650668538924606e-09
known O 0 1.2734781007495144e-09
to O 0 1.3478236582376013e-10
be O 0 6.448357403598948e-10
associated O 0 1.3804931420224875e-08
with O 0 3.767091527606681e-08
reduced O 0 1.6781761587481014e-05
expressivity O 0 0.030957495793700218
. O 0 1.773723397491267e-06

The O 0 3.2691878004698083e-07
presence O 0 1.7599542445623229e-07
of O 0 5.175871731211146e-09
a O 0 5.841968331310454e-08
constitutional O 0 2.296457751072012e-06
mutation O 0 4.272888691048138e-05
was O 0 3.7675512487567175e-08
not O 0 2.8368998816752367e-10
associated O 0 1.0337715128372338e-09
with O 0 2.5837559869401616e-10
an O 0 4.3474102096041634e-10
early O 0 3.6795253066657096e-08
age O 0 3.182148020641762e-07
at O 0 5.712464599127998e-07
treatment O 0 7.102685049176216e-05
. O 0 6.095007734074898e-07

In O 0 8.836674965095881e-07
1 O 0 1.1355765536791296e-06
patient O 0 2.5507502869004384e-05
, O 0 7.673467194990735e-09
somatic O 0 1.480815058130247e-06
mosaicism O 0 0.0009725323179736733
was O 0 2.603496973563324e-08
demonstrated O 0 1.6011375336688616e-08
by O 0 5.799242197568333e-10
molecular O 0 4.8432912791440685e-08
analysis O 0 9.370429987498596e-10
of O 0 3.620734823073235e-10
DNA O 0 7.871910412404759e-08
and O 0 1.636201618637756e-09
RNA O 0 2.3716330588285928e-07
from O 0 1.1388075371598916e-08
peripheral O 0 3.276360803283751e-05
blood O 0 7.135971827665344e-05
. O 0 4.7302575012508896e-07

In O 0 2.5177814677590504e-06
2 O 0 3.589942934922874e-06
patients O 0 7.960773473314475e-06
without O 0 2.3498035517377502e-08
a O 0 1.7923943573805445e-07
detectable O 0 4.313041063142009e-05
mutation O 0 5.324265202943934e-06
in O 0 1.012007455614139e-08
peripheral O 0 2.6241119485348463e-05
blood O 0 5.4950705816736445e-05
, O 0 3.0394566863378714e-08
mosaicism O 0 0.0010931565193459392
was O 0 7.128083012730713e-08
suggested O 0 1.2982591002241861e-08
because O 0 1.0233464076137011e-09
1 O 0 8.781976812421988e-10
of O 0 4.737936709631185e-10
the O 0 6.914891770293252e-08
patients O 0 0.001150003052316606
showed O 0 0.009125391021370888
multifocal O 1 0.9999897480010986
tumors B-Disease 1 0.9999904632568359
and O 0 2.4196822323574452e-08
the O 0 2.155567946360293e-09
other O 0 4.131233133364276e-10
later O 0 5.543503434068953e-09
developed O 0 9.933731348610308e-08
bilateral B-Disease 0 1.5233196108965785e-06
retinoblastoma I-Disease 0 0.07252797484397888
. O 0 1.8613045540405437e-06

In O 0 4.524352732460102e-07
conclusion O 0 5.111341465635633e-07
, O 0 1.5911002293478305e-08
our O 0 9.949579826695754e-09
results O 0 3.921379132520997e-08
emphasize O 0 1.2680156480371352e-08
that O 0 1.2662161597010169e-10
the O 0 3.0875182965850456e-10
manifestation O 0 3.3709621760635855e-08
and O 0 1.470406907344568e-09
transmissibility O 0 1.9825311028398573e-06
of O 0 1.91476434707738e-09
retinoblastoma B-Disease 0 2.9732058465015143e-05
depend O 0 7.584647576663883e-09
on O 0 7.717231853554551e-10
the O 0 4.2069889238938174e-10
nature O 0 1.5055752200510142e-09
of O 0 1.24359314512823e-10
the O 0 7.886841735249561e-10
first O 0 2.6512014805746276e-09
mutation O 0 1.1552279488569184e-07
, O 0 1.1995134052700251e-10
its O 0 1.3035578172448936e-10
time O 0 1.3692366684914248e-10
in O 0 1.3885381733302893e-10
development O 0 7.294830850490541e-10
, O 0 1.8625295750140936e-10
and O 0 6.527377943710277e-11
the O 0 8.254542882557558e-11
number O 0 6.930938462046399e-11
and O 0 1.319708786695628e-10
types O 0 1.2902257040536824e-09
of O 0 1.1184388970519876e-09
cells O 0 3.0425022146118863e-07
that O 0 9.22904475064712e-10
are O 0 1.3083010230729997e-09
affected O 0 3.8974953042725247e-08
. O 0 1.662105120203705e-08
. O 0 1.802214057988749e-07

Hereditary B-Disease 1 0.9992774128913879
deficiency I-Disease 1 0.997961163520813
of I-Disease 0 1.0917146653355303e-07
the I-Disease 0 2.2911887498366923e-08
fifth I-Disease 0 1.017838471284449e-07
component I-Disease 0 3.913384105658224e-08
of I-Disease 0 2.6988342671785404e-09
complement I-Disease 0 2.0767902242369018e-07
in O 0 8.528594719336979e-08
man O 0 4.483043994696345e-06
. O 0 4.0324141536984826e-07

I O 0 0.0004427050007507205
. O 0 4.579547021421604e-05

Clinical O 0 0.003546063555404544
, O 0 1.020564354803355e-06
immunochemical O 0 0.001299985684454441
, O 0 4.960199007086885e-08
and O 0 2.2951514466740264e-08
family O 0 5.987754434499948e-07
studies O 0 7.395115062536206e-07
. O 0 5.588763087871484e-07

The O 0 4.0132471212928067e-07
first O 0 1.1983647141278198e-07
recognized O 0 3.1564781011184095e-07
human O 0 1.765900634609352e-07
kindred O 0 3.897988426615484e-05
with O 0 2.0940938156854827e-06
hereditary B-Disease 1 0.9989045858383179
deficiency I-Disease 1 0.950226902961731
of I-Disease 0 3.39255579184794e-09
the I-Disease 0 2.4201607384810586e-09
fifth I-Disease 0 6.138792940646454e-08
component I-Disease 0 5.3720075499086306e-08
of I-Disease 0 1.4028392891773933e-09
complement I-Disease 0 2.597867592157854e-07
( O 0 6.556334852803047e-08
C5 O 0 0.0002490629267413169
) O 0 3.724659691783927e-08
is O 0 2.9726971106924793e-08
described O 0 6.808464831919991e-07
. O 0 3.335294991302362e-07

The O 0 4.5607637844113924e-07
proband O 0 6.298457446973771e-05
, O 0 2.7183224560189956e-08
a O 0 3.86428915533088e-08
20 O 0 3.967542383520595e-08
- O 0 9.049076652445365e-06
year O 0 1.1000463473465061e-07
- O 0 8.44280748424353e-06
old O 0 2.945801725218189e-06
black O 0 3.1810511700314237e-06
female O 0 1.3151843631931115e-05
with O 0 0.0019801792223006487
systemic B-Disease 1 0.9999984502792358
lupus I-Disease 1 0.9999982118606567
erythematosus I-Disease 1 0.9999966621398926
since O 0 0.00011081049160566181
age O 0 1.1573699794098502e-06
11 O 0 1.966184726143183e-07
, O 0 1.1629021301473585e-08
lacked O 0 6.733793270541355e-06
serum O 0 0.0009892672533169389
hemolytic O 0 0.24914461374282837
complement O 0 1.5285323229363712e-07
activity O 0 4.835012035186992e-08
, O 0 2.2329529336673204e-09
even O 0 8.56167758911397e-09
during O 0 2.898547961649456e-07
remission O 0 0.00031837631831876934
. O 0 4.068981240834546e-07

C5 O 0 0.15012860298156738
was O 0 1.0000131624110509e-05
undetectable O 0 0.00014479401579592377
in O 0 3.317839514238585e-08
her O 0 7.36451539751215e-08
serum O 0 2.1630376068060286e-06
by O 0 1.8039597593499934e-09
both O 0 3.831648776042584e-09
immunodiffusion O 0 0.00016639346722513437
and O 0 8.228403203247581e-07
hemolytic O 1 0.9977973699569702
assays O 0 0.0005913627101108432
. O 0 2.2061265099182492e-06

Other O 0 3.928895253579867e-08
complement O 0 1.1708849001479393e-07
components O 0 6.573727517888983e-08
were O 0 5.187366092229695e-09
normal O 0 8.821402275316359e-08
during O 0 1.7505884386537218e-07
remission O 0 0.0006172789144329727
of O 0 2.3510504831847356e-07
lupus O 1 0.9984642267227173
, O 0 1.7159031528990454e-08
but O 0 7.0514341032890115e-09
C1 O 0 6.136472075013444e-05
, O 0 8.199863898994408e-09
C4 O 0 5.321434582583606e-05
, O 0 2.7878005681714058e-08
C2 O 0 0.00030271674040704966
, O 0 3.4823208761025626e-09
and O 0 7.626367093394038e-09
C3 O 0 0.0013270069612190127
levels O 0 4.802077910426306e-06
fell O 0 3.1874573323875666e-05
during O 0 2.3105612854124047e-06
exacerbations O 0 0.37362027168273926
. O 0 2.2989338503975887e-06

A O 0 1.0907610885624308e-05
younger O 0 8.526555575372186e-06
half O 0 1.5533732948824763e-06
- O 0 7.856830052332953e-05
sister O 0 6.869794106023619e-06
, O 0 1.4037528472954364e-08
who O 0 2.4688183941634634e-08
had O 0 4.9530424206523094e-08
no O 0 5.486566010404204e-07
underlying O 0 0.0015649846754968166
disease O 0 0.07013733685016632
, O 0 1.962690276968715e-08
was O 0 1.971229224295712e-08
also O 0 1.5736096870000438e-09
found O 0 3.532776959858097e-09
to O 0 1.0359941793325333e-09
lack O 0 7.976443612278672e-07
immunochemically O 0 0.048755571246147156
detectable O 0 0.002888025948777795
C5 O 0 0.004392584785819054
. O 0 1.4946510873414809e-06

By O 0 2.0644931282731704e-05
hemolytic O 1 0.986962080001831
assay O 0 0.00043582660146057606
, O 0 1.4015834892688872e-07
she O 0 3.889363853204486e-08
exhibited O 0 5.304380934489927e-08
1 O 0 1.8953652869413418e-08
- O 0 3.4281649163858674e-07
2 O 0 3.2696907403817477e-09
% O 0 3.259576775160866e-10
of O 0 6.37067620878895e-11
the O 0 4.978477630146472e-10
normal O 0 4.48864305724328e-08
serum O 0 3.60361218554317e-06
C5 O 0 3.8723355828551576e-06
level O 0 9.3574321624601e-09
and O 0 5.844971728841131e-10
normal O 0 1.861771181665972e-08
concentrations O 0 2.7891836396065628e-08
of O 0 1.3055134751027708e-10
other O 0 1.674203692347831e-10
complement O 0 2.9444818139268136e-08
components O 0 4.116662637443369e-07
. O 0 3.942389241728961e-07

C5 O 0 0.0051340749487280846
levels O 0 3.013494961123797e-06
of O 0 6.393702456364281e-09
other O 0 9.308155357601322e-10
family O 0 1.264740312478807e-08
members O 0 6.256737350440744e-10
were O 0 4.572953682391301e-10
either O 0 1.241361347048553e-09
normal O 0 1.1245572473228549e-08
or O 0 3.407001625266304e-10
approximately O 0 2.1795838467397743e-09
half O 0 1.7693659870587908e-08
- O 0 8.557339242543094e-06
normal O 0 1.0596409794061401e-07
, O 0 2.680841992841465e-09
consistent O 0 1.9648327409527155e-08
with O 0 1.1223372453628144e-08
autosomal O 0 0.00012569442333187908
codominant O 0 0.00010205695434706286
inheritance O 0 8.935126629694423e-07
of O 0 5.367477573514634e-09
the O 0 9.949014412313772e-08
gene O 0 7.196223305072635e-05
determining O 0 0.002207178622484207
C5 B-Disease 1 0.9999232292175293
deficiency I-Disease 1 0.9999427795410156
. O 0 1.1420568625908345e-05

Normal O 0 0.0027407852467149496
hemolytic O 1 0.9983073472976685
titers O 0 0.02203611098229885
were O 0 1.5168483002980793e-07
restored O 0 8.067743237916147e-07
to O 0 7.2954891017218415e-09
both O 0 5.8670035940622256e-08
homozygous O 0 0.011507140472531319
C5 B-Disease 1 0.9998127818107605
- I-Disease 1 0.9988030195236206
deficient I-Disease 1 0.9998229146003723
( O 0 1.130404257310147e-06
C5D B-Disease 1 0.9783243536949158
) O 0 2.8654749684164926e-08
sera O 0 1.3178560038795695e-06
by O 0 4.4837866752800437e-10
addition O 0 1.3979832846899853e-09
of O 0 6.800334184653423e-10
highly O 0 1.316987408017667e-07
purified O 0 5.511672952707158e-06
human O 0 9.926123993864167e-07
C5 O 0 0.0008362983353435993
. O 0 7.748284929220972e-07

In O 0 6.180135869726655e-07
specific O 0 1.340822990414381e-07
C5 O 0 0.001255369745194912
titrations O 0 0.0036250525154173374
, O 0 4.518475194004168e-08
however O 0 5.818412418534535e-09
, O 0 7.374854060770986e-10
it O 0 1.7473365809816954e-10
was O 0 1.6211942899246878e-09
noted O 0 7.550377545406661e-10
that O 0 5.504030911596125e-11
when O 0 1.5147226528622326e-10
limited O 0 3.5651445684514727e-10
amounts O 0 8.908965232201638e-10
of O 0 3.2963456964019144e-10
C5 O 0 1.4197195241649752e-06
were O 0 3.3842556534935397e-10
assayed O 0 1.3099096918267605e-08
in O 0 2.572858315286197e-10
the O 0 7.809566882066576e-11
presence O 0 6.307854238940536e-10
of O 0 3.6476016651576515e-10
low O 0 2.0596580441178958e-07
dilutions O 0 2.7863020477525424e-06
of O 0 3.3563840595718375e-09
either O 0 1.1692401358232019e-07
C5D B-Disease 1 0.9654887914657593
serum O 0 7.032418216113001e-05
, O 0 1.7555287223913751e-09
curving O 0 5.479120446238994e-08
rather O 0 9.98569671395444e-10
than O 0 3.733945375117287e-10
linear O 0 8.903724335596053e-08
dose O 0 8.594028258812614e-06
- O 0 6.918426720403659e-07
response O 0 2.8587043843231186e-09
plots O 0 3.8068668217761115e-09
were O 0 7.178558303344573e-10
consistently O 0 1.3823507671872903e-08
obtained O 0 2.5583357654568317e-09
, O 0 8.273114415757732e-10
suggesting O 0 1.2170128904642752e-08
some O 0 9.59172852255108e-10
inhibitory O 0 1.1455083495093277e-06
effect O 0 2.336826980808837e-07
. O 0 9.687731505891861e-08

Further O 0 1.8513940176489996e-06
studies O 0 4.678029483784485e-07
suggested O 0 2.087138710749059e-07
that O 0 3.74129704994175e-09
low O 0 5.254946700006258e-07
dilutions O 0 4.385013380669989e-05
of O 0 9.50031662227957e-08
C5D B-Disease 1 0.9978952407836914
serum O 0 0.00036865900619886816
contain O 0 3.383445701388155e-08
a O 0 1.7092657955686263e-08
factor O 0 1.1374768682514969e-08
( O 0 6.732707724665943e-10
or O 0 5.907895284096298e-10
factors O 0 3.6205347053730463e-10
) O 0 1.9275332718837745e-10
interfering O 0 3.947650206725939e-09
at O 0 1.584530617826374e-09
some O 0 1.2298551066436403e-10
step O 0 8.809796447906137e-09
in O 0 1.3793028941222474e-09
the O 0 4.824977306583378e-09
hemolytic O 0 0.011207067407667637
assay O 0 1.4346338730319985e-06
of O 0 5.582827089511966e-09
C5 O 0 4.857791282120161e-05
, O 0 1.277984496006468e-09
rather O 0 1.2201383237098185e-09
than O 0 1.0204422862258866e-09
a O 0 3.661148184619378e-08
true O 0 5.040444648329867e-07
C5 O 0 0.0037280982360243797
inhibitor O 0 0.00040337175596505404
or O 0 5.564363618759671e-07
inactivator O 0 0.001949166413396597
. O 0 2.228513267255039e-06

Of O 0 1.0800496283991379e-06
clinical O 0 0.0007331017986871302
interest O 0 3.460427251411602e-07
are O 0 3.6293794636321763e-09
( O 0 3.211137356018412e-09
a O 0 6.908482230727486e-09
) O 0 6.014750364435884e-10
the O 0 6.285312270648546e-10
documentation O 0 3.5074933180112566e-08
of O 0 1.3282347310905607e-07
membranous O 1 0.9999065399169922
glomerulonephritis B-Disease 1 0.9999961853027344
, O 0 0.002397207310423255
vasculitis B-Disease 1 0.9999884366989136
, O 0 1.3324114661372732e-05
and O 0 9.646361286286265e-05
arthritis B-Disease 1 0.9999918937683105
in O 0 5.322602802948495e-08
an O 0 6.938352559160421e-09
individual O 0 7.131496460033304e-08
lacking O 0 6.738057891197968e-06
C5 O 0 0.0004235261003486812
( O 0 3.0393856320642954e-09
and O 0 2.566942214343726e-10
its O 0 1.1452458981153768e-09
biologic O 0 2.1577248787707504e-07
functions O 0 2.24342477928019e-09
) O 0 8.401489504095139e-10
, O 0 4.4516437758268523e-10
and O 0 5.877167086332236e-10
( O 0 2.4107393858940895e-09
b O 0 2.3011301308883958e-08
) O 0 3.0811764251126306e-10
a O 0 5.915994361060939e-09
remarkable O 0 1.923385752888862e-07
propensity O 0 9.817998943617567e-06
to O 0 1.85402910801713e-07
bacterial B-Disease 1 0.9991832375526428
infections I-Disease 1 0.9162914752960205
in O 0 1.038681496368099e-08
the O 0 6.606241775841681e-09
proband O 0 3.0425620934693143e-05
, O 0 1.0691574292565065e-09
even O 0 7.305301918947293e-10
during O 0 3.6736464981146355e-09
periods O 0 9.596673677947365e-09
of O 0 1.074364042175091e-09
low O 0 4.2365554691059515e-06
- O 0 1.6112575394799933e-05
dose O 0 1.6426522506662877e-06
or O 0 1.9643970894378526e-09
alternate O 0 1.8722193573239565e-08
- O 0 1.6005280485842377e-05
day O 0 2.6857418333747773e-07
corticosteroid O 0 0.0041761198081076145
therapy O 0 0.00034887820947915316
. O 0 9.78268644757918e-07

Other O 0 1.1679083655735667e-07
observations O 0 4.4143439481558744e-07
indicate O 0 2.49843054689336e-07
that O 0 3.2170595076763675e-09
the O 0 1.7299747412380384e-08
C5D B-Disease 1 0.5760613083839417
state O 0 3.737219955723958e-08
is O 0 8.910274185147671e-10
compatible O 0 7.584820771455725e-09
with O 0 2.643475882635471e-09
normal O 0 8.235965509584275e-08
coagulation O 0 1.1056706625822699e-06
function O 0 3.5850851176633114e-09
and O 0 1.8366079490572673e-10
the O 0 3.428952122241924e-10
capacity O 0 2.461510328899408e-09
to O 0 7.322516482055619e-10
mount O 0 1.1342010566295357e-06
a O 0 1.474172790949524e-06
neutrophilic O 1 0.9602352976799011
leukocytosis O 1 0.9951387643814087
during O 0 0.0004924021777696908
pyogenic B-Disease 1 0.9984714388847351
infection I-Disease 1 0.5177520513534546
. O 0 2.224427362307324e-07
. O 0 6.238582272999338e-07

Susceptibility O 1 0.9890590906143188
to O 0 0.0012848562328144908
ankylosing B-Disease 1 0.9999849796295166
spondylitis I-Disease 1 0.9999967813491821
in O 0 0.0002604572509881109
twins O 0 0.06463243812322617
: O 0 4.6177626167320796e-09
the O 0 3.954098715119869e-10
role O 0 1.422608919554591e-09
of O 0 6.088831661088534e-10
genes O 0 3.906880507997812e-08
, O 0 1.2706449226129735e-08
HLA O 0 0.00011747710959753022
, O 0 2.96574098612723e-09
and O 0 1.54418033915249e-09
the O 0 1.751890188472771e-08
environment O 0 2.409519311186159e-06
. O 0 1.9295092101856426e-07

OBJECTIVE O 0 4.209873623040039e-06
To O 0 1.1673756183938622e-08
determine O 0 1.946725802781657e-08
the O 0 2.2558852563747678e-09
relative O 0 4.8023203191860375e-08
effects O 0 1.1142452649437473e-07
of O 0 7.053478690011161e-09
genetic O 0 2.4682451567059616e-06
and O 0 8.9231697586456e-09
environmental O 0 4.3319778342265636e-07
factors O 0 2.7935493918107568e-08
in O 0 2.140627088920155e-07
susceptibility O 0 0.3018445372581482
to O 0 9.143476927420124e-05
ankylosing B-Disease 1 0.9999972581863403
spondylitis I-Disease 1 0.9999991655349731
( O 0 2.5590854420443065e-05
AS B-Disease 0 1.3227238014223985e-05
) O 0 2.6939531494463154e-07
. O 0 5.498728796737851e-07

METHODS O 0 5.210264862398617e-05
Twins O 0 0.001103865564800799
with O 0 6.471984903555494e-08
AS B-Disease 0 1.5064644287576812e-07
were O 0 1.849157271749391e-09
identified O 0 2.833483669917314e-09
from O 0 3.1515984266761166e-10
the O 0 2.1547539308386376e-09
Royal O 0 8.296638952742796e-06
National O 0 9.75815510173561e-06
Hospital O 0 0.4110614061355591
for O 0 9.006094478536397e-05
Rheumatic B-Disease 1 0.9999803304672241
Diseases I-Disease 1 0.9896031022071838
database O 0 0.00021158292656764388
. O 0 1.821005753299687e-06

Clinical O 0 0.002072603441774845
and O 0 4.58248450740939e-07
radiographic O 0 0.003652691375464201
examinations O 0 5.616369526251219e-05
were O 0 2.7981995387449388e-08
performed O 0 4.101543282786224e-08
to O 0 1.4139363013754291e-09
establish O 0 4.351803681856836e-07
diagnoses O 0 0.008529768325388432
, O 0 1.6896668739718734e-06
and O 0 1.6477404642500915e-05
disease O 1 0.8267809748649597
severity O 0 0.0005393467145040631
was O 0 5.6640768519855555e-08
assessed O 0 1.3953973088121074e-08
using O 0 5.756483623109432e-10
a O 0 7.1992118932939775e-09
combination O 0 4.225199390361922e-08
of O 0 2.1601569422102784e-09
validated O 0 3.2455787390972546e-07
scoring O 0 1.0917189285919449e-07
systems O 0 1.002689987217309e-05
. O 0 2.907473799496074e-07

HLA O 0 0.003186532761901617
typing O 0 4.741199882118963e-05
for O 0 3.509923374167556e-07
HLA O 0 0.004632948897778988
- O 0 8.016318315640092e-05
B27 O 0 3.4292679629288614e-05
, O 0 5.3718334669383694e-08
HLA O 0 0.0001769100344972685
- O 0 5.861584668309661e-06
B60 O 0 1.3528893987313495e-06
, O 0 2.802011289659845e-09
and O 0 6.587871137497814e-09
HLA O 0 0.0023783070500940084
- O 0 9.632811998017132e-05
DR1 O 0 0.011734481900930405
was O 0 1.3245924357363492e-08
performed O 0 3.040000251530728e-09
by O 0 3.5230179884493396e-10
polymerase O 0 1.6247339829078555e-07
chain O 0 8.150715871124703e-07
reaction O 0 5.27626564661432e-09
with O 0 3.672285808775655e-10
sequence O 0 4.448200030537919e-09
- O 0 3.4597071874031826e-08
specific O 0 1.7649283423626372e-10
primers O 0 3.9483143865481907e-08
, O 0 6.027647825312954e-10
and O 0 1.3067075199657552e-09
zygosity O 0 1.5995912690414116e-05
was O 0 1.513880754089314e-08
assessed O 0 6.259010376652441e-08
using O 0 7.289691694722933e-08
microsatellite O 0 0.0016342230373993516
markers O 0 5.378765126806684e-05
. O 0 4.4446576907830604e-07

Genetic O 0 0.0007064826204441488
and O 0 3.0778409154663677e-07
environmental O 0 5.857247629137419e-07
variance O 0 5.233431465967442e-08
components O 0 6.143760344912153e-08
were O 0 3.5012885923890735e-09
assessed O 0 2.1887919032792524e-08
with O 0 5.485901732882326e-10
the O 0 1.7477642666463566e-09
program O 0 2.6233307082179635e-08
Mx O 0 1.9109654658677755e-06
, O 0 2.911174079578416e-10
using O 0 2.0671764300317363e-10
data O 0 5.150608828330405e-10
from O 0 1.011435241116132e-10
this O 0 3.51607493120909e-11
and O 0 2.226716866449152e-10
previous O 0 5.143406145435847e-09
studies O 0 2.7206450425865114e-09
of O 0 2.9215105890045834e-09
twins O 0 0.00015910064394120127
with O 0 4.2717523740520846e-08
AS B-Disease 0 2.545488314353861e-06
. O 0 3.8759603171456547e-07

RESULTS O 0 2.2886699298396707e-05
Six O 0 3.4585963248900953e-07
of O 0 4.49528272383759e-08
8 O 0 5.090014383313246e-06
monozygotic O 0 0.10997488349676132
( O 0 1.75657828549447e-06
MZ O 1 0.9886069893836975
) O 0 3.936577002150443e-07
twin O 0 0.0014232058310881257
pairs O 0 8.385843102587387e-06
were O 0 3.0379445092876267e-07
disease O 0 0.002111575799062848
concordant O 0 0.0003049183578696102
, O 0 1.198579102634767e-08
compared O 0 9.191770899974472e-09
with O 0 4.811979148477974e-10
4 O 0 4.399530961762821e-09
of O 0 1.1277270228760017e-09
15 O 0 7.417761338501805e-08
B27 O 0 0.00012668423005379736
- O 0 0.0005715133738704026
positive O 0 1.5094815353222657e-07
dizygotic O 0 0.0012449370697140694
( O 0 9.134118528209001e-08
DZ O 0 0.04162755236029625
) O 0 1.0278776052530247e-08
twin O 0 4.4104694097768515e-05
pairs O 0 1.073189395128793e-07
( O 0 3.03528402412212e-09
27 O 0 2.3492614076303653e-08
% O 0 9.208314111219806e-10
) O 0 1.5881243542459345e-10
and O 0 1.2061136811514217e-10
4 O 0 3.055462993728497e-09
of O 0 1.6127899016282754e-09
32 O 0 3.063604708586354e-06
DZ O 1 0.9278927445411682
twin O 0 0.05174582079052925
pairs O 0 6.906165253894869e-06
overall O 0 9.132347145168751e-07
( O 0 5.562249771884353e-09
12 O 0 1.3306520330047533e-08
. O 0 8.201830326015624e-10
5 O 0 1.3018198075087639e-08
% O 0 2.954980260483353e-08
) O 0 5.13271665170123e-08
. O 0 2.3147462968609034e-07

Nonsignificant O 0 0.027825959026813507
increases O 0 3.770614421227947e-05
in O 0 3.957777039431676e-08
similarity O 0 6.815845665641973e-08
with O 0 4.553130317219711e-09
regard O 0 5.427630789256455e-09
to O 0 1.598768561983377e-09
age O 0 8.524762620254478e-07
at O 0 1.2616544154298026e-05
disease O 0 0.062426310032606125
onset O 0 0.0007687232573516667
and O 0 2.288968570240968e-09
all O 0 2.1399997052196085e-10
of O 0 2.4824160504977044e-09
the O 0 8.826415864859882e-07
disease O 0 0.040734145790338516
severity O 0 3.680970621644519e-05
scores O 0 6.691630005661864e-07
assessed O 0 4.75853170200935e-07
were O 0 1.0987604603940326e-08
noted O 0 9.808135814637353e-08
in O 0 5.420153001978179e-07
disease O 0 0.43617355823516846
- O 0 0.3212380111217499
concordant O 1 0.6813932657241821
MZ O 1 0.9997575879096985
twins O 0 0.11282595992088318
compared O 0 4.779156824952224e-06
with O 0 6.998176331762807e-07
concordant O 0 0.43348801136016846
DZ O 1 0.9992092251777649
twins O 0 0.15474212169647217
. O 0 2.5296612875536084e-06

HLA O 1 0.8236165046691895
- O 0 0.0005544624291360378
B27 O 0 2.081627280858811e-05
and O 0 3.843846130280326e-08
B60 O 0 8.698581950739026e-06
were O 0 9.388896771156396e-09
associated O 0 2.687678168911134e-08
with O 0 8.729442058097447e-09
the O 0 2.0508768727722781e-07
disease O 0 0.00045726902317255735
in O 0 1.6232093003054615e-08
probands O 0 0.00012304820120334625
, O 0 1.8823873570994465e-09
and O 0 6.456357115602884e-10
the O 0 3.800467940351382e-09
rate O 0 3.6416969351193984e-07
of O 0 2.0615516405086964e-08
disease O 0 0.0007237448007799685
concordance O 0 8.570357749704272e-06
was O 0 6.437328181618795e-08
significantly O 0 2.4000331677598297e-07
increased O 0 1.1331302118833264e-07
among O 0 1.693145712522437e-08
DZ O 0 0.39458534121513367
twin O 0 0.0016083347145467997
pairs O 0 1.8363999743087334e-07
in O 0 6.397223861753787e-10
which O 0 2.758689665594005e-10
the O 0 2.477595906213992e-09
co O 0 6.343673703668173e-06
- O 0 6.816080713178962e-05
twin O 0 0.00012819519906770438
was O 0 8.19076628744142e-09
positive O 0 9.089237140713635e-10
for O 0 1.8179097116544085e-10
both O 0 1.3433226753178928e-09
B27 O 0 6.518579994008178e-06
and O 0 1.2549702432806953e-07
DR1 O 1 0.6125783920288086
. O 0 1.3909497056374676e-06

Additive O 0 5.796709592686966e-05
genetic O 0 0.00025957863545045257
effects O 0 6.833131919847801e-06
were O 0 7.1293038139685905e-09
estimated O 0 2.7222435416973667e-09
to O 0 6.00640162606858e-11
contribute O 0 1.1008429723347035e-09
97 O 0 6.999269608343184e-09
% O 0 4.3285289241801195e-10
of O 0 8.885999575047876e-11
the O 0 1.6943693115223368e-09
population O 0 2.432291168474876e-08
variance O 0 6.545302539961995e-07
. O 0 2.8359514203657454e-07

CONCLUSION O 0 4.79899717902299e-05
Susceptibility O 0 0.0009862075094133615
to O 0 2.75682516814868e-08
AS B-Disease 0 2.476830047726253e-07
is O 0 3.89071974638e-09
largely O 0 1.53195962582231e-08
genetically O 0 7.500491250311825e-08
determined O 0 1.3602083903663242e-08
, O 0 3.1486785401213524e-10
and O 0 3.5265274034301797e-10
the O 0 2.483874883552062e-09
environmental O 0 8.646786682220409e-07
trigger O 0 1.6933513506955933e-06
for O 0 9.55178780515098e-09
the O 0 9.396072755407658e-07
disease O 0 0.025944381952285767
is O 0 2.673301580102816e-08
probably O 0 6.763023208122831e-08
ubiquitous O 0 3.983416263508843e-06
. O 0 3.5219071037317917e-07

HLA O 0 0.49669149518013
- O 0 0.00015354716742876917
B27 O 0 7.048316092550522e-06
accounts O 0 1.5784923590445032e-08
for O 0 5.531164415373269e-10
a O 0 3.621240862727859e-09
minority O 0 1.0103680558870565e-08
of O 0 4.012071230796721e-10
the O 0 5.480717213401931e-09
overall O 0 3.1224501526594395e-06
genetic O 0 6.835738895460963e-05
susceptibility O 0 0.00032548545277677476
to O 0 1.1129024812817079e-08
AS B-Disease 0 2.5393562737008324e-06
. O 0 5.188151135371299e-07

Cell O 0 0.0017035737400874496
cycle O 0 0.0001429164403816685
- O 0 1.5843575965845957e-05
dependent O 0 1.4467532594153454e-07
colocalization O 0 4.66590199721395e-06
of O 0 5.887761833633931e-09
BARD1 O 0 7.200994150480255e-05
and O 0 1.1093336027556688e-08
BRCA1 O 0 2.2899339455761947e-05
proteins O 0 1.6569110528052988e-08
in O 0 4.540433806710098e-09
discrete O 0 2.342737701610531e-07
nuclear O 0 4.851954145124182e-06
domains O 0 4.387241915537743e-06
. O 0 3.6671769976237556e-07

Germ O 0 0.31054237484931946
- O 0 0.0013456417946144938
line O 0 5.250626600172836e-06
mutations O 0 3.8033958844607696e-06
of O 0 4.8762593962692335e-09
the O 0 2.8531060181080647e-08
BRCA1 O 0 0.00025842987815849483
gene O 0 3.593196140627697e-07
predispose O 0 4.1464423361503577e-07
women O 0 1.9238255433151608e-08
to O 0 1.7290634479749656e-09
early O 0 7.257311267494515e-07
- O 0 0.35451963543891907
onset O 1 0.9996801614761353
breast B-Disease 1 0.999992847442627
and I-Disease 1 0.8587785959243774
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999912977218628
by O 0 3.980124319014067e-08
compromising O 0 3.957003173127305e-06
the O 0 7.034145710349549e-09
genes O 0 1.7536797258799197e-07
presumptive O 0 0.00019066856475546956
function O 0 3.170823958953406e-08
as O 0 8.98423913042734e-09
a O 0 4.5549099922936875e-06
tumor B-Disease 1 0.6836609840393066
suppressor O 0 0.0004714023962151259
. O 0 3.6991900742577855e-07

Although O 0 3.4227355172333773e-07
the O 0 2.0089352403829253e-08
biochemical O 0 1.4533414969264413e-06
properties O 0 8.886181745992872e-08
of O 0 9.999768124657749e-09
BRCA1 O 0 0.00021839089458808303
polypeptides O 0 8.083184184215497e-07
are O 0 1.456450737791215e-09
not O 0 3.8968742122058586e-10
understood O 0 2.03418570876579e-09
, O 0 1.6088563814520285e-10
their O 0 1.5550623289062315e-10
expression O 0 3.0689080166013127e-09
pattern O 0 2.7436010796577648e-08
and O 0 3.009284488264541e-10
subcellular O 0 8.742409107753701e-08
localization O 0 7.0538852980917e-08
suggest O 0 4.554589594363279e-09
a O 0 1.4745354937062416e-09
role O 0 6.1730291989192665e-09
in O 0 1.3933227904772139e-08
cell O 0 8.14097875263542e-05
- O 0 0.00027799568488262594
cycle O 0 1.1697597983584274e-05
regulation O 0 7.2643715611775406e-06
. O 0 3.745162189261464e-07

When O 0 8.091058589343447e-06
resting O 0 0.00015348759188782424
cells O 0 4.362783784017665e-06
are O 0 7.143663882658302e-09
induced O 0 8.324826126226981e-07
to O 0 3.995339892259864e-10
proliferate O 0 1.032857923632946e-07
, O 0 4.12506750979702e-10
the O 0 5.187967277997529e-10
steady O 0 4.3084849465913067e-08
- O 0 4.583866086704802e-07
state O 0 1.433843266340773e-09
levels O 0 3.0464315514677764e-09
of O 0 4.6094092431836486e-10
BRCA1 O 0 3.5568662042351207e-06
increase O 0 4.832556577127889e-09
in O 0 8.496504610988609e-10
late O 0 1.5755928117755502e-08
G1 O 0 1.274228543479694e-05
and O 0 3.6313024809331296e-10
reach O 0 1.3103089724353367e-09
a O 0 3.568452644486797e-09
maximum O 0 3.6882095599821696e-08
during O 0 1.7402830110313516e-07
S O 0 0.00047581782564520836
phase O 0 1.6729143681004643e-05
. O 0 5.188892941987433e-07

Moreover O 0 2.2155101760290563e-05
, O 0 2.072651028584005e-07
in O 0 7.175032834538797e-08
S O 0 5.035951471654698e-05
phase O 0 4.027704108011676e-06
cells O 0 2.486285211489303e-06
, O 0 1.0001752315247359e-08
BRCA1 O 0 1.033776698022848e-05
polypeptides O 0 6.369032945485742e-08
are O 0 5.209881970280605e-10
hyperphosphorylated O 0 1.6898119383768062e-06
and O 0 8.231733072960878e-10
accumulate O 0 3.42622250570912e-08
into O 0 1.0498547586834661e-09
discrete O 0 6.766481419617776e-08
subnuclear O 0 0.0001132043544203043
foci O 0 0.0002990484645124525
termed O 0 0.00012851183419115841
" O 0 9.444432862437679e-07
BRCA1 O 0 0.001861435710452497
nuclear O 0 4.73707405035384e-05
dots O 0 0.00015241811343003064
. O 0 7.149786256377411e-07

" O 0 0.00013829088129568845
BRCA1 O 0 0.3966946601867676
associates O 0 0.00021117780124768615
in O 0 1.4690598959532508e-07
vivo O 0 1.284757672692649e-05
with O 0 1.59435984414813e-08
a O 0 2.405145096417982e-07
structurally O 0 3.61260463250801e-05
related O 0 7.785823754602461e-07
protein O 0 6.146670784801245e-06
termed O 0 7.320973963942379e-05
BARD1 O 0 0.011628284119069576
. O 0 1.2652766372411861e-06

Here O 0 2.3195238441076071e-07
we O 0 5.0437214405008035e-09
show O 0 2.767967410832739e-09
that O 0 1.5607021230934492e-10
the O 0 4.253138952137192e-10
steady O 0 2.6806386443922747e-08
- O 0 2.7016486114916916e-07
state O 0 3.101520151815862e-09
levels O 0 5.441759487467834e-09
of O 0 3.3442792979343494e-10
BARD1 O 0 1.1097970855189487e-05
, O 0 6.430119214861918e-10
unlike O 0 2.4341464399668666e-09
those O 0 1.1618610934460705e-10
of O 0 1.3732495141027812e-09
BRCA1 O 0 3.206132896593772e-05
, O 0 1.5257592966833045e-09
remain O 0 3.6970118078016867e-09
relatively O 0 5.5954276767522515e-09
constant O 0 4.103045370129621e-08
during O 0 1.0842131814570166e-07
cell O 0 0.00011861388338729739
cycle O 0 5.103869625600055e-05
progression O 0 9.766668517841026e-05
. O 0 5.920060743846989e-07

However O 0 1.6791130974525004e-06
, O 0 1.608640900485625e-07
immunostaining O 0 0.0010120503138750792
revealed O 0 3.2489899695065105e-06
that O 0 1.1873206418044902e-08
BARD1 O 0 0.0002034180361079052
resides O 0 2.1445534912345465e-06
within O 0 7.206770646916993e-08
BRCA1 O 0 0.0008322240901179612
nuclear O 0 2.980233148264233e-06
dots O 0 3.0584258183807833e-06
during O 0 4.8508169925298716e-08
S O 0 1.9936076114390744e-06
phase O 0 2.6684313425562323e-08
of O 0 3.147729576991054e-10
the O 0 1.8422749992197396e-09
cell O 0 4.013501893496141e-06
cycle O 0 3.112728848009283e-07
, O 0 5.152928084228847e-10
but O 0 1.1677975253476802e-10
not O 0 6.358876619705356e-11
during O 0 1.7824670628385775e-09
the O 0 8.429648090668707e-09
G1 O 0 0.003970891237258911
phase O 0 2.3299060558201745e-05
. O 0 3.3387448183930246e-07

Nevertheless O 0 5.090696504339576e-05
, O 0 3.3722039916028734e-07
BARD1 O 0 0.00010360703163314611
polypeptides O 0 1.1341577419443638e-06
are O 0 9.864354888478033e-10
found O 0 1.3138350407615462e-09
exclusively O 0 7.716437488980432e-10
in O 0 2.1789342552480662e-10
the O 0 1.2342848965118947e-10
nuclear O 0 2.9421842739907333e-09
fractions O 0 7.749239583354495e-10
of O 0 8.466054940425849e-11
both O 0 5.653892909407432e-10
G1 O 0 0.00017025021952576935
- O 0 6.515584118460538e-06
and O 0 1.282502637423022e-08
S O 0 0.0002790949074551463
- O 0 0.00011065464786952361
phase O 0 2.158413735742215e-05
cells O 0 9.60345278144814e-06
. O 0 2.3888077294031973e-07

Therefore O 0 2.36840628531354e-06
, O 0 2.2270211275099427e-07
progression O 0 1.6924512237892486e-05
to O 0 8.68056204694767e-09
S O 0 5.926011726842262e-05
phase O 0 1.0448480907143676e-06
is O 0 1.5244850937179422e-09
accompanied O 0 2.4629380757090757e-09
by O 0 2.1875333489074222e-10
the O 0 2.0637568043380128e-10
aggregation O 0 8.456929379008216e-09
of O 0 8.564285947088024e-10
nuclear O 0 2.6671497721508786e-07
BARD1 O 0 1.185003111459082e-05
polypeptides O 0 1.3169974977245147e-07
into O 0 5.6196558517740414e-08
BRCA1 O 0 0.0005086073651909828
nuclear O 0 2.1599456886178814e-05
dots O 0 7.102549716364592e-05
. O 0 5.411434926827496e-07

This O 0 4.210629924727982e-07
cell O 0 5.039842289988883e-05
cycle O 0 1.222926402988378e-05
- O 0 2.154378535124124e-06
dependent O 0 4.169265110931519e-08
colocalization O 0 2.470607114446466e-06
of O 0 7.35683247654606e-09
BARD1 O 0 0.00045789583236910403
and O 0 1.0648845005789553e-07
BRCA1 O 0 0.0005524691077880561
indicates O 0 5.416454129658632e-08
a O 0 2.74031553004761e-09
role O 0 2.97729174647543e-09
for O 0 2.263824905313072e-09
BARD1 O 0 0.0002520148700568825
in O 0 4.2717363157862565e-07
BRCA1 O 0 0.11788871884346008
- O 0 0.008847726508975029
mediated O 0 0.008491920307278633
tumor B-Disease 1 0.9281459450721741
suppression O 0 5.543831139220856e-05
. O 0 6.784967467865499e-07

Ethnic O 0 1.4906695469107945e-06
differences O 0 1.569078108332178e-06
in O 0 6.056740886606349e-08
the O 0 3.205729015576253e-08
HFE O 0 0.0007946784608066082
codon O 0 1.2416516256053e-05
282 O 0 1.0803321856656112e-05
( O 0 5.530704925149621e-07
Cys O 0 0.18607990443706512
/ O 0 0.00010495449532754719
Tyr O 0 0.0004625014553312212
) O 0 1.4636870560025272e-07
polymorphism O 0 1.2469699868233874e-05
. O 0 3.722827273122675e-07

Recent O 0 1.0848625606740825e-05
studies O 0 5.862708007953188e-07
have O 0 1.5170776634931826e-08
shown O 0 1.3953925304122095e-07
that O 0 2.8193400680720515e-07
hereditary B-Disease 1 0.9999580383300781
hemochromatosis I-Disease 1 0.9999990463256836
( O 0 2.99292296404019e-05
HH B-Disease 1 0.9877268671989441
) O 0 4.2123566856844263e-08
is O 0 5.518447920849212e-09
likely O 0 5.118304002849072e-09
to O 0 1.3197490322802707e-10
be O 0 3.2181132758601905e-10
caused O 0 7.229870035985186e-09
by O 0 4.2183906368009616e-10
homozygosity O 0 1.1528467211974203e-06
for O 0 7.319667649774431e-10
a O 0 5.435683547716508e-08
Cys282Tyr O 0 0.00022133089078124613
mutation O 0 4.230019840179011e-06
in O 0 3.3842575408726816e-09
the O 0 1.357836598714357e-08
HFE O 0 0.0025609193835407495
gene O 0 1.238089112121088e-06
located O 0 2.287680587187424e-07
4 O 0 4.755142981593963e-07
. O 0 4.0931817579803464e-07

5 O 0 1.7101425328291953e-05
Mb O 0 0.0012790965847671032
telomeric O 0 0.015408310107886791
to O 0 1.1417325822549174e-06
HLA O 0 0.3624829947948456
- O 0 0.00035705367918126285
A O 0 2.922949988715118e-06
. O 0 1.1979904002146213e-06

Population O 0 2.2862266177980928e-06
studies O 0 1.6142270453656238e-07
of O 0 3.3833666979177224e-09
this O 0 1.458805520826445e-09
polymorphism O 0 9.086506480571188e-08
are O 0 1.4448733876015751e-10
facilitated O 0 7.07587366477469e-09
by O 0 4.67586580565893e-10
the O 0 4.500837758047993e-10
fact O 0 8.943851215192922e-10
that O 0 8.573728532690339e-11
the O 0 2.1598931532196275e-09
Cys282Tyr O 0 0.00012234084715601057
mutation O 0 6.5728895606298465e-06
creates O 0 7.743868479792582e-08
a O 0 5.937475933137648e-08
Rsal O 0 5.860495366505347e-05
restriction O 0 4.1684631923999405e-07
site O 0 8.083616194198839e-07
. O 0 2.8484359404501447e-07

We O 0 2.0034809722346836e-07
have O 0 1.8047281002964155e-08
studied O 0 1.967713103567803e-08
the O 0 4.411505383217218e-09
codon O 0 5.012603310206032e-07
282 O 0 1.4415406894840999e-06
( O 0 1.208526327900472e-07
Cys O 0 0.07350806146860123
/ O 0 2.5291179554187693e-05
Tyr O 0 3.386293610674329e-05
) O 0 2.3651802738555716e-09
polymorphism O 0 5.0602015022604974e-08
in O 0 6.070116631562428e-10
different O 0 3.9730588263786615e-10
ethnic O 0 1.8747849495071023e-08
groups O 0 5.005914971434322e-08
. O 0 2.3373104340862483e-07

In O 0 6.006507646816317e-07
agreement O 0 1.570425354202598e-07
with O 0 5.565242044980323e-09
previous O 0 9.46491773845537e-09
observations O 0 1.694670714869062e-08
the O 0 3.998169795238482e-09
Tyr O 0 8.941059604694601e-06
allele O 0 8.130657391802742e-08
appeared O 0 1.0798107297205206e-08
to O 0 3.6717115459161676e-10
be O 0 2.544688348926627e-10
rare O 0 6.2688649826725396e-09
or O 0 2.723115954950117e-09
absent O 0 7.493970599625754e-08
in O 0 8.362054160215848e-09
Asiatic O 0 2.6758784770208877e-06
( O 0 3.2528086890692975e-09
Indian O 0 4.8502961647045595e-09
, O 0 1.0363498947896232e-09
Chinese O 0 4.728225366790184e-09
) O 0 1.2386160541666413e-08
populations O 0 2.393354350260779e-07
. O 0 1.0495934787968508e-07

The O 0 2.8782110916836245e-07
highest O 0 5.835659067088272e-07
allele O 0 2.3959097461556667e-07
frequency O 0 1.1808529620793706e-07
( O 0 4.379153484279641e-09
7 O 0 7.820202263530973e-09
. O 0 4.4015260880492235e-10
5 O 0 3.3321834180810583e-09
% O 0 1.6493489907176695e-09
) O 0 1.3274041865685149e-09
was O 0 3.4966505246813995e-09
found O 0 5.830855354105324e-09
in O 0 1.7488789083586198e-08
Swedes O 0 9.511551070318092e-06
. O 0 3.5418807442511024e-07

Saamis O 0 0.0013632798800244927
( O 0 5.431195404526079e-07
2 O 0 1.0068747968716707e-07
% O 0 1.003477212435655e-08
) O 0 1.2908214497286963e-09
and O 0 1.4504794032532686e-09
Mordvinians O 0 2.538308081057039e-06
( O 0 1.5826880916947061e-09
1 O 0 2.065317028510094e-09
. O 0 1.8948791147277433e-10
8 O 0 3.703971129809247e-09
% O 0 1.1208990402522545e-09
) O 0 3.697729067386746e-10
had O 0 8.629975067897533e-10
significantly O 0 8.801533724067667e-09
lower O 0 4.814285858856238e-09
frequencies O 0 9.585620075469592e-10
of O 0 4.959068711229975e-10
the O 0 1.667315707720718e-08
Tyr O 0 9.068765211850405e-05
allele O 0 2.746806103459676e-06
. O 0 2.6918806383946503e-07

Comparisons O 0 1.5554294350295095e-06
with O 0 4.890727467454781e-08
allele O 0 3.373542085682857e-07
frequencies O 0 1.5919660256713541e-07
based O 0 2.582231317660444e-08
on O 0 1.4558071192993793e-08
prevalence O 0 1.075767522706883e-05
estimates O 0 7.006256907970965e-08
of O 0 5.7669264919013585e-09
HH B-Disease 0 0.10369859635829926
showed O 0 1.5359158567207487e-07
some O 0 2.335155402377609e-10
disagreements O 0 1.1459282411863114e-08
with O 0 8.203269730167051e-10
the O 0 1.6823608062210837e-09
RFLP O 0 3.211046305295895e-06
data O 0 9.0536680374953e-09
, O 0 1.835747220901851e-09
particularly O 0 7.695481585301422e-09
in O 0 2.874572935240849e-08
Finns O 0 1.5357592928921804e-05
. O 0 3.1350160156762286e-07

The O 0 6.198469009177643e-07
newly O 0 1.4069825738260988e-05
described O 0 4.898106453765649e-06
HFE O 0 0.012550374493002892
marker O 0 2.922147359640803e-06
provides O 0 3.0668324768612365e-08
a O 0 1.1675425959367658e-08
new O 0 1.577763142357469e-09
approach O 0 1.078085620775937e-09
to O 0 3.994438460552807e-11
the O 0 2.258493253526339e-10
screening O 0 8.176206733878644e-08
of O 0 1.5360170912970261e-09
HH B-Disease 0 0.0010588756995275617
as O 0 5.080001419521807e-10
well O 0 3.651513535984918e-10
as O 0 1.904244817385603e-10
studies O 0 3.130629366854265e-10
of O 0 4.7519078949509463e-11
the O 0 2.2796348142506417e-10
relationship O 0 3.545101989743671e-09
between O 0 1.7578675182150505e-09
the O 0 1.14826042008076e-08
HFE O 0 0.0032137183006852865
Tyr O 0 0.00014542596181854606
allele O 0 5.376886065278086e-07
and O 0 2.9809186230522755e-08
different O 0 1.5141803544338472e-07
disorders O 1 0.9365350604057312
including O 0 0.00038237354601733387
cancer B-Disease 1 0.9982028007507324

Autosomal B-Disease 1 0.99782395362854
dominant I-Disease 1 0.9948627352714539
neurohypophyseal I-Disease 1 0.9998065829277039
diabetes I-Disease 1 0.9999715089797974
insipidus I-Disease 1 0.9995946288108826
associated O 0 1.157396036433056e-05
with O 0 7.087060538424339e-08
a O 0 6.878217391204089e-07
missense O 0 0.0002585930342320353
mutation O 0 6.513633252325235e-06
encoding O 0 1.1310362424410414e-06
Gly23 O 0 0.0036849984899163246
- O 0 0.0032712887041270733
- O 0 0.0012535677524283528
> O 0 8.750583947403356e-05
Val O 0 0.0008410419686697423
in O 0 1.1178470060713153e-07
neurophysin O 0 0.0005235755234025419
II O 0 0.00030278629856184125
. O 0 8.938050655160623e-07

Autosomal B-Disease 1 0.9971374273300171
dominant I-Disease 1 0.9928539395332336
neurohypophyseal I-Disease 1 0.9997439980506897
diabetes I-Disease 1 0.9999773502349854
insipidus I-Disease 1 0.9997782111167908
( O 0 3.121113695669919e-05
ADNDI B-Disease 1 0.555853009223938
) O 0 5.565487981584738e-07
is O 0 2.9942415835648717e-07
an O 0 1.3291373761603609e-05
inherited B-Disease 1 0.9999948740005493
disease I-Disease 1 0.9999892711639404
caused O 0 0.0011422308161854744
by O 0 7.240457193802285e-07
progressive O 0 0.01445056777447462
degeneration O 0 0.037125881761312485
of O 0 1.0346952628026429e-08
the O 0 1.9978919851837418e-08
magnocellular O 0 0.0007424773648381233
neurons O 0 7.158874950619065e-07
of O 0 8.986018040779697e-10
the O 0 1.8385224453965066e-09
hypothalamus O 0 1.2476604069888708e-06
leading O 0 1.7736976332116683e-08
to O 0 3.01505848065986e-10
decreased O 0 8.078377788933722e-08
ability O 0 1.5101511152693092e-09
to O 0 1.6298529192937394e-10
produce O 0 1.983890385304221e-09
the O 0 4.765690952979185e-09
hormone O 0 1.3016481261729496e-06
arginine O 0 5.40387418368482e-07
vasopressin O 0 3.4356146443315083e-06
( O 0 4.8165755828222245e-08
AVP O 0 4.020691631012596e-05
) O 0 9.275977674860769e-08
. O 0 2.1847797881946462e-07

Affected O 0 5.2202161896275356e-05
individuals O 0 8.752835469749698e-07
are O 0 1.5426207866653385e-08
not O 0 8.667359274738828e-09
symptomatic O 0 0.00011631373490672559
at O 0 1.3653311725647654e-06
birth O 0 4.8023441195255145e-05
, O 0 2.9569761750281032e-08
but O 0 1.180402087186394e-08
usually O 0 1.6316981543695874e-07
develop O 0 0.00019982378580607474
diabetes B-Disease 1 0.9948615431785583
insipidus I-Disease 1 0.800218403339386
at O 0 6.20733601408574e-07
1 O 0 1.2879419273303938e-06
- O 0 0.00024639960611239076
6 O 0 4.026298938697437e-06
yr O 0 0.09493131935596466
of O 0 3.5473359361049006e-08
age O 0 1.5545929272775538e-06
. O 0 3.7745286363133346e-07

The O 0 9.091938864003168e-07
genetic O 0 1.719463944027666e-05
locus O 0 1.6592803149251267e-05
of O 0 8.512473925748054e-08
the O 0 1.3321016467671143e-06
disease O 0 0.010452047921717167
is O 0 1.1916313269466627e-08
the O 0 1.5551824716908413e-08
AVP O 0 0.0013146656565368176
- O 0 0.0022936053574085236
neurophysin O 0 0.008020875044167042
II O 0 0.00010111103620147333
( O 0 1.3423705702564348e-08
NPII O 0 2.532289181544911e-05
) O 0 3.312678131806024e-09
gene O 0 3.086390876205769e-08
, O 0 1.4973647877170038e-09
and O 0 6.687506548530564e-09
mutations O 0 3.278633812442422e-06
that O 0 1.9782564475434583e-09
cause O 0 2.73417271046128e-07
ADNDI B-Disease 0 0.0005334913730621338
have O 0 1.7260550766451388e-09
been O 0 7.531765211510333e-10
found O 0 3.806632231651008e-10
in O 0 6.937260488282249e-11
both O 0 3.3082925288141496e-11
the O 0 1.2964784801283713e-10
signal O 0 2.5455053620504486e-09
peptide O 0 5.933985303130385e-09
of O 0 1.8381288158231257e-10
the O 0 2.824321887473502e-09
prepro O 0 9.639556083129719e-05
- O 0 8.360893843928352e-05
AVP O 0 0.00014448686852119863
- O 0 1.7282887711189687e-05
NPII O 0 2.8472502890508622e-05
precursor O 0 2.866448767235852e-07
and O 0 7.206987895358452e-09
within O 0 6.647677963655951e-08
NPII O 0 0.0008946718298830092
itself O 0 2.343189635212184e-06
. O 0 7.088032702995406e-07

An O 0 1.0077948218167876e-06
affected O 0 3.652023451650166e-06
girl O 0 4.3172800360480323e-05
who O 0 1.2532141546728326e-08
presented O 0 1.2024465867455092e-08
at O 0 1.481694322791327e-08
9 O 0 4.6774136563954016e-08
months O 0 1.4898134281793318e-08
of O 0 3.526547665000379e-10
age O 0 2.2201245286623816e-08
and O 0 1.0203975442379942e-09
her O 0 1.498163157975796e-07
similarly O 0 5.67775941817672e-07
affected O 0 6.193682366983921e-08
younger O 0 1.1075517392100664e-07
brother O 0 9.575450121701579e-08
and O 0 1.5201472303161268e-09
father O 0 2.2459733628465983e-08
were O 0 3.069503817787478e-10
all O 0 5.4980079516875335e-11
found O 0 4.308513268380665e-10
to O 0 5.92877552607618e-11
have O 0 2.346558503063534e-10
a O 0 6.3994729515570725e-09
novel O 0 9.876129070107709e-08
missense O 0 9.13693947950378e-05
mutation O 0 3.1590816433890723e-06
( O 0 1.1189302817626867e-08
G1758 O 0 1.5168227037065662e-05
- O 0 0.0005063771386630833
- O 0 0.001066469238139689
> O 0 5.8307723520556465e-05
T O 0 1.4374729289556853e-05
) O 0 7.590978540195081e-11
encoding O 0 9.844656201352109e-10
the O 0 2.8816954378285686e-10
amino O 0 2.772120311078652e-09
acid O 0 1.8452228189858033e-08
substitution O 0 1.510252545244839e-08
Gly23 O 0 1.9762828742386773e-05
- O 0 0.00010493178706383333
- O 0 0.00011368445120751858
> O 0 2.2057789465179667e-05
Val O 0 0.0003345843288116157
within O 0 4.2102283259737305e-07
NPII O 0 0.0005760558415204287
. O 0 7.328104629777954e-07

The O 0 4.419619472173508e-06
mutation O 0 0.000730399857275188
was O 0 3.5277662391308695e-07
confirmed O 0 1.1526253018701027e-07
by O 0 1.3940565146697281e-08
restriction O 0 2.2863436299758177e-07
endonuclease O 0 9.490675438428298e-05
analysis O 0 1.4013605778018245e-06
. O 0 5.067377628620306e-07

A O 0 1.8110051314579323e-05
T1 O 0 0.04950901120901108
- O 0 1.2807453458663076e-05
weighted O 0 1.1334739014046136e-07
magnetic O 0 9.06275943179935e-08
resonance O 0 2.7159032356394164e-07
imaging O 0 2.3626985239388887e-06
of O 0 3.668542136736619e-09
the O 0 5.534335656420808e-08
fathers O 0 1.709759271761868e-05
pituitary O 0 0.012206993997097015
gland O 0 0.001800015801563859
demonstrates O 0 9.213906082550238e-07
an O 0 7.021521497563299e-08
attenuated O 0 0.0007383310585282743
posterior O 0 0.05607663840055466
pituitary O 0 0.051753658801317215
bright O 0 0.00014061266847420484
spot O 0 1.2014298590656836e-05
. O 0 1.439751940779388e-06

This O 0 4.122392510907957e-06
mutation O 0 0.0011134963715448976
may O 0 1.746178099892859e-07
be O 0 4.994627489374182e-10
valuable O 0 5.538311476094293e-10
for O 0 3.869817244428475e-10
developing O 0 1.5616743453961135e-08
models O 0 5.264597646714719e-08
of O 0 2.5091798860898962e-08
dominantly B-Disease 0 0.35500845313072205
inherited I-Disease 1 0.9966855645179749
neurodegeneration I-Disease 1 0.9999867677688599
, O 0 2.5278275472828682e-08
as O 0 5.508045131108474e-10
the O 0 4.641053374943027e-10
early O 0 3.934772951907917e-09
age O 0 5.630983235249687e-09
of O 0 2.8843032406911107e-09
onset O 0 0.0013442296767607331
of O 0 3.234541168239957e-07
symptoms O 0 0.022927237674593925
suggests O 0 1.1351636430845247e-07
that O 0 6.650640038685651e-10
this O 0 1.3105462270956991e-09
mutation O 0 1.259996679436881e-06
may O 0 5.74183633972325e-09
be O 0 1.47687667650942e-10
particularly O 0 7.132863744097051e-10
deleterious O 0 3.815700821974133e-08
to O 0 4.726112834418927e-10
the O 0 1.809080885095682e-08
magnocellular O 0 0.07130860537290573
neuron O 0 0.0008442988619208336
. O 0 5.0420506880755056e-08
. O 0 2.6313796297472436e-07

Frequent O 0 0.00010798992298077792
inactivation O 0 0.05823028087615967
of O 0 3.414031880311086e-06
PTEN O 0 0.4850143790245056
/ O 0 0.0005359784117899835
MMAC1 O 0 0.14359413087368011
in O 0 7.469193224096671e-05
primary O 1 0.9961054921150208
prostate B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999823570251465
. O 0 2.289510302944109e-05

Sporadic B-Disease 1 0.9995614886283875
prostate I-Disease 1 0.9999940395355225
carcinoma I-Disease 1 0.9999963045120239
is O 0 1.6827681292852503e-06
the O 0 3.1099155251013144e-08
most O 0 8.11251421595216e-09
common O 0 5.286241275825887e-07
male B-Disease 0 0.00012614612933248281
cancer I-Disease 0 0.23433655500411987
in O 0 4.381216722748604e-09
the O 0 1.077094968771064e-09
Western O 0 7.943337543281359e-09
world O 0 3.423627603638124e-09
, O 0 6.403425567569343e-10
yet O 0 2.399526688456888e-10
many O 0 1.5150859733470412e-11
of O 0 3.92004206872798e-11
the O 0 3.071430609846715e-10
major O 0 6.4633836061034344e-09
genetic O 0 3.254647396033761e-08
events O 0 5.75736180952191e-10
involved O 0 1.5345966719593207e-09
in O 0 5.213480203103416e-10
the O 0 9.455999316898556e-10
progression O 0 5.595018706117116e-07
of O 0 2.513599772768771e-09
this O 0 2.2991473613842572e-08
often O 0 4.4859989429824054e-06
fatal O 1 0.9998096823692322
cancer B-Disease 1 0.9935426712036133
remain O 0 2.365313065411101e-07
to O 0 3.562848904792304e-09
be O 0 2.9729068984352125e-08
elucidated O 0 6.153166759759188e-05
. O 0 6.716090865666047e-07

Numerous O 0 5.4421843742602505e-06
cytogenetic O 0 0.023877888917922974
and O 0 5.59911313757766e-07
allelotype O 0 0.0011369803687557578
studies O 0 8.025728561733558e-07
have O 0 3.1532252364741e-08
reported O 0 7.618518225172011e-07
frequent O 0 3.621353528160398e-07
loss O 0 4.489191724132979e-06
of O 0 7.669062718207442e-09
heterozygosity O 0 0.00011447650467744097
on O 0 1.3430178569251439e-07
chromosomal O 0 0.01974971406161785
arm O 0 0.0034364766906946898
10q O 0 0.0008796787005849183
in O 0 3.398269473109394e-05
sporadic B-Disease 1 0.993192732334137
prostate I-Disease 1 0.9999972581863403
cancer I-Disease 1 0.9999738931655884
. O 0 2.0718436644528992e-05

Deletion O 0 0.0012038591085001826
mapping O 0 0.00027291750302538276
studies O 0 3.5180369195586536e-06
have O 0 4.561981725714759e-08
unambiguously O 0 2.710463832045207e-06
identified O 0 1.0289215168768351e-07
a O 0 1.7863886370150794e-08
region O 0 3.101125400917226e-08
of O 0 1.6782072398413561e-09
chromosome O 0 4.842856924369698e-06
10q23 O 0 1.6856560023370548e-06
to O 0 1.6856425977263e-10
be O 0 8.795885547696614e-11
the O 0 5.385051293771426e-10
minimal O 0 1.0460180988047796e-07
area O 0 4.636651951273052e-08
of O 0 2.9571115334192655e-08
loss O 0 0.00012324076669756323
. O 0 5.253278345662693e-07

A O 0 1.636075285205152e-05
new O 0 7.150221790652722e-06
tumor B-Disease 0 0.1984678953886032
suppressor O 0 0.00018788338638842106
gene O 0 3.938434929295909e-06
, O 0 1.0327259758469154e-07
PTEN O 0 0.00212711188942194
/ O 0 3.463111352175474e-05
MMAC1 O 0 0.0035616764798760414
, O 0 2.3049341990599714e-08
was O 0 3.915033985890659e-08
isolated O 0 7.426389174725045e-07
recently O 0 9.451049010067436e-08
at O 0 2.656759701125111e-09
this O 0 1.2263766391296116e-10
region O 0 2.797226894557525e-09
of O 0 9.075725171392435e-10
chromosome O 0 2.638760633999482e-06
10q23 O 0 2.2998767690296518e-06
and O 0 1.6720919093771158e-09
found O 0 5.452166496056066e-10
to O 0 5.342081638159968e-11
be O 0 1.235917479469606e-10
inactivated O 0 2.0168563708011789e-07
by O 0 2.72676481394285e-09
mutation O 0 1.526967480458552e-06
in O 0 1.3119905872827076e-07
three O 0 0.0010648572351783514
prostate B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999929666519165
cell O 0 0.35936298966407776
lines O 0 0.0002971530775539577
. O 0 1.924847765621962e-06

We O 0 2.1883552108192816e-06
screened O 0 0.0001266277104150504
80 O 0 0.0008234978304244578
prostate B-Disease 1 0.9999756813049316
tumors I-Disease 1 0.9999184608459473
by O 0 1.3570098644777318e-07
microsatellite O 0 6.630647840211168e-05
analysis O 0 5.124284996327333e-08
and O 0 1.040938446550399e-08
found O 0 3.039555451778142e-08
chromosome O 0 4.353855729277711e-06
10q23 O 0 1.7133315850514919e-06
to O 0 3.5622355065711986e-10
be O 0 3.57276874751733e-10
deleted O 0 2.9075698293468122e-08
in O 0 9.522355348678957e-09
23 O 0 3.429231014706602e-07
cases O 0 5.183462121749471e-07
. O 0 3.596161377572571e-07

We O 0 2.195105395230712e-07
then O 0 2.9141768109752775e-08
proceeded O 0 3.559739525371697e-08
with O 0 1.1083854944970994e-09
sequence O 0 3.788706681717713e-09
analysis O 0 1.5764997085554455e-09
of O 0 3.2445285347293407e-10
the O 0 2.163368817420519e-09
entire O 0 3.709024554154894e-07
PTEN O 0 0.004792798310518265
/ O 0 1.4491199181065895e-05
MMAC1 O 0 0.0007220274419523776
coding O 0 1.834611248341389e-05
region O 0 2.5636475697865535e-07
and O 0 6.7512022638993585e-09
tested O 0 1.4578584739410871e-07
for O 0 5.363791077961366e-10
homozygous O 0 2.7964503601651813e-07
deletion O 0 7.078170938257244e-07
with O 0 4.266530684304826e-09
new O 0 3.388935709836005e-08
intragenic O 0 0.0001136790233431384
markers O 0 8.866853704603272e-07
in O 0 1.4601668762992404e-09
these O 0 1.9257254124660506e-10
23 O 0 1.6622603737914687e-08
cases O 0 1.067757970929506e-08
with O 0 4.481875848227901e-08
10q23 O 0 0.0005924486904405057
loss O 0 6.108960951678455e-05
of O 0 2.641205014697334e-07
heterozygosity O 0 0.029151901602745056
. O 0 2.545061079217703e-06

The O 0 1.630954500342341e-07
identification O 0 1.4054531050078367e-07
of O 0 5.938684655149018e-09
the O 0 4.451153223783422e-09
second O 0 3.2331037402855145e-08
mutational O 0 2.8801361622754484e-05
event O 0 5.634563748913024e-08
in O 0 2.176708813195205e-09
10 O 0 3.636974499343637e-09
( O 0 3.095185219237351e-09
43 O 0 1.1988048242983496e-07
% O 0 9.789353327960271e-08
) O 0 8.20041293536633e-07
tumors B-Disease 1 0.999782383441925
establishes O 0 0.0008986673201434314
PTEN O 0 0.23763416707515717
/ O 0 2.156930167984683e-05
MMAC1 O 0 6.997405580477789e-05
as O 0 1.0037523034966966e-09
a O 0 4.676920628554626e-09
main O 0 1.498582591352715e-08
inactivation O 0 3.5392684367252514e-05
target O 0 1.1031977109610125e-08
of O 0 3.1461586669223607e-09
10q O 0 4.219165202812292e-05
loss O 0 0.00010406279034214094
in O 0 7.140872185118496e-06
sporadic B-Disease 1 0.9984616041183472
prostate I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.999993085861206
. O 0 8.872960961525678e-07
. O 0 7.318878374462656e-07

Risk O 0 0.00037234683986753225
reversals O 0 2.9804874429828487e-05
in O 0 4.3611930777842645e-07
predictive O 0 3.7779678677907214e-05
testing O 0 0.00020150731143075973
for O 0 8.447558502666652e-05
Huntington B-Disease 1 0.9999231100082397
disease I-Disease 1 0.9998149275779724
. O 0 1.6658599633956328e-05

The O 0 1.1937234489778348e-07
first O 0 3.691552663553921e-08
predictive O 0 5.120267815073021e-06
testing O 0 3.593627843656577e-05
for O 0 9.636049071559682e-06
Huntington B-Disease 1 0.999977707862854
disease I-Disease 1 0.9990289211273193
( O 0 3.418787386522126e-08
HD B-Disease 0 9.523114385956433e-06
) O 0 1.210190725409177e-09
was O 0 9.05430286302078e-10
based O 0 5.122237634047622e-10
on O 0 2.595749171163675e-10
analysis O 0 1.0202748645937731e-09
of O 0 1.0270657657684978e-09
linked O 0 1.3225294424046297e-06
polymorphic O 0 1.6922254872042686e-05
DNA O 0 5.15652027388569e-06
markers O 0 1.8892643538492848e-07
to O 0 3.179408125664196e-10
estimate O 0 4.289525179501652e-09
the O 0 2.291562356537824e-10
likelihood O 0 5.700739880154515e-09
of O 0 3.659964831204121e-10
inheriting O 0 7.980255531947478e-07
the O 0 2.426017964296534e-08
mutation O 0 1.6048330735429772e-06
for O 0 9.263208866627792e-09
HD B-Disease 0 9.251371375285089e-05
. O 0 7.436502187374572e-07

Limits O 0 1.3393242852544063e-06
to O 0 5.789453361160213e-09
accuracy O 0 4.4806451882095644e-08
included O 0 3.6126657221302594e-09
recombination O 0 3.261408565435886e-08
between O 0 1.0328610189347387e-09
the O 0 2.3375137381265176e-09
DNA O 0 4.259020727204188e-07
markers O 0 1.2360641221675905e-07
and O 0 4.84297213443341e-10
the O 0 4.64178162573603e-09
mutation O 0 3.5818929973174818e-06
, O 0 3.757237632129318e-09
pedigree O 0 2.183743617933942e-06
structure O 0 2.977419342187204e-07
, O 0 1.0939399386344917e-09
and O 0 3.6254826918380445e-10
whether O 0 1.1241620967439303e-09
DNA O 0 8.07783848699728e-08
samples O 0 1.8382946276318535e-09
were O 0 1.6577123007621708e-10
available O 0 2.460636139289818e-10
from O 0 7.60953744460835e-10
family O 0 1.8651016731041636e-08
members O 0 2.3568777152149778e-08
. O 0 1.8013068370237306e-07

With O 0 1.2631183210487507e-07
direct O 0 7.635511423131902e-08
tests O 0 6.83263650103072e-08
for O 0 8.133798079512644e-10
the O 0 3.352123245647931e-09
HD B-Disease 0 4.7483266826020554e-05
mutation O 0 6.375532848323928e-06
, O 0 2.5517323809509662e-09
we O 0 1.5686883736432122e-10
have O 0 9.477987839012769e-11
assessed O 0 8.322351141565321e-10
the O 0 8.178987348506084e-11
accuracy O 0 2.354620720623757e-09
of O 0 3.3928776455027787e-10
results O 0 1.1584987191781693e-08
obtained O 0 1.1429915902638754e-09
by O 0 2.2088700313283027e-10
linkage O 0 1.8298891291124164e-08
approaches O 0 6.1739946488614805e-09
when O 0 4.979968659668543e-10
requested O 0 1.4465119102524682e-09
to O 0 1.343053029900787e-10
do O 0 3.4211322663679766e-10
so O 0 1.337620569863418e-10
by O 0 3.2562336160779637e-10
the O 0 2.8441828892056265e-09
test O 0 9.858249683247777e-08
individuals O 0 2.9770093945558074e-08
. O 0 2.1370493641370558e-07

For O 0 1.6665295277107361e-07
six O 0 4.7691123938875535e-08
such O 0 2.425059042465705e-09
individuals O 0 5.0043853505599145e-09
, O 0 1.6444613448740597e-09
there O 0 7.161846116154891e-10
was O 0 4.568161404705506e-09
significant O 0 6.139306396590882e-09
disparity O 0 3.7115333384463156e-07
between O 0 1.1593254356512261e-08
the O 0 5.3146905543144385e-08
tests O 0 1.87733996881434e-06
. O 0 2.084304355776112e-07

Three O 0 4.4410728605726035e-07
went O 0 1.446485669021058e-07
from O 0 7.2168231390890014e-09
a O 0 6.156228948839271e-08
decreased O 0 2.9041559628240066e-06
risk O 0 3.6409053905117617e-07
to O 0 1.1494163260072909e-10
an O 0 7.469532770087994e-10
increased O 0 1.9840166487483657e-07
risk O 0 1.6740078763177735e-06
, O 0 5.432299055030398e-10
while O 0 5.042603556937308e-10
in O 0 3.288972705295379e-10
another O 0 1.4781060819757386e-09
three O 0 1.798414972498108e-09
the O 0 1.587520337409387e-08
risk O 0 1.266031995328376e-05
was O 0 1.8518890954055678e-07
decreased O 0 8.105539563985076e-06
. O 0 2.847882001333346e-07

Knowledge O 0 5.525660071725724e-07
of O 0 2.40813484708724e-08
the O 0 3.093280298571699e-08
potential O 0 8.413331897827447e-08
reasons O 0 4.315045210034896e-09
for O 0 3.1381261478280464e-10
these O 0 1.5545878473410824e-10
changes O 0 4.190557678640516e-09
in O 0 3.3616378569689687e-09
results O 0 2.8522029182909137e-08
and O 0 9.221812202753199e-10
impact O 0 7.46737072176984e-09
of O 0 5.35165078918709e-10
these O 0 1.0575803566226227e-09
risk O 0 4.2980116177204764e-07
reversals O 0 6.533889518323122e-07
on O 0 1.0928768112705711e-08
both O 0 7.388655465234706e-09
patients O 0 1.8875243767979555e-06
and O 0 1.1618771500465641e-09
the O 0 4.100688677510789e-09
counseling O 0 9.245769660992664e-07
team O 0 3.581449137257664e-09
can O 0 9.612381723922425e-11
assist O 0 5.52714651824715e-10
in O 0 3.936767578593958e-10
the O 0 2.2277364675193922e-10
development O 0 1.0872626132751861e-09
of O 0 3.796531977684481e-10
strategies O 0 3.981415019893575e-08
for O 0 1.1690551859899756e-09
the O 0 8.50004155950046e-09
prevention O 0 4.832969352719374e-06
and O 0 1.2448182484803283e-09
, O 0 6.559081056067839e-10
where O 0 7.219683184622738e-10
necessary O 0 2.569966017773595e-09
, O 0 2.007241262091952e-09
management O 0 7.984383643133697e-08
of O 0 7.209624008908122e-10
a O 0 1.6744232311793894e-07
risk O 0 3.2337193260900676e-06
reversal O 0 5.935493732067698e-07
in O 0 5.900845367889929e-10
any O 0 2.733767656692976e-10
predictive O 0 2.539159993375506e-07
testing O 0 1.3343598084247787e-06
program O 0 1.1797599341889509e-07
. O 0 2.712702773521869e-08
. O 0 1.3361866990635463e-07

A O 0 1.563553996675182e-05
novel O 0 2.913521257141838e-06
common O 0 2.1123946680745576e-06
missense O 0 0.001183563843369484
mutation O 0 2.400276207481511e-05
G301C O 0 3.414715820326819e-06
in O 0 4.8364761084940255e-09
the O 0 4.8139279229530985e-09
N O 0 6.791009127482539e-06
- O 0 1.7990243577514775e-05
acetylgalactosamine O 0 0.00030880258418619633
- O 0 4.218839239911176e-05
6 O 0 1.2722061910608318e-06
- O 0 0.00012748768494930118
sulfate O 0 0.0007074507302604616
sulfatase O 0 0.007449522148817778
gene O 0 2.4544942789361812e-06
in O 0 3.0057628919166746e-07
mucopolysaccharidosis B-Disease 0 0.021353913471102715
IVA I-Disease 1 0.7484857439994812
. O 0 2.0372929157019826e-06

Mucopolysaccharidosis B-Disease 1 0.9928293824195862
IVA I-Disease 1 0.9991453886032104
( O 0 0.0002428456355119124
MPS B-Disease 1 0.9941230416297913
IVA I-Disease 1 0.9999140501022339
) O 0 8.44599298943649e-07
is O 0 1.1222757478890344e-07
an O 0 4.3405546534813766e-07
autosomal B-Disease 1 0.9704080820083618
recessive I-Disease 1 0.9985210299491882
lysosomal I-Disease 1 0.9998800754547119
storage I-Disease 1 0.998166024684906
disorder I-Disease 1 0.999896764755249
caused O 0 0.0005285892402753234
by O 0 2.628071911203733e-07
a O 0 2.4786315407254733e-05
genetic B-Disease 1 0.9256682991981506
defect I-Disease 1 0.9010359048843384
in O 0 1.8653902600362926e-07
N O 0 8.296419400721788e-05
- O 0 0.00015800775145180523
acetylgalactosamine O 0 0.005516109988093376
- O 0 0.0009542691987007856
6 O 0 2.794957072183024e-05
- O 0 0.02035975269973278
sulfate O 0 0.19266393780708313
sulfatase O 1 0.7720777988433838
( O 0 8.132329867294175e-07
GALNS O 0 0.0017078813398256898
) O 0 2.695996386137267e-07
. O 0 3.1199985528473917e-07

In O 0 7.179207273111388e-07
previous O 0 3.4427640116518887e-07
studies O 0 7.653473943491917e-08
, O 0 3.0669069506217284e-09
we O 0 2.0105585252228053e-10
have O 0 1.5511994466699264e-10
found O 0 5.717484818923424e-10
two O 0 5.045556750182811e-10
common O 0 1.4470701081847892e-08
mutations O 0 6.388926294675912e-07
in O 0 4.422026744776986e-09
Caucasians O 0 1.3812575616611866e-07
and O 0 2.5716919704876773e-09
Japanese O 0 1.1464795335314193e-07
, O 0 1.7453265499511872e-08
respectively O 0 4.808113089893595e-07
. O 0 2.537939849389659e-07

To O 0 2.5227754463230667e-07
characterize O 0 3.3088326745200902e-06
the O 0 7.653415678987585e-08
mutational O 0 8.477206574752927e-05
spectrum O 0 5.643468625748937e-07
in O 0 1.7923467154901118e-09
various O 0 3.130103953807861e-10
ethnic O 0 3.5810530096824778e-09
groups O 0 2.6285134069325977e-09
, O 0 2.6752435822174903e-09
mutations O 0 1.0825146290471821e-07
in O 0 4.916583251635132e-10
the O 0 9.859275618140373e-10
GALNS O 0 3.4647433494683355e-05
gene O 0 1.801471682938427e-07
in O 0 2.7804405888787187e-08
Colombian O 0 4.251013888278976e-05
MPS B-Disease 1 0.9798631072044373
IVA I-Disease 1 0.9999880790710449
patients O 0 0.004030375741422176
were O 0 3.797795855575714e-08
investigated O 0 2.0860254608123796e-06
, O 0 4.163882572072453e-09
and O 0 5.562759142208051e-09
genetic O 0 9.538734957459383e-07
backgrounds O 0 2.9611978646926218e-08
were O 0 1.0774813263836336e-09
extensively O 0 6.891136550279953e-09
analyzed O 0 8.396527917398089e-09
to O 0 7.168429738690918e-11
identify O 0 7.353335718107701e-10
racial O 0 3.2631863877696787e-09
origin O 0 8.429354991790206e-10
, O 0 5.135316616389218e-10
based O 0 6.371007610361801e-10
on O 0 4.947155463064234e-10
mitochondrial O 0 8.648931384414027e-07
DNA O 0 1.2017220797133632e-05
( O 0 1.489330347936857e-08
mtDNA O 0 3.951607538965618e-07
) O 0 1.5158541089022037e-08
lineages O 0 6.269010555115528e-07
. O 0 1.9913508708668815e-07

Three O 0 1.6969482885542675e-06
novel O 0 1.4268388440541457e-05
missense O 0 0.13776616752147675
mutations O 0 0.01374067272990942
never O 0 1.1183603874087567e-06
identified O 0 1.0863659838378226e-07
previously O 0 1.148749007029437e-08
in O 0 1.1872748340024941e-09
other O 0 3.1064384398149514e-10
populations O 0 8.642366822186887e-09
and O 0 5.839467243085039e-10
found O 0 7.690019176997964e-10
in O 0 2.2855821402156806e-10
16 O 0 9.0595020374451e-10
out O 0 1.17025486523481e-10
of O 0 3.4992439501557726e-10
19 O 0 1.4322823460588552e-07
Colombian O 0 5.224473170528654e-06
MPS B-Disease 0 0.41650286316871643
IVA I-Disease 1 0.9998996257781982
unrelated O 0 4.7446690587094054e-05
alleles O 0 1.008685330816661e-06
account O 0 2.801927401208104e-08
for O 0 1.4671188708348382e-08
84 O 0 5.718488864658866e-06
. O 0 4.836801394958457e-07

2 O 0 1.3071389730612282e-06
% O 0 5.84334998166014e-08
of O 0 2.912647234509791e-09
the O 0 5.833180605208099e-09
alleles O 0 8.034691489910983e-08
in O 0 9.100656228611115e-09
this O 0 4.87772000568043e-09
study O 0 2.1474933475928992e-07
. O 0 2.8158842724224087e-07

The O 0 4.2328386484769e-07
G301C O 0 2.7917445549974218e-05
and O 0 1.931788631281961e-07
S162F O 0 0.0003948747762478888
mutations O 0 3.536609801813029e-05
account O 0 5.885092591029206e-08
for O 0 5.373216893644894e-08
68 O 0 6.466940249083564e-06
. O 0 6.430167900361994e-07

4 O 0 8.425877240370028e-06
% O 0 7.314998811125406e-07
and O 0 7.80792461796409e-08
10 O 0 3.619868778059754e-07
. O 0 2.644179062372132e-07

5 O 0 1.8611838186188834e-06
% O 0 9.173699311304517e-08
of O 0 9.15759468256283e-09
mutations O 0 4.033616278320551e-06
, O 0 2.731897819074902e-09
respectively O 0 7.184712380592373e-09
, O 0 4.3879133659885383e-10
whereas O 0 2.6128379460033102e-09
the O 0 5.350742626752947e-10
remaining O 0 5.659937407642701e-09
F69V O 0 0.00012572148989420384
is O 0 1.987332964858979e-09
limited O 0 1.3136971510618878e-09
to O 0 1.4290207905887087e-10
a O 0 8.385164562696446e-09
single O 0 1.316819151497839e-07
allele O 0 1.814944539546559e-06
. O 0 2.63263473243569e-07

The O 0 4.900331305179861e-07
skewed O 0 5.3526737247011624e-06
prevalence O 0 3.2698681025067344e-05
of O 0 1.5843742318111254e-08
G301C O 0 7.831183211237658e-06
in O 0 9.015550084257029e-09
only O 0 1.5911602035956207e-09
Colombian O 0 6.723024625898688e-07
patients O 0 1.4719616956426762e-06
and O 0 2.3000583659893437e-09
haplotype O 0 3.3452413390477886e-06
analysis O 0 8.933489503704095e-09
by O 0 1.019084705511375e-09
restriction O 0 9.730338312863296e-09
fragment O 0 7.153920478231157e-08
length O 0 3.943610593637459e-08
polymorphisms O 0 1.3134878429355012e-07
in O 0 8.992825373255187e-10
the O 0 1.788818870807063e-09
GALNS O 0 0.0004288663330953568
gene O 0 4.5538882886830834e-07
suggest O 0 1.1862929305550551e-08
that O 0 3.18600062998442e-10
G301C O 0 2.9706347959290724e-07
originated O 0 4.4268877452680044e-09
from O 0 6.468744984111652e-10
a O 0 1.3333171011709055e-08
common O 0 5.101581734834326e-08
ancestor O 0 5.842330210725777e-07
. O 0 3.278914277871081e-07

Investigation O 0 1.2004494237771723e-05
of O 0 3.495565081834684e-08
the O 0 3.1150150903158647e-08
genetic O 0 1.2103595281587332e-06
background O 0 6.033622668155658e-08
by O 0 8.886156810383739e-10
means O 0 8.775513649084132e-10
of O 0 2.4243271279367207e-10
mtDNA O 0 7.149514402726709e-08
lineages O 0 5.313291495667727e-08
indicate O 0 1.4654631286248332e-08
that O 0 1.4970241712930488e-10
all O 0 1.302091628962998e-10
our O 0 1.2760414946910714e-08
patients O 0 7.121124099285225e-07
are O 0 3.301625084439763e-10
probably O 0 1.8576556959359891e-09
of O 0 8.353616687273302e-10
native O 0 3.420254657271471e-08
American O 0 2.867197679279343e-07
descent O 0 2.5209354134858586e-05

Low O 0 1.0983269021380693e-05
frequency O 0 2.6526249712333083e-06
of O 0 3.0215153401513817e-07
BRCA1 O 0 0.015074681490659714
germline O 0 0.01704489439725876
mutations O 0 0.0001530373265268281
in O 0 2.1212136402937176e-07
45 O 0 1.0016176929639187e-05
German O 1 0.9628665447235107
breast B-Disease 1 0.9999945163726807
/ I-Disease 1 0.9999847412109375
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999991774559021
families O 0 8.602222078479826e-05
. O 0 3.91371986552258e-06

In O 0 7.751373800601868e-07
this O 0 3.020224426109053e-08
study O 0 5.62822641825278e-08
we O 0 6.888087877854332e-09
investigated O 0 1.0403866781416582e-06
45 O 0 4.005938080808846e-06
German O 1 0.9659289717674255
breast B-Disease 1 0.999994158744812
/ I-Disease 1 0.9999887943267822
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999943971633911
families O 0 1.8765847471513553e-06
for O 0 2.12209371852623e-07
germline O 1 0.5998180508613586
mutations O 0 4.942730811308138e-05
in O 0 2.7602295560313905e-08
the O 0 1.5051647039854288e-07
BRCA1 O 0 0.008677310310304165
gene O 0 2.5113229639828205e-05
. O 0 8.864689107213053e-07

We O 0 9.627915460441727e-07
identified O 0 8.250027008216421e-07
four O 0 1.854174058735225e-07
germline O 0 0.014690905809402466
mutations O 0 0.0003521950857248157
in O 0 5.602905162049865e-07
three O 0 6.665592809440568e-05
breast B-Disease 1 0.9999351501464844
cancer I-Disease 1 0.9054349064826965
families O 0 1.2267901183804497e-07
and O 0 3.346924515312821e-08
in O 0 9.530151032777212e-07
one O 0 0.0031923723872750998
breast B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999986886978149
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999960660934448
family O 0 3.4639047044038307e-06
. O 0 1.961387052773489e-09
among O 0 3.3237460006496633e-10
these O 0 5.780510098363223e-11
were O 0 5.683431503200609e-10
one O 0 5.620821141860688e-09
frameshift O 0 0.007244812324643135
mutation O 0 8.021589565032627e-06
, O 0 2.3562740647520286e-09
one O 0 3.1223896801435558e-09
nonsense O 0 7.188948529801564e-06
mutation O 0 1.08230142359389e-06
, O 0 3.521889169189052e-10
one O 0 1.75349651465595e-10
novel O 0 3.786662094995563e-09
splice O 0 6.41661131339788e-07
site O 0 2.791132089896564e-07
mutation O 0 1.266634967578284e-06
, O 0 8.656154126818194e-10
and O 0 8.433568288168658e-10
one O 0 5.30484633998185e-08
missense O 0 0.0025012872647494078
mutation O 0 0.0002951802161987871
. O 0 6.587220013898332e-07

The O 0 5.145752311364049e-06
missense O 0 0.06443779915571213
mutation O 0 0.005066623445600271
was O 0 2.425208833756187e-07
also O 0 1.043100805731001e-08
found O 0 2.2683645184429224e-08
in O 0 1.747838318522099e-08
2 O 0 4.853028485740651e-07
. O 0 5.365166657611553e-07

8 O 0 1.2616631011042045e-06
% O 0 2.5340355591652042e-08
of O 0 8.286285546610372e-10
the O 0 1.2785744685217537e-09
general O 0 2.668944176775767e-09
population O 0 1.894677748026652e-09
, O 0 1.4511378765291738e-09
suggesting O 0 2.97115523295588e-08
that O 0 6.75382583192885e-10
it O 0 1.4476492227188942e-09
is O 0 2.3405979376889263e-08
not O 0 1.3511987617675913e-07
disease O 0 0.0067062899470329285
associated O 0 1.8875712157750968e-06
. O 0 3.457903403614182e-07

The O 0 7.210688863779069e-07
average O 0 5.99609029450221e-06
age O 0 1.9251783669460565e-06
of O 0 3.213743582364259e-07
disease O 0 0.10799010097980499
onset O 0 0.01605265960097313
in O 0 4.2916386888691704e-08
those O 0 6.035393518288856e-09
families O 0 3.482718398117868e-07
harbouring O 0 0.05718754604458809
causative O 0 0.03266797587275505
mutations O 0 9.670879080658779e-05
was O 0 2.1488695267635194e-08
between O 0 3.8106755084754695e-08
32 O 0 1.6012984360713745e-06
. O 0 3.349204860114696e-07

3 O 0 1.2394782970659435e-05
and O 0 7.473985306205577e-07
37 O 0 1.2554635759443045e-05
. O 0 2.293748138981755e-06

4 O 0 4.727921350422548e-06
years O 0 2.1983316855767043e-07
, O 0 3.1851636883573065e-09
whereas O 0 4.597014324758675e-09
the O 0 1.8834647175225427e-09
family O 0 7.236164378809917e-08
harbouring O 0 2.909742215706501e-05
the O 0 2.992608116869633e-08
missense O 0 0.0009451028308831155
mutation O 0 5.2922009672329295e-06
had O 0 1.366993296336716e-09
an O 0 2.8866464774068845e-10
average O 0 2.4635408379936052e-08
age O 0 1.4788906987917017e-08
of O 0 4.261066166577621e-09
onset O 0 0.00013472260616254061
of O 0 2.914332597470093e-08
51 O 0 9.935576599673368e-06
. O 0 3.8840676097606774e-07

2 O 0 3.233793540857732e-05
years O 0 5.338216851669131e-06
. O 0 3.1213753572956193e-06

These O 0 4.4823462985732476e-07
findings O 0 1.2074473261236562e-06
show O 0 1.351718168507432e-07
that O 0 2.601198723084508e-08
BRCA1 O 0 0.00036786054261028767
is O 0 1.8633130594025715e-08
implicated O 0 5.897227879358979e-07
in O 0 2.530585518911721e-09
a O 0 5.325301533076754e-09
small O 0 1.7372162375295375e-08
fraction O 0 4.49627322041124e-07
of O 0 6.863841463200515e-06
breast B-Disease 1 0.9999943971633911
/ I-Disease 1 0.9999947547912598
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999949932098389
families O 0 7.315591687984124e-07
suggesting O 0 1.6055189178132423e-07
the O 0 2.036674162653185e-09
involvement O 0 6.821359477271471e-08
of O 0 3.936019066230756e-09
another O 0 4.997672817808052e-07
susceptibility O 0 0.004417419899255037
gene O 0 3.0029548724996857e-05
( O 0 7.926727789708821e-07
s O 0 0.0006843993323855102
) O 0 1.4585832559532719e-06

Paternal O 0 0.11281105130910873
transmission O 1 0.9396395683288574
of O 0 0.08047118782997131
congenital B-Disease 1 0.9999665021896362
myotonic I-Disease 1 0.9999586343765259
dystrophy I-Disease 1 0.9999562501907349
. O 0 0.002313777571544051

We O 0 1.2388946970531833e-06
report O 0 1.8405746970984183e-07
a O 0 5.143320436218346e-08
rare O 0 3.8411127434301306e-07
case O 0 3.2756165069258714e-07
of O 0 3.91988777437291e-07
paternally O 1 0.9554688930511475
transmitted O 1 0.9994459748268127
congenital B-Disease 1 0.9999979734420776
myotonic I-Disease 1 0.9999972581863403
dystrophy I-Disease 1 0.9999972581863403
( O 0 0.047720763832330704
DM B-Disease 1 0.9999274015426636
) O 0 4.50827519671293e-06
. O 0 1.685668962636555e-06

The O 0 4.351172719907481e-07
proband O 0 9.95732334558852e-05
is O 0 2.016251876568731e-08
a O 0 3.891374689146687e-08
23 O 0 1.1879055250574311e-07
year O 0 6.813609587652536e-08
old O 0 9.92468721960904e-06
, O 0 1.5181159369603847e-06
mentally B-Disease 1 0.9986067414283752
retarded I-Disease 1 0.9879889488220215
male O 0 0.004542065318673849
who O 0 0.003146257484331727
suffers O 1 0.9998243451118469
severe O 1 0.9997640252113342
muscular B-Disease 1 0.9998730421066284
weakness I-Disease 1 0.9516614079475403
. O 0 1.2009991223749239e-05

He O 0 2.1399343950179173e-06
presented O 0 1.9009428342542378e-06
with O 0 3.3276426165684825e-06
respiratory O 1 0.9572633504867554
and O 0 6.746943768121128e-07
feeding O 0 8.994019299279898e-05
difficulties O 0 0.0001836489827837795
at O 0 9.994478205044288e-06
birth O 0 0.0004992192261852324
. O 0 2.0665734155045357e-06

His O 0 5.607306775345933e-06
two O 0 4.375892785901669e-06
sibs O 1 0.9633418917655945
suffer O 0 0.01094200648367405
from O 0 3.804317429967341e-06
childhood O 0 0.14890821278095245
onset O 1 0.9992153644561768
DM B-Disease 1 0.9998553991317749
. O 0 2.3969958419911563e-05

Their O 0 3.0175013421285257e-07
late O 0 5.437471486402501e-07
father O 0 1.911687519395855e-07
had O 0 4.879236570332068e-09
the O 0 1.1256511278645576e-09
adult O 0 7.967923210117078e-08
type O 0 4.2209867956444214e-07
of O 0 4.501494643704973e-08
DM B-Disease 1 0.9997469782829285
, O 0 9.921797605727534e-09
with O 0 1.2945402083630597e-08
onset O 0 9.915461851051077e-05
around O 0 2.3072567856274873e-08
30 O 0 8.923412053718494e-08
years O 0 1.1745095207515988e-07
. O 0 1.4347403975989437e-07

Only O 0 1.2148889538821095e-07
six O 0 3.636171896914675e-08
other O 0 1.3896966910564856e-09
cases O 0 6.4160090573750495e-09
of O 0 2.0762180863442836e-09
paternal O 0 1.5101169083209243e-05
transmission O 0 0.007697609718888998
of O 0 9.120610047830269e-05
congenital B-Disease 1 0.9999972581863403
DM I-Disease 1 0.9999957084655762
have O 0 2.9977213671372738e-06
been O 0 7.100441052898532e-07
reported O 0 9.278865945816506e-06
recently O 0 8.178987627616152e-06
. O 0 5.96685651998996e-07

We O 0 2.720673251133121e-07
review O 0 9.568530856540747e-08
the O 0 9.050577176594743e-09
sex O 0 1.1027016455500416e-07
related O 0 7.627796350107019e-08
effects O 0 1.7912239513862005e-07
on O 0 6.245058159493055e-08
transmission O 0 0.0002809905563481152
of O 0 3.898055729223415e-05
congenital B-Disease 1 0.9999818801879883
DM I-Disease 1 0.9999605417251587
. O 0 2.505588963686023e-05

Decreased O 0 0.0005258226301521063
fertility O 0 0.0003141365014016628
of O 0 4.001437403644559e-08
males O 0 4.606764036907407e-07
with O 0 5.8103200473169636e-08
adult O 0 3.133789141429588e-05
onset O 1 0.9808937311172485
DM B-Disease 1 0.9999548196792603
and O 0 5.052833174090665e-08
contraction O 0 1.5601432323819608e-06
of O 0 4.759420635380707e-10
the O 0 1.2870009502563562e-09
repeat O 0 1.0097827640720425e-07
upon O 0 2.4009425558801922e-09
male O 0 1.7304937216522376e-07
transmission O 0 8.419775667789509e-07
contribute O 0 2.1241168823848966e-09
to O 0 7.136098656435053e-11
the O 0 3.667847692234716e-10
almost O 0 1.0959866347803882e-09
absent O 0 1.4803864800683186e-08
occurrence O 0 3.363467371286788e-08
of O 0 3.0352955704415763e-09
paternal O 0 3.268991713412106e-05
transmission O 0 0.0043300543911755085
of O 0 0.00021182515774853528
congenital B-Disease 1 0.999988317489624
DM I-Disease 1 0.9999642372131348
. O 0 3.720990935107693e-05

Also O 0 2.3284691508251854e-07
the O 0 1.6284811721334336e-08
fathers O 0 7.730940154715427e-08
of O 0 3.3662832521486052e-09
the O 0 4.573674061703059e-08
reported O 0 5.831803719047457e-06
congenitally O 0 0.00039918397669680417
affected O 0 2.1785423598430498e-07
children O 0 4.738357262112913e-08
showed O 0 1.2397651971696177e-07
, O 0 4.4971479318256513e-10
on O 0 2.3398867288193514e-09
average O 0 6.122819939946567e-08
, O 0 5.956847015653466e-09
shorter O 0 1.5128263157748734e-06
CTG O 0 0.00017718654999043792
repeat O 0 5.203668024478247e-06
lengths O 0 6.4860623751883395e-06
and O 0 4.51187620598148e-09
hence O 0 1.612297779729488e-07
less O 0 7.522955911554163e-07
severe O 0 0.4615352749824524
clinical O 0 0.1878512054681778
symptoms O 0 0.009165837429463863
than O 0 9.893074803812851e-09
the O 0 1.0554087381819954e-08
mothers O 0 2.2308609004539903e-06
of O 0 7.634619159091471e-09
children O 0 2.3918787519505713e-06
with O 0 0.0009969571838155389
congenital B-Disease 1 0.9999901056289673
DM I-Disease 1 0.9999749660491943
. O 0 4.884408917860128e-05

We O 0 1.0346053613830009e-06
conclude O 0 1.4639596201959648e-06
that O 0 3.2934394766925834e-08
paternal O 0 3.759964238270186e-05
transmission O 0 0.005343220196664333
of O 0 0.00012615167361218482
congenital B-Disease 1 0.9999969005584717
DM I-Disease 1 0.9999961853027344
is O 0 1.1604646488194703e-06
rare O 0 6.582824312317825e-07
and O 0 8.571252152478337e-09
preferentially O 0 6.500556537503144e-07
occurs O 0 3.256957370467717e-08
with O 0 6.834210974915322e-09
onset O 0 5.946090095676482e-05
of O 0 5.032461913856423e-08
DM B-Disease 1 0.9971557855606079
past O 0 5.645945222454429e-08
30 O 0 1.6864513341374732e-08
years O 0 2.5589019791993906e-09
in O 0 6.803798635601765e-10
the O 0 1.7570898069863006e-09
father O 0 6.490713388984659e-08
. O 0 1.594341547672684e-08
. O 0 9.753512841825795e-08

The O 0 7.687601282668766e-06
RB1 O 0 0.29177790880203247
gene O 0 0.0001353712286800146
mutation O 0 0.00012910373334307224
in O 0 8.24428028067814e-08
a O 0 2.3696526341154822e-07
child O 0 1.8778195226332173e-05
with O 0 7.360143627010984e-06
ectopic B-Disease 1 0.9990078806877136
intracranial I-Disease 1 0.9998132586479187
retinoblastoma I-Disease 1 0.9956068396568298
. O 0 2.3728649466647767e-05

The O 0 2.1770022158307256e-06
RB1 O 0 0.257472962141037
gene O 0 0.0001712431840132922
mutation O 0 0.0004913812736049294
was O 0 2.2641462749106722e-07
investigated O 0 1.4575958857676596e-06
in O 0 1.1884807804563025e-08
a O 0 1.1272484812252515e-07
child O 0 5.02035754834651e-06
with O 0 5.612681661659735e-07
ectopic B-Disease 1 0.9001155495643616
intracranial I-Disease 1 0.9933479428291321
retinoblastoma I-Disease 0 0.0031216936185956
using O 0 7.08554708239717e-08
DNA O 0 9.382310395267268e-07
obtained O 0 3.993612551767001e-09
from O 0 2.587434988488013e-10
both O 0 2.2872391480799337e-10
the O 0 3.9212872948724e-09
pineal B-Disease 0 0.00010009062680182979
and I-Disease 0 6.923112323420355e-07
retinal I-Disease 1 0.978317379951477
tumours I-Disease 1 0.9995995163917542
of O 0 7.508607069439677e-08
the O 0 1.3154450471120072e-06
patient O 0 0.001223395112901926
. O 0 1.0436639286126592e-06

A O 0 2.0651134036597796e-05
nonsense O 0 0.0002079655387206003
mutation O 0 0.00012739471276290715
in O 0 9.98984006628234e-08
exon O 0 2.3239677830133587e-05
17 O 0 1.0171533659786292e-07
( O 0 2.550695876735176e-09
codon O 0 4.0287311264819436e-08
556 O 0 3.0063041833727766e-08
) O 0 2.7074018027484215e-10
of O 0 2.157631712185193e-10
the O 0 4.596233615927758e-09
RB1 O 0 0.00048179866280406713
gene O 0 1.010601664575006e-07
was O 0 3.62825836042191e-09
found O 0 4.25133817039125e-10
to O 0 2.6021476640103458e-11
be O 0 3.0598457795294465e-11
present O 0 4.0584663407727817e-10
homozygously O 0 2.0260763449186925e-06
in O 0 6.845100597452358e-10
both O 0 2.5956897742318574e-10
the O 0 5.801878533162608e-09
retinal B-Disease 0 9.166480595013127e-05
and I-Disease 0 2.550074640339517e-08
the I-Disease 0 8.965530469140504e-07
pineal I-Disease 1 0.7343002557754517
tumours I-Disease 1 0.9996126294136047
. O 0 8.1481812230777e-06

The O 0 5.46815783764032e-07
same O 0 1.3464341463986784e-07
mutation O 0 7.409223599097459e-06
was O 0 1.612556843610946e-08
present O 0 4.5275485582862984e-09
heterozygously O 0 6.46124408376636e-06
in O 0 2.7882247621846545e-09
the O 0 1.2256360371054598e-09
DNA O 0 3.3939553389927823e-08
from O 0 1.656959847107231e-10
the O 0 1.7553938858050344e-10
constitutional O 0 8.717595534335487e-09
cells O 0 8.291491049305932e-09
of O 0 2.2179426351076614e-10
the O 0 8.39134006724862e-09
patient O 0 8.644199624541216e-06
, O 0 3.6319973695242425e-09
proving O 0 4.4236574581191235e-07
it O 0 2.7719868067599407e-10
to O 0 6.775641159251222e-11
be O 0 3.643992330104595e-10
of O 0 3.840355589090905e-09
germline O 0 0.000211491365917027
origin O 0 1.849612090154551e-07
. O 0 5.792957153971656e-07

The O 0 1.0830398196048918e-06
initial O 0 4.186392288829666e-06
mutation O 0 2.268835851282347e-05
was O 0 1.6966694715847552e-08
shown O 0 3.425482342223063e-09
to O 0 1.3180560809455955e-10
have O 0 3.886386212847981e-10
occurred O 0 1.701050322822084e-08
in O 0 2.347938510283143e-09
the O 0 5.962780935675482e-09
paternally O 0 1.3288585250847973e-05
derived O 0 8.744725050746638e-07
RB1 O 0 0.0053609637543559074
allele O 0 6.3525849327561446e-06
. O 0 6.34350669770356e-07

The O 0 9.91949036688311e-07
mutation O 0 4.5004791900282726e-05
is O 0 6.014524434050372e-09
in O 0 6.199278868024294e-10
an O 0 1.1176557596082048e-10
area O 0 1.0005944961477553e-09
of O 0 8.231367670807899e-11
the O 0 2.940892251945826e-10
gene O 0 1.7378085637176355e-09
that O 0 2.018957917515607e-11
encodes O 0 4.2705913805285434e-10
the O 0 2.2380171327274212e-10
protein O 0 1.7627971971023726e-08
- O 0 8.294655913232418e-07
binding O 0 2.5535108250096528e-08
region O 0 1.2247159730804924e-08
known O 0 1.8520623923379276e-09
as O 0 1.4314269214388275e-10
the O 0 8.981083099435239e-10
pocket O 0 7.646114681847394e-06
region O 0 2.408107491191913e-08
and O 0 1.6447497808158573e-09
has O 0 2.4508757245911283e-09
been O 0 1.424895534896109e-09
detected O 0 8.729929135142811e-08
in O 0 5.074655695658237e-10
other O 0 2.7120533596658447e-10
cases O 0 1.1781460251825138e-08
of O 0 8.07424616056096e-09
retinoblastoma B-Disease 0 0.00424175476655364
. O 0 1.070543902415011e-07
. O 0 3.497673617403052e-07

Low O 0 3.586564344004728e-05
levels O 0 6.372921461661463e-07
of O 0 1.8162584325409625e-08
beta O 0 8.245363005698891e-07
hexosaminidase O 0 1.9032038835575804e-05
A O 0 4.242116915520455e-07
in O 0 2.710277335893352e-08
healthy O 0 6.235691216716077e-07
individuals O 0 5.906478861561482e-09
with O 0 1.8407132529318915e-07
apparent O 0 0.08478082716464996
deficiency O 1 0.8887583613395691
of O 0 7.524016076843054e-09
this O 0 1.5812647191637552e-08
enzyme O 0 4.828901182918344e-06
. O 0 3.308638838461775e-07

Appreciable O 0 0.0006203619414009154
beta O 0 0.0002435500646242872
hexosaminidase O 0 0.0006123704370111227
A O 0 1.0349024250899674e-06
( O 0 1.3418048894209278e-08
hex O 0 4.4848690095022903e-07
A O 0 2.9865695694297756e-08
) O 0 1.8229557863236323e-09
activity O 0 3.2716247488906447e-09
has O 0 6.63682775403629e-10
been O 0 8.222678649083548e-10
detected O 0 3.8927627343809945e-08
in O 0 1.927743742413668e-09
cultured O 0 1.0625001323205652e-06
skin O 0 0.00031702936394140124
fibroblasts O 0 1.0403000487713143e-05
and O 0 5.662365765601862e-06
melanoma B-Disease 1 0.9999654293060303
tissue O 0 0.0016649613389745355
from O 0 4.55151756284522e-08
healthy O 0 1.6901179833439528e-06
individuals O 0 7.644950450469423e-09
previously O 0 2.0476444717587583e-07
reported O 0 8.642203397357662e-07
as O 0 1.6744671427204594e-08
having O 0 1.76120283867931e-06
deficiency B-Disease 0 0.004033084958791733
of I-Disease 0 8.620597569120036e-10
hex I-Disease 0 7.36871584194887e-07
A I-Disease 0 1.2813241134779219e-08
activity O 0 1.8340742258260434e-09
indistinguishable O 0 6.576345690234575e-09
from O 0 3.6250330515130713e-10
that O 0 1.2483698796916798e-10
of O 0 5.1251420885023435e-09
patients O 0 7.30977626517415e-05
with O 0 0.00073617062298581
Tay B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999926090240479
Sachs I-Disease 1 0.9999790191650391
disease I-Disease 1 0.992544412612915
( O 0 3.7752126900159055e-06
TSD B-Disease 1 0.5706272721290588
) O 0 6.2029869241087e-07
. O 0 5.949684691586299e-07

Identification O 0 7.143964467104524e-06
and O 0 1.2474743016355205e-07
quantitation O 0 0.00014422080130316317
of O 0 2.5324023766870596e-08
hex O 0 8.553814041079022e-06
A O 0 2.0083132312720409e-07
, O 0 4.1462571154227135e-09
amounting O 0 4.4833633694452146e-08
to O 0 4.91444840378108e-09
3 O 0 2.9882110652579286e-07
. O 0 2.2569930990812281e-07

5 O 0 1.2603759387275204e-05
% O 0 2.642517983986181e-06
- O 0 0.0001221857819473371
6 O 0 4.721252480521798e-06
. O 0 1.6644025890855119e-06

9 O 0 2.2269709916145075e-06
% O 0 2.3209308253058225e-08
of O 0 1.4100016709761576e-09
total O 0 6.46221209876785e-09
beta O 0 2.634812403812248e-07
hexosaminidase O 0 6.0291235968179535e-06
activity O 0 1.5348025073080862e-08
, O 0 6.562810295207555e-10
has O 0 4.865693403743876e-10
been O 0 1.848740327492493e-10
obtained O 0 7.834455861832623e-10
by O 0 1.1035549141169554e-09
cellulose O 0 2.399390723439865e-06
acetate O 0 6.3717584453115705e-06
gel O 0 6.506674981210381e-05
electrophoresis O 0 1.8424063455313444e-05
, O 0 7.272940028002495e-09
DEAE O 0 1.2256059562787414e-05
- O 0 3.376894028406241e-06
cellulose O 0 6.7712971940636635e-06
ion O 0 6.420127192541258e-06
- O 0 5.531994247576222e-06
exchange O 0 3.841529760961748e-08
chromatography O 0 6.1605383052665275e-06
, O 0 7.922759337475327e-09
radial O 0 1.2744582818413619e-05
immunodiffusion O 0 9.406836034031585e-05
, O 0 2.70877862362795e-08
and O 0 4.338815884352698e-08
radioimmunoassay O 0 0.0010907113319262862
. O 0 1.404860995535273e-06

Previous O 0 9.597291864338331e-06
family O 0 6.8835984166071285e-06
studies O 0 4.3214060951868305e-07
suggested O 0 9.575651205295799e-08
that O 0 8.294049336221576e-10
these O 0 3.475901788618785e-10
individuals O 0 2.0162085334618496e-09
may O 0 5.764023480736569e-09
be O 0 2.241426350080289e-10
compound O 0 4.0179948257446085e-08
heterozygotes O 0 1.0446638043504208e-06
for O 0 5.88453730188121e-10
the O 0 1.5449699297676034e-09
common O 0 1.763880241867355e-08
mutant O 0 6.2994708969199564e-06
TSD B-Disease 0 0.007973414845764637
gene O 0 3.535043902047619e-07
and O 0 3.1677513945282954e-09
a O 0 2.427679746119793e-08
rare O 0 9.748974605372496e-08
( O 0 1.0750635937029074e-08
allelic O 0 1.3821308129990939e-05
) O 0 3.9826073106041804e-08
mutant O 0 2.264776048832573e-05
gene O 0 6.145005954749649e-06
. O 0 4.456202020719502e-07

Thus O 0 1.3776807463727891e-06
, O 0 3.833456574398042e-08
the O 0 1.5103850614650582e-08
postulated O 0 1.030597445605963e-06
rate O 0 2.149050430944044e-07
mutant O 0 5.731257601837569e-07
gene O 0 1.3322524239356426e-07
appears O 0 6.302830257709502e-09
to O 0 4.112150897572775e-11
code O 0 2.81376560939961e-10
for O 0 4.239521581017591e-11
the O 0 6.265965524221428e-11
expression O 0 6.581135636452018e-10
of O 0 4.6072817783127107e-10
low O 0 1.0136227501789108e-07
amounts O 0 4.831552047335208e-09
of O 0 9.756387919779286e-10
hex O 0 2.6612246983859222e-06
A O 0 5.318574380908103e-07
. O 0 2.1767480973267084e-07

Heterozygotes O 0 0.0006074772099964321
for O 0 1.1528221222079083e-07
the O 0 6.114020578706914e-08
rare O 0 6.49738922220422e-07
mutant O 0 6.8225049290049355e-06
may O 0 1.742625599376879e-08
be O 0 2.3987076214204706e-10
indistinguishable O 0 1.4330400865958381e-08
from O 0 1.636688451434054e-09
heterozygotes O 0 4.6689015675838164e-07
for O 0 1.134505600575153e-09
the O 0 8.627625724955124e-09
common O 0 8.073677690845216e-07
TSD B-Disease 0 0.09852095693349838
mutant O 0 0.0003792236384470016
. O 0 1.0265412129228935e-06

However O 0 1.7523490214443882e-07
, O 0 7.528480061580467e-09
direct O 0 3.734403009048037e-09
visualization O 0 1.5191777436029952e-07
and O 0 3.834726758356055e-09
quantitation O 0 1.912364677991718e-05
of O 0 5.2045012743917596e-09
hex O 0 1.6953193835433922e-06
A O 0 3.991497266042643e-08
by O 0 1.272079774849999e-09
the O 0 1.992414899731898e-09
methods O 0 3.302661255588646e-08
described O 0 4.2617310214154713e-07
may O 0 4.742362591514393e-08
prevent O 0 2.7256643875261943e-07
false O 0 6.025354082339618e-07
- O 0 6.533740815939382e-05
positive O 0 1.0000859163028508e-07
prenatal O 0 0.030987264588475227
diagnosis O 0 0.022156143561005592
of O 0 7.399433599175609e-08
TSD B-Disease 0 0.2547972798347473
in O 0 4.507457447289198e-07
fetuses O 0 0.00014992286742199212
having O 0 2.6290763344150037e-08
the O 0 4.2451495652073845e-09
incomplete O 0 5.711800099561515e-07
hex B-Disease 0 4.1843530198093504e-05
A I-Disease 0 2.0157376638962887e-05
deficiency I-Disease 0 0.052692193537950516
of O 0 2.5104853751400924e-09
the O 0 6.899553817163451e-09
type O 0 9.728836403155583e-07
described O 0 2.8679574270995545e-08
in O 0 2.623104400356624e-09
the O 0 3.0470823642048117e-09
four O 0 8.293534392578295e-08
healthy O 0 7.679042937525082e-06
individuals O 0 9.93956632555637e-07

The O 0 6.81410438119201e-06
tumor B-Disease 0 0.15293484926223755
suppressor O 0 0.0005685035139322281
gene O 0 1.7040698367054574e-05
Smad4 O 0 0.0009769767057150602
/ O 0 2.5984178137150593e-05
Dpc4 O 0 5.6690922065172344e-05
is O 0 4.1144145868088344e-09
required O 0 2.7417061954082556e-09
for O 0 7.454445949406363e-10
gastrulation O 0 2.4952119019872043e-06
and O 0 2.1582584608381694e-09
later O 0 2.3917188229916064e-09
for O 0 1.5239793871302254e-09
anterior O 0 1.8420427295495756e-05
development O 0 9.401369460704245e-09
of O 0 1.6784377221412683e-09
the O 0 1.7565477961056786e-08
mouse O 0 1.4330792510008905e-05
embryo O 0 2.7097299607703462e-05
. O 0 4.232079504618014e-07

Mutations O 0 0.006306725554168224
in O 0 4.927619556838181e-07
the O 0 2.504800420410902e-07
SMAD4 O 0 0.03059646487236023
/ O 0 0.000847797142341733
DPC4 O 1 0.5167354345321655
tumor B-Disease 0 0.4764399230480194
suppressor O 0 3.0792569305049255e-05
gene O 0 1.3833773948590533e-07
, O 0 6.221963499974947e-10
a O 0 8.984475385886981e-10
key O 0 1.679770100793121e-09
signal O 0 5.067713360062953e-09
transducer O 0 2.0311671278250287e-07
in O 0 1.899830737173147e-09
most O 0 1.1626286600119329e-09
TGFbeta O 0 7.306695624720305e-05
- O 0 1.3539202882384416e-05
related O 0 3.182608665497355e-08
pathways O 0 2.995341219502734e-07
, O 0 1.1917261621974262e-09
are O 0 1.187550474623933e-10
involved O 0 8.806885776202478e-10
in O 0 9.460653371817784e-10
50 O 0 1.5256116370210293e-08
% O 0 6.421214493457228e-08
of O 0 3.199451839464018e-06
pancreatic B-Disease 1 0.9999219179153442
cancers I-Disease 1 0.999595582485199
. O 0 5.38777112524258e-06

Homozygous O 0 0.00550453644245863
Smad4 O 0 0.13513028621673584
mutant O 0 0.0827999860048294
mice O 0 0.17663483321666718
die O 0 0.00019863518537022173
before O 0 7.864677087354721e-08
day O 0 8.351968006081734e-08
7 O 0 4.29638078003336e-07
. O 0 2.200504667371206e-07

5 O 0 8.179236829164438e-06
of O 0 1.0505502814339707e-06
embryogenesis O 0 0.00037705496652051806
. O 0 1.0669134098861832e-05

Mutant O 0 7.207183807622641e-05
embryos O 0 1.6264179066638462e-05
have O 0 1.4290120020632457e-07
reduced O 0 1.2908844837511424e-06
size O 0 7.097963248270389e-07
, O 0 1.2493859280482411e-08
fail O 0 2.443989899347798e-07
to O 0 7.946909241773881e-10
gastrulate O 0 2.1147101506358013e-05
or O 0 8.753668012673188e-09
express O 0 2.5249653035075426e-08
a O 0 2.1560870422376865e-08
mesodermal O 0 3.768636815948412e-05
marker O 0 1.2166158285253914e-06
, O 0 1.4224841304866231e-09
and O 0 1.2112275626918745e-09
show O 0 6.41695407921361e-08
abnormal O 0 1.2524596058938187e-05
visceral O 0 1.6325651813531294e-05
endoderm O 0 0.0009426640463061631
development O 0 2.120872977684485e-06
. O 0 7.225433478197374e-07

Growth B-Disease 0 0.4575406014919281
retardation I-Disease 1 0.9366492033004761
of O 0 9.727150285243624e-08
the O 0 3.8335667795763584e-07
Smad4 O 0 0.08125299215316772
- O 0 0.029081881046295166
deficient O 0 0.001571301487274468
embryos O 0 5.283817472445662e-07
results O 0 4.440217082901654e-08
from O 0 1.0565118779837235e-09
reduced O 0 6.10255668220816e-08
cell O 0 1.1702579740813235e-06
proliferation O 0 3.1079710538506333e-07
rather O 0 1.551803796573381e-09
than O 0 1.949823857927413e-09
increased O 0 1.9770791936934984e-07
apoptosis O 0 3.188606569892727e-05
. O 0 3.985609851042682e-07

Aggregation O 0 1.2230523680045735e-05
of O 0 2.036337889421702e-07
mutant O 0 7.287032349267974e-05
Smad4 O 0 0.0018079025903716683
ES O 0 0.00010304628813173622
cells O 0 1.7367808595736278e-06
with O 0 2.2819950373786924e-08
wild O 0 7.819771781214513e-07
- O 0 2.7282201699563302e-05
type O 0 1.2537541351775872e-06
tetraploid O 0 7.123801333364099e-05
morulae O 0 0.0019689202308654785
rescues O 0 0.0001686974719632417
the O 0 4.230949457451061e-07
gastrulation B-Disease 0 0.06517737358808517
defect I-Disease 0 0.05256947502493858
. O 0 2.2786125555285253e-06

These O 0 4.800671717930527e-07
results O 0 2.9401351184787927e-06
indicate O 0 2.1299830166299216e-07
that O 0 2.2774977459505408e-09
Smad4 O 0 6.203203611221397e-06
is O 0 2.182075409251638e-09
initially O 0 3.23143134473014e-09
required O 0 2.5843474582565307e-10
for O 0 6.568754568059276e-11
the O 0 1.457911985580651e-10
differentiation O 0 3.6776148792938557e-09
of O 0 1.2989066766611046e-10
the O 0 7.684125558071742e-10
visceral O 0 3.500162790714967e-07
endoderm O 0 2.1503314201254398e-05
and O 0 3.1743438988485195e-09
that O 0 4.742077286401525e-10
the O 0 8.389835493005648e-09
gastrulation B-Disease 0 0.000548958545550704
defect I-Disease 0 0.00019360228907316923
in O 0 8.747142565823651e-09
the O 0 5.4646211999909156e-09
epiblast O 0 0.00031271600164473057
is O 0 2.8636923943281545e-09
secondary O 0 3.2444827269273446e-08
and O 0 2.3636022028483694e-09
non O 0 1.8989591410445428e-07
- O 0 0.00014155123790260404
cell O 0 4.389573950902559e-05
autonomous O 0 2.771382014543633e-06
. O 0 3.076901862186787e-07

Rescued O 0 0.0007915511960163713
embryos O 0 0.00043854134855791926
show O 0 3.346718585817143e-05
severe O 0 0.12903350591659546
anterior O 0 0.055560287088155746
truncations O 0 0.019977960735559464
, O 0 1.851389157536687e-07
indicating O 0 4.779666937793081e-07
a O 0 1.0855515597540943e-08
second O 0 3.4760563316638127e-09
important O 0 4.6205528292375675e-10
role O 0 2.847906799274824e-09
for O 0 2.765956796935143e-09
Smad4 O 0 4.921166328131221e-05
in O 0 1.2092145595943293e-07
anterior O 0 0.0012035754043608904
patterning O 0 0.000835699203889817
during O 0 4.727759005618282e-06
embryogenesis O 0 0.00029071548487991095
. O 0 2.6406160031910986e-06

Prevalence O 0 0.0005045979632996023
of O 0 4.040143437578081e-07
p16 O 0 2.3965707441675477e-05
and O 0 1.343056226232875e-07
CDK4 O 0 0.0059434580616652966
germline O 0 0.3198540210723877
mutations O 0 0.002423421945422888
in O 0 2.0958200366294477e-06
48 O 0 0.004366528242826462
melanoma B-Disease 1 0.9999788999557495
- O 0 0.38241156935691833
prone O 0 0.0010549572762101889
families O 0 7.937101287325277e-08
in O 0 8.995629485752943e-08
France O 0 7.12931114321691e-06
. O 0 5.141094447935757e-07

The O 0 1.1389820429030806e-05
French O 0 0.0033146333880722523
Familial B-Disease 1 0.9995360374450684
Melanoma I-Disease 1 0.9999147653579712
Study O 0 9.505620982963592e-05
Group O 0 1.0945144822471775e-05
. O 0 1.1260154906267417e-06

Germline O 1 0.8833943605422974
mutations O 0 0.0024851448833942413
in O 0 1.2035289387313242e-07
the O 0 2.3216390587776914e-08
p16 O 0 2.4951546038209926e-06
and O 0 1.0682773776693466e-08
CDK4 O 0 5.482706910697743e-05
genes O 0 5.843729056209668e-08
have O 0 9.754825835983638e-10
been O 0 1.2057578269164537e-09
reported O 0 7.87310749927883e-09
in O 0 1.4012101201554827e-10
a O 0 1.9698149777980234e-09
subset O 0 5.543410708241936e-08
of O 0 5.6430387473938026e-08
melanoma B-Disease 1 0.9957713484764099
pedigrees O 0 1.6052545106504112e-05
, O 0 4.195212177648955e-09
but O 0 9.818440505071635e-10
their O 0 3.150506300286793e-09
prevalence O 0 1.5237063053064048e-05
is O 0 2.9107534160743853e-09
not O 0 4.4676182198166714e-10
well O 0 4.245538143266003e-09
known O 0 1.1116957665535665e-07
. O 0 2.286417810637431e-07

We O 0 3.6093689459448797e-07
searched O 0 1.3852984466211637e-06
for O 0 1.4240539414345221e-08
such O 0 2.2858328563302166e-08
germline O 0 0.005641884636133909
mutations O 0 3.097283479291946e-05
in O 0 6.766209992292715e-08
48 O 0 6.516901521536056e-06
French O 0 0.008626420982182026
melanoma B-Disease 1 0.9999843835830688
- O 0 0.26128721237182617
prone O 0 0.00028423406183719635
families O 0 1.0736025402025007e-08
selected O 0 1.4701321271459733e-09
according O 0 3.8206712793531494e-10
to O 0 3.8245698275041207e-11
two O 0 1.350886347228908e-10
major O 0 5.390890844836349e-09
criteria O 0 3.2699041696560016e-08
families O 0 2.950552024927333e-09
with O 0 3.2499560820298257e-09
at O 0 1.766122359470046e-08
least O 0 1.3759107186928077e-09
three O 0 2.094802331598089e-09
affected O 0 4.346980997382843e-09
members O 0 1.095347146318204e-09
( O 0 6.940271912725393e-09
n O 0 1.8988409919984406e-06
= O 0 6.170872097754909e-07
20 O 0 2.556696632183275e-09
) O 0 2.995500514302307e-10
or O 0 3.6248395951510304e-10
families O 0 6.162732546499683e-10
with O 0 6.031224408786784e-10
two O 0 8.769958093068908e-10
affected O 0 1.994076237465947e-09
members O 0 1.4179109275591628e-10
, O 0 6.490010612258956e-11
one O 0 4.461995356530579e-11
of O 0 3.4793428554946715e-11
them O 0 6.519476625221898e-11
affected O 0 8.143407059790775e-10
before O 0 2.5395782699000335e-10
the O 0 1.2228659751478688e-10
age O 0 6.808484886988708e-10
of O 0 7.684942959773622e-11
50 O 0 1.2617037414841548e-09
( O 0 8.492518355218692e-10
n O 0 5.11741916398023e-07
= O 0 4.997290830033307e-07
28 O 0 1.06023483326112e-08
) O 0 2.477986982274416e-10
, O 0 1.2320809650301356e-10
and O 0 2.606316273912057e-10
one O 0 1.125814219626875e-09
additional O 0 1.7435629828810306e-08
minor O 0 1.2441976650734432e-05
criterion O 0 4.291280856705271e-05
. O 0 1.3045722653259872e-06

Sixteen O 0 3.433865686019999e-06
different O 0 2.069577504926201e-07
p16 O 0 0.00028208544244989753
germline O 0 0.027322273701429367
mutations O 0 0.00021759689843747765
were O 0 1.9985627375262993e-08
found O 0 9.297796310647755e-09
in O 0 9.328416927800731e-10
21 O 0 5.20438225848352e-09
families O 0 1.1843435121505763e-09
, O 0 4.016374455240168e-10
while O 0 6.970647947746045e-10
one O 0 3.6982388262885024e-09
germline O 0 0.000433712120866403
mutation O 0 7.136541626096005e-06
, O 0 3.7113325745963266e-09
Arg24His O 0 1.7505211872048676e-05
, O 0 4.7366741640075816e-09
was O 0 1.3062122938833909e-08
detected O 0 9.04845762761397e-08
in O 0 1.5872892999979626e-09
the O 0 1.01947401631719e-08
CDK4 O 0 0.0032402740325778723
gene O 0 1.291277749260189e-05
. O 0 3.428655190873542e-07

The O 0 6.392765783402865e-08
frequency O 0 1.222916665710727e-07
of O 0 1.0314656684329293e-08
p16 O 0 2.7248970582149923e-05
gene O 0 4.009523308923235e-06
mutation O 0 4.046207322971895e-06
in O 0 2.3532737980502816e-09
our O 0 1.1685423739749012e-09
sample O 0 2.6234145966697042e-09
( O 0 5.678945091958099e-10
44 O 0 4.535976039221623e-09
% O 0 8.609128410164146e-10
) O 0 1.6001831804057787e-10
is O 0 9.357887381655772e-11
among O 0 9.945528428589867e-11
the O 0 6.776187388979338e-10
highest O 0 9.193963705911301e-07
rates O 0 2.2089633944233356e-07
yet O 0 7.522953815453093e-09
reported O 0 1.3936232612365984e-08
and O 0 2.1019734564031722e-10
the O 0 3.006314308606761e-09
CDK4 O 0 0.00410126056522131
mutation O 0 2.9960719984956086e-06
is O 0 5.062928409849121e-10
the O 0 7.335111407158479e-10
second O 0 1.0812558315365095e-07
mutation O 0 1.027539292408619e-05
detected O 0 5.153326583240414e-07
in O 0 1.6660369750454151e-09
this O 0 1.1307553782202717e-09
gene O 0 8.27417920845619e-08
worldwide O 0 1.6788860079941514e-07
. O 0 2.4637174078634416e-07

In O 0 8.20216484953562e-07
summary O 0 3.8751582565055287e-07
, O 0 1.4928740910136185e-08
our O 0 5.031365102325935e-09
results O 0 1.9358212810516306e-08
show O 0 1.7946970576332433e-09
frequent O 0 8.835728593226122e-09
involvement O 0 8.061012302107429e-09
of O 0 3.988723240588854e-10
the O 0 2.810704113898055e-09
p16 O 0 1.9704414171428652e-06
gene O 0 6.855558467577794e-07
in O 0 5.157422151569335e-07
familial B-Disease 1 0.9972636699676514
melanoma I-Disease 1 0.9999139308929443
and O 0 2.4564789313785695e-08
confirm O 0 1.1768995555883066e-08
the O 0 3.3151986711388304e-10
role O 0 1.0807209571694898e-09
of O 0 1.8743540053378638e-10
the O 0 1.6769210464673279e-09
CDK4 O 0 6.72995374770835e-05
gene O 0 1.1497643725988382e-07
as O 0 7.215157804552064e-09
a O 0 1.3954305359220598e-05
melanoma B-Disease 1 0.9998977184295654
- O 0 0.010037252679467201
predisposing O 0 0.00013845473586115986
gene O 0 8.57392205944052e-06
. O 0 7.800913692790346e-08
. O 0 3.098435854553827e-07

Progression O 0 0.0001817182928789407
of O 0 2.1317896425898653e-07
somatic O 0 6.958630547160283e-05
CTG O 0 0.005543846637010574
repeat O 0 1.9681652702274732e-05
length O 0 9.216050216309668e-07
heterogeneity O 0 2.4610997115814826e-06
in O 0 1.1199294824848494e-08
the O 0 1.3204630278096374e-08
blood O 0 1.3137565474607982e-05
cells O 0 3.3352964237565175e-05
of O 0 1.3882114217267372e-05
myotonic B-Disease 1 0.9999666213989258
dystrophy I-Disease 1 0.9999899864196777
patients O 1 0.9853159785270691
. O 0 1.3723733900405932e-05

The O 0 1.2386678918119287e-06
genetic O 0 2.454764580761548e-05
basis O 0 5.457665110952803e-07
of O 0 1.2026450349367224e-05
myotonic B-Disease 1 0.9999939203262329
dystrophy I-Disease 1 0.9999955892562866
( O 0 0.00010006067168433219
DM B-Disease 1 0.9999399185180664
) O 0 2.3953177219482313e-08
is O 0 7.029474780040346e-10
the O 0 3.513810908906123e-10
expansion O 0 9.020159730255273e-09
of O 0 3.285655636453555e-10
an O 0 2.647770225294721e-09
unstable O 0 3.9372687751892954e-05
CTG O 0 0.0003481270105112344
repeat O 0 5.871133907930925e-07
in O 0 8.8066343106874e-10
the O 0 3.504226353534534e-10
34 O 0 3.6867591202138783e-09
UTR O 0 8.385774208363728e-07
of O 0 6.01089678031741e-10
the O 0 9.592355354470783e-09
DM B-Disease 1 0.784611165523529
protein O 0 2.6711870759754675e-07
kinase O 0 1.8662547063286183e-06
gene O 0 1.905130062596072e-07
on O 0 1.5880228687592535e-08
chromosome O 0 2.6693925974541344e-05
19 O 0 6.455285870288208e-07
. O 0 2.3792402714661876e-07

One O 0 1.2118907477542962e-07
of O 0 9.081963625590106e-09
the O 0 2.5787501023444293e-09
principal O 0 9.761195407520518e-09
features O 0 3.5839091694356284e-09
of O 0 2.0974251224714635e-09
the O 0 1.6979652173176873e-07
DM B-Disease 1 0.9999271631240845
mutation O 0 9.274460899177939e-05
is O 0 2.2872927996075987e-09
an O 0 7.057081585770675e-10
extraordinarily O 0 1.6247693110926775e-06
high O 0 4.465799108288593e-08
level O 0 3.0229259095904126e-09
of O 0 4.222504290662954e-10
somatic O 0 2.5728838863869896e-06
mosaicism O 0 0.016283592209219933
, O 0 6.877979075170515e-09
due O 0 5.078260034707682e-09
to O 0 7.76220893117241e-11
an O 0 4.66814864541476e-10
extremely O 0 5.0856197475468434e-08
high O 0 8.474888346654552e-08
degree O 0 1.5132860298194828e-08
of O 0 5.642408762440709e-10
somatic O 0 2.4541338916606037e-06
instability O 0 1.2623900147445966e-06
both O 0 1.3216693295348136e-09
within O 0 1.4252787838842096e-09
and O 0 4.858033975096987e-10
between O 0 2.207165561429747e-09
different O 0 1.0628995461559043e-08
tissues O 0 2.094842420774512e-05
. O 0 3.7112218365109584e-07

This O 0 6.158120413601864e-07
instability O 0 1.414944290445419e-05
appears O 0 1.352636189722034e-07
to O 0 6.216672732151096e-10
be O 0 1.4642155543587165e-10
biased O 0 1.5122407770462587e-09
towards O 0 7.68968222430999e-10
further O 0 4.6033907241671557e-10
expansion O 0 6.709737210286448e-09
and O 0 8.601049039658193e-11
continuous O 0 4.154014909829584e-09
throughout O 0 1.0272341866013335e-09
the O 0 2.845918223304267e-10
life O 0 1.0604972455752204e-09
of O 0 1.1229486091002272e-10
an O 0 3.3694158574348876e-10
individual O 0 2.084598715867969e-09
, O 0 2.0531101263543405e-09
features O 0 1.3358473438529472e-08
that O 0 9.201326367502816e-10
could O 0 1.0569956021555527e-09
be O 0 3.262101977430376e-10
associated O 0 1.5585134294227032e-09
with O 0 7.158759696146433e-10
the O 0 5.41052447289303e-09
progressive O 0 6.14402142673498e-06
nature O 0 1.0380362880368921e-07
of O 0 1.4798274605709594e-08
the O 0 1.7724787539918907e-06
disease O 0 0.011987341567873955
. O 0 6.618666930080508e-07

Although O 0 8.763952337176306e-07
increasing O 0 3.129385106603877e-07
measured O 0 9.043675959219399e-07
allele O 0 7.60255090881401e-07
size O 0 8.413105661020381e-07
between O 0 2.218237113993382e-07
patients O 0 1.28447090901318e-05
clearly O 0 2.5353118715543133e-08
correlates O 0 7.354142184112789e-08
with O 0 1.238849356433036e-09
an O 0 2.902659224091053e-09
increased O 0 4.781444999935047e-07
severity O 0 2.2158799765747972e-05
of O 0 3.8566611237911275e-08
symptoms O 0 0.00015484158939216286
and O 0 1.412389205590614e-09
an O 0 1.0547399620364217e-09
earlier O 0 3.725639885487908e-08
age O 0 2.4174218182793084e-08
of O 0 3.286898531129623e-09
onset O 0 0.0015927432104945183
, O 0 4.293953637102277e-09
this O 0 2.330563242392003e-10
correlation O 0 1.1618623396714156e-08
is O 0 7.132019974598336e-10
not O 0 6.909081640138481e-11
precise O 0 1.6395692581383514e-09
and O 0 4.2886635909233917e-10
measured O 0 4.024245825462458e-08
allele O 0 2.364847873081999e-08
length O 0 7.609617114212597e-08
cannot O 0 1.5124657082310478e-09
be O 0 4.1207561668477055e-11
used O 0 5.905976402376112e-11
as O 0 1.972993990406735e-11
an O 0 6.847499650630695e-11
accurate O 0 4.2755408102834735e-09
predictor O 0 7.582146963613923e-07
of O 0 1.2532326287839624e-09
age O 0 9.498396735807546e-08
of O 0 6.23749940587004e-08
onset O 0 0.0514606349170208
. O 0 1.908066224132199e-06

In O 0 2.264973488763644e-07
order O 0 1.4325264530157256e-08
to O 0 1.0225738034108645e-09
further O 0 1.7783817751748643e-09
characterize O 0 4.81035051791423e-08
the O 0 4.2803716127082225e-09
dynamics O 0 3.64929383067647e-06
of O 0 3.836045792127152e-08
DM B-Disease 1 0.9996339082717896
CTG O 0 0.011534323915839195
repeat O 0 1.053167216014117e-05
somatic O 0 1.4402639862964861e-05
instability O 0 7.700719834247138e-06
, O 0 7.053949868662812e-09
we O 0 6.803473895367063e-10
have O 0 2.5751903387494224e-10
studied O 0 5.849547513037123e-09
repeat O 0 1.5067071501562168e-07
length O 0 2.5407580039882305e-08
changes O 0 1.6578711736769947e-09
over O 0 6.772608029947946e-10
time O 0 2.1938355576622826e-09
in O 0 6.53771579095519e-08
111 O 0 0.007573774550110102
myotonic B-Disease 1 0.9999961853027344
dystrophy I-Disease 1 0.9999972581863403
patients O 0 0.0325833335518837
with O 0 1.1810004707513144e-07
varying O 0 4.865401479037246e-06
clinical O 0 0.009014195762574673
severity O 0 0.0010793404653668404
and O 0 1.0559003982280046e-07
CTG O 0 0.0012704881373792887
repeat O 0 2.703395466596703e-06
size O 0 2.551874977996249e-08
over O 0 8.425464770311919e-10
time O 0 3.632521783369924e-10
intervals O 0 2.451203018338788e-09
of O 0 3.7927899709799817e-10
1 O 0 2.3486384392867876e-08
- O 0 9.727882570587099e-06
7 O 0 5.359128181225969e-07
years O 0 2.3441592134076927e-07
. O 0 2.340035933912077e-07

We O 0 3.207237284641451e-07
have O 0 9.8873016440848e-09
found O 0 2.5296011951780883e-09
a O 0 1.856338083250364e-09
direct O 0 2.142259258874901e-09
progression O 0 4.557185775411199e-07
of O 0 5.956321547095911e-10
the O 0 1.0512273274088102e-09
size O 0 2.641441021467017e-08
heterogeneity O 0 2.5116079882536724e-07
over O 0 1.6239207756285623e-09
time O 0 1.0060906552311621e-09
related O 0 2.907579510491587e-09
to O 0 1.8398897683180593e-10
initial O 0 7.11569398959e-08
CTG O 0 3.548339009284973e-05
repeat O 0 2.7209324571231264e-07
size O 0 1.769770996418174e-08
and O 0 1.6911752553916415e-10
the O 0 1.3169403068058472e-10
time O 0 2.949965549614575e-10
interval O 0 8.660022920992105e-09
and O 0 2.621477479536338e-10
always O 0 7.953157021844959e-10
biased O 0 3.7241036920931947e-09
towards O 0 5.06636022024054e-09
further O 0 1.6342873720986972e-08
expansion O 0 1.6365385135941324e-06
. O 0 4.6343572535079147e-07

Attempts O 0 1.3294212521941517e-06
to O 0 3.107265200696929e-08
mathematically O 0 3.252134774811566e-07
model O 0 6.832193122363606e-08
the O 0 7.090221298966526e-09
dynamics O 0 5.067641723144334e-06
have O 0 3.723009900369334e-09
proved O 0 4.662387098619547e-08
only O 0 8.314101074269331e-10
partially O 0 5.611825599771691e-07
successful O 0 5.585598827906324e-08
suggesting O 0 3.275060223018045e-08
that O 0 1.6554309312244442e-10
individual O 0 4.3093842383434833e-10
specific O 0 1.3007270815990069e-09
genetic O 0 3.8141041613926063e-07
and O 0 1.6930487234390057e-08
/ O 0 1.3988521459395997e-05
or O 0 3.998202302568643e-08
environmental O 0 5.51384744085226e-07
factors O 0 2.0289507851600774e-09
also O 0 1.9858276134598896e-10
play O 0 2.4047544511240915e-10
a O 0 2.361263629069299e-09
role O 0 8.415350194468374e-09
in O 0 2.693261613728737e-08
somatic O 0 2.9067634386592545e-05
mosaicism O 0 0.08476292341947556
. O 0 1.3263334608382138e-07
. O 0 3.3155373557747225e-07

Aspartylglucosaminuria B-Disease 0 0.347598671913147
among O 0 2.253542106700479e-06
Palestinian O 0 1.3248547475086525e-05
Arabs O 0 1.656042513786815e-05
. O 0 4.5042270357953385e-06

Aspartylglucosaminuria B-Disease 1 0.9989487528800964
( O 0 0.0001653924846323207
AGU B-Disease 1 0.9984810948371887
) O 0 6.262819738367398e-07
is O 0 7.034135052208512e-08
a O 0 4.3746814526457456e-07
rare O 0 7.168505817389814e-06
disorder B-Disease 0 0.008171279914677143
of I-Disease 0 5.492304211429655e-08
glycoprotein I-Disease 0 0.04613140970468521
metabolism I-Disease 0 0.030386967584490776
caused O 0 1.8296161215403117e-05
by O 0 3.330825393277337e-08
the O 0 1.5706186218267248e-07
deficiency B-Disease 0 0.004978961311280727
of I-Disease 0 1.405161098588792e-09
the I-Disease 0 3.1901567609793346e-08
lysosomal I-Disease 0 0.05281499773263931
enzyme I-Disease 0 7.805853238096461e-05
aspartylglucosaminidase I-Disease 0 0.0485839769244194
( O 0 2.3790155978531402e-07
AGA O 0 0.0003904392942786217
) O 0 2.324373440387717e-07
. O 0 2.837039119185647e-07

AGU B-Disease 1 0.9995619654655457
is O 0 1.932017221406568e-05
inherited O 0 0.010909276083111763
as O 0 2.0162025293757324e-07
an O 0 7.591697794850916e-07
autosomal O 1 0.8988506197929382
recessive O 1 0.7880512475967407
trait O 0 0.0010949433781206608
and O 0 1.2554396278119384e-07
occurs O 0 5.138750580613305e-08
with O 0 1.8742691842987824e-09
a O 0 8.713771038060258e-09
high O 0 3.633793710378086e-08
frequency O 0 1.608845678902071e-08
in O 0 2.2493673590417984e-09
Finland O 0 1.9026353470508184e-07
because O 0 5.123986235311406e-10
of O 0 3.0568661490981697e-10
a O 0 8.500354198304194e-08
founder O 0 7.855380317778327e-06
effect O 0 9.705149750516284e-07
. O 0 2.6058324920086307e-07

While O 0 3.74437649952597e-06
very O 0 3.3915486596924893e-07
few O 0 3.5277560073154746e-07
patients O 0 4.745909245684743e-05
with O 0 4.737765380014025e-07
AGU B-Disease 1 0.996547281742096
have O 0 3.5349403404438817e-09
been O 0 2.309659796750907e-09
reported O 0 2.0545371626212727e-08
from O 0 5.805971259320586e-10
non O 0 1.2475427801916794e-08
- O 0 6.952966941753402e-06
Finnish O 0 1.6845546269905753e-05
origin O 0 1.914447445017231e-08
, O 0 3.720186469990949e-08
we O 0 1.7218150105691166e-07
diagnosed O 0 0.18019230663776398
the O 0 5.021497599955183e-07
disorder O 0 0.4049866795539856
in O 0 2.951601629774814e-07
8 O 0 2.6072048058267683e-06
patients O 0 1.5559975281576044e-06
originating O 0 1.415426442719081e-08
from O 0 2.041208535530359e-09
3 O 0 2.6661776786340852e-08
unrelated O 0 2.341980547271305e-07
families O 0 2.6614461745566587e-09
, O 0 2.1916596315563197e-10
all O 0 2.4792100664083883e-11
Palestinian O 0 3.3195977078293026e-09
Arabs O 0 2.445225799618811e-09
from O 0 7.51440243362822e-10
the O 0 1.0840696118563642e-09
region O 0 1.5457487734238384e-08
of O 0 5.6210889276542275e-09
Jerusalem O 0 6.480633601313457e-06
. O 0 7.245741926453775e-07

The O 0 1.3734796993958298e-05
clinical O 0 0.13708530366420746
diagnosis O 1 0.9218337535858154
of O 0 1.0680597370082978e-05
AGU B-Disease 1 0.9999616146087646
is O 0 3.1095959229787695e-07
often O 0 2.3222016309887294e-08
difficult O 0 9.765016528717751e-08
, O 0 1.4796320835230858e-09
in O 0 5.676173420177122e-10
particular O 0 3.302960127626875e-10
early O 0 2.020439371364091e-09
in O 0 5.464388941334164e-10
the O 0 1.0611002076998943e-09
course O 0 3.947584303887197e-08
of O 0 1.5138800213421177e-09
the O 0 1.0542864004037256e-07
disease O 0 0.00021318247308954597
, O 0 1.138707017567242e-09
and O 0 2.839736501503154e-10
most O 0 1.0461403271433412e-10
of O 0 6.989699929960125e-10
the O 0 8.699494458141999e-08
patients O 0 0.0001677123800618574
are O 0 7.664050372113707e-08
diagnosed O 0 0.02429131604731083
after O 0 2.8475716007392293e-08
the O 0 2.319022307517571e-09
age O 0 1.4312127483151471e-08
of O 0 1.3649038566043714e-09
5 O 0 1.5111379525478696e-07
years O 0 2.8125404583079217e-07
. O 0 2.7892320986211416e-07

However O 0 1.5687414816056844e-06
, O 0 1.4013883742336475e-07
since O 0 1.2318359665641765e-07
these O 0 4.755276616918991e-09
patients O 0 1.1003332929249154e-06
excrete O 0 5.551626145461341e-07
early O 0 4.715409840372331e-09
large O 0 1.635852120429604e-09
amounts O 0 2.037731094972628e-09
of O 0 2.476290839048545e-10
aspartylglucosamine O 0 2.205262035204214e-06
in O 0 2.099458162874157e-09
urine O 0 1.3018899380767834e-07
, O 0 9.921963251002808e-10
biochemical O 0 2.8752180014635087e-07
screening O 0 5.774105034106469e-07
is O 0 2.1462631671909094e-09
easy O 0 9.381915688777553e-09
by O 0 9.500205067070056e-09
urine O 0 6.375161774485605e-06
chromatography O 0 0.00012931095261592418
. O 0 4.822136645543651e-08
. O 0 2.3566533968732983e-07

Detection O 0 0.00014608987839892507
of O 0 2.951328781364282e-07
heterozygous O 0 1.7950724213733338e-05
carriers O 0 3.201493882443174e-06
of O 0 3.497398992635681e-08
the O 0 1.948447788890917e-06
ataxia B-Disease 1 0.9999758005142212
- I-Disease 1 0.9852508306503296
telangiectasia I-Disease 1 0.99982088804245
( O 0 8.97033984870177e-08
ATM O 0 9.459772627451457e-06
) O 0 4.546552467843412e-09
gene O 0 2.4179660940149006e-08
by O 0 3.0747555612720134e-09
G2 O 0 0.00014103013381827623
phase O 0 1.6536154134882963e-06
chromosomal O 0 0.00030023339786566794
radiosensitivity O 0 7.525409455411136e-05
of O 0 7.599986417972104e-08
peripheral O 0 0.012734493240714073
blood O 0 0.07223021984100342
lymphocytes O 0 0.07462582737207413
. O 0 2.345881739529432e-06

In O 0 0.0006540065514855087
ataxia B-Disease 1 0.9999401569366455
- I-Disease 1 0.9996134638786316
telangiectasia I-Disease 1 0.999947190284729
( O 0 0.0003006604965776205
A B-Disease 1 0.9959977865219116
- I-Disease 1 0.9998527765274048
T I-Disease 1 0.9999319314956665
) O 0 2.19595975181619e-07
patients O 0 9.786337614059448e-06
, O 0 6.634122584614488e-09
mutations O 0 2.103600422742602e-07
in O 0 6.566052701550973e-10
a O 0 2.9754920749525127e-09
single O 0 6.238603855734937e-09
gene O 0 1.3546960886401394e-08
, O 0 1.3261109987894315e-09
ATM O 0 7.115895186871057e-06
, O 0 9.678068124685524e-09
result O 0 1.099236754953381e-07
in O 0 1.8251229505494848e-07
an O 0 0.00021123139595147222
autosomal B-Disease 1 0.9999974966049194
recessive I-Disease 1 0.9999963045120239
syndrome I-Disease 1 0.9999992847442627
that O 0 9.420974578233654e-08
embraces O 0 1.0944768291665241e-06
a O 0 6.786009976167406e-08
variety O 0 1.0428005126073003e-08
of O 0 4.913051743216101e-09
clinical O 0 1.0300766007276252e-05
features O 0 1.4051275343263114e-07
and O 0 2.0341982320815077e-08
manifests O 0 1.0186157624048064e-06
extreme O 0 2.524157252992154e-06
radiosensitivity O 0 1.990415512409527e-05
and O 0 1.2270535698633012e-09
a O 0 1.368105184695878e-08
strong O 0 5.239224165620726e-08
pre O 0 7.690217898925766e-05
- O 0 0.0004461790667846799
disposition O 0 1.631567647564225e-05
to O 0 1.438413477217182e-07
malignancy B-Disease 1 0.5819224119186401
. O 0 1.06693232737598e-06

Heterozygotes O 0 8.64610483404249e-05
for O 0 5.1993445993048226e-08
the O 0 9.561375691191643e-09
ATM O 0 1.030297607940156e-05
gene O 0 3.8676225244671514e-07
have O 0 1.146648997973898e-09
no O 0 2.323755410316153e-09
clinical O 0 1.1960698031998618e-07
expression O 0 6.067364388684382e-09
of O 0 8.83138184804011e-09
A B-Disease 0 0.14356182515621185
- I-Disease 1 0.9983193278312683
T I-Disease 1 0.9999591112136841
but O 0 1.008597010354606e-07
may O 0 7.773663242005568e-07
be O 0 5.715255042559875e-07
cancer B-Disease 1 0.7239607572555542
prone O 0 1.934723877639044e-05
with O 0 1.1233266761223604e-08
a O 0 1.6931124946495402e-07
moderate O 0 2.9835405257472303e-06
increase O 0 5.8466053332040246e-08
in O 0 4.8628572280051685e-09
in O 0 3.4552229521978006e-08
vitro O 0 8.068130409810692e-05
radiosensitivity O 0 0.002704375423491001
. O 0 5.07346101130679e-07

We O 0 4.6916250084905187e-07
performed O 0 2.724980845414393e-07
a O 0 9.424856983741847e-08
blind O 0 1.1675803079924663e-06
chromosomal O 0 4.6498069423250854e-05
analysis O 0 6.445621636430587e-08
on O 0 3.845077856112766e-08
G2 O 0 0.016235316172242165
- O 0 6.459916039602831e-05
phase O 0 2.0430773020052584e-06
lymphocytes O 0 1.618137684999965e-05
from O 0 5.65674307395625e-09
7 O 0 7.54220820908813e-07
unrelated O 0 0.00010602823022054508
A B-Disease 1 0.9764506220817566
- I-Disease 1 0.999954104423523
T I-Disease 1 0.9999899864196777
patients O 0 0.0001347753859590739
, O 0 9.274240042600468e-09
13 O 0 6.464224355795523e-08
obligate O 0 3.2613577332085697e-06
A B-Disease 0 0.40422093868255615
- I-Disease 1 0.9968665242195129
T I-Disease 1 0.9998354911804199
heterozygotes O 0 6.845680763944983e-05
( O 0 4.346384141484805e-09
parents O 0 6.88086565503454e-09
of O 0 7.490247866392963e-10
the O 0 1.8415697411455767e-08
patients O 0 2.2543611066794256e-06
) O 0 9.458525074279578e-10
, O 0 1.8772521037657697e-10
and O 0 2.641967478123064e-10
14 O 0 3.1632050312424553e-09
normal O 0 5.3323550019968025e-09
controls O 0 1.9908469539586804e-08
following O 0 5.008672587791807e-09
X O 0 2.328025630049524e-06
- O 0 1.0041223958978662e-06
irradiation O 0 9.853889082478418e-08
with O 0 7.138852287091879e-10
1 O 0 7.169011606578124e-09
Gy O 0 2.482606032572221e-05
in O 0 1.3519643182746677e-09
order O 0 5.945265946216693e-10
to O 0 1.6829440618870706e-10
evaluate O 0 8.86843309899632e-09
this O 0 2.708150648178531e-10
cytogenetic O 0 1.7748434402165003e-06
method O 0 1.7846236710639118e-09
as O 0 2.0410013956695394e-10
a O 0 9.424040436911696e-10
tool O 0 7.165976256828799e-09
for O 0 4.785810636676047e-10
detection O 0 2.507075578250806e-07
of O 0 8.18703327354342e-09
ATM O 0 0.0001926464174175635
carriers O 0 2.3241806047735736e-05
. O 0 6.310585831670323e-07

Both O 0 7.559745426988229e-06
A B-Disease 1 0.5468824505805969
- I-Disease 1 0.9931433200836182
T I-Disease 1 0.9985625147819519
homozygotes O 0 0.00014547559840139002
and O 0 1.765630486261216e-08
heterozygotes O 0 1.1983401236648206e-05
showed O 0 1.932374686930416e-07
significantly O 0 9.395994737815272e-08
increased O 0 2.825767353442643e-08
levels O 0 2.9619094732424855e-08
of O 0 1.3582820201918366e-08
radiation O 0 0.4187237024307251
- O 0 0.05561402067542076
induced O 0 0.03495626896619797
chromatid O 1 0.9928007125854492
damage O 0 0.00021388425375334918
relative O 0 7.735542340014945e-08
to O 0 2.4005383791880774e-10
that O 0 1.824944778627824e-10
of O 0 9.688997382184539e-10
normal O 0 3.514626314427005e-07
controls O 0 2.1049743281764677e-06
. O 0 3.2554333984080586e-07

These O 0 2.2174504010763485e-07
results O 0 4.166070652900089e-07
show O 0 9.208809714777999e-09
that O 0 4.723094138014972e-10
the O 0 2.0002626222037634e-09
G2 O 0 0.0003667378914542496
- O 0 8.233503649535123e-06
phase O 0 1.2864736618212191e-06
chromosomal O 0 0.00021345890127122402
radiosensitivity O 0 7.08760999259539e-05
assay O 0 2.5514038952678675e-06
can O 0 7.783814148787371e-10
be O 0 3.2356343299122514e-11
used O 0 4.0363930947640014e-11
for O 0 5.851907153298086e-11
the O 0 6.635536564658651e-10
detection O 0 5.737574610975571e-07
of O 0 2.2655713749486495e-08
A B-Disease 0 0.25738775730133057
- I-Disease 1 0.9977244734764099
T I-Disease 1 0.9997240900993347
heterozygotes O 0 0.00229068286716938
. O 0 1.10144628706621e-06

In O 0 7.693377597206563e-07
combination O 0 3.2350581022910774e-06
with O 0 5.518187862207924e-08
molecular O 0 2.0858999050688e-05
genetic O 0 1.789845191524364e-05
analyses O 0 4.866701033279242e-07
, O 0 2.9705644610800164e-09
this O 0 2.4536717102563443e-10
test O 0 8.411082497161715e-09
may O 0 8.102535309362224e-10
be O 0 1.6501466859608627e-11
of O 0 2.9176432103650285e-11
value O 0 1.6588826146080038e-10
in O 0 4.956912658116153e-10
studies O 0 1.3601687554043451e-09
of O 0 9.843754700256113e-10
familial B-Disease 0 0.0007032043649815023
and I-Disease 0 1.283997335121967e-07
sporadic I-Disease 0 9.64588180067949e-05
cancers I-Disease 0 0.06203997880220413
aimed O 0 4.848453158956545e-07
at O 0 2.480722649522704e-08
determination O 0 2.7245775413575757e-08
of O 0 2.50262921497324e-10
the O 0 4.936598352323074e-10
potential O 0 2.8236755156285653e-09
involvement O 0 1.7006286157084105e-08
of O 0 5.37057021077203e-09
ATM O 0 0.009418167173862457
mutations O 0 0.01843648962676525
in O 0 1.4010295672051143e-05
tumor B-Disease 1 0.9991610050201416
risk O 0 7.584666309412569e-05
or O 0 3.231722445207197e-08
development O 0 9.740647755052123e-08
. O 0 6.037617339416101e-08
. O 0 2.370366729564921e-07

Ataxia B-Disease 1 0.9998584985733032
- I-Disease 1 0.998062789440155
telangiectasia I-Disease 1 0.9995813965797424
: O 0 6.569421771018824e-07
identification O 0 1.905557240888811e-07
and O 0 8.423395314594018e-09
detection O 0 1.2208359976284555e-06
of O 0 8.734871492777074e-09
founder O 0 4.44754232375999e-06
- O 0 2.5527531761326827e-05
effect O 0 7.322914541418868e-08
mutations O 0 1.6199392405269464e-07
in O 0 2.9389130018486753e-10
the O 0 2.945804711274036e-10
ATM O 0 1.5829235735509428e-06
gene O 0 7.512431920986273e-08
in O 0 7.516442579458271e-09
ethnic O 0 3.5295119715783585e-08
populations O 0 1.0403210808362928e-06
. O 0 3.364032465924538e-07

To O 0 3.5776682949517635e-08
facilitate O 0 4.117297791594865e-08
the O 0 4.749393767156107e-09
evaluation O 0 3.505306267470587e-08
of O 0 1.6647916378786931e-09
ATM O 0 1.211229209729936e-05
heterozygotes O 0 9.897635209199507e-06
for O 0 8.94665408424089e-09
susceptibility O 0 2.5339364583487622e-05
to O 0 1.8588643957428985e-09
other O 0 9.686378810158658e-09
diseases O 0 0.000951298454310745
, O 0 2.076631133718365e-08
such O 0 4.490269844836803e-08
as O 0 3.083541014348157e-05
breast B-Disease 1 0.9999909400939941
cancer I-Disease 1 0.9971925616264343
, O 0 1.7642099336967476e-08
we O 0 4.4407716393024543e-10
have O 0 1.0706343450683775e-10
attempted O 0 3.733975795228162e-09
to O 0 6.905997995687585e-11
define O 0 1.869513432950498e-09
the O 0 5.022848248437128e-10
most O 0 4.1402808959034587e-10
common O 0 1.6766467325624035e-08
mutations O 0 1.141997856279886e-07
and O 0 1.4801759817828497e-10
their O 0 5.068425679155553e-10
frequencies O 0 4.9368765075996635e-08
in O 0 7.738485692243557e-07
ataxia B-Disease 1 0.9999631643295288
- I-Disease 1 0.9991241097450256
telangiectasia I-Disease 1 0.9999709129333496
( O 0 2.5678620659164153e-05
A B-Disease 1 0.900412917137146
- I-Disease 1 0.9983615279197693
T I-Disease 1 0.9995973706245422
) O 0 1.2233525303884107e-08
homozygotes O 0 2.8335987281025155e-06
from O 0 1.8650900823757866e-09
10 O 0 5.470357056225339e-09
ethnic O 0 5.964193405816332e-08
populations O 0 6.611733738282055e-07
. O 0 2.583599325589603e-07

Both O 0 1.323034098277276e-06
genomic O 0 0.0002899280225392431
mutations O 0 0.00012983310443814844
and O 0 1.0685749174399461e-08
their O 0 1.6672513369897501e-09
effects O 0 2.6650132767258583e-08
on O 0 3.570985507295177e-09
cDNA O 0 2.7039217798119353e-07
were O 0 1.4390715286083378e-08
characterized O 0 4.542196165857604e-06
. O 0 3.03793285638676e-07

Protein O 0 3.460430889390409e-05
- O 0 1.6998987121041864e-05
truncation O 0 3.2277696391247446e-06
testing O 0 1.0036249165068512e-07
of O 0 5.070330821865809e-10
the O 0 2.8951158137502375e-10
entire O 0 4.022325583719066e-09
ATM O 0 2.0468792172323447e-07
cDNA O 0 1.831595568546618e-07
detected O 0 8.392919426114531e-07
92 O 0 9.602243977724356e-08
( O 0 3.4631253420513985e-09
66 O 0 7.018776670975058e-08
% O 0 6.50809095503746e-09
) O 0 3.5388059149710216e-09
truncating O 0 2.8500385269580875e-06
mutations O 0 3.341124283906538e-07
in O 0 7.765870169151867e-10
140 O 0 1.0868236088867889e-08
mutant O 0 1.505839463789016e-06
alleles O 0 8.811689440335613e-07
screened O 0 2.468918410158949e-06
. O 0 2.82232605286481e-07

The O 0 7.685025593673345e-07
haplotyping O 0 0.0005631002713926136
of O 0 4.1513405335535936e-07
patients O 0 8.902826812118292e-05
with O 0 3.172935691964085e-07
identical O 0 0.0008433769107796252
mutations O 0 0.00061575579456985
indicates O 0 1.1020708257092338e-07
that O 0 8.774404119948898e-11
almost O 0 1.16393283899896e-10
all O 0 1.0572909735218072e-11
of O 0 2.987847122493115e-11
these O 0 4.515651047531932e-11
represent O 0 5.795084412341112e-10
common O 0 6.94282720203887e-09
ancestry O 0 3.655392077916986e-08
and O 0 2.0819206358879683e-09
that O 0 3.168764972638627e-10
very O 0 8.507952675707031e-10
few O 0 5.579175343939369e-09
spontaneously O 0 4.231215768868424e-07
recurring O 0 3.254531111451797e-05
ATM O 0 0.053979985415935516
mutations O 0 0.0004479957860894501
exist O 0 3.9638743487557804e-07
. O 0 4.151534653829003e-07

Assays O 0 8.934838842833415e-05
requiring O 0 8.52193079481367e-06
minimal O 0 1.6644232800899772e-06
amounts O 0 5.980574258046545e-08
of O 0 4.042137291548897e-09
genomic O 0 1.7290449250140227e-06
DNA O 0 8.38850951367931e-07
were O 0 7.002617374851638e-10
designed O 0 3.477601540069486e-09
to O 0 8.226658937404707e-11
allow O 0 9.745303453101428e-10
rapid O 0 3.380753241799539e-07
screening O 0 3.764283746932051e-07
for O 0 1.8847945426614388e-09
common O 0 5.886945331212701e-08
ethnic O 0 9.79102992459957e-07
mutations O 0 0.0002160606236429885
. O 0 4.0760031083664217e-07

These O 0 4.1006677520272206e-07
rapid O 0 2.6700494345277548e-05
assays O 0 5.971416612737812e-05
detected O 0 7.106018892955035e-05
mutations O 0 9.496804523223545e-06
in O 0 8.199989132151586e-09
76 O 0 9.809183865172599e-08
% O 0 5.04441421966817e-09
of O 0 7.230228860066745e-09
Costa O 0 1.8561797332949936e-05
Rican O 0 2.7652949938783422e-05
patients O 0 8.884265298547689e-06
( O 0 3.329794662221275e-09
3 O 0 5.50275558452995e-09
) O 0 4.803890618632067e-10
, O 0 2.2960598700105805e-10
50 O 0 7.569020965547679e-10
% O 0 9.636177411564972e-10
of O 0 1.3962910827558517e-09
Norwegian O 0 6.532712723128498e-05
patients O 0 5.1866691137547605e-06
( O 0 9.019983648883567e-10
1 O 0 2.0287262980644982e-09
) O 0 3.587443120345313e-10
, O 0 3.3696540002736697e-10
25 O 0 2.0993182747730543e-09
% O 0 8.827386044352181e-10
of O 0 1.6213209663717976e-09
Polish O 0 0.000846760522108525
patients O 0 6.486689380835742e-05
( O 0 6.034449384628715e-09
4 O 0 1.4759093502902942e-08
) O 0 4.836602784941135e-10
, O 0 2.0718815552100978e-10
and O 0 1.9186346955635258e-10
14 O 0 7.881281405275331e-09
% O 0 1.724774989497746e-09
of O 0 2.6540754038961722e-09
Italian O 0 0.00010994888725690544
patients O 0 2.7049407435697503e-05
( O 0 9.311320603444528e-09
1 O 0 1.7344284231057827e-08
) O 0 1.1175497194315653e-09
, O 0 3.755888378087491e-10
as O 0 1.4218703991986104e-10
well O 0 2.814211086388241e-10
as O 0 3.3042080183065536e-10
in O 0 1.9794794692273854e-09
patients O 0 4.6147356158598996e-08
of O 0 2.7102642352616613e-10
Amish O 0 6.545251949319209e-07
/ O 0 7.75073203840293e-06
Mennonite O 0 7.265660769917304e-06
and O 0 1.1486328332921403e-08
Irish O 0 4.975672709406354e-07
English O 0 9.0414879139189e-08
backgrounds O 0 2.0443890207388904e-06
. O 0 6.938063279449125e-07

Additional O 0 1.5916670008664369e-06
mutations O 0 5.8026707847602665e-05
were O 0 2.3015955363803187e-08
observed O 0 4.5308510721042694e-08
in O 0 2.258180087366668e-09
Japanese O 0 1.5974890743564174e-08
, O 0 2.6553210741298017e-09
Utah O 0 6.36608206150413e-08
Mormon O 0 5.390459190124375e-09
, O 0 5.01294228349991e-10
and O 0 7.004433699719925e-10
African O 0 1.4264625924909069e-08
American O 0 3.4962093309331976e-07
patients O 0 0.00010086315887747332
. O 0 4.993537459085928e-07

These O 0 6.268090402272719e-08
assays O 0 1.3551065194405965e-06
should O 0 9.60053725407306e-09
facilitate O 0 2.5119092583736347e-08
screening O 0 3.861890945699997e-06
for O 0 9.331591854788712e-08
A B-Disease 0 0.24229685962200165
- I-Disease 1 0.9954409599304199
T I-Disease 1 0.9992939233779907
heterozygotes O 0 5.586543011304457e-06
in O 0 2.154260769771099e-09
the O 0 2.54483545347739e-09
populations O 0 4.520233432003806e-08
studied O 0 5.2289216512235726e-08
. O 0 9.195400885175786e-09
. O 0 6.635593052806144e-08

The O 0 7.1359495450451504e-06
von B-Disease 0 0.47364795207977295
Hippel I-Disease 1 0.9839990735054016
- I-Disease 0 0.297184556722641
Lindau I-Disease 1 0.955414354801178
tumor I-Disease 1 0.8495210409164429
suppressor O 0 0.00010229770850855857
gene O 0 3.705570463807817e-07
is O 0 1.5665543307008534e-09
required O 0 2.0316963666999754e-09
for O 0 6.156141707513996e-10
cell O 0 2.0712514015031047e-06
cycle O 0 9.732214039104292e-07
exit O 0 9.918658179230988e-07
upon O 0 1.3405262677679275e-07
serum O 0 0.0006694981129840016
withdrawal O 0 6.823521107435226e-05
. O 0 8.801845865491487e-07

The O 0 1.263992317035445e-06
inactivation O 0 0.0010469092521816492
of O 0 4.519078444786828e-08
the O 0 4.245176228323544e-07
von B-Disease 1 0.7825661301612854
Hippel I-Disease 1 0.9976480603218079
- I-Disease 1 0.6120351552963257
Lindau I-Disease 1 0.840190052986145
( I-Disease 0 1.492150090598443e-06
VHL I-Disease 0 0.3637520372867584
) I-Disease 0 6.196388540047337e-07
tumor I-Disease 0 0.15224888920783997
suppressor O 0 0.00021271851437631994
gene O 0 2.1044966160843614e-06
predisposes O 0 1.4096297491050791e-05
affected O 0 5.123307289522927e-08
individuals O 0 1.5024084198955734e-09
to O 0 9.596412553491973e-10
the O 0 1.835592939869457e-07
human O 0 0.010118206962943077
VHL B-Disease 1 0.9999972581863403
cancer I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999909400939941
and O 0 3.2945015959739976e-07
is O 0 3.348080213072535e-08
associated O 0 4.865289682243201e-08
with O 0 1.0156353624779513e-07
sporadic B-Disease 0 0.09433571249246597
renal I-Disease 1 0.9999934434890747
cell I-Disease 1 0.9999724626541138
carcinomas I-Disease 1 0.9999971389770508
( O 0 2.2655882276012562e-05
RCC B-Disease 1 0.9869728684425354
) O 0 1.4588722763164697e-07
and O 0 6.72539670176775e-07
brain B-Disease 0 0.39340782165527344
hemangioblastomas I-Disease 0 0.19149716198444366
. O 0 1.8344866248298786e-06

VHL O 1 0.9776043891906738
- O 0 0.0005467082955874503
negative O 0 2.273017344123218e-06
786 O 0 5.2390874770935625e-05
- O 0 0.0002502989082131535
0 O 0 2.1054399894637754e-06
RCC B-Disease 0 0.04783007875084877
cells O 0 2.2071008061175235e-06
are O 0 2.3469175491896976e-09
tumorigenic O 0 1.362848615826806e-05
in O 0 3.2479871237001134e-08
nude O 0 5.179693107493222e-05
mice O 0 1.566352329973597e-05
which O 0 1.2250938041802328e-09
is O 0 1.2166594398621555e-09
suppressed O 0 1.1963363633071822e-08
by O 0 4.231017758371536e-10
the O 0 2.3133719384560436e-09
reintroduction O 0 1.9829358279821463e-06
of O 0 1.0278309048317169e-07
VHL B-Disease 0 0.176787868142128
. O 0 9.664704521128442e-07

Remarkably O 0 0.0010590808233246207
, O 0 1.637534694509668e-07
this O 0 8.64108073983516e-09
occurs O 0 1.8474379359645354e-08
without O 0 1.3278143029538114e-09
affecting O 0 8.47465830844385e-09
the O 0 2.6335817970846165e-09
growth O 0 7.069792928859897e-08
rate O 0 3.0971353481845654e-08
and O 0 9.242379639395892e-10
cell O 0 1.0045764611277264e-06
cycle O 0 2.17050427409049e-07
profile O 0 4.510415863023809e-08
of O 0 3.394197978234814e-10
these O 0 3.8761330256598114e-10
cells O 0 9.752117335892763e-08
in O 0 7.635682308659852e-09
culture O 0 2.2357460238708882e-07
. O 0 3.4959728623107367e-07

The O 0 6.729092092427891e-07
786 O 0 4.4789474486606196e-05
- O 0 5.072136627859436e-05
0 O 0 2.3895549361441226e-07
cell O 0 6.567100172105711e-06
line O 0 1.8672234602945537e-07
, O 0 4.129100172889366e-09
like O 0 1.1156739532225401e-08
many O 0 1.9070892420813834e-08
cancer B-Disease 0 0.21050456166267395
cells O 0 1.1655355365292053e-06
, O 0 1.7655589212850487e-09
fails O 0 2.2001808375193832e-08
to O 0 1.4673412485066706e-10
exit O 0 5.1445567805785686e-08
the O 0 5.9025930809752936e-09
cell O 0 1.0000417205446865e-05
cycle O 0 1.3137839687260566e-06
upon O 0 6.592637902258502e-08
serum O 0 0.0001872886932687834
withdrawal O 0 2.198043148382567e-05
. O 0 5.976207830826752e-07

Here O 0 7.246826498885639e-07
, O 0 1.9088396641109284e-08
it O 0 1.389267367812863e-09
is O 0 9.293997793591302e-10
shown O 0 6.708173461156264e-10
that O 0 8.449922705988655e-11
reintroduction O 0 2.2529754062361462e-08
of O 0 1.9445194066047833e-10
the O 0 2.280488464734276e-09
wild O 0 3.094065448294714e-07
- O 0 4.39814648416359e-05
type O 0 2.115406687153154e-06
VHL B-Disease 0 0.0009623134392313659
gene O 0 9.136975620549492e-08
restores O 0 2.464490762577043e-07
the O 0 1.0045585474571794e-09
ability O 0 6.342711689200087e-09
of O 0 1.9449331034593342e-08
VHL O 1 0.8685771822929382
- O 0 0.153873473405838
negative O 0 4.022171924589202e-05
RCC B-Disease 1 0.9995929598808289
cancer I-Disease 1 0.585706889629364
cells O 0 1.5038877165807207e-07
to O 0 1.5068644942939358e-10
exit O 0 3.491354050311202e-08
the O 0 2.177144908799278e-09
cell O 0 2.298090066688019e-06
cycle O 0 1.006761465305317e-07
and O 0 1.3368509632627479e-09
enter O 0 4.339635495398397e-08
G0 O 0 0.0017762427451089025
/ O 0 9.602839782019146e-06
quiescence O 0 0.00020985645824111998
in O 0 2.2472680427654268e-07
low O 0 7.203529094113037e-05
serum O 0 0.000427310325903818
. O 0 5.313079327606829e-07

Both O 0 2.713381263674819e-06
VHL O 1 0.621936023235321
- O 0 0.0002839472144842148
positive O 0 1.4099006762080535e-07
and O 0 6.809257513396005e-08
VHL O 0 0.36049526929855347
- O 0 0.00029012077720835805
negative O 0 2.6125908902940864e-07
RCC B-Disease 0 0.01579844206571579
cells O 0 3.3460952408859157e-07
exit O 0 1.1079215767040296e-07
the O 0 5.163457661438997e-09
cell O 0 2.457881464579259e-06
cycle O 0 1.9086982661065122e-07
by O 0 2.342977367675303e-09
contact O 0 2.6526959118200466e-07
inhibition O 0 1.3579497135651764e-05
. O 0 4.889720344181114e-07

The O 0 1.1692283123920788e-06
cyclin O 0 0.0020950352773070335
- O 0 2.5820923838182352e-05
dependent O 0 4.028593139082659e-07
kinase O 0 2.3441070879925974e-05
inhibitor O 0 2.1203986761975102e-05
, O 0 1.1186015669295557e-08
p27 O 0 3.3136768706754083e-06
, O 0 1.4870871201111413e-09
accumulates O 0 5.4921784453654254e-08
upon O 0 2.1977639708126162e-09
serum O 0 2.26517727242026e-06
withdrawal O 0 2.7607569563770085e-07
, O 0 2.241699881277981e-10
only O 0 3.472990992015035e-11
in O 0 8.05995895025724e-11
the O 0 8.160879610974447e-11
presence O 0 9.911806930773537e-10
of O 0 7.665300616466197e-10
VHL B-Disease 0 0.000548677402548492
, O 0 9.142720469590415e-10
as O 0 1.055596859922403e-10
a O 0 1.19746113025343e-09
result O 0 9.675424905708496e-10
of O 0 1.1279416289866617e-10
the O 0 3.335125786652071e-10
stabilization O 0 4.214928850387878e-08
of O 0 4.4622869288524214e-10
the O 0 4.0679699608858755e-09
protein O 0 6.087188353376405e-07
. O 0 1.7866517509901314e-07

We O 0 8.069982300185075e-07
propose O 0 1.9218598481529625e-06
that O 0 4.578786239051169e-09
the O 0 7.754565878315134e-09
loss O 0 1.0256312634737696e-06
of O 0 5.03428321252386e-09
wild O 0 1.3377975847106427e-06
- O 0 0.0007024746155366302
type O 0 1.4784537597734015e-05
VHL B-Disease 0 0.15269796550273895
gene O 0 1.6950607459875755e-06
results O 0 4.1924465676856926e-08
in O 0 8.008962937289255e-10
a O 0 5.064321850767328e-09
specific O 0 2.237847462893683e-09
cellular O 0 3.777228994295001e-05
defect O 0 0.0001080794318113476
in O 0 4.773398742941026e-08
serum O 0 0.00016351364320144057
- O 0 8.888722732081078e-06
dependent O 0 2.6639311201392957e-08
growth O 0 1.866927590299383e-08
control O 0 2.1107942060893947e-08
, O 0 1.159605633738181e-09
which O 0 1.8176576910278186e-09
may O 0 1.4011573057359783e-07
initiate O 0 4.577097206492908e-05
tumor B-Disease 1 0.8990888595581055
formation O 0 0.00016390765085816383
. O 0 1.0856881544896169e-06

This O 0 1.1261282679697615e-06
is O 0 1.6231201982463972e-07
corrected O 0 6.112750270403922e-07
by O 0 8.786802396798521e-10
the O 0 6.194302848427924e-10
reintroduction O 0 1.8638094445577735e-07
of O 0 2.4297073242252054e-09
wild O 0 1.7978931055040448e-06
- O 0 0.0022103667724877596
type O 0 4.421418270794675e-05
VHL B-Disease 0 0.17529526352882385
, O 0 3.1015925827659885e-08
implicating O 0 7.086582627380267e-05
VHL B-Disease 0 0.0187605582177639
as O 0 1.6065236918549886e-09
the O 0 2.3019368633470094e-09
first O 0 2.3501620205479412e-08
tumor B-Disease 0 0.0029726119246333838
suppressor O 0 1.8835161199604045e-06
involved O 0 1.3507838181325837e-09
in O 0 1.6135520697346806e-10
the O 0 1.2473796995315922e-10
regulation O 0 9.599200545551412e-09
of O 0 5.90645310438731e-10
cell O 0 1.3688559192814864e-05
cycle O 0 2.403494818281615e-06
exit O 0 1.0108549304277403e-06
, O 0 2.5194892838698024e-09
which O 0 4.82109241417561e-10
is O 0 3.487417299385953e-10
consistent O 0 1.4385878044365086e-09
with O 0 2.665239418053744e-10
its O 0 1.2869076915222877e-09
gatekeeper O 0 7.780934538459405e-06
function O 0 2.0426702107556594e-08
in O 0 1.5813855114288344e-08
the O 0 1.990593290202014e-07
kidney O 0 0.10471589118242264
. O 0 5.973642913659205e-08
. O 0 2.3927975689730374e-07

Piebaldism B-Disease 1 0.9983080625534058
with O 0 0.00039964145980775356
deafness B-Disease 1 0.9999284744262695
: O 0 1.202345515594061e-06
molecular O 0 2.3924694687593728e-05
evidence O 0 5.498551303162458e-08
for O 0 1.0106456116432128e-08
an O 0 1.4890598265537847e-07
expanded O 0 0.0026719640009105206
syndrome O 1 0.9998540878295898
. O 0 4.707567768491572e-06

In O 0 4.449607047263271e-07
a O 0 1.0580191656117677e-07
South O 0 3.334804787868961e-08
African O 0 1.6818674453134008e-08
girl O 0 8.733623531043122e-07
of O 0 9.630449326891721e-09
Xhosa O 0 0.00019482204515952617
stock O 0 4.409061148180626e-06
with O 0 3.7163289334785077e-07
severe O 0 0.09782727062702179
piebaldism B-Disease 1 0.8337935209274292
and O 0 7.655857916688547e-05
profound O 1 0.9952677488327026
congenital O 1 0.999998927116394
sensorineural B-Disease 1 0.9999985694885254
deafness I-Disease 1 0.9999986886978149
we O 0 3.752852762772818e-06
identified O 0 4.845614967052825e-07
a O 0 2.7565519644667802e-08
novel O 0 2.4498861606048195e-08
missense O 0 6.74505201914144e-07
substitution O 0 7.009917535327759e-09
at O 0 4.932374952915097e-09
a O 0 2.440184942997803e-09
highly O 0 3.1567619629413457e-09
conserved O 0 5.612828868351016e-09
residue O 0 7.46671613427452e-09
in O 0 1.446908426405713e-10
the O 0 1.671039001616137e-10
intracellular O 0 2.8354799397334318e-08
kinase O 0 3.018773142571263e-08
domain O 0 2.6508577555262036e-09
of O 0 3.454738162211868e-10
the O 0 3.2828511020710494e-09
KIT O 0 2.1160392861929722e-05
proto O 0 0.0020910862367600203
- O 0 0.0009348160238005221
oncogene O 0 0.0008565610623918474
, O 0 1.0194549560083033e-07
R796G O 0 4.302820161683485e-05
. O 0 6.427145535781165e-07

Though O 0 7.5453690442373045e-06
auditory B-Disease 0 0.0007793746190145612
anomalies I-Disease 0 0.012320470064878464
have O 0 6.694681786711953e-08
been O 0 1.4869858233623745e-08
observed O 0 4.6809390141788754e-08
in O 0 6.826172516127826e-09
mice O 0 2.7044063699577237e-06
with O 0 1.0837806208030543e-08
dominant O 0 6.8448589445324615e-06
white O 0 2.0614572349586524e-05
spotting O 0 0.0028655214700847864
( O 0 3.6655475810221105e-07
W O 0 0.00652459729462862
) O 0 4.7649093559698485e-09
due O 0 1.572536412197678e-08
to O 0 5.360448973590337e-09
KIT O 0 0.022834500297904015
mutations O 0 0.0024500065483152866
, O 0 1.4040895166544942e-06
deafness B-Disease 1 0.9998961687088013
is O 0 8.313664068282378e-08
not O 0 1.5858064861262733e-09
typical O 0 1.4674580484097532e-07
in O 0 2.589481518100456e-08
human O 0 2.893455359753716e-07
piebaldism B-Disease 0 0.0011647653300315142
. O 0 8.184771331798402e-07

Thus O 0 3.8312455217237584e-06
, O 0 5.643436651325828e-08
the O 0 1.9848867438554407e-08
occurrence O 0 4.7513713070657104e-06
of O 0 1.329187966803147e-06
sensorineural B-Disease 1 0.9999749660491943
deafness I-Disease 1 0.9999960660934448
in O 0 1.4568993719876744e-05
this O 0 1.5156885524447716e-07
patient O 0 4.55904082627967e-05
extends O 0 2.515313894946303e-07
considerably O 0 9.417525603794275e-08
the O 0 7.07446656811328e-10
phenotypic O 0 7.716915462196994e-08
range O 0 4.623429195049766e-09
of O 0 1.1677158129330678e-09
piebaldism B-Disease 0 2.0602052245521918e-05
due O 0 2.131203657995684e-08
to O 0 1.3869798642929254e-09
KIT O 0 6.731873145326972e-05
gene O 0 1.6909209534787806e-06
mutation O 0 3.020149506482994e-06
in O 0 1.6801225966034394e-09
humans O 0 2.3958919292965675e-09
and O 0 1.426777473945151e-09
tightens O 0 9.275813681597356e-06
the O 0 4.4990375869247146e-09
clinical O 0 4.199040972707735e-07
similarity O 0 9.062133266013461e-09
between O 0 4.112845619630434e-09
piebaldism B-Disease 0 7.06488481228007e-06
and O 0 8.20660372991e-10
the O 0 3.6045694207231804e-10
various O 0 1.034511143416239e-09
forms O 0 3.620366157974786e-07
of O 0 3.0125553166726604e-05
Waardenburg B-Disease 1 0.9999840259552002
syndrome I-Disease 1 0.999972939491272
. O 0 4.2686008328018943e-07
. O 0 7.788140692355228e-07

Cycloheximide O 0 0.00018573366105556488
facilitates O 0 4.070248905918561e-06
the O 0 3.0519466065470624e-08
identification O 0 7.30438927121213e-08
of O 0 3.2307163611022816e-09
aberrant O 0 1.9472327039693482e-06
transcripts O 0 3.2697928986635816e-07
resulting O 0 8.476020241232618e-08
from O 0 9.016543067730254e-10
a O 0 5.801856772791325e-09
novel O 0 7.970898607823074e-09
splice O 0 3.599548790589324e-06
- O 0 2.1692556401831098e-05
site O 0 2.1989522736021172e-07
mutation O 0 4.509753352976986e-07
in O 0 4.279310239496681e-09
COL17A1 O 0 8.20335335447453e-05
in O 0 1.5246255813394782e-08
a O 0 2.3834166995584383e-07
patient O 0 3.033207576663699e-05
with O 0 1.3425801625999156e-06
generalized O 0 0.46527963876724243
atrophic B-Disease 1 0.9999575614929199
benign I-Disease 1 0.9998621940612793
epidermolysis I-Disease 1 0.9998593330383301
bullosa I-Disease 1 0.9994606375694275
. O 0 2.8531487259897403e-05

Patients O 0 0.04136241227388382
with O 0 4.4243206502869725e-05
generalized O 1 0.8238049149513245
atrophic B-Disease 1 0.9998476505279541
benign I-Disease 1 0.9996646642684937
epidermolysis I-Disease 1 0.9998195767402649
bullosa I-Disease 1 0.9987456798553467
often O 0 6.069473670322623e-07
show O 0 6.698155630147085e-08
decreased O 0 5.817971100441355e-07
expression O 0 2.0426350388902392e-08
of O 0 4.899940453384488e-09
type O 0 6.118394594523124e-06
XVII O 0 0.0626065582036972
collagen O 0 9.428154589841142e-05
, O 0 3.842202112025461e-09
a O 0 1.851268649488702e-08
transmembrane O 0 1.7926643067767145e-06
hemidesmosomal O 0 6.450051387218991e-06
protein O 0 4.455028701499941e-08
encoded O 0 1.959615403279713e-08
by O 0 4.406150466707004e-08
COL17A1 O 0 0.00045437138760462403
. O 0 9.076621836356935e-07

This O 0 7.059564381961536e-07
report O 0 7.538081092661741e-08
documents O 0 1.3165975865092605e-08
a O 0 8.165527809467221e-09
novel O 0 2.3118644776332076e-08
splice O 0 4.776195055455901e-06
- O 0 3.0212268029572442e-05
site O 0 2.673893959581619e-07
mutation O 0 1.4317745353764622e-06
in O 0 4.155520372250976e-09
COL17A1 O 0 4.613667260855436e-05
in O 0 7.103080346126944e-09
a O 0 1.8924940548004088e-07
patient O 0 4.202203490422107e-05
with O 0 5.263252660370199e-07
generalized O 0 0.10632330924272537
atrophic B-Disease 1 0.9999794960021973
benign I-Disease 1 0.9997686743736267
epidermolysis I-Disease 1 0.9999419450759888
bullosa I-Disease 1 0.9997168183326721
, O 0 1.027133222919474e-07
and O 0 2.4882658156144544e-09
applies O 0 4.788853313897334e-09
a O 0 3.1958620194671994e-09
new O 0 2.2403245925062265e-09
methodology O 0 8.61803783891446e-09
to O 0 1.9345386403912812e-10
define O 0 8.569682741210727e-09
and O 0 1.1758937157324567e-09
characterize O 0 2.2589221160274064e-08
the O 0 7.712861460618115e-10
resulting O 0 1.6187634344078106e-08
mRNA O 0 7.438758586886252e-08
splice O 0 9.852694347500801e-06
variants O 0 2.549706096033333e-06
. O 0 7.477828489754756e-07

Mutational O 0 0.001880618860013783
analysis O 0 2.6316006369597744e-06
of O 0 2.056609815781485e-07
COL17A1 O 0 0.0053052352741360664
identified O 0 2.4867451884347247e-06
a O 0 3.9608664792467607e-07
maternally O 0 0.0004506945551838726
inherited O 0 0.11408436298370361
G O 0 0.02037576399743557
- O 0 1.8170132534578443e-05
to O 0 7.90515830573213e-09
- O 0 0.0005128964548930526
T O 0 0.0007891135755926371
transversion O 0 3.908829512511147e-06
at O 0 2.6965292221348136e-09
the O 0 1.2079676148246676e-09
- O 0 2.6570481281851244e-07
1 O 0 4.110884965768946e-09
position O 0 3.15888204482917e-09
of O 0 4.153396737649473e-09
exon O 0 1.9465665900497697e-05
32 O 0 8.232964319176972e-07
. O 0 3.1730809268992743e-07

This O 0 1.1006947886471607e-07
acceptor O 0 2.0640206912503345e-06
splice O 0 9.395540109835565e-05
- O 0 0.00014570425264537334
site O 0 6.556915650435258e-07
mutation O 0 7.530478569606203e-07
led O 0 3.4105207546986094e-09
to O 0 5.4271594163157744e-11
the O 0 3.7677846953521055e-10
formation O 0 2.832739376401605e-08
of O 0 4.1839587350267493e-10
aberrant O 0 1.7227414161880006e-07
transcripts O 0 3.5229813732939874e-08
present O 0 6.366625449061303e-09
at O 0 9.659520117111242e-08
extremely O 0 2.1769317299913382e-06
low O 0 2.7814816348836757e-05
levels O 0 4.0486738726031035e-06
. O 0 3.572411912955431e-07

Based O 0 7.554899070782994e-07
on O 0 3.582858454365123e-08
our O 0 1.2628770029721181e-08
recent O 0 1.9247210047979024e-08
finding O 0 1.3823534317225494e-08
that O 0 1.4155796534964793e-09
cycloheximide O 0 1.4472446309810039e-05
stabilized O 0 1.724177855066955e-05
mutant O 0 1.191253886645427e-06
COL17A1 O 0 1.552381036162842e-05
transcripts O 0 3.641710222268557e-08
in O 0 2.8452571410042538e-09
keratinocytes O 0 3.9787360606169386e-07
homozygous O 0 3.1465927463614207e-07
for O 0 3.5301364054163287e-09
a O 0 6.627484481214196e-07
frameshift O 0 0.21769733726978302
mutation O 0 1.6138626961037517e-05
, O 0 8.166209375382039e-10
the O 0 3.293121886294159e-10
effects O 0 2.784929620247567e-09
of O 0 1.3256019892882165e-10
the O 0 4.0956446567541605e-10
splice O 0 1.1000815902661998e-06
- O 0 2.1649857444572262e-06
site O 0 1.4749637955446815e-08
mutation O 0 1.784052905406952e-08
on O 0 1.383982511926618e-10
splicing O 0 5.321239893163465e-09
of O 0 5.632440625014112e-10
COL17A1 O 0 7.88581746746786e-06
transcripts O 0 2.890726591431303e-08
were O 0 4.489691673992269e-10
determined O 0 1.2701936169534633e-09
using O 0 6.666565632862387e-10
reverse O 0 8.770033588234583e-08
transcriptase O 0 1.4173467661748873e-06
polymerase O 0 5.237366167420987e-07
chain O 0 4.119285677006701e-07
reaction O 0 1.460244813955569e-09
of O 0 1.1081735529216985e-10
total O 0 2.445635083336839e-10
RNA O 0 7.3796138089221586e-09
from O 0 3.4596639442163735e-10
keratinocytes O 0 5.058580043737493e-08
incubated O 0 6.293090848430438e-08
for O 0 4.42390835075912e-09
2 O 0 1.9724313915503444e-07
. O 0 2.851942610959668e-07

5 O 0 8.34959701023763e-06
h O 0 8.15837483969517e-06
in O 0 1.2608624366805543e-08
the O 0 1.8340953200635113e-09
presence O 0 5.881554798747857e-09
or O 0 1.4109755586133588e-09
absence O 0 6.714051536960142e-09
of O 0 7.813026892122821e-10
10 O 0 1.7020498788156146e-08
microg O 0 4.066087058163248e-05
cycloheximide O 0 0.000499654735904187
per O 0 6.563153078786854e-07
ml O 0 0.0006571082631126046
. O 0 6.83606401707948e-07

Using O 0 4.358748242339061e-07
this O 0 1.5987572155040652e-08
approach O 0 5.145459169852984e-08
, O 0 1.6690074877701022e-09
an O 0 1.74731762392355e-09
abnormally O 0 4.037796315969899e-06
spliced O 0 3.7614809116348624e-06
transcript O 0 5.7353654483449645e-06
was O 0 4.402152242732882e-08
identified O 0 1.0132357175507423e-08
that O 0 6.24671772642138e-11
contains O 0 8.981866639334868e-11
an O 0 3.618095753554762e-11
extra O 0 3.965888728529876e-10
264 O 0 2.5580724205553906e-09
bases O 0 1.4389857083685342e-09
upstream O 0 2.5364714772990737e-09
from O 0 2.854480263270176e-10
exon O 0 1.6600860419657693e-07
32 O 0 1.0808307138177042e-08
, O 0 5.631066168909626e-10
resulting O 0 7.287575876091523e-09
in O 0 1.4998857711390201e-09
a O 0 4.940512354778548e-08
premature O 0 1.35048248921521e-05
termination O 0 2.3214934117277153e-05
codon O 0 1.5606730130457436e-06
27 O 0 3.161430868203752e-07
bp O 0 2.60801556350998e-07
downstream O 0 1.5799081154455052e-08
from O 0 7.427367054724243e-10
the O 0 1.6204677599773731e-09
cryptic O 0 5.147491606294352e-07
splice O 0 7.690679012739565e-06
site O 0 1.3999018619870185e-06
. O 0 3.0821294672023214e-07

Three O 0 2.606354598810867e-07
other O 0 1.0820910389952587e-08
splice O 0 2.7348348794475896e-06
variants O 0 3.4516799019002065e-07
, O 0 3.322917274672932e-09
including O 0 8.42143244028648e-10
one O 0 2.6091018234808416e-10
derived O 0 4.198459913062891e-10
from O 0 9.652489224576399e-11
the O 0 1.0668834565796814e-10
skipping O 0 4.36020064498166e-09
of O 0 2.746975702461185e-10
exon O 0 1.2915826346215908e-06
32 O 0 3.0639267123433456e-08
, O 0 9.215165852616281e-10
were O 0 8.344731017295715e-10
also O 0 1.0496190583353382e-08
identified O 0 6.265687488848926e-07
. O 0 2.0596147010110144e-07

These O 0 3.2977331443362345e-07
results O 0 1.5292803254851606e-06
indicate O 0 4.0548879809421123e-08
the O 0 2.856567649089925e-09
usefulness O 0 9.53222638599982e-08
of O 0 1.1946558409192676e-08
cycloheximide O 0 0.01335166022181511
treatment O 0 9.218131708621513e-06
in O 0 9.758701402518e-09
evaluating O 0 4.77178758728769e-08
the O 0 9.39569977376209e-10
abnormal O 0 2.6102691563778535e-08
processing O 0 1.5144402398803436e-09
of O 0 8.798067135940002e-11
mRNA O 0 1.5923896645730906e-09
due O 0 7.625403641853268e-10
to O 0 1.098392696241568e-10
splice O 0 2.9324514798645396e-06
- O 0 3.559034303179942e-05
site O 0 1.8274217836733442e-06
mutations O 0 1.4259247109293938e-05
, O 0 5.348183673703488e-09
because O 0 3.899895517633922e-09
( O 0 1.6552297310568065e-09
i O 0 9.202273942854333e-10
) O 0 1.1481935541235444e-10
aberrant O 0 9.882834106633709e-09
splicing O 0 3.2706154229344975e-08
often O 0 1.4779735213465983e-09
generates O 0 7.482041652906446e-09
a O 0 2.610747174003336e-08
premature O 0 4.100709247722989e-06
termination O 0 5.856667030457174e-06
codon O 0 5.165135235074558e-07
, O 0 2.7586333217755055e-09
( O 0 1.7414717445873862e-09
ii O 0 2.878809652884229e-07
) O 0 1.959935991280304e-09
transcripts O 0 5.48316663184778e-08
with O 0 3.3188396031391676e-08
premature O 0 0.0001669958874117583
termination O 0 0.0001528043212601915
codons O 0 6.0533157011377625e-06
can O 0 3.821022609429292e-09
occur O 0 5.975646200084839e-09
at O 0 8.337861956420056e-09
low O 0 2.309383972942669e-07
or O 0 7.703529369962325e-09
undetectable O 0 1.066819913830841e-05
levels O 0 2.6488880422448347e-08
due O 0 1.2849553643334843e-09
to O 0 8.825799119316358e-11
nonsense O 0 3.9007154839509894e-08
- O 0 3.524298364254719e-08
mediated O 0 1.5496278038540368e-08
mRNA O 0 9.176898352336593e-09
decay O 0 9.488328345241825e-08
, O 0 4.4515588437654685e-10
and O 0 2.2671640953486616e-10
( O 0 5.270590630601646e-10
iii O 0 2.2240624275582377e-07
) O 0 1.3680410970717816e-10
the O 0 1.398198640201187e-10
levels O 0 1.4021624972215818e-09
of O 0 3.1786667048505635e-11
these O 0 2.5004998072120088e-11
transcripts O 0 4.396997432820626e-09
can O 0 1.7343639024947066e-10
be O 0 3.687235516913745e-10
increased O 0 1.0720086152105068e-08
by O 0 2.120620479217905e-08
cycloheximide O 0 0.0005238248850218952
. O 0 5.289065256874892e-07

A O 0 2.6432198865222745e-05
deletion O 0 0.001939330599270761
mutation O 0 0.0006594482692889869
in O 0 1.4748758303539944e-07
COL17A1 O 0 0.0003221826918888837
in O 0 3.726052000274649e-08
five O 0 3.523747338363137e-08
Austrian O 0 6.857500557089224e-05
families O 0 1.0788271254114079e-07
with O 0 1.2818529739888618e-06
generalized O 0 0.4094342589378357
atrophic B-Disease 1 0.9999616146087646
benign I-Disease 1 0.9997503161430359
epidermolysis I-Disease 1 0.999931812286377
bullosa I-Disease 1 0.9995798468589783
represents O 0 2.349981741645024e-06
propagation O 0 1.3430779688405892e-07
of O 0 1.7753822856292345e-09
an O 0 1.0573873332475614e-08
ancestral O 0 3.942230250686407e-06
allele O 0 8.996296855912078e-06
. O 0 8.753235647418478e-07

Patients O 0 0.02952003665268421
with O 0 3.8557900552405044e-05
generalized O 1 0.8073959350585938
atrophic B-Disease 1 0.9999290704727173
benign I-Disease 1 0.9998537302017212
epidermolysis I-Disease 1 0.9998900890350342
bullosa I-Disease 1 0.9997407793998718
, O 0 1.2555514103951282e-06
a O 0 8.836760656549814e-08
usually O 0 1.092172485783749e-08
nonlethal O 0 2.7975386274192715e-07
form O 0 2.9685892855013662e-08
of O 0 1.0673999639720932e-07
junctional B-Disease 1 0.9936321377754211
epidermolysis I-Disease 1 0.9998075366020203
bullosa I-Disease 1 0.9996147155761719
, O 0 2.7046183959100745e-07
have O 0 1.117028070041215e-08
generalized O 0 5.51633183931699e-06
blistering B-Disease 0 0.0023423030506819487
, O 0 1.946490328919026e-06
nail B-Disease 1 0.9993896484375
dystrophy I-Disease 1 0.99992835521698
, O 0 4.77939065604005e-05
patchy B-Disease 1 0.9986556768417358
alopecia I-Disease 1 0.999985933303833
, O 0 5.300707016431261e-06
and O 0 3.10062023345381e-05
dental B-Disease 1 0.9998676776885986
abnormalities I-Disease 1 0.999775230884552
. O 0 1.9365144908078946e-05

Skin B-Disease 1 0.9402285218238831
fragility I-Disease 0 0.29768189787864685
in O 0 8.123741395138495e-07
most O 0 4.646186013701481e-08
cases O 0 2.2408946165342059e-07
is O 0 5.066514763285568e-09
due O 0 1.0353209844993216e-08
to O 0 8.163733022925612e-10
mutations O 0 8.750216551334233e-08
in O 0 3.577651230823875e-10
the O 0 4.2487927065515407e-10
gene O 0 1.871844368395159e-08
encoding O 0 2.2957738110562786e-07
type O 0 5.9345846239011735e-05
XVII O 1 0.7136451601982117
collagen O 0 0.017550595104694366
( O 0 5.32031947386713e-07
COL17A1 O 0 0.0012716236524283886
) O 0 1.9153209507294378e-07
. O 0 4.132065214434988e-07

Recently O 0 0.000124495622003451
, O 0 2.82687324215658e-07
we O 0 1.560745310769107e-08
reported O 0 1.5692560850766313e-07
five O 0 8.490271596883758e-09
Austrian O 0 1.4900207133905496e-05
families O 0 4.3959094142564936e-08
with O 0 5.969451422060956e-07
generalized O 0 0.18492238223552704
atrophic B-Disease 1 0.9999706745147705
benign I-Disease 1 0.9998204112052917
epidermolysis I-Disease 1 0.9998769760131836
bullosa I-Disease 1 0.9994762539863586
who O 0 3.047848906589934e-07
share O 0 3.932899161895875e-08
the O 0 1.2433477358797518e-08
same O 0 1.2958116712979972e-07
COL17A1 O 0 0.04453780874609947
mutation O 0 0.0005711680860258639
. O 0 9.13666838187055e-07

Affected O 0 1.683194568613544e-05
individuals O 0 1.8939311985377572e-07
in O 0 1.2491381262691448e-08
three O 0 5.9054872103558864e-09
families O 0 6.680775044287657e-09
are O 0 6.868143831439966e-10
homozygous O 0 1.1981065028976445e-07
for O 0 1.1508910491286883e-09
4003delTC O 0 5.328226961864857e-06
, O 0 2.663690823467846e-09
whereas O 0 7.1867543027792635e-09
those O 0 2.9809724133578186e-10
in O 0 4.991627666761644e-10
two O 0 4.3743261790574195e-10
others O 0 2.5874657971769466e-09
are O 0 1.9092682990162757e-09
compound O 0 5.29971657670103e-06
heterozygotes O 0 0.00026080661336891353
. O 0 8.247707228292711e-07

To O 0 2.1490176038696518e-07
determine O 0 2.393085196672473e-07
if O 0 4.971486333715802e-09
the O 0 8.02872435201607e-10
occurrence O 0 3.332788622856242e-08
of O 0 2.2543584776713033e-09
4003delTC O 0 1.4862513125990517e-05
in O 0 7.988371741873834e-09
these O 0 3.744543841666115e-10
unrelated O 0 7.214706698732698e-08
families O 0 3.157255790142699e-09
signifies O 0 7.335549057074786e-09
propagation O 0 1.7924426387594394e-09
of O 0 1.210751082725281e-10
an O 0 2.3269300375439173e-10
ancestral O 0 6.399438490234388e-08
allele O 0 6.100764693428573e-08
or O 0 3.287901728654674e-09
a O 0 1.4460437292029837e-08
mutational O 0 1.695051832939498e-05
hot O 0 2.698193100059143e-07
spot O 0 5.1924470056974315e-08
, O 0 1.2088272605126349e-09
haplotypes O 0 1.9853946753300988e-07
were O 0 1.806576555019035e-09
determined O 0 7.983222971574833e-09
for O 0 4.037111200894117e-10
polymorphisms O 0 6.067807021281624e-07
both O 0 7.143946545440372e-10
within O 0 7.710879046385344e-09
and O 0 2.9633053344468863e-08
flanking O 0 0.0028195062186568975
COL17A1 O 0 0.1967063695192337
. O 0 2.0909926661261125e-06

Five O 0 3.742641638382338e-06
intragenic O 0 0.00045031236368231475
polymorphisms O 0 9.506316564511508e-05
were O 0 1.3355416328408865e-08
chosen O 0 8.594219558233362e-09
based O 0 6.515057826561588e-09
on O 0 2.328733650358572e-09
their O 0 1.5549986187579634e-08
informativeness O 0 0.0002962535072583705
. O 0 5.862596026418032e-07

One O 0 1.22112069789182e-07
of O 0 5.2488635660097316e-09
these O 0 9.499312447758257e-10
, O 0 1.0361501656674932e-09
not O 0 2.6344043613235613e-10
previously O 0 6.280437947481232e-09
reported O 0 5.1171841874975144e-08
, O 0 5.954844395361647e-10
was O 0 5.479431575139415e-09
2988 O 0 2.8538900096464204e-06
A O 0 1.6451342332857166e-07
or O 0 1.5709085587900518e-08
C O 0 8.496836301219446e-08
that O 0 1.2419741624025704e-10
introduces O 0 6.767214344449712e-09
a O 0 2.1610182532327826e-09
new O 0 2.597181802954651e-09
restriction O 0 5.868679764375884e-09
site O 0 1.646357539186738e-08
for O 0 6.363736204662018e-09
Eco0109 O 0 2.8485703296610154e-05
I O 0 8.811680345388595e-07
. O 0 3.180855401296867e-07

All O 0 3.342038112918999e-08
the O 0 3.002717008371292e-08
4003delTC O 0 1.2136087207181845e-05
alleles O 0 9.718525006974232e-07
showed O 0 1.19300764822583e-07
the O 0 1.408735572638875e-09
same O 0 2.198392801133764e-09
haplotype O 0 1.0489364967725123e-06
for O 0 5.141294612265312e-10
these O 0 5.941094283201664e-10
five O 0 2.594395631660973e-08
polymorphic O 0 8.512833301210776e-05
markers O 0 4.429039836395532e-05
. O 0 5.224445658313925e-07

Fourteen O 0 2.2484058717964217e-05
microsatellite O 0 0.0036388260778039694
polymorphisms O 0 0.0003038652357645333
were O 0 2.2249698972132137e-08
selected O 0 4.667136010994e-09
based O 0 3.26602589417746e-09
on O 0 6.677383090902822e-10
their O 0 1.1841424507608167e-09
high O 0 2.2355605722168548e-07
heterozygosity O 0 1.874541885626968e-05
and O 0 8.771464110601812e-10
their O 0 4.517126395153781e-10
location O 0 5.3171311797939325e-09
within O 0 6.2549743162776394e-09
10q23 O 0 8.915617399907205e-06
- O 0 1.950967089214828e-05
q25 O 0 2.6866466214414686e-05
near O 0 7.4130330176558346e-06
COL17A1 O 0 0.0006953271804377437
. O 0 5.47338061096525e-07

Three O 0 6.07093284088478e-07
families O 0 2.101679399402201e-07
shared O 0 6.822894533797808e-07
microsatellite O 0 0.0044938684441149235
polymorphisms O 0 0.00023732961562927812
covering O 0 1.3072873343844549e-06
at O 0 5.0473616397539445e-08
most O 0 2.965882428540567e-09
19 O 0 9.384854848804025e-08
cM O 0 1.0684055951060145e-06
, O 0 1.256765691515227e-09
whereas O 0 4.935009290107928e-09
the O 0 7.015892311557081e-10
others O 0 7.772242294201703e-10
shared O 0 2.955305777874173e-09
smaller O 0 3.436766604636432e-08
regions O 0 2.5661075042648918e-08
consistent O 0 2.0459417271467828e-08
with O 0 3.746445820240751e-09
cross O 0 2.0200594974539854e-07
- O 0 7.427954074046283e-07
over O 0 1.0442907649732547e-09
events O 0 6.133357155491126e-10
during O 0 2.704528379027238e-09
passage O 0 3.884661481379226e-09
of O 0 2.7856611461984926e-10
this O 0 5.134807024020915e-10
mutation O 0 3.937162418310436e-08
through O 0 1.2046452724234769e-09
several O 0 4.810357445705904e-09
generations O 0 2.208059868280543e-07
. O 0 3.819822893547098e-07

These O 0 1.182856294690282e-06
results O 0 4.643365627998719e-06
indicate O 0 2.6589290769152285e-07
that O 0 7.836133519845134e-09
4003delTC O 0 1.1658862604235765e-05
occurs O 0 2.1014304962818642e-08
on O 0 1.908849744935992e-09
a O 0 5.08582065350538e-09
single O 0 1.3305428758769722e-08
ancestral O 0 8.633388688394916e-07
allele O 0 1.2043893775626202e-06
. O 0 5.0686633557006644e-08
. O 0 2.083626498006197e-07

The O 0 3.1280085295293247e-06
haptoglobin O 0 0.005229719448834658
- O 0 0.00015357618394773453
gene O 0 6.7540258896769956e-06
deletion O 0 1.8192271454609e-05
responsible O 0 4.968100597579905e-07
for O 0 1.2853928410549997e-07
anhaptoglobinemia B-Disease 0 0.004989797715097666
. O 0 1.2759802530126763e-06

We O 0 4.503096420194197e-07
have O 0 2.8920391414999358e-08
found O 0 1.450397046909302e-08
an O 0 1.9604369239090147e-09
allelic O 0 3.0474843697447795e-06
deletion O 0 6.414935000975674e-07
of O 0 1.331252996727983e-09
the O 0 5.885550269368878e-09
haptoglobin O 0 4.184041608823463e-05
( O 0 7.470334573156379e-09
Hp O 0 1.7665880136519263e-07
) O 0 8.959423203336314e-10
gene O 0 6.191341217487434e-09
from O 0 3.4056304998308917e-10
an O 0 3.124497049977748e-10
individual O 0 3.3399398802202995e-09
with O 0 3.7083768944512485e-08
anhaptoglobinemia B-Disease 0 0.0005662989569827914
. O 0 8.308218184538418e-07

The O 0 5.339268795978569e-07
Hp O 0 4.830255420529284e-06
gene O 0 9.97919187284424e-07
cluster O 0 4.3564460838751984e-07
consists O 0 1.1116465969962519e-08
of O 0 1.9775547865918952e-09
coding O 0 7.546165079475031e-07
regions O 0 2.2288265455472356e-08
of O 0 4.590869628895433e-10
the O 0 1.8967605264208487e-09
alpha O 0 9.277181334255147e-08
chain O 0 8.281969599011063e-07
and O 0 1.1157413881690559e-09
beta O 0 5.301468064544679e-08
chain O 0 5.850833417753165e-08
of O 0 1.7937959451153063e-10
the O 0 7.116217060065821e-10
haptoglobin O 0 3.900986939697759e-06
gene O 0 3.5564884370842265e-08
( O 0 9.012193213919772e-10
Hp O 0 1.425399087651158e-08
) O 0 1.7087782577807076e-10
and O 0 4.6718517943133975e-11
of O 0 3.9363453468999055e-11
the O 0 3.5444919221916393e-10
alpha O 0 3.856594688045334e-08
chain O 0 3.378667656761536e-07
and O 0 7.072119556639223e-10
beta O 0 5.1991467131529134e-08
chain O 0 5.8587286133615635e-08
of O 0 2.1904142388784464e-10
the O 0 3.6248273271866083e-09
haptoglobin O 0 0.00010811778338393196
- O 0 3.534765346557833e-05
related O 0 7.351000874677993e-08
gene O 0 1.7828529053076636e-07
( O 0 3.1337612504955814e-09
Hpr O 0 5.5924278967722785e-06
) O 0 1.1365068885993423e-09
, O 0 3.81403075788711e-10
in O 0 5.64669366820425e-10
tandem O 0 1.332936108155991e-07
from O 0 7.554453729241573e-10
the O 0 3.4211600219435923e-09
5 O 0 5.732789531975868e-08
side O 0 5.155254143573984e-07
. O 0 2.2361341223131603e-07

Southern O 0 9.075331945496146e-06
blot O 0 4.99949928780552e-05
and O 0 3.821381966417903e-08
PCR O 0 1.1062887097068597e-05
analyses O 0 4.019785251330177e-07
have O 0 5.4136628513390406e-09
indicated O 0 1.587689801851866e-08
that O 0 6.483502623666482e-11
the O 0 8.358872621849756e-11
individual O 0 3.416222305041572e-10
with O 0 1.3389178654676925e-09
anhaptoglobinemia B-Disease 0 4.060673018102534e-05
was O 0 2.7204647423673123e-08
homozygous O 0 9.68316840044281e-08
for O 0 1.3806655818626723e-10
the O 0 4.952678822611745e-10
gene O 0 1.3187438696604659e-08
deletion O 0 1.8088364583945804e-07
and O 0 3.1784380682964297e-10
that O 0 3.573271192824912e-11
the O 0 1.803735216743263e-10
gene O 0 8.575274712541159e-09
deletion O 0 2.9577981308648305e-07
was O 0 4.076855741885765e-09
included O 0 5.276605818949065e-10
at O 0 1.5282057841403685e-09
least O 0 3.3441263647127073e-10
from O 0 2.374635488244792e-10
the O 0 4.92019536224575e-10
promoter O 0 1.9926369532186072e-07
region O 0 2.7788276124596223e-09
of O 0 2.7072985520071313e-10
Hp O 0 5.2572623587821e-08
to O 0 4.986593360456482e-10
Hpr O 0 9.481411325396039e-06
alpha O 0 1.5788212692768866e-07
but O 0 4.0226302844281747e-10
not O 0 1.3092764372668597e-10
to O 0 7.566004489589773e-10
Hpr O 0 4.622254709829576e-05
beta O 0 2.9802786229993217e-06
( O 0 1.8587199335229343e-08
Hpdel O 0 3.1885094358585775e-05
) O 0 4.1866773159426884e-08
. O 0 1.1452185333382658e-07

In O 0 9.404275829183462e-07
addition O 0 2.1569370289853396e-07
, O 0 1.971898377917114e-08
we O 0 1.2301279994630931e-09
found O 0 1.7485011216678004e-09
seven O 0 1.534075866338469e-09
individuals O 0 3.509992851924437e-10
with O 0 2.0803168077065948e-09
hypohaptoglobinemia B-Disease 0 1.3616793694382068e-05
in O 0 4.607179082682933e-09
three O 0 1.6635284261212746e-09
families O 0 3.939661930019156e-09
, O 0 5.025646565570696e-10
and O 0 1.3835838030828995e-10
the O 0 3.888677435615051e-10
genotypes O 0 7.593958173401916e-08
of O 0 1.8285579994614665e-10
six O 0 5.90494320107382e-10
of O 0 9.197356071188878e-11
the O 0 6.722262191338757e-10
seven O 0 3.2639457803185223e-09
individuals O 0 5.717550322081877e-10
were O 0 3.574731899380623e-10
found O 0 7.678557789603246e-10
to O 0 2.0392580679651218e-10
be O 0 5.539803726861692e-09
Hp2 O 0 0.0004561810928862542
/ O 0 0.00023525019059889019
Hpdel O 0 0.0022812862880527973
. O 0 1.0738216360550723e-06

The O 0 6.593605803573155e-07
phenotypes O 0 0.00026800634805113077
and O 0 7.278424618561985e-08
genotypes O 0 5.063941443950171e-06
in O 0 4.155710442432792e-09
one O 0 2.341662697080693e-10
of O 0 7.138426655339813e-11
these O 0 4.497282754534204e-11
three O 0 4.733131664380608e-10
families O 0 2.4945525645136968e-09
showed O 0 3.969600825826092e-08
the O 0 7.583991767923237e-10
father O 0 1.0635159419791762e-08
to O 0 1.9899568104442267e-10
be O 0 5.362604249548042e-10
hypohaptoglobinemic B-Disease 0 4.97391147291637e-06
( O 0 5.187049456623072e-09
Hp2 O 0 3.4827955914806807e-06
) O 0 1.4261272163196281e-09
and O 0 1.893478263070847e-09
Hp2 O 0 1.94818785530515e-05
/ O 0 3.700061824929435e-06
Hpdel O 0 2.09526206162991e-05
, O 0 1.661010995412937e-09
the O 0 1.3745125038155948e-09
mother O 0 3.674244197782173e-08
to O 0 9.644170878564395e-11
be O 0 3.1974331515804977e-10
Hp2 O 0 2.670224375833641e-06
- O 0 1.0136242281078012e-06
1 O 0 3.949495397392866e-09
and O 0 2.2769157670410323e-09
Hp1 O 0 2.4412567654508166e-05
/ O 0 3.325611942273099e-06
Hp2 O 0 6.122930244600866e-06
, O 0 4.892121707733565e-10
one O 0 7.0796195295042e-11
of O 0 4.5819441990557763e-11
the O 0 1.5158006794191436e-10
two O 0 3.2639690950020395e-10
children O 0 1.5377846773745318e-09
to O 0 1.9104803850034102e-10
be O 0 8.247480476342162e-10
hypohaptoglobinemic B-Disease 0 9.273513569496572e-06
( O 0 3.3971661039799983e-09
Hp2 O 0 2.594213128759293e-06
) O 0 1.0952906359662506e-09
and O 0 1.3019060274288563e-09
Hp2 O 0 5.9965015680063516e-05
/ O 0 1.0560777809587307e-05
Hpdel O 0 5.033799970988184e-05
, O 0 1.7525711992760762e-09
and O 0 2.350195593692206e-10
the O 0 3.4052344277668567e-10
other O 0 1.3934543796612076e-10
child O 0 1.9969091269445016e-08
to O 0 1.4164081019174546e-10
be O 0 4.579832346696122e-10
Hp1 O 0 2.1982446014590096e-06
and O 0 9.009568202600349e-09
Hp1 O 0 0.0002499859838280827
/ O 0 1.6305113604175858e-05
Hpdel O 0 4.620157415047288e-05
, O 0 3.3974447699591792e-09
showing O 0 2.061579351675391e-08
an O 0 6.502205440739317e-10
anomalous O 0 2.2752331574338314e-07
inheritance O 0 4.771082444676722e-07
of O 0 5.413951953414653e-09
Hp O 0 9.148996468866244e-06
phenotypes O 0 2.521923670428805e-05
in O 0 6.383868544901361e-09
the O 0 7.07436287328278e-09
child O 0 1.1027958635168034e-06
with O 0 2.1607931444123096e-07
Hp1 O 0 0.0016963774105533957
. O 0 1.3947128536528908e-06

The O 0 2.3431764475390082e-06
Hp2 O 0 0.0014321880880743265
/ O 0 5.2832892833976075e-05
Hpdel O 0 9.632481669541448e-05
individuals O 0 2.2083792572402672e-08
had O 0 5.399411584505742e-09
an O 0 9.6732655219256e-10
extremely O 0 2.7874072827671625e-08
low O 0 5.831069671557998e-08
level O 0 3.543952908913184e-09
of O 0 7.582111605231034e-10
Hp O 0 1.8020216430159053e-07
( O 0 1.8484873631763321e-09
mean O 0 1.1108072683896353e-08
+ O 0 9.32913550855119e-08
/ O 0 4.4061422954655427e-07
- O 0 1.0270092616337934e-06
SD O 0 7.826297951396555e-05
= O 0 7.308151452889433e-07
0 O 0 1.40235583145909e-08
. O 0 1.4997342256961588e-09
049 O 0 5.006558694731211e-06
+ O 0 4.570377711843321e-07
/ O 0 4.334899301738915e-07
- O 0 3.895890472449537e-07
0 O 0 1.0262887428780232e-08
. O 0 1.1768809260459534e-09
043 O 0 3.503716925479239e-06
mg O 0 1.4146124158287421e-05
/ O 0 1.5633708017048775e-06
ml O 0 3.26830631820485e-05
; O 0 1.402270211059431e-08
n O 0 7.300210427274578e-07
= O 0 2.581660965006449e-07
6 O 0 7.673437885102885e-09
) O 0 2.759484585279637e-10
, O 0 3.3758873474454276e-10
compared O 0 2.6257476193336515e-09
with O 0 1.4021296623756285e-10
the O 0 2.3383689429223864e-10
level O 0 1.661625725901672e-09
( O 0 3.039500040546983e-10
1 O 0 6.672519203831939e-10
. O 0 1.4497678058056351e-10
64 O 0 7.347843666849485e-09
+ O 0 1.5124729202398157e-07
/ O 0 3.0309817589113663e-07
- O 0 3.4110891533600807e-07
1 O 0 2.4382866836702988e-09
. O 0 3.8835851201568516e-10
07 O 0 9.326644345719615e-08
mg O 0 3.7994370813976275e-06
/ O 0 6.148801503513823e-07
ml O 0 1.7795890698835137e-06
) O 0 7.140377733527714e-10
obtained O 0 9.398047895459172e-10
from O 0 4.662373820352173e-10
52 O 0 5.42290479188523e-08
healthy O 0 2.1070458444683027e-07
volunteers O 0 5.643598299798214e-08
having O 0 2.3427684681109895e-08
phenotype O 0 6.090050192142371e-06
Hp2 O 0 1.1603004168136977e-05
, O 0 1.5738558234446032e-09
whereas O 0 3.1344069562067034e-09
the O 0 2.3087436407109863e-09
serum O 0 1.084522978089808e-06
Hp O 0 3.399124892666805e-08
level O 0 1.1548777489878148e-09
of O 0 5.322087215375859e-11
an O 0 7.437201549054251e-11
individual O 0 5.232687616540943e-10
with O 0 4.54457538268116e-09
Hp1 O 0 0.00019969009736087173
/ O 0 2.908482747443486e-05
Hpdel O 0 0.0003291147295385599
was O 0 2.55681072758307e-07
0 O 0 1.49614857036795e-06
. O 0 5.28866166860098e-07

50 O 0 7.2331945375481155e-06
mg O 0 0.0004624536959454417
/ O 0 3.148377436446026e-05
ml O 0 6.456283153966069e-05
, O 0 3.522629965502233e-09
which O 0 4.026898536846346e-10
was O 0 3.041924212521252e-10
approximately O 0 3.1797658950338814e-10
half O 0 2.1756743628920105e-10
the O 0 7.530224360730031e-11
level O 0 4.392627928062609e-10
of O 0 1.10794526331226e-10
Hp O 0 6.287248055514283e-08
in O 0 2.5882160858969883e-09
control O 0 1.766394319702158e-07
sera O 0 1.2923144367960049e-06
from O 0 7.479027397394589e-10
the O 0 1.3520184971582694e-09
Hp1 O 0 1.5707184502389282e-05
phenotype O 0 2.953331886601518e-06
( O 0 1.7126717821724924e-09
1 O 0 2.5804378633864644e-09
. O 0 3.871980236436201e-10
26 O 0 8.886957836296006e-09
+ O 0 1.2653030978526658e-07
/ O 0 3.796949101797509e-07
- O 0 4.686772570039466e-07
0 O 0 7.72931496584306e-09
. O 0 2.219000261316495e-10
33 O 0 1.5297755950882674e-08
mg O 0 2.876114194805268e-06
/ O 0 1.3220452501627733e-06
ml O 0 2.43756494455738e-05
; O 0 1.5813553133625646e-08
n O 0 7.130434482860437e-07
= O 0 2.1773790592760633e-07
9 O 0 4.216100357723462e-09
) O 0 2.842771573696723e-10
, O 0 2.22775756175686e-10
showing O 0 9.032142145315447e-09
a O 0 3.562931993883467e-08
gene O 0 2.9569816888397327e-06
- O 0 0.00020542404672596604
dosage O 0 9.439615678275004e-05
effect O 0 9.625437087379396e-07
. O 0 1.6539215152988618e-07

The O 0 2.8503382054623216e-07
other O 0 7.091073062071018e-09
allele O 0 2.4251855279544543e-07
( O 0 9.218862118132165e-09
Hp2 O 0 2.0574016161845066e-06
) O 0 7.405582813646561e-10
of O 0 1.8008339264241613e-10
individuals O 0 5.623477794536313e-10
with O 0 3.760707301125876e-09
Hp2 O 0 0.00022626796271651983
/ O 0 1.71877854882041e-05
Hpdel O 0 0.00034678381052799523
was O 0 3.339005161251407e-08
found O 0 1.5976833189768058e-09
to O 0 6.655560130797156e-11
have O 0 1.0599831429258799e-10
, O 0 9.19563730716888e-11
in O 0 1.734162258237859e-10
all O 0 7.894873643721212e-11
exons O 0 2.2606121774515486e-07
, O 0 2.7870017405007275e-09
no O 0 7.956256098395897e-09
mutation O 0 3.5959214983449783e-07
, O 0 1.0511250758682422e-09
by O 0 2.955486300137977e-09
DNA O 0 1.4599804671888705e-06
sequencing O 0 2.107143473040196e-06
. O 0 4.1029758790500637e-07

On O 0 1.216882310473011e-07
the O 0 8.579642774009244e-09
basis O 0 4.4258747777803364e-09
of O 0 6.574837341233319e-10
the O 0 1.0390336369070496e-09
present O 0 3.3324885073682253e-09
study O 0 4.243134288373085e-09
, O 0 2.2470679483799216e-10
the O 0 1.9709413268120812e-10
mechanism O 0 3.208492360684545e-09
of O 0 2.8393573603402444e-10
anhaptoglobinemia B-Disease 0 2.647130713739898e-06
and O 0 5.20310905471888e-10
the O 0 4.941619335951941e-10
mechanism O 0 5.111065348728516e-09
of O 0 6.199692426100967e-10
anomalous O 0 3.0866388556205493e-07
inheritance O 0 4.960246542395907e-07
of O 0 8.71006644587169e-09
Hp O 0 1.3999519069329835e-05
phenotypes O 0 4.2799030779860914e-05
were O 0 9.475466633546148e-09
well O 0 2.7483725517640778e-08
explained O 0 8.90705166511907e-07
. O 0 2.705820350001886e-07

However O 0 6.281985633904696e-07
, O 0 1.2023181561460206e-08
the O 0 4.2039594028153715e-09
mechanism O 0 1.1231086460838924e-07
of O 0 4.612272164195019e-08
hypohaptoglobinemia B-Disease 0 0.003578225849196315
remains O 0 1.4325327356345952e-05
unknown O 0 1.3585999113274738e-05

ATM O 0 0.043698105961084366
mutations O 0 0.05054866895079613
and O 0 2.2283688849711325e-06
phenotypes O 0 0.07472576946020126
in O 0 8.419379446422681e-05
ataxia B-Disease 1 0.9999898672103882
- I-Disease 1 0.9949758052825928
telangiectasia I-Disease 1 0.9998672008514404
families O 0 1.0466162621014519e-06
in O 0 1.7527391094063205e-08
the O 0 4.556761634688655e-09
British O 0 8.681741547889033e-08
Isles O 0 1.1792031529012093e-07
: O 0 6.531553076172258e-10
expression O 0 6.494533244527645e-10
of O 0 1.6425044657708554e-10
mutant O 0 8.428011710748251e-08
ATM O 0 1.5006527291916427e-06
and O 0 4.070344949980154e-09
the O 0 2.5248496626772976e-08
risk O 0 2.105630119331181e-05
of O 0 2.7535993467608932e-06
leukemia B-Disease 1 0.9999823570251465
, O 0 0.0056182993575930595
lymphoma B-Disease 1 0.9999991655349731
, O 0 2.560003485996276e-05
and O 0 0.000981392920948565
breast B-Disease 1 0.9999797344207764
cancer I-Disease 1 0.9997417330741882
. O 0 6.631912583543453e-06

We O 0 3.099694936281594e-07
report O 0 2.6682940301725466e-08
the O 0 3.162794692812554e-09
spectrum O 0 1.903575075345998e-08
of O 0 2.9002020784929528e-09
59 O 0 1.1282288596703438e-06
ATM O 0 0.0002850781020242721
mutations O 0 0.0002388897119089961
observed O 0 1.71047452113271e-06
in O 0 1.910083483380731e-06
ataxia B-Disease 1 0.9999771118164062
- I-Disease 1 0.9990847110748291
telangiectasia I-Disease 1 0.9999594688415527
( O 0 3.577242387109436e-05
A B-Disease 1 0.9592377543449402
- I-Disease 1 0.9998881816864014
T I-Disease 1 0.9999700784683228
) O 0 1.1681177625177952e-07
patients O 0 1.5566566844427143e-06
in O 0 1.5394897578957512e-09
the O 0 4.245732654339918e-09
British O 0 2.3632343015833612e-07
Isles O 0 2.8108934202464297e-06
. O 0 2.8169534971311805e-07

Of O 0 6.662001510449045e-07
51 O 0 8.546263416064903e-06
ATM O 0 0.003999033942818642
mutations O 0 0.005279990844428539
identified O 0 1.1924017826459021e-06
in O 0 1.2469432597583818e-08
families O 0 1.2119122594356213e-08
native O 0 3.2117253301322535e-09
to O 0 1.5985297807663557e-10
the O 0 5.488779986073666e-10
British O 0 1.1081874085050458e-08
Isles O 0 4.719668211805583e-08
, O 0 1.4596543973510734e-09
11 O 0 8.168393961227594e-09
were O 0 1.0564211727626116e-09
founder O 0 4.700550562120043e-07
mutations O 0 4.316463559916883e-07
, O 0 2.562827727814465e-10
and O 0 1.1778460151656844e-10
2 O 0 5.849700723814522e-10
of O 0 1.0295306274166194e-10
these O 0 1.2777742752767551e-10
11 O 0 1.1235517405339124e-08
conferred O 0 2.794514841752971e-07
a O 0 3.266245869326667e-07
milder O 0 0.0001618445967324078
clinical O 0 0.0002843441325239837
phenotype O 0 1.7169732018373907e-05
with O 0 2.951666688844057e-09
respect O 0 2.629285456023922e-09
to O 0 8.315417243665024e-10
both O 0 7.075202290707239e-08
cerebellar B-Disease 1 0.9412564039230347
degeneration I-Disease 1 0.8302717804908752
and O 0 2.8086429892937304e-07
cellular O 0 0.0004981950623914599
features O 0 1.4616642147302628e-05
. O 0 1.8730605688688229e-06

We O 0 6.299551955635252e-07
report O 0 1.0899108104922561e-07
, O 0 2.729689141389713e-09
in O 0 1.2519139058753126e-09
two O 0 1.5075874770786868e-08
A B-Disease 0 0.02883552387356758
- I-Disease 1 0.9645524024963379
T I-Disease 1 0.9985634684562683
families O 0 1.8368199405927044e-08
, O 0 5.566884730967558e-10
an O 0 7.340667518285215e-10
ATM O 0 4.450973210623488e-05
mutation O 0 5.502177828020649e-06
( O 0 9.84349757260361e-09
7271T O 0 1.3428526472125668e-05
- O 0 0.00012063744361512363
- O 0 0.00020739686442539096
> O 0 3.1142935768002644e-05
G O 0 2.2059302864363417e-05
) O 0 1.4749265142555146e-09
that O 0 2.3623883405043955e-10
may O 0 1.4119959645952918e-09
be O 0 8.088078817802824e-11
associated O 0 5.557813653744859e-10
with O 0 1.7597182044859494e-10
an O 0 1.8629036091510898e-09
increased O 0 1.6977560335362796e-06
risk O 0 0.00019312772201374173
of O 0 1.5783132766955532e-05
breast B-Disease 1 0.9999902248382568
cancer I-Disease 1 0.9956392049789429
in O 0 8.636470738565549e-08
both O 0 1.708268371203303e-08
homozygotes O 0 0.00018724081746768206
and O 0 3.085013844383866e-08
heterozygotes O 0 4.0421593439532444e-05
( O 0 3.303795281794919e-08
relative O 0 1.0470325833011884e-06
risk O 0 2.8234937872184673e-06
12 O 0 2.633914775174162e-08
. O 0 1.952451311737491e-09
7 O 0 1.347524687389523e-07
; O 0 1.6205619601805665e-07
P O 0 0.004516086541116238
= O 0 5.907539616600843e-06
. O 0 2.4977757639987885e-09
0025 O 0 1.9895463992725126e-05
) O 0 1.4672805193072236e-09
, O 0 5.251564738628645e-10
although O 0 4.131666397899636e-10
there O 0 1.5064018088484232e-10
is O 0 6.062896296121778e-10
a O 0 3.2252813753075316e-08
less O 0 6.327278470052988e-07
severe O 1 0.5976583957672119
A B-Disease 1 0.935132622718811
- I-Disease 1 0.9997865557670593
T I-Disease 1 0.9999538660049438
phenotype O 0 1.866318598331418e-05
in O 0 1.044159314567139e-09
terms O 0 5.152938076236069e-10
of O 0 1.0468828581799983e-10
the O 0 7.106003563350782e-10
degree O 0 1.0961422702848722e-07
of O 0 2.331548927259064e-07
cerebellar B-Disease 1 0.9984764456748962
degeneration I-Disease 1 0.9985633492469788
. O 0 6.45848422209383e-06

This O 0 8.285302897093061e-07
mutation O 0 4.5501452405005693e-05
( O 0 1.481327558394696e-07
7271T O 0 5.640071685775183e-05
- O 0 0.0004355186829343438
- O 0 0.0005067220772616565
> O 0 1.5521738532697782e-05
G O 0 4.35268520959653e-06
) O 0 3.848228957714639e-10
also O 0 7.92792081982796e-11
allows O 0 1.4195020159313287e-10
expression O 0 5.024103355566467e-10
of O 0 7.30800212012106e-11
full O 0 2.303632395950217e-09
- O 0 6.927115236976533e-08
length O 0 3.0512290472017867e-09
ATM O 0 1.0343010359292748e-07
protein O 0 6.6616632210525495e-09
at O 0 6.622159487434942e-10
a O 0 5.871408359503505e-10
level O 0 2.667641219034067e-09
comparable O 0 1.4922306945663877e-08
with O 0 7.933823598094136e-10
that O 0 5.138431902196317e-10
in O 0 1.2804006743749596e-08
unaffected O 0 8.14309260022128e-06
individuals O 0 5.18670582039249e-08
. O 0 3.131463017780334e-07

In O 0 1.1016910548278247e-06
addition O 0 2.0740390027640387e-07
, O 0 1.0867116095880647e-08
we O 0 9.779266285647736e-10
have O 0 6.762178594854618e-10
studied O 0 1.5290696708802898e-08
18 O 0 1.3423625659925165e-06
A B-Disease 1 0.754917323589325
- I-Disease 1 0.9999326467514038
T I-Disease 1 0.9999856948852539
patients O 0 5.0375074351904914e-05
, O 0 1.940496652252932e-09
in O 0 8.628987524517129e-10
15 O 0 4.272760811829812e-09
families O 0 3.7265479591042094e-09
, O 0 4.10391232108509e-09
who O 0 8.165530829273848e-08
developed O 0 0.00012459918798413128
leukemia B-Disease 1 0.9999737739562988
, O 0 0.0003982747730333358
lymphoma B-Disease 1 0.9999988079071045
, O 0 2.6391985556983855e-06
preleukemic O 1 0.7241661548614502
T O 1 0.9794408082962036
- O 0 0.0015677505871281028
cell O 0 0.00015340755635406822
proliferation O 0 2.677188240340911e-05
, O 0 2.537155694426474e-07
or O 0 0.00024354913330171257
Hodgkin B-Disease 1 0.9999970197677612
lymphoma I-Disease 1 0.9999991655349731
, O 0 1.948358914205528e-07
mostly O 0 3.501023115859425e-08
in O 0 2.0672499090323981e-07
childhood O 0 0.00022236016229726374
. O 0 1.4425224890146637e-06

A O 0 1.3482358554028906e-06
wide O 0 2.838272905592021e-07
variety O 0 4.087478089331853e-08
of O 0 1.1240640418463954e-08
ATM O 0 0.00031791283981874585
mutation O 0 6.585346272913739e-05
types O 0 1.0979292142110353e-07
, O 0 6.26868557063176e-09
including O 0 4.930543440195834e-08
missense O 0 0.0022836807183921337
mutations O 0 1.5890031136223115e-05
and O 0 3.750593169371541e-09
in O 0 1.2529894455326485e-08
- O 0 5.700292149413144e-06
frame O 0 2.543981281633023e-06
deletions O 0 7.874415359765408e-07
, O 0 3.06611713796201e-09
were O 0 1.0129899141730903e-09
seen O 0 1.4720998642303584e-08
in O 0 5.078783171796886e-09
these O 0 9.552516111455134e-09
patients O 0 2.4278788259834982e-05
. O 0 5.899578923163062e-07

We O 0 1.1997255455753475e-07
also O 0 5.644488876299647e-09
show O 0 3.823756866694339e-09
that O 0 1.7100922067303514e-10
25 O 0 6.28450902429023e-10
% O 0 3.003854109895343e-10
of O 0 2.5482341237115236e-10
all O 0 3.764618838886236e-09
A B-Disease 1 0.5002391338348389
- I-Disease 1 0.9998681545257568
T I-Disease 1 0.9999845027923584
patients O 0 3.401946378289722e-05
carried O 0 5.6456865848986126e-08
in O 0 2.651383557150666e-09
- O 0 6.449999432334153e-07
frame O 0 1.144778821071668e-06
deletions O 0 2.9494842692656675e-06
or O 0 1.0416797380230491e-07
missense O 0 0.00036950327921658754
mutations O 0 2.149473857571138e-06
, O 0 4.550314847140413e-10
many O 0 3.394273750956245e-11
of O 0 1.0267987848866511e-10
which O 0 1.6947658554311573e-10
were O 0 2.0197832295565377e-10
also O 0 2.0909851627948228e-10
associated O 0 6.715188405337358e-10
with O 0 1.1020019619056853e-10
expression O 0 1.3881283900119001e-09
of O 0 6.616704961714959e-10
mutant O 0 2.1424336864583893e-06
ATM O 0 3.765425208257511e-05
protein O 0 2.357485755055677e-06
. O 0 2.0612770867955987e-07

The O 0 2.0288839550630655e-06
DMPK O 0 0.0008463575504720211
gene O 0 2.3850658180890605e-05
of O 0 1.271139012715139e-06
severely O 1 0.8812522292137146
affected O 0 0.397622287273407
myotonic B-Disease 1 0.9999978542327881
dystrophy I-Disease 1 0.999998927116394
patients O 1 0.9918053150177002
is O 0 9.124103144131368e-07
hypermethylated O 0 0.0003009131469298154
proximal O 0 3.372699211467989e-05
to O 0 4.585183344119059e-09
the O 0 7.155432246719329e-09
largely O 0 3.42519683727005e-08
expanded O 0 7.95973335243616e-07
CTG O 0 0.002103737322613597
repeat O 0 7.676859968341887e-05
. O 0 1.502427039667964e-06

Using O 0 2.2097206056059804e-06
methylation O 0 1.2570210856210906e-05
- O 0 5.769674771727296e-06
sensitive O 0 1.6776135680629523e-07
restriction O 0 4.53801192179526e-08
enzymes O 0 7.210098118548558e-08
, O 0 2.534957577182695e-09
we O 0 4.3496162227540935e-10
characterized O 0 1.422715545373876e-08
the O 0 6.084884818235992e-10
methylation O 0 4.338923531577166e-08
pattern O 0 2.9030813308850156e-08
on O 0 6.815553121874984e-10
the O 0 2.9892394115549337e-10
5 O 0 3.08578318453101e-09
side O 0 1.2573699859075305e-09
of O 0 1.6262011182099911e-10
the O 0 1.919953529494478e-09
CTG O 0 2.7538579161046073e-05
repeat O 0 3.0515221283167193e-07
in O 0 7.423146541896131e-10
the O 0 8.529530970413646e-10
DMPK O 0 8.733851245779078e-06
gene O 0 1.3344211957644347e-08
of O 0 3.4862532305446337e-10
normal O 0 2.453870706631278e-08
individuals O 0 1.0838834274551346e-09
and O 0 2.02293026774214e-09
of O 0 3.2927609083799325e-08
patients O 0 0.00020669485093094409
affected O 0 4.878624622506322e-06
with O 0 0.00039814249612390995
myotonic B-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.9999947547912598
, O 0 1.5893841975866962e-07
showing O 0 2.3410805738421914e-07
expansions O 0 4.5887557575952087e-07
of O 0 2.55015097927469e-09
the O 0 2.8560952713974075e-08
repetitive O 0 0.00017736978770699352
sequence O 0 2.065310127363773e-06
. O 0 5.623869014925731e-07

The O 0 9.02881879483175e-07
gene O 0 2.5990273115894524e-06
segment O 0 1.264882143914292e-06
analyzed O 0 1.4818320437370858e-07
corresponds O 0 1.2985612585225681e-08
to O 0 5.85365145244765e-10
the O 0 2.6376538730943366e-09
genomic O 0 7.841868523428275e-07
SacI O 0 4.828362580155954e-05
- O 0 5.187722763366764e-06
HindIII O 0 2.9263585474836873e-06
fragment O 0 1.0602393984981973e-07
carrying O 0 3.147949101389713e-08
exons O 0 1.3992826097819488e-06
11 O 0 3.147652307688986e-07
- O 0 2.0388133634696715e-05
15 O 0 4.560668003250612e-07
. O 0 3.190504287431395e-07

There O 0 5.728689984607627e-07
is O 0 5.601773267471799e-08
constitutive O 0 5.734800652135164e-07
methylation O 0 6.607832006011449e-07
in O 0 1.893255330287502e-08
intron O 0 2.3742910343571566e-05
12 O 0 1.1657201426373831e-08
at O 0 1.2390573012055484e-09
restriction O 0 1.1311004355363252e-09
sites O 0 4.184214086322413e-10
of O 0 2.1096530078423825e-10
SacII O 0 2.118600605172105e-06
and O 0 2.830728540459404e-09
HhaI O 0 8.628799150756095e-06
, O 0 3.6445853002220474e-09
localized O 0 1.6375331313156494e-07
1 O 0 4.169461664815799e-09
, O 0 1.0401678407490067e-09
159 O 0 7.673148161302379e-08
- O 0 8.803524451650446e-07
1 O 0 3.817453464449727e-09
, O 0 6.999198443047305e-10
232 O 0 1.1590247872561577e-08
bp O 0 9.278083723529562e-08
upstream O 0 3.064807740926767e-09
of O 0 2.0219340091109927e-10
the O 0 1.1624247120423092e-09
CTG O 0 1.0703294719860423e-05
repeat O 0 2.8371957228046085e-07
, O 0 9.092462338600171e-10
whereas O 0 2.37352271170721e-09
most O 0 2.359078765667988e-10
, O 0 2.7973107163958844e-10
if O 0 1.13067707974146e-10
not O 0 1.0206203937546121e-11
all O 0 8.03815434352595e-12
, O 0 1.9274623563880766e-11
of O 0 1.5366513617109945e-11
the O 0 5.810400077743694e-11
other O 0 1.618489196830719e-11
sites O 0 3.7119751716829796e-10
of O 0 2.8131535989572853e-10
SacII O 0 3.137560497634695e-06
, O 0 1.9452401911479456e-09
HhaI O 0 3.4785366551659536e-06
, O 0 1.3525086606236414e-09
and O 0 1.388673953606201e-09
HpaII O 0 6.884537015139358e-06
in O 0 2.567418277976685e-09
this O 0 3.728003461489493e-10
region O 0 8.506561677279478e-09
are O 0 5.708908901169707e-10
unmethylated O 0 3.994607595814159e-06
, O 0 2.2356121398559026e-09
in O 0 2.353044870062604e-09
normal O 0 6.051602241541332e-08
individuals O 0 5.088700016919745e-10
and O 0 1.5038612022344466e-10
most O 0 1.4936045455993252e-10
of O 0 1.4766802225452125e-09
the O 0 1.9065623746428173e-07
patients O 0 0.0001331097009824589
. O 0 7.089466294019076e-07

In O 0 2.2606811000969174e-07
a O 0 4.346635407159738e-08
number O 0 4.6672163911409825e-09
of O 0 3.6810534620457247e-09
young O 0 2.0549059343011322e-07
and O 0 2.595688215478731e-07
severely O 0 0.02104356326162815
affected O 0 4.9597438191995025e-06
patients O 0 2.0354600565042347e-05
, O 0 2.5319857321903783e-09
however O 0 6.849187883517516e-10
, O 0 1.5183557189324404e-10
complete O 0 1.791786274907281e-09
methylation O 0 4.1955803276039205e-09
of O 0 8.85132314665249e-11
these O 0 4.7407907460828014e-11
restriction O 0 1.0937853955894639e-09
sites O 0 1.2452836539722512e-09
was O 0 2.0137833622868584e-09
found O 0 1.0227727553768773e-09
in O 0 4.5301201678782377e-10
the O 0 2.6348279114074558e-09
mutated O 0 1.292764409299707e-06
allele O 0 1.1473866834421642e-06
. O 0 1.5395616514979338e-07

In O 0 2.7168951532985375e-07
most O 0 9.560663372099043e-09
of O 0 4.761329996938457e-09
these O 0 4.226905936377534e-09
patients O 0 1.4211134384822799e-06
, O 0 1.4741979859067555e-09
the O 0 6.49618492332138e-09
onset O 0 0.0002707864623516798
of O 0 6.938871166539684e-08
the O 0 4.541155067272484e-05
disease O 1 0.9963762164115906
was O 0 0.003384941490367055
congenital O 1 0.999914288520813
. O 0 1.572598011989612e-05

Preliminary O 0 3.9688064134679735e-05
in O 0 2.015131030930206e-06
vivo O 0 0.000900388287845999
footprinting O 0 0.02511841244995594
data O 0 1.1992725035270269e-07
gave O 0 1.1466452676245353e-08
evidence O 0 1.8347601216106568e-09
for O 0 6.419568210347393e-10
protein O 0 8.341715584947451e-08
- O 0 5.1969827836728655e-06
DNA O 0 2.4608550575067056e-07
contact O 0 6.073060720979129e-09
in O 0 9.789213883948378e-10
normal O 0 7.874489504899884e-09
genes O 0 2.288579992182349e-09
at O 0 7.49862449911376e-10
an O 0 1.7905554816621816e-10
Sp1 O 0 1.1480368584670941e-06
consensus O 0 1.4255207014812754e-09
binding O 0 2.8206987856549404e-09
site O 0 2.386587816260999e-09
upstream O 0 2.077303440373157e-09
of O 0 1.526096193860127e-10
the O 0 1.6322616591679662e-09
CTG O 0 1.4467051187239122e-05
repeat O 0 7.705943261271386e-08
and O 0 2.594195136484956e-10
for O 0 2.06991437878834e-10
a O 0 3.6337572950628783e-09
significant O 0 2.9544549029481004e-09
reduction O 0 5.9282193376475334e-08
of O 0 8.036931536947733e-11
this O 0 4.950210727439064e-11
interaction O 0 4.763544003694165e-10
in O 0 1.3702250445390973e-09
cells O 0 1.9337067058700086e-08
with O 0 9.011110746470763e-10
a O 0 4.913166407050085e-08
hypermethylated O 0 0.0005413984763436019
DMPK O 0 0.033450063318014145
gene O 0 3.863861820718739e-06
. O 0 1.9104277271253522e-08
. O 0 1.2096978707631934e-07

The O 0 4.809892288903939e-06
hemochromatosis B-Disease 1 0.9969490170478821
gene O 0 1.2907458767585922e-05
product O 0 3.755777981950814e-07
complexes O 0 9.499960924586048e-07
with O 0 2.963631784425047e-09
the O 0 1.897100476710989e-09
transferrin O 0 7.641288902959786e-06
receptor O 0 6.306428304014844e-07
and O 0 6.336267066586743e-09
lowers O 0 2.328709570065257e-06
its O 0 8.621173219758305e-10
affinity O 0 1.090045564922093e-08
for O 0 1.7891089720833975e-09
ligand O 0 4.663685899686243e-07
binding O 0 1.242413418367505e-06
. O 0 2.4287453470606124e-07

We O 0 1.2883128874818794e-06
recently O 0 1.4906994465491152e-06
reported O 0 4.0344211527099105e-08
the O 0 4.5051665176210065e-10
positional O 0 1.8586135297482542e-08
cloning O 0 3.050421781836121e-08
of O 0 1.128402593586486e-09
a O 0 4.578788903586428e-08
candidate O 0 6.996575052653498e-07
gene O 0 3.899261173501145e-06
for O 0 3.174598987243371e-06
hereditary B-Disease 1 0.9999651908874512
hemochromatosis I-Disease 1 0.9999960660934448
called O 0 0.022145574912428856
HFE O 1 0.9954254031181335
. O 0 6.336206297419267e-06

The O 0 3.186679009559157e-07
gene O 0 1.1961946029259707e-06
product O 0 4.8530747420727494e-08
, O 0 2.252303898941932e-09
a O 0 2.643949947866986e-09
member O 0 1.3942845766834466e-09
of O 0 4.6544126885983417e-10
the O 0 3.202280884906372e-09
major O 0 1.0677766226763197e-07
histocompatibility O 1 0.5966975688934326
complex O 0 3.7001416785642505e-05
class O 0 8.617812454758678e-06
I O 0 6.476009843936481e-07
- O 0 4.53546908829594e-06
like O 0 4.993048641210862e-09
family O 0 8.691148245532077e-09
, O 0 5.716982998116293e-10
was O 0 1.494805057511428e-09
found O 0 6.328919610609773e-10
to O 0 5.6731182251912315e-11
have O 0 1.9010330809532405e-10
a O 0 9.504174336427695e-09
mutation O 0 7.807059319020482e-07
, O 0 5.6761111366654404e-09
Cys O 0 0.0015237419866025448
- O 0 5.135536048328504e-05
282 O 0 1.3218788808444515e-05
- O 0 0.0007710091304033995
- O 0 0.00010292531078448519
> O 0 5.757033250120003e-06
Tyr O 0 4.143515070609283e-06
( O 0 1.991127041023333e-09
C282Y O 0 5.0280291929993837e-08
) O 0 3.236296231001745e-10
, O 0 1.682552569493012e-10
in O 0 3.155291583567532e-10
85 O 0 9.256003075108765e-09
% O 0 2.405223575863147e-09
of O 0 8.326927591895128e-09
patient O 0 3.157102037221193e-05
chromosomes O 0 1.999314918066375e-05
. O 0 5.807704610560904e-07

This O 0 1.6197196828215965e-06
mutation O 0 0.0003234549949411303
eliminates O 0 8.060805157583673e-06
the O 0 1.1329514215674408e-08
ability O 0 1.7101070781677663e-08
of O 0 2.493420359073184e-09
HFE O 0 6.43885214230977e-05
to O 0 8.867075407259506e-10
associate O 0 1.5676549836030063e-08
with O 0 1.526056969680667e-08
beta2 O 0 0.0037722240667790174
- O 0 0.00080350530333817
microglobulin O 0 0.000267151219304651
( O 0 1.3385303532231774e-08
beta2m O 0 9.511333701084368e-06
) O 0 1.981557140595669e-09
and O 0 2.97860958120566e-09
prevents O 0 7.813316074134491e-07
cell O 0 0.0001963083923328668
- O 0 0.0002774626773316413
surface O 0 7.5221623774268664e-06
expression O 0 1.168266521744954e-06
. O 0 3.1485771501138515e-07

A O 0 1.3314868738234509e-05
second O 0 2.052960326182074e-06
mutation O 0 3.998186002718285e-05
that O 0 7.118162059782662e-09
has O 0 4.337291414913125e-09
no O 0 1.2132923554730723e-09
effect O 0 4.40445102611875e-09
on O 0 4.168507317103831e-09
beta2m O 0 7.485122478101403e-05
association O 0 1.2092688450593414e-07
, O 0 3.8369587507247616e-09
H63D O 0 7.698692206759006e-05
, O 0 2.1342736467033774e-09
was O 0 2.5564430572444508e-09
found O 0 6.26297014250099e-10
in O 0 2.072885474380115e-10
eight O 0 3.5486319438504665e-10
out O 0 1.7717212419388062e-10
of O 0 3.2993083265431267e-10
nine O 0 5.337364328283911e-08
patients O 0 9.714123052617651e-07
heterozygous O 0 6.155747911407161e-08
for O 0 6.666260876642127e-10
the O 0 6.39293418203124e-09
C282Y O 0 3.969427052652463e-05
mutant O 0 3.402108632144518e-05
. O 0 5.864653758180793e-07

In O 0 8.552742656320333e-07
this O 0 1.4911153201069283e-08
report O 0 1.8067980889213686e-08
, O 0 8.631867998154519e-10
we O 0 1.8838339221893818e-10
demonstrate O 0 2.416268074512118e-09
in O 0 1.2147604033785342e-09
cultured O 0 1.923143599924515e-07
293 O 0 1.547361648590595e-06
cells O 0 2.4599592052254593e-06
overexpressing O 0 0.00031031123944558203
wild O 0 9.003316563394037e-07
- O 0 9.991390470531769e-06
type O 0 1.7418420839021564e-07
or O 0 3.2442457609249686e-09
mutant O 0 1.1237316357437521e-06
HFE O 0 5.7511413615429774e-05
proteins O 0 4.112759466323723e-09
that O 0 1.0496500196799374e-10
both O 0 7.885633812598769e-11
the O 0 7.027933235370654e-10
wild O 0 5.7136968933946264e-08
- O 0 6.158041742310161e-06
type O 0 1.1235436403467247e-07
and O 0 3.131526593591616e-09
H63D O 0 0.00040764600271359086
HFE O 0 0.0006341075641103089
proteins O 0 1.5188902580121066e-08
form O 0 1.578377961664046e-08
stable O 0 1.6180479178729001e-07
complexes O 0 7.580513994298599e-08
with O 0 1.162841600788056e-09
the O 0 5.174411121799949e-09
transferrin O 0 0.0004028191906400025
receptor O 0 9.5290073659271e-05
( O 0 2.3728320286409144e-07
TfR O 0 0.000560420099645853
) O 0 1.3573891521900805e-07
. O 0 2.4828347022776143e-07

The O 0 1.7880646510093356e-06
C282Y O 0 0.001125187729485333
mutation O 0 0.0005287905805744231
nearly O 0 4.980695962331083e-07
completely O 0 2.2151149892124522e-07
prevents O 0 8.336274959219736e-08
the O 0 1.0677246864432277e-09
association O 0 1.8436212556594e-09
of O 0 1.2455206310768574e-10
the O 0 1.588118969664265e-09
mutant O 0 1.1437726925578318e-06
HFE O 0 0.00022264316794462502
protein O 0 6.078080616589432e-08
with O 0 7.035018345646904e-09
the O 0 8.253059036178456e-08
TfR O 0 0.0015563047491014004
. O 0 6.79170113926375e-07

Studies O 0 3.769639761230792e-06
on O 0 2.4441180812573293e-07
cell O 0 9.847373439697549e-05
- O 0 1.0709738489822485e-05
associated O 0 2.9168129245249474e-08
transferrin O 0 2.601566848170478e-06
at O 0 1.048390618763051e-08
37 O 0 1.5995501811971735e-08
degrees O 0 2.4627045291936156e-08
C O 0 8.797945127980711e-08
suggest O 0 2.2804189647729345e-09
that O 0 9.873026701745502e-11
the O 0 9.247510535104198e-10
overexpressed O 0 2.4963781015685527e-06
wild O 0 1.384248378144548e-07
- O 0 8.506697668053675e-06
type O 0 4.2604017380654113e-07
HFE O 0 9.484486508881673e-05
protein O 0 5.466563024469906e-08
decreases O 0 3.436150564084528e-08
the O 0 1.6083163967284264e-10
affinity O 0 2.302138923937491e-09
of O 0 3.469113052378958e-10
the O 0 3.492271360983068e-09
TfR O 0 2.6046103812404908e-05
for O 0 2.4847858881571483e-08
transferrin O 0 0.0004804673371836543
. O 0 5.445706960927055e-07

The O 0 1.1544090057213907e-06
overexpressed O 0 0.0005427136202342808
H63D O 0 0.0025487984530627728
protein O 0 6.621989996347111e-06
does O 0 3.932974124154498e-08
not O 0 4.354605287471003e-10
have O 0 1.1952767942080555e-10
this O 0 7.278580516079103e-11
effect O 0 1.2133732907315675e-09
, O 0 4.928035063356262e-11
providing O 0 1.6407071534718654e-10
the O 0 6.717183059778975e-11
first O 0 8.4915414977349e-11
direct O 0 1.499098623014561e-10
evidence O 0 2.957289135796515e-10
for O 0 1.1586168829902377e-10
a O 0 3.334936549137524e-09
functional O 0 9.407848722275958e-08
consequence O 0 7.163328064052621e-08
of O 0 1.6830509208531907e-09
the O 0 6.048186662610533e-08
H63D O 0 0.08394584059715271
mutation O 0 0.0002533055667299777
. O 0 6.296284595919133e-07

Addition O 0 1.5095865819603205e-06
of O 0 2.819356268446427e-07
soluble O 0 0.0002154621615773067
wild O 0 1.5456402252311818e-05
- O 0 0.0005481305997818708
type O 0 2.1759478840976954e-05
HFE O 0 0.19897280633449554
/ O 0 3.417938933125697e-05
beta2m O 0 0.00010596901120152324
heterodimers O 0 3.952093538828194e-05
to O 0 1.939963967245717e-09
cultured O 0 2.069021149964101e-07
cells O 0 1.4423861216528167e-07
also O 0 5.62078605881311e-10
decreased O 0 1.7211149838658457e-08
the O 0 2.8076380109709476e-10
apparent O 0 1.8856727734828382e-08
affinity O 0 3.57728446864769e-09
of O 0 4.3489695178422494e-10
the O 0 9.950751334031338e-10
TfR O 0 1.5661449879189604e-06
for O 0 1.3342367488622386e-10
its O 0 3.9957742670182483e-10
ligand O 0 1.7720138245636008e-08
under O 0 6.03967720280707e-09
steady O 0 8.341459079019842e-07
- O 0 1.718011662887875e-05
state O 0 5.566518979094326e-08
conditions O 0 8.125230976929743e-08
, O 0 2.487310635235218e-10
both O 0 1.3661427544775506e-10
in O 0 9.124428435036691e-10
293 O 0 1.1731113858104436e-07
cells O 0 1.0546524720211892e-07
and O 0 2.537942522806702e-09
in O 0 9.97238274180745e-08
HeLa O 0 0.04399459809064865
cells O 0 2.368420064158272e-05
. O 0 3.857489048186835e-07

Furthermore O 0 5.7690144785738084e-06
, O 0 5.0678128360459596e-08
at O 0 1.7492123305373752e-08
4 O 0 1.5517247931029488e-08
degrees O 0 3.4019723926803636e-08
C O 0 8.256775174686481e-08
, O 0 5.022828819534197e-10
the O 0 7.960957448815975e-10
added O 0 5.1185580218771065e-09
soluble O 0 3.159164236876677e-07
complex O 0 6.231375948573259e-08
of O 0 5.911437561678667e-09
HFE O 0 0.019615568220615387
/ O 0 5.29003136762185e-06
beta2m O 0 1.3726992619922385e-05
inhibited O 0 5.56178569866006e-08
binding O 0 4.839308509474449e-09
of O 0 5.194819019394004e-10
transferrin O 0 5.448322099255165e-06
to O 0 2.6522082308133577e-09
HeLa O 0 0.00011017621727660298
cell O 0 1.223075742018409e-05
TfR O 0 2.8826369089074433e-05
in O 0 4.098217765147183e-09
a O 0 3.4179134189571414e-08
concentration O 0 4.1278359276475385e-05
- O 0 2.772302832454443e-05
dependent O 0 2.8311848154771724e-07
manner O 0 7.878246037762437e-07
. O 0 3.215497201836115e-07

Scatchard O 0 4.850375989917666e-05
plots O 0 2.3605275600857567e-06
of O 0 2.084989425554795e-08
these O 0 2.4786310781621523e-09
data O 0 1.4792292724052913e-08
indicate O 0 1.1985425985017173e-08
that O 0 2.446335078953865e-10
the O 0 7.963403270139224e-10
added O 0 6.755426884552662e-09
heterodimer O 0 2.9232149245217443e-05
substantially O 0 5.313170277077006e-07
reduced O 0 1.5547080067790375e-08
the O 0 3.2430563789986877e-10
affinity O 0 1.3627714068320529e-08
of O 0 4.736547598582774e-09
TfR O 0 6.127478263806552e-05
for O 0 4.6333894943018095e-08
transferrin O 0 0.001481850864365697
. O 0 1.072059603757225e-06

These O 0 5.426308007372427e-07
results O 0 1.0008451454268652e-06
establish O 0 1.2760298773173417e-07
a O 0 5.1335391049178725e-08
molecular O 0 1.3464267567542265e-06
link O 0 1.9725931110770034e-07
between O 0 1.3573653312448641e-08
HFE O 0 0.00043775083031505346
and O 0 1.514604996977198e-09
a O 0 3.0677143048052358e-09
key O 0 4.686582677493334e-09
protein O 0 1.808218463850153e-08
involved O 0 3.800054937386221e-09
in O 0 2.8384277150905746e-09
iron O 0 3.5298530747240875e-06
transport O 0 7.531024692752908e-08
, O 0 1.0237446446126341e-09
the O 0 1.927100257148595e-09
TfR O 0 1.6883148418855853e-05
, O 0 1.4331623665597704e-09
and O 0 7.09415470812047e-10
raise O 0 8.416940033839637e-09
the O 0 1.3168882651015679e-09
possibility O 0 1.5261967689639278e-08
that O 0 2.8223709480634795e-10
alterations O 0 9.011152712901094e-08
in O 0 7.577095617605778e-10
this O 0 3.0497962488773567e-10
regulatory O 0 2.8942446306245984e-07
mechanism O 0 4.051269897331622e-08
may O 0 1.2803071935962862e-09
play O 0 9.179024901273536e-11
a O 0 8.535063766856865e-10
role O 0 2.8794224782302535e-09
in O 0 1.5757420923634413e-09
the O 0 1.2237118873770214e-08
pathogenesis O 0 0.00048464417341165245
of O 0 5.531662282010075e-06
hereditary B-Disease 1 0.9999737739562988
hemochromatosis I-Disease 1 0.9999970197677612
. O 0 8.308879841933958e-06
. O 0 2.9638761134265224e-06

Genomic O 0 0.00015175971202552319
organization O 0 3.8951807823650597e-07
of O 0 1.0052088939005444e-08
the O 0 3.247825830499096e-08
UBE3A O 0 0.003992416430264711
/ O 0 8.338558836840093e-05
E6 O 0 0.009953428991138935
- O 0 0.0008091056952252984
AP O 0 5.0271369218535256e-06
gene O 0 3.415913738535892e-07
and O 0 2.8868145207638918e-08
related O 0 8.333738037435978e-07
pseudogenes O 0 0.00017965692677535117
. O 0 1.8404551838102634e-06

The O 0 8.604357049080136e-07
UBE3A O 0 0.0003593399014789611
gene O 0 9.183702331938548e-07
encodes O 0 1.6623229726064892e-07
the O 0 1.8961030079367447e-08
E6 O 0 8.265969518106431e-05
- O 0 1.2644368325709365e-05
AP O 0 4.281916972104227e-07
ubiquitin O 0 3.2200696864492784e-07
- O 0 2.2338244889397174e-06
protein O 0 4.267892350640068e-08
ligase O 0 3.184039201187261e-07
and O 0 2.3443049723681497e-09
has O 0 2.715771607597617e-09
recently O 0 2.0974340486645815e-08
been O 0 3.504172785273596e-10
shown O 0 5.229604527201559e-10
to O 0 9.133286488216541e-11
be O 0 1.6146243231318635e-09
mutated O 0 3.8702604797435924e-05
in O 0 0.0013452144339680672
Angelman B-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999996423721313
patients O 0 0.19311903417110443
who O 0 1.443383865762371e-07
lack O 0 6.146549935692747e-07
15q11 O 0 0.00037999788764864206
- O 0 0.00017795524036046118
q13 O 0 1.8607970559969544e-05
deletions O 0 2.362103714403929e-06
or O 0 5.752877996201278e-08
chromosome O 0 3.339414979564026e-05
15 O 0 5.746177293985966e-07
paternal O 0 0.00012330917525105178
uniparental B-Disease 1 0.9827053546905518
disomy I-Disease 0 0.49049142003059387
. O 0 3.3752487524907338e-06

Previous O 0 8.774767593422439e-06
UBE3A O 0 0.00014308333629742265
cDNA O 0 3.1477411539526656e-06
analysis O 0 4.040898602397647e-07
has O 0 2.7054120721459185e-08
shown O 0 1.1504351249413958e-08
a O 0 1.2874830090936484e-08
coding O 0 6.248716317713843e-07
region O 0 2.508342511475803e-08
of O 0 7.953733782706252e-10
approximately O 0 3.816909455167661e-08
2 O 0 2.1637461600221286e-07
. O 0 2.126644176314585e-07

6 O 0 2.671151378308423e-06
kb O 0 2.520171256037429e-05
and O 0 3.46893145319882e-08
a O 0 8.84073969587007e-08
3 O 0 6.214094128154102e-07
- O 0 0.00011744228686438873
untranslated O 0 0.0001407643867423758
region O 0 3.246290418701392e-07
( O 0 7.404653779019554e-09
UTR O 0 5.648725164064672e-06
) O 0 1.1463735516414886e-09
of O 0 6.524592532919371e-10
< O 0 3.623481745762547e-07
50 O 0 5.3019104662155314e-09
bp O 0 1.7664261520167202e-07
, O 0 4.4751230499073813e-10
whereas O 0 1.1997541848884907e-09
Northern O 0 2.745102145595979e-09
analysis O 0 2.0422368240957667e-09
has O 0 4.567131117738654e-10
indicated O 0 1.4984533613926487e-09
mRNA O 0 1.2553331707465532e-09
sizes O 0 5.8663967017480445e-09
of O 0 5.339537700876917e-10
5 O 0 3.7426122645456417e-08
- O 0 7.363710210483987e-06
8 O 0 3.1741703310217417e-07
kb O 0 0.0002718916512094438
. O 0 5.303096486386494e-07

We O 0 1.5782190132540563e-07
have O 0 4.293658761866936e-09
analyzed O 0 1.2502488822008218e-08
additional O 0 1.3392039699411384e-09
cDNA O 0 4.326147973188199e-08
clones O 0 1.1449149184272756e-07
and O 0 4.1884060109076415e-10
provide O 0 7.07721992121435e-10
evidence O 0 7.766551846088987e-10
for O 0 1.306280777990665e-10
an O 0 6.362494975320487e-10
additional O 0 2.264737553048235e-08
0 O 0 9.193805681206868e-07
. O 0 3.0213945478863025e-07

5 O 0 1.4570872508556931e-06
kb O 0 9.184953341900837e-06
of O 0 5.366743138779384e-08
5 O 0 3.7592968737953925e-07
- O 0 1.2708123904303648e-05
UTR O 0 7.585925050079823e-05
and O 0 7.95651367013761e-09
> O 0 3.61598040399258e-07
2 O 0 1.4026180217285855e-08
kb O 0 4.4824541873822454e-06
of O 0 1.535475924185903e-08
3 O 0 3.8127332118165214e-06
- O 0 0.0013662772253155708
UTR O 0 0.009106048382818699
. O 0 9.404257070855238e-07

We O 0 2.8310279276411165e-07
have O 0 6.845247479958516e-09
established O 0 5.709706485390598e-09
the O 0 1.5123676755379734e-09
genomic O 0 2.297843764154095e-07
organization O 0 9.333404271671952e-09
of O 0 1.2077855382486291e-09
UBE3A O 0 1.56371188495541e-05
and O 0 8.636693582531052e-10
the O 0 7.655628353475663e-10
sequence O 0 1.003477212435655e-08
of O 0 9.489791175099072e-09
intron O 0 0.015053498558700085
- O 0 0.0006601733039133251
exon O 0 0.00037399772554636
borders O 0 7.008668944763485e-06
. O 0 9.20409604532324e-07

We O 0 4.391677634885127e-07
have O 0 2.3327181963850308e-08
also O 0 2.6889741544522394e-09
mapped O 0 9.378645415836218e-08
two O 0 8.775998816545894e-10
highly O 0 3.842231421913311e-09
homologous O 0 4.616073923102704e-08
processed O 0 2.018591338526221e-08
pseudogenes O 0 1.1763203247028287e-06
, O 0 1.0983644216366883e-08
UBE3AP1 O 0 9.978139132726938e-05
and O 0 1.4640522572051395e-08
UBE3AP2 O 0 0.0001817964657675475
, O 0 8.465655398914862e-10
to O 0 6.246980016610948e-11
chromosomes O 0 9.895905428436436e-09
2 O 0 2.0795987154542672e-09
and O 0 3.3022420908856986e-10
21 O 0 7.683747860198764e-09
, O 0 4.772893191784533e-10
respectively O 0 3.1845199810476288e-09
, O 0 4.6388054508739174e-10
and O 0 5.235413214066398e-10
determined O 0 1.7963518672559076e-08
their O 0 7.696772996723666e-09
genomic O 0 1.6525558748980984e-05
organization O 0 3.6029067018716887e-07
. O 0 2.5706933115543507e-07

These O 0 1.7451142753088789e-07
results O 0 5.212362452766683e-07
will O 0 1.694608453561841e-09
form O 0 1.0446793430318735e-09
the O 0 3.379043989060193e-10
basis O 0 3.7387345996897636e-10
for O 0 1.8264352530383832e-10
studies O 0 1.8883856700568913e-09
of O 0 1.2954186612290641e-09
mutation O 0 6.435756745304388e-07
and O 0 3.4356508749056047e-09
imprinting O 0 7.061954420350958e-06
of O 0 2.134259204922273e-07
UBE3A O 0 0.05278540402650833
. O 0 2.631590632518055e-06

Mutation O 0 0.0006994217983447015
spectrum O 0 1.5951247405610047e-05
and O 0 2.829635263879027e-07
genotype O 0 0.0004477311158552766
- O 0 0.0010495585156604648
phenotype O 0 0.00023182915174402297
analyses O 0 3.910119630745612e-06
in O 0 7.131624784051382e-07
Cowden B-Disease 1 0.9853734374046326
disease I-Disease 1 0.7516672611236572
and O 0 9.546283763484098e-06
Bannayan B-Disease 1 0.9996806383132935
- I-Disease 1 0.9999641180038452
Zonana I-Disease 1 0.999977707862854
syndrome I-Disease 1 0.9999744892120361
, O 0 3.2497598567715613e-07
two O 0 1.8030890487352735e-06
hamartoma B-Disease 1 0.999495267868042
syndromes I-Disease 1 0.9949224591255188
with O 0 6.65704210405238e-05
germline O 1 0.9986485838890076
PTEN O 1 0.9979111552238464
mutation O 0 0.016950536519289017
. O 0 1.9964879811595893e-06

The O 0 2.3261141905095428e-05
tumour B-Disease 1 0.9997532963752747
suppressor O 0 0.09156624972820282
gene O 0 0.00020026613492518663
PTEN O 0 0.011259319260716438
, O 0 1.5142042286697688e-08
which O 0 4.019097055163456e-09
maps O 0 3.401797243895999e-08
to O 0 8.292597719616879e-09
10q23 O 0 3.0715313187101856e-05
. O 0 6.221405328687979e-07

3 O 0 1.416903387507773e-06
and O 0 2.2597923532430286e-08
encodes O 0 6.998163826210657e-08
a O 0 2.1381088899374845e-08
403 O 0 6.336052393862701e-08
amino O 0 8.255951478020052e-09
acid O 0 3.924491309703626e-08
dual O 0 3.7877331493518795e-08
specificity O 0 1.1101531782742313e-07
phosphatase O 0 0.00015364325372502208
( O 0 3.857828723141665e-09
protein O 0 2.8337661106547785e-08
tyrosine O 0 5.53968959593476e-07
phosphatase O 0 0.0030744357500225306
; O 0 1.8888261621441416e-08
PTPase O 0 6.613105142605491e-06
) O 0 1.5020615862226805e-09
, O 0 5.37415445478473e-10
was O 0 9.8893349065321e-10
shown O 0 2.2422996792670347e-09
recently O 0 7.287992431770363e-09
to O 0 4.3949975603307934e-11
play O 0 1.5618545345930102e-10
a O 0 2.4411392907097706e-09
broad O 0 3.820835559054103e-08
role O 0 5.1465981698584073e-08
in O 0 1.7792230266877596e-07
human O 0 6.458089956140611e-06
malignancy B-Disease 1 0.8137147426605225
. O 0 1.8570171960163862e-06

Somatic O 0 0.0044055660255253315
PTEN O 0 0.2978675365447998
deletions O 0 0.0003367036406416446
and O 0 4.531792967554793e-07
mutations O 0 5.092667561257258e-05
were O 0 2.204650506598682e-08
observed O 0 1.249716490292485e-07
in O 0 3.61247458613434e-08
sporadic B-Disease 0 9.996767767006531e-05
breast I-Disease 1 0.9953298568725586
, I-Disease 0 3.0162750590534415e-06
brain I-Disease 0 0.40448489785194397
, I-Disease 0 1.5293986507458612e-05
prostate I-Disease 1 0.9999812841415405
and I-Disease 0 0.000683364924043417
kidney I-Disease 1 0.9999755620956421
cancer I-Disease 1 0.999739944934845
cell O 0 0.0014316445449367166
lines O 0 1.9441656604612945e-06
and O 0 1.877747290990328e-09
in O 0 1.5298068367641804e-09
several O 0 3.4678315774527846e-09
primary O 0 9.141191185335629e-06
tumours B-Disease 1 0.9807263016700745
such O 0 2.2454000259131135e-07
as O 0 7.896609895396978e-05
endometrial B-Disease 1 0.9999887943267822
carcinomas I-Disease 1 0.9999984502792358
, O 1 0.9985045194625854
malignant B-Disease 1 0.9999996423721313
melanoma I-Disease 1 0.9999996423721313
and O 1 0.9222354888916016
thyroid B-Disease 1 0.9999921321868896
tumours I-Disease 1 0.999971866607666
. O 0 5.009655069443397e-05

In O 0 7.682094178562693e-07
addition O 0 1.6727824458939722e-07
, O 0 4.819212762185998e-08
PTEN O 0 0.00025468060630373657
was O 0 3.77141198271147e-08
identified O 0 8.671923623637667e-09
as O 0 4.1748074441905203e-10
the O 0 1.6691285020797864e-09
susceptibility O 0 3.681744146888377e-06
gene O 0 2.332756707801309e-07
for O 0 2.3298099449675647e-08
two O 0 8.87437545316061e-06
hamartoma B-Disease 1 0.9999459981918335
syndromes I-Disease 1 0.9999822378158569
Cowden B-Disease 1 0.9999774694442749
disease I-Disease 1 0.997802197933197
( O 0 4.0097808096106746e-07
CD B-Disease 0 4.766220627061557e-06
; O 0 1.425607649707672e-07
MIM O 0 0.0008000748348422348
158350 O 0 1.3241549822851084e-05
) O 0 7.417829017697386e-09
and O 0 1.7686506481595643e-08
Bannayan B-Disease 0 0.003301515243947506
- I-Disease 0 0.024105722084641457
Zonana I-Disease 0 0.4397238790988922
( I-Disease 0 2.4715511415251967e-08
BZS I-Disease 0 1.9650464309961535e-05
) I-Disease 0 2.92120971856491e-09
or I-Disease 0 9.423703595246025e-09
Ruvalcaba I-Disease 0 0.0017088667955249548
- I-Disease 0 0.0015869424678385258
Riley I-Disease 0 0.00022066776000428945
- I-Disease 0 0.49807924032211304
Smith I-Disease 0 0.006085108034312725
syndrome I-Disease 1 0.9998340606689453
( O 0 1.323677679465618e-06
MIM O 0 0.028117066249251366
153480 O 0 0.0009079155279323459
) O 0 3.249134010729904e-07
. O 0 5.630598707284662e-07

Constitutive O 0 8.67621783982031e-05
DNA O 0 5.28434720763471e-05
from O 0 9.284456581326594e-08
37 O 0 1.7431649723675946e-07
CD B-Disease 0 9.447534665696367e-08
families O 0 5.416854076401023e-09
and O 0 2.6721480583802304e-09
seven O 0 2.606468108012905e-08
BZS B-Disease 0 2.422296347504016e-05
families O 0 1.6764165167160172e-08
was O 0 1.7770704019426375e-08
screened O 0 3.170379727635009e-07
for O 0 1.1652515752302861e-07
germline O 1 0.6715400815010071
PTEN O 1 0.9163655042648315
mutations O 0 0.004183216951787472
. O 0 1.2381316309983958e-06

PTEN O 1 0.9224019050598145
mutations O 0 0.003404127899557352
were O 0 1.2211742728140962e-07
identified O 0 5.968597349692573e-08
in O 0 1.377283842529664e-09
30 O 0 1.3813616916991123e-09
of O 0 2.657204456468776e-10
37 O 0 1.9797068873117496e-08
( O 0 2.1249759729613515e-09
81 O 0 6.238046523776575e-08
% O 0 1.1899500274026309e-09
) O 0 3.343960386370526e-10
CD B-Disease 0 1.463591647876683e-08
families O 0 2.051403269476282e-09
, O 0 1.0316225651507693e-09
including O 0 7.2985368859690425e-09
missense O 0 2.836945714079775e-05
and O 0 1.0467840816374974e-08
nonsense O 0 3.0530870844813762e-06
point O 0 6.461439028271343e-08
mutations O 0 1.3211429177317768e-06
, O 0 1.1138108213515352e-09
deletions O 0 1.088404744109539e-07
, O 0 1.1977512315297645e-09
insertions O 0 5.833227305629407e-07
, O 0 4.467756831161296e-09
a O 0 3.874126264236111e-08
deletion O 0 8.870178135111928e-06
/ O 0 9.555433280183934e-07
insertion O 0 4.292568007713271e-07
and O 0 1.0767565505886978e-08
splice O 0 6.13840384176001e-05
site O 0 2.732396751525812e-05
mutations O 0 0.00030969089129939675
. O 0 5.140103667145013e-07

These O 0 9.073168030226952e-07
mutations O 0 9.371774649480358e-05
were O 0 2.4053806058077498e-08
scattered O 0 3.9492711323418916e-08
over O 0 3.33262217822039e-09
the O 0 6.770580207593468e-10
entire O 0 9.96937377095719e-09
length O 0 2.789843200901032e-08
of O 0 1.457912568447739e-09
PTEN O 0 7.87903118180111e-05
, O 0 1.0202282352267389e-09
with O 0 2.1862696375496427e-10
the O 0 2.2468452098856062e-10
exception O 0 7.593212170142749e-10
of O 0 6.300228394540142e-11
the O 0 2.301935586590531e-10
first O 0 5.818021064918355e-10
, O 0 6.268849883639405e-10
fourth O 0 2.7847979922057675e-08
and O 0 3.316800167851852e-09
last O 0 1.9095867287433066e-07
exons O 0 9.975356988434214e-06
. O 0 3.3310607250314206e-07

A O 0 7.600719072797801e-06
hot O 0 3.122086809526081e-06
spot O 0 8.334636163453979e-07
for O 0 2.4065187176347536e-08
PTEN O 0 0.0017211055383086205
mutation O 0 1.3267944268591236e-05
in O 0 4.4261114773291865e-09
CD B-Disease 0 6.173384292651463e-08
was O 0 6.2464380334859015e-09
identified O 0 8.672618179161873e-09
in O 0 1.5281708121150928e-09
exon O 0 1.4197222526490805e-06
5 O 0 6.595716417479025e-09
that O 0 4.4437179630429924e-11
contains O 0 1.3389989117484902e-10
the O 0 5.298955718657794e-10
PTPase O 0 3.915963588951854e-06
core O 0 2.71943832785837e-07
motif O 0 1.8404534785076976e-07
, O 0 2.418618361144098e-10
with O 0 1.2627913992258044e-10
13 O 0 7.179201677587344e-10
of O 0 8.685223373827711e-11
30 O 0 1.345130229424285e-09
( O 0 5.169003003402395e-10
43 O 0 5.229178423604708e-09
% O 0 1.1365068885993423e-09
) O 0 9.987640714470558e-10
CD B-Disease 0 2.536732210955961e-07
mutations O 0 4.252910002833232e-06
identified O 0 3.1739705974587196e-08
in O 0 3.434622142250987e-09
this O 0 6.633249505227923e-09
exon O 0 8.43707675812766e-05
. O 0 4.745421051666199e-07

Seven O 0 3.2143873340828577e-07
of O 0 1.1905590291405588e-08
30 O 0 2.134743226633873e-08
( O 0 2.1924886350888073e-09
23 O 0 1.0744691358866021e-08
% O 0 8.373701176900283e-10
) O 0 1.3943424193030296e-10
were O 0 4.234923176027472e-11
within O 0 8.599589096380811e-11
the O 0 1.4486482846631787e-10
core O 0 4.2301504521446986e-08
motif O 0 1.9507703541421506e-07
, O 0 4.3847844799493885e-10
the O 0 2.4575311230456975e-10
majority O 0 2.1720432119565203e-09
( O 0 1.5149911880563138e-10
five O 0 1.6713130879253413e-10
of O 0 5.006576056509893e-11
seven O 0 4.996085212205514e-10
) O 0 9.824280278181163e-11
of O 0 7.299476301181329e-11
which O 0 4.529912833728389e-10
were O 0 2.836024970420681e-09
missense O 0 0.00024614649009890854
mutations O 0 1.3024257896177005e-05
, O 0 4.597268343786709e-09
possibly O 0 9.829276059747372e-09
pointing O 0 9.342524087685433e-09
to O 0 4.746563211921462e-11
the O 0 3.573382145738435e-10
functional O 0 2.995875192368658e-08
significance O 0 8.783019644909018e-09
of O 0 1.3715114599577305e-09
this O 0 6.648817052479217e-09
region O 0 6.064046829123981e-07
. O 0 4.32143906436977e-07

Germline O 1 0.9954600930213928
PTEN O 1 0.9934765696525574
mutations O 0 0.10930349677801132
were O 0 3.600141837978299e-07
identified O 0 1.6743624087212083e-07
in O 0 1.2938605742363052e-09
four O 0 5.585870654911673e-10
of O 0 2.6038518563531454e-10
seven O 0 9.434457659551754e-09
( O 0 8.29851565242734e-09
57 O 0 2.0431463099157554e-07
% O 0 2.085212180702456e-08
) O 0 9.327139949277807e-09
BZS B-Disease 0 4.451813583727926e-05
families O 0 7.134148916065897e-08
studied O 0 3.577976031010621e-07
. O 0 3.594419695218676e-07

Interestingly O 0 0.00016082529327832162
, O 0 3.8362841792149993e-07
none O 0 5.402978686674942e-08
of O 0 2.239700869210992e-09
these O 0 3.0298872299994173e-09
mutations O 0 1.7030978369803051e-06
was O 0 6.765252802409805e-09
observed O 0 4.583565971216785e-09
in O 0 1.1018890244685053e-09
the O 0 2.9990179228889247e-09
PTPase O 0 6.446987390518188e-05
core O 0 4.387560238683363e-06
motif O 0 2.606632733659353e-05
. O 0 6.501536518044304e-07

It O 0 2.2790248976889416e-07
is O 0 1.8974452231645955e-08
also O 0 2.410468269431476e-09
worthy O 0 2.2374731400987002e-08
of O 0 2.1345301082220658e-09
note O 0 2.382813768520009e-08
that O 0 2.874613880265997e-10
a O 0 4.561127031621481e-09
single O 0 8.121260997029367e-09
nonsense O 0 5.634562967316015e-07
point O 0 1.4643399381952804e-08
mutation O 0 3.8718300743312284e-07
, O 0 6.804175001207113e-10
R233X O 0 4.230836623264622e-07
, O 0 1.126901350012588e-09
was O 0 1.6593769691652938e-09
observed O 0 2.0010564316663704e-09
in O 0 2.2531622401178453e-10
the O 0 1.1263555643736822e-09
germline O 0 2.061056329694111e-05
DNA O 0 1.1219118078997781e-07
from O 0 2.7820928893973473e-10
two O 0 4.558324273595815e-10
unrelated O 0 4.93506888687989e-08
CD B-Disease 0 9.666062084079385e-08
families O 0 8.406206397637561e-09
and O 0 4.828806687839915e-09
one O 0 5.6800558922986966e-08
BZS B-Disease 0 0.0014846494887024164
family O 0 2.3922234504425433e-06
. O 0 5.696676907973597e-07

Genotype O 0 0.04601423442363739
- O 0 0.0051802536472678185
phenotype O 0 0.000804129580501467
studies O 0 2.985567846280901e-07
were O 0 2.073258231760633e-09
not O 0 3.2725591680993205e-10
performed O 0 3.6779794765351426e-09
on O 0 8.898724535022495e-10
this O 0 2.2878850203245094e-10
small O 0 3.442118146068651e-09
group O 0 8.146408880804756e-09
of O 0 4.0451220151283e-09
BZS B-Disease 0 0.0005769262206740677
families O 0 3.5519946095519117e-07
. O 0 3.818624634277512e-07

However O 0 1.4375251566889347e-06
, O 0 1.1356942053453167e-07
genotype O 0 4.104746403754689e-05
- O 0 8.706419612281024e-05
phenotype O 0 1.3559568287746515e-05
analysis O 0 3.104866053149635e-08
inthe O 0 9.330627108283807e-06
group O 0 1.4243039636596677e-08
of O 0 1.0231240299418687e-09
CD B-Disease 0 1.862528336005198e-07
families O 0 2.2097191632042268e-08
revealed O 0 8.888216029845353e-08
two O 0 8.213995039696442e-10
possible O 0 3.4964038331253278e-09
associations O 0 2.247360519902486e-09
worthy O 0 1.0312630749353957e-08
of O 0 7.286181658017199e-10
follow O 0 6.651506456734069e-09
- O 0 9.726702501211548e-07
up O 0 4.78845185725163e-09
in O 0 3.98224075937037e-09
independent O 0 7.37280743123847e-08
analyses O 0 9.993400453822687e-07
. O 0 2.259896518808091e-07

The O 0 5.354959284886718e-07
first O 0 6.884491909886492e-08
was O 0 2.3567608309349453e-08
an O 0 2.6605426750592187e-09
association O 0 1.6979189609855894e-08
noted O 0 1.8142978230883955e-09
in O 0 4.5830830797122246e-10
the O 0 4.0886280472385295e-10
group O 0 1.1096399354926234e-09
of O 0 2.5532012615236965e-10
CD B-Disease 0 3.1564658797833545e-07
families O 0 4.230372780966718e-07
with O 0 0.0002365339605603367
breast B-Disease 1 0.999972939491272
disease I-Disease 1 0.9954302310943604
. O 0 5.979889465379529e-06

A O 0 2.59994953921705e-06
correlation O 0 1.3146750461601187e-06
was O 0 4.3298545193692917e-08
observed O 0 8.40623926023909e-09
between O 0 8.478114321697205e-10
the O 0 7.079542507781866e-10
presence O 0 1.8122028322409278e-08
/ O 0 2.610837555039325e-07
absence O 0 1.3646493712826668e-08
of O 0 8.900049031090873e-10
a O 0 3.2955512097032624e-07
PTEN O 0 0.014966524206101894
mutation O 0 2.4793735065031797e-06
and O 0 8.224482206387052e-10
the O 0 2.430096568417639e-09
type O 0 3.9902266735225567e-07
of O 0 7.748211316993547e-08
breast O 1 0.8929404616355896
involvement O 0 2.5937533791875467e-05
( O 0 5.523842219190556e-07
unaffected O 0 0.001866137026809156
versus O 0 0.027775341644883156
benign O 1 0.9874449968338013
versus O 1 0.9313857555389404
malignant O 1 0.9998774528503418
) O 0 8.470685202155437e-07
. O 0 5.433376486507768e-07

Specifically O 0 2.4370849587285193e-06
and O 0 2.9336177931327256e-08
more O 0 2.9331801432164184e-09
directly O 0 5.4643813918175965e-09
, O 0 1.3572765134028941e-09
an O 0 1.7339778501934688e-09
association O 0 3.566556117107211e-08
was O 0 2.183515812603787e-09
also O 0 3.422868377622734e-10
observed O 0 9.254551014414858e-10
between O 0 1.9822779528944068e-10
the O 0 1.7447790434665933e-10
presence O 0 1.512823644134187e-09
of O 0 2.080348560085099e-09
a O 0 3.872904017043766e-06
PTEN O 1 0.8889382481575012
mutation O 0 0.28691574931144714
and O 0 0.00042422773549333215
malignant B-Disease 1 0.9999877214431763
breast I-Disease 1 0.9999805688858032
disease I-Disease 1 0.9986547231674194
. O 0 7.256478511408204e-06

Secondly O 0 0.0007281533908098936
, O 0 3.1621755169908283e-07
there O 0 1.545471661756892e-08
appeared O 0 1.8047865424364318e-08
to O 0 3.0516000837366164e-10
be O 0 1.7802778695674704e-10
an O 0 2.3188928555128996e-10
interdependent O 0 5.618433078780072e-07
association O 0 3.41626460453881e-08
between O 0 1.098247182085288e-08
mutations O 0 6.855231617919344e-07
upstream O 0 9.610558571182537e-09
and O 0 3.403715087557657e-10
within O 0 5.000842517866033e-10
the O 0 8.067407297751572e-10
PTPase O 0 1.4583216625396744e-06
core O 0 1.476328037597341e-07
motif O 0 2.258644826724776e-07
, O 0 3.2998495602676314e-10
the O 0 3.069169918212822e-10
core O 0 7.132431978362774e-09
motif O 0 1.4524512259583844e-08
containing O 0 1.39679190436226e-09
the O 0 4.5735995546358765e-10
majority O 0 3.772388623701772e-09
of O 0 2.2938153598772715e-09
missense O 0 0.0003134591970592737
mutations O 0 3.0257306207204238e-06
, O 0 5.964188587448405e-10
and O 0 1.3844682344998915e-10
the O 0 2.5864085873017473e-10
involvement O 0 1.1888003470517106e-08
of O 0 6.289329612663153e-10
all O 0 6.86473877742344e-10
major O 0 8.633276138425572e-08
organ O 0 1.665726631472353e-05
systems O 0 2.7620269975159317e-05
( O 0 1.8481639330047983e-08
central O 0 1.1572237212931213e-07
nervous O 0 0.00014759099576622248
system O 0 7.500570063712075e-05
, O 0 3.988338903582189e-06
thyroid O 1 0.9998394250869751
, O 0 3.81501522497274e-05
breast O 1 0.9997391104698181
, O 0 4.287386400392279e-05
skin O 1 0.9976016879081726
and O 0 0.0033320686779916286
gastrointestinal O 1 0.9999814033508301
tract O 1 0.9959815740585327
) O 0 2.0487043457251275e-06
. O 0 8.763108212406223e-07

However O 0 6.226504751793982e-07
, O 0 1.59364841323395e-08
these O 0 6.52110920817961e-10
observations O 0 5.381501022583279e-09
would O 0 5.90906712449879e-10
need O 0 1.5659948338075935e-10
to O 0 5.017885412739176e-11
be O 0 1.6136690594859004e-10
confirmed O 0 1.8355336139919132e-09
by O 0 1.8214742214528457e-10
studying O 0 1.2133595239660622e-09
a O 0 1.4142033100128515e-09
larger O 0 3.0853417598564192e-09
number O 0 2.0514923093628568e-10
of O 0 5.443895334522608e-10
CD B-Disease 0 3.573488527308655e-07
families O 0 1.4047698471131298e-07
. O 0 2.1699868568703096e-07

Molecular O 1 0.8138293027877808
defects O 1 0.989588737487793
leading O 0 5.790941486338852e-06
to O 0 7.3193642258218006e-09
human O 0 6.198421687031441e-08
complement B-Disease 0 5.031194177718135e-06
component I-Disease 0 0.05873173847794533
C6 I-Disease 1 0.9999936819076538
deficiency I-Disease 1 0.9999536275863647
in O 0 1.1746300820902889e-08
an O 0 1.8218956343574177e-09
African O 0 1.6277047265589317e-08
- O 0 1.463226362830028e-05
American O 0 5.356373833365069e-08
family O 0 6.60943271668657e-07
. O 0 3.3781589081627317e-07

Complement B-Disease 0 0.009156733751296997
component I-Disease 1 0.9804792404174805
C6 I-Disease 1 0.9999445676803589
deficiency I-Disease 1 0.9999812841415405
( O 0 7.91052298154682e-06
C6D B-Disease 0 0.026380037888884544
) O 0 3.3007788147187966e-07
was O 0 2.5217561869794736e-06
diagnosed O 0 0.014728240668773651
in O 0 5.707289751910594e-09
a O 0 1.3302765111689041e-08
16 O 0 7.388545952835557e-08
- O 0 7.862313395889942e-06
year O 0 2.6136817155020253e-08
- O 0 6.620668386858597e-07
old O 0 7.501578380697538e-08
African O 0 2.843781654604527e-09
- O 0 4.3511644776117464e-07
American O 0 9.577473925048707e-09
male O 0 7.896043143773568e-07
with O 0 1.1603357961575966e-05
meningococcal B-Disease 1 0.9997333884239197
meningitis I-Disease 1 0.9991256594657898
. O 0 2.673832796062925e-06

The O 0 1.0894846127484925e-05
patients O 0 0.00035231446963734925
father O 0 1.3902603086535237e-06
and O 0 1.1371318997532853e-08
two O 0 5.589176677034402e-09
brothers O 0 5.257127781987947e-07
also O 0 4.230196637422523e-09
had O 0 1.8318516481485858e-08
C6D B-Disease 0 0.0003117705346085131
, O 0 4.147538756882341e-09
but O 0 8.890987945875395e-10
gave O 0 1.6264222191253452e-09
no O 0 7.63451357688183e-10
history O 0 2.0202928219248406e-09
of O 0 1.501681445859049e-08
meningitis B-Disease 1 0.7509989142417908
or O 0 3.7885207859744696e-08
other O 0 6.785634809602925e-08
neisserial B-Disease 1 0.9212287664413452
infection I-Disease 1 0.6695963144302368
. O 0 1.3490963510776055e-06

By O 0 2.8580578259607137e-07
using O 0 1.292960263299392e-07
exon O 0 3.346211451571435e-05
- O 0 3.1851338917476824e-06
specific O 0 1.3680425681172892e-08
polymerase O 0 3.441776925683371e-06
chain O 0 5.490028343047015e-06
reaction O 0 5.242263156901572e-08
( O 0 1.7986208078468735e-09
PCR O 0 5.0248846861222773e-08
) O 0 4.900750916192465e-10
/ O 0 1.4569877748726867e-08
single O 0 3.8378149547213525e-09
- O 0 3.2373989711231843e-07
strand O 0 1.0709420905641309e-07
conformation O 0 5.4603212618076213e-08
polymorphism O 0 2.0542158196690252e-08
as O 0 1.0110687287401277e-10
a O 0 1.2675603899836574e-09
screening O 0 2.0785847709703376e-08
step O 0 1.7299409682536293e-09
and O 0 5.978159633990288e-11
nucleotide O 0 1.205934796466579e-09
sequencing O 0 1.0254996851699616e-09
of O 0 9.45767214544091e-11
target O 0 2.279392674608971e-09
exons O 0 8.125169159711731e-08
, O 0 9.850178450676594e-10
we O 0 1.3694403944164435e-10
determined O 0 1.2025217488442763e-09
that O 0 2.769839392569029e-11
the O 0 2.6277649500805467e-10
proband O 0 2.6638806502887746e-06
was O 0 1.828412532489665e-09
a O 0 2.2717017156281827e-09
compound O 0 4.319543478459309e-08
heterozygote O 0 3.3054470804927405e-07
for O 0 2.322780634500532e-09
two O 0 5.092210386692386e-08
C6 O 0 0.4501083791255951
gene O 0 0.0004841337213292718
mutations O 0 0.0007424388313665986
. O 0 1.333755335508613e-06

The O 0 1.5283748666661268e-07
first O 0 2.6967466482119562e-08
, O 0 1.0292567687031351e-08
1195delC O 0 1.90056948667916e-06
located O 0 5.5713623936526346e-08
in O 0 6.979951283625496e-09
exon O 0 3.7033485114079667e-06
7 O 0 1.7094212978463474e-07
, O 0 2.5887492149934133e-09
is O 0 1.3072732896191042e-09
a O 0 1.0586345133845043e-08
novel O 0 3.862631103856984e-08
mutation O 0 3.738018676813226e-07
, O 0 2.6843863243364297e-10
while O 0 1.7872593682799476e-10
the O 0 2.2240001507078944e-10
second O 0 1.7551302633478372e-09
, O 0 6.038245459194513e-10
1936delG O 0 5.468898507388076e-07
in O 0 2.6174369338605175e-09
exon O 0 1.7114307411247864e-06
12 O 0 1.9017750929606336e-08
, O 0 1.0809229067376691e-09
has O 0 1.4996397457167632e-09
been O 0 6.609742198016022e-10
described O 0 3.140930182610191e-09
before O 0 8.741934953704344e-10
to O 0 5.923850299183187e-10
cause O 0 2.64224809143343e-07
C6D B-Disease 0 9.011799556901678e-05
in O 0 2.234269436129921e-09
an O 0 9.234185638362646e-10
unrelated O 0 1.5477480985737202e-07
African O 0 8.62787352673422e-09
- O 0 5.142936061020009e-06
American O 0 1.6132952751490848e-08
individual O 0 5.975375216848988e-08
. O 0 1.4934072112282593e-07

Both O 0 3.5767654935625615e-06
mutations O 0 0.0214200709015131
result O 0 5.673067789757624e-06
in O 0 4.0252712096844334e-07
premature O 0 0.000184209828148596
termination O 0 0.0001175794459413737
codons O 0 1.521927333669737e-05
and O 0 2.4927663844209746e-07
C6 O 0 0.09505762904882431
null O 0 9.610663255443797e-05
alleles O 0 2.5907673261826858e-05
. O 0 1.6527372963537346e-06

Allele O 0 0.0001393684360664338
- O 0 2.6415265892865136e-05
specific O 0 6.339848113157132e-08
PCR O 0 4.814155545318499e-06
indicated O 0 7.323794193325739e-08
that O 0 2.142258037629574e-10
the O 0 7.026780823871093e-10
probands O 0 2.8658141673076898e-06
two O 0 6.207126368451554e-09
brothers O 0 1.3199212389736203e-06
also O 0 5.281028503389962e-09
inherited O 0 2.908110900534666e-06
the O 0 5.292412730284468e-09
1195delC O 0 1.3372949069889728e-05
mutation O 0 5.644739076160477e-07
from O 0 3.2307700958966734e-10
their O 0 7.763426568274667e-10
heterozygous O 0 1.7824483222739218e-07
mother O 0 9.20839227092074e-08
and O 0 4.0096995168603655e-10
the O 0 2.103305973832903e-09
1936delG O 0 1.4629695215262473e-05
mutation O 0 3.809193458437221e-07
from O 0 3.379134194680944e-10
their O 0 1.3405431209534413e-09
homozygous O 0 2.7137746201333357e-06
father O 0 1.395638804524424e-07
. O 0 2.012256317129868e-08
. O 0 1.511529887920915e-07

PAX6 O 1 0.9861272573471069
mutations O 1 0.9575127959251404
reviewed O 0 0.000760232622269541
. O 0 5.210343806538731e-05

Mutations O 0 0.02101277932524681
in O 0 2.8067897801520303e-06
PAX6 O 0 0.014684916473925114
are O 0 4.446810919489508e-08
responsible O 0 1.2997089982036414e-07
for O 0 4.499432382232271e-09
human O 0 9.060097738711193e-08
aniridia B-Disease 1 0.601813793182373
and O 0 2.134502885553502e-08
have O 0 2.2556487788705226e-09
also O 0 2.4468493897700228e-09
been O 0 3.1186755400369748e-09
found O 0 3.130542935991798e-08
in O 0 4.500756389802518e-08
patients O 0 2.0201676306896843e-05
with O 0 7.952160672175523e-07
Peters B-Disease 1 0.9931685924530029
anomaly I-Disease 1 0.9998459815979004
, O 0 2.554691855038982e-05
with O 0 0.024192415177822113
congenital B-Disease 1 0.9999991655349731
cataracts I-Disease 1 0.9999873638153076
, O 0 1.9374117528059287e-06
with O 0 2.188764256061404e-06
autosomal B-Disease 0 0.3801226019859314
dominant I-Disease 0 0.0006766571314074099
keratitis I-Disease 0 0.40164440870285034
, O 0 1.0275525852421197e-07
and O 0 4.326618352479272e-08
with O 0 4.058609192725271e-06
isolated B-Disease 0 0.25516730546951294
foveal I-Disease 1 0.9998281002044678
hypoplasia I-Disease 1 0.9997846484184265
. O 0 1.6872878404683433e-05

No O 0 8.386494414480694e-07
locus O 0 3.2112914141180227e-06
other O 0 5.912136558094971e-09
than O 0 5.69571856345874e-09
chromosome O 0 6.177299383125501e-06
11p13 O 0 1.2257754860911518e-05
has O 0 1.1444690528605861e-08
been O 0 3.2769831292966956e-09
implicated O 0 7.766905127937207e-07
in O 0 1.2177656572021078e-07
aniridia B-Disease 1 0.7392181754112244
, O 0 1.9367483616861136e-08
and O 0 9.638995379646076e-09
PAX6 O 0 0.019907044246792793
is O 0 1.725243059524928e-08
clearly O 0 6.627596693675741e-09
the O 0 1.3540392140853896e-09
major O 0 8.803279882840798e-09
, O 0 1.0728793409242598e-09
if O 0 3.601229869865108e-10
not O 0 5.926265728151137e-11
only O 0 9.98481644587379e-11
, O 0 1.487566625435477e-09
gene O 0 2.1637049485434545e-07
responsible O 0 6.524996933876537e-07
. O 0 2.71799677875606e-07

Twenty O 0 8.346078175236471e-06
- O 0 8.483267265546601e-06
eight O 0 8.05863322739242e-08
percent O 0 7.504955590320606e-08
of O 0 4.004061526785563e-09
identified O 0 7.16092301900062e-07
PAX6 O 0 0.03635750710964203
mutations O 0 0.00022779057326260954
are O 0 2.650924812996891e-08
C O 0 7.121723319869488e-05
- O 0 0.022833751514554024
T O 0 0.006022656336426735
changes O 0 1.4412250948225847e-08
at O 0 9.160651792683439e-09
CpG O 0 4.961514719070692e-07
dinucleotides O 0 2.035814759437926e-06
, O 0 8.225816139351139e-10
20 O 0 7.403322399568424e-10
% O 0 4.209790294140703e-10
are O 0 5.6724468872060285e-11
splicing O 0 5.494326416055628e-08
errors O 0 2.6093911742464115e-07
, O 0 3.8762659748670103e-10
and O 0 6.634849614162164e-11
more O 0 2.8173890304072913e-11
than O 0 1.7112734840285526e-10
30 O 0 3.0650708637836033e-09
% O 0 9.629379515985192e-10
are O 0 4.1827138974603884e-10
deletion O 0 6.198085316100332e-07
or O 0 8.220784941670445e-09
insertion O 0 2.644120968398056e-06
events O 0 2.2670091937015968e-07
. O 0 2.3139253357840062e-07

There O 0 3.1970529335012543e-07
is O 0 1.766681556603089e-08
a O 0 4.527809593923848e-08
noticeably O 0 1.31115666590631e-06
elevated O 0 7.184535206761211e-06
level O 0 2.2163209933978578e-08
of O 0 1.7713132072216808e-09
mutation O 0 7.46649050142878e-07
in O 0 5.815857795354873e-10
the O 0 2.6466429048355167e-10
paired O 0 1.351062817178672e-08
domain O 0 5.701936256485851e-09
compared O 0 1.0494128233062838e-08
with O 0 2.1454762966222063e-10
the O 0 2.798730414088624e-10
rest O 0 1.0623355528593947e-09
of O 0 3.648826241153813e-10
the O 0 1.3250548214216451e-08
gene O 0 1.275886461371556e-06
. O 0 2.285288474013214e-07

Increased O 0 3.116224252153188e-05
mutation O 0 9.744231647346169e-05
in O 0 6.455143619632508e-08
the O 0 1.9170052212302835e-08
homeodomain O 0 3.887542334268801e-05
is O 0 8.898831005410557e-09
accounted O 0 1.2854120434724337e-08
for O 0 6.52110920817961e-10
by O 0 1.2659464587727598e-09
the O 0 6.209317060523745e-09
hypermutable O 0 7.753714453428984e-05
CpG O 0 1.762258034432307e-05
dinucleotide O 0 5.011155371903442e-05
in O 0 6.349480941025831e-08
codon O 0 1.9271180917712627e-06
240 O 0 1.0791559361678082e-06
. O 0 3.712128204824694e-07

Very O 0 5.183512143958069e-07
nearly O 0 2.6376883965895104e-07
all O 0 1.2749005406931246e-08
mutations O 0 7.723946509941015e-06
appear O 0 4.569087508343728e-08
to O 0 1.6651410250645426e-09
cause O 0 5.680846015820862e-07
loss O 0 3.3093331808231596e-07
of O 0 2.1203917788259474e-10
function O 0 1.1734694327358852e-09
of O 0 2.3569468599049515e-10
the O 0 6.740532021431989e-10
mutant O 0 2.2962007051319233e-07
allele O 0 2.126704323757167e-08
, O 0 1.932753540545562e-10
and O 0 6.285152953644513e-11
more O 0 2.0420672097731796e-11
than O 0 6.886819586826576e-11
80 O 0 7.750481367807538e-10
% O 0 1.9253543204200696e-10
of O 0 2.670394183557079e-10
exonic O 0 4.394092229631497e-06
substitutions O 0 7.82644278274347e-08
result O 0 5.755874710189346e-08
in O 0 2.498958906471671e-08
nonsense O 0 7.788135917508043e-06
codons O 0 1.1406516023271251e-05
. O 0 6.28800364665949e-07

In O 0 4.215451383515756e-07
a O 0 1.8698750636758632e-07
gene O 0 2.2432297441810078e-07
with O 0 5.730960594974022e-09
such O 0 1.967832119476043e-09
extraordinarily O 0 6.821099759690696e-06
high O 0 5.027319502914906e-07
sequence O 0 3.147288651916824e-08
conservation O 0 1.2872865440272108e-08
throughout O 0 5.885985032705321e-10
evolution O 0 2.3759416656332633e-09
, O 0 6.164412869047453e-10
there O 0 3.569649020818133e-10
are O 0 5.740486419547608e-10
presumed O 0 1.2083874025847763e-06
undiscovered O 0 3.758024831768125e-05
missense O 0 0.015738194808363914
mutations O 0 7.046825339784846e-05
, O 0 2.227898754370017e-09
these O 0 1.1608908973004262e-10
are O 0 1.2873145605052372e-10
hypothesized O 0 8.628893155560036e-09
to O 0 7.231931720141915e-11
exist O 0 4.797746644413792e-10
in O 0 4.461435942904046e-10
as O 0 3.2212836842404613e-09
- O 0 1.790601345419418e-05
yet O 0 4.695649025165949e-08
unidentified O 0 8.103475920506753e-06
phenotypes O 0 2.615517587400973e-05
. O 0 1.986348685534267e-08
. O 0 1.6121209966968308e-07

Genetic O 0 0.0015975245041772723
heterogeneity O 0 0.0008495713700540364
and O 0 5.11114649270894e-07
penetrance O 0 0.0009631761349737644
analysis O 0 1.3689239608538628e-07
of O 0 1.493731360824313e-08
the O 0 4.486348714749511e-08
BRCA1 O 0 0.00042702953214757144
and O 0 1.9104118109680712e-07
BRCA2 O 0 0.005092244129627943
genes O 0 5.747533214162104e-05
in O 0 0.0001801957841962576
breast B-Disease 1 0.9999591112136841
cancer I-Disease 1 0.9994747042655945
families O 0 1.1266653018537909e-05
. O 0 2.747969574556919e-06

The O 0 0.06588060408830643
Breast B-Disease 1 0.9999357461929321
Cancer I-Disease 1 0.9998341798782349
Linkage O 0 0.03947161138057709
Consortium O 0 0.0024850424379110336
. O 0 1.0867761375266127e-05

The O 0 1.3490058847764885e-07
contribution O 0 2.0584012361268833e-07
of O 0 3.843420870452974e-08
BRCA1 O 0 0.004820224363356829
and O 0 2.29068314183678e-06
BRCA2 O 1 0.7612704634666443
to O 0 8.405509288422763e-05
inherited B-Disease 1 0.9999986886978149
breast I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999985694885254
was O 0 3.1176953143585706e-06
assessed O 0 1.304442491800728e-07
by O 0 1.329887644452299e-09
linkage O 0 3.1519687127001816e-07
and O 0 1.0926559212975917e-08
mutation O 0 7.142501203816209e-07
analysis O 0 3.5350617988427757e-09
in O 0 7.466683937806806e-10
237 O 0 2.3995106346319517e-08
families O 0 2.739244164828847e-09
, O 0 3.6663930225167007e-10
each O 0 9.19293668966148e-11
with O 0 4.962739663660898e-10
at O 0 4.058298141984551e-09
least O 0 7.551760328183832e-10
four O 0 4.65818938977236e-09
cases O 0 1.361662498311489e-07
of O 0 1.7573171362528228e-06
breast B-Disease 1 0.9999858140945435
cancer I-Disease 1 0.9907464981079102
, O 0 7.765785348112786e-09
collected O 0 2.5785191759553072e-09
by O 0 2.220348882531198e-08
the O 0 3.716791616170667e-05
Breast B-Disease 1 0.9999936819076538
Cancer I-Disease 1 0.999962329864502
Linkage O 0 0.0006347055314108729
Consortium O 0 0.00019004383648280054
. O 0 9.70808400779788e-07

Families O 0 3.118141194136115e-06
were O 0 5.6262514647187345e-08
included O 0 1.635603297245325e-08
without O 0 4.952492194121305e-09
regard O 0 2.8007183239253663e-09
to O 0 2.3644486368823436e-10
the O 0 1.6125376589570806e-09
occurrence O 0 9.613144129616558e-07
of O 0 3.4209210753033403e-07
ovarian B-Disease 1 0.9999120235443115
or I-Disease 0 7.364907901319384e-07
other I-Disease 0 8.871082286532328e-07
cancers I-Disease 1 0.9778695702552795
. O 0 2.563258931331802e-06

Overall O 0 0.007257958874106407
, O 0 6.213648157427087e-05
disease O 0 0.3917047083377838
was O 0 1.6287253856717143e-06
linked O 0 4.655132670450257e-06
to O 0 4.1648839932406645e-09
BRCA1 O 0 2.5181723685818724e-05
in O 0 1.2314520514422611e-09
an O 0 4.0383590915737955e-10
estimated O 0 5.081137732787511e-09
52 O 0 8.599155165711636e-09
% O 0 3.48844148012617e-10
of O 0 1.120385589858941e-10
families O 0 1.4761001310148458e-09
, O 0 3.748002186387822e-10
to O 0 1.8635031018288117e-10
BRCA2 O 0 4.194936991552822e-06
in O 0 1.3592870162781878e-09
32 O 0 5.20787768465425e-09
% O 0 3.471661569331985e-10
of O 0 1.2486033040826072e-10
families O 0 2.1933919125416423e-09
, O 0 6.184174283774269e-10
and O 0 2.0859340643664126e-10
to O 0 1.41375758322404e-10
neither O 0 2.493805828507334e-09
gene O 0 2.409962451821457e-09
in O 0 2.2453029713265238e-10
16 O 0 1.853436959464716e-09
% O 0 3.8014083547643907e-10
( O 0 2.4020496702803484e-10
95 O 0 2.6169477695958676e-09
% O 0 1.2003927851722551e-09
confidence O 0 3.4906882717677945e-08
interval O 0 4.625036638117308e-07
[ O 0 3.0343773005370167e-07
CI O 0 0.0003929472586605698
] O 0 3.4554272332343317e-08
6 O 0 1.370735347450136e-08
% O 0 3.998597009058358e-09
- O 0 1.0187352472712519e-06
28 O 0 2.8788088357600827e-08
% O 0 2.4305091272935897e-09
) O 0 5.125628255164827e-10
, O 0 7.668942147986968e-10
suggesting O 0 1.718726672095272e-08
other O 0 3.212043964140321e-09
predisposition O 0 6.589511031052098e-05
genes O 0 1.906272927953978e-06
. O 0 3.4399417359054496e-07

The O 0 4.4777405605600507e-07
majority O 0 4.659280250507436e-07
( O 0 2.221785067035853e-08
81 O 0 1.383745455996177e-07
% O 0 3.4863216757941018e-09
) O 0 6.502851035428137e-10
of O 0 5.060604379991673e-09
the O 0 5.477178274304606e-05
breast B-Disease 1 0.999996542930603
- I-Disease 1 0.9999982118606567
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999953508377075
families O 0 4.3922639747506764e-07
were O 0 3.946061699622305e-09
due O 0 3.362024258990459e-08
to O 0 4.091633254432736e-09
BRCA1 O 0 0.0002935465890914202
, O 0 1.891067302750571e-09
with O 0 1.142209216098422e-09
most O 0 5.757669341299732e-10
others O 0 1.7293536602736026e-09
( O 0 1.0815250917062258e-09
14 O 0 9.889716601207965e-09
% O 0 5.8654903156707405e-09
) O 0 4.159310673657046e-09
due O 0 3.736086284789053e-08
to O 0 2.5862338048909805e-08
BRCA2 O 0 0.0023904163390398026
. O 0 8.647858749100124e-07

Conversely O 0 4.657195313484408e-05
, O 0 5.345504305864779e-08
the O 0 3.551301253068573e-09
majority O 0 8.867993450678568e-09
of O 0 6.619053083412041e-10
families O 0 4.1007663931225125e-09
with O 0 5.020762472440765e-09
male B-Disease 0 4.319955735354597e-07
and I-Disease 0 1.8560209014140128e-07
female I-Disease 0 0.14405176043510437
breast I-Disease 1 0.9999891519546509
cancer I-Disease 1 0.9942519664764404
were O 0 3.868913367455207e-08
due O 0 9.726556271516529e-08
to O 0 9.453588134533675e-09
BRCA2 O 0 0.0007640090771019459
( O 0 4.1295905361948826e-08
76 O 0 1.7064436406144523e-06
% O 0 5.263242286446257e-08
) O 0 5.1790447486155244e-08
. O 0 2.5913698209478753e-07

The O 0 6.356145263453072e-07
largest O 0 3.588012532418361e-06
proportion O 0 5.026888629799942e-07
( O 0 2.118194863953704e-08
67 O 0 8.620129676728538e-08
% O 0 1.9571415599273223e-09
) O 0 2.0970639114104017e-10
of O 0 1.3730706849290897e-10
families O 0 2.0526753630178973e-09
due O 0 2.9073965457371287e-09
to O 0 4.0984951543698855e-11
other O 0 8.463923312218569e-11
genes O 0 3.375477231060131e-09
was O 0 2.4790283159603632e-09
found O 0 1.0375821313246547e-09
in O 0 3.488907218685e-10
families O 0 5.097258171105068e-10
with O 0 6.566466259627646e-10
four O 0 1.611947242352585e-09
or O 0 1.390006887369566e-09
five O 0 4.5775112589296896e-09
cases O 0 2.686842748289564e-08
of O 0 1.3194249959269655e-07
female O 1 0.7181788086891174
breast B-Disease 1 0.9999933242797852
cancer I-Disease 1 0.999302864074707
only O 0 1.6780936107352318e-07
. O 0 7.716826075920835e-07

These O 0 2.3762106593494536e-07
estimates O 0 5.606422632808972e-07
were O 0 7.610442054328814e-09
not O 0 2.7283044712334004e-09
substantially O 0 1.7660185847034882e-07
affected O 0 5.848632689264832e-09
either O 0 8.271788809466329e-10
by O 0 4.3860476361956557e-10
changing O 0 6.154218912257647e-09
the O 0 1.4041938722897385e-09
assumed O 0 2.1652240889125096e-07
penetrance O 0 9.566863445797935e-05
model O 0 3.5745111404139607e-07
for O 0 1.4285726379625885e-08
BRCA1 O 0 6.547794328071177e-05
or O 0 3.0089473135319622e-09
by O 0 6.813759556578702e-10
including O 0 3.278533666772887e-09
or O 0 5.280859838308061e-08
excluding O 0 1.0435473086545244e-05
BRCA1 O 0 0.3984187841415405
mutation O 0 0.00021876934624742717
data O 0 7.231183190015145e-07
. O 0 7.778595545460121e-07

Among O 0 4.276432150618348e-07
those O 0 5.0434159959422686e-08
families O 0 2.5286530558332743e-07
with O 0 3.2447167086502304e-06
disease O 0 0.08822622895240784
due O 0 3.4241165280946007e-07
to O 0 1.3337468907081984e-08
BRCA1 O 0 0.0006597664323635399
that O 0 8.73813410517954e-10
were O 0 4.80134432212509e-10
tested O 0 1.1147401224320674e-08
by O 0 7.05333708106437e-11
one O 0 4.996911912025226e-11
of O 0 2.8664653983767607e-11
the O 0 1.4597317798958898e-10
standard O 0 1.714784225725907e-08
screening O 0 6.803402641253342e-08
methods O 0 5.774840161620887e-09
, O 0 3.80589382231733e-09
mutations O 0 1.7599121804323659e-07
were O 0 6.677994268677878e-10
detected O 0 2.7478483488607708e-08
in O 0 1.7337585533905298e-10
the O 0 1.9716181465234683e-10
coding O 0 5.940873748500053e-08
sequence O 0 3.1794036292609462e-09
or O 0 2.6000801511827376e-10
splice O 0 2.9398803391700312e-08
sites O 0 1.024559326268104e-09
in O 0 2.021575545851917e-10
an O 0 1.4693997407722037e-10
estimated O 0 1.7380968886371306e-09
63 O 0 7.457379602726633e-09
% O 0 5.927692781071414e-10
( O 0 5.195889274389742e-10
95 O 0 6.329986312891833e-09
% O 0 1.2219066647389809e-08
CI O 0 0.0001352665713056922
51 O 0 1.723349356552717e-07
% O 0 1.9145788954233467e-08
- O 0 5.606076683761785e-06
77 O 0 3.1709180348116206e-07
% O 0 3.039677309857325e-08
) O 0 3.207955856510125e-08
. O 0 1.6429251559202385e-07

The O 0 3.0875926881890337e-07
estimated O 0 2.282139206499778e-07
sensitivity O 0 3.0116538596303144e-07
was O 0 1.523207160403217e-08
identical O 0 2.0522419319490837e-08
for O 0 1.3837025969465344e-10
direct O 0 4.975743705948332e-10
sequencing O 0 1.4099405198919612e-08
and O 0 8.003663842792719e-10
other O 0 8.511263915877976e-10
techniques O 0 1.328032084302322e-07
. O 0 2.2333996696488612e-07

The O 0 2.8866111279057804e-06
penetrance O 0 0.004822858143597841
of O 0 2.6929129148811626e-07
BRCA2 O 0 0.002505960175767541
was O 0 4.8070855740434126e-08
estimated O 0 8.17575074307797e-09
by O 0 7.286487524460483e-10
maximizing O 0 2.3760652112514435e-08
the O 0 3.4324674214047945e-09
LOD O 0 7.847185770515352e-05
score O 0 4.4188080750018344e-08
in O 0 1.0759706725593787e-07
BRCA2 O 0 0.0035039526410400867
- O 0 0.00026111339684575796
mutation O 0 2.8474032660597004e-06
families O 0 4.323761793045833e-09
, O 0 6.179127765015835e-10
over O 0 6.581311606801421e-10
all O 0 4.4295375700720285e-10
possible O 0 6.618427761395651e-08
penetrance O 0 0.00027294771280139685
functions O 0 3.7201016311882995e-07
. O 0 4.2442212588866823e-07

The O 0 8.015433081709489e-07
estimated O 0 1.3378689800447319e-06
cumulative O 0 2.7274032618151978e-05
risk O 0 0.0003526170621626079
of O 0 5.973010047455318e-06
breast B-Disease 1 0.9999279975891113
cancer I-Disease 1 0.9808681607246399
reached O 0 3.902583785020397e-07
28 O 0 1.7245298522539088e-07
% O 0 5.84653525592671e-09
( O 0 1.2371963453716717e-09
95 O 0 8.828838993224508e-09
% O 0 7.927051903777738e-09
CI O 0 0.00014845069381408393
9 O 0 8.303522491814874e-08
% O 0 6.674113706139906e-09
- O 0 3.182651937549963e-07
44 O 0 7.721240535829565e-09
% O 0 8.228656644959642e-10
) O 0 6.475704694697271e-11
by O 0 1.0521757076720206e-10
age O 0 1.2958536466101123e-09
50 O 0 5.305346717499049e-10
years O 0 3.198323828002003e-10
and O 0 1.128899335123279e-10
84 O 0 1.0590747834271497e-08
% O 0 5.755297904919132e-10
( O 0 3.153378391740347e-10
95 O 0 2.3954624950306425e-09
% O 0 4.285420018845798e-09
CI O 0 7.305678445845842e-05
43 O 0 3.5756627880800806e-08
% O 0 4.222457938851676e-09
- O 0 2.6102549099960015e-07
95 O 0 4.954948451540986e-09
% O 0 1.3070090565392434e-09
) O 0 2.3447152552869e-10
by O 0 4.6290651867231247e-10
age O 0 1.4555490146506145e-08
70 O 0 2.5543680948203473e-08
years O 0 4.5295031725345325e-08
. O 0 1.3254926045647153e-07

The O 0 0.0005333762965165079
corresponding O 1 0.9983698725700378
ovarian B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999958276748657
risks O 0 0.17985272407531738
were O 0 7.43010787118692e-07
0 O 0 7.866197847761214e-06
. O 0 1.3869164376956178e-06

4 O 0 6.9009051912871655e-06
% O 0 1.2965398354936042e-07
( O 0 9.997823013918605e-09
95 O 0 3.966717443404377e-08
% O 0 2.134718712909489e-08
CI O 0 0.0002594806719571352
0 O 0 7.020570791382852e-08
% O 0 1.563796558912145e-08
- O 0 5.754808967139979e-07
1 O 0 4.707743972431899e-09
% O 0 7.655248657201241e-10
) O 0 8.509506294052116e-11
by O 0 8.948965873889492e-11
age O 0 2.104208807196528e-09
50 O 0 6.065186131110067e-10
years O 0 4.975686529462564e-10
and O 0 2.1526579130348722e-10
27 O 0 8.331376477599406e-09
% O 0 4.774022288600577e-10
( O 0 3.5337588411010756e-10
95 O 0 3.102028856005745e-09
% O 0 4.988821800111509e-09
CI O 0 0.00010693496005842462
0 O 0 2.7252063716787234e-08
% O 0 1.1200149252488245e-08
- O 0 1.2377255416140542e-06
47 O 0 4.03750810562542e-08
% O 0 5.419694137920317e-10
) O 0 1.828708018347669e-10
by O 0 3.8183983752659856e-10
age O 0 1.5597869662542507e-08
70 O 0 2.8636501170353768e-08
years O 0 5.540398007042313e-08
. O 0 1.1326256554866632e-07

The O 0 6.7751861934084445e-06
lifetime O 0 0.006089608650654554
risk O 0 0.014766269363462925
of O 0 8.149600762408227e-05
breast B-Disease 1 0.9999920129776001
cancer I-Disease 1 0.9998366832733154
appears O 0 1.4169061159918783e-06
similar O 0 1.7226847504048237e-08
to O 0 4.910182815898168e-10
the O 0 1.1479451167417665e-08
risk O 0 1.3794872302241856e-06
in O 0 4.214301441152202e-08
BRCA1 O 0 0.0009010458015836775
carriers O 0 1.6237811450992012e-06
, O 0 1.5564577404703073e-09
but O 0 2.5343713239145416e-10
there O 0 7.624555847796088e-11
was O 0 2.486177097527076e-10
some O 0 5.200586489229053e-11
suggestion O 0 1.851359399118735e-09
of O 0 3.7267450236910804e-10
a O 0 1.1482631379067243e-07
lower O 0 1.8728227587416768e-05
risk O 0 1.1273810741840862e-05
in O 0 7.364206311422095e-08
BRCA2 O 0 0.00015789720055181533
carriers O 0 1.9553986021492165e-06
< O 0 5.932516842221958e-07
50 O 0 2.5195372455044662e-09
years O 0 2.8396840434652404e-09
of O 0 2.2319608383725154e-09
age O 0 3.9816964658712095e-07
. O 0 2.297359458225401e-07

Eye B-Disease 1 0.7199483513832092
movement I-Disease 0 0.0007029963308013976
abnormalities I-Disease 1 0.7880510687828064
correlate O 0 2.1631822164636105e-05
with O 0 8.210883493120491e-07
genotype O 0 0.0011593402596190572
in O 0 6.176168426463846e-06
autosomal O 1 0.94935542345047
dominant O 1 0.7926052808761597
cerebellar B-Disease 1 0.9998840093612671
ataxia I-Disease 1 0.9999500513076782
type I-Disease 1 0.8966600298881531
I I-Disease 0 0.00012725921988021582
. O 0 1.439114839740796e-06

We O 0 1.4484502344203065e-06
compared O 0 2.1938863028481137e-06
horizontal O 0 6.419263809220865e-05
eye O 0 6.809272599639371e-05
movements O 0 1.116506709308851e-07
( O 0 5.4056248366407544e-09
visually O 0 9.118225818838255e-08
guided O 0 8.613554314251815e-08
saccades O 0 0.0002180203446187079
, O 0 1.284211226248999e-08
antisaccades O 0 6.717321866744896e-06
, O 0 1.100929014619112e-09
and O 0 4.0800432477006154e-10
smooth O 0 7.877498120478776e-08
pursuit O 0 2.173058106791359e-07
) O 0 8.223761116532557e-10
in O 0 5.409779291198902e-10
control O 0 1.2103599011936694e-08
subjects O 0 5.826319426915916e-09
( O 0 8.477407220652822e-09
n O 0 1.742576159813325e-06
= O 0 9.848690751823597e-07
14 O 0 1.713718411622267e-08
) O 0 2.028416545840628e-09
and O 0 7.696097981124694e-09
patients O 0 1.2206788824187242e-06
with O 0 2.0798407440736355e-09
three O 0 2.1917276882277292e-09
forms O 0 1.509947189504146e-08
of O 0 4.643935724857329e-08
autosomal O 0 0.0727936327457428
dominant O 0 0.0029892227612435818
cerebellar B-Disease 1 0.9920620918273926
ataxias I-Disease 1 0.9923162460327148
type I-Disease 0 0.008802318014204502
I I-Disease 0 1.085493840946583e-05
spinocerebellar B-Disease 1 0.8518421053886414
ataxias I-Disease 0 0.00220710807479918
1 I-Disease 0 5.920715651086539e-08
and I-Disease 0 1.8932400092097623e-09
2 I-Disease 0 2.9682890811955076e-08
( O 0 1.3337825066628284e-08
SCA1 B-Disease 0 0.00031279976246878505
, O 0 9.356504904189933e-09
n O 0 2.073759560516919e-06
= O 0 8.325833960043383e-07
11 O 0 1.723575415724099e-08
; O 0 4.356933480664793e-09
SCA2 B-Disease 0 4.7346802602987736e-05
, O 0 6.883372982713354e-09
n O 0 8.771904731474933e-07
= O 0 2.530389906496566e-07
10 O 0 2.442471114250111e-09
) O 0 1.132551163962603e-09
and O 0 1.605066657361931e-08
SCA3 B-Disease 1 0.9844133853912354
/ O 0 0.0009220395586453378
Machado B-Disease 0 0.015722136944532394
- I-Disease 0 0.05965953692793846
Joseph I-Disease 0 0.000848316412884742
disease I-Disease 0 0.06294015794992447
( O 0 2.050556133781356e-07
MJD B-Disease 1 0.8932132720947266
) O 0 1.9693350949978594e-08
( O 0 1.6591057416803778e-08
n O 0 6.854735147499014e-06
= O 0 3.3993437682511285e-06
16 O 0 7.554115200036904e-08
) O 0 4.768166661506257e-08
. O 0 1.1831750157398346e-07

In O 0 7.999578883755021e-07
SCA1 B-Disease 0 0.00011601797450566664
, O 0 2.103391416596878e-08
saccade O 0 4.529379111772869e-06
amplitude O 0 3.3632241525083373e-07
was O 0 3.3921693898264493e-08
significantly O 0 7.33413898501567e-08
increased O 0 2.3665986503829117e-08
, O 0 2.4647803797961387e-09
resulting O 0 1.0011661544240269e-07
in O 0 5.9048030465191914e-08
hypermetria B-Disease 0 0.0008457726798951626
. O 0 1.1640580623861752e-06

The O 0 2.162863097510126e-07
smooth O 0 3.280788860138273e-06
pursuit O 0 4.085820819454966e-06
gain O 0 1.031451802191441e-06
was O 0 3.1345913953373383e-07
decreased O 0 9.324738130089827e-06
. O 0 6.942299251022632e-07

In O 0 3.2823943456605775e-06
SCA2 B-Disease 0 0.0004168076266068965
, O 0 1.4579529761249432e-07
saccade O 0 2.3688719011261128e-05
velocity O 0 3.2969326184684178e-06
was O 0 1.8159056480726576e-07
markedly O 0 1.4912135156919248e-05
decreased O 0 1.9054123185924254e-05
. O 0 6.288639156082354e-07

The O 0 5.310931214808079e-07
percentage O 0 2.3756222162774066e-06
of O 0 1.1336042327059204e-08
errors O 0 1.0533652812227956e-06
in O 0 2.7901254640028128e-08
antisaccades O 0 4.955100666848011e-05
was O 0 1.4324198716053615e-08
greatly O 0 1.2359469891976005e-08
increased O 0 1.152774409263202e-08
and O 0 1.297379537135157e-09
was O 0 7.573659921433773e-09
significantly O 0 5.933581093131579e-08
correlated O 0 8.876729395979055e-08
with O 0 1.1665365562407715e-08
age O 0 1.8735750018095132e-06
at O 0 2.2660247850581072e-05
disease O 1 0.825797975063324
onset O 1 0.6958884596824646
. O 0 2.6378875190857798e-06

In O 0 6.102208089941996e-07
addition O 0 1.6399491187257809e-07
, O 0 7.063589269051818e-09
a O 0 2.798187459518431e-09
correlation O 0 7.731850715231303e-09
between O 0 1.6424394067016124e-09
smooth O 0 4.863601432703035e-08
pursuit O 0 1.383026528856135e-07
gain O 0 1.2029260254564633e-08
and O 0 2.191592740619086e-10
the O 0 1.42299907968102e-10
number O 0 6.345842740174135e-10
of O 0 2.8836102394791396e-09
trinucleotide O 0 0.0032495043706148863
repeats O 0 6.722813850501552e-06
was O 0 1.66658821854071e-07
found O 0 1.6024503679545887e-07
. O 0 2.1586635057246895e-07

In O 0 6.60701562082977e-06
SCA3 B-Disease 1 0.6629247069358826
, O 0 1.164282963372898e-07
gaze B-Disease 0 2.0508296074694954e-05
- I-Disease 0 9.76493683992885e-05
evoked I-Disease 0 1.0040783308795653e-05
nystagmus I-Disease 0 0.0005277686286717653
was O 0 3.489143551860252e-08
often O 0 9.577615367462045e-10
present O 0 4.746746884443098e-10
as O 0 3.2632654911601833e-10
was O 0 3.850800567306578e-09
saccade O 0 1.2592541906997212e-06
hypometria O 0 3.3831861401267815e-06
and O 0 1.8548090841008502e-09
smooth O 0 6.690583376212089e-08
pursuit O 0 5.667037044077006e-07
gain O 0 2.0835828706822213e-07
was O 0 1.411694228181659e-07
markedly O 0 1.1405220902815927e-05
decreased O 0 1.068693381967023e-05
. O 0 4.352201870005956e-07

Three O 0 5.625639118989056e-07
major O 0 2.3280115613033558e-07
criteria O 0 8.843033327821104e-08
, O 0 4.244081086568485e-09
saccade O 0 1.6091210000013234e-06
amplitude O 0 8.320422040242192e-08
, O 0 2.0784607368540264e-09
saccade O 0 1.4818435829511145e-06
velocity O 0 5.959236659691669e-08
, O 0 3.7634606542269466e-10
and O 0 5.982847550711767e-11
presence O 0 9.693600366844635e-10
of O 0 8.500816162104741e-10
gaze B-Disease 0 5.723279173253104e-06
- I-Disease 0 5.337825496098958e-05
evoked I-Disease 0 2.9473978884198004e-06
nystagmus I-Disease 0 5.073085048934445e-05
, O 0 7.93228094320142e-10
permitted O 0 4.273671694310366e-10
the O 0 3.653896629707276e-10
correct O 0 4.186323732113806e-09
assignment O 0 1.9674868401153844e-09
of O 0 5.82698056472708e-11
90 O 0 6.778811401098039e-10
% O 0 1.3065397375111587e-10
of O 0 5.97299640303639e-11
the O 0 1.051558284892451e-09
SCA1 B-Disease 0 7.562789051007712e-06
, O 0 4.6502510175905343e-10
90 O 0 9.807248346760389e-10
% O 0 3.1495434038575354e-10
of O 0 1.0116204401944273e-10
the O 0 7.89171672455069e-10
SCA2 B-Disease 0 7.475064649042906e-06
, O 0 4.0131428735712404e-10
and O 0 3.2139296779476467e-10
93 O 0 1.9118273186791157e-08
% O 0 7.023069348299771e-10
of O 0 4.934179176352416e-10
the O 0 2.3302277440961916e-08
patients O 0 3.045383891731035e-06
with O 0 8.250064631454279e-09
SCA3 B-Disease 0 0.3142162263393402
to O 0 8.038193444193098e-10
their O 0 1.1385187015378051e-08
genetically O 0 3.828119133686414e-06
confirmed O 0 1.98528982764401e-06
patient O 0 6.036712875356898e-06
group O 0 1.3749065885804157e-08
and O 0 1.0023900598454816e-09
, O 0 1.4222644173500498e-09
therefore O 0 2.56507859397459e-09
, O 0 2.367346763065825e-09
may O 0 7.305625882025879e-09
help O 0 6.879198988229973e-09
orient O 0 1.993318619497586e-06
diagnoses O 0 6.3331194724014495e-06
of O 0 3.2532554428144067e-09
SCA1 B-Disease 0 0.004998310934752226
, O 0 2.1837003316704795e-08
SCA2 B-Disease 0 0.00030194365535862744
, O 0 6.410296737868748e-09
and O 0 6.740574320929227e-09
SCA3 B-Disease 0 0.27508115768432617
at O 0 6.24277163296938e-08
early O 0 8.887673885737968e-08
clinical O 0 5.465225058287615e-06
stages O 0 1.0634530553943478e-06
of O 0 1.4528112934897308e-08
the O 0 1.0914247923210496e-06
diseases O 0 0.02326926216483116
. O 0 5.7811138987062805e-08
. O 0 2.8053881351297605e-07

Genetic O 0 6.628889968851581e-05
basis O 0 3.3475572536190157e-07
and O 0 8.20257355371723e-08
molecular O 0 0.00015425302262883633
mechanism O 0 0.00018758569785859436
for O 0 0.00021588560775853693
idiopathic B-Disease 1 0.9999887943267822
ventricular I-Disease 1 0.9999322891235352
fibrillation I-Disease 1 0.9999469518661499
. O 0 0.00021273190213833004

Ventricular B-Disease 1 0.9976600408554077
fibrillation I-Disease 1 0.9987291693687439
causes O 0 0.00011753235594369471
more O 0 1.4073989085261474e-08
than O 0 2.7033268956699885e-09
300 O 0 4.515733120769028e-09
, O 0 8.061284972882277e-10
000 O 0 1.152732664877476e-08
sudden O 0 1.8120839513358078e-06
deaths O 0 1.274698036013433e-07
each O 0 5.813240444574319e-10
year O 0 8.932398820604703e-09
in O 0 1.8781984856275358e-09
the O 0 9.351454721695518e-09
USA O 0 3.936534994863905e-06
alone O 0 6.639206731051672e-07
. O 0 1.9935056627673475e-07

In O 0 2.799492051508423e-07
approximately O 0 8.602899015386356e-08
5 O 0 6.081165082605366e-08
- O 0 7.103204211489356e-07
12 O 0 4.384928864453741e-09
% O 0 7.650767241962342e-10
of O 0 2.724512282448188e-10
these O 0 2.895629569454883e-10
cases O 0 1.71037459750778e-08
, O 0 1.4166682271721243e-09
there O 0 4.3209316680226095e-10
are O 0 3.2270996985772626e-10
no O 0 5.5470357196441e-09
demonstrable O 0 0.0003619062772486359
cardiac O 1 0.8670174479484558
or O 0 5.929287567596475e-07
non O 0 0.00012690645235124975
- O 1 0.9890764951705933
cardiac O 1 0.9957668781280518
causes O 0 1.0642016832207446e-06
to O 0 2.48297354898952e-10
account O 0 1.0823257845515855e-09
for O 0 2.1584549425579524e-10
the O 0 5.432900240798233e-10
episode O 0 8.601976908551023e-09
, O 0 1.732781029772923e-09
which O 0 9.119174304572653e-10
is O 0 3.004594573141617e-09
therefore O 0 2.5816994764227275e-08
classified O 0 1.7375235984218307e-05
as O 0 0.0002131225191988051
idiopathic B-Disease 1 0.9999980926513672
ventricular I-Disease 1 0.9999902248382568
fibrillation I-Disease 1 0.9999960660934448
( O 0 0.0011605295585468411
IVF B-Disease 1 0.999812662601471
) O 0 1.7900403008752619e-06
. O 0 5.631221711155376e-07

A O 0 4.430473381944466e-06
distinct O 0 9.484019187766535e-07
group O 0 5.275097123558226e-07
of O 0 1.8299211035355256e-07
IVF B-Disease 1 0.9998637437820435
patients O 0 0.0012906171614304185
has O 0 3.3111511754668754e-08
been O 0 2.431589596341155e-09
found O 0 4.843101475415779e-10
to O 0 4.2010856599050683e-11
present O 0 5.531797797608817e-10
with O 0 2.1640993441707224e-09
a O 0 1.3208577342993522e-07
characteristic O 0 7.185782123997342e-06
electrocardiographic O 0 0.017560726031661034
pattern O 0 9.124941425397992e-05
. O 0 7.106294219738629e-07

Because O 0 5.2363276381584e-07
of O 0 7.9802999763956e-09
the O 0 3.060788511533019e-09
small O 0 4.515646967462317e-09
size O 0 1.4882739485244656e-08
of O 0 3.4545866167690065e-10
most O 0 3.319064190154819e-10
pedigrees O 0 1.3419423794402974e-07
and O 0 1.0139912243189997e-09
the O 0 3.895791245156488e-09
high O 0 2.766243824225967e-06
incidence O 0 0.0003589589905459434
of O 0 3.757926947400847e-08
sudden B-Disease 0 0.000350369286024943
death I-Disease 0 2.5392425868631108e-06
, O 0 3.770820544701792e-09
however O 0 9.827377800419868e-10
, O 0 1.3221432837440261e-09
molecular O 0 6.767422746634111e-07
genetic O 0 1.227608777298883e-06
studies O 0 1.0968153496548894e-08
of O 0 6.972686428241559e-09
IVF B-Disease 1 0.9352731704711914
have O 0 6.152411469173558e-09
not O 0 5.071462139127902e-10
yet O 0 2.9065592155319564e-09
been O 0 3.911143409141005e-09
done O 0 4.239423034846368e-08
. O 0 9.456476846025907e-08

Because O 0 0.0010010626865550876
IVF B-Disease 1 0.999284565448761
causes O 0 0.2100054919719696
cardiac O 1 0.9987528324127197
rhythm O 0 0.10237707942724228
disturbance O 0 0.012974019162356853
, O 0 4.862061686594643e-08
we O 0 2.5643007717235378e-09
investigated O 0 1.8358328190970497e-07
whether O 0 3.898571243610149e-09
malfunction O 0 8.388530659431126e-06
of O 0 1.4119986291305509e-09
ion O 0 2.458985818520887e-06
channels O 0 2.7744658837036695e-07
could O 0 6.361614879324407e-08
cause O 0 9.133523235504981e-07
the O 0 5.523926915884658e-08
disorder O 0 0.0011539453407749534
by O 0 7.162095805313129e-09
studying O 0 4.874987880043591e-08
mutations O 0 3.6520927437777573e-07
in O 0 1.2656493630913701e-09
the O 0 4.678651688294622e-09
cardiac O 0 0.0023964978754520416
sodium O 0 1.1012593859049957e-05
channel O 0 6.62125103190192e-06
gene O 0 9.291502465202939e-06
SCN5A O 0 0.0015815121587365866
. O 0 6.138600383565063e-07

We O 0 3.7368923244684993e-07
have O 0 2.60648818084519e-08
now O 0 2.7545075553803144e-08
identified O 0 4.310325962819661e-08
a O 0 7.873937590829883e-08
missense O 0 0.00025971134891733527
mutation O 0 7.107281817297917e-06
, O 0 1.5544047160531704e-09
a O 0 1.1451590786748511e-08
splice O 0 1.822668855311349e-05
- O 0 0.000168540864251554
donor O 0 3.7746976886410266e-06
mutation O 0 4.955734766554087e-06
, O 0 1.203306343455779e-09
and O 0 1.4400811654269319e-09
a O 0 1.913214191517909e-07
frameshift O 0 0.016932904720306396
mutation O 0 2.6851500933844363e-06
in O 0 8.190653155715211e-10
the O 0 1.0441792985815823e-09
coding O 0 4.686124839281547e-07
region O 0 2.3356342637725902e-08
of O 0 1.2902502399825266e-09
SCN5A O 0 0.00014418353384826332
in O 0 2.1212152034877363e-08
three O 0 1.3652760344484705e-07
IVF B-Disease 1 0.832315981388092
families O 0 8.839236329549749e-07
. O 0 5.74108298678766e-07

We O 0 2.434598798117804e-07
show O 0 3.150585925482119e-08
that O 0 1.4752725707722902e-09
sodium O 0 1.7413098518659353e-08
channels O 0 4.6073282966574425e-09
with O 0 6.524816797970345e-10
the O 0 8.843889176546327e-09
missense O 0 0.00015435101522598416
mutation O 0 1.5818422980373725e-05
recover O 0 7.597477633680683e-07
from O 0 3.311540819339598e-09
inactivation O 0 2.3448941647075117e-05
more O 0 3.966766359830842e-10
rapidly O 0 1.9735237444251652e-08
than O 0 4.0355407904257845e-10
normal O 0 5.25271914852965e-09
and O 0 2.360501238918289e-10
that O 0 2.860699177542614e-10
the O 0 2.2055505866092062e-08
frameshift O 0 0.10808493196964264
mutation O 0 1.653608887863811e-05
causes O 0 7.237158428097246e-08
the O 0 1.3283412148012985e-09
sodium O 0 8.30178024102679e-08
channel O 0 1.92643998531139e-08
to O 0 3.977403406629776e-10
be O 0 9.023459757173669e-10
non O 0 4.0168075088331534e-08
- O 0 1.2643379704968538e-05
functional O 0 3.178216047672322e-06
. O 0 4.606768584380916e-07

Our O 0 1.028335373121081e-05
results O 0 1.2166100532340351e-05
indicate O 0 4.840714495912835e-07
that O 0 1.1611400729805155e-08
mutations O 0 1.7260417735087685e-06
in O 0 2.4411729526718773e-08
cardiac O 0 0.002081560669466853
ion O 0 2.2137655832921155e-05
- O 0 3.7938250443403376e-06
channel O 0 9.800450584407372e-08
genes O 0 8.465401712953735e-09
contribute O 0 1.2241968549986382e-09
to O 0 1.6083041842751555e-10
the O 0 2.803882459545548e-09
risk O 0 4.155622548296378e-07
of O 0 5.8548157433335746e-09
developing O 0 6.659101018158253e-06
IVF B-Disease 1 0.9763993620872498
. O 0 1.5744893744340516e-07
. O 0 4.935021706842235e-07

Molecular O 0 0.0002606012858450413
heterogeneity O 0 0.0004863399371970445
in O 0 1.9434814930718858e-06
mucopolysaccharidosis B-Disease 0 0.03979148715734482
IVA I-Disease 1 0.5534970760345459
in O 0 3.762452749356271e-08
Australia O 0 5.896989119236196e-09
and O 0 2.280323263548212e-09
Northern O 0 1.2540036209429672e-07
Ireland O 0 1.704214156461603e-07
: O 0 8.935602480164562e-09
nine O 0 2.2506732477722835e-08
novel O 0 1.1576344149943907e-07
mutations O 0 9.844154646998504e-07
including O 0 7.910287536105898e-09
T312S O 0 5.132078968017595e-06
, O 0 2.0216497365055375e-09
a O 0 5.904856603677899e-09
common O 0 1.206519861796096e-08
allele O 0 6.367951499441915e-08
that O 0 2.00942462669218e-09
confers O 0 5.4650063248118386e-06
a O 0 1.0647260751284193e-05
mild O 0 0.06441514194011688
phenotype O 0 0.021638715639710426
. O 0 1.2409143437253078e-06

Mucopolysaccharidosis B-Disease 1 0.9903102517127991
IVA I-Disease 1 0.9989544153213501
( O 0 9.124950156547129e-05
MPS B-Disease 1 0.9718983173370361
IVA I-Disease 1 0.9998853206634521
) O 0 5.386925181483093e-07
is O 0 8.064552758924037e-08
an O 0 3.887421087256371e-07
autosomal B-Disease 1 0.9717234969139099
recessive I-Disease 1 0.9995923638343811
lysosomal I-Disease 1 0.9999576807022095
storage I-Disease 1 0.9998748302459717
disorder I-Disease 1 0.9999603033065796
caused O 0 0.0005500847473740578
by O 0 1.283412274233342e-07
a O 0 1.0293302693753503e-05
genetic B-Disease 1 0.8815712332725525
defect I-Disease 1 0.9320625066757202
in O 0 2.3540881954886572e-07
N O 0 0.00010120653314515948
- O 0 0.000104528822703287
acetylgalactosamine O 0 0.00788072869181633
- O 0 0.0010742760496214032
6 O 0 2.699840479181148e-05
- O 0 0.09542901813983917
sulfate O 1 0.6885056495666504
sulfatase O 1 0.8248909711837769
( O 0 5.442648784992343e-07
GALNS O 0 0.004752479027956724
) O 0 2.6029439936792187e-07
. O 0 4.075917559021036e-07

Previous O 0 8.318600521306507e-06
studies O 0 4.3531650817385525e-07
of O 0 5.580210782341055e-08
patients O 0 4.785952569363872e-06
from O 0 3.4779996660461165e-09
a O 0 2.7357524245985587e-08
British O 0 5.573949692916358e-07
- O 0 1.4790319255553186e-05
Irish O 0 3.031848905266088e-07
population O 0 1.046035613683216e-08
showed O 0 4.211569404333204e-08
that O 0 2.111198715848417e-10
the O 0 1.210116784555737e-09
I113F O 0 1.4753128198208287e-05
mutation O 0 2.977804115289473e-06
is O 0 5.947988213073074e-10
the O 0 3.586416719159047e-10
most O 0 5.377086553792765e-10
common O 0 9.305354708999403e-09
single O 0 3.3162393719976535e-07
mutation O 0 3.669667785288766e-05
among O 0 3.417953564621712e-07
MPS B-Disease 1 0.9537523984909058
IVA I-Disease 1 0.9999924898147583
patients O 0 0.0038550335448235273
and O 0 6.328793489274176e-08
produces O 0 2.781252533168299e-06
a O 0 2.043761924142018e-05
severe O 1 0.7603352069854736
clinical O 1 0.553463876247406
phenotype O 0 0.3134041130542755
. O 0 3.6859212286799448e-06

We O 0 3.2330177646144875e-07
studied O 0 6.158590508675843e-07
mutations O 0 5.272484031593194e-06
in O 0 5.973218808463798e-09
the O 0 3.6182721263600115e-09
GALNS O 0 3.0297729608719237e-05
gene O 0 1.0599845978731537e-07
from O 0 3.521105185200213e-09
23 O 0 8.409995189140318e-08
additional O 0 2.2558397461125423e-07
MPS B-Disease 1 0.8653447031974792
IVA I-Disease 1 0.9999871253967285
patients O 0 0.000695681432262063
( O 0 4.069630410441505e-09
15 O 0 3.08822678540821e-09
from O 0 5.30623767147631e-10
Australia O 0 6.42686959206884e-10
, O 0 2.4797175424140505e-10
8 O 0 1.8113277544529183e-09
from O 0 3.8950612180066457e-10
Northern O 0 1.4746825982570044e-08
Ireland O 0 3.385666502708773e-08
) O 0 1.2214539379939993e-09
, O 0 2.947040944611956e-10
with O 0 7.807663959802369e-10
various O 0 4.853664581361272e-09
clinical O 0 0.0025839819572865963
phenotypes O 0 0.02820632979273796
( O 0 6.898687274770055e-07
severe O 0 0.00431106798350811
, O 0 1.9002374784804488e-08
16 O 0 1.5930200447655807e-07
cases O 0 7.668759138823589e-08
; O 0 2.0249695253937716e-08
intermediate O 0 1.53882035647257e-06
, O 0 1.793195814059345e-08
4 O 0 8.709428698239208e-07
cases O 0 6.004245847179845e-07
; O 0 6.450615046560415e-07
mild O 0 0.004740934818983078
, O 0 6.169076272044549e-08
3 O 0 7.288815595529741e-07
cases O 0 5.107452807351365e-07
) O 0 1.453247051586004e-07
. O 0 3.4344478194725525e-07

We O 0 3.0541511364390317e-07
found O 0 5.5334488990865793e-08
two O 0 7.774677790450824e-09
common O 0 6.252842155163307e-08
mutations O 0 5.469952384373755e-07
that O 0 1.1533428379006949e-10
together O 0 2.402260335099271e-10
accounted O 0 1.2582935804417161e-09
for O 0 1.216714645702055e-10
32 O 0 2.5531685654556213e-09
% O 0 2.358575001970564e-10
of O 0 5.183276377551671e-11
the O 0 5.811333636529525e-10
44 O 0 4.4242394636739846e-08
unrelated O 0 3.6612399867408385e-07
alleles O 0 1.6892659004952293e-07
in O 0 2.6258890173380678e-08
these O 0 1.656332848654074e-08
patients O 0 4.4564687414094806e-05
. O 0 6.945928703316895e-07

One O 0 2.5621810095799447e-07
is O 0 2.0268087652652866e-08
the O 0 2.0737811468052314e-08
T312S O 0 3.361409471835941e-05
mutation O 0 1.0510420906939544e-05
, O 0 3.1471070194299955e-09
a O 0 1.3145551314153181e-08
novel O 0 6.765952065279635e-08
mutation O 0 9.339459552393237e-07
found O 0 4.849704193787829e-09
exclusively O 0 1.5744271664175358e-08
in O 0 1.4565284800482914e-07
milder O 0 0.0004518297500908375
patients O 0 0.00019652787887025625
. O 0 7.276598239513987e-07

The O 0 1.362462711540502e-07
other O 0 5.073709452574349e-09
is O 0 5.246441503459209e-09
the O 0 2.8674855823140888e-09
previously O 0 1.7595958468064055e-08
described O 0 4.9790997991294716e-08
I113F O 0 4.350896688265493e-06
that O 0 2.71096345372257e-09
produces O 0 1.847984663072566e-07
a O 0 3.784963837460964e-06
severe O 0 0.18247336149215698
phenotype O 0 0.044071730226278305
. O 0 1.910008904815186e-06

The O 0 1.0952745697068167e-06
I113F O 0 4.8747577238827944e-05
and O 0 2.4415297161795024e-07
T312S O 0 0.0001043720476445742
mutations O 0 2.0505833163042553e-05
accounted O 0 7.924878531184731e-08
for O 0 1.4622291155674816e-09
8 O 0 1.310781971852748e-08
( O 0 1.5297630939770102e-09
18 O 0 3.851108765218214e-09
% O 0 1.189975007420685e-09
) O 0 3.32273819569906e-10
and O 0 5.099864419655376e-10
6 O 0 1.6855253193170938e-08
( O 0 1.3442786883643976e-09
14 O 0 8.500787629373008e-09
% O 0 9.265254119483757e-10
) O 0 2.005862559384397e-10
of O 0 5.672341485407628e-10
44 O 0 7.836151638684896e-08
unrelated O 0 2.3638162929273676e-06
alleles O 0 6.932619953659014e-07
, O 0 3.295494011013034e-08
respectively O 0 7.685054583816964e-07
. O 0 3.618308994646213e-07

The O 0 7.916128765828034e-07
relatively O 0 8.77809725352563e-07
high O 0 1.1917106803593924e-06
residual O 0 4.380293830763549e-06
GALNS O 0 0.00018315478519070894
activity O 0 4.156600397209331e-08
seen O 0 8.061904033240808e-09
when O 0 6.614080949596257e-10
the O 0 3.8516434486268736e-10
T312S O 0 6.147100606312961e-08
mutant O 0 3.369477141745847e-08
cDNA O 0 4.02717148517695e-08
is O 0 1.8033921023175026e-09
overexpressed O 0 2.1125649141140457e-07
in O 0 1.2467810117655631e-09
mutant O 0 4.656832857108384e-07
cells O 0 3.861025277274166e-08
provides O 0 8.902935055843386e-10
an O 0 1.7320100909046232e-10
explanation O 0 1.8507028132219716e-09
for O 0 8.695636988242939e-10
the O 0 3.4882653210388526e-08
mild O 0 0.0035595514345914125
phenotype O 0 0.004567807074636221
in O 0 6.623390049753652e-07
patients O 0 2.807801683957223e-05
with O 0 6.315347889085388e-08
this O 0 1.059521679280806e-07
mutation O 0 8.202837489079684e-05
. O 0 3.155006140787009e-07

The O 0 6.639973548772105e-08
distribution O 0 3.9248661209967395e-08
and O 0 1.8666417300750027e-09
relative O 0 7.902777099388913e-09
frequencies O 0 5.744925424266967e-09
of O 0 3.6045694207231804e-10
the O 0 1.8810952795433877e-09
I113F O 0 1.0937964134427602e-06
and O 0 1.6337326158577525e-08
T312S O 0 3.980070323450491e-05
mutations O 0 6.029566520737717e-06
in O 0 2.4267801101984787e-09
Australia O 0 1.0402432248923787e-09
corresponded O 0 2.034946211537658e-09
to O 0 6.672414704089746e-11
those O 0 1.8924736777670148e-10
observed O 0 2.1125452498438335e-09
in O 0 4.824495802857598e-10
Northern O 0 4.873274672689831e-09
Ireland O 0 1.6043962602907413e-08
and O 0 1.436169738688875e-09
are O 0 1.009423170050816e-10
unique O 0 6.0854532524246e-10
to O 0 6.917098144265665e-11
these O 0 4.27685803439104e-11
two O 0 3.1274424716620786e-10
populations O 0 8.685463903645996e-09
, O 0 5.926223400898323e-10
suggesting O 0 7.357716658162872e-09
that O 0 1.2864752318986206e-10
both O 0 5.669940628116876e-10
mutations O 0 3.146322740121832e-07
were O 0 3.0807359441276105e-10
probably O 0 3.731339959234248e-10
introduced O 0 2.9033883630624757e-10
to O 0 3.329988021438801e-11
Australia O 0 1.4492976263547064e-10
by O 0 1.7786419559406852e-10
Irish O 0 1.2317673991901756e-08
migrants O 0 1.6918181300340507e-09
during O 0 1.8195446260804715e-09
the O 0 6.018686660169692e-10
19th O 0 2.6382689810589e-08
century O 0 1.1027962898424448e-07
. O 0 1.5221448279589822e-07

Haplotype O 0 0.0002928282192442566
analysis O 0 7.384501827800705e-07
using O 0 7.638934107490059e-08
6 O 0 2.0205411033202836e-07
RFLPs O 0 5.34561877429951e-06
provides O 0 9.200979533829923e-09
additional O 0 2.067082727208458e-09
data O 0 2.4240323082125315e-09
that O 0 2.319582859122704e-10
the O 0 1.7506535110456412e-09
I113F O 0 1.7754695363692008e-05
mutation O 0 1.4741109453098034e-06
originated O 0 7.448068828352916e-09
from O 0 8.44771919084053e-10
a O 0 1.3062396497787176e-08
common O 0 6.914298467108893e-08
ancestor O 0 1.1426976698203362e-06
. O 0 6.120275202192715e-07

The O 0 4.88160367240198e-07
other O 0 2.540258670080675e-08
9 O 0 6.451008403018932e-07
novel O 0 5.259605018181901e-07
mutations O 0 2.1470978026627563e-05
identified O 0 1.009542032193167e-07
in O 0 3.603072951108288e-09
these O 0 6.354878845371559e-10
23 O 0 3.671932802262745e-07
patients O 0 4.231486059325107e-07
were O 0 1.5169836220518818e-10
each O 0 7.867816120832316e-11
limited O 0 8.674433393807135e-10
to O 0 1.7564252829949112e-10
a O 0 1.1003774780249387e-08
single O 0 7.81300428798204e-08
family O 0 7.576869620606885e-07
. O 0 4.1121188587567303e-07

These O 0 7.159967907455211e-08
data O 0 5.4160413043291555e-08
provide O 0 1.1668680244270035e-08
further O 0 1.7402663754495507e-09
evidence O 0 1.077487432610269e-09
for O 0 5.659460122764415e-10
extensive O 0 1.7675452568255423e-07
allelic O 0 9.173047874355689e-05
heterogeneity O 0 0.00023169259657151997
in O 0 8.481403597215831e-07
MPS B-Disease 0 0.25247687101364136
IVA I-Disease 1 0.9995488524436951
in O 0 4.2535086208772555e-07
British O 0 3.2068113796412945e-05
- O 0 0.06247938051819801
Irish O 0 0.00012755554053001106
patients O 0 1.6373363905586302e-05
and O 0 2.370410090435371e-09
provide O 0 1.8589032535487604e-09
evidence O 0 1.349233724745602e-09
for O 0 2.4851626312383246e-10
their O 0 7.700161619439427e-10
transmission O 0 2.9696803949263995e-07
to O 0 1.5195637803611106e-10
Australia O 0 8.483646563028913e-10
by O 0 8.120235039932311e-10
British O 0 1.5477201031899313e-07
- O 0 1.4020787602930795e-05
Irish O 0 3.864212203552597e-07
migrants O 0 4.844279999360879e-08
. O 0 1.1254112308733966e-08
. O 0 7.222086395586302e-08

Identification O 0 7.804062079230789e-06
of O 0 3.7035354694126e-07
constitutional O 0 8.45702234073542e-05
WT1 O 1 0.9657860398292542
mutations O 0 0.02484639547765255
, O 0 1.0467765321209299e-07
in O 0 1.7542602392950357e-07
patients O 0 3.725670467247255e-05
with O 0 8.416090508944762e-07
isolated O 0 0.15673255920410156
diffuse B-Disease 1 0.9999144077301025
mesangial I-Disease 1 0.9999988079071045
sclerosis I-Disease 1 0.9999973773956299
, O 0 6.780330608080476e-08
and O 0 3.77186326616652e-09
analysis O 0 9.502905129465944e-09
of O 0 8.048291810780484e-09
genotype O 0 0.00011861829261761159
/ O 0 3.6018445825902745e-05
phenotype O 0 1.7136262613348663e-05
correlations O 0 1.335142201241979e-07
by O 0 2.6151003584828914e-10
use O 0 1.9901691405976862e-10
of O 0 6.539344066247565e-10
a O 0 9.219604635291034e-08
computerized O 0 0.0009459597058594227
mutation O 0 0.00020926541765220463
database O 0 4.963879746355815e-06
. O 0 6.192454407027981e-07

Constitutional O 0 2.697565287235193e-05
mutations O 0 6.561727059306577e-05
of O 0 2.3764732404174538e-08
the O 0 1.8019935765778428e-08
WT1 O 0 0.0002673790149856359
gene O 0 2.532997598336806e-07
, O 0 1.1312126790841148e-09
encoding O 0 1.3324933156866337e-08
a O 0 2.3230128931572835e-07
zinc O 0 0.00033902449649758637
- O 0 2.979957571369596e-06
finger O 0 8.267805640116421e-08
transcription O 0 2.5881680798534035e-08
factor O 0 6.443418687496205e-09
involved O 0 5.326906471481152e-09
in O 0 3.466450948508282e-08
renal O 1 0.5695831179618835
and O 0 7.665673251722183e-08
gonadal O 0 0.010668765753507614
development O 0 2.081668242226442e-07
, O 0 5.023789384495103e-09
are O 0 4.5547610127982807e-10
found O 0 3.4489924249925252e-09
in O 0 2.792855280375761e-09
most O 0 3.3941673915904857e-09
patients O 0 2.9042389542155433e-06
with O 0 8.033830454223789e-07
Denys B-Disease 1 0.9971840977668762
- I-Disease 1 0.9999285936355591
Drash I-Disease 1 0.9999605417251587
syndrome I-Disease 1 0.9999927282333374
( O 0 7.965542863530573e-06
DDS B-Disease 1 0.999910831451416
) O 0 1.6644311529034894e-07
, O 0 1.5092194871613174e-07
or O 0 1.44328751048306e-05
diffuse B-Disease 1 0.9998519420623779
mesangial I-Disease 1 0.999998927116394
sclerosis I-Disease 1 0.9999995231628418
( O 0 0.00017861055675894022
DMS B-Disease 1 0.9967164397239685
) O 0 3.553715188786555e-08
associated O 0 4.0112951182891265e-08
with O 0 2.0076290851989143e-08
pseudohermaphroditism B-Disease 1 0.6044784784317017
and O 0 3.951117832912132e-07
/ O 0 0.0007500526262447238
or O 0 4.702054138761014e-05
Wilms B-Disease 1 0.9999840259552002
tumor I-Disease 1 0.9999148845672607
( O 0 5.670860446116421e-06
WT B-Disease 1 0.9939972162246704
) O 0 6.05046068358206e-07
. O 0 3.4937926329803304e-07

Most O 0 6.211242634890368e-06
mutations O 0 0.029041999951004982
in O 0 2.0184266759315506e-05
DDS B-Disease 1 0.9999487400054932
patients O 0 0.05808423087000847
lie O 0 1.1014967640221585e-05
in O 0 1.7217848480299836e-08
exon O 0 8.957138561527245e-06
8 O 0 3.966422568169037e-08
or O 0 2.5623696497945048e-09
exon O 0 1.229473923558544e-06
9 O 0 3.657330793771507e-08
, O 0 7.506666954704144e-10
encoding O 0 7.588730710494929e-08
zinc O 0 0.000274305057246238
finger O 0 4.00987482862547e-06
2 O 0 1.0092436042441477e-07
or O 0 3.6116613699732625e-08
zinc O 0 4.106187407160178e-05
finger O 0 6.361851774272509e-07
3 O 0 2.4467761150503975e-08
, O 0 8.148176577904565e-10
respectively O 0 5.423791193948091e-09
, O 0 2.598453952007418e-10
with O 0 6.040848932187259e-10
a O 0 3.1390154475730014e-08
hot O 0 1.0543643611526932e-06
spot O 0 2.966396834835905e-07
( O 0 6.40821840036665e-09
R394W O 0 1.230356019732426e-06
) O 0 3.5997347325178453e-09
in O 0 1.652520786876721e-08
exon O 0 4.062013249495067e-05
9 O 0 2.263972191940411e-06
. O 0 4.155325257215736e-07

We O 0 2.912060779181047e-07
analyzed O 0 4.7546623704874946e-07
a O 0 1.9099614334550097e-08
series O 0 1.5079383075544683e-08
of O 0 9.049731630739188e-09
24 O 0 6.023045102665492e-07
patients O 0 4.9281175051874015e-06
, O 0 4.388970520352586e-09
10 O 0 1.6930487234390057e-08
with O 0 1.0635630331989887e-07
isolated B-Disease 0 0.0007384669152088463
DMS I-Disease 1 0.9898263216018677
( O 0 2.7313240025250707e-07
IDMS B-Disease 0 0.09531889855861664
) O 0 6.263761065383733e-09
, O 0 1.9045620636148897e-09
10 O 0 4.204215642289455e-09
with O 0 3.75019411080757e-08
DDS B-Disease 1 0.9983036518096924
, O 0 2.1149734408254517e-08
and O 0 7.153849068686213e-09
4 O 0 3.3350085004713037e-07
with O 0 6.415797884073982e-07
urogenital B-Disease 1 0.998588502407074
abnormalities I-Disease 1 0.9991105198860168
and O 0 8.49134630698245e-06
/ O 0 0.017149707302451134
or O 0 2.1583025954896584e-05
WT B-Disease 1 0.9990782737731934
. O 0 4.281788278603926e-06

We O 0 4.540307600109372e-06
report O 0 1.4319043657451402e-06
WT1 O 0 0.0071163056418299675
heterozygous O 0 0.00012721518578473479
mutations O 0 6.28408815828152e-05
in O 0 6.433179322584692e-08
16 O 0 1.1392265832910198e-06
patients O 0 8.028169759199955e-06
, O 0 2.375139640520274e-09
4 O 0 1.1887391515585932e-08
of O 0 1.4866277098235514e-09
whom O 0 8.909364623832516e-08
presented O 0 6.14899477113795e-07
with O 0 1.3368716054174001e-06
IDMS B-Disease 1 0.9735296368598938
. O 0 3.7617317047988763e-06

One O 0 2.7059624585490383e-07
male O 0 6.068755737942411e-07
and O 0 8.605980816867032e-09
two O 0 1.5729233027172995e-08
female O 0 1.957928907359019e-05
IDMS B-Disease 1 0.9992338418960571
patients O 0 0.010153518058359623
with O 0 1.423359844920924e-05
WT1 O 1 0.9995079040527344
mutations O 1 0.650027871131897
underwent O 1 0.8677033185958862
normal O 0 0.00012601749040186405
puberty O 0 0.0009403232834301889
. O 0 1.4545547628586064e-06

Two O 0 1.3683520592167042e-05
mutations O 0 0.02068937011063099
associated O 0 2.284500624227803e-06
with O 0 1.5913846596049552e-07
IDMS B-Disease 0 0.17116598784923553
are O 0 2.3875073029699934e-09
different O 0 3.4731914566599187e-10
from O 0 2.2245529862630065e-09
those O 0 4.9543720237466005e-09
described O 0 9.025564509101969e-07
in O 0 4.2340598156442866e-06
DDS B-Disease 1 0.9999433755874634
patients O 0 0.12274476885795593
. O 0 3.620674078774755e-06

No O 0 9.691178092907649e-06
WT1 O 0 0.3080737292766571
mutations O 0 0.0010706919711083174
were O 0 5.888483656235621e-08
detected O 0 8.422160817644908e-07
in O 0 1.196166832251322e-09
the O 0 1.5272907383234724e-09
six O 0 1.687349104884106e-08
other O 0 1.4272191428688075e-08
IDMS B-Disease 1 0.9871190786361694
patients O 0 0.00015662217629142106
, O 0 2.1579136699756418e-08
suggesting O 0 4.377026527890848e-07
genetic O 0 3.337415364512708e-06
heterogeneity O 0 1.6008456441340968e-05
of O 0 9.061341899041508e-08
this O 0 1.028818928716646e-06
disease O 0 0.01769317127764225
. O 0 6.490131454484072e-07

We O 0 1.2446073469618568e-06
analyzed O 0 7.832131814211607e-06
genotype O 0 0.0005335882888175547
/ O 0 7.967407873366028e-05
phenotype O 0 0.00012405407323967665
correlations O 0 1.6011044863262214e-06
, O 0 2.5679862680760834e-09
on O 0 4.786440133131009e-10
the O 0 1.5022127985986344e-10
basis O 0 2.1774219927106486e-10
of O 0 1.466876758948743e-10
the O 0 5.345651699073528e-10
constitution O 0 2.4333619563776665e-09
of O 0 2.8826080411548105e-10
a O 0 3.905748258148378e-08
WT1 O 0 0.0005205016350373626
mutation O 0 4.852917641073873e-07
database O 0 6.249202932906428e-09
of O 0 9.078702789544479e-10
84 O 0 7.889087783041759e-07
germ O 0 0.005595443304628134
- O 0 0.0005182491149753332
line O 0 4.165548034507083e-06
mutations O 0 1.495925971539691e-06
, O 0 2.560531231488028e-10
to O 0 3.84866721825361e-11
compare O 0 8.537472950820302e-10
the O 0 1.375891484078906e-10
distribution O 0 8.782847782384806e-10
and O 0 6.532500096412264e-10
type O 0 6.337635483077975e-08
of O 0 3.289081007551431e-09
mutations O 0 4.189419996691868e-06
, O 0 1.1372137675991212e-09
according O 0 4.6191164781994587e-10
to O 0 1.461364224075723e-10
the O 0 3.0468731981869723e-09
different O 0 2.700452483850313e-08
symptoms O 0 0.00029900140361860394
. O 0 3.5280589827380027e-07

This O 0 3.93039130131001e-07
demonstrated O 0 1.6362138239855994e-06
( O 0 1.737202914853242e-08
1 O 0 9.414145019093212e-09
) O 0 1.0085057233766292e-09
the O 0 9.856117033635314e-10
association O 0 6.520266992993129e-09
between O 0 4.881591575411903e-09
mutations O 0 3.4523185377111076e-07
in O 0 1.8609609409026007e-09
exons O 0 3.7919119222351583e-07
8 O 0 3.441082796484807e-08
and O 0 2.7452957684914736e-09
9 O 0 4.788732894667191e-07
and O 0 7.249578715118332e-08
DMS B-Disease 1 0.9061341881752014
; O 0 8.633885073550118e-08
( O 0 5.074716202813079e-09
2 O 0 2.11529211924244e-08
) O 0 3.730331155082922e-09
among O 0 8.707856657963475e-09
patients O 0 3.1529236821370432e-06
with O 0 3.645324397894001e-08
DMS B-Disease 0 0.17343395948410034
, O 0 1.0741919576062742e-09
a O 0 2.2742552285848205e-09
higher O 0 2.8133966267773758e-09
frequency O 0 1.895516188454849e-09
of O 0 6.635865745785452e-10
exon O 0 4.890176569460891e-06
8 O 0 1.8692955450205773e-07
mutations O 0 1.0685788538467023e-06
among O 0 3.864257802632665e-09
46 O 0 4.5461294462256774e-07
, O 0 6.828779675061014e-08
XY O 0 0.0234818272292614
patients O 0 1.329563201579731e-05
with O 0 1.2281732963970171e-08
female O 0 9.315512556895555e-07
phenotype O 0 1.7112713976530358e-05
than O 0 1.7753822856292345e-09
among O 0 2.600443416156395e-09
46 O 0 5.978128569950059e-07
, O 0 9.458875638301834e-08
XY O 0 0.07730986177921295
patients O 0 1.2436258657544386e-05
with O 0 8.213372204579628e-09
sexual O 0 1.23315359701337e-07
ambiguity O 0 1.6105028066704108e-07
or O 0 4.3370285141008935e-08
male O 0 1.5909993180684978e-06
phenotype O 0 9.500065061729401e-05
; O 0 1.2461825349419087e-08
and O 0 1.3470327075992827e-09
( O 0 1.77381853649905e-09
3 O 0 1.540715288683714e-08
) O 0 1.349310996268116e-09
statistically O 0 8.396751738359853e-09
significant O 0 1.567492802223569e-09
evidence O 0 1.8629924269930598e-09
that O 0 3.4447303343121405e-10
mutations O 0 8.165858389475034e-08
in O 0 8.572555443286944e-10
exons O 0 1.0930835969702457e-07
8 O 0 1.934813553816639e-08
and O 0 1.7786768724548097e-09
9 O 0 5.912004041874752e-08
preferentially O 0 5.0212918267789064e-08
affect O 0 7.786371547524595e-09
amino O 0 2.4724171598933253e-09
acids O 0 6.887296288837774e-10
with O 0 9.009491069855713e-11
different O 0 1.354141798692865e-10
functions O 0 4.212242110668285e-09
. O 0 7.706233873250312e-09
. O 0 6.430076382457628e-08

The O 0 4.921936124446802e-06
185delAG O 0 0.003579584416002035
BRCA1 O 0 0.1855369508266449
mutation O 0 4.077358971699141e-05
originated O 0 1.0206885292518564e-07
before O 0 2.031274037861408e-09
the O 0 2.926852371576416e-10
dispersion O 0 4.714024726126809e-09
of O 0 1.987142395076802e-10
Jews O 0 9.490728203331855e-10
in O 0 4.638433803716424e-10
the O 0 2.9251781552552814e-10
diaspora O 0 8.871258394549386e-09
and O 0 1.10582198953324e-09
is O 0 1.2685906769505095e-09
not O 0 2.7207264219342164e-10
limited O 0 4.807917175497778e-09
to O 0 6.347153469477007e-09
Ashkenazim O 0 1.3773268619843293e-05
. O 0 5.711277140107995e-07

The O 0 1.515668373031076e-06
185delAG O 0 0.002063967753201723
mutation O 0 0.0017831797013059258
in O 0 1.0742988933998276e-06
BRCA1 O 0 0.0030186481308192015
is O 0 7.671670232411998e-08
detected O 0 5.064740093985165e-07
in O 0 2.2376256403333628e-09
Ashkenazi O 0 4.194894245301839e-07
Jews O 0 7.1232140186339166e-09
both O 0 7.291023784716799e-09
in O 0 1.7617588810026064e-06
familial B-Disease 1 0.999804675579071
breast I-Disease 1 0.9999966621398926
and I-Disease 1 0.9979094862937927
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
and O 0 1.3195747783356637e-07
in O 0 1.076892175433386e-08
the O 0 8.194266598593458e-09
general O 0 5.506265310373237e-08
population O 0 1.746337972008405e-07
. O 0 2.54456324455532e-07

All O 0 7.380601232398476e-07
tested O 0 3.5517110518412665e-05
Ashkenazi O 0 0.00038176545058377087
mutation O 0 0.00013741673319600523
carriers O 0 1.1626513014562079e-06
share O 0 9.441550652411479e-09
the O 0 1.346477818131575e-09
same O 0 2.1084070045418457e-09
allelic O 0 2.6881659778155154e-06
pattern O 0 5.769360313934158e-07
at O 0 2.192255443844715e-08
the O 0 5.198442565301775e-08
BRCA1 O 0 0.0004050612624268979
locus O 0 6.072206451790407e-05
. O 0 7.243108939292142e-07

Our O 0 1.0439835023134947e-06
previous O 0 3.979790790253901e-07
study O 0 2.1064953159566357e-07
showed O 0 2.2192614324012538e-07
that O 0 1.1402849775521418e-09
this O 0 1.2107654878690255e-09
Ashkenazi O 0 2.9074066333123483e-05
mutation O 0 1.722284832794685e-05
also O 0 7.125116496808914e-09
occurs O 0 5.415790482743432e-09
in O 0 3.195409215006606e-10
Iraqi O 0 1.650910075312595e-09
Jews O 0 1.7156667198037212e-09
with O 0 2.2835222601713667e-09
a O 0 7.277896685309315e-08
similar O 0 4.5328476971917553e-07
allelic O 0 0.00035574185312725604
pattern O 0 9.019484423333779e-05
. O 0 9.45164060794923e-07

We O 0 1.5274596876224678e-07
extended O 0 6.976866018248984e-08
our O 0 4.946449916332085e-09
analysis O 0 2.0066366346327413e-09
to O 0 6.880070818615636e-11
other O 0 9.28871285443833e-11
non O 0 3.9696370635056155e-09
- O 0 1.2150673001087853e-07
Ashkenazi O 0 1.1764993246288213e-07
subsets O 0 3.845004670210983e-08
354 O 0 2.306878421620695e-08
of O 0 5.705578232095831e-10
Moroccan O 0 9.1864990281465e-08
origin O 0 2.1542114758688058e-09
, O 0 6.096722016124545e-10
200 O 0 1.871397259378682e-09
Yemenites O 0 5.472842872222827e-07
and O 0 1.7312283828729846e-09
150 O 0 1.2725901221699587e-08
Iranian O 0 6.093693372122289e-08
Jews O 0 1.3925807706982596e-07
. O 0 3.3238447372241353e-07

Heteroduplex O 0 0.00019170402083545923
analysis O 0 5.284688882056798e-07
complemented O 0 3.313691365747218e-07
by O 0 5.041105310965577e-09
direct O 0 4.335769521190969e-09
DNA O 0 1.0177025444590981e-07
sequencing O 0 2.6945151887503016e-08
of O 0 1.6901666732849208e-09
abnormally O 0 2.832345217029797e-06
migrating O 0 3.264955950044168e-08
bands O 0 3.5560887567953614e-08
were O 0 7.792404055351199e-09
employed O 0 2.852687828180933e-07
. O 0 3.260162202423089e-07

Four O 0 2.412397179796244e-07
of O 0 1.3407636778595133e-08
Moroccan O 0 6.968393790884875e-07
origin O 0 1.43030396415611e-08
( O 0 4.215207738411664e-09
1 O 0 5.0310773325179525e-09
. O 0 4.740413617199124e-10
1 O 0 3.6428620120432242e-09
% O 0 1.386709969075639e-09
) O 0 2.7811591918336376e-10
and O 0 1.889227801976645e-10
none O 0 4.3064099508605125e-10
of O 0 5.0780615823420305e-11
the O 0 2.637410845274246e-10
Yemenites O 0 2.3493716128086817e-07
or O 0 5.874791209059538e-10
Iranians O 0 1.1079331896368672e-09
was O 0 1.4432874895220493e-09
a O 0 5.185535556506693e-09
carrier O 0 2.0474570305850648e-07
of O 0 7.500941534566152e-10
the O 0 4.934955910584904e-08
185delAG O 0 0.0008898425148800015
mutation O 0 0.00017536293307784945
. O 0 4.4441406998885213e-07

BRCA1 O 1 0.9400714039802551
allelic O 0 0.02758544124662876
patterns O 0 3.379934059921652e-05
were O 0 2.940082133306987e-08
determined O 0 1.4804768966314441e-08
for O 0 3.2928892945705e-10
four O 0 6.083909487308858e-10
of O 0 2.398496956601548e-10
these O 0 1.0815905115979518e-10
individuals O 0 1.7969463417255582e-10
and O 0 1.6820261850014617e-10
for O 0 1.0020492768880729e-10
12 O 0 2.3269044469031996e-09
additional O 0 3.0450488797129083e-09
non O 0 9.02052477158577e-08
- O 0 1.3478730579663534e-05
Ashkenazi O 0 4.182134580332786e-05
185delAG O 0 0.00025971134891733527
mutation O 0 3.760365871130489e-05
carriers O 0 1.3167279576009605e-05
who O 0 5.804836291645188e-07
had O 0 0.00014041477697901428
breast B-Disease 1 0.9999808073043823
/ I-Disease 1 0.9999707937240601
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999884366989136
. O 0 1.896858520922251e-05

Six O 0 3.349171038280474e-06
non O 0 2.3937523110362235e-06
- O 0 6.249349826248363e-05
Ashkenazi O 0 1.3228335774329025e-05
individuals O 0 7.084489883624201e-09
shared O 0 9.785895649372378e-09
the O 0 5.0656834282847285e-09
common O 0 4.748001103394017e-08
Ashkenazi O 0 2.3341313863056712e-05
haplotype O 0 3.946557626477443e-05
, O 0 4.045932033847066e-09
four O 0 2.9816618063449596e-09
had O 0 2.061546711118467e-09
a O 0 8.45896153123249e-09
closely O 0 3.173946083734336e-08
related O 0 5.567984473486831e-08
pattern O 0 5.326289738150081e-07
, O 0 1.2713328167990312e-09
and O 0 5.908120659370297e-10
the O 0 1.4492514965880332e-09
rest O 0 1.1076929595787988e-08
( O 0 3.726988495600381e-09
n O 0 1.5039134950711741e-06
= O 0 6.238153673621127e-07
6 O 0 9.130213030061896e-09
) O 0 4.709744261255366e-10
displayed O 0 4.877533932301503e-09
a O 0 1.4939336878683207e-08
distinct O 0 7.294274269042944e-07
BRCA1 O 0 0.0047545051202178
allelic O 0 0.0014134361408650875
pattern O 0 7.302015001187101e-05
. O 0 1.500114763075544e-06

We O 0 6.234026272977644e-07
conclude O 0 3.667232704174239e-07
that O 0 2.563503631591857e-09
the O 0 1.1721279058463097e-08
185delAG O 0 0.0011009890586137772
BRCA1 O 0 0.3994464874267578
mutation O 0 5.17827138537541e-05
occurs O 0 2.774210905442942e-08
in O 0 7.544331270814553e-10
some O 0 2.682083444227601e-10
non O 0 1.4783154256292619e-08
- O 0 4.529750640358543e-06
Ashkenazi O 0 6.912847311468795e-06
populations O 0 6.345896963466657e-08
at O 0 3.035876261492376e-08
rates O 0 7.448284833344587e-08
comparable O 0 4.1638529069132346e-08
with O 0 6.052243151088987e-10
that O 0 5.189590424059531e-10
of O 0 7.0242385241670036e-09
Ashkenazim O 0 2.5859439119813032e-05
. O 0 5.374650982048479e-07

The O 0 4.2401271116432326e-07
majority O 0 2.0950118084783753e-07
of O 0 6.062737423206954e-09
Jewish O 0 3.7100824101798935e-07
185delAG O 0 0.0005762806977145374
mutation O 0 0.0001301490410696715
carriers O 0 2.056828861896065e-06
have O 0 9.63871427117624e-10
a O 0 7.08754432920955e-09
common O 0 3.7097986904655045e-08
allelic O 0 7.532416202593595e-05
pattern O 0 2.6212608190689934e-06
, O 0 3.1536564470968642e-09
supporting O 0 9.221288621574786e-09
the O 0 2.4070638815487655e-09
founder O 0 1.7886974035263847e-07
effect O 0 7.844418448144097e-09
notion O 0 7.612880104090891e-09
, O 0 6.456455370340564e-10
but O 0 2.045424662977524e-10
dating O 0 1.1770162622326552e-08
the O 0 1.030684426694961e-09
mutations O 0 3.808996851262236e-08
origin O 0 1.7398607554675039e-10
to O 0 3.6071676895454985e-11
an O 0 1.1083849810189506e-10
earlier O 0 6.717190359495362e-09
date O 0 4.6853134705315824e-09
than O 0 1.0162701791216477e-09
currently O 0 1.9724589961356287e-08
estimated O 0 1.1632286600615771e-07
. O 0 1.8572657722870645e-07

However O 0 7.94392917669029e-07
, O 0 1.3296244993910022e-08
the O 0 2.190908343635556e-09
different O 0 2.1373656178269584e-09
allelic O 0 7.746498340566177e-06
pattern O 0 1.0408450634713518e-06
at O 0 2.5572441941790203e-08
the O 0 1.2335824806086748e-08
BRCA1 O 0 3.152469071210362e-05
locus O 0 5.07463710164302e-07
even O 0 3.4538638615799755e-09
in O 0 5.1131204825694e-10
some O 0 1.9194619504947497e-10
Jewish O 0 4.771095873934428e-08
mutation O 0 5.140641405887436e-06
carriers O 0 1.1332571148159332e-06
, O 0 7.978747440517964e-09
might O 0 6.036797728370402e-09
suggest O 0 2.853001168645619e-09
that O 0 1.3154591305131191e-10
the O 0 2.7726754225909644e-09
mutation O 0 1.4957134908399894e-06
arose O 0 6.016063736069555e-08
independently O 0 3.541393667205739e-08
. O 0 1.4186481323008593e-08
. O 0 1.4375659418419673e-07

Crystal O 0 0.0006641446379944682
structure O 0 7.150903456931701e-06
of O 0 3.737141440751657e-08
the O 0 1.2850152586452168e-07
hemochromatosis B-Disease 1 0.9997187256813049
protein O 0 1.277193587156944e-05
HFE O 0 0.0030976126436144114
and O 0 2.6796507235360423e-09
characterization O 0 1.5665669650388736e-08
of O 0 2.216631461715579e-10
its O 0 7.358821885183886e-10
interaction O 0 5.138042435959278e-09
with O 0 3.100995371596582e-08
transferrin O 0 0.0015885040629655123
receptor O 0 0.00010046269017038867
. O 0 5.915083534091536e-07

HFE O 1 0.5512523055076599
is O 0 1.6554837429794134e-06
an O 0 1.5722881130386668e-07
MHC O 0 0.11580803990364075
- O 0 0.00010065735114039853
related O 0 6.370174787662108e-08
protein O 0 3.480781884945827e-08
that O 0 4.5259229697336423e-10
is O 0 5.429937055545508e-10
mutated O 0 3.7576118216975374e-08
in O 0 1.5423847754547637e-09
the O 0 2.507711016619396e-08
iron B-Disease 0 0.12820282578468323
- I-Disease 1 0.9899218678474426
overload I-Disease 1 0.9994454979896545
disease I-Disease 1 0.9998350143432617
hereditary B-Disease 1 0.9999773502349854
hemochromatosis I-Disease 1 0.9999902248382568
. O 0 0.00011488406744319946

HFE O 0 0.006657786667346954
binds O 0 6.505414148705313e-06
to O 0 7.812229796400061e-08
transferrin O 0 9.14951233426109e-05
receptor O 0 2.118640077242162e-05
( O 0 7.659870959741966e-08
TfR O 0 1.907222940644715e-05
) O 0 1.740917188186586e-09
and O 0 5.853160733870766e-10
reduces O 0 2.0059410132944322e-08
its O 0 8.732985445902841e-10
affinity O 0 1.2476879085454584e-08
for O 0 1.4249824653589371e-09
iron O 0 8.236032954300754e-06
- O 0 1.2102764230803587e-06
loaded O 0 4.2961758595083666e-08
transferrin O 0 2.0025361664011143e-05
, O 0 1.3738579163202758e-08
implicating O 0 3.721665052580647e-05
HFE O 0 0.02583433873951435
in O 0 4.955546728524496e-07
iron O 0 0.0020472430624067783
metabolism O 0 0.00022668128076475114
. O 0 1.191483420370787e-06

The O 0 6.3674210650788154e-06
2 O 0 1.1620390068856068e-05
. O 0 3.818376626441022e-06

6 O 0 1.3212954399932642e-05
A O 0 2.159237055820995e-06
crystal O 0 4.885424277745187e-05
structure O 0 1.3158767160348361e-06
of O 0 1.5188931001830497e-08
HFE O 0 0.008301657624542713
reveals O 0 3.6140809811513464e-07
the O 0 2.041675939423726e-09
locations O 0 1.760035495124157e-08
of O 0 8.93170479798755e-08
hemochromatosis B-Disease 1 0.9999822378158569
mutations O 0 0.0018410927150398493
and O 0 1.7106877692185662e-08
a O 0 2.3269220150723413e-07
patch O 0 0.0008494778885506094
of O 0 6.384939688075519e-09
histidines O 0 0.00021486764308065176
that O 0 1.0782892356786533e-09
could O 0 3.95473986891659e-10
be O 0 4.655875338044346e-11
involved O 0 9.795134703338704e-10
in O 0 9.515982668517609e-09
pH O 0 0.0004639573162421584
- O 0 3.457376442383975e-05
dependent O 0 1.4359628153215453e-07
interactions O 0 3.434575432947895e-07
. O 0 2.8043982069902995e-07

We O 0 4.560015725019184e-07
also O 0 3.4381042013365004e-08
demonstrate O 0 1.403504370500741e-07
that O 0 1.0305178044234253e-08
soluble O 0 2.2626472855336033e-05
TfR O 0 0.000251826539169997
and O 0 1.8310762683881876e-08
HFE O 0 0.000306450470816344
bind O 0 1.3117804087414697e-07
tightly O 0 1.4476172793820297e-07
at O 0 2.7276907399453876e-09
the O 0 3.211429733251947e-10
basic O 0 3.3989744352425078e-09
pH O 0 1.6068409536273975e-07
of O 0 2.1180029952105883e-10
the O 0 2.3699400220067446e-09
cell O 0 2.692198904696852e-06
surface O 0 2.562865404343029e-07
, O 0 6.845544131550696e-10
but O 0 1.3258548425820749e-10
not O 0 3.1264033029110294e-11
at O 0 7.465046358845484e-10
the O 0 1.0239790126931325e-09
acidic O 0 1.8483492567611393e-06
pH O 0 4.629839168046601e-06
of O 0 3.4977309937289647e-09
intracellular O 0 2.08136516448576e-05
vesicles O 0 0.00019938206241931766
. O 0 5.232952275946445e-07

TfR O 1 0.9172365665435791
HFE O 1 0.5451271533966064
stoichiometry O 0 0.000857230625115335
( O 0 5.513862788575352e-07
2 O 0 1.0257080163000865e-07
1 O 0 2.1429102048386994e-08
) O 0 2.0049837345936794e-09
differs O 0 2.0188684501931675e-08
from O 0 4.723808455509015e-09
TfR O 0 7.016462768660858e-05
transferrin O 0 2.07180819415953e-05
stoichiometry O 0 2.1204075437708525e-06
( O 0 4.248957186092639e-09
2 O 0 3.980304530415424e-09
2 O 0 4.4825405609572044e-09
) O 0 6.697498111662981e-10
, O 0 3.9996478351511655e-10
implying O 0 3.152910821313526e-09
a O 0 3.898792677592411e-10
different O 0 3.579751772786466e-11
mode O 0 8.611690249793469e-10
of O 0 8.703995857395341e-11
binding O 0 3.6184859553145543e-09
for O 0 1.0536200800714823e-09
HFE O 0 4.7764744522282854e-05
and O 0 1.7265457952220231e-09
transferrin O 0 5.102202976559056e-06
to O 0 1.037049779384347e-09
TfR O 0 3.8362260966096073e-05
, O 0 1.3626095807239835e-09
consistent O 0 4.834723732471957e-09
with O 0 2.959907319244337e-10
our O 0 7.981665328671284e-10
demonstration O 0 4.1103536574382815e-08
that O 0 7.453507810950555e-10
HFE O 0 4.631352931028232e-05
, O 0 2.985901748076003e-09
transferrin O 0 9.009259883896448e-06
, O 0 1.4483285681876623e-09
and O 0 2.844584345851331e-09
TfR O 0 5.986914038658142e-05
form O 0 3.404497661563255e-08
a O 0 1.4727885400134255e-07
ternary O 0 6.667511479463428e-05
complex O 0 4.845226067118347e-05
. O 0 1.3363311381908716e-06

Identification O 0 2.3430823148373747e-06
of O 0 5.8104088651589336e-08
three O 0 5.717643247749038e-08
novel O 0 3.627748412782239e-07
mutations O 0 1.098980533242866e-06
and O 0 1.5417905840919843e-09
a O 0 3.278664673089793e-09
high O 0 8.776288140666111e-09
frequency O 0 2.4551523036819844e-09
of O 0 2.6289934118572944e-10
the O 0 4.85370144076569e-09
Arg778Leu O 0 0.0003031369124073535
mutation O 0 1.5336254364228807e-05
in O 0 6.027664056773574e-08
Korean O 0 2.3125776351662353e-05
patients O 0 0.0002089281042572111
with O 0 4.40398434875533e-06
Wilson B-Disease 0 0.01587584614753723
disease I-Disease 0 0.4139285087585449
. O 0 1.456267682442558e-06

Four O 0 5.469062671181746e-06
mutations O 0 0.0010087731061503291
- O 0 8.747329411562532e-05
- O 0 1.707857518340461e-05
R778L O 0 3.0359281026903773e-06
, O 0 4.204816939079592e-09
A874V O 0 9.538498488836922e-07
, O 0 2.676514565536081e-09
L1083F O 0 3.602924039114441e-07
, O 0 5.46049205851773e-10
and O 0 9.389179433938466e-10
2304delC O 0 6.640779247391038e-06
- O 0 1.0856191693164874e-05
- O 0 9.083765348805173e-07
in O 0 7.445210004064506e-10
the O 0 8.819274199822758e-10
copper O 0 4.1428253894082445e-07
- O 0 1.0341037892658278e-07
transporting O 0 1.106421798624524e-08
enzyme O 0 8.986317112658071e-08
, O 0 1.2609683075481826e-08
P O 0 7.010262925177813e-05
- O 0 7.066030320856953e-06
type O 0 2.078791681014991e-07
ATPase O 0 1.7664661982053076e-06
( O 0 5.400997871163327e-09
ATP7B O 0 1.2157402125012595e-05
) O 0 8.62717786098699e-10
, O 0 3.905878398491325e-10
were O 0 5.285681337063863e-10
identified O 0 1.3737374793265644e-08
in O 0 1.735096866184449e-08
Korean O 0 1.855070331657771e-05
Patients O 0 0.00022512055875267833
with O 0 5.541704922507051e-06
Wilson B-Disease 0 0.02639126591384411
disease I-Disease 0 0.1580531746149063
. O 0 1.7886990235638223e-06

Arg778Leu O 0 0.0016279899282380939
, O 0 1.7157010745449952e-07
the O 0 1.3844854152011976e-08
most O 0 3.736433829004682e-09
frequently O 0 2.8749237657166304e-08
reported O 0 7.42573078582609e-08
mutation O 0 5.9206932689903624e-08
of O 0 2.2955169709515388e-10
this O 0 1.8568045712097359e-10
enzyme O 0 1.9191491062997557e-08
, O 0 1.469593891023635e-09
was O 0 2.771972207327167e-09
found O 0 1.622329492967367e-09
in O 0 3.876798326807318e-10
six O 0 1.3100839302282452e-09
of O 0 6.016528941721333e-10
eight O 0 1.2419189943102538e-07
unrelated O 0 1.4264661331253592e-05
patients O 0 8.143706509144977e-06
studied O 0 7.446378624820227e-09
, O 0 1.403721860970819e-10
an O 0 1.238536911918331e-10
allele O 0 5.595790497636699e-09
frequency O 0 4.6723109825563824e-09
of O 0 2.4452353475368227e-09
37 O 0 3.2573433372817817e-07
. O 0 2.0762277586072742e-07

5 O 0 3.537448719725944e-06
% O 0 1.667278155537133e-07
, O 0 7.27425764068812e-09
which O 0 1.6701029448284999e-09
is O 0 1.4523063862625918e-09
considerably O 0 6.897372628600351e-08
higher O 0 4.014660603957054e-09
than O 0 1.6663030677488422e-10
those O 0 7.564384535418966e-11
in O 0 2.775118468356652e-10
other O 0 4.5620118793721076e-10
Asian O 0 5.247624912385618e-08
populations O 0 5.858024110239057e-07
. O 0 1.621291545461645e-07

The O 0 4.4568309931491967e-07
novel O 0 5.450497155834455e-07
single O 0 1.8447413197009155e-07
nucleotide O 0 2.3808613605069695e-06
deletion O 0 1.0942838343908079e-05
, O 0 1.3160527778666165e-08
2304delC O 0 6.666979970759712e-06
, O 0 9.314801374671333e-09
was O 0 1.5930467611724453e-08
found O 0 7.679982871877655e-09
in O 0 6.391982942943741e-09
one O 0 6.13031048146695e-08
patient O 0 0.00016333319945260882
. O 0 1.085087774299609e-06

Since O 0 7.728433956799563e-06
a O 0 6.526534548356722e-07
mutation O 0 4.821346010430716e-06
at O 0 3.763981837323627e-08
cDNA O 0 4.6425543587247375e-07
nucleotide O 0 3.8090952330094296e-06
2302 O 0 0.0007383296615444124
( O 0 2.0819969748231415e-08
2302insC O 0 4.200068360660225e-06
) O 0 3.059160036400499e-09
had O 0 2.9923215016935956e-09
been O 0 6.968401411455716e-10
previously O 0 4.467611613989675e-09
described O 0 1.3796086939521501e-08
, O 0 2.329905712805669e-10
this O 0 3.9232284088086544e-11
region O 0 6.063242685705461e-10
of O 0 9.391896982346992e-11
the O 0 3.6989795670905323e-09
ATP7B O 0 0.008290179073810577
gene O 0 6.318360306067916e-07
may O 0 1.0062831456991717e-08
be O 0 8.84238349208033e-10
susceptible O 0 2.5262619374188944e-07
to O 0 2.965616419103867e-09
gene O 0 7.605127393617295e-06
rearrangements O 0 0.06031101569533348
causing O 0 0.18734578788280487
Wilson B-Disease 0 0.06464668363332748
disease I-Disease 1 0.5073446035385132
. O 0 1.354080836790672e-06

Disruption O 0 2.1633657524944283e-05
of O 0 3.878400178791708e-08
splicing O 0 1.654730795053183e-06
regulated O 0 4.220028984036617e-07
by O 0 5.541727077229552e-09
a O 0 5.2437428621487925e-08
CUG O 0 8.828834688756615e-05
- O 0 9.547521585773211e-06
binding O 0 8.179355859283532e-07
protein O 0 7.058163646433968e-06
in O 0 8.44640817376785e-06
myotonic B-Disease 1 0.9998194575309753
dystrophy I-Disease 1 0.9999033212661743
. O 0 1.206479464599397e-05

Myotonic B-Disease 1 0.9999305009841919
dystrophy I-Disease 1 0.999966025352478
( O 0 0.006064674351364374
DM B-Disease 1 0.9999186992645264
) O 0 6.136815500212833e-07
is O 0 3.942978921145368e-08
caused O 0 1.66512819532727e-07
by O 0 2.3720112540814853e-09
a O 0 2.4666862330491313e-08
CTG O 0 3.366135206306353e-05
expansion O 0 1.6305284589179792e-07
in O 0 1.1948443345843884e-09
the O 0 7.078408414962212e-10
3 O 0 5.852270223982714e-09
untranslated O 0 1.7361119262204738e-06
region O 0 3.604174381166558e-08
of O 0 3.453112906726119e-09
the O 0 5.022699838264089e-07
DM B-Disease 1 0.9998639822006226
gene O 0 7.783509499859065e-05
. O 0 7.574745950478246e-07

One O 0 6.108460866016685e-07
model O 0 1.758151825015375e-06
of O 0 4.979955292583327e-07
DM B-Disease 1 0.9999157190322876
pathogenesis O 0 0.13777324557304382
suggests O 0 1.0207619425273151e-06
that O 0 1.9243566740101414e-09
RNAs O 0 2.1562809138231387e-07
from O 0 1.5199841385538093e-10
the O 0 8.356290659428112e-11
expanded O 0 1.1190364190838409e-09
allele O 0 1.2872907184657834e-09
create O 0 5.515025103264293e-10
a O 0 1.4180469021241038e-09
gain O 0 7.856067796296884e-09
- O 0 2.3563141837712465e-07
of O 0 9.301162617880721e-10
- O 0 8.627405350125628e-07
function O 0 1.727923759631267e-08
mutation O 0 1.4048795549115312e-07
by O 0 1.0566141711576549e-10
the O 0 1.0432391062131785e-10
inappropriate O 0 7.896715503719065e-10
binding O 0 1.091701173905335e-09
of O 0 9.465667138996992e-11
proteins O 0 4.2553133239309204e-10
to O 0 1.5699515298894795e-10
the O 0 5.5146704980302275e-09
CUG O 0 0.0002980641438625753
repeats O 0 1.7740883777150884e-05
. O 0 3.8482994568767026e-07

Data O 0 3.707765927174478e-06
presented O 0 1.141841380558617e-06
here O 0 5.001324510089944e-08
indicate O 0 2.6435278854819444e-08
that O 0 2.2706304891872975e-10
the O 0 6.616831527139766e-10
conserved O 0 2.6143098352804373e-08
heterogeneous O 0 7.460782285306777e-07
nuclear O 0 1.4812028894084506e-05
ribonucleoprotein O 0 0.0004276161198504269
, O 0 1.37468632033233e-08
CUG O 0 0.0001143849513027817
- O 0 2.5774395453481702e-06
binding O 0 7.958293224419322e-08
protein O 0 8.79865069691732e-08
( O 0 8.460058431580819e-09
CUG O 0 0.0002963348524644971
- O 0 7.223270949907601e-05
BP O 0 7.421449936373392e-06
) O 0 1.3247786201375789e-09
, O 0 4.548961207717639e-10
may O 0 9.815145363134548e-10
mediate O 0 1.3329458425914709e-08
the O 0 5.6482045707184625e-09
trans O 0 3.0393057386390865e-06
- O 0 1.9982749108748976e-06
dominant O 0 5.413397019538024e-08
effect O 0 3.6671921055386747e-09
of O 0 4.031755485023325e-10
the O 0 1.2325664933143798e-08
RNA O 0 2.445279733365169e-06
. O 0 1.5649415274765488e-07

CUG O 1 0.9105256199836731
- O 0 0.024951396510004997
BP O 0 0.000340844999300316
was O 0 7.883900821070711e-08
found O 0 3.2813423089805838e-09
to O 0 1.855101766645717e-10
bind O 0 3.820862737313746e-09
to O 0 1.7541620933592128e-10
the O 0 7.46049533262294e-09
human O 0 2.9802417884639e-06
cardiac O 1 0.999595582485199
troponin O 1 0.9999141693115234
T O 1 0.8582125306129456
( O 0 2.1673804084798576e-08
cTNT O 0 1.3572457646660041e-06
) O 0 2.853169922545362e-09
pre O 0 3.862646451580076e-07
- O 0 2.404548808954132e-07
messenger O 0 2.25860308233905e-08
RNA O 0 2.0918808019132484e-08
and O 0 3.674191506597424e-10
regulate O 0 5.811048531256802e-09
its O 0 3.622325328578313e-09
alternative O 0 6.853898781855605e-08
splicing O 0 5.354777840693714e-06
. O 0 3.748320978047559e-07

Splicing O 0 2.0188463167869486e-05
of O 0 3.228408615996159e-07
cTNT O 0 0.00011957793321926147
was O 0 5.808081482427951e-07
disrupted O 0 3.657369961729273e-05
in O 0 3.0540829811798176e-06
DM B-Disease 1 0.9999181032180786
striated O 1 0.8971028923988342
muscle O 0 0.000270134856691584
and O 0 1.2864322940231432e-08
in O 0 9.020332036868695e-09
normal O 0 2.004392740673211e-07
cells O 0 9.61030579560429e-08
expressing O 0 1.4819572236035583e-08
transcripts O 0 4.7733895058854614e-08
that O 0 1.5307730638625117e-09
contain O 0 8.73252687938475e-08
CUG O 0 0.0005777862970717251
repeats O 0 1.6809151929919608e-05
. O 0 7.799572472322325e-07

Altered O 0 2.032978954957798e-05
expression O 0 6.92899106979894e-07
of O 0 3.0418114249641803e-08
genes O 0 3.338050760248734e-07
regulated O 0 2.6615089154802263e-07
posttranscriptionally O 0 1.0217650924460031e-05
by O 0 5.275705206031489e-08
CUG O 0 0.011308944784104824
- O 0 0.0004886509268544614
BP O 0 4.7101679228944704e-05
therefore O 0 1.513880754089314e-08
may O 0 5.6662567970988675e-09
contribute O 0 1.3622361016984996e-08
to O 0 7.751759056873198e-08
DM B-Disease 1 0.9998160004615784
pathogenesis O 0 0.044794753193855286
. O 0 1.6862753682289622e-07
. O 0 5.675398710991431e-07

Identification O 0 3.6659673696703976e-06
of O 0 8.573839949121975e-08
a O 0 5.590362661678228e-07
novel O 0 1.1706911209330428e-06
nonsense O 0 2.3132435671868734e-05
mutation O 0 5.846588464919478e-06
and O 0 1.7146329911454927e-09
a O 0 6.418077624914531e-09
missense O 0 5.757729013566859e-07
substitution O 0 3.2157587703807167e-09
in O 0 1.1477868655518364e-09
the O 0 1.9381294347198263e-09
vasopressin O 0 1.7457032299716957e-06
- O 0 1.4031997125130147e-05
neurophysin O 0 2.6668252758099698e-05
II O 0 8.196087946998887e-06
gene O 0 2.9715350180481437e-08
in O 0 6.996609402953879e-10
two O 0 1.3603269621853542e-09
Spanish O 0 1.8948652780181874e-07
kindreds O 0 5.664494165102951e-05
with O 0 2.1399262095656013e-06
familial B-Disease 1 0.9993653893470764
neurohypophyseal I-Disease 1 0.9998283386230469
diabetes I-Disease 1 0.9999626874923706
insipidus I-Disease 1 0.9994220733642578
. O 0 3.650686630862765e-05

Familial B-Disease 1 0.9991350769996643
neurohypophyseal I-Disease 1 0.9997140765190125
diabetes I-Disease 1 0.9999809265136719
insipidus I-Disease 1 0.999868631362915
( O 0 9.3033020675648e-05
FNDI B-Disease 1 0.9991711378097534
) O 0 2.4356020844606974e-07
is O 0 5.5326577097503105e-08
an O 0 2.3721759134787135e-07
autosomal B-Disease 1 0.9580689072608948
dominant I-Disease 1 0.9785778522491455
disease I-Disease 1 0.9996386766433716
caused O 0 0.002580834086984396
by O 0 1.2364369467832148e-05
deficiency O 1 0.9499841332435608
in O 0 2.2146686262658477e-08
the O 0 3.732966646907698e-08
antidiuretic O 0 0.000333707983372733
hormone O 0 8.81247251527384e-06
arginine O 0 4.021514996566111e-07
vasopressin O 0 1.1805392432506778e-06
( O 0 4.0566727754765e-09
AVP O 0 3.7128859275981085e-07
) O 0 2.6989463441928763e-10
encoded O 0 5.673813086026769e-10
by O 0 3.7274558439825967e-10
the O 0 2.1564725560807574e-09
AVP O 0 6.305583519861102e-05
- O 0 0.00016105471877381206
neurophysin O 0 0.00125004758592695
II O 0 0.0001537500647827983
( O 0 4.5798895342841206e-08
AVP O 0 6.247240526136011e-05
- O 0 4.9473761464469135e-05
NPII O 0 9.51432521105744e-05
) O 0 9.13073527897268e-09
gene O 0 7.376141297754657e-08
on O 0 3.696625938687248e-08
chromosome O 0 3.743420529644936e-05
20p13 O 0 5.903911733184941e-05
. O 0 6.375493057930726e-07

In O 0 3.5008437748729193e-07
this O 0 8.179182664491691e-09
study O 0 1.1593918713970197e-08
, O 0 9.807286094343226e-10
we O 0 1.1389584414489562e-10
analyzed O 0 1.0202924061175622e-09
two O 0 1.0488775126216154e-10
families O 0 6.964760435046458e-10
with O 0 1.315605291374311e-09
FNDI B-Disease 0 0.0003802272549364716
using O 0 3.6213290699471656e-10
direct O 0 3.173337703721302e-10
automated O 0 1.5935472674755147e-07
fluorescent O 0 1.2893059420093778e-06
, O 0 1.0550418316768173e-09
solid O 0 3.691926053761563e-08
phase O 0 4.593729485691256e-08
, O 0 7.276349522911119e-10
single O 0 3.552073746249107e-09
- O 0 1.6876958852662938e-07
stranded O 0 9.329666816881854e-09
DNA O 0 9.808525547327918e-09
sequencing O 0 5.293139704320993e-09
of O 0 8.66629712437117e-10
PCR O 0 1.2543163165901206e-06
- O 0 1.0103777867698227e-06
amplified O 0 5.685528776666615e-07
AVP O 0 8.984933083411306e-05
- O 0 0.00011820593499578536
NPII O 0 0.0006807447061873972
DNA O 0 2.59638163697673e-05
. O 0 5.962157842986926e-07

In O 0 5.960998237242165e-07
one O 0 1.6160763394168498e-08
of O 0 3.3228029217013955e-09
the O 0 4.423478028314776e-09
families O 0 2.5305483930537775e-08
, O 0 8.047279287382025e-09
affected O 0 1.4955929827920045e-08
individuals O 0 1.5473556880252204e-09
presented O 0 1.0007687123447795e-08
a O 0 2.3521307568330485e-08
novel O 0 1.2937607607454993e-07
nonsense O 0 2.747149437709595e-06
mutation O 0 4.657112526729179e-07
in O 0 6.654294337771205e-10
exon O 0 1.68433544445179e-07
3 O 0 2.2646240438461973e-09
of O 0 1.0164790537059432e-10
the O 0 4.5610026866427233e-10
gene O 0 6.716677436457985e-09
, O 0 3.6976091633000863e-10
consisting O 0 1.4458555464003098e-09
in O 0 1.6679605474578807e-09
a O 0 6.626764559314324e-08
G O 0 1.751648414938245e-05
to O 0 3.2614566602973127e-09
T O 0 0.00016363529721274972
transition O 0 6.775081828891416e-08
at O 0 7.69640617903633e-09
nucleotide O 0 1.6930626145494898e-07
2101 O 0 3.3021688068402e-06
, O 0 4.837645284361258e-10
which O 0 1.3389606090541406e-10
produces O 0 6.395443064022288e-10
a O 0 4.3434733587588426e-10
stop O 0 8.820216224059152e-10
signal O 0 3.3493494644432076e-09
in O 0 1.3763121753385121e-09
codon O 0 1.5987518509064103e-07
82 O 0 3.644598223218054e-07
( O 0 2.375915464369882e-08
Glu O 0 0.0025544308591634035
) O 0 8.889398550593341e-09
of O 0 1.674480110125387e-08
NPII O 0 0.001534758135676384
. O 0 1.3328195791473263e-06

The O 0 4.5180972847447265e-06
premature O 0 0.0003501333703752607
termination O 0 0.00013028499961365014
eliminates O 0 5.142975624039536e-06
part O 0 1.511872405046688e-08
of O 0 1.325142551245051e-09
the O 0 5.905543609685537e-09
C O 0 2.527989977352263e-07
- O 0 4.999274096917361e-07
terminal O 0 1.1091901086501821e-07
domain O 0 2.7107878164400745e-09
of O 0 5.253688595274753e-10
NPII O 0 1.5257784070854541e-05
, O 0 4.757460536630731e-10
including O 0 1.225331502929805e-10
a O 0 5.621665355448613e-10
cysteine O 0 3.289551520069267e-09
residue O 0 8.696603437385875e-09
in O 0 2.936145215848285e-10
position O 0 1.2856172793007659e-09
85 O 0 6.603243729585984e-09
, O 0 3.4918432034736213e-10
which O 0 1.5181964019284067e-10
could O 0 1.2256727577319992e-10
be O 0 4.04176275781154e-11
involved O 0 1.9020270081160362e-10
in O 0 2.366090656735764e-10
the O 0 8.674400642227909e-10
correct O 0 3.8979784733328415e-08
folding O 0 1.2556663477880647e-06
of O 0 4.163517530741956e-09
the O 0 1.050222238063725e-07
prohormone O 0 0.004322195891290903
. O 0 9.503359024165547e-07

In O 0 2.74602598437923e-07
the O 0 1.7483385406080743e-08
second O 0 2.973269808137502e-08
family O 0 2.1067199540425463e-08
, O 0 7.765781351309897e-10
a O 0 1.9508656912137212e-09
G279A O 0 1.1869838090206031e-07
substitution O 0 3.0706059916951745e-09
at O 0 2.9346405305830103e-09
position O 0 1.8096391052324634e-09
- O 0 3.1258412747092734e-08
1 O 0 2.1286908347128985e-10
of O 0 2.837840032410277e-11
the O 0 1.3857072433953732e-10
signal O 0 1.1730651117147772e-08
peptide O 0 1.4229318878733466e-07
was O 0 2.376662200376245e-09
observed O 0 3.0798914529839294e-09
in O 0 5.589141927053731e-10
all O 0 4.4753450945123063e-10
affected O 0 4.0847815796496434e-08
individuals O 0 3.032716122675083e-08
. O 0 2.2531308729867305e-07

This O 0 1.6796014961073524e-06
missense O 0 0.020448343828320503
mutation O 0 0.0014722547493875027
, O 0 3.539685167197604e-08
which O 0 6.580963773927806e-09
replaces O 0 3.428512172831688e-06
Ala O 0 2.6786694434122182e-05
with O 0 3.976542828354468e-08
Thr O 0 0.011244879104197025
, O 0 2.7055358842176247e-08
is O 0 4.005963560871351e-09
frequent O 0 3.8481047681671043e-07
among O 0 4.5532630110756145e-07
FNDI B-Disease 1 0.9999504089355469
patients O 0 0.0009458849090151489
and O 0 1.3871338744309014e-08
is O 0 5.904788658028792e-09
thought O 0 7.187737627312174e-10
to O 0 4.822672122761773e-11
reduce O 0 5.683867598804682e-09
the O 0 2.3173277186039343e-10
efficiency O 0 2.5022689698062095e-08
of O 0 6.853618228497282e-10
cleavage O 0 7.0972578214423265e-06
by O 0 4.4001184917874525e-09
signal O 0 2.59193342344588e-07
peptidases O 0 1.4691072465211619e-05
. O 0 5.0948724350519115e-08
. O 0 1.7946213404229638e-07

Genetic O 0 0.0006079078302718699
heterogeneity O 0 0.0006228457787074149
of O 0 7.5726534305431414e-06
Saethre B-Disease 1 0.9988172054290771
- I-Disease 1 0.9997727274894714
Chotzen I-Disease 1 0.9998513460159302
syndrome I-Disease 1 0.9999721050262451
, O 0 9.107519360895822e-08
due O 0 4.9102528265621004e-08
to O 0 2.0840262848764723e-09
TWIST O 0 3.840043063974008e-06
and O 0 1.7981058419991314e-07
FGFR O 0 0.3132631778717041
mutations O 0 0.0013812441611662507
. O 0 7.151559202611679e-07

Thirty O 0 5.402705573942512e-05
- O 0 0.00023781297204550356
two O 0 2.0215645690768724e-07
unrelated O 0 1.7529520846437663e-05
patients O 0 2.005131818805239e-06
with O 0 1.1118792553332923e-09
features O 0 1.3569640522348436e-08
of O 0 3.122593383864114e-08
Saethre B-Disease 1 0.9051891565322876
- I-Disease 1 0.9963704347610474
Chotzen I-Disease 1 0.9996683597564697
syndrome I-Disease 1 0.9999462366104126
, O 0 8.574183141263347e-08
a O 0 7.789388973833411e-07
common O 0 9.042244528245647e-06
autosomal B-Disease 1 0.8178859353065491
dominant I-Disease 0 0.025581371039152145
condition I-Disease 0 0.01143477763980627
of O 0 8.298358693537011e-07
craniosynostosis B-Disease 1 0.9999148845672607
and O 0 5.467638038680889e-05
limb B-Disease 1 0.9925493001937866
anomalies I-Disease 0 0.01862773858010769
, O 0 1.2339542720951613e-08
were O 0 1.9154435815238458e-09
screened O 0 1.4828852101800294e-07
for O 0 5.778994616179034e-09
mutations O 0 1.3660318245456438e-06
in O 0 8.478830082481181e-09
TWIST O 0 2.200593826273689e-06
, O 0 2.6200705605106123e-08
FGFR2 O 0 0.0002651213435456157
, O 0 1.0616757251113995e-08
and O 0 3.654757563253952e-08
FGFR3 O 0 0.004809987731277943
. O 0 1.0547154261075775e-06

Nine O 0 3.646851610028534e-06
novel O 0 8.241400450970104e-07
and O 0 1.8481957297922236e-08
three O 0 4.8037122724053916e-08
recurrent O 0 0.0007659649709239602
TWIST O 0 0.00017245773051399738
mutations O 0 8.446785068372265e-05
were O 0 4.792764407568484e-09
found O 0 7.6771851098556e-09
in O 0 5.0542183771540294e-09
12 O 0 5.463248342607585e-08
families O 0 9.923259369770676e-08
. O 0 2.2974647606588405e-07

Seven O 0 1.7719785319059156e-06
families O 0 1.5665675334730622e-07
were O 0 7.2473773649051054e-09
found O 0 2.656323827565643e-09
to O 0 1.1868983573748437e-10
have O 0 1.2128914539388802e-10
the O 0 7.809317081886036e-10
FGFR3 O 0 0.00019831539248116314
P250R O 0 8.510633779224008e-05
mutation O 0 5.331805368768983e-06
, O 0 5.735079633417683e-10
and O 0 2.431161660876313e-10
one O 0 4.550332333153051e-10
individual O 0 1.5415319021272467e-09
was O 0 7.193721618392601e-09
found O 0 8.378606142223077e-10
to O 0 3.9061000961515546e-11
have O 0 1.1050160092507255e-10
an O 0 9.086082441989163e-10
FGFR2 O 0 0.0003336682275403291
VV269 O 0 0.00011181140871485695
- O 0 5.585593680734746e-05
270 O 0 1.525095854049141e-06
deletion O 0 7.288032793439925e-05
. O 0 6.884175718369079e-07

To O 0 9.296984870843517e-08
date O 0 1.5879417958331032e-07
, O 0 4.578113887987456e-09
our O 0 5.338542496957643e-09
detection O 0 2.361675797146745e-06
rate O 0 7.051087180798277e-08
for O 0 7.942788093906472e-10
TWIST O 0 6.202465669957746e-07
or O 0 3.805082826602302e-08
FGFR O 0 0.011464932933449745
mutations O 0 3.7386071198852733e-06
is O 0 1.3714068769488108e-09
68 O 0 2.742350702078511e-08
% O 0 1.288609885463643e-09
in O 0 1.3422957190201146e-09
our O 0 3.738132292596674e-08
Saethre B-Disease 0 0.10640032589435577
- I-Disease 1 0.9955095052719116
Chotzen I-Disease 1 0.9999294281005859
syndrome I-Disease 1 0.9999947547912598
patients O 0 0.003723817178979516
, O 0 5.8461790963804106e-09
including O 0 2.6894717564118764e-09
our O 0 1.7051725365035963e-08
five O 0 1.8739704898962373e-07
patients O 0 1.4920342437108047e-05
elsewhere O 0 3.632009963894234e-07
reported O 0 6.478659884123772e-07
with O 0 5.0466685053152105e-08
TWIST O 0 0.0007108403369784355
mutations O 0 0.00044521800009533763
. O 0 6.611683716073458e-07

More O 0 5.8855867735019274e-08
than O 0 1.3218035554984908e-08
35 O 0 9.687930457857874e-09
different O 0 1.2367150636904967e-09
TWIST O 0 1.7354001329294988e-06
mutations O 0 2.3365175820799777e-06
are O 0 5.831041760551159e-10
now O 0 1.9610129076141902e-09
known O 0 2.8418838393662327e-09
in O 0 9.736423889350476e-10
the O 0 2.695053513690482e-09
literature O 0 4.45130012849404e-08
. O 0 1.6728445473290776e-07

The O 0 2.528561253711814e-07
most O 0 1.3332051018721813e-08
common O 0 1.8547746449826263e-08
phenotypic O 0 2.0321895135566592e-06
features O 0 3.0057543654038454e-07
, O 0 5.408193004541317e-09
present O 0 1.0969046781994507e-09
in O 0 2.5048499385782463e-10
more O 0 7.045323352494748e-11
than O 0 1.162989635150602e-10
a O 0 1.3044388902372361e-09
third O 0 4.723871516176814e-09
of O 0 1.0668107508493563e-09
our O 0 3.195649966869496e-08
patients O 0 1.8229865190733108e-06
with O 0 2.2064510218910982e-08
TWIST O 0 9.910907101584598e-05
mutations O 0 7.065727004373912e-06
, O 0 1.3464342973890098e-09
are O 0 2.9547633784154925e-10
coronal B-Disease 0 3.873838522849837e-06
synostosis I-Disease 0 0.00010015278530772775
, O 0 2.07570440835525e-08
brachycephaly B-Disease 0 0.00016417795268353075
, O 0 7.618810116127861e-08
low B-Disease 0 0.00038337401929311454
frontal I-Disease 1 0.9997159838676453
hairline I-Disease 1 0.9999829530715942
, O 0 2.3701572899881285e-06
facial B-Disease 1 0.8605130314826965
asymmetry I-Disease 0 0.030268972739577293
, O 0 6.7881796894653235e-06
ptosis B-Disease 1 0.9979900121688843
, O 0 8.306529934998252e-07
hypertelorism B-Disease 1 0.8933826088905334
, O 0 1.9293196373837418e-07
broad B-Disease 0 5.2972759476688225e-06
great I-Disease 0 4.0528047406951373e-07
toes I-Disease 0 2.9492925023077987e-05
, O 0 8.441135790349108e-09
and O 0 3.67617190022429e-08
clinodactyly B-Disease 0 0.0008805033867247403
. O 0 1.3231098137111985e-06

Significant O 0 1.7433989114579163e-06
intra O 0 4.228784018778242e-05
- O 0 4.366540088085458e-05
and O 0 1.7589851353250197e-08
interfamilial O 0 3.41040467901621e-05
phenotypic O 0 4.096971679246053e-05
variability O 0 0.00014962110435590148
is O 0 9.351633245557878e-09
present O 0 2.258787157316533e-09
for O 0 1.5884794590803608e-09
either O 0 3.104031165435117e-08
TWIST O 0 5.287724343361333e-05
mutations O 0 0.00022305046149995178
or O 0 9.840343864198076e-07
FGFR O 0 0.4107109010219574
mutations O 0 0.002244180766865611
. O 0 1.2908068356409785e-06

The O 0 3.255930209888902e-07
overlap O 0 1.1771137451432878e-06
in O 0 9.719008886577285e-08
clinical O 0 4.9327441047353204e-06
features O 0 3.634057321733053e-08
and O 0 2.353000017052409e-09
the O 0 1.7352680403703857e-09
presence O 0 1.292667484165122e-08
, O 0 6.557817067154303e-10
in O 0 2.7000068847371494e-10
the O 0 2.536789389662175e-10
same O 0 5.64574553774122e-10
genes O 0 2.1838282293629163e-09
, O 0 1.6263561330998044e-10
of O 0 1.793207665690133e-10
mutations O 0 3.839376461201027e-08
for O 0 6.55792711801162e-11
more O 0 6.062291640906992e-11
than O 0 2.7722404927210675e-10
one O 0 3.242043744577927e-09
craniosynostotic B-Disease 0 0.0005576302064582705
condition I-Disease 0 1.3334310096979607e-05
- O 0 9.868989536698791e-07
such O 0 3.0107830117920287e-10
as O 0 1.5461343316758303e-09
Saethre B-Disease 0 2.8192907848278992e-05
- I-Disease 0 8.301767593366094e-06
Chotzen I-Disease 0 6.140893219708232e-06
, I-Disease 0 3.508454859968424e-09
Crouzon I-Disease 0 9.517303624306805e-06
, I-Disease 0 1.0845684350613283e-08
and I-Disease 0 5.5550639643797695e-08
Pfeiffer I-Disease 0 0.36104661226272583
syndromes I-Disease 1 0.560278594493866
- O 0 1.9400171368033625e-05
support O 0 6.40836539389511e-09
the O 0 2.3949142669010826e-09
hypothesis O 0 1.6099262367674783e-08
that O 0 1.2378897906728525e-10
TWIST O 0 2.11634123559179e-08
and O 0 5.351446508150559e-10
FGFRs O 0 4.990452566744352e-07
are O 0 1.2102246982337306e-10
components O 0 5.101109534777493e-10
of O 0 1.1462111815241371e-10
the O 0 3.611148324811353e-10
same O 0 5.539526615194745e-10
molecular O 0 7.82959332923383e-08
pathway O 0 1.6144959147368354e-08
involved O 0 1.1900407326237428e-09
in O 0 3.664729075758544e-10
the O 0 5.995279273030008e-10
modulation O 0 5.579560706792108e-07
of O 0 1.5350417470472166e-07
craniofacial O 1 0.9899494647979736
and O 0 1.744526571201277e-06
limb O 0 0.05396515876054764
development O 0 1.5640299011465686e-07
in O 0 3.695138417469934e-08
humans O 0 6.827581700008523e-08
. O 0 2.2144744704633013e-08
. O 0 1.3374310015024093e-07

Mutation O 0 0.0014549036277458072
analysis O 0 7.296615876839496e-06
of O 0 3.769650675167213e-06
UBE3A O 1 0.99506014585495
in O 1 0.5539072155952454
Angelman B-Disease 1 0.9999896287918091
syndrome I-Disease 1 0.999997615814209
patients O 1 0.998501181602478
. O 0 3.394939631107263e-05

Angelman B-Disease 1 0.9999915361404419
syndrome I-Disease 1 0.9999971389770508
( O 0 9.888550266623497e-05
AS B-Disease 0 3.4973956644535065e-05
) O 0 9.472940831756205e-08
is O 0 9.157070657295208e-09
caused O 0 9.515206045307423e-08
by O 0 4.7056971652637e-09
chromosome O 0 1.4765937521588057e-05
15q11 O 0 5.5859560234239325e-05
- O 0 2.131234396074433e-05
q13 O 0 2.3346024136117194e-06
deletions O 0 1.5093749539119017e-07
of O 0 1.6254143586635905e-09
maternal O 0 1.753436663420871e-06
origin O 0 7.2281607366164735e-09
, O 0 2.737969628796577e-09
by O 0 4.526926833392508e-09
paternal O 0 6.470699736382812e-05
uniparental B-Disease 1 0.9735852479934692
disomy I-Disease 1 0.7801504731178284
( O 0 1.3166361441108165e-06
UPD B-Disease 1 0.996166467666626
) O 0 1.1716316805632232e-08
15 O 0 9.299641057225472e-09
, O 0 1.5320932300610934e-09
by O 0 3.8238883171004545e-09
imprinting O 0 0.0012281639501452446
defects O 0 0.27382075786590576
, O 0 4.17769285832037e-09
and O 0 1.6481257469891375e-09
by O 0 4.7006731840326665e-09
mutations O 0 7.609934868924029e-07
in O 0 3.977837614854707e-09
the O 0 3.545415339090141e-08
UBE3A O 0 0.003699971828609705
gene O 0 9.045280421560165e-06
. O 0 4.137917244406708e-07

UBE3A O 0 0.000973822083324194
encodes O 0 7.496595571865328e-06
a O 0 5.287915882945526e-07
ubiquitin O 0 3.865649432555074e-06
- O 0 1.0391063369752374e-05
protein O 0 1.4297644668204157e-07
ligase O 0 8.801216040410509e-07
and O 0 8.798881623306443e-09
shows O 0 2.600594370960607e-07
brain O 0 0.0010577394859865308
- O 0 1.880145282484591e-05
specific O 0 1.2087475909083878e-07
imprinting O 0 0.00015543983317911625
. O 0 5.925302275500144e-07

Here O 0 1.8045442402581102e-06
we O 0 9.8684651561598e-08
describe O 0 6.38797530427837e-07
UBE3A O 0 0.0005470867035910487
coding O 0 0.00039149579242803156
- O 0 0.00030909714405424893
region O 0 1.5194543721008813e-06
mutations O 0 1.240595884155482e-05
detected O 0 6.20999458078586e-07
by O 0 2.2475106220554153e-09
SSCP O 0 1.3552586096921004e-05
analysis O 0 1.3739680504443186e-08
in O 0 1.0431167929425555e-08
13 O 0 5.701569349980673e-08
AS B-Disease 0 1.4273817328103178e-07
individuals O 0 5.220687437912375e-09
or O 0 1.6860559171050227e-08
families O 0 2.6414090825710446e-07
. O 0 3.0917414051145897e-07

Two O 0 6.91320281021035e-07
identical O 0 1.477228943258524e-05
de O 0 4.960320893587777e-06
novo O 0 6.983468665566761e-06
5 O 0 2.241484651221981e-07
- O 0 2.401480742264539e-06
bp O 0 4.087556533249881e-07
duplications O 0 2.304961412846751e-07
in O 0 6.08407502156183e-09
exon O 0 2.2441572582465596e-06
16 O 0 3.514363910994689e-08
were O 0 7.260562817634764e-09
found O 0 1.2211452826704772e-07
. O 0 2.526160756133322e-07

Among O 0 1.3697781753307936e-07
the O 0 7.325342110675592e-09
other O 0 9.067696038478346e-10
11 O 0 1.4134678316679583e-08
unique O 0 2.6806031172554867e-08
mutations O 0 2.699147444218397e-06
, O 0 1.9672166118311907e-09
8 O 0 5.261272306711362e-09
were O 0 2.1066534627856015e-10
small O 0 1.876307997861204e-09
deletions O 0 3.7488965176635247e-07
or O 0 7.625639675268303e-09
insertions O 0 6.497390586446272e-06
predicted O 0 1.1632147334239562e-06
to O 0 8.87113549286056e-10
cause O 0 1.653295527148657e-07
frameshifts O 0 1.4432255738938693e-05
, O 0 2.471144400217895e-09
1 O 0 6.49573905775469e-09
was O 0 6.548084297008927e-09
a O 0 2.471890603317206e-08
mutation O 0 2.5015086180246726e-07
to O 0 6.40956870912035e-11
a O 0 9.53521817059766e-10
stop O 0 2.6922739593260303e-09
codon O 0 2.0889700635962072e-08
, O 0 4.910182815898168e-10
1 O 0 1.489880885330308e-09
was O 0 2.481753247352003e-09
a O 0 2.80979453037844e-08
missense O 0 6.110567483119667e-05
mutation O 0 2.912043328251457e-06
, O 0 8.352198932470856e-10
and O 0 4.194010139180193e-10
1 O 0 1.3025848843994936e-08
was O 0 4.266126296670336e-08
predicted O 0 8.56119157788271e-08
to O 0 2.019382577822526e-10
cause O 0 1.0616737711188762e-08
insertion O 0 3.218184119191392e-08
of O 0 3.4620670219531746e-10
an O 0 8.326606071307197e-10
isoleucine O 0 2.163107637898065e-06
in O 0 1.1392872201199111e-09
the O 0 3.861301556273844e-10
hect O 0 1.2638378166229813e-07
domain O 0 9.690660496275427e-10
of O 0 6.713494343779658e-11
the O 0 2.8955135511488095e-10
UBE3A O 0 2.0781740204256494e-06
protein O 0 8.992159905574226e-09
, O 0 1.3720602431988027e-10
which O 0 2.2265456839365427e-11
functions O 0 1.4364949507683633e-10
in O 0 6.513712347278044e-10
E2 O 0 8.990583637569216e-07
binding O 0 3.481658339410387e-08
and O 0 3.249001512273253e-09
ubiquitin O 0 5.96727716128953e-07
transfer O 0 3.46759918556927e-07
. O 0 3.431098889450368e-07

Eight O 0 5.080966047898983e-07
of O 0 2.0980062132025523e-08
the O 0 1.9043339349877897e-08
cases O 0 5.651763501646201e-08
were O 0 6.122887974413516e-09
familial O 0 0.001481632236391306
, O 0 1.069496491368227e-08
and O 0 2.294624934506828e-09
five O 0 5.884708276227002e-09
were O 0 6.464000446015916e-09
sporadic O 0 5.513734322448727e-06
. O 0 4.202149455068138e-07

In O 0 1.0203123110841261e-06
two O 0 1.8205180651875708e-07
familial O 0 0.12078478187322617
cases O 0 9.141112968791276e-07
and O 0 5.754005716340771e-09
one O 0 3.879922161331706e-09
sporadic O 0 5.280255663819844e-07
case O 0 1.0471539013678921e-07
, O 0 6.066219082612179e-09
mosaicism O 0 0.00011040401295758784
for O 0 6.145845787841608e-08
UBE3A O 0 0.35254335403442383
mutations O 0 0.00015404372243210673
was O 0 3.98971629067546e-08
detected O 0 1.3394299003266497e-07
in O 0 6.404085595157483e-10
the O 0 8.01229360636313e-10
mother O 0 7.216907960128083e-08
of O 0 4.919228357991301e-10
three O 0 4.532957564862272e-09
AS B-Disease 0 3.587809942473541e-07
sons O 0 9.925528274834505e-07
, O 0 1.5050584112330512e-09
in O 0 6.855474521394456e-10
the O 0 8.579393306895611e-10
maternal O 0 4.1624645064075594e-07
grandfather O 0 8.982461707773837e-08
of O 0 1.8741574958625051e-10
two O 0 5.151640780631794e-10
AS B-Disease 0 6.672853825051561e-09
first O 0 1.2027304707729058e-09
cousins O 0 2.0699171443538944e-07
, O 0 1.634785418147544e-09
and O 0 5.112720802280535e-10
in O 0 1.0401718375518954e-09
the O 0 1.5650251095067347e-09
mother O 0 1.527027109204937e-07
of O 0 1.278281924754765e-09
an O 0 1.510678870886295e-08
AS B-Disease 0 1.1108751095889602e-05
daughter O 0 0.00042446740553714335
. O 0 1.0214670282948646e-06

The O 0 1.6338314878794336e-07
frequencies O 0 2.7462590423965594e-07
with O 0 1.4955016780504593e-08
which O 0 3.802701264987718e-09
we O 0 1.988333941937981e-09
detected O 0 3.3944027677534905e-07
mutations O 0 2.0188500116091745e-07
were O 0 3.658192082589551e-10
5 O 0 1.9233254988648696e-09
( O 0 3.859990660437518e-10
14 O 0 2.234452400884379e-09
% O 0 4.347542881255606e-10
) O 0 6.569231270070475e-11
of O 0 6.989536033286115e-11
35 O 0 2.3536552706815428e-09
in O 0 5.448070883318223e-10
sporadic O 0 2.7951651304647385e-07
cases O 0 1.4636976963799953e-08
and O 0 1.1486849249564557e-09
8 O 0 1.2155699558036304e-08
( O 0 9.160490144211053e-10
80 O 0 2.2636048591095914e-09
% O 0 6.489048187674484e-10
) O 0 8.431055159574541e-11
of O 0 1.561228923918634e-10
10 O 0 6.528168672303991e-09
in O 0 4.900924466255674e-08
familial O 0 0.12910975515842438
cases O 0 2.832523250617669e-06
. O 0 6.052017909041751e-08
. O 0 4.2118790588574484e-07

The O 0 1.8756398276309483e-05
hemochromatosis B-Disease 1 0.9995348453521729
845 O 0 0.10440225899219513
G O 0 0.3146735727787018
- O 0 0.0005599881405942142
- O 0 1.567010986036621e-05
> O 0 2.6182129886365146e-07
A O 0 7.824633385666857e-09
and O 0 1.0660500260328831e-09
187 O 0 6.981112932180622e-08
C O 0 5.771022415501648e-07
- O 0 1.9981522200396284e-05
- O 0 0.00011609123612288386
> O 0 0.00010636637307470664
G O 0 0.0023214544635266066
mutations O 0 8.996485121315345e-06
: O 0 9.425177083244307e-09
prevalence O 0 3.1872125418885844e-06
in O 0 1.581153163954241e-08
non O 0 8.649442406749586e-07
- O 0 0.0004230537742841989
Caucasian O 0 0.00013468932593241334
populations O 0 3.4222236990899546e-06
. O 0 4.454582835933252e-07

Hemochromatosis B-Disease 1 0.99822598695755
, O 0 2.7787718863692135e-05
the O 0 2.8412290703272447e-05
inherited B-Disease 1 0.9998348951339722
disorder I-Disease 1 0.999798595905304
of I-Disease 0 7.45218471820408e-07
iron I-Disease 0 0.20857343077659607
metabolism I-Disease 0 0.0032202776055783033
, O 0 9.650404564354176e-08
leads O 0 2.903790345953894e-06
, O 0 6.56285337186091e-08
if O 0 8.465647738375992e-08
untreated O 0 0.00027380575193092227
, O 0 5.3321622672797275e-09
to O 0 3.2328675292347953e-09
progressive O 0 0.001608515391126275
iron B-Disease 1 0.5534917712211609
overload I-Disease 0 0.4718617796897888
and O 0 1.908404783534934e-06
premature B-Disease 0 0.0066411192528903484
death I-Disease 0 5.7354387536179274e-05
. O 0 1.0676824331312673e-06

The O 0 1.0752351954579353e-05
hemochromatosis B-Disease 1 0.9995406866073608
gene O 0 0.0004274317470844835
, O 0 5.629395900541567e-07
HFE O 0 0.03521532937884331
, O 0 6.675274732970138e-08
recently O 0 3.6112970747126383e-07
has O 0 4.214452342665709e-09
been O 0 1.8467992690673896e-09
identified O 0 9.509777854077583e-09
, O 0 3.5176195289920997e-10
and O 0 1.7197250568035116e-10
characterization O 0 8.102910342699943e-09
of O 0 3.47746692552775e-10
this O 0 4.783136664521237e-10
gene O 0 2.8718108779912654e-08
has O 0 2.04578065599037e-09
shown O 0 1.6828936022506014e-09
that O 0 4.7136784059320647e-11
it O 0 2.508544240387156e-11
contains O 0 1.5764567429243925e-10
two O 0 7.605590601755807e-10
mutations O 0 1.832567022574949e-07
that O 0 9.960925140273247e-11
result O 0 7.001762503122677e-10
in O 0 3.1782440568228765e-10
amino O 0 1.6661639845594323e-09
acid O 0 1.0574963127396586e-08
substitutions O 0 4.165169986691808e-09
- O 0 3.2945827399544214e-08
cDNA O 0 6.610479630353439e-08
nucleotides O 0 1.4658411373602576e-07
845 O 0 4.237113444105489e-06
G O 0 0.0001502822560723871
- O 0 2.904723987739999e-05
- O 0 1.0880205991270486e-05
> O 0 6.851101375104918e-07
A O 0 1.6486358944689528e-08
( O 0 1.1565376434319319e-09
C282Y O 0 8.95259759658984e-08
) O 0 4.36984837204335e-10
and O 0 5.878490472177589e-10
187 O 0 1.1155296419929073e-07
C O 0 2.261130248371046e-06
- O 0 0.00019853086268994957
- O 0 0.0007031628047116101
> O 0 0.00021692448353860527
G O 0 0.0006462017772719264
( O 0 7.326519124717379e-08
H63D O 0 0.000185221855645068
) O 0 8.61412985386778e-08
. O 0 1.727634497683539e-07

Although O 0 0.00022570989676751196
hemochromatosis B-Disease 1 0.999772846698761
is O 0 6.169130415401014e-07
common O 0 1.886461120648164e-07
in O 0 2.808562094003264e-08
Caucasians O 0 1.8910196786237066e-06
, O 0 1.3043848667848579e-08
affecting O 0 3.517905611261085e-07
> O 0 4.5134198444429785e-05
= O 0 1.9491910734359408e-06
1 O 0 1.7713952971121216e-08
/ O 0 1.1261932542083741e-07
300 O 0 1.0667883243442589e-09
individuals O 0 1.7558024478780965e-10
of O 0 9.369566927874828e-11
northern O 0 5.993327167885809e-09
European O 0 1.8756283193255285e-09
origin O 0 1.7000959529056558e-09
, O 0 1.093651946781904e-09
it O 0 3.1302771485997027e-10
has O 0 8.07729161333981e-10
not O 0 6.903311255967992e-11
been O 0 2.2561122414721524e-10
recognized O 0 8.604597590000651e-10
in O 0 7.437488958039751e-10
other O 0 1.1910217256883016e-09
populations O 0 2.914817400778702e-07
. O 0 1.0466965960631569e-07

The O 0 2.5137552484011394e-07
present O 0 7.070723739843743e-08
study O 0 1.457271192606413e-08
used O 0 2.6770046179791507e-09
PCR O 0 1.3200417470216053e-07
and O 0 1.2238186020141484e-09
restriction O 0 9.071817963501871e-09
- O 0 2.046533609245671e-07
enzyme O 0 8.084355407333987e-09
digestion O 0 7.8148374882403e-08
to O 0 7.03930594370128e-11
analyze O 0 7.539152635516189e-10
the O 0 6.025322601965755e-11
frequency O 0 4.5214015864658563e-10
of O 0 1.0173052678030814e-10
the O 0 1.0996005217478455e-09
845 O 0 5.749335286964197e-06
G O 0 0.00015811414050403982
- O 0 2.4618489987915382e-05
- O 0 6.537805802508956e-06
> O 0 1.3643077068081766e-07
A O 0 6.933086993399229e-09
and O 0 1.0066665279140352e-09
187 O 0 7.344623753624546e-08
C O 0 5.186201974538562e-07
- O 0 2.601725464046467e-05
- O 0 4.416559750097804e-05
> O 0 1.3687319551536348e-05
G O 0 0.00011541639833012596
mutations O 0 1.2066692534062895e-06
in O 0 3.473895615613287e-09
HLA O 0 1.2112268450437114e-05
- O 0 2.6613568593347736e-07
typed O 0 1.3451590952229253e-08
samples O 0 1.4091869893206876e-09
from O 0 5.0519222138945e-10
non O 0 7.984167105234974e-09
- O 0 3.4918450637633214e-06
Caucasian O 0 1.2175584060969413e-06
populations O 0 9.71196367771654e-09
, O 0 3.683804927767653e-10
comprising O 0 1.948820216313152e-09
Australian O 0 1.0594909838346211e-08
Aboriginal O 0 2.4122677189097885e-08
, O 0 1.1759431206570525e-09
Chinese O 0 1.3041950852610285e-09
, O 0 1.9911954307616497e-09
and O 0 7.314019168092045e-09
Pacific O 0 3.0079245334491134e-06
Islanders O 0 1.6893454812816344e-05
. O 0 6.55139729133225e-07

Results O 0 0.00011286957305856049
showed O 0 3.030590733033023e-06
that O 0 8.1619155878343e-09
the O 0 1.526214177260954e-08
845 O 0 7.120752707123756e-05
G O 0 0.009974585846066475
- O 0 0.0004291713994462043
- O 0 5.955839151283726e-05
> O 0 1.7153622593468754e-06
A O 0 1.1173141700737688e-07
mutation O 0 2.0334689452283783e-06
was O 0 3.563841000087109e-09
present O 0 4.3822429018902653e-10
in O 0 3.6704861372527375e-10
these O 0 7.317207256773983e-11
populations O 0 7.578468408375727e-10
( O 0 1.3664555598147388e-10
allele O 0 1.4494119238150915e-09
frequency O 0 8.535779305596236e-10
0 O 0 1.586956233090575e-09
. O 0 8.579029153743534e-11
32 O 0 2.040165592021026e-09
% O 0 6.244624262130571e-10
) O 0 1.580714309445952e-10
, O 0 2.43576603331519e-10
and O 0 3.0583649501814136e-10
, O 0 4.182299229160691e-10
furthermore O 0 3.5980667334456484e-09
, O 0 2.882047378527375e-10
it O 0 1.1426531942859697e-10
was O 0 2.0190911165229863e-09
always O 0 7.687745995355044e-10
seen O 0 3.2665490312666634e-09
in O 0 4.615628990123355e-10
conjunction O 0 4.9425484149878685e-08
with O 0 4.388428820334411e-08
HLA O 0 0.0008476287475787103
haplotypes O 0 2.8520669275167165e-06
common O 0 1.8355940767378343e-08
in O 0 5.045636353173677e-09
Caucasians O 0 1.783931082854906e-07
, O 0 1.6413433945317024e-09
suggesting O 0 1.4334721853970223e-08
that O 0 7.709214377982221e-10
845 O 0 5.829057045048103e-06
G O 0 0.0016831082757562399
- O 0 0.00024750715238042176
- O 0 7.008344255154952e-05
> O 0 2.9138159334252123e-06
A O 0 9.55941032998453e-08
may O 0 3.5550966615005564e-09
have O 0 7.761246506587938e-11
been O 0 1.169045693583115e-10
introduced O 0 3.8365466359380207e-10
into O 0 1.7887737124855363e-10
these O 0 2.2985838232791878e-10
populations O 0 5.572167172118725e-09
by O 0 5.8826659099509016e-09
Caucasian O 0 9.850928108789958e-06
admixture O 0 3.753504643100314e-05
. O 0 5.246074579190463e-07

187 O 0 0.00010294964158674702
C O 0 3.173190270899795e-05
- O 0 7.62730633141473e-05
- O 0 3.644522439572029e-05
> O 0 7.857530363253318e-06
G O 0 3.7139943742658943e-06
was O 0 1.5611613113364342e-09
present O 0 3.618580990405462e-10
at O 0 3.768057532660407e-10
an O 0 6.54061318994259e-11
allele O 0 1.994920895143082e-09
frequency O 0 2.4519186681004612e-09
of O 0 2.0947383827518706e-09
2 O 0 2.2964044887885393e-07
. O 0 2.9176428029131785e-07

68 O 0 3.4258755476912484e-05
% O 0 1.440248666995103e-07
in O 0 3.6397573843771625e-09
the O 0 1.1170020464135177e-09
two O 0 1.1495527862948052e-09
populations O 0 8.97250984621678e-09
analyzed O 0 1.731744347921449e-08
( O 0 1.9129497985659327e-09
Australian O 0 1.0158849761410238e-08
Aboriginal O 0 2.1965247398725296e-08
and O 0 1.4611502008321509e-09
Chinese O 0 5.983778361695613e-09
) O 0 3.3749635974800185e-08
. O 0 1.0264086114375459e-07

In O 0 2.845335700385476e-07
the O 0 1.2026920792607143e-08
Australian O 0 3.316162988653559e-08
Aboriginal O 0 2.4097889905760894e-08
samples O 0 1.4815163318360192e-08
, O 0 1.7047977474149434e-09
187 O 0 6.344638592281626e-08
C O 0 3.8280066405604884e-07
- O 0 1.7299773389822803e-05
- O 0 3.423432644922286e-05
> O 0 4.5829751798009966e-06
G O 0 1.2323839655437041e-05
was O 0 4.899024741433777e-09
found O 0 8.963217390522971e-10
to O 0 1.343568034606335e-10
be O 0 3.00667990504877e-10
associated O 0 6.557357767889016e-09
with O 0 1.9657399263905972e-08
HLA O 0 0.0009379756520502269
haplotypes O 0 4.558908585750032e-06
common O 0 2.8866494972135115e-08
in O 0 7.5226385121141e-09
Caucasians O 0 7.573387961201661e-07
, O 0 5.1094768416248826e-09
suggesting O 0 3.042182683543615e-08
that O 0 1.2694807705049271e-10
it O 0 1.184211895211007e-10
was O 0 6.116406270351149e-10
introduced O 0 2.6322308777082526e-09
by O 0 1.731274568150809e-09
recent O 0 5.180062245813133e-08
admixture O 0 9.87942530628061e-06
. O 0 5.331214083525992e-07

In O 0 8.944387985820867e-08
the O 0 1.382342862399355e-08
Chinese O 0 6.804256269532516e-09
samples O 0 1.9963948716394952e-08
analyzed O 0 2.8911070870663025e-08
, O 0 2.214587180304761e-09
187 O 0 9.019716173952474e-08
C O 0 1.5345352721851668e-06
- O 0 4.104613253730349e-05
- O 0 2.8678547096205875e-05
> O 0 7.143746188376099e-06
G O 0 1.1499772881506942e-05
was O 0 4.852424240198161e-09
present O 0 1.0464721311720382e-09
in O 0 1.4322852903703165e-09
association O 0 6.8483028137222846e-09
with O 0 4.3379344560889876e-10
a O 0 3.849728535954e-09
wide O 0 5.721807916359012e-09
variety O 0 2.2319905923495753e-09
of O 0 1.7652592720907023e-09
HLA O 0 0.00017836701590567827
haplotypes O 0 2.7374101136956597e-06
, O 0 3.10604297837358e-09
showing O 0 7.03367959431489e-08
this O 0 6.558079634899627e-10
mutation O 0 6.802105190217844e-08
to O 0 9.920273630337206e-11
be O 0 1.4731967035164217e-10
widespread O 0 1.7775720451140842e-08
and O 0 2.7490840714960996e-09
likely O 0 4.7019645954549105e-09
to O 0 1.2921262670939626e-10
predate O 0 5.5390348308037574e-08
the O 0 3.333255893522846e-10
more O 0 1.6287372839318692e-10
genetically O 0 6.9992021067832866e-09
restricted O 0 1.000530058803406e-08
845 O 0 6.175402631924953e-06
G O 0 0.0011630738154053688
- O 0 0.00019956122559960932
- O 0 0.00010812839900609106
> O 0 4.972294391336618e-06
A O 0 8.440976557722024e-07
mutation O 0 3.779679173021577e-05
. O 0 2.3673260329815093e-07

Genotype O 0 0.05335118994116783
- O 0 0.00872761569917202
phenotype O 0 0.007761146407574415
correlations O 0 0.0012194918235763907
in O 0 0.00013352972746361047
attenuated B-Disease 1 0.9921126365661621
adenomatous I-Disease 1 0.9999396800994873
polyposis I-Disease 1 0.999879002571106
coli I-Disease 1 0.9992972612380981
. O 0 8.289010293083265e-05

Germ O 0 0.11726833134889603
- O 0 0.00044722098391503096
line O 0 4.6559362090192735e-06
mutations O 0 2.26344332077133e-06
of O 0 5.8834510596739165e-09
the O 0 4.788006791045518e-08
tumor B-Disease 0 0.012241910211741924
suppressor O 0 6.154851871542633e-05
APC O 0 1.0481991921551526e-05
are O 0 9.16517794991023e-09
implicated O 0 2.5954457669286057e-05
in O 0 1.673882798058912e-05
attenuated B-Disease 1 0.9994626641273499
adenomatous I-Disease 1 0.9999978542327881
polyposis I-Disease 1 0.9999980926513672
coli I-Disease 1 0.9999831914901733
( O 0 0.0001300127332797274
AAPC B-Disease 1 0.9996253252029419
) O 0 2.7567885751977883e-08
, O 0 3.203759257885963e-09
a O 0 7.386235267858865e-08
variant O 0 5.823336687171832e-05
of O 0 2.2839252778794616e-05
familial B-Disease 1 0.9999946355819702
adenomatous I-Disease 1 0.9999973773956299
polyposis I-Disease 1 0.9999982118606567
( O 0 0.0006672521121799946
FAP B-Disease 1 0.9729791879653931
) O 0 2.257515234305174e-06
. O 0 1.709590719656262e-06

AAPC B-Disease 1 0.9983664155006409
is O 0 1.5329321740864543e-06
recognized O 0 1.9638966364254884e-07
by O 0 5.225070154324385e-09
the O 0 2.6329087798870887e-09
occurrence O 0 1.3305051993484085e-07
of O 0 5.271618697122449e-09
< O 0 5.5256832638406195e-06
100 O 0 4.961476207654414e-08
colonic B-Disease 0 0.04798747971653938
adenomas I-Disease 0 0.0007877121679484844
and O 0 4.350996007929098e-09
a O 0 6.027974563949101e-08
later O 0 3.923549343198829e-07
onset O 1 0.8051007390022278
of O 0 0.15489476919174194
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999997615814209
( O 0 1.1372369499440538e-06
age O 0 9.399057034897851e-07
> O 0 9.506853530183434e-06
40 O 0 5.92333648796739e-08
years O 0 3.691067007594029e-08
) O 0 2.8913165195376678e-08
. O 0 1.0932046023981457e-07

The O 0 2.044124727262897e-07
aim O 0 3.3916393249455723e-07
of O 0 5.754642096178486e-09
this O 0 1.9203820755819834e-09
study O 0 8.654012617625995e-09
was O 0 1.7144105024513578e-09
to O 0 5.764207444691749e-10
assess O 0 2.1964204677260568e-07
genotype O 0 6.755493086529896e-05
- O 0 0.0018836699891835451
phenotype O 0 0.000506237440276891
correlations O 0 2.5668998205219395e-05
in O 0 1.8247695834361366e-06
AAPC B-Disease 1 0.9972764849662781
families O 0 2.0465406578296097e-06
. O 0 1.2534587767731864e-06

By O 0 4.663027937112929e-07
protein O 0 1.6864858025655849e-06
- O 0 6.536359251185786e-06
truncation O 0 3.4828156003641197e-06
test O 0 8.118151839653365e-08
( O 0 3.9666021578455e-09
PTT O 0 1.4724149366429629e-07
) O 0 6.966368037986115e-10
assay O 0 4.1448913634667406e-08
, O 0 4.0714065452363e-10
the O 0 1.4077301824233501e-10
entire O 0 4.157874933241601e-09
coding O 0 2.104326739527096e-07
region O 0 4.870301051340675e-09
of O 0 1.7689118225749922e-10
the O 0 1.3315069047337147e-09
APC B-Disease 0 1.8335980485062464e-06
gene O 0 1.0912005166119343e-07
was O 0 7.763134135529981e-09
screened O 0 1.304773462607045e-07
in O 0 3.808101389779495e-09
affected O 0 1.0563049102074729e-08
individuals O 0 1.7129985208086396e-09
from O 0 6.7862666597307e-09
11 O 0 1.6095367527668714e-06
AAPC B-Disease 1 0.9940588474273682
kindreds O 0 0.00022730826458428055
, O 0 3.3994347337085173e-09
and O 0 3.075411036945752e-10
their O 0 4.106212314614055e-10
phenotypic O 0 7.659877496735135e-07
differences O 0 2.776329210973927e-07
were O 0 5.38661772964133e-08
examined O 0 8.593421625846531e-06
. O 0 2.748252825313102e-07

Five O 0 2.8702913823508425e-06
novel O 0 3.816833213932114e-06
germ O 0 0.0037619059439748526
- O 0 0.00018909235950559378
line O 0 2.4926835067162756e-06
APC B-Disease 0 5.687698649126105e-05
mutations O 0 6.768520961486502e-06
were O 0 3.806823301033546e-09
identified O 0 2.1112654735588876e-08
in O 0 1.0865292665585002e-08
seven O 0 3.0874983281137247e-07
kindreds O 0 0.0003720035601872951
. O 0 7.838877422727819e-07

Mutations O 0 0.005340079311281443
were O 0 2.732189159360132e-07
located O 0 1.8086707598286011e-07
in O 0 6.6810810217532435e-09
three O 0 8.155313091506855e-10
different O 0 1.2015077821558862e-10
regions O 0 1.7784054229252888e-09
of O 0 2.7375818278940756e-10
the O 0 1.283103845395317e-09
APC B-Disease 0 2.177143414883176e-06
gene O 0 5.109001577352501e-08
( O 0 9.468416051205963e-10
1 O 0 1.2918657255056587e-09
) O 0 1.244722658277908e-10
at O 0 4.552190013829005e-10
the O 0 1.4972353912234837e-10
5 O 0 8.148441366095938e-10
end O 0 8.288323916083584e-10
spanning O 0 2.473602478403336e-08
exons O 0 2.2102551611169474e-07
4 O 0 1.9803639617066437e-08
and O 0 1.103824365245032e-09
5 O 0 1.480109812490582e-08
, O 0 1.1722212089892992e-09
( O 0 5.753256204776847e-10
2 O 0 2.0017587587517482e-09
) O 0 4.149372234696358e-10
within O 0 1.3078967908697336e-09
exon O 0 1.790559281289461e-06
9 O 0 9.29572578911575e-08
, O 0 7.716334238239142e-10
and O 0 3.9231554116447853e-10
( O 0 5.655208523691613e-10
3 O 0 1.8506816079622013e-09
) O 0 1.9179101362620798e-10
at O 0 5.252346335637981e-10
the O 0 3.735968756579666e-10
3 O 0 2.979660740365375e-09
distal O 0 6.958273388590897e-07
end O 0 8.391452865907922e-09
of O 0 1.1611084316243137e-09
the O 0 2.1221175927621516e-08
gene O 0 2.8072608984075487e-06
. O 0 4.4748247773895855e-07

Variability O 0 0.0003503094776533544
in O 0 2.579224656074075e-07
the O 0 4.5090221334476155e-08
number O 0 8.526269823505572e-08
of O 0 2.1241205104161054e-05
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999746084213257
was O 0 3.428947138672811e-06
most O 0 1.2470146693033257e-08
apparent O 0 3.2772341000963934e-06
in O 0 1.64220530507464e-08
individuals O 0 3.048838070895954e-09
with O 0 2.3223167389119226e-08
mutations O 0 5.1124507081112824e-06
in O 0 6.19369178167517e-09
region O 0 2.1273331540783147e-08
1 O 0 1.5634952887921827e-08
, O 0 6.844046218645872e-09
and O 0 5.095299471236103e-08
upper O 1 0.6587862968444824
- O 1 0.9685907363891602
gastrointestinal O 1 0.9767741560935974
manifestations O 0 4.619557876139879e-05
were O 0 4.438303591314252e-08
more O 0 1.7936883978109108e-08
severe O 0 0.0004261426511220634
in O 0 1.3530434550546033e-08
them O 0 8.127754469455795e-09
. O 0 2.0404493739079044e-07

In O 0 6.735050419592881e-07
individuals O 0 9.276880064135185e-08
with O 0 3.8602891549999185e-08
mutations O 0 1.2698384125542361e-05
in O 0 8.671758422451603e-09
either O 0 1.0982010856253055e-08
region O 0 6.843109190413088e-08
2 O 0 2.338223836773068e-08
or O 0 4.3404937422053536e-09
region O 0 1.3602783788257966e-08
3 O 0 6.633667393174392e-09
, O 0 2.09236530879231e-10
the O 0 1.743109129259679e-10
average O 0 4.237901141124212e-09
number O 0 2.510106011932578e-10
of O 0 3.4236404822252098e-09
adenomas B-Disease 0 0.005662297829985619
tended O 0 1.4220175614809705e-07
to O 0 2.4996951730749117e-10
be O 0 2.9764385400810056e-10
lower O 0 2.296903112153359e-08
than O 0 1.9518991978273448e-10
those O 0 9.82686640393915e-11
in O 0 3.7596725732669256e-10
individuals O 0 3.804599968404432e-10
with O 0 7.937657642287377e-09
mutations O 0 1.4824174741079332e-06
in O 0 3.019180461194537e-09
region O 0 1.8348973895854215e-08
1 O 0 9.863004635235484e-09
, O 0 1.1959204737621576e-09
although O 0 3.727073760728672e-09
age O 0 5.4521308356925147e-08
at O 0 3.1657540944252105e-07
diagnosis O 0 0.014023015275597572
was O 0 4.423050086188596e-07
similar O 0 4.197135012873332e-07
. O 0 3.006634585744905e-07

In O 0 1.0534376997384243e-06
all O 0 1.405855414304824e-07
AAPC B-Disease 1 0.8939602971076965
kindreds O 0 0.00015595232252962887
, O 0 5.448343998182281e-09
a O 0 1.0906028968804549e-08
predominance O 0 2.694459226404433e-06
of O 0 1.0942559924842499e-07
right O 0 0.0003182888904120773
- O 1 0.991805911064148
sided O 1 0.9998741149902344
colorectal B-Disease 1 0.9999996423721313
adenomas I-Disease 1 0.999972939491272
and O 0 0.000281472661299631
rectal B-Disease 1 0.9999494552612305
polyp I-Disease 1 0.9997598528862
sparing O 0 0.00017579518316779286
was O 0 2.486346829755348e-06
observed O 0 1.594112745806342e-06
. O 0 4.1679143691908394e-07

No O 0 0.0001464463712181896
desmoid B-Disease 1 0.9831753969192505
tumors I-Disease 1 0.9998855590820312
were O 0 1.8755402209080785e-07
found O 0 8.995612432727285e-08
in O 0 1.6380946377125838e-08
these O 0 1.8487209985096342e-08
kindreds O 0 0.00013964246318209916
. O 0 9.118379580286273e-07

Our O 0 4.88706746182288e-07
data O 0 2.1508301983885758e-07
suggest O 0 8.5124092663591e-08
that O 0 2.534537024700967e-09
, O 0 3.6890241972287185e-09
in O 0 2.8459805179181785e-08
AAPC B-Disease 0 0.4898243248462677
families O 0 1.0581984177804316e-08
, O 0 3.6377079126737044e-10
the O 0 8.613953300651289e-11
location O 0 1.258905868439797e-09
of O 0 3.034032192150704e-10
the O 0 2.1279054962519695e-08
APC B-Disease 0 0.0019582160748541355
mutation O 0 0.00015956905554048717
may O 0 1.7466011570377304e-07
partially O 0 3.259193590565701e-06
predict O 0 1.1451791692707047e-07
specific O 0 1.1565558288850752e-08
phenotypic O 0 1.1526199159561656e-05
expression O 0 4.894870471616741e-06
. O 0 1.0249310662402422e-06

This O 0 1.2757620027059602e-07
should O 0 1.2346652589201312e-08
help O 0 3.7102214633932817e-09
in O 0 6.514171979610239e-10
the O 0 4.373124917744775e-10
design O 0 1.2558701634191038e-08
of O 0 2.431195467167413e-09
tailored O 0 2.3269352823263034e-05
clinical O 0 0.003866065526381135
- O 0 0.0005565523752011359
management O 0 8.244403488788521e-07
protocols O 0 7.339064467259959e-08
in O 0 2.2158210821743296e-09
this O 0 5.248290690929025e-10
subset O 0 1.491521430807552e-07
of O 0 1.896935515333098e-07
FAP B-Disease 1 0.9895794987678528
patients O 0 0.0008354021701961756
. O 0 4.587950286349951e-08
. O 0 2.713800597575755e-07

Wilms B-Disease 1 0.9974561333656311
' I-Disease 0 0.0019577734638005495
tumor I-Disease 0 0.1303868144750595
1 O 0 1.330780605712789e-07
and O 0 6.770429106239817e-09
Dax O 0 3.500645834719762e-05
- O 0 3.501475703160395e-06
1 O 0 1.3690343969585683e-08
modulate O 0 1.3066986070953135e-07
the O 0 5.265468505655235e-09
orphan O 0 4.985190116713056e-06
nuclear O 0 1.125020503423002e-06
receptor O 0 4.564185019262368e-06
SF O 0 0.03015371412038803
- O 0 3.31813566845085e-06
1 O 0 4.923708996074083e-09
in O 0 2.2876285310502453e-09
sex O 0 7.309350991135943e-08
- O 0 2.9024727155047003e-06
specific O 0 9.73687352967545e-09
gene O 0 9.710907988846884e-07
expression O 0 6.513196808555222e-07
. O 0 3.486796060769848e-07

Products O 0 1.1455706498963991e-06
of O 0 1.768794675172103e-07
steroidogenic O 0 0.0018102576723322272
factor O 0 5.721482807530265e-07
1 O 0 1.868160381945927e-07
( O 0 7.286397618599949e-08
SF O 0 0.057769548147916794
- O 0 1.6861393305589445e-05
1 O 0 2.3662556358772235e-08
) O 0 6.544437880506848e-09
and O 0 1.7107488758938416e-07
Wilms B-Disease 1 0.9996441602706909
tumor I-Disease 1 0.9484589099884033
1 O 0 2.1215353740444698e-07
( O 0 1.5016471621720484e-08
WT1 O 0 9.420409332960844e-05
) O 0 1.641590752221589e-09
genes O 0 2.610895055710216e-09
are O 0 3.876293730442626e-11
essential O 0 1.3692576239510146e-10
for O 0 1.3898815431900857e-10
mammalian O 0 5.784665546570977e-08
gonadogenesis O 0 9.286452950618695e-06
prior O 0 9.09388919723142e-09
to O 0 1.0800593752691157e-09
sexual O 0 1.559647984095136e-07
differentiation O 0 6.544037205458153e-06
. O 0 6.169477728690254e-07

In O 0 1.1250183433730854e-06
males O 0 4.97739438287681e-06
, O 0 9.451265725601843e-08
SF O 0 0.00829633604735136
- O 0 4.288269792596111e-06
1 O 0 7.595678752636559e-09
participates O 0 1.8316455907552154e-08
in O 0 1.342380095969986e-09
sexual O 0 4.838800915507591e-09
development O 0 1.4128958003567504e-09
by O 0 2.4967075629156454e-10
regulating O 0 1.9188050259799638e-08
expression O 0 2.1621107126890138e-09
of O 0 2.1181119358448797e-10
the O 0 3.707137485875478e-09
polypeptide O 0 1.578204864927102e-05
hormone O 0 2.74960657407064e-05
Mullerian O 0 0.020745346322655678
inhibiting O 0 0.00016394109115935862
substance O 0 5.060656985733658e-05
( O 0 1.8836998094684532e-07
MIS O 0 0.002104870742186904
) O 0 1.2737561405629094e-07
. O 0 2.0375189535570826e-07

Here O 0 7.846260245969461e-07
, O 0 3.670636772312719e-08
we O 0 2.658817832568161e-09
show O 0 7.218984521273342e-09
that O 0 1.4300250983367846e-09
WT1 O 0 0.00011934965732507408
- O 0 5.939485163253266e-06
KTS O 0 6.534818385262042e-05
isoforms O 0 2.8610568136855363e-08
associate O 0 1.9730421740860038e-08
and O 0 2.580241131866501e-09
synergize O 0 2.26965821639169e-05
with O 0 1.4873239706503227e-07
SF O 1 0.7203226089477539
- O 0 2.4453951482428238e-05
1 O 0 8.168721699064463e-09
to O 0 1.3929023490177883e-09
promote O 0 8.777898585776711e-08
MIS O 0 0.002066858345642686
expression O 0 3.8027649225114146e-06
. O 0 8.012085004338587e-07

In O 0 1.2683417480729986e-06
contrast O 0 6.676810698991176e-06
, O 0 7.254280944835045e-07
WT1 O 0 0.4502226412296295
missense O 0 0.4407474100589752
mutations O 0 0.0026149186305701733
, O 0 4.461661617938262e-08
associated O 0 3.9090945591624404e-08
with O 0 9.156459590542454e-09
male B-Disease 0 2.501243898223038e-06
pseudohermaphroditism I-Disease 1 0.8705955147743225
in O 0 1.8590319541544886e-06
Denys B-Disease 1 0.9910557270050049
- I-Disease 1 0.9998412132263184
Drash I-Disease 1 0.9999275207519531
syndrome I-Disease 1 0.9999749660491943
, O 0 1.6692716542365815e-07
fail O 0 1.0982240610246663e-06
to O 0 2.3242519020527652e-09
synergize O 0 0.0001470895658712834
with O 0 1.1783515674324008e-06
SF O 1 0.9819313287734985
- O 0 0.00040157424518838525
1 O 0 5.663806064148957e-07
. O 0 3.948119626784319e-07

Additionally O 0 1.2800443982996512e-05
, O 0 6.171924837872211e-08
the O 0 3.647995328037723e-08
X O 0 9.847570618148893e-05
- O 0 4.512972736847587e-05
linked O 0 2.295840204169508e-06
, O 0 3.743417131829574e-09
candidate O 0 7.651007649656094e-08
dosage O 0 5.202631200518226e-06
- O 0 8.620965559202887e-07
sensitive O 0 3.6897436217486757e-08
sex O 0 8.436375509290883e-08
- O 0 2.5315630409750156e-06
reversal O 0 4.797047381543962e-07
gene O 0 3.054602260021966e-08
, O 0 1.5443305523277218e-09
Dax O 0 1.0598793778626714e-05
- O 0 2.236996579085826e-06
1 O 0 6.601228896840894e-09
, O 0 9.77533276547149e-10
antagonizes O 0 2.636013789469871e-07
synergy O 0 2.417390021491883e-07
between O 0 2.6617215098667657e-08
SF O 0 0.1872645765542984
- O 0 2.3354561562882736e-05
1 O 0 1.316210873625323e-08
and O 0 3.739035747685193e-09
WT1 O 0 0.0002272556012030691
, O 0 1.736549459785408e-09
most O 0 2.619353345334474e-10
likely O 0 3.8900793697393965e-10
through O 0 1.147521452860012e-10
a O 0 2.359686335218214e-10
direct O 0 5.211670539573277e-10
interaction O 0 5.083260479210594e-09
with O 0 5.850007767094212e-08
SF O 1 0.618821918964386
- O 0 0.00011049985187128186
1 O 0 3.3940372645702155e-07
. O 0 2.983848617077456e-07

We O 0 1.006707520900818e-06
propose O 0 9.981876019082847e-07
that O 0 7.700768023255478e-09
WT1 O 0 1.992033503483981e-05
and O 0 1.9328918909877757e-08
Dax O 0 0.00014315362204797566
- O 0 5.1233164413133636e-05
1 O 0 9.035833414827721e-08
functionally O 0 1.0094262279380928e-06
oppose O 0 2.6982746703652083e-08
each O 0 1.7016391073987336e-10
other O 0 6.894153997683006e-11
in O 0 6.134083241349231e-10
testis O 0 4.502724095800659e-06
development O 0 8.893977998525315e-09
by O 0 7.559949111168862e-09
modulating O 0 9.333407069789246e-05
SF O 1 0.9511412382125854
- O 0 6.34528769296594e-05
1 O 0 1.0415744355896095e-07
- O 0 5.943689757259563e-06
mediated O 0 5.5209529818966985e-06
transactivation O 0 0.00041929955477826297
. O 0 1.1612811334771322e-07
. O 0 3.695794532632135e-07

A O 0 7.792935321049299e-06
mouse O 0 2.9273713153088465e-05
model O 0 5.518226316780783e-06
for O 0 3.5618970741779776e-06
Prader B-Disease 1 0.9999767541885376
- I-Disease 1 0.9999476671218872
Willi I-Disease 1 0.9999805688858032
syndrome I-Disease 1 0.9999842643737793
imprinting O 1 0.9952661991119385
- O 0 0.4645247161388397
centre O 0 0.0007786173955537379
mutations O 0 0.002155616879463196
. O 0 2.3759257601341233e-06

Imprinting O 0 0.00023696872813161463
in O 0 2.1778444647679862e-07
the O 0 7.442263694201756e-08
15q11 O 0 0.0001906613033497706
- O 0 8.941521809902042e-05
q13 O 0 1.2125444300181698e-05
region O 0 5.8887081877401215e-08
involves O 0 2.7685022274681614e-08
an O 0 2.622253969519761e-09
imprinting O 0 9.15329837880563e-06
centre O 0 1.2929752983836806e-06
( O 0 1.3508103080539513e-08
IC O 0 4.421542143973056e-06
) O 0 2.3097830315066403e-09
, O 0 3.1704938674437244e-10
mapping O 0 1.3462218007020965e-08
in O 0 4.2354911244935067e-10
part O 0 5.369051869763553e-10
to O 0 7.413605840334014e-11
the O 0 5.254971457979707e-10
promoter O 0 1.3735100878875528e-07
and O 0 4.2262754407218495e-10
first O 0 4.0378065335744395e-09
exon O 0 5.440274890133878e-06
of O 0 3.798353631623286e-08
SNRPN O 0 0.008058857172727585
. O 0 9.393734785589913e-07

Deletion O 0 9.02409665286541e-05
of O 0 1.2913089619814855e-07
this O 0 2.3252020753261604e-08
IC O 0 3.0449655241682194e-05
abolishes O 0 3.0408071324927732e-05
local O 0 6.036477628867942e-08
paternally O 0 4.083997737325262e-06
derived O 0 2.4513960639183097e-08
gene O 0 8.629292125306165e-08
expression O 0 2.023363343539586e-08
and O 0 9.367861153464219e-09
results O 0 1.4448465890382067e-06
in O 0 1.8062255549011752e-05
Prader B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999957084655762
Willi I-Disease 1 0.9999983310699463
syndrome I-Disease 1 0.9999969005584717
( O 0 0.0003653672174550593
PWS B-Disease 1 0.9998317956924438
) O 0 3.00969509225979e-06
. O 0 1.2680889085459057e-06

We O 0 1.900713044733493e-07
have O 0 8.395407036232427e-09
created O 0 1.533497417938179e-08
two O 0 5.3278412792678864e-09
deletion O 0 3.61263555532787e-05
mutations O 0 2.32494312513154e-05
in O 0 9.278738133389197e-08
mice O 0 8.336223800142761e-06
to O 0 2.1624695367705726e-09
understand O 0 1.1072075523088643e-07
PWS B-Disease 1 0.854485034942627
and O 0 1.5600182257102801e-09
the O 0 1.0509205727871063e-09
mechanism O 0 1.6414475112469518e-08
of O 0 9.40333810817151e-10
this O 0 1.0855598198133976e-08
IC O 0 7.082435331540182e-05
. O 0 5.980883202028053e-07

Mice O 0 0.008499645628035069
harbouring O 0 0.0006992518901824951
an O 0 1.904334538949115e-07
intragenic O 0 0.00024010450579226017
deletion O 0 5.741917630075477e-05
in O 0 8.336562018484983e-08
Snrpn O 0 0.00010198096424574032
are O 0 1.3000878595903487e-08
phenotypically O 0 4.797821748070419e-05
normal O 0 6.006833928040578e-07
, O 0 7.27757454299649e-09
suggesting O 0 4.0775578469265383e-08
that O 0 8.012782659605477e-10
mutations O 0 6.598600776897001e-08
of O 0 1.1557305112930294e-09
SNRPN O 0 8.550078928237781e-05
are O 0 6.862644341687485e-10
not O 0 2.0209316164976343e-10
sufficient O 0 3.629794909087991e-09
to O 0 5.587876383827961e-09
induce O 0 4.264811650500633e-05
PWS B-Disease 1 0.9984330534934998
. O 0 1.8241379393657553e-06

Mice O 0 0.0012321432586759329
with O 0 1.4852898289063887e-07
a O 0 6.817977293849253e-08
larger O 0 8.004740692513224e-08
deletion O 0 2.3949717160576256e-06
involving O 0 1.4487676480712253e-07
both O 0 6.3687144447044375e-09
Snrpn O 0 7.0216806307144e-06
and O 0 3.308662011036745e-09
the O 0 1.675585359350862e-08
putative O 0 0.0004014661244582385
PWS O 1 0.9996274709701538
- O 0 0.002185318386182189
IC O 0 6.608144758502021e-05
lack O 0 1.6522000123586622e-07
expression O 0 1.2149209638323555e-08
of O 0 8.305589549451042e-10
the O 0 5.531082702958656e-09
imprinted O 0 1.0597814252832904e-05
genes O 0 1.0610000344968284e-07
Zfp127 O 0 8.437840733677149e-06
( O 0 4.456080393566708e-09
mouse O 0 1.303557155551971e-07
homologue O 0 2.4270991616504034e-07
of O 0 1.7515018324587572e-09
ZNF127 O 0 2.123512967955321e-05
) O 0 4.790296603829347e-09
, O 0 5.074870745858107e-09
Ndn O 0 3.212352021364495e-05
and O 0 1.705292129727809e-09
Ipw O 0 3.851519068120979e-06
, O 0 4.241386353243115e-09
and O 0 2.267000809297315e-09
manifest O 0 1.4462166575412994e-07
several O 0 9.865864569746918e-09
phenotypes O 0 0.00011192651436431333
common O 0 1.1410163551772712e-06
to O 0 7.471462595276535e-07
PWS B-Disease 1 0.999783456325531
infants O 1 0.5464096665382385
. O 0 7.106320026650792e-06

These O 0 1.3760234196524834e-07
data O 0 1.0760281554667017e-07
demonstrate O 0 5.5423427625100885e-08
that O 0 5.294217286788694e-10
both O 0 1.231493657050109e-10
the O 0 1.3549893151942882e-10
position O 0 5.736338071216096e-10
of O 0 7.248447675411995e-11
the O 0 4.658258223599887e-10
IC O 0 5.930876341153635e-07
and O 0 3.2923305748333576e-10
its O 0 3.0356009372844994e-10
role O 0 1.3536027854144095e-09
in O 0 2.6021487742333704e-10
the O 0 1.2926019976600145e-10
coordinate O 0 1.953665673681826e-09
expression O 0 2.0539834277855107e-09
of O 0 3.1823443880085733e-10
genes O 0 3.763462874672996e-09
is O 0 1.38132935645352e-10
conserved O 0 7.652707911809387e-10
between O 0 3.407183424286586e-10
mouse O 0 4.696616429100686e-08
and O 0 4.149973975575705e-10
human O 0 2.2159816204236904e-09
, O 0 9.881302442948936e-10
and O 0 1.4694706562679016e-09
indicate O 0 6.381372763542004e-09
that O 0 9.582763749182988e-11
the O 0 4.799110553399544e-10
mouse O 0 1.3959608224922704e-07
is O 0 2.550470667994631e-10
a O 0 6.443304778613879e-10
suitable O 0 7.481114394636279e-09
model O 0 1.208406530395223e-07
system O 0 2.1018558982177638e-07
in O 0 1.1215406381381854e-09
which O 0 1.0032617792088416e-10
to O 0 4.361444191913755e-11
investigate O 0 1.3770186102490811e-09
the O 0 2.0613254159140837e-10
molecular O 0 4.4007585131566884e-08
mechanisms O 0 5.6850169016797736e-09
of O 0 5.049561879744147e-10
imprinting O 0 2.0376910470076837e-06
in O 0 2.029244772216998e-09
this O 0 2.4380808483215333e-10
region O 0 3.569848194828751e-09
of O 0 3.910939905260591e-10
the O 0 7.116370159820917e-09
genome O 0 1.6333249277522555e-06
. O 0 1.952184192077766e-08
. O 0 1.0507532266501585e-07

Mutations O 0 0.0002945117303170264
of O 0 4.5270326154422946e-08
the O 0 1.8002175750098104e-08
ATM O 0 2.0952580598532222e-05
gene O 0 4.662379069486633e-06
detected O 0 1.4088126590650063e-05
in O 0 1.8499454768061696e-07
Japanese O 0 0.000416888709878549
ataxia B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999830722808838
telangiectasia I-Disease 1 0.9999972581863403
patients O 1 0.8751702308654785
: O 0 5.583308748668969e-08
possible O 0 1.3299085388496223e-08
preponderance O 0 1.6930348465393763e-06
of O 0 5.013430226519233e-10
the O 0 1.5961361121696882e-09
two O 0 9.570278791670717e-09
founder O 0 5.9250414778944105e-06
mutations O 0 1.7361950085614808e-05
4612del165 O 0 4.446497041499242e-05
and O 0 5.6228508071853867e-08
7883del5 O 0 9.759536624187604e-05
. O 0 5.246504315437051e-07

The O 0 1.6719816358090611e-06
ATM O 0 0.0007546860724687576
( O 0 2.391680482105585e-06
A O 0 0.04915625602006912
- O 1 0.9411555528640747
T O 1 0.9975333213806152
, O 0 1.1175097291982183e-08
mutated O 0 2.538297962928482e-07
) O 0 1.906560909148425e-09
gene O 0 2.2128276100374933e-08
on O 0 6.744329539287719e-09
human O 0 1.0777042547260862e-07
chromosome O 0 9.794965444598347e-05
11q22 O 0 0.00015222611546050757
. O 0 7.585488219774561e-07

3 O 0 5.464260993903736e-06
has O 0 1.8794973755120736e-07
recently O 0 3.343180026149639e-07
been O 0 6.0135376678260855e-09
identified O 0 5.577228456843386e-09
as O 0 1.9033115361555275e-10
the O 0 5.439950712116115e-10
gene O 0 1.380672287609741e-08
responsible O 0 8.512176741248823e-09
for O 0 1.9299843945219664e-09
the O 0 5.5014989897017585e-08
human O 0 7.50938052078709e-05
recessive B-Disease 1 0.9997836947441101
disease I-Disease 1 0.9999685287475586
ataxia B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999524354934692
telangiectasia I-Disease 1 0.9999890327453613
( O 0 0.00031443554325960577
A B-Disease 1 0.9939565658569336
- I-Disease 1 0.9998353719711304
T I-Disease 1 0.9998575448989868
) O 0 3.9766038639754697e-07
. O 0 4.4967578105570283e-07

In O 0 6.206927309904131e-07
order O 0 4.5387739788793624e-08
to O 0 1.4571953643738311e-09
define O 0 1.1748854333859526e-08
the O 0 1.7379045980092656e-09
types O 0 1.548546180174526e-08
of O 0 4.120966679010962e-08
disease O 0 0.04128124564886093
- O 0 0.00041698035784065723
causing O 0 3.5639084217109485e-06
ATM O 0 0.0002354534954065457
mutations O 0 3.753748023882508e-05
in O 0 5.218997856104579e-08
Japanese O 0 1.4122186257736757e-05
A B-Disease 1 0.9537460803985596
- I-Disease 1 0.9999631643295288
T I-Disease 1 0.9999932050704956
patients O 0 2.5794763132580556e-05
as O 0 4.727158664508124e-10
well O 0 3.0743904644303655e-10
as O 0 9.842698184270304e-11
to O 0 6.133986374390332e-11
look O 0 2.1893959978314115e-09
for O 0 1.9681577201335898e-10
possible O 0 4.7937520619711904e-09
mutational O 0 1.093701666832203e-05
hotspots O 0 5.267310143608483e-07
, O 0 3.215280486301708e-09
reverse O 0 2.603693758373993e-07
- O 0 4.268605096058309e-07
transcribed O 0 1.2184157682781915e-08
RNA O 0 3.3013261457881526e-08
derived O 0 6.384643924661759e-10
from O 0 3.599252007546738e-10
ten O 0 2.1120296622711976e-09
patients O 0 5.76189371770397e-08
belonging O 0 4.658660124334801e-09
to O 0 9.078628820935464e-11
eight O 0 5.110324607926486e-09
unrelated O 0 1.225232040269475e-06
Japanese O 0 3.5321293125889497e-06
A B-Disease 0 0.16399820148944855
- I-Disease 1 0.98155677318573
T I-Disease 1 0.9989738464355469
families O 0 3.0952929108707394e-08
was O 0 2.1906755520717525e-08
analyzed O 0 3.143329152521801e-08
for O 0 2.3536419480052473e-09
mutations O 0 8.813447749389525e-08
by O 0 1.9624861458122922e-10
the O 0 5.395641156091813e-10
restriction O 0 2.54192613624582e-08
endonuclease O 0 4.901597094431054e-06
fingerprinting O 0 4.981397978554014e-06
method O 0 4.258045862570725e-07
. O 0 2.748567453636497e-07

As O 0 3.597416764478112e-07
has O 0 1.1471357197478937e-07
been O 0 1.473105371019301e-08
reported O 0 5.264989155762123e-08
by O 0 1.0741857403573363e-09
others O 0 5.440576433812794e-09
, O 0 5.663955082724215e-09
mutations O 0 4.065994403390505e-07
that O 0 2.605232696240023e-10
lead O 0 1.269615346188857e-08
to O 0 3.4670361026556407e-10
exon O 0 3.5069163004664006e-06
skipping O 0 2.443382300043595e-06
or O 0 1.9742843804237964e-08
premature O 0 2.4936750833148835e-06
protein O 0 3.396506897956897e-08
truncation O 0 1.6532371205357776e-07
were O 0 1.118605319483379e-09
also O 0 6.743605673875663e-10
predominant O 0 1.721646825103562e-08
in O 0 3.943270598938398e-09
our O 0 3.033398598972781e-08
mutants O 0 8.633985089545604e-06
. O 0 3.001600816787686e-07

Six O 0 1.446480382583104e-06
different O 0 5.987879347912894e-08
mutations O 0 8.95638731890358e-06
were O 0 5.075819320410346e-09
identified O 0 7.342267238641398e-09
on O 0 6.539356278700836e-10
12 O 0 8.684896135591202e-10
of O 0 1.7347442926585188e-10
the O 0 2.621003858394033e-09
16 O 0 9.186848615172494e-08
alleles O 0 2.0581787794071715e-06
examined O 0 1.5281564628821798e-05
. O 0 4.974790499545634e-07

Four O 0 4.94237895054539e-07
were O 0 3.332350217988278e-08
deletions O 0 3.6769474718312267e-06
involving O 0 2.0433990357560106e-06
a O 0 7.176031431299634e-07
loss O 0 3.5791201753454516e-06
of O 0 1.4075537402291616e-09
a O 0 5.417009507624471e-09
single O 0 2.6084475024390485e-08
exon O 0 6.1016999097773805e-06
exon O 0 1.836813498812262e-05
7 O 0 9.514171495084156e-08
, O 0 1.019290651882443e-09
exon O 0 8.723252449271968e-07
16 O 0 1.6164586114086887e-08
, O 0 2.659223730105964e-09
exon O 0 6.162183581182035e-06
33 O 0 1.7729763612805982e-07
or O 0 2.2029018609259765e-08
exon O 0 7.63181087677367e-05
35 O 0 1.8769051166600548e-06
. O 0 4.05916011914087e-07

The O 0 3.982391660883877e-07
others O 0 4.597051628252302e-08
were O 0 2.833548506941952e-09
minute O 0 8.871681167477163e-09
deletions O 0 3.8891565168341913e-07
, O 0 3.912717705389923e-09
4649delA O 0 1.237510787177598e-06
in O 0 5.562801330682987e-09
exon O 0 4.142993475397816e-06
33 O 0 6.087653048325592e-08
and O 0 4.194499858556355e-09
7883del5 O 0 3.8971566027612425e-06
in O 0 8.700191500565779e-08
exon O 0 0.00020413615857250988
55 O 0 5.551792582991766e-06
. O 0 4.780934546033677e-07

The O 0 1.4903682767908322e-06
mutations O 0 0.00020280877652112395
4612del165 O 0 3.979554458055645e-05
and O 0 2.180387426164998e-08
7883del5 O 0 5.01473004987929e-06
were O 0 4.714843182540562e-09
found O 0 3.785449287363463e-09
in O 0 2.997300740936737e-10
more O 0 8.009508334350102e-11
than O 0 1.040068170476971e-10
two O 0 1.9887348712277486e-10
unrelated O 0 2.616819294587458e-08
families O 0 2.8653424077873524e-09
; O 0 2.1531394445162277e-09
44 O 0 8.010938579161575e-09
% O 0 8.06205380232683e-10
( O 0 2.8008773078624927e-10
7 O 0 1.94593785529662e-09
of O 0 6.915963635112377e-11
16 O 0 1.0641281189549545e-09
) O 0 8.726753347731986e-11
of O 0 4.385000001994044e-11
the O 0 3.094699219108321e-10
mutant O 0 9.963256530909348e-08
alleles O 0 7.58421325741665e-09
had O 0 3.874432996653354e-10
one O 0 5.049106618915111e-11
of O 0 8.6544986455106e-11
the O 0 9.766796260635147e-10
two O 0 2.4086862282501897e-08
mutations O 0 2.160386611649301e-05
. O 0 2.3937286641739774e-07

The O 0 2.226274546046625e-06
4612del165 O 0 0.0004724565951619297
mutations O 0 0.00013559497892856598
in O 0 2.2425274082138458e-08
three O 0 2.304194834934492e-09
different O 0 2.6265975505701533e-10
families O 0 1.1438661129403727e-09
were O 0 1.767158364085475e-10
all O 0 2.615632710423199e-11
ascribed O 0 1.3611912708100249e-09
to O 0 5.0920469230053556e-11
the O 0 6.161169352481011e-10
same O 0 2.7597820917435456e-08
T O 0 0.0076221865601837635
- O 0 1.1321605597913731e-05
- O 0 1.995970251300605e-06
> O 0 4.9635684007398595e-08
A O 0 1.4756440513963298e-09
substitution O 0 4.708944900677636e-10
at O 0 4.0542574852864277e-10
the O 0 1.626436901824846e-10
splice O 0 1.2848474284510303e-07
donor O 0 4.196494884922686e-08
site O 0 1.8368513821087618e-08
in O 0 2.3290192885383476e-08
intron O 0 0.00038751380634494126
33 O 0 2.6446327865414787e-06
. O 0 4.181322594831727e-07

Microsatellite O 0 0.0023737302981317043
genotyping O 0 0.00035629046033136547
around O 0 2.1719827714150597e-07
the O 0 3.053856190149418e-08
ATM O 0 1.1179252396686934e-05
locus O 0 2.0181649233563803e-05
also O 0 5.410083758761175e-08
indicated O 0 9.316954674432054e-08
that O 0 3.5049885216409393e-10
a O 0 3.0934381722858006e-09
common O 0 1.9769297310290312e-08
haplotype O 0 8.35155606182525e-06
was O 0 5.6038866880214755e-09
shared O 0 8.922774186181925e-10
by O 0 2.5975172013303904e-10
the O 0 6.38106512074188e-10
mutant O 0 2.1845985997970274e-07
alleles O 0 7.111596289632871e-08
in O 0 1.0011754092431602e-08
both O 0 2.998573478407707e-08
mutations O 0 2.2838230506749824e-05
. O 0 4.062769392021437e-07

This O 0 2.136984136313913e-07
suggests O 0 2.2797117082973273e-07
that O 0 1.2026225570949123e-09
these O 0 3.6468361663821725e-10
two O 0 1.814616235051858e-09
founder O 0 3.625345470936736e-06
mutations O 0 1.11138797365129e-05
may O 0 5.7186873014813955e-09
be O 0 1.3851893243543856e-10
predominant O 0 6.558646070686791e-09
among O 0 1.2768490709191838e-09
Japanese O 0 4.44882992667317e-08
ATM O 0 1.988040457945317e-05
mutant O 0 4.8521062126383185e-05
alleles O 0 8.884205271897372e-06
. O 0 6.020747491675138e-07

W474C O 0 0.0003241959202568978
amino O 0 4.157071089139208e-06
acid O 0 1.971223127839039e-06
substitution O 0 4.999512270842388e-08
affects O 0 4.8795740781315544e-08
early O 0 4.90357754401316e-09
processing O 0 2.8635829263379264e-09
of O 0 1.495968071640874e-10
the O 0 2.7702584670663555e-10
alpha O 0 7.087084696877355e-09
- O 0 1.0810635941993496e-08
subunit O 0 2.2137511823672185e-09
of O 0 6.109795447351019e-10
beta O 0 5.420106390374713e-07
- O 0 3.104305960732745e-06
hexosaminidase O 0 1.4404741705220658e-05
A O 0 8.018309927138034e-08
and O 0 3.7105896133482474e-09
is O 0 6.375642680467308e-09
associated O 0 6.524449247535813e-08
with O 0 6.138290586932271e-07
subacute O 1 0.9998237490653992
G B-Disease 1 0.9452871084213257
( I-Disease 0 5.252832693258824e-07
M2 I-Disease 0 0.014595143496990204
) I-Disease 0 1.511734666337361e-07
gangliosidosis I-Disease 0 0.0002924164291471243
. O 0 4.732531238005322e-07

Mutations O 0 0.0017865754198282957
in O 0 3.0256910577008966e-07
the O 0 4.9753687392239954e-08
HEXA O 0 0.0008868453442119062
gene O 0 1.0376759718155881e-07
, O 0 5.23240839545025e-10
encoding O 0 1.6915502332182086e-09
the O 0 3.866814091146864e-10
alpha O 0 9.623545516035392e-09
- O 0 1.553623008021532e-08
subunit O 0 5.844773998120445e-09
of O 0 9.224310204558606e-10
beta O 0 1.0293243803971563e-06
- O 0 7.445972642017296e-06
hexosaminidase O 0 1.997729305003304e-05
A O 0 5.667318703217461e-08
( O 0 2.2638033669863944e-09
Hex O 0 1.5322730462230538e-07
A O 0 6.698012366967987e-09
) O 0 3.5055502944913997e-10
, O 0 7.178691668885406e-11
that O 0 5.006661404904911e-11
abolish O 0 1.8213267338751393e-08
Hex O 0 8.719229072085e-08
A O 0 3.280843330344396e-08
enzyme O 0 1.0491626198927406e-06
activity O 0 7.637660019099712e-06
cause O 0 0.16265134513378143
Tay B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999889135360718
Sachs I-Disease 1 0.999987006187439
disease I-Disease 1 0.8966164588928223
( O 0 4.068725161232578e-07
TSD B-Disease 0 0.07135161757469177
) O 0 2.3797706916184325e-08
, O 0 5.564647853617544e-09
the O 0 3.128722170231413e-08
fatal O 0 0.022607240825891495
infantile B-Disease 0 0.018150273710489273
form I-Disease 0 2.2747209982298955e-07
of I-Disease 0 7.102947563453199e-08
G I-Disease 0 0.002063542604446411
( I-Disease 0 2.7543444858224575e-08
M2 I-Disease 0 0.00013571242743637413
) I-Disease 0 9.809610901356791e-09
gangliosidosis I-Disease 0 3.6361216189106926e-05
, I-Disease 0 1.604347232841974e-08
Type I-Disease 0 5.870170980415423e-07
1 I-Disease 0 3.002287769504619e-07
. O 0 2.078236605029815e-07

Less O 0 0.0006033320096321404
severe O 1 0.9391250610351562
, O 0 1.3791472156299278e-05
subacute O 1 0.999390721321106
( O 0 4.026262467959896e-05
juvenile O 1 0.999363124370575
- O 1 0.7834169864654541
onset O 1 0.8721591234207153
) O 0 6.265066190280777e-07
and O 0 1.3498697626346257e-06
chronic O 1 0.9520820379257202
( O 0 1.6370788102904044e-07
adult O 0 1.074670217349194e-05
- O 0 0.0075800600461661816
onset O 0 0.014711200259625912
) O 0 1.451625841752957e-08
variants O 0 1.792549966239676e-07
are O 0 1.2586608422182621e-09
characterized O 0 8.614080826419013e-08
by O 0 4.153600796641399e-10
a O 0 5.32708943623561e-09
broad O 0 9.3786987065414e-08
spectrum O 0 2.2239839836402098e-07
of O 0 6.972260546689313e-09
clinical O 0 2.556997242209036e-05
manifestations O 0 2.684428181964904e-06
and O 0 6.910577443619559e-09
are O 0 8.501366832724955e-10
associated O 0 6.05522565422234e-09
with O 0 1.5684197274268286e-09
residual O 0 9.650309493736131e-07
levels O 0 2.0466833561272324e-08
of O 0 5.900958055526928e-10
Hex O 0 3.6439135442378756e-07
A O 0 8.146335517267289e-08
enzyme O 0 8.04680439614458e-07
activity O 0 3.974136006945628e-07
. O 0 3.2553867868045927e-07

We O 0 5.678495540450967e-07
identified O 0 3.609678458360577e-07
a O 0 1.8372864474258677e-07
1422 O 0 0.00020537941600196064
G O 0 0.0012816886883229017
- O 0 0.0002223694755230099
- O 0 4.0540413465350866e-05
> O 0 1.2065931969118537e-06
C O 0 5.1128619560358857e-08
( O 0 9.965680503043473e-10
amino O 0 3.681180027470532e-09
acid O 0 2.85945827016576e-08
W474C O 0 5.045378870249806e-08
) O 0 9.402095074717565e-11
substitution O 0 2.390185549483448e-10
in O 0 1.0926235610719814e-10
the O 0 5.622906654179083e-11
first O 0 7.109687838458001e-11
position O 0 2.742379379139237e-10
of O 0 1.5248508011822537e-10
exon O 0 4.110562201731227e-07
13 O 0 5.452481577350454e-09
of O 0 9.784042465099674e-10
HEXA O 0 0.00040049655945040286
of O 0 8.79943062859212e-10
a O 0 1.1066138227988631e-08
non O 0 5.158922533610166e-08
- O 0 5.616597718471894e-06
Jewish O 0 1.8294360870640958e-07
proband O 0 0.0001626757439225912
who O 0 3.21082076482071e-08
manifested O 0 1.0637288596626604e-06
a O 0 5.04013712543383e-07
subacute O 1 0.6736711263656616
variant O 0 0.00016806682106107473
of O 0 2.4953564548013674e-07
G B-Disease 0 0.009437127970159054
( I-Disease 0 1.6282722015148465e-07
M2 I-Disease 0 0.003002815181389451
) I-Disease 0 3.229437197660445e-07
gangliosidosis I-Disease 0 0.00017899947124533355
. O 0 6.782244099667878e-07

On O 0 2.5564011707501777e-07
the O 0 3.3409293109798455e-08
second O 0 3.1446489856534754e-07
maternally O 0 8.16279134596698e-05
inherited O 0 0.0006695951451547444
allele O 0 5.4070578698883764e-06
, O 0 2.5278758641889e-08
we O 0 1.7316179601323256e-09
identified O 0 2.170214052910069e-08
the O 0 6.638527061397781e-09
common O 0 5.089169462735299e-06
infantile O 1 0.999764621257782
disease O 1 0.997816801071167
- O 0 0.0343734435737133
causing O 0 4.7926270781317726e-05
4 O 0 1.057032363860344e-06
- O 0 4.1240582504542544e-05
bp O 0 1.3885351108910982e-06
insertion O 0 4.2922280840684834e-07
, O 0 7.923364186979143e-09
+ O 0 4.5293992911865644e-07
TATC O 0 0.00011569559865165502
1278 O 0 3.505289350869134e-05
, O 0 4.226486716163436e-09
in O 0 1.1496454455084404e-08
exon O 0 2.7487887564348057e-05
11 O 0 1.1436744671300403e-06
. O 0 3.547966116457246e-07

Pulse O 0 0.0009973294800147414
- O 0 6.689132715109736e-05
chase O 0 8.639780730845814e-07
analysis O 0 1.3767724738045217e-08
using O 0 5.983264994569026e-09
proband O 0 1.423481990059372e-05
fibroblasts O 0 4.5242703095027537e-07
revealed O 0 1.2423608097833494e-07
that O 0 3.3351829631378394e-10
the O 0 3.9440581356409155e-10
W474C O 0 1.8855689631891437e-07
- O 0 4.692434885100738e-08
containing O 0 1.6451890960667015e-09
alpha O 0 1.2640867019797497e-08
- O 0 2.4395253817033336e-08
subunit O 0 5.40406830396023e-09
precursor O 0 2.04442809348393e-08
was O 0 1.4481406074295933e-09
normally O 0 7.829257242519816e-10
synthesized O 0 9.228362962687697e-09
, O 0 3.978708473795223e-10
but O 0 1.3034931467537092e-10
not O 0 3.492627714818397e-11
phosphorylated O 0 2.5512896240087457e-09
or O 0 4.75783246134398e-10
secreted O 0 4.485088744843324e-09
, O 0 1.6870127517165656e-10
and O 0 1.248831871247802e-10
the O 0 5.500643829314811e-10
mature O 0 4.67920706626046e-08
lysosomal O 0 1.7575923266122118e-05
alpha O 0 4.811011535821308e-07
- O 0 1.3652581856149482e-06
subunit O 0 1.2725590181617008e-07
was O 0 1.2805154270267849e-08
not O 0 3.708339635366542e-09
detected O 0 1.2909496263091569e-06
. O 0 1.0506570191637365e-07

When O 0 3.78300853753899e-07
the O 0 2.9122544376036785e-08
W474C O 0 2.3063387288857484e-06
- O 0 2.3536571802651451e-07
containing O 0 7.1970291948275644e-09
alpha O 0 4.191103641915106e-08
- O 0 7.884592889695341e-08
subunit O 0 4.49221424503321e-08
was O 0 7.322827677569421e-09
transiently O 0 1.7569988131072023e-06
co O 0 2.484497827026644e-06
- O 0 8.541526881344907e-07
expressed O 0 6.194338375564712e-10
with O 0 2.597358716993625e-10
the O 0 6.239040395428219e-10
beta O 0 2.539459309502945e-08
- O 0 4.553167443077655e-08
subunit O 0 2.0202659545276447e-09
to O 0 6.085090070717669e-11
produce O 0 6.95520252502746e-10
Hex O 0 7.411622959807573e-08
A O 0 5.998187280198408e-09
( O 0 1.4619335741983264e-09
alphabeta O 0 1.1183550441273837e-06
) O 0 6.755758730214723e-10
in O 0 2.2739037319752242e-09
COS O 0 3.171944263158366e-05
- O 0 4.329868716013152e-06
7 O 0 6.5636797330626e-08
cells O 0 2.5175115325737352e-08
, O 0 1.6609025266234312e-10
the O 0 1.590052117750318e-10
mature O 0 5.121438384492194e-09
alpha O 0 1.1539821542783102e-08
- O 0 3.4018363237464655e-08
subunit O 0 7.058727380382379e-09
was O 0 7.078084229839021e-10
present O 0 3.013604088497601e-10
, O 0 1.213446843006949e-10
but O 0 2.4817505689389563e-11
its O 0 8.974160303765188e-11
level O 0 1.5635452932372118e-09
was O 0 7.359060028022668e-10
much O 0 2.614357064167905e-10
lower O 0 9.97085702891809e-09
than O 0 7.876164304088107e-11
that O 0 1.5322437763032326e-11
from O 0 5.608543143797995e-11
normal O 0 1.361658674703392e-09
alpha O 0 6.2343925577579284e-09
- O 0 3.202233855859049e-08
subunit O 0 1.1382603304355143e-08
transfections O 0 2.2080016606196295e-06
, O 0 5.173244055356463e-10
although O 0 2.142376692715331e-10
higher O 0 6.468757196564923e-10
than O 0 7.737050583545013e-11
in O 0 1.304776703348054e-10
those O 0 1.578252945000358e-10
cells O 0 9.320346272545521e-09
transfected O 0 5.326619998413662e-07
with O 0 4.008277598721577e-10
an O 0 4.6447107271418986e-10
alpha O 0 1.3833404466367938e-07
- O 0 1.8581191625344218e-06
subunit O 0 4.834038804801821e-07
associated O 0 3.0910987902643683e-07
with O 0 2.93918020588535e-07
infantile O 1 0.7995738983154297
TSD B-Disease 1 0.9409201741218567
. O 0 2.8014922008878784e-06

Furthermore O 0 5.196709935262334e-06
, O 0 2.2370720387243637e-08
the O 0 2.2153985312911573e-09
precursor O 0 2.1680294892689744e-08
level O 0 3.2279385830946694e-09
of O 0 1.559868623157712e-10
the O 0 2.2573951041771068e-10
W474C O 0 1.0855602283754706e-07
alpha O 0 1.9649752047712354e-08
- O 0 9.276509160827118e-08
subunit O 0 1.4507123502482955e-08
was O 0 2.4857516045528882e-09
found O 0 7.940667012817926e-10
to O 0 1.7110318717428186e-10
accumulate O 0 9.090823738233667e-08
in O 0 2.80854839385114e-10
comparison O 0 7.451176342598842e-10
to O 0 3.789201591386515e-11
the O 0 3.1917604670361754e-10
normal O 0 1.159263529615373e-08
alpha O 0 4.112094487140894e-08
- O 0 3.288411960511439e-07
subunit O 0 2.420310352135857e-07
precursor O 0 1.3876891671316116e-06
levels O 0 1.292302158617531e-06
. O 0 3.0998307920526713e-07

We O 0 4.799362613994163e-07
conclude O 0 4.1183903931596433e-07
that O 0 4.88790874442202e-09
the O 0 1.2928277115520359e-08
1422 O 0 0.00012796485680155456
G O 0 0.0060760872438549995
- O 0 0.0005945564480498433
- O 0 0.00029326125513762236
> O 0 2.6457442800165154e-05
C O 0 2.011525111811352e-06
mutation O 0 8.167008900272776e-07
is O 0 6.482318570810719e-10
the O 0 7.482166552996716e-10
cause O 0 9.077080420638595e-09
of O 0 1.0317779963742169e-09
Hex B-Disease 0 2.4259325073217042e-05
A I-Disease 0 0.0003876100527122617
enzyme I-Disease 1 0.9939401149749756
deficiency I-Disease 1 0.9999252557754517
in O 0 5.1834426528785116e-08
the O 0 1.4280161053648044e-07
proband O 0 0.010836957022547722
. O 0 1.0372135648140102e-06

The O 0 2.5245324764000543e-07
resulting O 0 5.883560447728087e-07
W474C O 0 2.564914211689029e-06
substitution O 0 5.5932325437879626e-08
clearly O 0 1.4473322984542847e-08
interferes O 0 4.9020744796735016e-08
with O 0 1.775582125773667e-09
alpha O 0 1.9699511355497634e-08
- O 0 2.0815404511154156e-08
subunit O 0 7.729049400495569e-09
processing O 0 1.3213523608612832e-08
, O 0 9.163355629837611e-10
but O 0 1.7309864652759188e-10
because O 0 1.4156141536769695e-10
the O 0 1.0484774853880552e-10
base O 0 3.167630602263216e-09
substitution O 0 3.1031770486578125e-09
falls O 0 7.106890507202479e-07
at O 0 5.589280704931809e-10
the O 0 7.794759282475638e-11
first O 0 8.89184906260887e-11
position O 0 2.5332114184095644e-10
of O 0 1.3876828852676937e-10
exon O 0 5.159661213838262e-07
13 O 0 1.4831759820310708e-08
, O 0 5.900429034255694e-10
aberrant O 0 1.932822470962492e-07
splicing O 0 1.3046632147961645e-06
may O 0 3.340113607919193e-08
also O 0 6.401325025606752e-10
contribute O 0 2.0550376955696947e-09
to O 0 9.34408661557029e-10
Hex B-Disease 0 6.450978253269568e-05
A I-Disease 0 0.00010765668412204832
deficiency I-Disease 1 0.6930170655250549
in O 0 1.0881261225392791e-08
this O 0 4.032988165647566e-09
proband O 0 0.00011142993753310293
. O 0 3.048327812393836e-08
. O 0 2.0548981183310389e-07

Two O 0 5.1335182433831505e-06
frequent O 0 0.00018707984418142587
missense O 1 0.8908891677856445
mutations O 1 0.9623066782951355
in O 0 0.002244473434984684
Pendred B-Disease 1 0.9996919631958008
syndrome I-Disease 1 0.9999653100967407
. O 0 0.00010528932034503669

Pendred B-Disease 1 0.999900221824646
syndrome I-Disease 1 0.9999934434890747
is O 0 0.011993036605417728
an O 0 0.10904789716005325
autosomal B-Disease 1 0.9999949932098389
recessive I-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9999992847442627
characterized O 1 0.593347430229187
by O 0 5.507953119376907e-06
early O 0 0.00021537694556172937
childhood O 1 0.9980511665344238
deafness B-Disease 1 0.9999960660934448
and O 0 0.23175035417079926
goiter B-Disease 1 0.9999923706054688
. O 0 6.503399345092475e-05

A O 0 2.159968062187545e-06
century O 0 1.4713327800564002e-07
after O 0 2.654289410486399e-08
its O 0 3.6842144890414374e-09
recognition O 0 3.683485161332101e-08
as O 0 1.550083084111975e-08
a O 0 7.432017355313292e-06
syndrome O 1 0.9737340807914734
by O 0 1.4880129128869157e-08
Vaughan O 0 1.6621104350633686e-06
Pendred O 0 0.00021822916460223496
, O 0 4.0435885750866873e-08
the O 0 3.7066695313114906e-07
disease O 0 0.015441637486219406
gene O 0 2.2055521640140796e-06
( O 0 2.842839386119067e-08
PDS O 0 0.00016862459597177804
) O 0 3.2137599248471815e-09
was O 0 4.648018414599164e-09
mapped O 0 7.960206716006724e-08
to O 0 1.6747346842649335e-09
chromosome O 0 1.006472302833572e-05
7q22 O 0 0.0001826620864449069
- O 0 0.0004424024955369532
q31 O 0 0.00018518863362260163
. O 0 6.787394681850856e-07

1 O 0 1.3416790807241341e-06
and O 0 1.026420335392686e-07
, O 0 3.670069403938214e-08
recently O 0 4.417266552536603e-07
, O 0 1.1758712892273593e-09
found O 0 4.0473502327387223e-10
to O 0 1.0984408521652611e-10
encode O 0 6.631364346532109e-09
a O 0 1.974509160618254e-07
putative O 0 0.00036145735066384077
sulfate O 0 0.011262616142630577
transporter O 0 0.00520546268671751
. O 0 1.1223414730920922e-06

We O 0 3.879303278608859e-07
performed O 0 7.015310075075831e-07
mutation O 0 3.4530532957433024e-06
analysis O 0 1.1632902641167675e-08
of O 0 1.0556094887093082e-09
the O 0 1.2221444301019346e-08
PDS B-Disease 0 0.0012267072452232242
gene O 0 1.9032992213396938e-06
in O 0 3.192439379517964e-08
patients O 0 2.879935436794767e-07
from O 0 8.243674631813747e-10
14 O 0 1.3961666489592517e-08
Pendred B-Disease 0 5.127216354594566e-06
families O 0 3.3084728290333487e-09
originating O 0 4.156677668731845e-09
from O 0 4.989999524696032e-10
seven O 0 7.236599652848952e-10
countries O 0 6.435624949618912e-11
and O 0 7.529553092133767e-10
identified O 0 2.0525472876897766e-08
all O 0 4.604605141622642e-09
mutations O 0 2.126459548890125e-05
. O 0 3.0365944780896825e-07

The O 0 1.975777877305518e-06
mutations O 0 7.116339838830754e-05
include O 0 4.1678102746800505e-08
three O 0 6.4459264592642285e-09
single O 0 2.0412057821772578e-08
base O 0 1.266464408899992e-07
deletions O 0 1.458423071198922e-07
, O 0 7.388497036409092e-10
one O 0 3.787729296877984e-10
splice O 0 2.619916301682679e-07
site O 0 1.4815721272043447e-07
mutation O 0 1.1416193501645466e-06
and O 0 5.065181163388388e-09
10 O 0 2.9552182922998327e-07
missense O 0 0.0023503575939685106
mutations O 0 0.0006955525022931397
. O 0 9.68100380305259e-07

One O 0 9.092397704080213e-06
missense O 0 0.1257837414741516
mutation O 0 0.0011782196816056967
( O 0 1.1736081972912871e-07
L236P O 0 1.944130599440541e-05
) O 0 7.666942636319618e-09
was O 0 6.101879002073929e-09
found O 0 1.2813576866221865e-09
in O 0 5.742183395440748e-10
a O 0 1.13721867478489e-08
homozygous O 0 6.07804679475521e-07
state O 0 4.136951670119515e-09
in O 0 4.048848201154698e-10
two O 0 6.696003751471835e-10
consanguineous O 0 9.345284524897579e-06
families O 0 7.897412501733925e-09
and O 0 1.5717439572071612e-09
in O 0 1.8285554181929342e-09
a O 0 1.6313286721469922e-08
heterozygous O 0 1.1218412510061171e-07
state O 0 2.2164761137588584e-09
in O 0 4.234553818704967e-10
five O 0 7.880014973871141e-10
additional O 0 3.2779456926590456e-09
non O 0 3.081841271068697e-07
- O 0 0.0004267081094440073
consanguineous O 0 0.0024403005372732878
families O 0 1.008831532089971e-06
. O 0 7.109059652066207e-07

Another O 0 6.353631033562124e-05
missense O 0 0.34773433208465576
mutation O 0 0.006576918065547943
( O 0 1.9840186382680258e-07
T416P O 0 1.18993702926673e-05
) O 0 6.537364427572356e-09
was O 0 5.963963989330523e-09
found O 0 1.5246596207774132e-09
in O 0 3.865988362772299e-10
a O 0 1.042659292238568e-08
homozygous O 0 2.9055530603727675e-07
state O 0 2.6898923088936044e-09
in O 0 3.3665317755726676e-10
one O 0 2.2568612256801401e-10
family O 0 2.474535687468915e-09
and O 0 2.889218864154941e-10
in O 0 9.70695968049995e-10
a O 0 2.5280106896730103e-08
heterozygous O 0 5.448527531370928e-07
state O 0 6.435680433014568e-09
in O 0 3.3786977660099637e-09
four O 0 9.684087309835832e-09
families O 0 1.278398968906913e-07
. O 0 3.641492014594405e-07

Pendred B-Disease 1 0.8783309459686279
patients O 0 0.0018411320634186268
in O 0 8.721624311647247e-08
three O 0 2.4422440958460356e-08
non O 0 1.5538429920525232e-07
- O 0 9.42751194088487e-06
consanguineous O 0 6.409941852325574e-05
families O 0 2.3356921730055547e-08
were O 0 1.7881467417879549e-09
shown O 0 1.5648640161458616e-09
to O 0 8.027219167150434e-11
be O 0 2.1004185890571847e-10
compound O 0 4.3798241478043565e-08
heterozygotes O 0 9.434440357836138e-07
for O 0 8.109744875639535e-09
L236P O 0 2.0250687157385983e-05
and O 0 7.655912526161046e-08
T416P O 0 0.00011935090878978372
. O 0 8.539759051018336e-07

In O 0 2.3532217596766714e-07
total O 0 3.4797860593016594e-08
, O 0 2.992424086301071e-09
one O 0 4.144017906604347e-10
or O 0 2.428788836716933e-10
both O 0 6.219362524984007e-11
of O 0 2.727855719086847e-10
these O 0 6.185023604388107e-10
mutations O 0 1.8170560167618532e-07
were O 0 3.175638363384081e-10
found O 0 3.4881689203736244e-10
in O 0 1.4874013132271102e-10
nine O 0 3.3474001348565707e-10
of O 0 1.8710821780842934e-10
the O 0 1.3652631247751401e-09
14 O 0 3.406017512475046e-08
families O 0 4.9604736318542564e-08
analyzed O 0 2.071537892334163e-06
. O 0 3.509628925257857e-07

The O 0 3.1946817102834757e-07
identification O 0 2.552936848587706e-07
of O 0 7.922547951011438e-09
two O 0 1.7562930665349086e-08
frequent O 0 3.563758809832507e-06
PDS B-Disease 0 0.11912869662046432
mutations O 0 1.9060011254623532e-05
will O 0 1.045071917893381e-09
facilitate O 0 4.899931571600291e-09
the O 0 2.8843929911204214e-08
molecular O 0 0.0004098642966710031
diagnosis O 1 0.708533525466919
of O 0 0.00013596811913885176
Pendred B-Disease 1 0.9999731779098511
syndrome I-Disease 1 0.9999914169311523
. O 0 4.088728383067064e-05

Insertional O 0 0.0337614007294178
mutation O 0 0.0011063895653933287
by O 0 1.2917659830691264e-07
transposable O 0 8.367912960238755e-05
element O 0 5.442145720735425e-07
, O 0 2.0766073305367172e-08
L1 O 0 5.0392372941132635e-05
, O 0 4.008065435101571e-09
in O 0 2.927802889018949e-09
the O 0 3.5059212422083874e-08
DMD B-Disease 1 0.9994708895683289
gene O 0 1.1303566679998767e-05
results O 0 1.4723688082085573e-06
in O 0 3.4267102932972193e-07
X B-Disease 1 0.7682305574417114
- I-Disease 1 0.9929012656211853
linked I-Disease 1 0.9560425281524658
dilated I-Disease 1 0.9997046589851379
cardiomyopathy I-Disease 1 0.9999613761901855
. O 0 1.7539536202093586e-05

X B-Disease 1 0.9965364933013916
- I-Disease 1 0.997414231300354
linked I-Disease 1 0.9821352958679199
dilated I-Disease 1 0.999705970287323
cardiomyopathy I-Disease 1 0.999983549118042
( O 0 9.857976692728698e-06
XLDCM B-Disease 0 0.0277948509901762
) O 0 3.161319028777143e-08
is O 0 8.781980476157969e-09
a O 0 1.6191360430184432e-07
clinical O 0 4.694414383266121e-05
phenotype O 0 2.9617616746691056e-05
of O 0 1.9312004440052988e-08
dystrophinopathy B-Disease 0 0.0034778390545397997
which O 0 1.3032360079989758e-08
is O 0 5.930998359104933e-09
characterized O 0 3.735253244485648e-07
by O 0 6.444573763531025e-09
preferential O 0 4.367271685623564e-06
myocardial B-Disease 1 0.9995158910751343
involvement I-Disease 0 5.776060788775794e-06
without O 0 3.561410011343469e-08
any O 0 3.106481294423702e-09
overt O 0 8.214744866563706e-07
clinical O 0 0.0011941707925871015
signs O 0 6.178467447170988e-05
of O 0 7.971029845066369e-06
skeletal B-Disease 1 0.9999364614486694
myopathy I-Disease 1 0.9999878406524658
. O 0 6.104732165113091e-05

To O 0 1.333995385266462e-07
date O 0 1.5544743803275196e-07
, O 0 4.6700034950220015e-09
several O 0 4.4296921686282076e-09
mutations O 0 1.3338317330635618e-06
in O 0 2.9230168507865528e-08
the O 0 1.1880499641847564e-06
Duchenne B-Disease 1 0.9999300241470337
muscular I-Disease 1 0.9998819828033447
dystrophy I-Disease 1 0.9998924732208252
gene O 0 0.0012154983123764396
, O 0 1.61940465659427e-06
DMD O 1 0.9996981620788574
, O 0 3.315460972430628e-08
have O 0 2.9846889404439025e-09
been O 0 7.673115476336534e-09
identified O 0 1.354787144691727e-07
in O 0 4.4972722434977186e-08
patients O 0 3.3057006021408597e-06
with O 0 1.4896030187117049e-08
XLDCM B-Disease 0 0.005589188542217016
, O 0 7.207564767242047e-09
but O 0 4.250057250576589e-10
a O 0 1.5289346455560349e-09
pathogenic O 0 1.4507816281650321e-08
correlation O 0 2.2334383231736865e-09
of O 0 2.3610460808676237e-10
these O 0 6.6591948622019e-10
cardiospecific O 0 0.00026110169710591435
mutations O 0 2.8347387342364527e-05
in O 0 1.0530122551699606e-07
DMD O 1 0.9893184304237366
with O 0 3.5220676153358e-08
the O 0 5.044532258580148e-08
XLDCM B-Disease 0 0.12436086684465408
phenotype O 0 0.0005345343961380422
has O 0 1.5157846533497832e-08
remained O 0 2.228023099348775e-08
to O 0 5.063343633260331e-10
be O 0 4.30973168263904e-09
elucidated O 0 1.2657712431973778e-05
. O 0 3.550748601810483e-07

We O 0 5.795123456664442e-07
report O 0 3.409494908623856e-08
here O 0 1.0392953164739538e-09
the O 0 2.995174941400336e-10
identification O 0 1.891990786262454e-09
of O 0 2.864739556684981e-10
a O 0 3.7642813310867496e-09
unique O 0 7.008232660865588e-09
de O 0 2.3549235095288168e-07
novo O 0 6.835607564426027e-07
L1 O 0 2.6616562536219135e-06
insertion O 0 1.283546851027495e-07
in O 0 1.4996827113478162e-09
the O 0 2.0830606128896534e-09
muscle O 0 2.9539291972469073e-06
exon O 0 7.928285413072444e-06
1 O 0 6.200076541063027e-08
in O 0 9.9274046760911e-08
DMD O 1 0.9948710203170776
in O 0 5.170231176521156e-08
three O 0 1.512011493787213e-07
XLDCM B-Disease 0 0.33269500732421875
patients O 0 1.1587434528337326e-05
from O 0 2.872318827229492e-09
two O 0 6.8719208101697404e-09
unrelated O 0 2.6912900921161054e-06
Japanese O 0 9.32964894673205e-07
families O 0 3.004344364399003e-07
. O 0 5.568949745793361e-07

The O 0 2.786010213640111e-07
insertion O 0 5.657152087223949e-06
was O 0 9.831209979438427e-08
a O 0 4.1279054840970275e-08
5 O 0 5.00090457933311e-08
- O 0 8.380833378396346e-07
truncated O 0 8.758917147133616e-08
form O 0 1.4907336476355226e-09
of O 0 2.2350907236123874e-10
human O 0 3.0421696273208454e-09
L1 O 0 3.625241788540734e-06
inversely O 0 8.883707636186955e-08
integrated O 0 4.539527154179268e-08
in O 0 1.4815720872363158e-09
the O 0 2.1012691586719257e-09
5 O 0 3.4147468852552265e-08
- O 0 3.2277728223562008e-06
untranslated O 0 2.753998387561296e-06
region O 0 3.746905008483736e-08
in O 0 1.6268131286523158e-09
the O 0 1.3898769912756848e-09
muscle O 0 2.132197323589935e-06
exon O 0 5.061696811026195e-06
1 O 0 1.530096582769147e-08
, O 0 6.391296936136825e-10
which O 0 2.366307150225566e-10
affected O 0 8.541122253902245e-10
the O 0 1.328431809000108e-10
transcription O 0 2.7345825603930507e-09
or O 0 3.198994680264633e-10
the O 0 1.756492451487901e-10
stability O 0 5.312721818029331e-09
of O 0 1.710901420537425e-10
the O 0 1.88541271484155e-09
muscle O 0 5.332327646101476e-07
form O 0 1.3371160845210284e-09
of O 0 7.49659390120172e-10
dystrophin O 0 3.2361138437408954e-05
transcripts O 0 1.5213552728710056e-07
but O 0 1.082554934583868e-09
not O 0 5.1697694736230204e-11
that O 0 1.6228011989749547e-11
of O 0 9.948317170049847e-11
the O 0 5.271850067600781e-09
brain O 0 4.297316991141997e-05
or O 0 3.314955421274135e-08
Purkinje O 0 0.002933164592832327
cell O 0 3.103217386524193e-05
form O 0 4.793059815710876e-08
, O 0 6.569851773718938e-09
probably O 0 5.822186732729051e-09
due O 0 1.4887757693315962e-09
to O 0 3.866037698307956e-11
its O 0 4.156755217810115e-10
unique O 0 1.179780273474762e-09
site O 0 1.2794217241207662e-08
of O 0 2.4861925851382694e-09
integration O 0 6.389060445144423e-07
. O 0 3.431321431435208e-07

We O 0 6.352236141538015e-07
speculate O 0 3.554655165771692e-07
that O 0 1.0422929186404417e-09
this O 0 8.461890216304724e-11
insertion O 0 4.188911439939602e-09
of O 0 1.7396316331907968e-10
an O 0 5.317087881095972e-10
L1 O 0 2.5974564778152853e-05
sequence O 0 1.8752467667582096e-07
in O 0 1.1452731740746458e-07
DMD O 1 0.9898431897163391
is O 0 7.228532883374328e-09
responsible O 0 5.979396977551232e-09
for O 0 1.1609329469974838e-10
some O 0 1.8602279439061675e-11
of O 0 6.714237499316766e-11
the O 0 2.991264180796094e-10
population O 0 4.973323974866162e-10
of O 0 1.6339436470502733e-09
Japanese O 0 2.4527487312298035e-06
patients O 0 1.6922222130233422e-05
with O 0 8.212201407786779e-08
XLDCM B-Disease 0 0.059981733560562134
. O 0 6.148894726720755e-08
. O 0 2.3845058194638113e-07

Severe O 1 0.9625334739685059
early O 0 0.0011206308845430613
- O 1 0.9940488338470459
onset O 1 0.9998376369476318
obesity B-Disease 1 0.9999728202819824
, O 0 0.0003008712374139577
adrenal B-Disease 1 0.999927282333374
insufficiency I-Disease 1 0.9999537467956543
and O 0 5.64964248042088e-05
red O 0 0.467585951089859
hair O 1 0.967574954032898
pigmentation O 1 0.5844523310661316
caused O 0 3.4162119845859706e-05
by O 0 5.921912702433474e-07
POMC O 1 0.9940813183784485
mutations O 0 0.0004872645949944854
in O 0 8.71382610512228e-08
humans O 0 5.35977733306936e-07
. O 0 3.327790238927264e-07

Sequential O 0 1.3931128705735318e-05
cleavage O 0 7.25102872820571e-05
of O 0 1.492902512723049e-08
the O 0 1.0287720009216628e-08
precursor O 0 1.5681251852583955e-07
protein O 0 2.3609545962699485e-07
pre O 0 1.3357423995330464e-05
- O 0 1.7531692719785497e-05
pro O 0 3.4591871553857345e-06
- O 0 2.6060162781504914e-05
opiomelanocortin O 0 4.347679714555852e-05
( O 0 1.6418358228520447e-08
POMC O 0 4.820936737814918e-05
) O 0 1.4240668644305288e-09
generates O 0 2.9261728595741943e-09
the O 0 2.658077535855341e-09
melanocortin O 0 0.0002932187635451555
peptides O 0 1.9681724552356172e-06
adrenocorticotrophin O 0 6.138942262623459e-05
( O 0 1.5009771203722266e-08
ACTH O 0 5.296922608977184e-06
) O 0 4.354931526506789e-09
, O 0 5.155614601903835e-09
melanocyte O 0 0.0008984587620943785
- O 0 5.1303766667842865e-05
stimulating O 0 1.741052869874693e-06
hormones O 0 4.845933858632634e-07
( O 0 2.3798421011633764e-09
MSH O 0 1.2977601727470756e-05
) O 0 2.960212353020353e-10
alpha O 0 2.8145559216596894e-09
, O 0 1.5216838900045104e-10
beta O 0 3.891335698114062e-09
and O 0 6.725824064357511e-11
gamma O 0 6.788557715964316e-09
as O 0 4.775440459736657e-11
well O 0 6.617938835828951e-11
as O 0 6.784887929267569e-11
the O 0 6.504760619030492e-10
opioid O 0 1.5262947954397532e-06
- O 0 2.6508444079809124e-06
receptor O 0 8.149876862262317e-07
ligand O 0 3.3195851756318007e-06
beta O 0 6.929950905032456e-05
- O 0 0.0002382912061875686
endorphin O 0 0.0013123212847858667
. O 0 9.491674859418708e-07

While O 0 1.0402080761195975e-06
a O 0 3.2707876584936457e-07
few O 0 4.007777221204378e-08
cases O 0 7.296564064063205e-08
of O 0 6.17946298575589e-08
isolated O 0 0.012429497204720974
ACTH B-Disease 1 0.9985402822494507
deficiency I-Disease 1 0.9950883984565735
have O 0 4.7712326534110616e-08
been O 0 4.702765821207322e-08
reported O 0 1.3141961971996352e-06
( O 0 6.924842921307572e-08
OMIM O 0 0.23677586019039154
201400 O 0 8.94980548764579e-05
) O 0 1.1131148447418582e-08
, O 0 3.952102645143896e-09
an O 0 3.5584225344109655e-08
inherited O 1 0.8536314368247986
POMC O 1 0.9998346567153931
defect O 0 0.24593478441238403
has O 0 4.501640660237172e-08
not O 0 5.926223400898323e-10
been O 0 3.084729804925246e-09
described O 0 2.823623113101803e-08
so O 0 3.652616209492976e-09
far O 0 5.62345192633984e-08
. O 0 9.395493805186561e-08

Recent O 0 6.0530674090841785e-06
studies O 0 3.4179794283772935e-07
in O 0 1.3519239061565713e-08
animal O 0 6.285617359935713e-08
models O 0 3.9877456003978295e-08
elucidated O 0 3.663852510271681e-07
a O 0 4.23885504474697e-09
central O 0 2.618605332571633e-09
role O 0 3.4645655233589423e-09
of O 0 1.5395572594556484e-09
alpha O 0 1.6834839016155456e-06
- O 0 4.618967795977369e-05
MSH O 0 0.0006704402039758861
in O 0 9.130939893076118e-10
the O 0 1.8455306727283016e-10
regulation O 0 2.652283948023637e-09
of O 0 8.601885870263004e-11
food O 0 8.130571771403083e-10
intake O 0 1.060451282342001e-08
by O 0 1.7806106589191018e-10
activation O 0 5.578398631911341e-09
of O 0 4.898658145791046e-10
the O 0 8.239780413532571e-09
brain O 0 2.871623291866854e-05
melanocortin O 0 0.005155647173523903
- O 0 7.758275387459435e-06
4 O 0 1.3537085408188432e-07
- O 0 1.1068396815971937e-05
receptor O 0 2.8579590889421524e-06
( O 0 4.5070702725524825e-08
MC4 O 0 0.137815460562706
- O 0 0.0002419627708150074
R O 0 2.65613471128745e-05
; O 0 1.890007039762054e-09
refs O 0 7.473700947002726e-08
3 O 0 1.663764059856021e-08
- O 0 5.787799750578415e-07
5 O 0 3.5367679895870197e-09
) O 0 1.8977582005863525e-10
and O 0 8.066756984614898e-11
the O 0 1.3110432184326726e-10
linkage O 0 4.098516726003254e-08
of O 0 3.805792125888274e-09
human O 0 5.356425276659138e-07
obesity B-Disease 0 0.06561791151762009
to O 0 1.0980077957967183e-09
chromosome O 0 1.6354650824723649e-06
2 O 0 5.068660602347563e-09
in O 0 3.562962425096572e-10
close O 0 1.8866286310981195e-09
proximity O 0 8.25349566468958e-09
to O 0 1.729164866848265e-10
the O 0 1.6814786230057166e-09
POMC O 0 0.00019759361748583615
locus O 0 5.718068223359296e-07
, O 0 9.97956606241246e-10
led O 0 1.952697115115143e-09
to O 0 5.5776487595249336e-11
the O 0 3.787382629738545e-10
proposal O 0 4.557474397870465e-09
of O 0 1.2352223410783125e-10
an O 0 3.861507502644912e-10
association O 0 1.2073348543140128e-08
of O 0 5.046569828692782e-09
POMC O 0 0.1906961053609848
with O 0 1.0042048188552144e-06
human O 0 3.267271677032113e-05
obesity B-Disease 1 0.9942828416824341
. O 0 2.309400088051916e-06

The O 0 1.2373084246064536e-07
dual O 0 6.418214866243943e-07
role O 0 1.45039209087372e-07
of O 0 1.4669201853223512e-08
alpha O 0 5.842887276230613e-06
- O 0 4.24440331698861e-05
MSH O 0 0.0002329285634914413
in O 0 1.2644140179318697e-09
regulating O 0 3.904377621211097e-08
food O 0 4.8212878134279435e-09
intake O 0 1.0841655750937207e-07
and O 0 1.7312876687824996e-09
influencing O 0 2.8544025099108694e-07
hair O 0 0.17596295475959778
pigmentation O 0 0.188396155834198
predicts O 0 2.6010009605670348e-05
that O 0 1.2814114214165784e-09
the O 0 6.1212297453039355e-09
phenotype O 0 2.5041294065886177e-05
associated O 0 6.864744506174247e-08
with O 0 6.746825764736286e-09
a O 0 5.240438554210414e-07
defect O 0 0.0009060527663677931
in O 0 6.390108353571122e-08
POMC O 0 0.02218112349510193
function O 0 2.220095467464489e-07
would O 0 1.935005400355294e-08
include O 0 7.026243338259519e-07
obesity B-Disease 1 0.9127480983734131
, O 0 2.2110937081265547e-08
alteration O 0 1.0301807378709782e-05
in O 0 4.927271675114753e-07
pigmentation O 0 0.39771977066993713
and O 0 4.6887060307199135e-05
ACTH B-Disease 1 0.9986926913261414
deficiency I-Disease 1 0.9992300271987915
. O 0 2.866333488782402e-06

The O 0 5.377614229473693e-07
observation O 0 3.1401764317706693e-06
of O 0 3.034220341646687e-08
these O 0 1.811121208561417e-08
symptoms O 0 1.9651773982332088e-05
in O 0 1.5482471971139944e-09
two O 0 2.470220694661407e-09
probands O 0 3.1842399039305747e-05
prompted O 0 7.860028006234643e-08
us O 0 9.936071965199744e-10
to O 0 5.965061083967882e-11
search O 0 3.520198799122909e-09
for O 0 1.286068584960276e-09
mutations O 0 2.6366600991423184e-07
within O 0 5.3899449348193684e-09
their O 0 3.7913906680842047e-08
POMC O 0 0.03485018387436867
genes O 0 5.236150173004717e-06
. O 0 5.418540354185097e-07

Patient O 0 0.00287787732668221
1 O 0 9.230546424987551e-07
was O 0 1.0122819560365315e-07
found O 0 3.5422633715143093e-09
to O 0 1.7581214262207823e-10
be O 0 7.7134604259399e-11
a O 0 1.9872798961984017e-09
compound O 0 6.477554137518382e-08
heterozygote O 0 1.4805834780418081e-06
for O 0 9.052679161847266e-10
two O 0 2.9175235560785495e-09
mutations O 0 3.170262061757967e-07
in O 0 3.3295024515211935e-09
exon O 0 3.4162433166784467e-06
3 O 0 2.911287921847361e-08
( O 0 3.7241461026127354e-09
G7013T O 0 1.0787709925352829e-06
, O 0 3.0775602066768215e-09
C7133delta O 0 5.600999884336488e-06
) O 0 4.762090166643418e-10
which O 0 8.126474493330704e-11
interfere O 0 3.5010466747920077e-10
with O 0 7.058249124058946e-11
appropriate O 0 1.6405569958077848e-10
synthesis O 0 1.947564109983091e-09
of O 0 9.488411167879462e-10
ACTH O 0 6.687306267849635e-06
and O 0 2.7584505346567312e-08
alpha O 0 5.065283039584756e-05
- O 0 0.004630302544683218
MSH O 0 0.19013075530529022
. O 0 1.3275334822537843e-06

Patient O 0 0.0026444268878549337
2 O 0 1.0089007673741435e-06
was O 0 1.0177801357258431e-07
homozygous O 0 7.877405323597486e-07
for O 0 2.343759630818454e-09
a O 0 5.836755789800918e-08
mutation O 0 2.1298824322002474e-06
in O 0 7.839153326472115e-09
exon O 0 4.5492624849430285e-06
2 O 0 4.010231435813694e-08
( O 0 9.014673452156785e-09
C3804A O 0 2.3359341412287904e-06
) O 0 3.6746277132237992e-09
which O 0 9.78464509415744e-09
abolishes O 0 0.00013333099195733666
POMC O 0 0.04861292988061905
translation O 0 1.0793370393002988e-06
. O 0 5.236407218944805e-07

These O 0 3.32806337155489e-07
findings O 0 2.2160762114253885e-07
represent O 0 7.163557746991955e-09
the O 0 1.0416072449004332e-09
first O 0 7.099771881513561e-10
examples O 0 2.4881232629780925e-09
of O 0 4.692709776321635e-09
a O 0 5.626976872008527e-06
genetic B-Disease 1 0.5728022456169128
defect I-Disease 0 0.482744961977005
within O 0 3.353282451712403e-08
the O 0 2.5049908813912225e-08
POMC O 0 0.010129847563803196
gene O 0 1.1848032244188289e-07
and O 0 1.209426891968235e-09
define O 0 2.1957790252713494e-08
a O 0 1.1276591749265208e-07
new O 0 2.8716303859255277e-06
monogenic B-Disease 1 0.9982233643531799
endocrine I-Disease 1 0.9996753931045532
disorder I-Disease 1 0.9108629822731018
resulting O 0 7.291468136827461e-06
in O 0 2.8828205245190475e-07
early O 0 1.7508151358924806e-05
- O 1 0.9819855690002441
onset O 1 0.9997954964637756
obesity B-Disease 1 0.9999778270721436
, O 0 0.0002451202308293432
adrenal B-Disease 1 0.999927282333374
insufficiency I-Disease 1 0.999932050704956
and O 0 1.7439246221329086e-05
red O 0 0.2911415994167328
hair O 1 0.9273115992546082
pigmentation O 1 0.5526067018508911
. O 0 3.294938437647943e-07
. O 0 8.123167276608001e-07

A O 0 1.2497749594331253e-05
European O 0 8.375596735277213e-06
multicenter O 1 0.689032793045044
study O 0 6.077702892071102e-06
of O 0 6.868752279842738e-06
phenylalanine B-Disease 1 0.9999186992645264
hydroxylase I-Disease 1 0.9999815225601196
deficiency I-Disease 1 0.999994158744812
: O 0 5.189348257772508e-07
classification O 0 2.9041755169600947e-06
of O 0 3.229989165021152e-09
105 O 0 3.007939426424855e-07
mutations O 0 2.7995665732305497e-06
and O 0 5.768397981498197e-10
a O 0 4.875859271891159e-09
general O 0 3.041507934398169e-09
system O 0 6.839416499815343e-08
for O 0 7.758323761208885e-09
genotype O 0 1.5460043869097717e-05
- O 0 2.8333632144494914e-05
based O 0 6.947042408000925e-08
prediction O 0 9.487747547609615e-07
of O 0 4.122279761986647e-08
metabolic O 0 0.043576713651418686
phenotype O 0 0.011359047144651413
. O 0 8.487893410347169e-07

Phenylketonuria B-Disease 1 0.9957797527313232
( O 0 0.0001919267961056903
PKU B-Disease 1 0.9935983419418335
) O 0 1.0511155323911225e-06
and O 0 1.6907468989302288e-06
mild B-Disease 1 0.6344941258430481
hyperphenylalaninemia I-Disease 1 0.9999657869338989
( O 0 0.00017218645371031016
MHP B-Disease 1 0.9999650716781616
) O 0 3.1603124739376653e-07
are O 0 2.1463344523908745e-07
allelic B-Disease 1 0.8382867574691772
disorders I-Disease 1 0.9972569346427917
caused O 0 3.0892129871062934e-05
by O 0 5.248866230544991e-08
mutations O 0 2.953717739728745e-06
in O 0 2.3824124895099885e-09
the O 0 1.8401853374427901e-09
gene O 0 7.289470005389376e-08
encoding O 0 1.1311635716992896e-06
phenylalanine O 0 0.0075081223621964455
hydroxylase O 1 0.9158421754837036
( O 0 2.2585900296689942e-05
PAH O 1 0.999505877494812
) O 0 4.1612420886849577e-07
. O 0 5.146308694747859e-07

Previous O 0 7.94481638877187e-06
studies O 0 7.898408398432366e-07
have O 0 8.149051211603364e-09
suggested O 0 2.5307029360988054e-08
that O 0 5.593610574727848e-10
the O 0 1.2020263673306886e-09
highly O 0 5.550583992430802e-08
variable O 0 2.2664547941531055e-05
metabolic O 0 0.16824744641780853
phenotypes O 0 0.20216557383537292
of O 0 0.0009320079116150737
PAH B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9999377727508545
correlate O 0 0.0018501987215131521
with O 0 0.00013769454380962998
PAH O 1 0.9998612403869629
genotypes O 0 0.12124554067850113
. O 0 2.7119663172925357e-06

We O 0 8.436099960817955e-07
identified O 0 7.308674412342953e-07
both O 0 4.529364616701059e-08
causative O 0 0.00035356258740648627
mutations O 0 0.00021173973800614476
in O 0 9.890172947280007e-08
686 O 0 0.00014396249025594443
patients O 0 1.5106094906514045e-05
from O 0 8.005759610796304e-09
seven O 0 2.868909376729789e-08
European O 0 8.470703249940925e-08
centers O 0 1.542831910228415e-06
. O 0 5.618722411782073e-07

On O 0 6.487482551165158e-08
the O 0 3.161781281235676e-09
basis O 0 1.3517271746366077e-09
of O 0 1.8610522845019517e-10
the O 0 5.221122978404935e-10
phenotypic O 0 1.2439316776635678e-07
characteristics O 0 3.214104538074025e-08
of O 0 5.856536144932534e-09
297 O 0 5.553057690121932e-06
functionally O 0 0.0009810428600758314
hemizygous O 0 0.09567798674106598
patients O 0 1.0444662621011958e-05
, O 0 4.760419280991357e-10
105 O 0 1.0582018594718079e-09
of O 0 1.031476432045153e-10
the O 0 9.709569814830843e-10
mutations O 0 4.5451500341187057e-08
were O 0 1.1139270755800013e-10
assigned O 0 6.599362167847289e-10
to O 0 1.5178741943899787e-11
one O 0 5.1891522329094997e-11
of O 0 8.610109847317915e-11
four O 0 2.9661482159326624e-09
arbitrary O 0 1.2939050009208586e-07
phenotype O 0 0.00013683618453796953
categories O 0 2.124516868207138e-06
. O 0 6.216933456926199e-07

We O 0 1.2087424465789809e-06
proposed O 0 9.967587857317994e-07
and O 0 1.6875517871994816e-08
tested O 0 1.6020163684515865e-07
a O 0 3.6091534205695552e-09
simple O 0 4.2722474447032255e-09
model O 0 3.61448537766762e-09
for O 0 1.8960215342200826e-10
correlation O 0 5.508352440841691e-09
between O 0 3.6325513708135304e-09
genotype O 0 5.822478783557017e-07
and O 0 1.1184160264576803e-08
phenotypic O 0 3.484273111098446e-05
outcome O 0 1.106476611312246e-05
. O 0 1.0324281447537942e-06

The O 0 3.3096468996518524e-06
observed O 0 9.236673577106558e-06
phenotype O 0 0.0007675071246922016
matched O 0 4.5804799810866825e-06
the O 0 2.9542139401428358e-08
predicted O 0 4.585719750593853e-07
phenotype O 0 2.365196451137308e-06
in O 0 2.920841790654549e-09
79 O 0 3.8618797049139175e-08
% O 0 9.511423870733893e-10
of O 0 1.850264247371669e-10
the O 0 1.0833129948650821e-09
cases O 0 1.3116047803407582e-08
, O 0 5.821195747657271e-10
and O 0 3.6549838156041403e-10
in O 0 3.086069733093666e-10
only O 0 4.642865952808606e-11
5 O 0 8.463895695420831e-10
of O 0 5.44460143636627e-10
184 O 0 7.034953455331561e-07
patients O 0 5.059737304691225e-06
was O 0 1.1880183947710066e-08
the O 0 2.9357154485154524e-09
observed O 0 4.231102579410617e-08
phenotype O 0 3.0277314522209053e-07
more O 0 9.16331593936448e-11
than O 0 1.0399690136830841e-10
one O 0 1.7502387039680656e-10
category O 0 2.649775954211009e-09
away O 0 1.0114626913804159e-09
from O 0 7.420740133490256e-10
that O 0 9.601686112858943e-10
expected O 0 4.005774911775006e-08
. O 0 1.2503078039571847e-07

Among O 0 2.1099414482250722e-07
the O 0 1.849355868444036e-08
seven O 0 1.3902170081792065e-08
contributing O 0 2.5925752211719555e-08
centers O 0 4.063249292585169e-08
, O 0 5.935906766119103e-10
the O 0 8.975706289326979e-10
proportion O 0 3.1720215787345296e-08
of O 0 4.1504986114659914e-09
patients O 0 1.7547715742693981e-06
for O 0 1.110683767180376e-09
whom O 0 4.605360537368597e-09
the O 0 4.731536051849616e-09
observed O 0 1.689534911974988e-07
phenotype O 0 6.53152392260381e-06
did O 0 1.0106913084229063e-09
not O 0 4.591059823977339e-11
match O 0 9.36975164123055e-10
the O 0 1.6417284198766424e-09
predicted O 0 1.25765652114751e-07
phenotype O 0 3.760146967124456e-07
was O 0 1.85527615492731e-09
4 O 0 6.550832321039479e-09
% O 0 6.512747230402738e-09
- O 0 1.4149346725389478e-06
23 O 0 5.749642539853994e-08
% O 0 8.720306254872412e-09
( O 0 1.111729197589284e-08
P O 0 2.7717213015421294e-05
< O 0 9.086001000468968e-07
. O 0 6.714958034059748e-10
0001 O 0 1.5017466239442001e-06
) O 0 1.184449760494033e-09
, O 0 4.1177883325360654e-10
suggesting O 0 3.148788119133883e-09
that O 0 5.504219649510311e-11
differences O 0 4.361895289406448e-10
in O 0 1.9411953988690556e-10
methods O 0 5.466661567865572e-10
used O 0 4.089376892668639e-10
for O 0 3.1025495506042944e-09
mutation O 0 5.973853149043862e-06
detection O 0 5.137749758432619e-05
or O 0 4.423337145453843e-07
phenotype O 0 0.002846166491508484
classification O 0 4.931233706884086e-05
may O 0 9.041932536035802e-09
account O 0 4.62965693559525e-10
for O 0 1.0969815333883304e-10
a O 0 2.7403519453628178e-09
considerable O 0 1.2636166779600444e-08
proportion O 0 4.3717200526316446e-08
of O 0 1.9681598573129122e-08
genotype O 0 0.0004919229540973902
- O 0 0.04945123940706253
phenotype O 0 0.0016582016833126545
inconsistencies O 0 4.2227555240970105e-05
. O 0 1.1347678992024157e-06

Our O 0 1.079967091754952e-06
data O 0 2.76731498161098e-07
indicate O 0 2.1955324314149038e-07
that O 0 3.922880686957342e-09
the O 0 5.986714768368984e-08
PAH O 1 0.9994809031486511
- O 0 0.00048680329928174615
mutation O 0 6.018812200636603e-06
genotype O 0 5.343221118891961e-07
is O 0 2.524144226967451e-10
the O 0 8.616023866592215e-11
main O 0 1.7715328093359517e-09
determinant O 0 2.998928039232851e-08
of O 0 5.255695878503275e-09
metabolic O 0 0.0032939983066171408
phenotype O 0 0.00029021562659181654
in O 0 1.1390339693662099e-07
most O 0 4.4521240738504275e-07
patients O 0 0.04250030964612961
with O 0 0.025122664868831635
PAH B-Disease 1 0.9999929666519165
deficiency I-Disease 1 0.9998669624328613
. O 0 6.340963864204241e-06

In O 0 3.7368280914051866e-07
the O 0 4.4826794720620455e-08
present O 0 1.748051658978511e-08
study O 0 1.776965241617745e-08
, O 0 1.187426490467658e-09
the O 0 1.0741385558787897e-09
classification O 0 4.3861524545718567e-07
of O 0 2.0739790329571406e-08
105 O 0 0.00013608277367893606
PAH O 1 0.9999772310256958
mutations O 0 0.00021411789930425584
may O 0 4.719197477243142e-09
allow O 0 2.892069361770666e-10
the O 0 6.403279018130092e-10
prediction O 0 1.4925609193028322e-08
of O 0 6.177852673872053e-11
the O 0 7.749475505747228e-10
biochemical O 0 2.4307112198584946e-06
phenotype O 0 6.8750828177144285e-06
in O 0 6.000865582223014e-09
> O 0 3.632397920227959e-07
10 O 0 1.3468631765434225e-09
, O 0 2.6036331424172943e-10
000 O 0 4.013328336327504e-09
genotypes O 0 1.071714109457389e-06
, O 0 2.5628437150260197e-09
which O 0 8.768286097193823e-10
may O 0 1.2152540085352825e-09
be O 0 2.4545972893141865e-11
useful O 0 1.1848580450113388e-10
for O 0 1.5551779308786706e-10
the O 0 1.6391533685933268e-09
management O 0 3.026781598691741e-07
of O 0 3.4750502919678183e-08
hyperphenylalaninemia B-Disease 1 0.9943536520004272
in O 0 3.7887991766183404e-06
newborns O 0 0.040467649698257446
. O 0 1.2127165973652154e-06

Somatic O 0 0.0001112838217522949
instability O 0 1.7351421774947084e-05
of O 0 3.012049631934133e-08
the O 0 3.5249236418621877e-08
CTG O 0 0.00027506533660925925
repeat O 0 2.5009123874042416e-06
in O 0 2.1623593582376088e-08
mice O 0 2.4103260329866316e-06
transgenic O 0 6.771438165742438e-07
for O 0 1.8302729998254108e-08
the O 0 3.2062541777122533e-06
myotonic B-Disease 1 0.999992847442627
dystrophy I-Disease 1 0.9999946355819702
region O 0 3.097463559242897e-05
is O 0 4.591137070519835e-08
age O 0 1.0375197234679945e-07
dependent O 0 4.5215184485414284e-08
but O 0 5.402931990694526e-10
not O 0 3.810785714764009e-11
correlated O 0 1.5663033092749856e-09
to O 0 2.501224921624967e-11
the O 0 1.6420158288621423e-10
relative O 0 1.0483305779018792e-08
intertissue O 0 4.508868642005837e-06
transcription O 0 5.986178166494938e-07
levels O 0 2.1729772470280295e-07
and O 0 1.600401766665982e-08
proliferative O 0 0.07799059897661209
capacities O 0 1.4874296539346687e-05
. O 0 8.427592206317058e-07

A O 0 2.1862359062652104e-05
( O 0 4.5011685756435327e-07
CTG O 0 0.0001103467438952066
) O 0 2.5583565488318527e-08
nexpansion O 0 1.6279986994049978e-06
in O 0 1.863294407655758e-09
the O 0 2.0191410765590945e-09
3 O 0 8.954543773143087e-08
- O 0 1.4866736819385551e-05
untranslated O 0 1.7467342331656255e-05
region O 0 1.6835002725201775e-07
( O 0 3.0490940883254325e-09
UTR O 0 2.904366510847467e-06
) O 0 4.0094702558057804e-10
of O 0 1.916122260858799e-10
the O 0 5.055760698979839e-09
DM O 1 0.8307135701179504
protein O 0 3.293669124104781e-07
kinase O 0 3.585190597732435e-06
gene O 0 2.872189668323699e-07
( O 0 4.8471329172627975e-09
DMPK O 0 3.552564885467291e-05
) O 0 2.6224888927117718e-09
is O 0 3.2059843668719168e-09
responsible O 0 2.314168199291089e-07
for O 0 1.5063867522258079e-06
causing O 1 0.9961552023887634
myotonic B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999988079071045
( O 0 0.006250504404306412
DM B-Disease 1 0.9999616146087646
) O 0 1.3650759456140804e-06
. O 0 8.868198051459331e-07

Major O 0 6.156096060294658e-05
instability O 0 0.00011133636871818453
, O 0 9.099774445076036e-08
with O 0 1.1314268633100255e-08
very O 0 4.201931247393986e-09
large O 0 5.421516124926029e-09
expansions O 0 1.2084433365089353e-07
between O 0 2.3381068192662724e-09
generations O 0 5.737851083154055e-09
and O 0 7.301874660470276e-10
high O 0 3.008817017757792e-08
levels O 0 5.066437491763054e-09
of O 0 2.1611243350427856e-10
somatic O 0 1.025783831209992e-06
mosaicism O 0 0.0034386147744953632
, O 0 1.8024953973849733e-08
is O 0 7.676219659913386e-09
observed O 0 1.9478181911836145e-07
in O 0 1.7631106175031164e-07
patients O 0 4.4240503484616056e-05
. O 0 4.6316003476931655e-07

There O 0 7.046407972666202e-07
is O 0 1.6582768935791137e-08
a O 0 1.1376958930497949e-08
good O 0 4.350672266895117e-09
correlation O 0 5.575175876515459e-09
between O 0 3.806823301033546e-09
repeat O 0 4.5501462864194764e-07
size O 0 6.383237405316322e-08
( O 0 8.168420939647092e-10
at O 0 1.1360777874003247e-09
least O 0 5.754090537379852e-10
in O 0 2.8327704626462946e-09
leucocytes O 0 3.807463144767098e-05
) O 0 9.25462639855823e-09
, O 0 1.602924903920666e-08
clinical O 0 2.743775985436514e-05
severity O 0 3.318918606964871e-05
and O 0 1.0989008814021872e-08
age O 0 2.466559578806482e-07
of O 0 7.40830188306063e-08
onset O 0 0.07261116057634354
. O 0 1.2509045745900949e-06

The O 0 6.52338758300175e-06
trinucleotide O 0 0.3428500294685364
repeat O 0 0.000418849173001945
instability O 0 2.6159441404161043e-05
mechanisms O 0 3.1152851533988724e-06
involved O 0 4.256146155512397e-07
in O 0 6.740126536897151e-07
DM B-Disease 1 0.9997060894966125
and O 0 5.057258789520347e-08
other O 0 2.5065011399760806e-08
human O 0 0.00012393086217343807
genetic B-Disease 1 0.9998828172683716
diseases I-Disease 1 0.9999535083770752
are O 0 3.5773959439211467e-07
unknown O 0 7.1542453952133656e-06
. O 0 6.759128154953942e-07

We O 0 5.113954557600664e-07
studied O 0 5.617174565486494e-07
somatic O 0 9.561281331116334e-06
instability O 0 5.112870439916151e-06
by O 0 1.6548421299944494e-08
measuring O 0 1.610121671546949e-06
the O 0 3.8023113546614695e-08
CTG O 0 0.0004078961501363665
repeat O 0 2.233087570857606e-06
length O 0 1.4158023020627297e-07
at O 0 4.634456374219553e-09
several O 0 6.525824880476705e-10
ages O 0 8.19331358314912e-09
in O 0 5.083199972055752e-10
various O 0 1.906116375849365e-10
tissues O 0 6.240129124535088e-08
of O 0 1.0302637631909306e-09
transgenic O 0 9.402787100043497e-07
mice O 0 9.385889825352933e-07
carrying O 0 1.0867738708952857e-08
a O 0 1.1482341299995369e-08
( O 0 5.763055810348305e-09
CTG O 0 1.6884790966287255e-05
) O 0 3.876992948903535e-09
55expansion O 0 3.6823516893491615e-06
surrounded O 0 1.3884712757317175e-07
by O 0 8.64493365781982e-10
45 O 0 2.4636943596334504e-09
kb O 0 2.358555519776928e-07
of O 0 8.013302799092514e-10
the O 0 5.155260662803585e-09
human O 0 3.8273131508503866e-07
DM B-Disease 1 0.9995917677879333
region O 0 2.1163741337204556e-07
, O 0 6.756248338568582e-10
using O 0 1.768083013331534e-09
small O 0 4.9488686926224545e-08
- O 0 3.161844870191999e-05
pool O 0 1.630716724321246e-05
PCR O 0 7.766811904730275e-05
. O 0 5.129849114382523e-07

These O 0 6.727796630912053e-07
mice O 0 7.694867963436991e-05
have O 0 8.896624770216022e-09
been O 0 1.6716199535693477e-09
shown O 0 1.0321362653442634e-09
to O 0 1.0214348811210527e-10
reproduce O 0 4.678490928000656e-09
the O 0 3.3640859542494184e-10
intergenerational O 0 1.663285615904897e-07
and O 0 5.164410565861033e-10
somatic O 0 1.5104794215403672e-07
instability O 0 1.0341589984363964e-07
of O 0 2.315578007117125e-10
the O 0 1.2941295812751719e-09
55 O 0 1.0052935550675102e-07
CTG O 0 0.00010466008097864687
repeat O 0 3.6830190310865873e-06
suggesting O 0 5.923313395328478e-08
that O 0 1.2342120381259036e-10
surrounding O 0 4.01724964405048e-09
sequences O 0 2.5453839036515546e-09
and O 0 3.450096042190154e-10
the O 0 6.970528043659385e-10
chromatin O 0 2.351055400140467e-06
environment O 0 2.575891357992077e-07
are O 0 6.432486765461931e-10
involved O 0 1.1038964409237906e-08
in O 0 3.440255724740382e-08
instability O 0 7.77853074396262e-06
mechanisms O 0 1.1435128726589028e-05
. O 0 9.299304792875773e-07

As O 0 1.4769970846373326e-07
observed O 0 7.536255708373574e-08
in O 0 1.3212810845431022e-09
some O 0 1.3618034477858032e-10
of O 0 1.8287149572415728e-10
the O 0 2.4237918339053977e-09
tissues O 0 5.411458460002905e-06
of O 0 1.0564539252300165e-06
DM B-Disease 1 0.9999949932098389
patients O 0 0.003326455131173134
, O 0 1.095193091771307e-08
there O 0 1.270249239126997e-09
is O 0 1.0271283823470867e-09
a O 0 4.381033313904936e-09
tendency O 0 2.160780177007382e-08
for O 0 1.7466712520786132e-09
repeat O 0 5.374097327148775e-07
length O 0 4.333374192810879e-08
and O 0 6.828083654042416e-10
somatic O 0 4.2148965917476744e-07
mosaicism O 0 6.594817386940122e-05
to O 0 1.1378864517297416e-09
increase O 0 1.2146080585750951e-08
with O 0 4.884728177501074e-10
the O 0 7.828928616504527e-10
age O 0 6.73238931270248e-09
of O 0 1.129711990621729e-09
the O 0 2.1947322181858908e-08
mouse O 0 1.6363217582693323e-05
. O 0 4.517820286764618e-07

Furthermore O 0 2.661890903254971e-05
, O 0 8.560750330843803e-08
we O 0 3.317319086093562e-09
observed O 0 5.650035994619884e-09
no O 0 3.062801401387816e-10
correlation O 0 1.7008808805840658e-09
between O 0 8.372439408432797e-10
the O 0 2.516098884797202e-09
somatic O 0 4.539801466307836e-06
mutation O 0 8.657572470838204e-05
rate O 0 1.4887673387420364e-06
and O 0 1.564166574041792e-08
tissue O 0 8.869187149684876e-05
proliferation O 0 4.342488318798132e-05
capacity O 0 9.270712553188787e-07
. O 0 4.526247039393638e-07

The O 0 1.869880065896723e-06
somatic O 0 0.0003601707285270095
mutation O 0 0.015475486405193806
rates O 0 2.4728583412070293e-06
in O 0 3.06195624411032e-09
different O 0 4.166121059245853e-10
tissues O 0 1.5485838389395212e-07
were O 0 8.763838543757174e-10
also O 0 2.660886233574189e-10
not O 0 6.991429657432491e-11
correlated O 0 3.1442870529474476e-09
to O 0 3.866074821390342e-11
the O 0 4.2054568161198347e-10
relative O 0 4.5288633288009805e-08
inter O 0 1.0911937806667993e-06
- O 0 4.840431938646361e-05
tissue O 0 1.178665115730837e-06
difference O 0 2.353417460909668e-09
in O 0 9.812388401808647e-11
transcriptional O 0 1.2804446392067348e-08
levels O 0 3.3182621095306786e-09
of O 0 5.090396160145616e-11
the O 0 1.6307111216917747e-10
three O 0 5.598029262365856e-10
genes O 0 4.995849067768177e-09
( O 0 1.1625975737672434e-09
DMAHP O 0 8.187181265384424e-06
, O 0 2.158958345432893e-09
DMPK O 0 3.5628854675451294e-05
and O 0 1.2169015128904448e-08
59 O 0 5.191446916796849e-07
) O 0 2.3117046055176615e-09
surrounding O 0 3.6631529809483254e-08
the O 0 2.3229945966818377e-08
repeat O 0 4.225169959681807e-06
. O 0 2.3370647639353592e-08
. O 0 1.782557035312493e-07

A O 0 6.015493636368774e-05
novel O 0 3.915715933544561e-05
missense O 0 0.12937511503696442
mutation O 0 0.009804354049265385
in O 0 8.587421120864747e-07
patients O 0 1.5548421288258396e-05
from O 0 9.438777759385175e-09
a O 0 1.135398548512967e-07
retinoblastoma B-Disease 0 0.0013059790944680572
pedigree O 0 7.786791684338823e-05
showing O 0 1.1136157809232827e-06
only O 0 4.673719189440817e-09
mild O 0 5.560386398428818e-06
expression O 0 2.6988255186211063e-08
of O 0 1.266174010083887e-08
the O 0 1.4465589401879697e-06
tumor B-Disease 1 0.9645372033119202
phenotype O 0 0.0026552255731076
. O 0 1.170264681604749e-06

We O 0 8.64659099875098e-08
have O 0 3.782085755688058e-09
used O 0 5.103386602200999e-10
single O 0 3.0420419516730135e-09
strand O 0 1.828419158300676e-07
conformation O 0 1.2308741759170516e-07
polymorphism O 0 7.582726624377756e-08
analysis O 0 2.104325158569509e-09
to O 0 1.4607205722771965e-10
study O 0 6.410525998923333e-10
the O 0 3.1109623210845427e-10
27 O 0 7.20613568816475e-09
exons O 0 2.4388832287058904e-08
of O 0 7.694450077089243e-10
the O 0 1.0593131705149972e-08
RB1 O 0 0.00032332364935427904
gene O 0 4.274735942999541e-08
in O 0 1.0057568111676574e-09
individuals O 0 4.5017478633724295e-10
from O 0 5.979576833681222e-10
a O 0 1.1048063797147734e-08
family O 0 1.289265014747798e-07
showing O 0 1.5820104408703628e-06
mild O 0 1.5414232620969415e-05
expression O 0 4.9862180162563163e-08
of O 0 6.014432507583933e-09
the O 0 1.4900840028531093e-07
retinoblastoma B-Disease 0 0.1617174744606018
phenotype O 0 0.01993335224688053
. O 0 1.7386055333190598e-06

In O 0 8.347411153408757e-07
this O 0 2.4533138187621262e-08
family O 0 1.3215796457188844e-07
affected O 0 8.775020177154147e-08
individuals O 0 3.378454493940808e-08
developed O 0 2.260464862047229e-05
unilateral B-Disease 1 0.6093044877052307
tumors I-Disease 1 0.9999725818634033
and O 0 2.301902846113535e-08
, O 0 9.656415667080864e-10
as O 0 2.1223502122413862e-10
a O 0 2.720779823661701e-09
result O 0 2.4179276358893276e-09
of O 0 2.558968870136624e-10
linkage O 0 1.029860001722227e-07
analysis O 0 2.1971951369437193e-08
, O 0 7.336108609479197e-09
unaffected O 0 6.95832659403095e-06
mutation O 0 4.650353730539791e-06
carriers O 0 3.906139909304329e-07
were O 0 8.132914341985042e-10
also O 0 2.1188808485561594e-09
identified O 0 9.824889346532473e-09
within O 0 4.113426044227708e-09
the O 0 2.2110768327365804e-08
pedigree O 0 5.0857081077992916e-05
. O 0 3.4094304623977223e-07

A O 0 2.0303007204347523e-06
single O 0 1.303501164784393e-07
band O 0 5.9345545366795704e-08
shift O 0 2.62514792126467e-08
using O 0 5.697761373824051e-09
SSCP O 0 1.3754485735262278e-05
was O 0 9.045037607791073e-09
identified O 0 5.730676377879718e-09
in O 0 1.5292029864610868e-09
exon O 0 1.6364698467441485e-06
21 O 0 1.6475670605586856e-08
which O 0 2.821380629125514e-10
resulted O 0 6.791588624821543e-09
in O 0 1.2861420817245062e-09
a O 0 2.4878684001805595e-08
missense O 0 2.1926582121523097e-05
mutation O 0 5.968518053123262e-07
converting O 0 3.473950371812862e-08
a O 0 3.4665842463255103e-07
cys O 0 0.24142463505268097
- O 0 0.0002830201992765069
- O 0 7.846931111998856e-05
> O 0 2.6682082534534857e-06
arg O 0 4.813462510355748e-06
at O 0 3.845538110169855e-09
nucleotide O 0 4.619931814886513e-08
position O 0 4.671972142489267e-09
28 O 0 1.4329472719509795e-08
in O 0 2.6960356169780653e-09
the O 0 2.4818017863026398e-08
exon O 0 7.766515773255378e-05
. O 0 7.637680141669989e-07

The O 0 2.1542593913181918e-06
mutation O 0 8.988747140392661e-05
destroyed O 0 2.083462732116459e-06
an O 0 3.690968242153758e-08
NdeI O 0 4.982108293916099e-05
restriction O 0 1.6010175158953643e-06
enzyme O 0 5.4744791668781545e-06
site O 0 3.6731375985255e-06
. O 0 7.076658903315547e-07

Analysis O 0 5.511444669537013e-07
of O 0 1.6255764734296463e-08
all O 0 1.9008310481183344e-09
family O 0 2.0051913907082053e-08
members O 0 1.6587062834361177e-09
demonstrated O 0 3.060013398226147e-08
that O 0 4.477530846092037e-10
the O 0 7.47267137057861e-09
missense O 0 0.0005499268881976604
mutation O 0 0.00022145098773762584
co O 0 4.520825677900575e-05
- O 0 0.00010597769141895697
segregated O 0 7.989135156094562e-06
with O 0 8.179137580555107e-07
patients O 0 0.0007151949102990329
with O 0 4.9813643272500485e-06
tumors B-Disease 1 0.9998505115509033
or O 0 5.919654455510681e-08
who O 0 4.824461719010742e-09
, O 0 3.476996190965309e-10
as O 0 1.168093816117377e-10
a O 0 1.2833780704823994e-09
result O 0 1.6248007383978802e-09
of O 0 1.5321743873641935e-10
linkage O 0 1.5823303556317114e-07
analysis O 0 2.5047567575597895e-08
had O 0 6.3929097571246984e-09
been O 0 1.6779895251062271e-09
predicted O 0 7.51908046936478e-09
to O 0 1.1489143664222823e-10
carry O 0 3.909323531559039e-09
the O 0 1.6764868604468575e-08
predisposing O 0 6.911840318934992e-05
mutation O 0 0.00013553138705901802
. O 0 4.3186622633584193e-07

These O 0 1.2289447681723686e-07
observations O 0 3.573979370230518e-07
point O 0 1.6399328117699952e-08
to O 0 7.939122692590672e-10
another O 0 4.6750474602674785e-09
region O 0 5.482431841841162e-09
of O 0 3.255786473754796e-10
the O 0 5.182371864975721e-09
RB1 O 0 0.0008794046589173377
gene O 0 3.6367342204357556e-07
where O 0 1.6586689355335693e-08
mutations O 0 1.7012051500842063e-07
only O 0 1.0116166238027802e-10
modify O 0 3.58431950786553e-09
the O 0 1.4388340519033704e-10
function O 0 3.4324265651974883e-10
of O 0 8.21444509635505e-11
the O 0 5.71288460982089e-10
gene O 0 1.4686643012851164e-08
and O 0 8.823817787551036e-10
raise O 0 9.682425528012573e-09
important O 0 1.9838400366900544e-10
questions O 0 1.6603521890701245e-09
for O 0 1.485221945429771e-09
genetic O 0 1.1269147535131196e-06
counseling O 0 1.1852117722810362e-06
in O 0 5.725552476576468e-09
families O 0 4.593552205278684e-09
with O 0 3.3451612591051116e-09
these O 0 3.195673059508408e-09
distinctive O 0 8.214609806600492e-06
phenotypes O 0 0.000207366407266818
. O 0 7.736723262041778e-08
. O 0 2.1905944436184654e-07

Maternal B-Disease 0 0.03861973434686661
disomy I-Disease 1 0.8304777145385742
and O 0 0.0028857479337602854
Prader B-Disease 1 0.9999923706054688
- I-Disease 1 0.9999903440475464
Willi I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999778270721436
consistent O 0 5.902296834392473e-06
with O 0 3.334047704584009e-08
gamete O 0 4.0610215364722535e-05
complementation O 0 0.0007295985124073923
in O 0 1.8896910702892455e-08
a O 0 3.041915874746337e-08
case O 0 1.9985893828788903e-08
of O 0 2.4903739070936126e-09
familial O 0 0.004480818752199411
translocation O 0 0.0001507987326476723
( O 0 1.8620127661961305e-08
3 O 0 3.791810243569671e-08
; O 0 3.645711732502832e-09
15 O 0 1.1111462860924348e-08
) O 0 1.876444111204023e-09
( O 0 4.136904596663271e-09
p25 O 0 2.6790241918206448e-06
; O 0 1.732200161086439e-08
q11 O 0 4.743719728139695e-06
. O 0 2.633988804845444e-09
2 O 0 5.132628899673364e-08
) O 0 3.5406305443075325e-08
. O 0 1.4429998884679662e-07

Maternal B-Disease 1 0.7849896550178528
uniparental I-Disease 1 0.9976366758346558
disomy I-Disease 1 0.9705130457878113
( I-Disease 0 2.0566423700074665e-05
UPD I-Disease 1 0.9941186904907227
) I-Disease 0 2.31663186411879e-08
for I-Disease 0 4.08009936947451e-09
chromosome I-Disease 0 2.6235318273393204e-06
15 I-Disease 0 2.7442291994361767e-08
is O 0 5.217837273363557e-10
responsible O 0 2.6388211615824275e-09
for O 0 1.1347345285628307e-10
an O 0 3.145629035028463e-10
estimated O 0 3.6221456944929287e-09
30 O 0 1.0466258970609488e-09
% O 0 3.7329059288104816e-10
of O 0 1.0363736535623502e-09
cases O 0 1.1669641963862887e-07
of O 0 7.065855243126862e-06
Prader B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999967813491821
Willi I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999971389770508
( O 0 0.0006419416749849916
PWS B-Disease 1 0.9998526573181152
) O 0 2.2937088033359032e-06
. O 0 1.0075257250719005e-06

We O 0 8.916655360735604e-07
report O 0 6.167547184077193e-08
on O 0 2.544689792216559e-09
an O 0 8.523318162367843e-10
unusual O 0 2.138427213083105e-08
case O 0 1.257948678556886e-08
of O 0 1.303125829466012e-09
maternal B-Disease 0 1.1844110304082278e-05
disomy I-Disease 0 0.0006308435113169253
15 I-Disease 0 4.436044207523082e-07
in O 0 2.391654732036841e-07
PWS B-Disease 1 0.9988586902618408
that O 0 5.336343811279676e-09
is O 0 1.6698290528083248e-09
most O 0 2.481808925036688e-10
consistent O 0 2.9531870282539785e-09
with O 0 6.87592927040015e-10
adjacent O 0 1.928627995084753e-07
- O 0 3.1150857466855086e-06
1 O 0 7.738268692492056e-09
segregation O 0 7.487055597721337e-08
of O 0 6.622677961587442e-10
a O 0 5.072715580922704e-08
paternal O 0 9.805404260987416e-05
t O 0 0.0028985224198549986
( O 0 2.3905513124589106e-09
3 O 0 7.671696167221853e-09
; O 0 2.1599140254124904e-09
15 O 0 4.025073163660409e-09
) O 0 8.403412965485302e-10
( O 0 1.5082511906072682e-09
p25 O 0 7.181782848419971e-07
; O 0 3.0161471098466563e-09
q11 O 0 4.4718595404447115e-07
. O 0 2.662506048967117e-10
2 O 0 5.932262459040771e-10
) O 0 9.201883005571787e-11
with O 0 2.2582219427746963e-10
simultaneous O 0 2.0588050375636158e-08
maternal O 0 1.0998855032084975e-05
meiotic O 0 0.0019562479574233294
nondisjunction O 0 0.0009593602153472602
for O 0 4.4487453720876147e-08
chromosome O 0 0.0001807626395020634
15 O 0 8.519098741999187e-07
. O 0 3.2924347692642186e-07

The O 0 9.597108146408573e-06
patient O 0 0.0023827776312828064
( O 0 4.4609811311602243e-07
J O 0 9.606099047232419e-05
. O 0 5.718425288847584e-09
B O 0 6.254082052237209e-08
. O 0 3.1039684711409166e-10
) O 0 1.5800721842040844e-10
, O 0 1.4463373554374215e-10
a O 0 3.564602391037397e-09
17 O 0 1.3317239222487842e-07
- O 0 9.144539035332855e-06
year O 0 1.0724956212015968e-07
- O 0 1.5576928490190767e-05
old O 0 2.8752858725056285e-06
white O 0 3.996380826265522e-07
male O 0 1.2605455879111105e-07
with O 0 1.341889799277851e-07
PWS B-Disease 1 0.9990273714065552
, O 0 3.098695344760927e-08
was O 0 2.265575638205064e-08
found O 0 1.42564038352333e-09
to O 0 5.2702259223380565e-11
have O 0 8.320188288335473e-11
47 O 0 4.156329058702113e-09
chromosomes O 0 1.3374942042787552e-08
with O 0 7.70032315688951e-10
a O 0 1.7713817968001422e-08
supernumerary O 0 2.9647117116837762e-05
, O 0 9.592831418103742e-09
paternal O 0 5.41946883458877e-06
der O 0 5.710993355023675e-05
( O 0 1.2879488586747811e-09
15 O 0 1.1199587923726995e-09
) O 0 1.1911756303550902e-10
consisting O 0 5.043651607472555e-10
of O 0 2.1857565757343878e-10
the O 0 2.551250544158279e-09
short O 0 1.1751257744663235e-07
arm O 0 2.698491243791068e-06
and O 0 1.1615093331585058e-09
the O 0 1.7047783185120124e-09
proximal O 0 1.582654113008175e-05
long O 0 6.313038738881005e-06
arm O 0 4.896882728644414e-06
of O 0 2.5107489420861384e-09
chromosome O 0 3.6163467029837193e-06
15 O 0 1.8616043817587524e-08
, O 0 1.5839082267987692e-09
and O 0 1.4758840372053328e-08
distal O 0 0.009361455217003822
chromosome O 1 0.7782288193702698
arm O 0 0.10422416031360626
3p O 0 0.2563121020793915
. O 0 2.9705317956540966e-06

The O 0 1.6161635358002968e-05
t O 0 0.0050125145353376865
( O 0 4.984677914876556e-08
3 O 0 3.613191168483354e-08
; O 0 3.74511710532488e-09
15 O 0 4.315588775227752e-09
) O 0 3.9842823484903533e-10
was O 0 5.47824785535056e-10
present O 0 1.9114498872596641e-10
in O 0 1.6258755453080198e-10
the O 0 3.8430944537815037e-10
balanced O 0 2.7822336434724093e-08
state O 0 4.743653914118795e-09
in O 0 2.7804976099332634e-09
the O 0 5.080607223817424e-08
patients O 0 1.6824644262669608e-05
father O 0 1.684042985061751e-07
and O 0 1.4081989796466132e-08
a O 0 1.555822450427513e-06
sister O 0 0.00015789146709721535
. O 0 7.422353291985928e-07

Fluorescent O 0 0.0003260724770370871
in O 0 2.410463082469505e-07
situ O 0 5.213896201894386e-06
hybridization O 0 7.027724677755032e-07
analysis O 0 7.7687516863989e-08
demonstrated O 0 8.974412679663146e-08
that O 0 1.5090597660361027e-09
the O 0 1.300276419868851e-08
PWS B-Disease 1 0.8980084657669067
critical O 0 5.023543394599983e-07
region O 0 1.29860382003244e-07
resided O 0 6.696776466696974e-08
on O 0 8.140984553151043e-10
the O 0 8.892667713311653e-10
derivative O 0 4.9118547451598715e-08
chromosome O 0 5.927415713813389e-07
3 O 0 3.1578459847025897e-09
and O 0 2.1507043368451662e-10
that O 0 9.106967957528411e-11
there O 0 1.9214399515909975e-10
was O 0 9.178154347644352e-10
no O 0 3.2818914252885634e-10
deletion O 0 6.802662966265416e-08
of O 0 7.633974563603374e-10
the O 0 2.2799328647238326e-08
PWS B-Disease 1 0.9520081281661987
region O 0 9.738696604699726e-08
on O 0 2.020289047166557e-09
the O 0 1.259852111523685e-09
normal O 0 2.373904273156313e-08
pair O 0 1.5088417626429873e-08
of O 0 1.2499763446527368e-09
15s O 0 3.885922524204943e-06
present O 0 3.321423136526391e-08
in O 0 2.3019539696633728e-07
J O 0 0.001224370440468192
. O 0 3.890788491389685e-07

B O 0 0.006307719741016626
. O 0 4.45619662059471e-05

Methylation O 0 2.7082238375442103e-05
analysis O 0 8.400021442867001e-07
at O 0 1.0234411007559174e-07
exon O 0 5.280746790958801e-06
alpha O 0 1.0509937453662133e-07
of O 0 9.242925869124008e-10
the O 0 1.91006965799545e-09
small O 0 2.5783041479598978e-08
nuclear O 0 1.3488735021383036e-05
ribonucleoprotein O 0 0.009047829546034336
- O 0 3.352765997988172e-05
associated O 0 7.918592359601462e-08
polypeptide O 0 3.4164813769166358e-06
N O 0 2.9869397621951066e-06
( O 0 3.6789475910126157e-09
SNRPN O 0 1.3154352018318605e-05
) O 0 2.3684352257191676e-09
gene O 0 2.6011939269210416e-08
showed O 0 1.8188861972134873e-08
a O 0 6.523924511725454e-09
pattern O 0 8.737275436487835e-08
characteristic O 0 1.1864898397107027e-08
of O 0 2.3530929982307214e-10
only O 0 1.8480915409124776e-10
the O 0 1.960646311971459e-09
maternal O 0 8.56532460602466e-06
chromosome O 0 5.184644760447554e-05
15 O 0 2.2965730295254616e-07
in O 0 1.4560994543444394e-07
J O 0 0.0008378987549804151
. O 0 9.77627905740519e-07

B O 0 0.0035861453507095575
. O 0 6.357862002914771e-05

Maternal B-Disease 0 0.012372108176350594
disomy I-Disease 0 0.08321865648031235
was O 0 2.8181029847473837e-06
confirmed O 0 2.2714952763180918e-07
by O 0 4.5775467860664776e-09
polymerase O 0 9.852815310296137e-07
chain O 0 2.311301614099648e-06
reaction O 0 1.507305746883958e-08
analysis O 0 1.8431641768401619e-09
of O 0 6.363380933294138e-10
microsatellite O 0 8.133912160701584e-06
repeats O 0 1.44321177231177e-07
at O 0 2.653285813281059e-09
the O 0 1.8172277016503813e-09
gamma O 0 1.2547421874842257e-06
- O 0 2.5810602437559282e-06
aminobutyric O 0 1.9383729522814974e-05
acid O 0 7.714442062933813e-07
receptor O 0 9.83777340479719e-07
beta3 O 0 1.4113664292381145e-05
subunit O 0 1.524517188045138e-06
( O 0 8.875611712255704e-08
GABRB3 O 0 0.00018216780154034495
) O 0 1.2183151909539447e-07
locus O 0 1.3884337931813207e-05
. O 0 4.2601419636412174e-07

A O 0 4.179829920758493e-05
niece O 0 0.0012323239352554083
( O 0 9.263848710361344e-08
B O 0 7.162179826991633e-07
. O 0 1.962438433977809e-09
B O 0 1.8712768223849707e-08
. O 0 1.0611685835604234e-10
) O 0 4.405572434640348e-11
with O 0 1.089213094718211e-10
45 O 0 5.708984951446894e-10
chromosomes O 0 4.7480623877049766e-09
and O 0 1.1438677782749096e-10
the O 0 2.461875425741056e-10
derivative O 0 9.992675131798023e-09
3 O 0 4.276845988471223e-09
but O 0 3.7776429206992646e-10
without O 0 5.76242664696025e-10
the O 0 1.6162142735254292e-09
der O 0 5.05743128087488e-06
( O 0 1.1074134942390401e-09
15 O 0 2.320026615265647e-09
) O 0 4.855819635274372e-10
demonstrated O 0 1.6707410566141334e-08
a O 0 3.9689499686801355e-08
phenotype O 0 5.570157100009965e-06
consistent O 0 2.399684539966529e-08
with O 0 1.8606273188837008e-09
that O 0 6.789628859138475e-10
reported O 0 2.5227461009080798e-08
for O 0 6.543623420895983e-10
haploinsufficiency O 0 1.1944757716264576e-05
of O 0 1.3617321492631618e-08
distal O 0 0.0007416659500449896
3 O 0 3.471043601166457e-05
p O 0 0.0010987226851284504
. O 0 1.3256990314403083e-06

Uniparental B-Disease 1 0.9986982345581055
disomy I-Disease 1 0.9969649910926819
associated O 0 3.386700336704962e-05
with O 0 1.2196950649467908e-07
unbalanced O 0 1.1822781743831001e-05
segregation O 0 3.910320629074704e-06
of O 0 1.4972313167049833e-08
non O 0 3.132914798698039e-07
- O 0 7.948753045639023e-05
Robertsonian O 0 8.016013453016058e-05
translocations O 0 6.524171476485208e-05
has O 0 4.882925708216135e-08
been O 0 1.6945154612812985e-08
reported O 0 1.0784690829268584e-07
previously O 0 1.0854417809014194e-08
but O 0 4.5350653787856743e-10
has O 0 3.203146636820975e-10
not O 0 4.1363718006337535e-11
, O 0 4.636874911811972e-11
to O 0 8.89209886278941e-12
our O 0 8.2133799761408e-11
knowledge O 0 2.907539209395793e-10
, O 0 7.74291575300623e-10
been O 0 1.7397221441228794e-09
observed O 0 5.195693653092803e-09
in O 0 1.2745400290725684e-09
a O 0 2.6598032221158974e-08
case O 0 1.618503091549428e-07
of O 0 2.3043328667426977e-07
PWS B-Disease 1 0.9988079071044922
. O 0 2.925716671597911e-06

Furthermore O 0 2.9326078220037743e-05
, O 0 1.3182088309804385e-07
our O 0 4.084851568109116e-08
findings O 0 4.340264325719545e-08
are O 0 2.9588351213583053e-10
best O 0 8.165788600855706e-10
interpreted O 0 2.066964377434033e-09
as O 0 5.836860994534732e-10
true O 0 1.419584716444433e-08
gamete O 0 9.55459017859539e-06
complementation O 0 0.0005719250766560435
resulting O 0 2.7278279048914555e-06
in O 0 3.988937180565699e-07
maternal B-Disease 0 0.002318558283150196
UPD I-Disease 1 0.9992520213127136
15 I-Disease 0 1.4923615708539728e-05
and O 0 4.561052264762111e-06
PWS B-Disease 1 0.9969794750213623

Schwartz B-Disease 1 0.7229906916618347
- I-Disease 1 0.995429515838623
Jampel I-Disease 1 0.9986748695373535
syndrome I-Disease 1 0.9999085664749146
type I-Disease 0 2.8712564017041586e-05
2 I-Disease 0 3.5996853853248467e-07
and O 0 4.4851682901025924e-07
Stuve B-Disease 1 0.9539957642555237
- I-Disease 1 0.9997549653053284
Wiedemann I-Disease 1 0.9999244213104248
syndrome I-Disease 1 0.9999641180038452
: O 0 7.404925383980299e-08
a O 0 8.723154110157338e-08
case O 0 2.955735567411466e-08
for O 0 4.9071515739740335e-09
" O 0 2.3922403613596543e-08
lumping O 0 5.985960797261214e-06
" O 0 1.5402476094550366e-07
. O 0 3.4055830155921285e-07

Recent O 0 3.425260274525499e-06
studies O 0 3.5694012012754683e-07
demonstrated O 0 1.896138002166481e-07
the O 0 3.879115695326618e-09
existence O 0 9.102392617421629e-09
of O 0 6.636194371800741e-10
a O 0 2.461812087517501e-08
genetically O 0 1.6008648628940136e-07
distinct O 0 1.5302015654583556e-08
, O 0 1.911571345658558e-09
usually O 0 2.4650717023178004e-09
lethal O 0 3.0269486472889184e-08
form O 0 1.345256017692975e-09
of O 0 9.031328462860699e-10
the O 0 2.4250324415220348e-08
Schwartz B-Disease 0 0.001778912148438394
- I-Disease 1 0.7993776202201843
Jampel I-Disease 1 0.9958298802375793
syndrome I-Disease 1 0.9998974800109863
( O 0 5.112950134389393e-07
SJS B-Disease 1 0.8531562685966492
) O 0 1.0107727987929138e-08
of O 0 1.8631851617101347e-08
myotonia B-Disease 1 0.9952095150947571
and O 0 5.593638888967689e-06
skeletal B-Disease 1 0.9983845949172974
dysplasia I-Disease 1 0.9998804330825806
, O 0 9.273430379153069e-08
which O 0 6.532266283443278e-09
we O 0 3.5586922297881074e-09
called O 0 1.2272797675905167e-06
SJS B-Disease 1 0.9852146506309509
type I-Disease 0 1.8531874957261607e-05
2 I-Disease 0 1.1726510820153635e-06
. O 0 5.929852591179952e-07

This O 0 1.8259695934830233e-05
disorder O 1 0.7341289520263672
is O 0 2.401299354914954e-07
reminiscent O 0 4.220658865961013e-06
of O 0 1.532140814219929e-08
another O 0 3.3144812050522887e-07
rare O 0 3.501876335576526e-06
condition O 0 1.6429234165116213e-05
, O 0 1.001125671251657e-08
the O 0 2.66145832483744e-07
Stuve B-Disease 1 0.9816147685050964
- I-Disease 1 0.9996746778488159
Wiedemann I-Disease 1 0.9999251365661621
syndrome I-Disease 1 0.9999793767929077
( O 0 7.725382147327764e-07
SWS B-Disease 0 0.3124066889286041
) O 0 5.784640766393068e-09
, O 0 7.902094534273374e-10
which O 0 3.2948432870938404e-10
comprises O 0 5.529985358521117e-09
campomelia B-Disease 0 2.6150461053475738e-05
at O 0 2.7740583163904375e-07
birth O 0 2.010776188399177e-05
with O 0 1.4255724636313971e-06
skeletal B-Disease 1 0.9926971793174744
dysplasia I-Disease 1 0.9998993873596191
, O 0 1.456587028769718e-06
contractures B-Disease 1 0.902677595615387
, O 0 5.5041230240249206e-08
and O 0 1.6611322095627656e-08
early B-Disease 0 5.181480560167984e-07
death I-Disease 0 6.207381829881342e-06
. O 0 4.868743985753099e-07

To O 0 2.712310447350319e-07
test O 0 2.935292400252365e-07
for O 0 5.528551394462511e-09
possible O 0 2.426332379457108e-08
nosologic O 0 6.770333129679784e-05
identity O 0 5.61840124646551e-07
between O 0 8.973523080157975e-08
these O 0 6.148730591348794e-08
disorders O 0 0.13876405358314514
, O 0 1.0603440792067431e-08
we O 0 4.000197117992599e-10
reviewed O 0 3.3831861756539183e-09
the O 0 2.1824989038243814e-10
literature O 0 3.118947600189159e-10
and O 0 1.222227041797197e-10
obtained O 0 1.309489294776256e-09
a O 0 2.7939741631399784e-09
follow O 0 1.571408114742212e-09
- O 0 7.80405358113967e-08
up O 0 3.59317464670994e-10
of O 0 4.444819859394933e-11
the O 0 1.954947037585697e-10
only O 0 9.44946759728893e-11
two O 0 9.73731539843925e-10
surviving O 0 2.4557400593039347e-06
patients O 0 1.9911828985641478e-06
, O 0 7.391245393506551e-10
one O 0 3.9269512641659787e-10
with O 0 1.5096707883799354e-08
SJS B-Disease 1 0.6531084179878235
type I-Disease 0 6.19764136899903e-07
2 I-Disease 0 1.2929337600553481e-08
at O 0 1.119957282469386e-08
age O 0 1.1687792067505143e-08
10 O 0 1.3858110214926e-09
years O 0 7.915021971172109e-10
and O 0 1.3541677501560656e-10
another O 0 2.3344217670029366e-09
with O 0 2.1735196753525088e-08
SWS B-Disease 0 0.16042275726795197
at O 0 1.5210825665690209e-07
age O 0 2.164889707501061e-07
7 O 0 4.2209990169794764e-07
years O 0 1.6929510593399755e-07
. O 0 2.456414165408205e-07

Patients O 0 0.06945996731519699
reported O 0 1.5145374163694214e-05
as O 0 2.81211054442565e-08
having O 0 1.7380041583692218e-07
either O 0 2.675679525054875e-06
neonatal O 1 0.9999350309371948
SJS B-Disease 1 0.9999275207519531
or O 0 1.1308203283988405e-05
SWS B-Disease 1 0.7490144371986389
presented O 0 1.2713314845314017e-07
a O 0 5.3636529884215634e-08
combination O 0 2.959014011594263e-07
of O 0 8.63495142056081e-09
a O 0 2.2310098302114056e-06
severe O 0 0.01627102494239807
, O 0 1.4539085668729967e-06
prenatal O 1 0.9991783499717712
- O 1 0.9999099969863892
onset O 1 0.9999659061431885
neuromuscular B-Disease 1 0.9999960660934448
disorder I-Disease 1 0.9999573230743408
( O 0 1.4845599253021646e-05
with O 0 0.00037522995262406766
congenital B-Disease 1 0.9999971389770508
joint I-Disease 1 0.9989972710609436
contractures I-Disease 1 0.9999945163726807
, O 0 0.0011282697087153792
respiratory O 1 0.9975587129592896
and O 0 3.494785971724923e-07
feeding O 0 3.472649405011907e-05
difficulties O 0 1.3535614925785922e-05
, O 0 2.778887342458347e-08
tendency O 0 2.202129536499342e-07
to O 0 6.433176658049433e-09
hyperthermia B-Disease 0 0.2744789719581604
, O 0 8.599515766150034e-09
and O 0 2.675401900020802e-09
frequent O 0 2.5289327254540694e-07
death O 0 8.378196980629582e-07
in O 0 2.8697028753299492e-08
infancy O 0 7.40531004339573e-06
) O 0 1.2898910828340604e-09
with O 0 9.659401056794081e-10
a O 0 1.7490423331878446e-08
distinct O 0 2.693776082196564e-07
campomelic B-Disease 0 0.26921021938323975
- I-Disease 1 0.7779901027679443
metaphyseal I-Disease 1 0.9863386750221252
skeletal I-Disease 1 0.9994495511054993
dysplasia I-Disease 1 0.9996588230133057
. O 0 7.74912132328609e-06

The O 0 1.782386931381552e-07
similarity O 0 3.848456913146947e-07
of O 0 1.6160239368900875e-08
the O 0 4.085677218768069e-08
clinical O 0 3.341013871249743e-05
and O 0 8.130223250191193e-08
radiographic O 0 0.20050546526908875
findings O 0 3.904589448211482e-06
is O 0 5.9874203373055934e-09
so O 0 2.379869412649782e-09
extensive O 0 2.7361184606888855e-07
that O 0 6.377965711124034e-09
these O 0 1.2946217431419882e-08
disorders O 0 0.0072128018364310265
appear O 0 2.8049003120145244e-08
to O 0 3.5315755875231503e-10
be O 0 3.9072345359159044e-10
a O 0 1.2477284982992387e-08
single O 0 8.175941701438205e-08
entity O 0 4.700183581007877e-06
. O 0 3.424537737828359e-07

The O 0 1.6745750031077478e-07
follow O 0 9.431654035552128e-08
- O 0 7.831503694433195e-07
up O 0 2.5956961025030978e-09
observation O 0 2.0597319405624148e-08
of O 0 1.9263203532293716e-10
an O 0 4.724869384631347e-10
identical O 0 6.514948580615965e-08
and O 0 5.377537859452275e-10
unique O 0 6.842753919045208e-09
pattern O 0 8.716025945432193e-07
of O 0 1.8568778159533395e-07
progressive O 1 0.9012343287467957
bone B-Disease 1 0.9986588954925537
dysplasia I-Disease 1 0.9987138509750366
in O 0 5.529545532567681e-08
the O 0 2.1400223815248864e-08
two O 0 7.471106755474466e-08
patients O 0 7.061045380396536e-06
( O 0 1.2818490713328856e-09
one O 0 6.48773645917089e-10
with O 0 3.5474847948080424e-08
SJS B-Disease 1 0.983421266078949
type I-Disease 0 5.2635914471466094e-06
2 I-Disease 0 3.0076581225557675e-08
, O 0 8.691408703853654e-10
one O 0 6.90974388817267e-10
with O 0 2.1918038939361395e-08
SWS B-Disease 0 0.22290734946727753
) O 0 4.967648070675068e-09
surviving O 0 2.376126815306634e-07
beyond O 0 1.0547611140054869e-07
infancy O 0 3.302508957858663e-06
adds O 0 2.0591663485447498e-08
to O 0 5.944832126569821e-11
the O 0 2.2496324247889277e-10
evidence O 0 1.1958976031678503e-09
in O 0 1.2037930652297746e-09
favor O 0 7.158995618539166e-09
of O 0 3.4428404571684723e-09
identity O 0 9.502298894403793e-07
. O 0 2.446464293370809e-07

The O 0 1.0216872396995313e-06
hypothesis O 0 7.692131475778297e-06
that O 0 4.622206262183681e-08
SWS B-Disease 0 0.010114510543644428
and O 0 3.861298409901792e-07
SJS B-Disease 1 0.9623771905899048
type I-Disease 0 3.0745979984203586e-06
2 I-Disease 0 2.5186738028537548e-08
are O 0 4.681595111577508e-10
the O 0 3.3518676723076624e-09
same O 0 1.9746917701013444e-07
disorder O 0 0.010628921911120415
should O 0 1.7185292078281122e-09
be O 0 1.5210978310253864e-10
testable O 0 6.995998891312638e-09
by O 0 5.524058432904155e-10
molecular O 0 3.6798797964365804e-07
methods O 0 3.41580879137382e-08
. O 0 2.135720578166911e-08
. O 0 1.5284754795175104e-07

A O 0 1.3982014024804812e-05
mouse O 0 4.1166953451465815e-05
model O 0 7.750377335469238e-06
of O 0 5.1004908527829684e-06
severe O 1 0.9997863173484802
von B-Disease 1 0.9999972581863403
Willebrand I-Disease 1 0.9999974966049194
disease I-Disease 1 0.9999970197677612
: O 0 0.009197378531098366
defects O 1 0.9994562268257141
in O 0 2.761134055617731e-05
hemostasis O 1 0.9994593262672424
and O 0 0.0002143775491276756
thrombosis B-Disease 1 0.9997753500938416
. O 0 1.2625125236809254e-05

von B-Disease 1 0.9844331741333008
Willebrand I-Disease 1 0.9889280796051025
factor I-Disease 0 0.0004112039168830961
( I-Disease 0 2.140249307558406e-05
vWf I-Disease 1 0.524749219417572
) I-Disease 0 0.0009820711566135287
deficiency I-Disease 1 0.9999023675918579
causes O 1 0.9817832112312317
severe O 1 0.9999600648880005
von B-Disease 1 0.999997615814209
Willebrand I-Disease 1 0.9999934434890747
disease I-Disease 1 0.9999701976776123
in O 0 4.238657311361749e-06
humans O 0 3.844686034426559e-06
. O 0 1.3271663874547812e-06

We O 0 1.0392962934702155e-07
generated O 0 9.088829244774388e-08
a O 0 3.345871490978425e-08
mouse O 0 6.586730023627752e-07
model O 0 8.211465285512531e-08
for O 0 4.912545925606082e-09
this O 0 4.795160268855625e-09
disease O 0 1.941451273523853e-06
by O 0 4.73945493961736e-10
using O 0 5.13157871750991e-09
gene O 0 2.7811441327685316e-07
targeting O 0 7.525668479502201e-07
. O 0 4.3339446165191475e-07

vWf B-Disease 1 0.937153160572052
- I-Disease 1 0.924230694770813
deficient I-Disease 1 0.809603214263916
mice O 0 0.00048159717698581517
appeared O 0 3.027749073680752e-07
normal O 0 3.4490736311454384e-07
at O 0 3.1406443667947315e-08
birth O 0 9.220164542966813e-07
; O 0 2.500330831267661e-09
they O 0 2.7525559609387074e-10
were O 0 8.844880383662712e-10
viable O 0 1.0870977007471083e-07
and O 0 1.1724655024636377e-08
fertile O 0 1.0106869012815878e-05
. O 0 7.522963301198615e-07

Neither O 0 0.00026849177083931863
vWf O 0 0.006052709184587002
nor O 0 6.948663940420374e-05
vWf O 0 0.002343413420021534
propolypeptide O 0 0.0069556389935314655
( O 0 7.42360612093762e-07
von B-Disease 0 0.035645779222249985
Willebrand I-Disease 1 0.6802175641059875
antigen O 0 0.0016364119946956635
II O 0 2.895221405196935e-05
) O 0 2.2129489352096243e-09
were O 0 5.562055260810439e-10
detectable O 0 4.213690729670816e-08
in O 0 5.114749179746525e-10
plasma O 0 1.5509456829931878e-07
, O 0 2.8316575750864104e-09
platelets O 0 1.0583698895061389e-06
, O 0 5.950212544902911e-10
or O 0 1.4850576324221265e-09
endothelial O 0 9.178439768220414e-07
cells O 0 2.4416527466541993e-08
of O 0 2.964325451770833e-10
the O 0 5.469563912896547e-09
homozygous O 0 1.3639030839840416e-05
mutant O 0 7.018711039563641e-05
mice O 0 0.00011711460683727637
. O 0 4.613398232322652e-07

The O 0 4.221802555548493e-06
mutant O 0 0.003605735255405307
mice O 0 0.042074352502822876
exhibited O 0 0.00010848358215298504
defects O 1 0.7788121700286865
in O 0 3.068327885102917e-07
hemostasis O 0 0.02387492172420025
with O 0 8.477120161387575e-08
a O 0 1.0427307870486402e-06
highly O 0 7.403029030683683e-06
prolonged O 0 0.3382420539855957
bleeding O 1 0.654588520526886
time O 0 2.1103151226498085e-08
and O 0 1.7741983882046952e-08
spontaneous O 0 7.677022040297743e-06
bleeding O 0 0.01998022198677063
events O 0 2.3826762785006395e-09
in O 0 1.2451364383991859e-09
approximately O 0 2.9452500438509333e-09
10 O 0 2.6823303578282776e-09
% O 0 3.842348661464712e-09
of O 0 6.838200672376615e-09
neonates O 0 0.0003057153953704983
. O 0 4.4112300656706793e-07

As O 0 2.4553085609113623e-07
in O 0 6.981445466180958e-08
the O 0 3.181133934049285e-08
human O 0 6.469293793998077e-07
disease O 0 0.00020299838797654957
, O 0 1.0579073173033748e-09
the O 0 6.759960924362929e-10
factor O 0 5.076361997424783e-09
VIII O 0 5.43803389518871e-06
level O 0 3.460129249788224e-08
in O 0 2.62507127146705e-09
these O 0 5.246199030750631e-10
mice O 0 4.974761509402015e-07
was O 0 5.132361646786876e-09
reduced O 0 3.7542591257988533e-08
strongly O 0 1.6548382664183237e-09
as O 0 1.290677981158339e-10
a O 0 1.865559706715203e-09
result O 0 1.4128794800782885e-09
of O 0 1.5423073929099473e-10
the O 0 1.2556181649969744e-09
lack O 0 2.179194247275973e-08
of O 0 1.971874885597913e-09
protection O 0 5.07928064052976e-07
provided O 0 3.190777775330389e-08
by O 0 1.6948362713264942e-07
vWf O 0 0.0003169063711538911
. O 0 1.2093996701878496e-06

Defective O 1 0.9965484738349915
thrombosis B-Disease 1 0.9995245933532715
in O 0 6.234125521586975e-06
mutant O 0 0.001024400582537055
mice O 0 0.0005742142675444484
was O 0 5.843505945790639e-08
also O 0 8.930384765015731e-10
evident O 0 6.0054681227939e-09
in O 0 2.1221113755132137e-10
an O 0 2.873084548049576e-10
in O 0 3.1717053428081954e-09
vivo O 0 4.124618044443196e-06
model O 0 4.961268587067025e-07
of O 0 1.117405076911382e-06
vascular B-Disease 1 0.9998307228088379
injury I-Disease 1 0.8224001526832581
. O 0 4.68561620436958e-06

In O 0 2.240057170865839e-07
this O 0 8.316832555976816e-09
model O 0 3.2144232164910136e-08
, O 0 9.780012355520284e-10
the O 0 2.275734711787436e-09
exteriorized O 0 3.517786899465136e-05
mesentery O 0 0.00026984320720657706
was O 0 8.012744245888825e-08
superfused O 0 1.142949167842744e-05
with O 0 3.63093235478118e-08
ferric O 0 0.0014005557168275118
chloride O 0 5.233918727753917e-06
and O 0 1.0718158582889714e-09
the O 0 1.2129846016506463e-09
accumulation O 0 1.379756611186167e-07
of O 0 1.298426810514286e-09
fluorescently O 0 0.00022533725132234395
labeled O 0 2.872057848435361e-06
platelets O 0 1.702088411548175e-05
was O 0 1.2857479525507642e-08
observed O 0 9.763541974905365e-09
by O 0 4.2690544432844035e-09
intravital O 0 1.894273555080872e-05
microscopy O 0 8.63904097059276e-06
. O 0 8.300163472085842e-07

We O 0 9.912710083881393e-07
conclude O 0 1.4505790204566438e-06
that O 0 7.364512111251997e-09
these O 0 4.523164065517449e-09
mice O 0 2.6322281883039977e-06
very O 0 1.6798862745304177e-08
closely O 0 4.335466030624957e-07
mimic O 0 0.0004385661450214684
severe O 1 0.7116884589195251
human O 0 0.007841826416552067
von B-Disease 1 0.9999969005584717
Willebrand I-Disease 1 0.9999960660934448
disease I-Disease 1 0.9999716281890869
and O 0 1.7554114606355142e-07
will O 0 5.114614953782848e-09
be O 0 1.7148905906427814e-10
very O 0 1.4194263819877762e-10
useful O 0 1.738702931630698e-10
for O 0 1.1540954303335127e-10
investigating O 0 1.2759100442849558e-08
the O 0 4.438654443994494e-10
role O 0 2.716227243126923e-09
of O 0 9.450085158846377e-10
vWf O 0 1.1918175459868507e-06
in O 0 5.939511549257759e-09
normal O 0 9.46577074500965e-08
physiology O 0 7.632335154994507e-07
and O 0 1.6752785825246974e-08
in O 0 2.106780669919317e-07
disease O 0 0.0003083054325543344
models O 0 5.63280082133133e-07
. O 0 2.803210286117519e-08
. O 0 1.9796432582097623e-07

Oral O 0 0.00032687297789379954
contraceptives O 0 0.00105124874971807
and O 0 1.761915626730115e-07
the O 0 5.051551852375269e-07
risk O 0 0.0011749056866392493
of O 0 8.486175647703931e-05
hereditary B-Disease 1 0.9999823570251465
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999874830245972
. O 0 8.212088141590357e-05

Hereditary B-Disease 1 0.9998793601989746
Ovarian I-Disease 1 0.9999849796295166
Cancer I-Disease 1 0.9999061822891235
Clinical O 1 0.6139508485794067
Study O 0 4.222840289003216e-05
Group O 0 5.209691153140739e-06
. O 0 1.180730691885401e-06

BACKGROUND O 0 7.526148692704737e-05
Women O 0 2.184880941058509e-06
with O 0 1.6359348364858306e-07
mutations O 0 1.3494989616447128e-05
in O 0 7.641393295898524e-09
either O 0 4.959335608845095e-09
the O 0 1.2122867154573669e-08
BRCA1 O 0 3.366183227626607e-05
or O 0 6.986717870915982e-09
the O 0 9.73130376280551e-09
BRCA2 O 0 2.4782792024780065e-05
gene O 0 6.47177458290571e-08
have O 0 8.172816312601583e-10
a O 0 1.5232652472718655e-08
high O 0 4.187902050034609e-06
lifetime O 0 0.0010077875340357423
risk O 0 0.2585383355617523
of O 0 0.04390059411525726
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999840259552002
. O 0 1.7023188775056042e-05

Oral O 0 0.04809170588850975
contraceptives O 1 0.9924088716506958
protect O 1 0.8984190821647644
against O 1 0.9990096092224121
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999990701675415
in O 0 3.6323632457424537e-07
general O 0 1.017469628550316e-07
, O 0 4.170853884488679e-09
but O 0 9.522895805247344e-10
it O 0 2.8649146943671155e-10
is O 0 2.5199398123731953e-10
not O 0 6.486112341663741e-11
known O 0 9.402297829197437e-10
whether O 0 5.219589205296415e-10
they O 0 1.2936947346720018e-10
also O 0 4.5578546492563987e-10
protect O 0 3.102817558442439e-08
against O 0 1.0501681657615336e-07
hereditary B-Disease 0 0.02401099167764187
forms I-Disease 0 0.00017704893252812326
of I-Disease 0 0.06701742857694626
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999867677688599
. O 0 1.3121601114107762e-05

METHODS O 0 6.325628419290297e-06
We O 0 1.4153798133520468e-07
enrolled O 0 6.278415867200238e-07
207 O 0 1.8612654457683675e-06
women O 0 4.789440936292522e-06
with O 0 0.0006766145233996212
hereditary B-Disease 1 0.9999972581863403
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999942779541016
and O 0 2.822906886024157e-08
161 O 0 4.980192258585703e-08
of O 0 7.849832450723682e-10
their O 0 1.5833403477216734e-09
sisters O 0 1.2932845550039929e-07
as O 0 6.122358731097677e-10
controls O 0 2.7890239451267007e-08
in O 0 3.501201772948548e-09
a O 0 6.052387391264347e-08
case O 0 4.1673263240227243e-07
- O 0 4.578433436108753e-05
control O 0 3.5453247164696222e-06
study O 0 5.304259502736386e-07
. O 0 2.462643919898255e-07

All O 0 1.9019606156689406e-07
the O 0 2.1899366231536987e-07
patients O 0 1.012348093354376e-05
carried O 0 1.2600455079336825e-07
a O 0 1.5376659234789258e-07
pathogenic O 0 1.4755633856111672e-05
mutation O 0 1.9507904653437436e-05
in O 0 2.2646595709829853e-08
either O 0 7.740619878404686e-08
BRCA1 O 0 0.00023566281015519053
( O 0 1.3995768988195323e-08
179 O 0 6.506194267785759e-07
women O 0 1.576158439320352e-07
) O 0 1.3578521418367018e-08
or O 0 9.098021536146916e-08
BRCA2 O 0 0.0005425067502073944
( O 0 3.593726560779942e-08
28 O 0 4.483192697080085e-07
women O 0 2.989320080359903e-07
) O 0 1.3019420919135882e-07
. O 0 3.0273128004409955e-07

The O 0 3.428969250762748e-07
control O 0 1.3993974334880477e-06
women O 0 5.903732969159137e-08
were O 0 2.834662060635651e-09
enrolled O 0 6.015972076056642e-08
regardless O 0 9.334205408606522e-09
of O 0 8.036108445352852e-10
whether O 0 1.7838818200388573e-09
or O 0 2.853126401802797e-09
not O 0 2.811539057123724e-10
they O 0 3.0766195147080566e-10
had O 0 5.963326721314388e-09
either O 0 5.153592042006494e-08
mutation O 0 2.4695476895431057e-05
. O 0 1.896794401545776e-07

Lifetime O 0 0.00017522452981211245
histories O 0 3.911842668458121e-06
of O 0 1.5409305831326492e-07
oral O 0 2.6170117052970454e-05
- O 0 8.403929678024724e-05
contraceptive O 0 1.4301984265330248e-05
use O 0 2.5268138692524644e-09
were O 0 5.910081313231785e-10
obtained O 0 1.3658386643911058e-09
by O 0 9.300364367526015e-10
interview O 0 2.031360146759198e-08
or O 0 1.2219153466830335e-09
by O 0 5.54965740029445e-10
written O 0 4.2260658861259515e-10
questionnaire O 0 8.562493825081674e-09
and O 0 2.852624247928759e-10
were O 0 1.1265187671583021e-09
compared O 0 4.886699400685757e-08
between O 0 3.61022891581797e-08
patients O 0 8.502333912474569e-06
and O 0 8.461737088794052e-09
control O 0 1.0254140079268836e-06
women O 0 1.0084584545211328e-07
, O 0 1.8209611596375908e-09
after O 0 1.1016837220267917e-08
adjustment O 0 9.600119454944434e-08
for O 0 8.494235870237787e-10
year O 0 6.725240808691524e-09
of O 0 1.2324364861981962e-09
birth O 0 1.4526140148518607e-06
and O 0 4.2242806586045845e-08
parity O 0 4.718300624517724e-05
. O 0 7.844508900234359e-07

RESULTS O 0 1.724742105579935e-05
The O 0 1.8626809605848393e-07
adjusted O 0 1.8947903299704194e-05
odds O 0 0.0006385399028658867
ratio O 0 0.0016968827694654465
for O 0 0.06869512051343918
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999971389770508
associated O 0 2.957850256279926e-06
with O 0 6.7161907146839894e-09
any O 0 4.2188574855828165e-10
past O 0 1.0502473335449736e-09
use O 0 7.51797180065239e-10
of O 0 1.7870079860315968e-09
oral O 0 7.115515472833067e-06
contraceptives O 0 0.00044656789395958185
was O 0 8.644387321510294e-07
0 O 0 9.590993386154878e-07
. O 0 2.2971381952174852e-07

5 O 0 1.2770223065672326e-06
( O 0 1.843752173158464e-08
95 O 0 3.1091744290279166e-08
percent O 0 5.395131452701207e-08
confidence O 0 2.8700641863110832e-08
interval O 0 2.9281840951966842e-08
, O 0 3.8279510117256166e-10
0 O 0 1.9570483011932538e-09
. O 0 1.0969145730621577e-10
3 O 0 7.139859814486726e-10
to O 0 1.1735271088220145e-10
0 O 0 1.557955364717145e-08
. O 0 1.5663033092749856e-09
8 O 0 7.240568322686158e-08
) O 0 3.2942562455673396e-08
. O 0 1.889583387537641e-07

The O 0 1.0210706022917293e-05
risk O 0 0.00021068907517474145
decreased O 0 6.109922196628759e-06
with O 0 8.039331866882549e-09
increasing O 0 4.956586607818281e-08
duration O 0 1.227753330113046e-07
of O 0 6.708186228721047e-10
use O 0 1.565849228057914e-09
( O 0 4.162516997752164e-09
P O 0 1.051438403010252e-06
for O 0 4.767197747668206e-10
trend O 0 4.949491483330348e-08
, O 0 1.7444470312710791e-09
< O 0 3.6593479535440565e-07
0 O 0 8.317689648151827e-09
. O 0 3.985361762826045e-10
001 O 0 1.1953628131777805e-07
) O 0 1.7366347249136993e-10
; O 0 6.314098549564662e-11
use O 0 5.781325765341627e-11
for O 0 5.989721219012978e-11
six O 0 8.174219079393197e-10
or O 0 2.9524421796267575e-10
more O 0 1.67283104035576e-10
years O 0 2.312233737811198e-09
was O 0 1.2468546195520958e-09
associated O 0 1.0147980233909948e-09
with O 0 2.8200569657244046e-10
a O 0 9.42780253865294e-09
60 O 0 6.508254557502369e-08
percent O 0 6.746178087269072e-07
reduction O 0 6.148758075141814e-06
in O 0 1.6132852920236473e-07
risk O 0 6.142081110738218e-05
. O 0 4.4879240590489644e-07

Oral O 0 0.001026503392495215
- O 0 0.0006111585535109043
contraceptive O 0 0.0008331136195920408
use O 0 1.792539592315734e-06
protected O 0 0.009745653718709946
against O 1 0.6171157956123352
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999734163284302
both O 0 1.1991097004226958e-08
for O 0 2.8979791899530483e-09
carriers O 0 3.006000781624607e-07
of O 0 4.043263057695867e-09
the O 0 2.63485020468579e-07
BRCA1 O 0 0.3449806571006775
mutation O 0 0.00016228623280767351
( O 0 2.0635738451346697e-08
odds O 0 2.076634928016574e-06
ratio O 0 8.397716300123648e-08
, O 0 7.40982164515458e-10
0 O 0 1.7954400188813224e-09
. O 0 1.289017365069256e-10
5 O 0 7.963372183894535e-10
; O 0 2.977426361017166e-10
95 O 0 2.557964950966607e-09
percent O 0 1.4515704194195678e-08
confidence O 0 1.1316513059966837e-08
interval O 0 2.579091074039752e-08
, O 0 5.237220657150488e-10
0 O 0 1.113216185899546e-09
. O 0 6.128022395079924e-11
3 O 0 2.6677213216252937e-10
to O 0 2.593822726049133e-11
0 O 0 1.4189858177360293e-09
. O 0 1.2672744797992408e-10
9 O 0 5.280484050018686e-09
) O 0 1.6478859943269697e-10
and O 0 9.833053815633264e-11
for O 0 4.0095238240667186e-10
carriers O 0 7.05243223819707e-08
of O 0 1.0367926517318438e-09
the O 0 8.050076161225661e-08
BRCA2 O 0 0.020878512412309647
mutation O 0 3.212401134078391e-05
( O 0 6.563839249906778e-09
odds O 0 1.036930598274921e-06
ratio O 0 8.591912603606033e-08
, O 0 7.584440853136698e-10
0 O 0 1.9455073108076704e-09
. O 0 8.121438244135248e-11
4 O 0 1.0150690288313058e-09
; O 0 3.05769437547454e-10
95 O 0 4.166504474767407e-09
percent O 0 2.7630159493696738e-08
confidence O 0 1.7789218986763444e-08
interval O 0 1.6172263528346775e-08
, O 0 3.1998248495312964e-10
0 O 0 1.3645029550701793e-09
. O 0 6.195859797442083e-11
2 O 0 6.267498742218436e-10
to O 0 9.515192106457349e-11
1 O 0 5.686253690129206e-09
. O 0 1.4485882493531221e-09
1 O 0 3.135628290351633e-08
) O 0 2.563192147420068e-08
. O 0 8.680829921559052e-08

CONCLUSIONS O 0 3.089366146014072e-05
Oral O 0 0.0001565808051964268
- O 0 0.0002590646327007562
contraceptive O 0 0.0001100372028304264
use O 0 6.907812633016874e-08
may O 0 9.926873900667488e-08
reduce O 0 3.428367563174106e-07
the O 0 8.711681687145756e-08
risk O 0 0.0007033980218693614
of O 0 0.0008399932412430644
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999959468841553
in O 0 5.251620791568712e-07
women O 0 2.0494964303452434e-07
with O 0 5.562443305962006e-08
pathogenic O 0 5.143201633472927e-05
mutations O 0 1.0604254384816159e-05
in O 0 1.974401087068145e-08
the O 0 1.008379655331737e-07
BRCA1 O 0 0.002549456898123026
or O 0 4.23760639023385e-06
BRCA2 O 0 0.031958915293216705
gene O 0 0.00037791041540913284

A O 0 1.0919934538833331e-05
Japanese O 0 8.175727089110296e-06
family O 0 3.3537671697558835e-06
with O 0 8.606343726569321e-07
adrenoleukodystrophy B-Disease 1 0.999330997467041
with O 0 4.5237182888513416e-08
a O 0 6.866473256650352e-08
codon O 0 6.987306164774054e-07
291 O 0 5.430408123174857e-07
deletion O 0 1.4600066606362816e-05
: O 0 1.775694791206206e-08
a O 0 4.356894223178642e-08
clinical O 0 5.883218364033382e-06
, O 0 4.882019677410199e-09
biochemical O 0 2.8062436285836156e-06
, O 0 1.6369078537081805e-08
pathological O 0 3.188819027855061e-05
, O 0 2.2827437717864996e-08
and O 0 1.6182268325337645e-07
genetic O 0 0.00016272925131488591
report O 0 1.547311399008322e-06
. O 0 5.747382942900003e-07

We O 0 1.1790540384026826e-06
report O 0 1.7381086081513786e-07
a O 0 5.957645399234934e-08
Japanese O 0 2.461127337483049e-07
family O 0 1.2802806850231718e-06
with O 0 2.4915261747082695e-05
adrenoleukodystrophy B-Disease 1 0.9999938011169434
( O 0 3.79397242795676e-05
ALD B-Disease 1 0.9999492168426514
) O 0 1.8877599927691335e-08
with O 0 3.3756446526922446e-09
a O 0 1.5910091022419692e-08
three O 0 5.6349476196260184e-09
base O 0 2.3054712983139325e-07
pair O 0 3.6546188653119316e-07
deletion O 0 6.010426204738906e-06
( O 0 1.5463443858720893e-08
delGAG O 0 6.51388199912617e-06
291 O 0 2.119407866985057e-07
) O 0 5.205494257864984e-09
in O 0 1.469998345271506e-08
the O 0 2.8682919150924135e-07
ALD B-Disease 1 0.9994848966598511
gene O 0 0.0001393742859363556
. O 0 9.60565785135259e-07

A O 0 1.1840436400234466e-06
variety O 0 1.0325526034193899e-07
of O 0 1.825190310000835e-08
phenotypes O 0 3.950846439693123e-05
were O 0 1.3397384535096535e-08
observed O 0 4.243128159941989e-08
within O 0 6.631516225041878e-09
this O 0 3.6872653819131074e-09
family O 0 4.0066959172690986e-07
. O 0 2.8128275175731687e-07

While O 0 1.378890033265634e-06
the O 0 2.4907890860959014e-07
proband O 0 0.0007163647678680718
( O 0 2.3810994775885774e-07
patient O 0 1.5709418221376836e-05
1 O 0 3.64216887760449e-08
) O 0 3.450255414705339e-09
was O 0 3.982794982704263e-09
classified O 0 1.2731582010871989e-08
as O 0 4.023543165310173e-10
having O 0 2.4288178135378757e-09
a O 0 1.0346399292870956e-08
rare O 0 7.59581268994225e-08
intermediate O 0 3.5018589983337733e-07
type O 0 3.2767852076176496e-07
of O 0 5.611180409204053e-09
adult O 0 2.432208930258639e-06
cerebral O 0 0.15254302322864532
and O 0 1.8001097714659409e-06
cerebello O 1 0.9957411289215088
- O 1 0.99037104845047
brain O 0 0.12694545090198517
stem O 0 8.180610166164115e-06
forms O 0 3.066206488711032e-08
, O 0 3.145378624225259e-09
his O 0 1.2312576735951097e-08
younger O 0 6.710040452162502e-07
brother O 0 1.8930550140794367e-06
( O 0 4.0753803887128015e-08
patient O 0 4.5299448174773715e-06
2 O 0 1.3211558069770035e-08
) O 0 1.634529733784973e-09
and O 0 4.825253085982695e-09
nephew O 0 3.089675374212675e-05
( O 0 2.1253080717542616e-07
patient O 0 3.126124283880927e-05
3 O 0 1.0207176615040225e-07
) O 0 6.866470503297251e-09
had O 0 5.416857007389808e-08
a O 0 4.758146133099217e-06
childhood O 0 0.2830546498298645
ALD B-Disease 1 0.999967098236084
type O 0 0.013724714517593384
. O 0 4.054558758070925e-06

Another O 0 1.3595241398434155e-05
nephew O 0 0.0010493631707504392
( O 0 1.068301685336337e-06
patient O 0 5.0146445573773235e-05
4 O 0 7.416416991645747e-08
) O 0 2.4178723467827012e-09
of O 0 2.7434845506491e-09
patient O 0 1.1194616490683984e-05
1 O 0 5.712193384965758e-08
was O 0 2.5267478775958807e-08
classified O 0 8.056666445099836e-08
as O 0 1.3371264095951574e-09
having O 0 9.122901545310924e-09
an O 0 1.0075122958141947e-08
adolescent O 0 0.00031415390549227595
form O 0 2.1575572191068204e-06
. O 0 1.0339533673686674e-06

The O 0 3.9531758488919877e-07
tau O 0 7.846987500670366e-06
level O 0 2.3724022923943267e-07
in O 0 2.0629638441960196e-08
the O 0 3.9545021479625575e-08
cerebrospinal O 0 0.007546947803348303
fluid O 0 0.00046779285185039043
( O 0 2.2185122361406684e-07
CSF O 0 0.06506863236427307
) O 0 1.0975707454008443e-08
in O 0 1.1834092816798147e-08
patient O 0 1.962647502296022e-06
1 O 0 9.900625208558722e-09
was O 0 2.3458659459407727e-09
as O 0 4.714184043130842e-10
high O 0 2.403028176445332e-08
as O 0 3.4363764611633485e-10
that O 0 2.1834066499248905e-10
of O 0 1.0175081222030258e-08
patients O 0 0.0005779564962722361
with O 0 9.927250357577577e-05
Alzheimers B-Disease 1 0.9999958276748657
disease I-Disease 1 0.9958792924880981
( O 0 1.828741744702711e-07
AD B-Disease 0 2.2337030713970307e-06
) O 0 6.449383960216437e-08
. O 0 2.1588488152701757e-07

His O 0 8.823336429486517e-06
brain O 0 0.0012806685408577323
magnetic O 0 6.614454832742922e-06
resonance O 0 2.8287575332797132e-05
image O 0 3.5236418625572696e-05
( O 0 3.711462568389834e-07
MRI O 0 0.002401672536507249
) O 0 9.740238482436325e-08
showed O 0 3.756583737413166e-06
abnormalities B-Disease 0 0.00032627646578475833
in I-Disease 0 3.646476676166799e-09
the I-Disease 0 3.0842473019987438e-09
bilateral I-Disease 0 3.013739728885412e-07
cerebellar I-Disease 0 0.10550879687070847
hemispheres I-Disease 0 3.5920274967793375e-05
and O 0 9.901079920382472e-07
brain O 0 0.03662610054016113
stem O 0 3.887868660967797e-05
, O 0 5.961086735339904e-09
but O 0 8.588758038108324e-10
not O 0 2.542718813280942e-10
in O 0 2.763267392680291e-09
the O 0 3.910757584435487e-08
cerebral O 0 0.014826265163719654
white O 0 3.581605824365397e-06
matter O 0 6.7844161399932545e-09
, O 0 1.0304053166265703e-09
where O 0 1.7444603539473746e-09
marked O 0 9.527082056592917e-08
reductions O 0 8.398435511480784e-07
of O 0 9.657742383595291e-10
the O 0 1.813108774229022e-08
cerebral O 0 0.0019974636379629374
blood O 0 4.8930269258562475e-06
flow O 0 5.54631931493077e-08
and O 0 3.04339975443213e-09
oxygen O 0 6.481953960246756e-07
metabolism O 0 8.064550911512924e-07
were O 0 1.597296406252724e-09
clearly O 0 6.622971504555153e-09
demonstrated O 0 1.5518342166842558e-08
by O 0 2.3320230191359315e-09
positron O 0 6.986544030951336e-05
emission O 0 1.7012185708153993e-05
tomography O 0 8.451643225271255e-05
( O 0 1.3746135607561882e-07
PET O 0 1.8993294361280277e-05
) O 0 9.947704882051767e-08
. O 0 1.9287769248421682e-07

In O 0 1.2554420209198724e-05
patients O 0 7.4593277531676e-05
2 O 0 7.061194651214464e-08
and O 0 4.732032543586229e-09
3 O 0 1.9513354487799006e-08
, O 0 1.3594503300851102e-09
the O 0 1.3093152340104552e-08
autopsy O 0 0.000469568301923573
findings O 0 3.259495315433014e-06
showed O 0 1.2122784028179012e-05
massive O 0 0.004873023834079504
demyelination B-Disease 1 0.999021053314209
of I-Disease 0 5.2643063241930577e-08
the I-Disease 0 7.057665811771585e-07
cerebral I-Disease 0 0.26324623823165894
white I-Disease 0 3.818890490947524e-06
matter I-Disease 0 3.869782272403199e-09
with O 0 8.71097582955116e-10
sparing O 0 2.4256246788922908e-08
of O 0 8.649090332824017e-10
the O 0 8.220816916093554e-09
U O 0 3.2228705094894394e-05
- O 0 6.117634620750323e-05
fibers O 0 3.255082390296593e-07
, O 0 3.860947950240501e-10
compatible O 0 2.6758204541010855e-09
with O 0 8.495564252086751e-10
the O 0 3.5128342457113604e-09
findings O 0 1.0378541759337168e-07
of O 0 8.813851337663436e-08
childhood O 0 0.10663235187530518
ALD B-Disease 1 0.9999048709869385
. O 0 1.110101948142983e-05

Oleic O 0 0.012590342201292515
and O 0 9.713631925478694e-07
erucic O 0 0.00247355829924345
acids O 0 9.272278020944213e-07
( O 0 1.2927882764302012e-08
Lorenzos O 0 2.4938747174019227e-06
Oil O 0 1.069096811079362e-08
) O 0 8.000383133754951e-10
were O 0 4.091046390541919e-10
administered O 0 2.7220842468977935e-08
to O 0 8.299935738698139e-10
patients O 0 7.336446401495778e-07
1 O 0 4.366642603059745e-09
and O 0 8.334661849573877e-10
4 O 0 1.632069412949022e-08
, O 0 1.3599871229175164e-09
but O 0 8.599429501821021e-10
sufficient O 0 8.796498640606387e-09
effectiveness O 0 2.997590229369962e-07
was O 0 1.689055650899718e-08
not O 0 1.5390229091138963e-09
obtained O 0 7.327999895778703e-08
. O 0 1.1874253402766044e-07

The O 0 5.231929094406951e-07
findings O 0 6.653893365182739e-07
in O 0 9.656642596667098e-09
this O 0 1.0560041729945624e-09
family O 0 2.2251693820862783e-08
suggest O 0 1.8980280458436027e-08
that O 0 3.6428599026194775e-10
delGAG291 O 0 1.3690262221643934e-06
is O 0 5.290906046617749e-10
part O 0 8.018194441739013e-10
of O 0 3.9930239670304957e-10
the O 0 5.09049824515273e-09
cause O 0 1.9239912774082768e-07
of O 0 6.478169556345392e-09
Japanese O 0 6.038716037437553e-06
ALD B-Disease 1 0.9977974891662598
with O 0 1.6461072505080665e-07
phenotypic O 0 0.00020976425730623305
variations O 0 3.063942858716473e-05
. O 0 1.1789607015089132e-06

Moreover O 0 2.517725806683302e-05
, O 0 5.348104892277661e-08
although O 0 3.741932541601045e-09
the O 0 7.046482841666091e-10
scale O 0 4.97244698749455e-08
of O 0 5.122833268700333e-10
the O 0 2.8053588341236946e-09
study O 0 8.198441037166049e-09
is O 0 8.516558014370901e-10
limited O 0 2.833359324938556e-09
, O 0 5.963414762000241e-10
there O 0 2.7152002868291447e-10
is O 0 4.5983186702791556e-10
a O 0 1.0419991980370469e-08
possibility O 0 6.043954670076346e-08
that O 0 8.120126238075898e-10
PET O 0 2.996603598148795e-06
can O 0 4.5072656718048165e-09
detect O 0 1.7249425354748382e-06
an O 0 1.825803153110428e-08
insidious B-Disease 0 0.0020233422983437777
lesion I-Disease 0 0.12721729278564453
which O 0 3.755775690450491e-09
is O 0 3.766837952667856e-09
undetectable O 0 8.888077900337521e-07
by O 0 1.20918230983591e-09
computed O 0 2.7357950216355675e-07
tomogram O 0 3.8163401768542826e-05
( O 0 2.608686244798264e-08
CT O 0 0.001418653060682118
) O 0 1.891824918942575e-09
or O 0 2.7912896438664347e-09
MRI O 0 3.5780960843112553e-06
analysis O 0 2.643899543741668e-09
, O 0 2.182432290442904e-10
and O 0 9.647666693313184e-11
that O 0 3.291148256701071e-11
the O 0 1.2470086074856113e-10
higher O 0 1.155472606484409e-09
level O 0 5.095761035356361e-10
of O 0 2.260885229032894e-10
tau O 0 2.0343676965239865e-07
reflects O 0 1.7811552233126804e-09
the O 0 1.8646550969947384e-10
process O 0 7.24195703405428e-10
of O 0 5.586618723185666e-09
neuronal B-Disease 0 0.000653678085654974
degeneration I-Disease 1 0.9829404950141907
in O 0 6.99563097441569e-05
ALD B-Disease 1 0.9998505115509033
. O 0 1.2021726433886215e-05

Lorenzos O 0 0.0014950871700420976
Oil O 0 1.4422790854951018e-06
should O 0 2.117152853031712e-08
be O 0 7.344224672856114e-10
given O 0 5.941547809307224e-10
in O 0 5.967863425659914e-10
the O 0 1.157963502862458e-09
early O 0 2.4674061904761402e-08
stage O 0 1.28618421513238e-06
. O 0 1.772176005943038e-08
. O 0 1.9635707815268688e-07

Nonsense O 0 0.003189848270267248
mutation O 0 0.0009617369505576789
in O 0 2.5919729296219884e-07
exon O 0 1.6262427379842848e-05
4 O 0 4.995185065581609e-08
of O 0 1.9593864308831144e-09
human O 0 9.082951279992812e-09
complement O 0 1.3857938085948263e-07
C9 O 0 0.017533354461193085
gene O 0 2.038554157479666e-06
is O 0 5.495623511819758e-09
the O 0 3.1852731563475345e-09
major O 0 7.155162506933266e-08
cause O 0 1.912955127636451e-07
of O 0 6.561235998958637e-09
Japanese O 0 4.915791123494273e-06
complement B-Disease 0 0.0006592792924493551
C9 I-Disease 1 0.9996360540390015
deficiency I-Disease 1 0.999396800994873
. O 0 4.488857939577429e-06

Deficiency B-Disease 1 0.9945940375328064
of I-Disease 0 1.1175549730069179e-07
the I-Disease 0 2.6446118184253464e-08
ninth I-Disease 0 5.321892331267009e-07
component I-Disease 0 5.6925397728946336e-08
of I-Disease 0 1.4503658274378495e-09
human I-Disease 0 1.0805729644403073e-08
complement I-Disease 0 9.731752470543142e-08
( O 0 1.8069911789098114e-08
C9 O 0 0.000948010419961065
) O 0 2.0935482236694725e-09
is O 0 7.77440667398821e-10
the O 0 8.376560556300205e-10
most O 0 1.1810861177963261e-09
common O 0 7.966963266881066e-07
complement B-Disease 0 0.478375643491745
deficiency I-Disease 1 0.999927282333374
in O 0 6.476244607256376e-08
Japan O 0 1.745835191968581e-07
but O 0 3.959738315018058e-09
is O 0 2.406618460071286e-09
rare O 0 1.222125778355121e-08
in O 0 7.504262211632806e-10
other O 0 4.168108358459932e-10
countries O 0 7.153112768776282e-09
. O 0 1.4144177384878276e-07

We O 0 2.2266176813445782e-07
studied O 0 8.629719872033093e-08
the O 0 3.984740537532616e-09
molecular O 0 1.5715340850874782e-07
basis O 0 5.412083226019604e-09
of O 0 1.133158278321389e-07
C9 B-Disease 1 0.9997569918632507
deficiency I-Disease 1 0.9804850816726685
in O 0 1.430620510944891e-08
four O 0 5.003442993256613e-08
Japanese O 0 3.6236169762560166e-06
C9 B-Disease 1 0.9989792108535767
- I-Disease 1 0.9975845813751221
deficient I-Disease 1 0.9964990615844727
patients O 0 0.0018858398543670774
who O 0 5.021885840506002e-07
had O 0 1.8462916386852157e-06
suffered O 0 0.159371018409729
from O 0 4.0628965507494286e-05
meningococcal B-Disease 1 0.9998732805252075
meningitis I-Disease 1 0.9997130036354065
. O 0 4.4027960939274635e-06

Direct O 0 2.9673108770111867e-07
sequencing O 0 1.0850443459275994e-06
of O 0 2.0479797413486267e-08
amplified O 0 4.4587014258468116e-07
C9 O 0 4.4103770051151514e-05
cDNA O 0 6.377359795806115e-07
and O 0 2.5769963940547314e-08
DNA O 0 3.8419516386056785e-06
revealed O 0 3.760465858704265e-07
a O 0 2.570300594584296e-08
nonsense O 0 4.1584965515539807e-07
substitution O 0 2.7283579839831873e-08
( O 0 7.480001507076395e-09
CGA O 0 1.7410149666829966e-05
- O 0 3.2733278203522786e-05
- O 0 1.7570275304024108e-05
> O 0 1.0005435342463898e-06
TGA O 0 4.473242370295338e-06
) O 0 4.2252756848881745e-10
at O 0 6.635536564658651e-10
codon O 0 8.369299031585342e-09
95 O 0 1.1470778771283108e-09
in O 0 3.428866912624784e-10
exon O 0 8.708226317821754e-08
4 O 0 4.89537255177197e-09
in O 0 4.5560641370734345e-10
the O 0 1.5183737600565905e-09
four O 0 1.1402794797277238e-07
C9 B-Disease 1 0.9351511597633362
- I-Disease 1 0.6460370421409607
deficient I-Disease 0 0.08817193657159805
individuals O 0 2.429885341825866e-07
. O 0 3.5766387895819207e-07

An O 0 7.908568591119547e-07
allele O 0 2.6031302695628256e-05
- O 0 2.6513493139646016e-05
specific O 0 4.329317704332425e-08
polymerase O 0 5.813928055431461e-06
chain O 0 2.200526068918407e-05
reaction O 0 1.64434368343791e-07
system O 0 8.114714944440493e-08
designed O 0 1.7100287408311488e-08
to O 0 3.0969019015891774e-10
detect O 0 5.5788913044807487e-08
exclusively O 0 7.930495704577822e-10
only O 0 3.694681713350967e-11
one O 0 3.3928630738255805e-11
of O 0 3.18327759984971e-11
the O 0 1.5210049886249521e-10
normal O 0 5.777164968634452e-09
and O 0 6.37792541002824e-10
mutant O 0 5.26351357166277e-07
alleles O 0 5.369917488451392e-08
indicated O 0 8.66276472777372e-09
that O 0 3.938823572857686e-11
all O 0 1.816338746074564e-11
the O 0 4.0045791682707943e-10
four O 0 1.3089357153717174e-08
patients O 0 3.821236589374166e-07
were O 0 6.076208980410058e-10
homozygous O 0 4.699421296550099e-08
for O 0 2.417737399174058e-10
the O 0 1.3488041794573746e-09
mutation O 0 1.4990234831202542e-07
in O 0 1.1120192544566976e-09
exon O 0 5.421786681836238e-07
4 O 0 1.2869869614462459e-08
and O 0 4.0193476325001143e-10
that O 0 5.4971693863592463e-11
the O 0 1.7642418081997846e-10
parents O 0 3.5832667943935803e-09
of O 0 3.2364708690835187e-09
patient O 0 7.939165698189754e-06
2 O 0 1.0281878104478892e-07
were O 0 1.811905647741696e-08
heterozygous O 0 9.737647815200035e-06
. O 0 3.4305065810258384e-07

The O 0 1.0937839078906109e-06
common O 0 1.1201045708730817e-06
mutation O 0 1.4154220480122603e-05
at O 0 3.085637700905863e-08
codon O 0 1.0694601826344297e-07
95 O 0 1.2049905073752143e-08
in O 0 1.8468028217810684e-09
exon O 0 1.566820174048189e-06
4 O 0 6.426029841577474e-08
might O 0 2.1254502602374714e-09
be O 0 6.007765118720698e-11
responsible O 0 1.713835184879997e-09
for O 0 8.476529478329553e-10
most O 0 1.791424963926147e-08
Japanese O 0 0.00012146877270424739
C9 B-Disease 1 0.9998925924301147
deficiency I-Disease 1 0.9995899796485901
. O 0 2.445391089622717e-07
. O 0 8.060906111495569e-07

BRCA1 O 0 0.014300473034381866
required O 0 8.351456131094892e-07
for O 0 2.9181483895968086e-08
transcription O 0 5.85170937483781e-06
- O 0 9.778783714864403e-05
coupled O 0 1.5231193174258806e-05
repair O 0 0.0005025676218792796
of O 0 2.3112083624710067e-07
oxidative O 1 0.6623115539550781
DNA O 0 0.146430104970932
damage O 0 0.036145471036434174
. O 0 4.926745077682426e-06

The O 0 0.0004294073150958866
breast B-Disease 1 0.9998362064361572
and I-Disease 1 0.9251225590705872
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999951124191284
susceptibility O 1 0.9316204786300659
gene O 0 0.0001925283286254853
BRCA1 O 0 0.0007936516194604337
encodes O 0 5.316809392752475e-07
a O 0 6.005213322168856e-07
zinc O 0 3.9678070606896654e-05
finger O 0 6.041506139808916e-07
protein O 0 3.154356065238062e-08
of O 0 2.793595799133186e-09
unknown O 0 1.1697787982711816e-07
function O 0 2.1930883065124362e-07
. O 0 3.7784184314659797e-07

Association O 0 8.85851136445126e-07
of O 0 1.3366679318949082e-08
the O 0 1.120232795415177e-08
BRCA1 O 0 1.9602679458330385e-05
protein O 0 1.6415288683901963e-08
with O 0 1.003289118450823e-09
the O 0 1.9498871406398166e-09
DNA O 0 1.479265279158426e-06
repair O 0 6.205256067914888e-05
protein O 0 5.790361683466472e-07
Rad51 O 0 0.00010437603486934677
and O 0 1.5086482063608742e-09
changes O 0 2.0138333223229665e-09
in O 0 1.6279079473324742e-10
the O 0 5.375668313267745e-11
phosphorylation O 0 6.979748445878897e-10
and O 0 1.057747361921102e-10
cellular O 0 2.6276225639776385e-08
localization O 0 1.0808038908294293e-08
of O 0 1.8706040882943142e-10
the O 0 5.12387909878953e-10
protein O 0 1.927233839182918e-08
after O 0 1.9621587910023663e-08
exposure O 0 3.781543966852041e-07
to O 0 5.735003583140497e-10
DNA O 0 3.418955202505458e-06
- O 0 1.892637556011323e-05
damaging O 0 2.9167852062528254e-06
agents O 0 1.8037059845710246e-08
are O 0 1.0450414839047184e-10
consistent O 0 1.29861499331696e-09
with O 0 2.3837706808471637e-10
a O 0 2.0743973205838984e-09
role O 0 7.010452218736418e-09
for O 0 1.9043957522058008e-08
BRCA1 O 0 0.002485246630385518
in O 0 3.9108476812543813e-07
DNA O 0 0.0001530262379674241
repair O 0 0.007578517310321331
. O 0 1.059571673067694e-06

Here O 0 9.165179335468565e-07
, O 0 2.1498534508168632e-08
it O 0 1.5927664742676484e-09
is O 0 1.3340896165559002e-09
shown O 0 3.892775879421606e-09
that O 0 8.353521763204697e-10
mouse O 0 1.4775705494685099e-06
embryonic O 0 3.2223786547547206e-05
stem O 0 3.769276736420579e-05
cells O 0 4.6069235395407304e-05
deficient B-Disease 0 0.0025327512994408607
in I-Disease 0 5.985413054077071e-08
BRCA1 I-Disease 0 0.00021702214144170284
are O 0 3.104585921676062e-09
defective O 0 1.0650545618773322e-06
in O 0 1.0685824447520531e-09
the O 0 3.2819855166899004e-10
ability O 0 4.865099434425701e-10
to O 0 4.207324072469376e-11
carry O 0 2.586186542696822e-10
out O 0 3.0458607858108167e-10
transcription O 0 4.019957700052146e-08
- O 0 2.7915416467294563e-06
coupled O 0 6.238356036192272e-07
repair O 0 1.874377267085947e-05
of O 0 1.1148911127634165e-08
oxidative O 0 0.06046309694647789
DNA O 0 0.012763723731040955
damage O 0 0.0002675080322660506
, O 0 2.109010299733427e-09
and O 0 8.495175674028133e-10
are O 0 7.729518136656566e-10
hypersensitive O 0 1.1135372915305197e-05
to O 0 1.3342735805110806e-08
ionizing O 0 0.03587210178375244
radiation O 0 0.00418309448286891
and O 0 3.93855934532894e-08
hydrogen O 0 2.4214648874476552e-05
peroxide O 0 0.012641115114092827
. O 0 1.4525476217386313e-06

These O 0 5.821540298711625e-07
results O 0 4.185362286079908e-06
suggest O 0 3.6765615618605807e-07
that O 0 8.346486168875344e-09
BRCA1 O 0 4.609207826433703e-05
participates O 0 1.6491571841470432e-07
, O 0 1.8285345460000713e-09
directly O 0 7.926835854377146e-10
or O 0 8.085059843843112e-10
indirectly O 0 5.978564754371973e-09
, O 0 3.9587697009402234e-10
in O 0 7.945424318478445e-10
transcription O 0 1.8258472778143187e-07
- O 0 2.1833520804648288e-05
coupled O 0 3.6747251215274446e-06
repair O 0 9.94255969999358e-05
of O 0 4.307728929120458e-08
oxidative O 0 0.22579997777938843
DNA O 0 0.03272542357444763
damage O 0 0.001267572632059455
. O 0 9.327997219088502e-08
. O 0 4.1687172824822483e-07

Truncation O 0 0.0025678130332380533
mutations O 0 0.0020842012017965317
in O 0 1.9920231864034577e-07
the O 0 4.409404397165417e-08
transactivation O 0 3.6138106224825606e-05
region O 0 2.4876175075405627e-07
of O 0 6.183328515874109e-09
PAX6 O 0 0.0005732558784075081
result O 0 2.1552405371494388e-07
in O 0 2.7215650177936368e-08
dominant O 0 1.3064213817415293e-05
- O 0 0.0005117810796946287
negative O 0 1.2789089396392228e-06
mutants O 0 1.1574888048926368e-05
. O 0 2.616333460991882e-07

PAX6 O 0 0.09507880359888077
is O 0 2.8389118256200163e-07
a O 0 3.1656270493840566e-08
transcription O 0 6.149563347435105e-08
factor O 0 1.3043525370903808e-08
with O 0 1.1432707003322662e-09
two O 0 2.054199033096893e-09
DNA O 0 9.025478675539489e-07
- O 0 9.424871905139298e-07
binding O 0 2.1202726685487505e-08
domains O 0 4.482012627704535e-08
( O 0 3.303327389403421e-09
paired O 0 1.0198867528288247e-07
box O 0 9.533189881949511e-08
and O 0 3.1613713868949844e-09
homeobox O 0 3.0440601221926045e-06
) O 0 5.931243829415678e-10
and O 0 5.588129403655273e-10
a O 0 4.605131831425524e-09
proline O 0 1.3086182661936618e-06
- O 0 5.281079211272299e-06
serine O 0 7.64630897265306e-07
- O 0 7.806486792105716e-06
threonine O 0 1.3453909559757449e-06
( O 0 2.4831086520293866e-08
PST O 0 5.245576903689653e-05
) O 0 1.638544588900004e-08
- O 0 1.502809709563735e-06
rich O 0 1.1279603739922095e-07
transactivation O 0 3.630165520007722e-05
domain O 0 2.3482141386921285e-06
. O 0 4.174995069661236e-07

PAX6 O 1 0.8035212755203247
regulates O 0 0.013313834555447102
eye O 0 0.006617254577577114
development O 0 1.0890666999330278e-06
in O 0 7.23199775620742e-08
animals O 0 3.454708874528478e-08
ranging O 0 1.2413363492669305e-07
from O 0 2.996982439995577e-09
jellyfish O 0 9.799627775919362e-08
to O 0 3.9722328204483404e-10
Drosophila O 0 9.437625791974824e-09
to O 0 2.2456552173366617e-09
humans O 0 7.25042212934568e-08
. O 0 1.671320291052325e-07

Heterozygous O 0 0.0013831483665853739
mutations O 0 0.0008359731873497367
in O 0 1.2857569231528032e-07
the O 0 1.557206807945022e-08
human O 0 1.340462318921709e-07
PAX6 O 0 0.010060001164674759
gene O 0 1.2839158216593205e-06
result O 0 4.00417050627766e-08
in O 0 1.5104334449844714e-09
various O 0 1.2502577861894792e-09
phenotypes O 0 8.146106665662955e-06
, O 0 1.0037680908681068e-08
including O 0 2.6710037559496413e-07
aniridia B-Disease 1 0.9995798468589783
, O 0 4.821346010430716e-06
Peters B-Disease 1 0.9346138834953308
anomaly I-Disease 1 0.9968144297599792
, O 0 1.4695071968162665e-06
autosomal B-Disease 0 0.2142680585384369
dominant I-Disease 0 0.00323682464659214
keratitis I-Disease 1 0.9243625998497009
, O 0 7.765831355754926e-07
and O 0 2.95792938231898e-06
familial B-Disease 1 0.9996784925460815
foveal I-Disease 1 0.999754011631012
dysplasia I-Disease 1 0.9999154806137085
. O 0 6.42880258965306e-05

It O 0 3.9935235918164835e-07
is O 0 3.194644904169763e-08
believed O 0 1.3355363925882102e-08
that O 0 2.398249931978569e-10
the O 0 4.382911811262602e-10
mutated O 0 1.977114472140329e-08
allele O 0 6.080246528483713e-09
of O 0 9.024630487353136e-10
PAX6 O 0 2.722694625845179e-05
produces O 0 1.251909687027819e-08
an O 0 8.237104331954015e-10
inactive O 0 1.3448517677261407e-07
protein O 0 9.00816203852628e-08
and O 0 3.9697827247664463e-08
aniridia B-Disease 1 0.9648213386535645
is O 0 1.220266341306342e-07
caused O 0 7.465856697308482e-07
due O 0 8.202417234315362e-08
to O 0 1.5586390844646303e-08
genetic O 0 0.00010356208076700568
haploinsufficiency O 0 0.019422972574830055
. O 0 1.8738573999144137e-06

However O 0 6.763248165952973e-07
, O 0 1.4455694419268639e-08
several O 0 7.27404980693791e-09
truncation O 0 1.459644681744976e-05
mutations O 0 2.439767195028253e-05
have O 0 3.882513421871181e-09
been O 0 1.9075210300201206e-09
found O 0 1.4810775939011478e-09
to O 0 1.8501442045071315e-10
occur O 0 3.0379134763336424e-09
in O 0 9.722170846160338e-10
the O 0 3.778005019938746e-09
C O 0 7.369355330411054e-07
- O 0 1.2849642416767892e-06
terminal O 0 2.7656741963255627e-07
half O 0 3.285224980942303e-09
of O 0 1.0196815614094135e-09
PAX6 O 0 0.0012849541381001472
in O 0 5.9594068346768836e-08
patients O 0 1.830554538173601e-06
with O 0 1.672338356684122e-08
Aniridia B-Disease 0 0.12812955677509308
resulting O 0 1.6552344561659993e-07
in O 0 1.651672243419e-09
mutant O 0 5.93450941721585e-08
proteins O 0 1.065712518233397e-09
that O 0 7.736534329838562e-11
retain O 0 2.596844739244375e-09
the O 0 1.001659977184488e-09
DNA O 0 2.0402217160153668e-07
- O 0 1.2427958040461817e-07
binding O 0 4.78797668179709e-09
domains O 0 1.6364895216725017e-08
but O 0 5.930610447180129e-10
have O 0 2.402370524734465e-10
lost O 0 3.335528298009649e-09
most O 0 6.870445878881526e-11
of O 0 1.184243675345087e-10
the O 0 3.745517229702955e-09
transactivation O 0 1.3654281246999744e-05
domain O 0 1.6072898461061413e-06
. O 0 3.947758102640364e-07

It O 0 2.3631756107533874e-07
is O 0 1.998036758266153e-08
not O 0 7.695654113959449e-10
clear O 0 5.6984785778979585e-09
whether O 0 6.990232837011945e-10
such O 0 6.970289345709091e-10
mutants O 0 9.321494189862278e-07
really O 0 1.7583579037250274e-08
behave O 0 1.674313843125219e-08
as O 0 2.1431789676285007e-09
loss O 0 1.052218749464373e-06
- O 0 2.1086701451622503e-07
of O 0 3.8996550433267885e-10
- O 0 4.3202402366659953e-07
function O 0 6.400254548566409e-09
mutants O 0 2.106402945400987e-07
as O 0 2.574695567858498e-09
predicted O 0 1.8149673053358129e-07
by O 0 1.2459305587242397e-08
haploinsufficiency O 0 0.00013920241326559335
. O 0 3.689902428050118e-07

Contrary O 0 2.1686928448616527e-06
to O 0 1.0447774201338689e-08
this O 0 9.835084968656815e-10
theory O 0 3.682654625691839e-09
, O 0 3.6671063408100224e-10
our O 0 6.44726327880818e-10
data O 0 2.2007338174034885e-09
showed O 0 7.835117443732997e-09
that O 0 3.4317573088804565e-11
these O 0 2.7269854777078884e-11
mutants O 0 8.373306492615029e-09
are O 0 1.42866107832873e-10
dominant O 0 6.1883568491794e-08
- O 0 1.8630414615472546e-06
negative O 0 3.938767534350518e-09
in O 0 5.420748294682198e-10
transient O 0 2.1905673008859594e-07
transfection O 0 4.926660767523572e-05
assays O 0 7.526056151618832e-07
when O 0 2.479387584131132e-09
they O 0 1.3158329981166617e-10
are O 0 2.029267032188642e-10
coexpressed O 0 1.6710234831407433e-06
with O 0 3.2815567152510994e-08
wild O 0 4.0061977415462025e-06
- O 0 0.0011942458804696798
type O 0 6.295874482020736e-05
PAX6 O 0 0.05950991064310074
. O 0 1.9044595092054806e-06

We O 0 4.517643787949055e-07
found O 0 5.967038418930315e-08
that O 0 1.25324695066098e-09
the O 0 3.2566824792468196e-09
dominant O 0 1.3145872799213976e-06
- O 0 2.4435488739982247e-05
negative O 0 2.2127560228568655e-08
effects O 0 4.354883742507809e-08
result O 0 3.17018122863999e-09
from O 0 1.0537863637249956e-10
the O 0 1.3565822076788692e-10
enhanced O 0 4.611524317965632e-08
DNA O 0 1.2910614088923467e-07
binding O 0 5.965829608101103e-09
ability O 0 2.538538046437111e-09
of O 0 6.272605768131712e-10
these O 0 2.191179904187379e-09
mutants O 0 2.9988307232997613e-06
. O 0 1.3747983018674859e-07

Kinetic O 0 1.653493927733507e-05
studies O 0 3.7627762594638625e-07
of O 0 1.0656298066180625e-08
binding O 0 1.8837303628060909e-07
and O 0 1.1582689474209928e-08
dissociation O 0 3.6774312320631e-05
revealed O 0 1.0128883332072292e-07
that O 0 5.855859547265752e-11
various O 0 4.8971420668619814e-11
truncation O 0 1.0513064552242213e-07
mutants O 0 1.2354254863566894e-07
have O 0 3.033361062332318e-10
3 O 0 9.57539203483293e-09
- O 0 1.3011442661081674e-06
5 O 0 2.257190523380359e-08
- O 0 1.2551251984405098e-06
fold O 0 6.680624409227676e-08
higher O 0 1.6408988612326425e-09
affinity O 0 1.066753796408193e-09
to O 0 3.3537186916454687e-11
various O 0 1.280130723646522e-10
DNA O 0 9.71272697825043e-08
- O 0 6.70223201382214e-08
binding O 0 4.024665933854976e-09
sites O 0 1.0194968202981158e-09
when O 0 6.215676862098007e-10
compared O 0 3.3283469313971636e-09
with O 0 4.704187039905605e-10
the O 0 3.1309175252403065e-09
wild O 0 5.393700348577113e-07
- O 0 0.00010055756865767762
type O 0 2.0937757653882727e-05
PAX6 O 0 0.008851437829434872
. O 0 1.1753851367757306e-06

These O 0 1.8098786824793933e-07
results O 0 3.2418850537396793e-07
provide O 0 4.674316489428065e-09
a O 0 7.040199534458225e-09
new O 0 1.3899830175745365e-09
insight O 0 1.7032830701424473e-09
into O 0 2.945771127027541e-10
the O 0 3.457269470708013e-10
role O 0 8.540682605584493e-10
of O 0 1.7477242986174701e-09
mutant O 0 9.008073902805336e-06
PAX6 O 0 0.0029453991446644068
in O 0 2.7235182642471045e-07
causing O 0 0.00012664317910093814
aniridia B-Disease 1 0.9618188738822937
. O 0 1.6699755178706255e-07
. O 0 4.2244661813128914e-07

Reversal O 0 0.028065809980034828
of O 0 0.00034616596531122923
severe O 1 0.9998471736907959
hypertrophic B-Disease 1 0.9999887943267822
cardiomyopathy I-Disease 1 0.9999921321868896
and O 0 3.0781159239268163e-06
excellent O 0 2.6713076294981875e-05
neuropsychologic O 0 0.013881715945899487
outcome O 0 2.5888230084092356e-06
in O 0 2.2938559496310518e-08
very B-Disease 0 4.3071700872587826e-08
- I-Disease 0 5.780959691037424e-05
long I-Disease 0 1.072335635399213e-06
- I-Disease 0 1.530990812170785e-05
chain I-Disease 0 9.03715772437863e-06
acyl I-Disease 0 6.9413067649293225e-06
- I-Disease 0 3.559264951036312e-05
coenzyme I-Disease 0 1.8368906239629723e-05
A I-Disease 0 6.822637078585103e-05
dehydrogenase I-Disease 1 0.963424563407898
deficiency I-Disease 1 0.9989907145500183
. O 0 3.934778305847431e-06

Very B-Disease 0 1.121187142416602e-05
- I-Disease 0 0.0003748813469428569
long I-Disease 0 6.1790788095095195e-06
- I-Disease 0 2.9256803827593103e-05
chain I-Disease 0 8.694601092429366e-06
acyl I-Disease 0 1.994834065044415e-06
- I-Disease 0 2.4717996893741656e-06
coenzyme I-Disease 0 2.1225147861514415e-07
A I-Disease 0 1.8409153312859416e-07
dehydrogenase I-Disease 0 7.09020605427213e-05
( I-Disease 0 1.508117406956444e-06
VLCAD I-Disease 1 0.9274064898490906
) I-Disease 0 3.267751890234649e-05
deficiency I-Disease 1 0.9872277975082397
is O 0 1.0735251265714396e-07
a O 0 1.127823225033353e-06
disorder O 0 0.006422689650207758
of O 0 7.520259259763407e-08
fatty O 0 0.00014296061999630183
acid O 0 2.180368210247252e-05
beta O 0 1.2953263421877637e-06
oxidation O 0 1.1783301943069091e-06
that O 0 2.518480313185023e-09
reportedly O 0 2.483867262981221e-07
has O 0 1.0363542912728008e-08
high O 0 1.0746718999143923e-06
rates O 0 5.785410053249507e-07
of O 0 5.4585612474511436e-08
morbidity O 0 0.09797607362270355
and O 0 9.060258889803663e-07
mortality O 0 0.001918167108669877
. O 0 1.957673021024675e-06

We O 0 2.6249807660860824e-07
describe O 0 1.7288705578266672e-07
the O 0 3.903526835102866e-09
outcome O 0 5.702262217965881e-09
of O 0 4.694882815847734e-10
a O 0 1.035512564584451e-08
5 O 0 2.372139107365001e-08
- O 0 3.9051556086633354e-06
year O 0 5.830213467561407e-08
- O 0 2.0002227756776847e-05
old O 0 1.0535147339396644e-05
girl O 0 0.0008158428245224059
with O 0 2.080972262774594e-05
VLCAD B-Disease 1 0.9999954700469971
deficiency I-Disease 1 0.9999881982803345
who O 0 3.7681765263641864e-08
was O 0 4.3127088567018745e-09
first O 0 4.822913735047507e-10
seen O 0 4.561440114514426e-09
at O 0 1.7796134565983834e-09
5 O 0 4.3360008916693005e-09
months O 0 7.308232241598489e-09
of O 0 1.4502994361009769e-09
age O 0 1.4936309753466048e-06
with O 0 0.00017518374079372734
severe O 1 0.9999644756317139
hypertrophic B-Disease 1 0.9999978542327881
cardiomyopathy I-Disease 1 0.9999995231628418
, O 0 0.19130539894104004
hepatomegaly B-Disease 1 0.9999971389770508
, O 0 0.0032543253619223833
encephalopathy B-Disease 1 0.9998364448547363
, O 0 1.214997155329911e-06
and O 0 1.399370717081183e-06
hypotonia B-Disease 1 0.7822948694229126
. O 0 6.5274134612991475e-06

Biochemical O 0 0.4160766899585724
studies O 0 0.008023647591471672
indicated O 1 0.9521400332450867
VLCAD B-Disease 1 0.999988317489624
deficiency I-Disease 1 0.9999920129776001
caused O 0 0.0003479269507806748
by O 0 4.702424760694157e-08
a O 0 6.211782874743221e-07
stable O 0 2.486854100425262e-05
yet O 0 3.4271843674105185e-07
inactive O 0 8.565177267882973e-06
enzyme O 0 4.141504177823663e-06
. O 0 3.6998005725763505e-07

Molecular O 0 0.0004990750458091497
genetic O 0 7.711146463407204e-05
analysis O 0 2.5751447196853405e-07
of O 0 1.0785016435477246e-08
her O 0 1.364815602755698e-06
VLCAD O 0 0.03578198701143265
gene O 0 1.535492810944561e-05
revealed O 0 1.5953112324496033e-06
a O 0 1.4471729059550853e-07
T1372C O 0 1.303457156609511e-05
( O 0 2.084015271464068e-08
F458L O 0 6.621529337280663e-06
) O 0 2.4208548055071333e-08
missense O 0 5.868929292773828e-05
mutation O 0 2.7715566375263734e-06
and O 0 3.597250053388734e-09
a O 0 1.2930206594319316e-07
1668 O 0 0.00019991776207461953
ACAG O 0 0.0022905345540493727
1669 O 0 9.899929136736318e-05
splice O 0 0.0001981135574169457
site O 0 2.5808145437622443e-05
mutation O 0 0.00012046202755300328
. O 0 5.702672751795035e-07

After O 0 2.0598752598743886e-05
initial O 0 5.210371909925016e-06
treatment O 0 3.990237019024789e-06
with O 0 7.121285339195538e-09
intravenous O 0 2.7993742151011247e-06
glucose O 0 1.6097479601739906e-05
and O 0 2.4459829717216053e-08
carnitine O 0 0.0011682853801175952
, O 0 8.82190409612349e-09
the O 0 1.134579807882119e-08
patient O 0 3.96976383854053e-06
has O 0 2.8844793220628162e-09
thrived O 0 5.466354835448328e-08
on O 0 1.2073894106734429e-09
a O 0 2.349911198962218e-08
low O 0 3.108355485892389e-06
- O 0 1.1113604159618262e-05
fat O 0 7.428974413414835e-07
diet O 0 6.084332682121385e-08
supplemented O 0 5.1151225477497064e-09
with O 0 7.55343065872438e-10
medium O 0 5.989798523842182e-08
- O 0 3.221173756173812e-06
chain O 0 1.236492721545801e-06
triglyceride O 0 1.2483030786825111e-06
oil O 0 1.1149739798099745e-08
and O 0 1.9415444807435733e-09
carnitine O 0 1.878260081866756e-05
and O 0 5.725126595024221e-09
avoidance O 0 3.894652309099911e-06
of O 0 2.4565773415474723e-08
fasting O 0 1.1466558134998195e-05
. O 0 5.440651307253574e-07

Her O 0 0.0011214130790904164
ventricular O 1 0.9102280735969543
hypertrophy O 1 0.9011777639389038
resolved O 0 4.122234167880379e-05
significantly O 0 3.2973100587696536e-06
over O 0 3.087921740529964e-08
1 O 0 4.444284229521145e-08
year O 0 1.9381340976565298e-08
, O 0 1.971145469070734e-09
and O 0 1.2401786264604198e-08
cognitively O 0 0.0005362447118386626
, O 0 1.594019316542017e-08
she O 0 1.4480199261868165e-08
is O 0 1.1293888046992606e-09
in O 0 8.711889543100426e-10
the O 0 2.6343554004881753e-09
superior O 0 3.319658162581618e-06
range O 0 9.216790886057424e-08
for O 0 1.4198935360809628e-08
age O 0 1.5930640984151978e-06
. O 0 1.015315433505748e-06

Clinical O 0 0.0016085675451904535
recognition O 0 4.817191438633017e-05
of O 0 0.00016974109166767448
VLCAD B-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9999942779541016
is O 0 1.3250881636395206e-07
important O 0 7.469721730046786e-09
because O 0 9.621600405296249e-09
it O 0 1.6690257509388573e-10
is O 0 1.118527978571926e-10
one O 0 7.819941222342308e-11
of O 0 9.413489432397171e-11
the O 0 1.3609680049597728e-09
few O 0 1.8076045549264563e-08
directly O 0 1.3090226502754376e-06
treatable O 1 0.9964413046836853
causes O 0 4.8288093239534646e-05
of O 0 2.5188310246448964e-06
cardiomyopathy B-Disease 1 0.9999854564666748
in O 0 1.4645070223195944e-06
children O 0 9.93903540802421e-07
. O 0 6.538476782225189e-08
. O 0 3.75518339978953e-07

Cloning O 0 1.8858956536860205e-05
of O 0 6.165876698105421e-08
a O 0 5.4958775308477925e-08
novel O 0 1.4950481741493604e-08
member O 0 1.204748523164767e-09
of O 0 3.0624514035793027e-10
the O 0 3.65926866585653e-09
low O 0 1.378890033265634e-06
- O 0 2.223015144409146e-05
density O 0 3.686002401082078e-06
lipoprotein O 1 0.9578949809074402
receptor O 0 0.0003454680263530463
family O 0 3.7008346680522664e-06
. O 0 5.908768798690289e-07

A O 0 1.1278102647338528e-06
gene O 0 5.891662908652506e-07
encoding O 0 2.1677406891740247e-07
a O 0 6.397254992407397e-08
novel O 0 6.186680678865741e-08
transmembrane O 0 2.815207380990614e-06
protein O 0 1.3480722316216998e-07
was O 0 1.145799277679771e-08
identified O 0 3.6505267697606314e-09
by O 0 2.5141883019941247e-10
DNA O 0 3.183270180784348e-08
sequence O 0 2.5138731096774336e-09
analysis O 0 1.0005448691785546e-09
within O 0 1.7404324648140346e-09
the O 0 1.4114204027748656e-08
insulin B-Disease 0 0.003329746425151825
- I-Disease 0 0.27059581875801086
dependent I-Disease 0 0.0044018481858074665
diabetes I-Disease 1 0.9999909400939941
mellitus I-Disease 1 0.9998701810836792
( O 0 1.4285529914559447e-06
IDDM B-Disease 0 0.013565785251557827
) O 0 7.876370489157125e-08
locus O 0 3.2674775866325945e-05
IDDM4 O 0 0.001164141809567809
on O 0 3.629852471931372e-07
chromosome O 0 0.00031078170286491513
11q13 O 0 0.0002163015742553398
. O 0 7.270293167493946e-07

Based O 0 6.856879508632119e-07
on O 0 2.442784641232265e-08
its O 0 2.7462503382480463e-08
chromosomal O 0 0.00012031509686494246
position O 0 6.765912985429168e-08
, O 0 3.232657919127746e-09
this O 0 5.847893280730432e-10
gene O 0 1.3513669294695774e-08
is O 0 5.893432963866019e-10
a O 0 4.083517524122726e-09
candidate O 0 2.0551249590994303e-08
for O 0 4.565914313303665e-09
conferring O 0 8.300336048705503e-05
susceptibility O 0 0.2472217082977295
to O 0 3.6194448966853088e-06
diabetes B-Disease 1 0.9978001713752747
. O 0 3.968370947404765e-06

The O 0 6.03994465109281e-07
gene O 0 3.020932808794896e-06
, O 0 4.203391767987341e-08
termed O 0 1.3256333204481052e-06
low O 0 3.0207540930859977e-06
- O 0 2.6087070637004217e-06
density O 0 1.3958636202460184e-07
lipoprotein O 0 0.021198706701397896
receptor O 0 1.7722961729305098e-06
related O 0 2.4880201010546443e-08
protein O 0 4.412592602420773e-08
5 O 0 1.5305635869822254e-08
( O 0 1.4966823336237667e-09
LRP5 O 0 2.0452764601941453e-06
) O 0 3.2415040096545056e-10
, O 0 7.836185866860745e-11
encodes O 0 7.815173508340933e-10
a O 0 9.486204044506508e-10
protein O 0 2.031250723177891e-09
of O 0 3.109853208282942e-10
1615 O 0 1.0016933060796873e-07
amino O 0 5.261523217114927e-09
acids O 0 1.906619084834915e-09
that O 0 2.2530751569993512e-11
contains O 0 8.553622393714377e-11
conserved O 0 1.6586935158713345e-09
modules O 0 4.041396994836077e-09
which O 0 1.0689325119495052e-10
are O 0 2.4906849152572796e-11
characteristic O 0 1.130690652217936e-09
of O 0 1.8385987177182983e-10
the O 0 2.668542053996248e-09
low O 0 2.5268691388191655e-06
- O 0 4.5533837692346424e-05
density O 0 5.26240683029755e-06
lipoprotein O 1 0.9925249218940735
( O 0 8.767287908995058e-07
LDL O 0 0.48170793056488037
) O 0 6.896135573697393e-08
receptor O 0 5.717692602047464e-06
family O 0 1.196058860841731e-06
. O 0 4.7224190780070785e-07

These O 0 1.3134878429355012e-07
modules O 0 6.792827775825572e-07
include O 0 2.3387324077361882e-08
a O 0 1.7423131382088286e-08
putative O 0 6.478981049440335e-07
signal O 0 4.0328750117168966e-08
peptide O 0 3.089606792627819e-08
for O 0 1.4946902049395305e-10
protein O 0 1.695879214835827e-09
export O 0 4.0580483418040103e-10
, O 0 2.6367169558838555e-10
four O 0 2.284101574545616e-09
epidermal O 0 7.786160495015793e-06
growth O 0 2.0312677406764124e-07
factor O 0 3.156185712782644e-08
( O 0 8.327658562734541e-09
EGF O 0 3.5748314985539764e-05
) O 0 2.83481349505621e-09
repeats O 0 5.085998111553636e-08
with O 0 1.4304615270077647e-09
associated O 0 4.0330498940477355e-09
spacer O 0 1.913139442422107e-07
domains O 0 5.990597884419913e-08
, O 0 3.4050025021770125e-09
three O 0 3.270889692430501e-08
LDL O 0 0.19759796559810638
- O 0 1.5469260688405484e-05
receptor O 0 9.821893627304235e-07
( O 0 5.792081925193315e-09
LDLR O 0 1.1261239706072956e-05
) O 0 9.206487239232786e-10
repeats O 0 1.5493794691678886e-08
, O 0 4.235878869884857e-10
a O 0 1.2756952161296908e-09
single O 0 2.4849835522644526e-09
transmembrane O 0 1.0683409357170603e-07
spanning O 0 3.7469906288833954e-08
domain O 0 1.59657531639823e-08
, O 0 4.614977566763656e-10
and O 0 3.4300379203600073e-10
a O 0 1.0038255560118614e-08
cytoplasmic O 0 2.7450439574749907e-06
domain O 0 1.477976411479176e-06
. O 0 4.23800457838297e-07

The O 0 7.057397510834562e-08
encoded O 0 8.89825813032985e-08
protein O 0 2.1104929714965692e-07
has O 0 7.252037192984062e-09
a O 0 3.119871472279101e-09
unique O 0 2.746589400359767e-09
organization O 0 2.129479703683046e-09
of O 0 1.0582685838755879e-09
EGF O 0 1.4136926438368391e-05
and O 0 1.6275308212243544e-08
LDLR O 0 0.0071156322956085205
repeats O 0 3.2638906759530073e-06
; O 0 8.084663605245623e-09
therefore O 0 2.778774543799045e-09
, O 0 2.2190860260451473e-09
LRP5 O 0 0.00013987488637212664
likely O 0 3.092094758017083e-08
represents O 0 1.0308264464242711e-08
a O 0 4.4197081550123585e-09
new O 0 2.7314026596059193e-09
category O 0 1.2411062400019546e-08
of O 0 7.145991021140219e-10
the O 0 1.905082314124229e-08
LDLR O 0 0.003200759179890156
family O 0 6.188975021359511e-06
. O 0 6.907548026902077e-07

Both O 0 4.159218462973513e-07
human O 0 3.053979185096978e-07
and O 0 4.881733772776897e-08
mouse O 0 1.455402252759086e-05
LRP5 O 0 0.0008699678000994027
cDNAs O 0 4.1377279558219016e-05
have O 0 3.4904135137736603e-09
been O 0 1.1719708536972462e-09
isolated O 0 1.263727611444665e-08
and O 0 1.2784617808847543e-10
the O 0 8.920642696752523e-11
encoded O 0 4.980129642007114e-10
mature O 0 7.252189071493831e-09
proteins O 0 4.753832327786256e-10
are O 0 4.0062272943508503e-11
95 O 0 6.831326615497346e-10
% O 0 8.571313103722389e-10
identical O 0 3.1494383989638663e-08
, O 0 9.500725761668605e-10
indicating O 0 1.563760676503989e-08
a O 0 7.783966360364047e-09
high O 0 9.665749445275651e-08
degree O 0 3.212266008745246e-08
of O 0 3.0660236571833366e-09
evolutionary O 0 6.32852731996536e-07
conservation O 0 3.4674107496357465e-07
. O 0 1.1635609808990921e-08
. O 0 1.270216500870447e-07

The O 0 1.0336674449717975e-06
APC B-Disease 0 1.7275273421546444e-05
variants O 0 8.186581794689118e-07
I1307K O 0 1.7543919966556132e-05
and O 0 3.9407382246281486e-08
E1317Q O 0 4.108874054509215e-05
are O 0 7.500033660789995e-08
associated O 0 5.523630534298718e-05
with O 1 0.8706367611885071
colorectal B-Disease 1 1.0
tumors I-Disease 1 0.9999997615814209
, O 0 8.558993158658268e-07
but O 0 1.0427468666307504e-08
not O 0 4.700546063496347e-10
always O 0 1.3893786121599305e-09
with O 0 1.5326251379121913e-09
a O 0 3.304129236880726e-08
family O 0 2.328047230548691e-07
history O 0 5.800309850201302e-07
. O 0 3.974510889293015e-07

Classical O 0 0.30476000905036926
familial B-Disease 1 0.9999454021453857
adenomatous I-Disease 1 0.9999793767929077
polyposis I-Disease 1 0.9999861717224121
( O 0 0.0004347305803094059
FAP B-Disease 1 0.8612930178642273
) O 0 2.2437923519191827e-07
is O 0 3.6905881017901265e-08
a O 0 5.987902795823175e-07
high O 0 0.0003809442277997732
- O 1 0.8349942564964294
penetrance O 1 0.9990731477737427
autosomal B-Disease 1 0.9993782043457031
dominant I-Disease 1 0.9068481922149658
disease I-Disease 1 0.8973720669746399
that O 0 8.645153037889486e-09
predisposes O 0 1.5323768138841842e-06
to O 0 9.12126207897046e-10
hundreds O 0 6.9015806403172064e-09
or O 0 4.664128194775685e-09
thousands O 0 2.1600637012397783e-07
of O 0 3.311940236017108e-05
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999970197677612
and I-Disease 0 0.0652686133980751
carcinoma I-Disease 1 0.9999995231628418
and O 0 3.1675477885073633e-07
that O 0 3.903720457998361e-09
results O 0 1.0060992394755885e-07
from O 0 5.571656913616607e-09
truncating O 0 3.957746957894415e-05
mutations O 0 2.338149442948634e-06
in O 0 2.981349167541225e-09
the O 0 1.2720319908510191e-08
APC B-Disease 0 2.3120615878724493e-05
gene O 0 4.496004294196609e-06
. O 0 2.637489728840592e-07

A O 0 1.6794761904748157e-05
variant O 0 0.0001329422666458413
of O 0 1.6947568610703456e-06
FAP B-Disease 1 0.8529247045516968
is O 0 3.832281436189078e-05
attenuated B-Disease 1 0.9927515983581543
adenomatous I-Disease 1 0.9999923706054688
polyposis I-Disease 1 0.9999926090240479
coli I-Disease 1 0.999872088432312
, O 0 3.79087794044608e-07
which O 0 8.062704281996957e-09
results O 0 4.63799629812911e-08
from O 0 4.50085702041747e-09
germ O 0 0.00025282110436819494
- O 0 4.3165469833184034e-05
line O 0 8.980420602711092e-07
mutations O 0 4.088258549472812e-07
in O 0 5.282949633311773e-10
the O 0 1.5826087662595967e-10
5 O 0 1.172165253748858e-09
and O 0 2.427288370299152e-10
3 O 0 2.8334512514049948e-09
regions O 0 1.945410721404528e-09
of O 0 4.5139486593015477e-10
the O 0 2.3913097280114926e-08
APC B-Disease 0 8.351267752004787e-05
gene O 0 4.891491698799655e-06
. O 0 3.555716148184729e-07

Attenuated B-Disease 1 0.9980722665786743
adenomatous I-Disease 1 0.9999536275863647
polyposis I-Disease 1 0.999968409538269
coli I-Disease 1 0.9999428987503052
patients O 1 0.9834290146827698
have O 0 3.100980165982037e-06
" O 0 1.2020335589113529e-06
multiple O 0 0.0004596022190526128
" O 0 0.03104364685714245
colorectal B-Disease 1 0.9999996423721313
adenomas I-Disease 1 0.9999576807022095
( O 0 2.1239625880298263e-07
typically O 0 3.434021067505455e-08
fewer O 0 1.0117873650017373e-08
than O 0 5.879129405528261e-10
100 O 0 7.370213328528052e-10
) O 0 2.001078192037653e-10
without O 0 6.181014033934673e-10
the O 0 2.1047465992296566e-09
florid O 0 8.700559556018561e-05
phenotype O 0 1.56958049046807e-05
of O 0 1.2737070953505736e-08
classical O 0 2.8644858502957504e-06
FAP B-Disease 0 0.02454514428973198
. O 0 9.96044263956719e-07

Another O 0 3.6054682368558133e-06
group O 0 7.291491783689708e-07
of O 0 5.9175771838226865e-08
patients O 0 1.0979279068124015e-05
with O 0 3.018393002207631e-08
multiple O 0 1.5526120478170924e-05
adenomas B-Disease 1 0.7840423583984375
has O 0 2.114618951054581e-07
no O 0 4.009137910543359e-08
mutations O 0 5.295172513797297e-07
in O 0 8.039327537012753e-10
the O 0 1.4036878326351143e-09
APC B-Disease 0 1.1925633316423045e-06
gene O 0 2.341472971068015e-08
, O 0 5.324181651111815e-10
and O 0 4.830472133399155e-10
their O 0 5.28369836771958e-09
phenotype O 0 2.7387253794586286e-05
probably O 0 3.1814252565709467e-08
results O 0 8.780842719602333e-09
from O 0 2.0021395652491947e-10
variation O 0 4.109661944085019e-09
at O 0 1.3960141931335102e-09
a O 0 4.9511226229981276e-09
locus O 0 2.1024332852448424e-07
, O 0 1.044372477387867e-09
or O 0 1.2420788841893682e-09
loci O 0 9.39015478707006e-08
, O 0 3.003047810423709e-09
elsewhere O 0 1.07079056732573e-08
in O 0 2.858371761504941e-09
the O 0 1.9138120421757776e-08
genome O 0 3.32573563355254e-06
. O 0 2.983865670103114e-07

Recently O 0 9.621538629289716e-05
, O 0 6.85171599457135e-08
however O 0 1.3007128707442916e-08
, O 0 2.7561930515673794e-09
a O 0 3.087745170660128e-08
missense O 0 2.493700958439149e-05
variant O 0 2.4787941583781503e-06
of O 0 1.184924869335191e-08
APC B-Disease 0 1.6677833627909422e-05
( O 0 7.477575891812194e-09
I1307K O 0 2.4715898234717315e-06
) O 0 1.934067350717328e-09
was O 0 2.2805493049560255e-09
described O 0 2.4568762579946224e-09
that O 0 9.906887116217789e-11
confers O 0 9.09853881125855e-09
an O 0 1.3162076983874726e-09
increased O 0 4.69641963718459e-06
risk O 0 0.013977308757603168
of O 0 0.009728392586112022
colorectal B-Disease 1 1.0
tumors I-Disease 1 0.9999996423721313
, O 0 2.924565478679142e-07
including O 0 1.3249618291411025e-07
multiple O 0 2.1849476979696192e-05
adenomas B-Disease 1 0.5095843076705933
, O 0 8.33246005527144e-08
in O 0 1.713487165488914e-07
Ashkenazim O 0 0.00013494541053660214
. O 0 8.898425107872754e-07

We O 0 4.157406010563136e-07
have O 0 1.2965813311893726e-08
studied O 0 2.6851111556425167e-08
a O 0 4.92934626450392e-09
set O 0 3.076421561942766e-09
of O 0 1.8000929635775265e-09
164 O 0 4.477617494558217e-06
patients O 0 5.1508777687558904e-05
with O 0 4.206161520414753e-06
multiple O 1 0.989447832107544
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999940395355225
and I-Disease 0 0.00021331383322831243
/ I-Disease 1 0.6405134797096252
or I-Disease 0 0.0012558114249259233
carcinoma I-Disease 1 0.9999985694885254
and O 0 2.410378101558308e-07
analyzed O 0 1.3461481103149708e-06
codons O 0 9.545819921186194e-06
1263 O 0 0.00011005063424818218
- O 0 3.0549945222446695e-05
1377 O 0 9.406129720446188e-06
( O 0 5.2037965048157275e-09
exon O 0 2.2797407837060746e-06
15G O 0 2.7679325285134837e-06
) O 0 2.5121366098446174e-10
of O 0 9.793485467035623e-11
the O 0 6.49471920688427e-10
APC B-Disease 0 2.3662742876240372e-07
gene O 0 3.582393759415936e-08
for O 0 6.31397245598464e-09
germ O 0 0.00035477220080792904
- O 0 2.5228160666301847e-05
line O 0 8.020671202757512e-07
variants O 0 8.297155886793917e-07
. O 0 2.7189247475689626e-07

Three O 0 7.1553031375515275e-06
patients O 0 2.4983854018501006e-05
with O 0 1.0871263000922227e-08
the O 0 7.121203626780925e-09
I1307K O 0 1.829720190471562e-06
allele O 0 1.7642864236222522e-07
were O 0 3.726035924245252e-09
detected O 0 6.076307101920975e-08
, O 0 2.203244392484649e-10
each O 0 2.5109486712082685e-10
of O 0 2.635330398348401e-09
Ashkenazi O 0 3.048024700547103e-05
descent O 0 8.693970812601037e-06
. O 0 8.652974088363408e-07

Four O 0 3.0486698960885406e-05
patients O 0 0.00011443622497608885
had O 0 7.758549003256121e-08
a O 0 8.659910832875539e-08
germ O 0 0.0004759851726703346
- O 0 3.215882315998897e-05
line O 0 5.831241765008599e-07
E1317Q O 0 9.039261385623831e-06
missense O 0 2.4703793314984068e-05
variant O 0 6.959328402444953e-07
of O 0 2.430245116258334e-09
APC O 0 1.4389007674253662e-06
that O 0 2.9666444301135186e-10
was O 0 1.1346701356274025e-09
not O 0 2.6867105762384824e-11
present O 0 1.1521445603124292e-10
in O 0 2.2319639192414087e-10
controls O 0 1.1105974806469021e-08
; O 0 4.372599504698371e-10
one O 0 7.271961505184166e-11
of O 0 7.08905087409839e-11
these O 0 7.193549228512452e-11
individuals O 0 1.838346141980196e-10
had O 0 4.1971950914820866e-10
an O 0 1.6607472341778617e-10
unusually O 0 8.686544816782771e-08
large O 0 2.2821635692338305e-09
number O 0 7.085810271867388e-10
of O 0 3.8448413341996e-09
metaplastic B-Disease 0 0.005815133452415466
polyps I-Disease 0 0.0018164702923968434
of I-Disease 0 4.8797486051910255e-09
the I-Disease 0 4.2396170130132305e-08
colorectum I-Disease 0 0.0012349579483270645
. O 0 6.62381978600024e-07

There O 0 5.498288260241679e-07
is O 0 2.8077424829575648e-08
increasing O 0 6.392278351086134e-08
evidence O 0 7.961629577835083e-09
that O 0 5.689776427786342e-10
there O 0 1.0534453309674063e-09
exist O 0 7.26620141833223e-09
germ O 0 5.9981717640766874e-05
- O 0 3.123528131254716e-06
line O 0 1.1239032815524297e-08
variants O 0 1.581113129311973e-09
of O 0 1.2034961915929898e-10
the O 0 1.0030422048501464e-09
APC B-Disease 0 1.2610880730790086e-06
gene O 0 1.9367483616861136e-08
that O 0 8.325141270804082e-11
predispose O 0 3.830114447822552e-09
to O 0 6.297128790633266e-11
the O 0 6.792608697736569e-10
development O 0 7.618457864566608e-09
of O 0 1.6785195100510464e-07
multiple O 1 0.9654670357704163
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999984502792358
and I-Disease 0 0.36864402890205383
carcinoma I-Disease 1 0.9999996423721313
, O 0 5.443521331471857e-07
but O 0 4.670591469135843e-09
without O 0 4.718360369082575e-09
the O 0 4.0598542305758656e-09
florid O 0 6.797510286560282e-05
phenotype O 0 5.724840320908697e-06
of O 0 1.5798108377040876e-09
classical O 0 1.0052935550675102e-07
FAP B-Disease 0 0.00020055084314662963
, O 0 1.8648553812283808e-09
and O 0 4.893334626387968e-10
possibly O 0 4.296239364265375e-09
with O 0 6.375204808506396e-09
importance O 0 8.494707799400203e-06
for O 1 0.7828020453453064
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risk O 0 0.03660280629992485
in O 0 2.6504647365754863e-08
the O 0 6.560272769462472e-09
general O 0 1.6104607425404538e-08
population O 0 1.8553407699073432e-08
. O 0 1.4677990378686445e-08
. O 0 1.689256237114023e-07

Genomic O 0 0.0002045825676759705
structure O 0 1.0699039194150828e-05
of O 0 8.342510682268767e-08
the O 0 1.6816932202345924e-06
human O 0 0.037680841982364655
congenital B-Disease 1 0.9999972581863403
chloride I-Disease 1 0.9999860525131226
diarrhea I-Disease 1 0.9999973773956299
( O 0 0.0002349704154767096
CLD B-Disease 1 0.9990254640579224
) O 0 1.4688808960272581e-06
gene O 0 1.4692138393002097e-05
. O 0 6.97231598678627e-07

Congenital B-Disease 1 0.9999812841415405
chloride I-Disease 1 0.9999282360076904
diarrhea I-Disease 1 0.9999862909317017
( O 0 0.0002694221038836986
CLD B-Disease 1 0.9978664517402649
) O 0 9.817715636017965e-07
is O 0 5.645342326943137e-08
caused O 0 4.895636607216147e-07
by O 0 9.030282299704595e-09
mutations O 0 1.0483864798516151e-06
in O 0 2.2950801259469245e-09
a O 0 9.809460799203862e-09
gene O 0 1.793927673077178e-08
which O 0 8.963045861065666e-10
encodes O 0 6.982164535429547e-08
an O 0 1.8393727430066065e-07
intestinal O 1 0.9891932606697083
anion O 0 0.11348994076251984
transporter O 0 0.12583422660827637
. O 0 4.127853117097402e-06

We O 0 9.232236948264472e-07
report O 0 7.067460217058397e-08
here O 0 2.687646105670183e-09
the O 0 6.044882927547235e-10
complete O 0 1.5473121450781946e-08
genomic O 0 3.067716249915975e-07
organization O 0 2.6723825374830312e-09
of O 0 1.7341092450884332e-10
the O 0 1.5413613718706642e-09
human O 0 2.5599529607234217e-08
CLD B-Disease 0 0.050610147416591644
gene O 0 2.2553622613941116e-07
which O 0 1.1025176327450481e-09
spans O 0 6.555559650678333e-08
approximately O 0 6.614109704372595e-09
39kb O 0 1.0236739399260841e-05
, O 0 1.3026735246057797e-09
and O 0 8.936484885424534e-10
comprises O 0 4.6929898189773667e-08
21 O 0 3.2573120734014083e-07
exons O 0 1.6330104699591175e-05
. O 0 7.769987746542029e-07

All O 0 2.381537598239447e-07
exon O 0 0.00011851710587507114
/ O 0 4.904487013845937e-06
intron O 0 6.673058669548482e-05
boundaries O 0 9.6641826985433e-08
conform O 0 1.514784031542149e-07
to O 0 1.8673680379777124e-09
the O 0 1.633523716293439e-08
GT O 0 0.00018089608056470752
/ O 0 0.0012202534126117826
AG O 1 0.9956028461456299
rule O 0 1.7625134205445647e-05
. O 0 7.40499615403678e-07

An O 0 8.128951378694182e-08
analysis O 0 2.959159672855094e-08
of O 0 1.8403889523455064e-09
the O 0 2.9408715462864166e-09
putative O 0 2.635674491102691e-06
promoter O 0 1.8718926639849087e-06
region O 0 2.4390786279582244e-08
sequence O 0 5.73680036808355e-09
shows O 0 2.8431632603798107e-09
a O 0 1.0481866041800458e-08
putative O 0 5.729111308028223e-06
TATA O 0 0.0001248633343493566
box O 0 1.6493771681780345e-06
and O 0 4.779546092237297e-09
predicts O 0 1.7945272645647492e-07
multiple O 0 3.471334153459793e-08
transcription O 0 2.8513522920547985e-07
factor O 0 1.0913691284031302e-07
binding O 0 2.386116193520138e-07
sites O 0 1.9827096764402086e-07
. O 0 2.896660760143277e-07

The O 0 5.204553872317774e-07
genomic O 0 3.324829231132753e-05
structure O 0 7.68252994021168e-06
was O 0 2.7966841287252464e-08
determined O 0 6.050538292612373e-09
using O 0 1.386339820719229e-09
DNA O 0 7.555627945521337e-08
from O 0 4.6364967420942094e-10
several O 0 1.7807737229258436e-10
sources O 0 3.30163757444879e-10
including O 0 4.254226138034056e-10
multiple O 0 2.0813260448449e-08
large O 0 6.621281301022464e-08
- O 0 1.7154019587906078e-05
insert O 0 8.715219337318558e-07
libaries O 0 5.831675935041858e-06
and O 0 1.4183173524529025e-09
genomic O 0 7.773418815304467e-07
DNA O 0 2.7372823296900606e-06
from O 0 5.5990177827425214e-08
Finnish O 0 0.009846387431025505
CLD B-Disease 1 0.9989455342292786
patients O 0 0.000171748484717682
and O 0 5.86590687134958e-08
controls O 0 8.413992873101961e-06
. O 0 9.980809636545018e-07

Exon O 0 0.0029687308706343174
- O 0 5.4854474001331255e-05
specific O 0 1.0001126327097154e-07
primers O 0 1.984316668313113e-06
developed O 0 2.1394842519839585e-07
in O 0 3.765380007791919e-09
this O 0 3.2801455995823403e-10
study O 0 1.201169275155678e-09
will O 0 1.5313504631020436e-10
facilitate O 0 5.683954640289812e-09
mutation O 0 1.7189682921525673e-06
screening O 0 7.187168193922844e-07
studies O 0 1.6178002937294877e-08
of O 0 1.0910605752201263e-08
patients O 0 1.4728189853485674e-05
with O 0 9.549168566991284e-08
the O 0 2.4141447738657007e-06
disease O 0 0.049229696393013
. O 0 1.0889793884416576e-06

Genomic O 0 2.2334763343678787e-05
sequencing O 0 2.159232963094837e-06
of O 0 3.810297144468677e-08
a O 0 9.664095159678254e-07
BAC O 0 0.0023300645407289267
clone O 0 0.0021496149711310863
H O 1 0.9067174196243286
_ O 0 2.6103046479875047e-07
RG364P16 O 0 1.6916128515731543e-06
revealed O 0 1.4877461040896378e-08
the O 0 1.622396661460357e-10
presence O 0 4.408667875210881e-10
of O 0 1.0182059362318086e-10
another O 0 1.1059780868905023e-09
, O 0 2.478752758605651e-10
highly O 0 9.626789365668742e-10
homologous O 0 1.933773319251486e-08
gene O 0 1.2018436024163748e-08
3 O 0 2.0002779432815032e-09
of O 0 2.356695394389874e-10
the O 0 6.320274525961622e-09
CLD B-Disease 0 0.06737446784973145
gene O 0 4.084735394371819e-07
, O 0 1.223785850434922e-09
with O 0 4.355477367656846e-10
a O 0 5.5588342817713965e-09
similar O 0 1.279253325492391e-08
genomic O 0 1.1450846386651392e-06
structure O 0 6.605299063267012e-07
, O 0 4.538477149651499e-09
recently O 0 2.849212989985972e-07
identified O 0 3.277053295391852e-08
as O 0 7.069479224242059e-09
the O 0 6.322534773062216e-06
Pendred B-Disease 1 0.9999920129776001
syndrome I-Disease 1 0.9999990463256836
gene O 0 0.0041056107729673386
( O 0 8.215426419155847e-07
PDS B-Disease 0 0.007707614451646805
) O 0 2.9291225445149394e-08
. O 0 2.5067020459346168e-08
. O 0 2.5579180373824784e-07

The O 0 1.965175897566951e-06
APCI1307K O 0 0.0038658708799630404
allele O 0 0.0005582005251199007
and O 0 5.296111703501083e-05
cancer B-Disease 1 0.997938334941864
risk O 0 6.0432877944549546e-05
in O 0 9.274770285117029e-09
a O 0 2.90687136583756e-08
community O 0 3.1117608045860834e-08
- O 0 1.281291406485252e-05
based O 0 8.749895918924722e-09
study O 0 2.2272486077667963e-09
of O 0 2.6441617784200844e-09
Ashkenazi O 0 2.007155489991419e-05
Jews O 0 4.817356398234551e-07
. O 0 6.613934715460346e-07

Mutations O 0 0.10343583673238754
in O 0 2.6214859190076822e-06
APC O 0 0.000943344144616276
are O 0 1.8573312843273015e-07
classically O 0 0.014955498278141022
associated O 0 3.184315573889762e-05
with O 0 0.0002937386161647737
familial B-Disease 1 0.999990701675415
adenomatous I-Disease 1 0.999996542930603
polyposis I-Disease 1 0.9999980926513672
( O 0 0.00014403679233510047
FAP B-Disease 1 0.7239177227020264
) O 0 1.0005133077584105e-07
, O 0 1.8869393159093306e-08
a O 0 1.0012832944994443e-06
highly O 0 0.00016522905207239091
penetrant O 1 0.9997867941856384
autosomal B-Disease 1 0.9999850988388062
dominant I-Disease 1 0.9995087385177612
disorder I-Disease 1 0.999993085861206
characterized O 0 0.07911568880081177
by O 0 8.852212886267807e-06
multiple O 1 0.5126017332077026
intestinal O 1 0.9999945163726807
polyps B-Disease 1 0.9936182498931885
and O 0 9.733869177352972e-08
, O 0 1.754100509288037e-08
without O 0 9.144472556954497e-08
surgical O 0 0.0037596975453197956
intervention O 0 9.013195381157857e-07
, O 0 3.3249079045560848e-09
the O 0 5.952428772104668e-09
development O 0 1.0854511174329673e-06
of O 0 0.06205848604440689
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
( O 0 3.8863709050929174e-05
CRC B-Disease 0 0.08088020980358124
) O 0 5.353320489120961e-07
. O 0 7.655415288354561e-07

APC B-Disease 0 0.00342335132881999
is O 0 1.0713482652136008e-06
a O 0 3.2399332212662557e-06
tumour O 1 0.9988476037979126
- O 0 0.00012493324175011367
suppressor O 0 3.337784801260568e-05
gene O 0 2.340779161613682e-07
, O 0 1.858010190147752e-09
and O 0 4.805011499797729e-09
somatic O 0 5.8784342400031164e-05
loss O 0 0.003789464244619012
occurs O 0 4.4648386392509565e-06
in O 0 3.2191499030886916e-06
tumours B-Disease 1 0.9991175532341003
. O 0 2.6040986540465383e-06

The O 0 4.599271051120013e-06
germline O 1 0.8364545702934265
T O 0 0.33706429600715637
- O 0 3.844099410343915e-06
to O 0 2.40346720303819e-09
- O 0 8.645038747090439e-07
A O 0 2.5453804397557178e-08
transversion O 0 2.406584371783538e-06
responsible O 0 5.6319175989472114e-09
for O 0 1.7004256336328183e-10
the O 0 6.370849958692304e-10
APC O 0 1.7071681668312522e-07
I1307K O 0 1.241049858435872e-07
allele O 0 6.83383261090853e-09
converts O 0 1.8242254373745936e-09
the O 0 8.886140157038369e-10
wild O 0 3.5577031098910084e-08
- O 0 1.1584676258280524e-06
type O 0 3.2713142417151175e-08
sequence O 0 4.4376240460053396e-09
to O 0 5.830985694288415e-10
a O 0 3.8905440646885836e-07
homopolymer O 0 0.1063503548502922
tract O 0 0.033360227942466736
( O 0 8.145868690689895e-08
A8 O 0 0.0016762646846473217
) O 0 7.249353561888938e-09
that O 0 9.60403090388695e-10
is O 0 6.805048080593679e-09
genetically O 0 1.3277449397719465e-06
unstable O 0 5.863883416168392e-05
and O 0 5.30790309483109e-08
prone O 0 0.00026403189986012876
to O 0 6.642709138304781e-08
somatic O 0 0.000529525219462812
mutation O 0 0.0023627295158803463
. O 0 8.974333240985288e-07

The O 0 5.663741262651456e-07
I1307K O 0 2.31683789024828e-05
allele O 0 6.741412562405458e-06
was O 0 2.423756768621388e-07
found O 0 6.95260879979287e-08
in O 0 3.1911611131363316e-08
6 O 0 5.413850772129081e-07
. O 0 4.0301995340996655e-07

1 O 0 1.1214062851649942e-06
% O 0 4.764566696735528e-08
of O 0 4.611161674716868e-09
unselected O 0 2.1208052203292027e-05
Ashkenazi O 0 1.91803937923396e-05
Jews O 0 4.244666129693542e-08
and O 0 7.221380826649693e-09
higher O 0 7.072827656884328e-08
proportions O 0 4.0369198472944845e-07
of O 0 9.137612888565627e-10
Ashkenazim O 0 7.436587452502863e-07
with O 0 8.341664248234792e-09
family O 0 6.429425525311672e-08
or O 0 2.7623821008404548e-09
personal O 0 4.1569968800558854e-08
histories O 0 2.575365840584709e-07
of O 0 4.4312322700079676e-08
CRC B-Disease 0 0.0029165304731577635
( O 0 1.3072707361061475e-07
ref O 0 0.002059160964563489
. O 0 5.436344263642923e-09
2 O 0 5.5453249103720736e-08
) O 0 5.6429740880048485e-08
. O 0 2.4616673499622266e-07

To O 0 9.839596515348603e-08
evaluate O 0 3.1514639431406977e-07
the O 0 4.8693911125496925e-09
role O 0 1.0764916957839432e-08
of O 0 3.942014714652942e-09
I1307K O 0 0.00012595525186043233
in O 0 2.653566070875968e-06
cancer B-Disease 0 0.34727856516838074
, O 0 4.110916052013636e-09
we O 0 6.102551242115339e-10
genotyped O 0 2.098282038787147e-06
5 O 0 1.86232878007786e-08
, O 0 2.8443458699456414e-09
081 O 0 2.4107323042699136e-05
Ashkenazi O 0 1.901750874822028e-05
volunteers O 0 1.859658311786916e-07
in O 0 6.415617370691962e-09
a O 0 4.0660481204213283e-08
community O 0 1.3874573312477878e-07
survey O 0 2.1195990029809764e-06
. O 0 2.740918887411681e-07

Risk O 0 0.002381958533078432
of O 0 2.8331662633718224e-06
developing O 0 0.116581991314888
colorectal B-Disease 1 0.9999978542327881
, I-Disease 0 0.00015831344353500754
breast I-Disease 1 0.9930530190467834
and I-Disease 0 9.139625234411142e-08
other I-Disease 0 4.934993569349899e-08
cancers I-Disease 0 0.07701440155506134
were O 0 7.057246342867529e-09
compared O 0 3.4814856775255976e-08
between O 0 7.048314820679025e-09
genotyped O 0 6.168248364701867e-05
I1307K O 0 1.1312517926853616e-05
carriers O 0 2.690274243377644e-07
and O 0 1.010190264771893e-09
non O 0 1.6751602771591934e-08
- O 0 1.2552495718409773e-06
carriers O 0 1.6968053628829693e-08
and O 0 1.4206262555216398e-10
their O 0 2.8991165024194743e-10
first O 0 7.231580223532319e-09
- O 0 1.7689020751276985e-05
degree O 0 6.378223815772799e-07
relatives O 0 2.074388476103195e-06
. O 0 3.323388284570683e-07

Sperm O 0 0.00011129995255032554
DNA O 0 4.1381146729690954e-05
analysis O 0 3.761742846108973e-07
in O 0 4.7381675472024654e-08
a O 0 1.8086622048940626e-06
Friedreich B-Disease 1 0.8018896579742432
ataxia I-Disease 1 0.9951004385948181
premutation O 1 0.7641879916191101
carrier O 0 0.0032304066698998213
suggests O 0 1.6397693514136336e-07
both O 0 2.2109576391926566e-09
meiotic O 0 1.1870230082422495e-05
and O 0 9.456544880492856e-09
mitotic O 0 2.1453784938785248e-05
expansion O 0 6.368285880853364e-07
in O 0 1.2314126607293474e-08
the O 0 4.959517596603291e-08
FRDA B-Disease 0 0.0064401524141430855
gene O 0 2.1374140487750992e-05
. O 0 5.07764298163238e-07

Friedreich B-Disease 1 0.9993081092834473
ataxia I-Disease 1 0.9997385144233704
is O 0 3.8169808249222115e-05
usually O 0 1.066506001734524e-06
caused O 0 7.549692782049533e-07
by O 0 1.1134878574736717e-09
an O 0 3.391673886188329e-10
expansion O 0 2.689339595463025e-08
of O 0 1.4255125968531956e-09
a O 0 8.633012527070605e-08
GAA O 0 6.667906563961878e-05
trinucleotide O 0 0.0011818965431302786
repeat O 0 1.886660470518109e-06
in O 0 7.4492763069144985e-09
intron O 0 1.3356736417335924e-05
1 O 0 5.963098903549735e-09
of O 0 1.9760315606021095e-09
the O 0 3.632795753105711e-08
FRDA B-Disease 0 0.004084970336407423
gene O 0 1.2491744200815447e-05
. O 0 6.805199177506438e-07

Occasionally O 0 2.5727438242029166e-06
, O 0 4.12733029975243e-08
a O 0 2.5187890884126318e-08
fully O 0 1.4196226416629543e-08
expanded O 0 2.245112362686541e-08
allele O 0 4.569750089444824e-08
has O 0 2.0265489286686034e-09
been O 0 9.972107584133028e-10
found O 0 1.040094455007079e-09
to O 0 1.0631032165697718e-10
arise O 0 5.008710779463854e-09
from O 0 4.5215228783312966e-10
a O 0 5.206824749137695e-09
premutation O 0 2.2356061890604906e-06
of O 0 6.929540274924761e-10
100 O 0 4.61915439231575e-09
or O 0 4.0214662710980065e-09
less O 0 6.035924826619521e-08
triplet O 0 0.0030811994802206755
repeats O 0 7.313610694836825e-05
. O 0 1.3268588645587442e-06

We O 0 3.294991870461672e-07
have O 0 1.0898418167926138e-08
examined O 0 7.78606334961296e-08
the O 0 1.9661363648282304e-09
sperm O 0 1.2153500961176178e-07
DNA O 0 1.3406439336449694e-07
of O 0 3.7451242107522376e-09
a O 0 3.257268872403074e-07
premutation O 0 0.005635620094835758
carrier O 0 0.0004912622971460223
. O 0 6.533409191433748e-07

This O 0 1.7551620601352624e-07
mans O 0 1.2901821719424333e-05
leucocyte O 0 0.0004904979141429067
DNA O 0 4.536783308140002e-05
showed O 0 4.1164585695696587e-07
one O 0 1.9114909655115753e-09
normal O 0 1.490250944868876e-08
allele O 0 8.721153577084806e-09
and O 0 3.345887178429763e-10
one O 0 1.6751747211607437e-10
allele O 0 3.0448281673756128e-09
of O 0 2.711029456481384e-10
approximately O 0 3.783759527919983e-09
100 O 0 1.4228864309018263e-08
repeats O 0 1.0294392041032552e-06
. O 0 2.136087715598478e-07

His O 0 1.1317656571918633e-06
sperm O 0 5.981566573609598e-06
showed O 0 9.744327655880625e-08
an O 0 8.461635836454207e-10
expanded O 0 9.975878789703074e-09
allele O 0 1.5220630089629594e-08
in O 0 2.0065982209160893e-09
a O 0 8.520071759221537e-09
tight O 0 2.2541323119185108e-07
range O 0 3.3918634567697836e-09
centering O 0 6.072689906488904e-09
on O 0 8.91862250718134e-10
a O 0 4.911449469346962e-09
size O 0 1.0700066610525027e-08
of O 0 1.1847547387588975e-09
approximately O 0 5.546784365151325e-08
320 O 0 2.9685634217457846e-06
trinucleotide O 0 0.0029093504417687654
repeats O 0 2.653291630849708e-05
. O 0 1.8229936813440872e-06

His O 0 1.0456681593495887e-05
affected O 0 1.5667481420678087e-05
son O 0 2.2011137843946926e-05
has O 0 6.799938745416512e-08
repeat O 0 7.934949621812848e-07
sizes O 0 2.0167851744190557e-07
of O 0 5.027930516376955e-09
1040 O 0 2.9166989406803623e-05
and O 0 4.045748625003398e-08
540 O 0 2.99532644021383e-06
. O 0 4.798108648174093e-07

These O 0 1.552456581066508e-07
data O 0 2.0735289751883101e-07
suggest O 0 7.619769348821137e-08
that O 0 1.1651527520584182e-09
expansion O 0 7.413489555574415e-08
occurs O 0 3.9902543491621145e-09
in O 0 2.022836759207891e-10
two O 0 2.539980170634948e-10
stages O 0 4.537579201269182e-08
, O 0 1.92698190737417e-10
the O 0 1.2610296140636024e-10
first O 0 2.3871146725973347e-10
during O 0 1.3254155550868063e-09
meiosis O 0 4.151592847279062e-08
followed O 0 1.0575683662139568e-09
by O 0 1.3890680272687916e-10
a O 0 2.3802688708940423e-09
second O 0 2.8673174057303186e-08
mitotic O 0 9.95745649561286e-05
expansion O 0 3.063787880819291e-05
. O 0 5.671200256074371e-07

We O 0 1.9177042531737243e-07
also O 0 1.3886799266060734e-08
show O 0 4.5329922038206405e-09
that O 0 1.4059030328805733e-10
in O 0 2.1291698959480243e-10
all O 0 9.691247110366064e-11
informative O 0 9.301841075171069e-09
carrier O 0 3.565254701243248e-06
father O 0 2.4273463239410376e-08
to O 0 4.141868792384429e-10
affected O 0 1.4272681703175749e-08
child O 0 2.2803205013133265e-07
transmissions O 0 3.5057752256761887e-07
, O 0 7.745633578970512e-10
with O 0 2.794612319334533e-10
the O 0 4.0366879283659785e-10
notable O 0 1.5711114631500323e-09
exception O 0 2.523808273480199e-09
of O 0 2.1442161934892567e-10
the O 0 3.3425588963353903e-09
premutation O 0 0.00015951247769407928
carrier O 0 4.27958411819418e-06
, O 0 2.9861735306724313e-10
the O 0 4.3847261932405956e-10
expansion O 0 6.84001690842706e-08
size O 0 4.098517365491716e-07
decreases O 0 2.3655800305277808e-06
. O 0 1.7872475055469295e-08
. O 0 1.518776429065838e-07

The O 0 8.364289101336908e-07
R496H O 0 9.54271963564679e-05
mutation O 0 3.8948081055423245e-05
of O 0 4.8680192321626237e-08
arylsulfatase O 0 0.002043843036517501
A O 0 6.43597422822495e-06
does O 0 7.476266432604461e-07
not O 0 2.808798740261409e-07
cause O 0 0.0003317504597362131
metachromatic B-Disease 1 0.9991451501846313
leukodystrophy I-Disease 1 0.9996577501296997
. O 0 1.8876879039453343e-05

Deficiency B-Disease 1 0.9980031847953796
of I-Disease 0 7.658189815629157e-07
arylsulfatase I-Disease 0 0.004034816287457943
A I-Disease 0 3.951678536395775e-06
( O 0 1.6768792931998178e-07
ARSA O 0 0.003065511817112565
) O 0 3.922912483744767e-08
enzyme O 0 2.25474809667503e-06
activity O 0 6.572814072569599e-06
causes O 0 0.002560652792453766
metachromatic B-Disease 1 0.9998761415481567
leukodystrophy I-Disease 1 0.9999641180038452
( O 0 0.00020983023568987846
MLD B-Disease 1 0.9987118244171143
) O 0 1.1351143029969535e-06
. O 0 9.481993856752524e-07

A O 0 1.0091134754475206e-06
number O 0 2.5133612524541604e-08
of O 0 1.6528895585565806e-08
ARSA O 0 0.21971987187862396
gene O 0 5.747812974732369e-05
mutations O 0 0.00018873123917728662
responsible O 0 1.4178158380673267e-06
for O 0 1.2098558954676264e-07
MLD B-Disease 1 0.9989089965820312
have O 0 1.0150699125688334e-07
been O 0 6.803220742312988e-08
identified O 0 7.811170235072495e-07
. O 0 2.8164672016828263e-07

Recently O 0 1.0479652701178566e-05
, O 0 2.795580300585243e-08
the O 0 8.777392146441798e-09
R496H O 0 5.782294010714395e-06
mutation O 0 2.3102836621546885e-06
of O 0 8.647148774798552e-09
ARSA O 0 0.08343880623579025
was O 0 7.988405315018099e-08
proposed O 0 3.162235273634906e-08
to O 0 2.948396249369267e-10
be O 0 5.855549933819759e-10
a O 0 4.5396738812542026e-08
cause O 0 2.4325285608028935e-07
of O 0 1.5447053414163747e-08
MLD B-Disease 1 0.9678480625152588
( O 0 2.391287523551e-07
Draghia O 0 0.0030639676842838526
et O 0 0.00013995266635902226
al O 0 9.562243121763458e-07
. O 0 5.313552264851751e-09
, O 0 1.7389599094030928e-08
1997 O 0 3.766589031783951e-07
) O 0 6.120391304875739e-08
. O 0 1.591286178381779e-07

We O 0 2.9489117991943203e-07
have O 0 2.3227464396313735e-08
investigated O 0 3.140860656003497e-07
the O 0 1.4521408964185412e-08
R496H O 0 4.602839544531889e-05
mutation O 0 1.5618490579072386e-05
and O 0 6.2574323500541595e-09
found O 0 8.196642475866156e-09
this O 0 7.976156402023094e-10
mutation O 0 3.147067104691814e-07
at O 0 2.6587518853204983e-09
a O 0 4.284014476496623e-09
relatively O 0 6.604957025757585e-09
high O 0 1.9280941288002396e-08
frequency O 0 2.1858661547469183e-09
in O 0 1.2760474621398288e-10
an O 0 4.9602578988672263e-11
African O 0 1.7358896264862977e-10
American O 0 2.699522827498413e-10
population O 0 5.220625043378391e-10
( O 0 1.6678682879245343e-09
f O 0 3.2307741548720514e-07
= O 0 5.191179752728203e-08
0 O 0 3.411620319582198e-09
. O 0 5.932522806340046e-10
09 O 0 1.670349831783824e-07
, O 0 6.9108274658447044e-09
n O 0 3.324159706608043e-06
= O 0 3.912282863893779e-06
61 O 0 3.101829975094006e-07
subjects O 0 8.571812060154116e-08
) O 0 4.825218979931378e-08
. O 0 2.145127098174271e-07

The O 0 1.0716731821958092e-06
ARSA O 0 0.0036194834392517805
enzyme O 0 2.6405252810945967e-06
activity O 0 1.3870418058559153e-07
in O 0 3.03236746823643e-09
subjects O 0 2.8382109995561677e-09
with O 0 1.3062863013502124e-09
and O 0 7.453877515217755e-10
without O 0 1.4221315236540022e-09
the O 0 2.5616071486211922e-09
R496H O 0 2.3649987269891426e-05
mutation O 0 3.82626512873685e-06
was O 0 8.085465630358613e-09
determined O 0 8.840432386136854e-09
and O 0 7.023269743555716e-10
found O 0 2.1202877231729644e-09
to O 0 5.600016006468422e-10
be O 0 2.9202069651290685e-09
normal O 0 4.419424044499465e-07
. O 0 1.6036457850532315e-07

It O 0 6.932190217412426e-07
is O 0 5.7079237336665756e-08
therefore O 0 2.037428892265325e-08
concluded O 0 6.06144467951708e-08
that O 0 4.920561180732363e-10
the O 0 1.1333138871805204e-09
R496H O 0 4.03835065299063e-06
mutation O 0 1.9661899841594277e-06
of O 0 1.0526905569463452e-08
ARSA O 0 0.06091195344924927
does O 0 1.1484970308117681e-08
not O 0 1.2055870191041151e-10
negatively O 0 3.944780335718434e-10
influence O 0 1.8714318983370504e-10
the O 0 1.3900776363318101e-10
activity O 0 9.366570852265e-10
of O 0 1.0619405355072331e-09
ARSA O 0 0.025017675012350082
and O 0 6.760235038427709e-09
is O 0 4.233473571702007e-09
not O 0 1.2483039046884414e-09
a O 0 1.408830883065093e-07
cause O 0 5.834568128193496e-06
of O 0 1.4821290506006335e-06
MLD B-Disease 1 0.9980999827384949

Down O 0 2.6954387067235075e-05
- O 0 7.111133072612574e-06
regulation O 0 2.904876907905418e-07
of O 0 1.8125209777508644e-08
transmembrane O 0 3.720302629517391e-05
carbonic O 0 0.0006034689140506089
anhydrases O 0 0.003624466946348548
in O 0 1.3051364476268645e-05
renal B-Disease 1 0.9999725818634033
cell I-Disease 1 0.9999344348907471
carcinoma I-Disease 1 0.9999992847442627
cell O 0 0.33602625131607056
lines O 0 2.8112794097978622e-05
by O 0 5.0612438684538574e-08
wild O 0 1.9736610283871414e-06
- O 0 0.0013745400356128812
type O 0 0.00014950986951589584
von B-Disease 1 0.7631654739379883
Hippel I-Disease 1 0.9886482357978821
- I-Disease 0 0.11762339621782303
Lindau I-Disease 0 0.34617379307746887
transgenes O 0 0.0010977225610986352
. O 0 1.3282832469485584e-06

To O 0 4.5371854184850235e-07
discover O 0 4.193144832242979e-06
genes O 0 1.2493618442022125e-06
involved O 0 2.7423675419413485e-07
in O 0 2.957552567295352e-07
von B-Disease 0 0.43279173970222473
Hippel I-Disease 1 0.9874128103256226
- I-Disease 0 0.2168576419353485
Lindau I-Disease 1 0.6479594111442566
( O 0 2.3666127901833534e-07
VHL B-Disease 0 0.003701206296682358
) O 0 1.8822985836663975e-08
- O 0 3.65537539437355e-06
mediated O 0 5.755770871473942e-06
carcinogenesis O 0 0.005726878996938467
, O 0 1.5844740630654996e-08
we O 0 3.547977245332845e-09
used O 0 1.9748236468331015e-07
renal B-Disease 1 0.9999592304229736
cell I-Disease 1 0.9999092817306519
carcinoma I-Disease 1 0.9999988079071045
cell O 0 0.09832727909088135
lines O 0 2.9095757781760767e-05
stably O 0 9.210474672727287e-05
transfected O 0 0.00030641802004538476
with O 0 9.192194738716353e-08
wild O 0 6.7902965383837e-06
- O 0 0.0010373108088970184
type O 0 0.00018971941608469933
VHL O 1 0.9449980854988098
- O 0 0.002079650992527604
expressing O 0 7.238604212034261e-06
transgenes O 0 0.00021659959747921675
. O 0 1.2852572126575978e-06

Large O 0 4.239029294694774e-06
- O 0 1.1373994311725255e-05
scale O 0 8.143381364789093e-07
RNA O 0 2.579490114840155e-07
differential O 0 9.308730852808367e-08
display O 0 8.736204648585044e-09
technology O 0 8.34963920226528e-09
applied O 0 1.6846503081424657e-09
to O 0 1.0899239150097273e-10
these O 0 1.2927672821128056e-10
cell O 0 3.154949297368148e-07
lines O 0 8.258633243940494e-08
identified O 0 2.1864747790090178e-09
several O 0 2.909958385366451e-10
differentially O 0 4.58810802683729e-08
expressed O 0 2.1861703558556655e-09
genes O 0 2.3227051393348574e-09
, O 0 1.8526620515491032e-10
including O 0 2.922311559405699e-10
an O 0 1.3792660347178298e-09
alpha O 0 1.356756570203288e-06
carbonic O 0 0.00017532179481349885
anhydrase O 0 0.0008907383307814598
gene O 0 3.375374490133254e-06
, O 0 7.138899604797189e-08
termed O 0 2.5617007850087248e-05
CA12 O 0 0.005241949111223221
. O 0 1.0612606047288864e-06

The O 0 1.4709188178585464e-07
deduced O 0 3.041614604626375e-07
protein O 0 1.335185402240313e-07
sequence O 0 7.770618992708478e-08
was O 0 6.010315356519413e-09
classified O 0 1.1327073501377072e-08
as O 0 3.0600338929431814e-10
a O 0 4.5178008001300896e-09
one O 0 3.813014348708066e-09
- O 0 1.0686832865758333e-05
pass O 0 1.4653157620614365e-07
transmembrane O 0 4.33377135777846e-05
CA O 0 2.4453072455798974e-07
possessing O 0 1.1721636994366236e-08
an O 0 5.723420626324582e-10
apparently O 0 2.1825094620453456e-08
intact O 0 4.035198486462832e-08
catalytic O 0 3.099309964227359e-08
domain O 0 7.615465591470638e-09
in O 0 1.949329364592245e-09
the O 0 7.480829289363555e-09
extracellular O 0 4.747032562590903e-06
CA O 0 2.8155673135188408e-05
module O 0 0.0001257705589523539
. O 0 8.093243195617106e-07

Reintroduced O 0 0.0007252389332279563
wild O 0 0.00018040310533251613
- O 0 0.009094808250665665
type O 0 3.0065511964494362e-05
VHL B-Disease 0 0.006732369773089886
strongly O 0 1.369168245446417e-07
inhibited O 0 8.757329794661928e-08
the O 0 1.4793921643274643e-09
overexpression O 0 1.425015057066048e-07
of O 0 7.192839657221839e-10
the O 0 2.802016618730363e-09
CA12 O 0 3.324160206830129e-05
gene O 0 7.393987999648743e-08
in O 0 3.858270147816256e-09
the O 0 4.8696723098373695e-08
parental O 0 0.0035084146074950695
renal B-Disease 1 0.9999903440475464
cell I-Disease 1 0.9999771118164062
carcinoma I-Disease 1 0.9999995231628418
cell O 1 0.9900982975959778
lines O 0 0.000722631870303303
. O 0 1.1836846169899218e-06

Similar O 0 1.1138792615383863e-05
results O 0 1.0963927934426465e-06
were O 0 8.970575393618674e-09
obtained O 0 1.4279571303177363e-08
with O 0 1.2978036423305639e-08
CA9 O 0 0.0006198350456543267
, O 0 2.1571884278870357e-09
encoding O 0 2.6290361887504332e-08
another O 0 2.3440919960648898e-07
transmembrane O 0 0.0011459433007985353
CA O 0 9.484689371674904e-07
with O 0 1.5598458080745559e-09
an O 0 1.2590786191424286e-09
intact O 0 2.5830547656369163e-07
catalytic O 0 8.35465868931351e-07
domain O 0 4.3704278596123913e-07
. O 0 1.48996321058803e-07

Although O 0 3.7985932976880576e-07
both O 0 1.6086493914713174e-08
domains O 0 8.215083369123022e-08
of O 0 4.439232981212626e-09
the O 0 1.0300266417573312e-08
VHL B-Disease 0 0.0013448987156152725
protein O 0 1.0884628665053242e-07
contribute O 0 4.903829786684355e-09
to O 0 2.6408036868375007e-10
regulation O 0 1.8718765204539523e-08
of O 0 1.1546288369856939e-09
CA12 O 0 4.59596594737377e-05
expression O 0 3.4480468258379915e-08
, O 0 6.276650865721933e-10
the O 0 8.064914847061289e-10
elongin O 0 2.3105831132852472e-06
binding O 0 4.920913454498077e-08
domain O 0 1.1428203805508019e-07
alone O 0 8.779573335004898e-08
could O 0 1.1901957641669014e-08
effectively O 0 2.1691923279831826e-07
regulate O 0 2.760588131422992e-06
CA9 O 0 0.008481022901833057
expression O 0 2.4796074740152108e-06
. O 0 7.759006734886498e-07

We O 0 1.6415685877291253e-06
mapped O 0 6.324348214548081e-05
CA12 O 0 0.0021855118684470654
and O 0 2.932376901298994e-07
CA9 O 0 0.011097040958702564
loci O 0 4.504244316194672e-06
to O 0 1.0604431999183817e-08
chromosome O 0 1.8087404896505177e-05
bands O 0 1.4714536291648983e-06
15q22 O 0 1.2201330719108228e-05
and O 0 6.220379589194636e-08
17q21 O 0 0.0001467373949708417
. O 0 7.9735082181287e-07

2 O 0 6.652721822320018e-06
respectively O 0 2.5071308300539386e-06
, O 0 6.076249547959378e-08
regions O 0 3.9128099160734564e-07
prone O 0 1.4839429240964819e-05
to O 0 9.610114926061897e-10
amplification O 0 8.375704396712536e-07
in O 0 6.712899569549791e-09
some O 0 8.172071908063572e-09
human O 0 6.015576218487695e-06
cancers B-Disease 1 0.787342369556427
. O 0 1.2738572650050628e-06

Additional O 0 7.620916449013748e-07
experiments O 0 2.109202114297659e-06
are O 0 3.5754292859735415e-09
needed O 0 8.64345484075102e-09
to O 0 2.673278542975055e-10
define O 0 4.108721363138557e-09
the O 0 7.011973224280155e-10
role O 0 8.489203118244859e-09
of O 0 1.0683914197784361e-08
CA O 0 5.826283086207695e-06
IX O 0 0.00012416009849403054
and O 0 5.8676526748513425e-08
CA O 0 1.5361137002400937e-06
XII O 0 2.4142530037352117e-06
enzymes O 0 1.2062897347675516e-08
in O 0 4.415947607583348e-10
the O 0 1.9670919060299497e-10
regulation O 0 8.781076310526714e-09
of O 0 3.337543852399705e-10
pH O 0 1.0419793170513003e-06
in O 0 3.351456889788551e-10
the O 0 1.2550020744850343e-10
extracellular O 0 1.112185188389958e-08
microenvironment O 0 2.0044626580784097e-06
and O 0 6.226166249234666e-10
its O 0 2.767022611038783e-09
potential O 0 7.286911340997904e-08
impact O 0 3.0156977004480723e-07
on O 0 1.4259395584304002e-06
cancer B-Disease 1 0.9616114497184753
cell O 0 0.009012410417199135
growth O 0 6.82227118886658e-06
. O 0 3.7935032537461666e-07

A O 0 1.4001315093992162e-06
gene O 0 4.916728926218639e-07
encoding O 0 1.4183903829234623e-07
a O 0 9.738121775626496e-08
transmembrane O 0 5.710646291845478e-06
protein O 0 5.300154271026258e-07
is O 0 1.4142607973610666e-08
mutated O 0 3.348825885041151e-06
in O 0 1.483636395960275e-07
patients O 0 0.0006855155806988478
with O 0 0.00041424803202971816
diabetes B-Disease 1 0.9999960660934448
mellitus I-Disease 1 0.9999834299087524
and O 0 0.047553107142448425
optic B-Disease 1 0.999995231628418
atrophy I-Disease 1 0.9999897480010986
( O 1 0.9055178761482239
Wolfram B-Disease 1 0.9999845027923584
syndrome I-Disease 1 0.9999954700469971
) O 0 1.064647949533537e-05
. O 0 2.992237114085583e-06

Wolfram B-Disease 1 0.9998160004615784
syndrome I-Disease 1 0.9999897480010986
( O 0 0.0007415016298182309
WFS B-Disease 1 0.9963885545730591
; O 0 2.934014810307417e-05
OMIM O 1 0.9794892072677612
222300 O 0 0.002052012598142028
) O 0 6.158624898944254e-08
is O 0 7.5971449575718e-08
an O 0 2.335034196221386e-06
autosomal B-Disease 1 0.9998636245727539
recessive I-Disease 1 0.999988317489624
neurodegenerative I-Disease 1 0.999996542930603
disorder I-Disease 1 0.9998384714126587
defined O 0 1.9221226466470398e-05
by O 0 1.5266836328464706e-07
young O 0 2.3262546164914966e-06
- O 0 0.000999760814011097
onset O 0 0.016888245940208435
non O 0 1.2443744708434679e-05
- O 0 0.02071467973291874
immune O 0 0.17148873209953308
insulin B-Disease 1 0.5589798092842102
- I-Disease 0 0.39495065808296204
dependent I-Disease 0 0.014643123373389244
diabetes I-Disease 1 0.9999912977218628
mellitus I-Disease 1 0.9999465942382812
and O 0 6.70481167617254e-05
progressive O 1 0.9944484233856201
optic B-Disease 1 0.999970555305481
atrophy I-Disease 1 0.9996662139892578
. O 0 1.5786084986757487e-05

Linkage O 0 4.1665498429210857e-05
to O 0 9.098437914190072e-08
markers O 0 3.855396244034637e-06
on O 0 1.53677603975666e-07
chromosome O 0 0.00039886217564344406
4p O 1 0.7644265294075012
was O 0 3.7290067211870337e-07
confirmed O 0 8.007199170378954e-08
in O 0 3.707830265042844e-09
five O 0 1.5078347459507313e-08
families O 0 1.0827231733401277e-07
. O 0 2.1696145324767713e-07

On O 0 1.0314779075315528e-07
the O 0 8.204995793903436e-09
basis O 0 7.386330658221141e-09
of O 0 5.537521996501482e-09
meiotic O 0 0.00165742973331362
recombinants O 0 0.19317147135734558
and O 0 1.3294135897012893e-05
disease O 1 0.9303293824195862
- O 0 0.010694035328924656
associated O 0 3.1618711204828287e-07
haplotypes O 0 2.336161287530558e-06
, O 0 3.6941218972685874e-09
the O 0 3.825062488971298e-09
WFS B-Disease 0 0.0010227934690192342
gene O 0 2.463663406615524e-07
was O 0 6.244436523417107e-09
localized O 0 9.418100432867504e-08
to O 0 3.4625885492189923e-10
a O 0 3.749950749920572e-08
BAC O 0 6.931972893653437e-05
/ O 0 2.3954103198775556e-06
P1 O 0 1.6220341422013007e-05
contig O 0 2.331736595806433e-06
of O 0 3.981016072351906e-10
less O 0 1.013436334851292e-09
than O 0 1.50425494283013e-09
250 O 0 4.7385199763994024e-08
kb O 0 3.824632221949287e-05
. O 0 4.781508664564171e-07

Mutations O 0 0.006112601608037949
in O 0 3.734654967502138e-07
a O 0 2.156634621997e-07
novel O 0 2.0360232610983076e-07
gene O 0 3.601522564622428e-07
( O 0 1.3255123221256326e-08
WFS1 O 0 3.0252026590460446e-06
) O 0 4.0905623333031826e-10
encoding O 0 1.7788871486956737e-09
a O 0 4.2650500908791855e-09
putative O 0 7.474056360479153e-07
transmembrane O 0 2.603713710414013e-06
protein O 0 7.158070047807996e-08
were O 0 8.426782049930637e-10
found O 0 1.7438482879938988e-09
in O 0 7.600746698699368e-10
all O 0 2.1158912122398732e-10
affected O 0 3.5367948569842156e-09
individuals O 0 6.408191199902546e-10
in O 0 1.5872529957050574e-09
six O 0 4.1176512866059056e-08
WFS B-Disease 0 0.0030264160595834255
families O 0 3.482701060875115e-08
, O 0 1.403998362015102e-09
and O 0 4.917962148631716e-10
these O 0 4.108288154114348e-10
mutations O 0 5.644803309223789e-07
were O 0 1.62229851774498e-09
associated O 0 1.7382701500423536e-08
with O 0 2.589333547575734e-08
the O 0 3.5566085898608435e-06
disease O 1 0.7994815111160278
phenotype O 0 0.035387348383665085
. O 0 2.2572610305360286e-06

WFS1 O 0 0.020433926954865456
appears O 0 1.5767494687679573e-06
to O 0 3.0307716336608337e-09
function O 0 1.7944923769164234e-08
in O 0 5.978644690429746e-09
survival O 0 1.5213611277431482e-06
of O 0 9.28110654996317e-09
islet O 0 0.00011233057011850178
beta O 0 3.683077738969587e-05
- O 0 8.034242637222633e-05
cells O 0 7.271714821399655e-07
and O 0 7.310505090174502e-09
neurons O 0 1.4588754311262164e-06
. O 0 2.931783171788993e-08
. O 0 1.7867898804979632e-07

Stable O 0 1.2013221748929936e-05
interaction O 0 2.7374392175261164e-07
between O 0 1.5346385495718096e-08
the O 0 2.8111437622158064e-09
products O 0 1.9587997890369024e-09
of O 0 6.321005940890245e-10
the O 0 5.566239913434856e-09
BRCA1 O 0 0.00016778899589553475
and O 0 2.2275054334386368e-07
BRCA2 O 0 0.07118738442659378
tumor B-Disease 0 0.041874099522829056
suppressor O 0 8.882934707798995e-06
genes O 0 2.6179876044807315e-08
in O 0 6.937928898054224e-09
mitotic O 0 3.754628778551705e-05
and O 0 1.092433308258478e-07
meiotic O 0 0.11997608095407486
cells O 0 0.0002639191225171089
. O 0 9.48941192291386e-07

BRCA1 O 1 0.9809699058532715
and O 0 1.037492256728001e-05
BRCA2 O 0 0.014854679815471172
account O 0 1.2866928500443464e-07
for O 0 6.555519238560237e-09
most O 0 1.3465086823316597e-09
cases O 0 8.000569984289996e-09
of O 0 3.2066693744781105e-09
familial O 0 0.010310030542314053
, O 0 2.1771299429929059e-07
early O 0 5.136030267749447e-06
onset O 1 0.9845841526985168
breast B-Disease 1 0.9998347759246826
and I-Disease 0 6.416320047719637e-06
/ I-Disease 1 0.8544982671737671
or I-Disease 1 0.5308411121368408
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999880790710449
and O 0 1.0459857868738709e-08
encode O 0 8.59215454340756e-09
products O 0 5.460058183359706e-09
that O 0 1.317932846189862e-10
each O 0 3.577255436315596e-10
interact O 0 1.0291095087211488e-08
with O 0 6.606119029584079e-08
hRAD51 O 0 0.00031611998565495014
. O 0 7.266453394549899e-07

Results O 0 2.6880461518885568e-05
presented O 0 5.478221396515437e-07
here O 0 2.159947953828123e-08
show O 0 3.012526761381196e-08
that O 0 5.6983155971579436e-09
BRCA1 O 0 2.7871054044226184e-05
and O 0 2.5802325609447507e-08
BRCA2 O 0 0.00011660726158879697
coexist O 0 1.5608947023793007e-07
in O 0 2.955249378544522e-09
a O 0 1.0140709605366283e-08
biochemical O 0 5.574539727604133e-07
complex O 0 2.335955713306248e-07
and O 0 4.642206175020647e-09
colocalize O 0 1.081419668480521e-05
in O 0 5.201583608283045e-09
subnuclear O 0 1.5372363122878596e-05
foci O 0 1.2665407211898128e-06
in O 0 1.5954115806238178e-09
somatic O 0 4.082219788870134e-07
cells O 0 1.293590372597464e-07
and O 0 1.6658327495200353e-10
on O 0 1.0675205858179382e-10
the O 0 1.7146584152527566e-10
axial O 0 2.8541293772832432e-08
elements O 0 1.2378833513793097e-09
of O 0 2.152626077389641e-09
developing O 0 4.978122092325066e-07
synaptonemal O 0 0.0020590678323060274
complexes O 0 0.00035204485175199807
. O 0 8.974410548034939e-07

Like O 0 1.800223981263116e-05
BRCA1 O 0 0.07766666263341904
and O 0 1.299423047385062e-06
RAD51 O 1 0.5498251914978027
, O 0 6.013872848598112e-07
BRCA2 O 0 0.00013477925676852465
relocates O 0 9.123668291977083e-07
to O 0 5.548348003259207e-09
PCNA O 0 0.00017827485862653702
+ O 0 5.175189130568469e-07
replication O 0 3.196830391516414e-07
sites O 0 1.0100866809636955e-08
following O 0 1.1531614774185073e-08
exposure O 0 4.7065705643944966e-07
of O 0 2.943885357709064e-09
S O 0 1.5871433788561262e-05
phase O 0 1.1367229717507144e-06
cells O 0 2.741818150298059e-07
to O 0 2.3879356270128937e-09
hydroxyurea O 0 0.00013164746633265167
or O 0 2.888853316562745e-07
UV O 0 0.005742490291595459
irradiation O 0 3.0048944609006867e-05
. O 0 4.512859561600635e-07

Thus O 0 9.048731953953393e-06
, O 0 5.117857995173836e-07
BRCA1 O 0 0.0012487128842622042
and O 0 1.247153136318957e-07
BRCA2 O 0 0.00014219600416254252
participate O 0 2.2859419246401558e-08
, O 0 2.4944430965234687e-09
together O 0 1.9129646755544627e-09
, O 0 6.62936261441871e-10
in O 0 7.23499815613593e-10
a O 0 1.113121150808638e-08
pathway O 0 1.6311038564253977e-07
( O 0 1.527256721089998e-08
s O 0 3.8500502341776155e-06
) O 0 1.0313293552499658e-09
associated O 0 1.3630359063654396e-09
with O 0 1.8391528577854643e-10
the O 0 2.2825019652117362e-10
activation O 0 1.04606554529596e-08
of O 0 1.04534103595455e-09
double O 0 3.2220432331087068e-06
- O 0 3.7308185710571706e-05
strand O 0 6.077134912629845e-06
break O 0 8.996158271656896e-07
repair O 0 0.00011316940071992576
and O 0 2.9742169616042702e-08
/ O 0 5.051694643043447e-06
or O 0 1.037214971688627e-07
homologous O 0 2.5683813873911276e-05
recombination O 0 6.738759111613035e-05
. O 0 1.4610307061957428e-06

Dysfunction O 0 0.11479508131742477
of O 0 1.768087969367116e-07
this O 0 1.5909940032088343e-08
pathway O 0 5.960787348158192e-07
may O 0 1.3981360957870947e-08
be O 0 1.6236906263955575e-10
a O 0 2.0523425181551147e-09
general O 0 3.291151795536962e-09
phenomenon O 0 2.7737559804563716e-08
in O 0 3.08765374379405e-10
the O 0 2.925590880664686e-10
majority O 0 1.4859615760087763e-09
of O 0 2.448160008050593e-10
cases O 0 1.3095600159829246e-08
of O 0 3.828889560963944e-08
hereditary B-Disease 1 0.9586926698684692
breast I-Disease 1 0.9997397065162659
and I-Disease 0 2.429122650937643e-05
/ I-Disease 1 0.9936203360557556
or I-Disease 1 0.9935192465782166
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999951124191284
. O 0 1.2952634733665036e-06
. O 0 1.6767415900176275e-06

A O 0 8.724702638573945e-06
novel O 0 3.776055336857098e-06
Arg362Ser O 0 0.0003754065546672791
mutation O 0 4.179180177743547e-05
in O 0 1.3077678495676537e-08
the O 0 8.726861899788219e-09
sterol O 0 0.0003286340506747365
27 O 0 6.125885647634277e-06
- O 0 0.00015169662947300822
hydroxylase O 0 0.00014693227421958
gene O 0 5.695004006156523e-07
( O 0 2.4380181429251024e-08
CYP27 O 0 5.79309489694424e-05
) O 0 3.070752541134425e-09
: O 0 4.1490874624905416e-10
its O 0 2.8215418890198407e-10
effects O 0 2.2521664533314834e-09
on O 0 5.237180689121601e-10
pre O 0 6.852447853589183e-08
- O 0 2.1191729260294778e-08
mRNA O 0 4.131802455731304e-09
splicing O 0 4.03182873753849e-08
and O 0 2.37319675022718e-09
enzyme O 0 2.8509418825706234e-07
activity O 0 2.4502702444806346e-07
. O 0 1.3449762548134458e-07

A O 0 7.113778337952681e-06
novel O 0 1.2105857649657992e-06
C O 0 4.93968343562301e-07
to O 0 3.2004734418222824e-09
A O 0 1.0226762015008717e-07
mutation O 0 4.814288558918633e-07
in O 0 1.2964619378053044e-09
the O 0 2.1471067146450196e-09
sterol O 0 0.00011653466208372265
27 O 0 1.7050903124982142e-06
- O 0 2.8738259061356075e-05
hydroxylase O 0 6.578121974598616e-05
gene O 0 3.727886905835476e-07
( O 0 5.514775747172962e-09
CYP27 O 0 1.5589665053994395e-05
) O 0 1.3946409582743513e-09
was O 0 1.4137583326245817e-09
identified O 0 1.6293596472038985e-09
by O 0 2.73127104266635e-10
sequencing O 0 1.638882274335174e-08
amplified O 0 1.7024598264470114e-07
CYP27 O 0 2.2688227545586415e-05
gene O 0 3.887805988256332e-08
products O 0 2.991648040406858e-09
from O 0 1.4334111675395889e-09
a O 0 9.297623648762965e-08
patient O 0 5.3436677262652665e-05
with O 0 2.2361093670042465e-06
cerebrotendinous B-Disease 1 0.9997629523277283
xanthomatosis I-Disease 1 0.9996992349624634
( O 0 1.4665302842331585e-05
CTX B-Disease 1 0.9658726453781128
) O 0 4.908661708213913e-07
. O 0 4.1462681110715494e-07

The O 0 1.0975329587381566e-06
mutation O 0 4.3380761781008914e-05
changed O 0 1.6517574863428308e-07
the O 0 4.969590516878952e-09
adrenodoxin O 0 5.88739396789606e-07
cofactor O 0 6.769191429611965e-08
binding O 0 1.313184725404426e-07
residue O 0 4.387826209040213e-07
362Arg O 0 4.741268639918417e-06
to O 0 2.2415982403600765e-09
362Ser O 0 1.3304941603564657e-05
( O 0 3.011411919828788e-08
CGT O 0 2.91559481411241e-05
362Arg O 0 1.8995038999491953e-06
to O 0 2.162601653310503e-09
AGT O 0 0.001104806549847126
362Ser O 0 2.0643099560402334e-05
) O 0 2.5831363714701183e-09
, O 0 4.45565306872453e-10
and O 0 6.933745244630529e-10
was O 0 1.6026469040753e-08
responsible O 0 2.488130235178687e-07
for O 0 1.8364438858498033e-07
deficiency O 0 0.1615414172410965
in O 0 3.986200258765393e-09
the O 0 5.536951341866825e-09
sterol O 0 0.0003286823339294642
27 O 0 1.2302574532441213e-06
- O 0 4.625871497410117e-06
hydroxylase O 0 9.49161585594993e-06
activity O 0 6.716600609024681e-09
, O 0 4.720293045323842e-10
as O 0 2.5998814212613297e-10
confirmed O 0 1.649421377258875e-09
by O 0 6.918166733926867e-11
expression O 0 2.409474009201773e-10
of O 0 6.425750903593652e-11
mutant O 0 1.294145235419819e-08
cDNA O 0 1.6211796349807628e-08
into O 0 7.644440636056515e-09
COS O 0 0.0001411264529451728
- O 0 2.5941910280380398e-05
1 O 0 2.494749651305028e-07
cells O 0 2.8150623165856814e-06
. O 0 2.4344177518287324e-07

Quantitative O 0 4.3456925595819484e-06
analysis O 0 4.524166854480427e-07
showed O 0 1.3278787491799449e-07
that O 0 2.7749383346709067e-10
the O 0 2.173480145861717e-10
expression O 0 1.1070122596379406e-09
of O 0 4.3886502765211333e-10
CYP27 O 0 3.7389493172668153e-06
gene O 0 2.1212677836501825e-08
mRNA O 0 1.4620180621705003e-08
in O 0 2.382049224536331e-09
the O 0 5.329853891566927e-09
patient O 0 2.536601868996513e-06
represented O 0 5.7618500193257205e-08
52 O 0 1.2726187605949235e-06
. O 0 2.2312558201065258e-07

5 O 0 1.6488455685248482e-06
% O 0 8.183243238590876e-08
of O 0 4.056177616007517e-09
the O 0 1.3849026814227727e-08
normal O 0 3.8924810041862656e-07
level O 0 8.47417538807349e-07
. O 0 5.286892132971843e-07

As O 0 2.9873791618229006e-07
the O 0 1.181643725089998e-07
mutation O 0 2.394446164544206e-05
occurred O 0 2.2628100282418018e-07
at O 0 5.683878256945718e-09
the O 0 1.0071504741304693e-09
penultimate O 0 1.5397260710869887e-07
nucleotide O 0 4.2276418810160976e-08
of O 0 2.0122399302380245e-09
exon O 0 3.5595130611909553e-06
6 O 0 6.063826418767349e-08
( O 0 2.4803810116935665e-09
- O 0 2.0531665256839915e-07
2 O 0 2.0128081423820277e-09
position O 0 8.10244316085118e-10
of O 0 2.9749061547512667e-10
exon O 0 1.8863869399865507e-06
6 O 0 3.398548926725198e-07
- O 0 1.5512250683968887e-05
intron O 0 8.39603235363029e-05
6 O 0 2.9415968327839437e-08
splice O 0 2.3502747126258328e-07
site O 0 2.8578865940431797e-09
) O 0 8.0473322450203e-11
of O 0 3.789519392727314e-11
the O 0 3.556084871014775e-10
gene O 0 1.7937669127832123e-08
, O 0 1.3165467604991932e-09
we O 0 1.9852179622414923e-10
hypothesized O 0 8.395407036232427e-09
that O 0 2.4252613806119427e-10
the O 0 1.1433519908621292e-08
mutation O 0 2.1077155906823464e-05
may O 0 6.791798767835644e-08
partially O 0 2.450071576731716e-07
affect O 0 7.315480443637057e-10
the O 0 1.592787013393604e-10
normal O 0 2.5819246740610424e-09
splicing O 0 2.582162395015075e-08
efficiency O 0 1.0746128964456148e-07
in O 0 3.0208107126838968e-09
exon O 0 2.7573648821999086e-06
6 O 0 5.031866479043856e-08
and O 0 1.4091064981514023e-09
cause O 0 2.4575804502546816e-08
alternative O 0 6.463852120219826e-09
splicing O 0 2.740788147548301e-07
elsewhere O 0 5.8745062148091165e-08
, O 0 6.121436690875726e-10
which O 0 1.6967001414958105e-10
resulted O 0 5.9211195946318185e-09
in O 0 2.43453657233772e-09
decreased O 0 8.630441357126983e-07
transcript O 0 8.599730563219055e-07
in O 0 1.0778498094055067e-08
the O 0 8.52027071118755e-08
patient O 0 9.73949208855629e-05
. O 0 5.684195230060141e-07

Transfection O 0 0.002175715286284685
of O 0 3.0653126259494456e-07
constructed O 0 7.82810639066156e-06
minigenes O 0 0.0003015840193256736
, O 0 8.878521029487274e-09
with O 0 3.192273778651611e-09
or O 0 1.883069700170381e-09
without O 0 2.1004196160134825e-09
the O 0 2.8474995694693916e-09
mutation O 0 3.154524961246352e-07
, O 0 3.309278961971529e-10
into O 0 1.17382537023758e-09
COS O 0 6.02021100348793e-05
- O 0 4.630006969819078e-06
1 O 0 2.3967023921045438e-08
cells O 0 9.073794160485704e-08
confirmed O 0 2.333188753311788e-09
that O 0 3.044964627663127e-11
the O 0 1.8042099758641683e-10
mutant O 0 1.3899975215281302e-07
minigene O 0 7.795774763508234e-06
was O 0 5.681797254908361e-09
responsible O 0 3.3650506825466664e-09
for O 0 2.1262884508654878e-10
a O 0 2.876030080756209e-09
mRNA O 0 1.651691938775457e-08
species O 0 1.4012668803076167e-09
alternatively O 0 9.821742530391475e-09
spliced O 0 1.7179999645122734e-07
at O 0 4.822529930947894e-09
an O 0 1.1173472147518737e-09
activated O 0 5.44770159649488e-07
cryptic O 0 1.072816857572434e-07
5 O 0 2.474974447608247e-09
splice O 0 1.9857429833791684e-07
site O 0 5.308247352786566e-08
88 O 0 3.413249061168244e-08
bp O 0 5.8049145934546686e-08
upstream O 0 3.0075759660519452e-09
from O 0 1.2542579475027793e-10
the O 0 1.2714582164896626e-10
3 O 0 8.648364802077424e-10
end O 0 1.8339763041552715e-09
of O 0 4.22579349290686e-09
exon O 0 6.173967267386615e-05
6 O 0 2.453251681799884e-06
. O 0 4.485237070639414e-07

Our O 0 7.053890840325039e-07
data O 0 1.72661003716712e-07
suggest O 0 6.32758627716612e-08
that O 0 4.932362851484129e-10
the O 0 5.896491073187349e-10
C O 0 8.188376199314007e-09
to O 0 1.524199377822555e-10
A O 0 2.464367732102346e-08
mutation O 0 3.2975694352899154e-07
at O 0 1.0488381274598169e-09
the O 0 2.4849350355182764e-10
penultimate O 0 3.0687694163589185e-08
nucleotide O 0 1.7098722437935976e-08
of O 0 6.508683036976493e-10
exon O 0 1.0805358670040732e-06
6 O 0 6.061141810675963e-09
of O 0 3.5008063115071764e-10
the O 0 5.323473661889011e-09
CYP27 O 0 0.0012913744430989027
gene O 0 5.238145490693569e-07
not O 0 8.031144083098241e-10
only O 0 8.443579169181703e-10
causes O 0 1.9505712600675906e-07
the O 0 1.227803778647285e-07
deficiency B-Disease 0 0.00632236385717988
in I-Disease 0 1.149618511497863e-09
the I-Disease 0 3.2114313430753327e-09
sterol I-Disease 0 0.0005227176588959992
27 I-Disease 0 2.657871618794161e-06
- I-Disease 0 2.3021564629743807e-05
hydroxylase I-Disease 0 1.5358882592408918e-05
activity I-Disease 0 1.6856120055308565e-08
, O 0 8.553022179391689e-10
but O 0 4.75105843555923e-10
also O 0 1.1659375687145257e-09
partially O 0 2.346019840615554e-07
leads O 0 7.695422965525722e-09
to O 0 9.715622750761099e-11
alternative O 0 1.65150226827393e-09
pre O 0 5.4583217945491924e-08
- O 0 1.3153651501340846e-08
mRNA O 0 1.6934808000357293e-09
splicing O 0 6.931764939821505e-09
of O 0 6.771109783976215e-10
the O 0 1.4478210630386457e-08
gene O 0 9.489764920544985e-07
. O 0 2.4377260388064315e-07

To O 0 3.827867089967185e-08
our O 0 1.441087604803215e-08
knowledge O 0 1.4563181771620748e-08
, O 0 3.4785234692691347e-09
this O 0 3.315520913371728e-10
is O 0 2.608459837016852e-10
the O 0 3.303728957071428e-10
first O 0 1.0460011745649922e-09
report O 0 1.0405964978588145e-09
regarding O 0 2.4090696104650533e-10
effects O 0 3.6214202747686386e-09
on O 0 4.1265313388549885e-10
pre O 0 6.109381445185136e-08
- O 0 8.026155740026297e-09
mRNA O 0 8.425046216231635e-10
splicing O 0 3.4176643737282575e-09
of O 0 2.3704091467458e-10
a O 0 4.883919935139147e-09
mutation O 0 6.545825925741156e-08
at O 0 6.846875844068734e-10
the O 0 3.3543859356832684e-10
- O 0 2.062590738205472e-07
2 O 0 1.3817306188101952e-09
position O 0 9.619209873079626e-10
of O 0 2.7549931780335157e-10
a O 0 8.474189350238248e-09
5 O 0 2.45153177758084e-08
splice O 0 6.751307864760747e-06
site O 0 1.2281790304768947e-06
. O 0 2.8273586849536514e-07

ATM O 0 0.032259341329336166
germline O 1 0.9308649897575378
mutations O 0 0.17961756885051727
in O 0 2.0819052224396728e-05
classical O 0 0.0020725105423480272
ataxia B-Disease 1 0.9999867677688599
- I-Disease 1 0.9999175071716309
telangiectasia I-Disease 1 0.9999867677688599
patients O 0 0.44415104389190674
in O 0 8.925386651981171e-08
the O 0 4.403478826020546e-08
Dutch O 0 1.1104683835583273e-05
population O 0 4.519156391324941e-07
. O 0 6.86989835685381e-07

Germline O 1 0.9618357419967651
mutations O 0 0.011210665106773376
in O 0 1.1617098749638899e-07
the O 0 1.0929769089784713e-08
ATM O 0 5.423191396403126e-06
gene O 0 2.268871384103477e-07
are O 0 1.7186996270623922e-09
responsible O 0 8.126594508439666e-08
for O 0 1.1722546844339377e-07
the O 0 0.0009546043584123254
autosomal B-Disease 1 0.9999966621398926
recessive I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999998807907104
ataxia B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999793767929077
telangiectasia I-Disease 1 0.9999827146530151
( O 0 0.0007102495874278247
A B-Disease 1 0.9970763921737671
- I-Disease 1 0.9998438358306885
T I-Disease 1 0.9998524188995361
) O 0 4.061614902184374e-07
. O 0 5.906999263061152e-07

In O 0 3.0331906941682973e-07
our O 0 7.762797338273231e-08
study O 0 4.0260271561010086e-08
, O 0 2.8322517664491897e-09
we O 0 3.3353483863685085e-10
have O 0 1.317550790691513e-10
determined O 0 9.864373762269452e-10
the O 0 3.383274493895527e-10
ATM O 0 1.7663634253040073e-06
mutation O 0 3.79542115069853e-07
spectrum O 0 2.748330629742668e-08
in O 0 2.1179837883522623e-09
19 O 0 9.578738513482676e-08
classical O 0 1.0421044862596318e-06
A B-Disease 1 0.9145947098731995
- I-Disease 1 0.9999210834503174
T I-Disease 1 0.999984860420227
patients O 0 2.1319683582987636e-05
, O 0 8.214120494898225e-10
including O 0 5.14104925297687e-10
some O 0 2.40529540729284e-10
immigrant O 0 1.6238371358667791e-07
populations O 0 1.573070385063602e-08
, O 0 3.870245235404468e-10
as O 0 9.846791437784219e-11
well O 0 1.2028834872612748e-10
as O 0 1.2869121046588106e-10
12 O 0 1.0042329190440569e-09
of O 0 3.7124989193948466e-10
Dutch O 0 1.5378815021449554e-07
ethnic O 0 2.7036891836473842e-08
origin O 0 1.1433404978333783e-07
. O 0 1.4639216772138752e-07

Both O 0 1.1710680070109447e-07
the O 0 3.076904064869268e-08
protein O 0 1.758090348857877e-07
truncation O 0 4.385430656839162e-06
test O 0 1.0482670376177339e-07
( O 0 5.538810743388467e-09
PTT O 0 1.056905375662609e-06
) O 0 1.0161654850904256e-09
and O 0 2.0853374582685547e-10
the O 0 4.5412196225669277e-10
restriction O 0 1.0728267163528926e-08
endonuclease O 0 2.9288601126609137e-06
fingerprinting O 0 3.5906552966480376e-06
( O 0 1.682477090980683e-08
REF O 0 2.467591366439592e-05
) O 0 2.022096101672588e-10
method O 0 3.0787561389189477e-10
were O 0 4.14571536822006e-11
used O 0 5.475863165682604e-11
and O 0 1.287005363392879e-10
compared O 0 1.3346088678645174e-09
for O 0 3.411525575924834e-11
their O 0 1.937788401962237e-10
detection O 0 2.1216648349309253e-07
efficiency O 0 2.8520048545033205e-07
, O 0 7.949061964218629e-10
identifying O 0 1.7478017255712075e-08
76 O 0 4.607049319815815e-08
% O 0 5.985202333746997e-10
and O 0 1.8666941603573406e-10
60 O 0 1.2271378357908702e-09
% O 0 2.0078913531840215e-10
of O 0 1.8038073812398636e-10
the O 0 7.811749469510687e-09
mutations O 0 3.93736854675808e-06
, O 0 1.0089756585784926e-08
respectively O 0 3.051563055578299e-07
. O 0 3.003522408562276e-07

Most O 0 2.640187858560239e-06
patients O 0 2.849135489668697e-05
were O 0 1.155285911380588e-08
found O 0 1.0156195884292174e-08
to O 0 8.310422350277236e-10
be O 0 3.715504570678263e-09
compound O 0 2.1630871742672753e-06
heterozygote O 0 0.0004340260347817093
. O 0 8.593220854891115e-07

Seventeen O 0 4.87151337438263e-05
mutations O 0 0.00031632560421712697
were O 0 3.9007005625535385e-08
distinct O 0 5.125106028458504e-08
, O 0 1.3760497186154907e-09
of O 0 2.3175399099795158e-10
which O 0 4.586580837351306e-10
10 O 0 2.011234734311529e-09
were O 0 8.886071878322355e-10
not O 0 1.8202249707499618e-09
reported O 0 3.106204928826628e-07
previously O 0 1.6774440325662e-07
. O 0 1.735281216497242e-07

Mutations O 0 0.04742024093866348
are O 0 1.1325781201776408e-07
small O 0 9.968616865307922e-08
deletions O 0 4.137493306188844e-06
or O 0 8.855911914906756e-08
point O 0 2.1386233584053116e-07
mutations O 0 7.97273332864279e-06
frequently O 0 7.395680512445324e-08
affecting O 0 2.849120619430323e-07
splice O 0 3.212860247003846e-05
sites O 0 1.6702077800800907e-06
. O 0 6.353902222144825e-07

Moreover O 0 3.2408821425633505e-05
, O 0 2.886319805384119e-07
a O 0 5.196975507715251e-07
16 O 0 1.2741440968966344e-06
. O 0 5.85399220653926e-07

7 O 0 2.698844218684826e-05
- O 0 3.0207340387278236e-05
kb O 0 2.6992560378857888e-05
genomic O 0 8.273584171547554e-06
deletion O 0 2.90463231067406e-06
of O 0 2.8732229928607467e-09
the O 0 2.0707366932271043e-09
3 O 0 4.2246006692892024e-09
end O 0 8.538548201819651e-10
of O 0 8.971559606330004e-11
the O 0 7.041780492045291e-10
gene O 0 2.120224174007035e-08
, O 0 4.07534561652767e-10
most O 0 1.7092900705950598e-10
likely O 0 1.9329167155746063e-09
a O 0 2.203791815702516e-09
result O 0 8.578607824105688e-10
of O 0 9.93241044966453e-11
recombination O 0 2.2841810221052583e-08
between O 0 5.737607611244755e-10
two O 0 4.158951794064336e-10
LINE O 0 5.701460636942102e-08
elements O 0 7.805672552763099e-09
, O 0 6.857021173090061e-09
was O 0 7.187099981820211e-08
identified O 0 3.5921991070608783e-07
. O 0 1.4044697138615447e-07

The O 0 4.957839223607152e-07
most O 0 2.5301428507873425e-08
frequently O 0 5.87894497527941e-08
found O 0 1.2270406557490787e-07
mutation O 0 3.663373945528292e-06
, O 0 3.5226435102231335e-09
identified O 0 9.088894969977446e-09
in O 0 8.319780420151801e-10
three O 0 2.9790414579622393e-09
unrelated O 0 8.161948130691599e-07
Turkish O 0 1.1576312317629345e-05
A B-Disease 1 0.8231217861175537
- I-Disease 1 0.9961701035499573
T I-Disease 1 0.9996815919876099
individuals O 0 7.79856001997814e-09
, O 0 1.6099931388069422e-09
was O 0 5.817380355210844e-09
previously O 0 4.307989520668798e-09
described O 0 2.4417816657518188e-09
to O 0 5.275193823428559e-11
be O 0 1.0207630574132764e-10
a O 0 3.124296155121442e-09
Turkish O 0 2.2956126031203894e-06
A B-Disease 0 0.3245585262775421
- I-Disease 1 0.9994295239448547
T I-Disease 1 0.9999334812164307
founder O 0 0.00029803687357343733
mutation O 0 0.00011790525604737923
. O 0 2.728259858031379e-07

The O 0 1.2760540357703576e-07
presence O 0 1.0849475273744247e-07
of O 0 7.170255500454914e-09
a O 0 1.4673544512788794e-07
founder O 0 3.891819687851239e-06
mutation O 0 5.52876144865877e-06
among O 0 1.851952813325397e-09
relatively O 0 9.710871218260309e-09
small O 0 1.5440448919434857e-09
ethnic O 0 1.4833648753764805e-09
population O 0 7.500526866266455e-10
groups O 0 4.852171997526966e-10
in O 0 5.870535169094637e-10
Western O 0 4.723483826296615e-09
Europe O 0 7.165593896019118e-09
could O 0 1.1339345018512859e-09
indicate O 0 2.4477084803464777e-09
a O 0 9.511318843635763e-09
high O 0 1.9532126316335052e-07
carrier O 0 1.4449348100242787e-06
frequency O 0 1.3360001993589776e-08
in O 0 2.7789546219736394e-09
such O 0 4.26719815038723e-09
communities O 0 2.0890225016501063e-07
. O 0 3.081550516981224e-07

In O 0 1.8671003090275917e-06
patients O 0 5.036743914388353e-06
of O 0 5.339927611203166e-09
Dutch O 0 1.6391204837873374e-07
ethnic O 0 5.162364757893556e-09
origin O 0 2.7865341145627553e-09
, O 0 1.7579747657592293e-09
however O 0 9.192555050496765e-10
, O 0 7.790468270485462e-10
no O 0 1.6418035819754095e-09
significant O 0 9.523336785832726e-09
founder O 0 7.375380732810299e-07
effect O 0 1.0497155500388544e-07
could O 0 6.923704276573517e-09
be O 0 3.3447915548379115e-09
identified O 0 2.3556287942483323e-07
. O 0 1.2259083348453714e-07

The O 0 4.7286428639381484e-07
observed O 0 7.786952096466848e-07
genetic O 0 2.590388930912013e-06
heterogeneity O 0 3.3435160275985254e-06
including O 0 3.736569276213686e-09
the O 0 1.6004588765383687e-09
relative O 0 4.1826545782441826e-08
high O 0 9.959646263268951e-08
percentage O 0 5.63028770272922e-08
of O 0 1.464328103217838e-09
splice O 0 3.466431735432707e-05
- O 0 0.00022050268307793885
site O 0 1.5004195574874757e-06
mutations O 0 3.832027687167283e-06
had O 0 3.873843912316488e-09
no O 0 9.384631960429601e-10
reflection O 0 1.7635505500379622e-08
on O 0 7.513775379663912e-09
the O 0 5.335552444307723e-08
phenotype O 0 0.00011015928612323478
. O 0 5.599374048870231e-07

All O 0 1.9370438621990616e-06
patients O 0 0.00011506913870107383
manifested O 0 1.374659132125089e-05
classical O 0 4.538316716207191e-06
A B-Disease 0 0.006681945640593767
- I-Disease 0 0.17052020132541656
T I-Disease 0 0.34060341119766235
and O 0 2.268454091236549e-09
increased O 0 4.224184024792521e-08
cellular O 0 6.336913884297246e-06
radioresistant O 0 0.0003702047688420862
DNA O 0 1.3531767763197422e-05
synthesis O 0 1.9265228274889523e-06
. O 0 4.2980855141649954e-07

Determination O 0 5.997051175654633e-06
of O 0 4.167714706682091e-08
the O 0 1.6285961024209428e-08
genomic O 0 1.6176403505596681e-06
structure O 0 8.452659017166297e-08
of O 0 1.1300416158377402e-09
the O 0 2.5643496215366213e-09
COL4A4 O 0 2.4110473532346077e-05
gene O 0 6.836625487949277e-08
and O 0 1.1943429578664677e-09
of O 0 5.919877033022658e-09
novel O 0 1.5404357327497564e-05
mutations O 0 0.02248040959239006
causing O 0 0.4676222801208496
autosomal B-Disease 1 0.999840259552002
recessive I-Disease 1 0.9999631643295288
Alport I-Disease 1 0.999982476234436
syndrome I-Disease 1 0.9999850988388062
. O 0 7.354062108788639e-05

Autosomal B-Disease 1 0.9997329115867615
recessive I-Disease 1 0.99994957447052
Alport I-Disease 1 0.99998939037323
syndrome I-Disease 1 0.999988317489624
is O 0 0.00022893583809491247
a O 0 0.00024808457237668335
progressive O 1 0.9510459899902344
hematuric B-Disease 1 0.9997356534004211
glomerulonephritis I-Disease 1 0.9999895095825195
characterized O 0 0.031055178493261337
by O 0 1.6009869341360172e-06
glomerular B-Disease 1 0.9982043504714966
basement I-Disease 1 0.8751307725906372
membrane I-Disease 0 0.11894235014915466
abnormalities I-Disease 1 0.9687079787254333
and O 0 8.993261246814654e-08
associated O 0 2.0313568427354767e-07
with O 0 7.030621418380179e-08
mutations O 0 6.7113987824996e-06
in O 0 3.0586699839574294e-09
either O 0 1.9825172614673647e-09
the O 0 1.9534420747646664e-09
COL4A3 O 0 4.7798741434235126e-05
or O 0 3.0736237999207106e-09
the O 0 1.8450423411309202e-09
COL4A4 O 0 5.571145811700262e-05
gene O 0 4.213409354747455e-08
, O 0 1.546505007388177e-10
which O 0 4.3935893118129954e-11
encode O 0 2.6979116163339256e-10
the O 0 5.592565299750163e-10
alpha3 O 0 2.9236750833661063e-06
and O 0 8.412557761516837e-09
alpha4 O 0 0.0004148005973547697
type O 0 9.511195821687579e-05
IV O 0 0.093290314078331
collagen O 0 0.013297853991389275
chains O 0 0.00010374464909546077
, O 0 4.608244807968731e-08
respectively O 0 7.317775612136757e-07
. O 0 3.939927353258099e-07

To O 0 9.112592636029149e-08
date O 0 2.5421061877750617e-07
, O 0 1.8977022619992567e-08
mutation O 0 1.2078861573172617e-06
screening O 0 2.504795588720299e-07
in O 0 8.635079873364759e-10
the O 0 2.746588234625591e-10
two O 0 9.086619789933081e-10
genes O 0 1.5776405959400108e-08
has O 0 1.867090482221556e-09
been O 0 9.897335173647548e-10
hampered O 0 2.9499412335098896e-07
by O 0 3.069784981768464e-10
the O 0 1.1263296961772085e-09
lack O 0 9.757472163585135e-09
of O 0 2.2710691105487513e-09
genomic O 0 8.196251656045206e-06
structure O 0 2.150745103790541e-06
information O 0 9.680361756636557e-08
. O 0 3.884308341639553e-07

We O 0 9.022122640089947e-07
report O 0 8.682585672659116e-08
here O 0 2.1581390008407197e-09
the O 0 4.352421201225809e-10
complete O 0 3.599205822268914e-09
characterization O 0 1.3382445374077179e-08
of O 0 1.441790020706435e-10
the O 0 3.6221581289908045e-10
48 O 0 3.1380020804050446e-09
exons O 0 2.258301634583404e-08
of O 0 2.860393588655086e-10
the O 0 2.458094838786451e-09
COL4A4 O 0 5.7464916608296335e-05
gene O 0 7.059780671170302e-08
, O 0 5.973067596087844e-10
a O 0 1.3660810260773815e-09
comprehensive O 0 5.5339135940357664e-08
gene O 0 3.794486858055279e-08
screen O 0 6.220403037104916e-08
, O 0 5.931515278945199e-10
and O 0 9.350999835566753e-11
the O 0 1.1842458957911361e-10
subsequent O 0 2.0413333245983267e-09
detection O 0 8.255594252659648e-08
of O 0 5.58303736575283e-10
10 O 0 8.1270874474626e-09
novel O 0 6.942220664996057e-08
mutations O 0 1.1820646932392265e-06
in O 0 3.1099926189881444e-08
eight O 0 7.850849215174094e-06
patients O 0 0.28234073519706726
diagnosed O 1 0.9993496537208557
with O 0 0.0036310339346528053
autosomal B-Disease 1 0.9999346733093262
recessive I-Disease 1 0.9999784231185913
Alport I-Disease 1 0.9999876022338867
syndrome I-Disease 1 0.9999717473983765
. O 0 0.000146489663165994

Furthermore O 0 1.7195263353642076e-05
, O 0 1.5474323333819484e-07
we O 0 8.537559104127013e-09
identified O 0 2.2999367743636867e-08
a O 0 1.1140450340008101e-08
glycine O 0 1.5360916449935758e-07
to O 0 3.2072428046703294e-10
alanine O 0 5.05258270777631e-08
substitution O 0 3.257229153064145e-09
in O 0 3.2299568575311355e-10
the O 0 6.510744166021709e-10
collagenous O 0 6.280695288296556e-06
domain O 0 2.0353006391360395e-08
that O 0 3.8558770065755255e-10
is O 0 1.1532994559360077e-09
apparently O 0 1.682554184867513e-08
silent O 0 8.571468868012744e-08
in O 0 6.395101670442216e-10
the O 0 2.4682427213207347e-09
heterozygous O 0 4.5876748799855704e-07
carriers O 0 3.889631159381679e-07
, O 0 2.871524573677675e-09
in O 0 1.033178698151005e-08
11 O 0 2.9429301662275975e-07
. O 0 2.6656493901100475e-07

5 O 0 8.934539437177591e-07
% O 0 1.8800058398937836e-08
of O 0 4.549715881818628e-10
all O 0 1.0447365195176417e-10
control O 0 1.913885050441877e-08
individuals O 0 6.020994813837888e-10
, O 0 4.05418004723046e-10
and O 0 2.17647955214062e-10
in O 0 4.1705974784811417e-10
one O 0 2.3997323572721996e-10
control O 0 1.913666203279263e-08
individual O 0 2.4801773967908503e-09
homozygous O 0 1.881536491055158e-07
for O 0 6.913197236890767e-10
this O 0 2.0066517336658762e-09
glycine O 0 1.216678469972976e-06
substitution O 0 2.2811775579612004e-07
. O 0 2.626580908327014e-07

There O 0 6.417070608222275e-07
has O 0 5.755918408567595e-08
been O 0 4.4817878297465086e-09
no O 0 1.231649338073737e-09
previous O 0 1.6491885634906112e-09
finding O 0 1.1951177825153536e-09
of O 0 1.566535512420586e-10
a O 0 2.6342752423857974e-09
glycine O 0 4.962593180835029e-08
substitution O 0 4.903483841189882e-09
that O 0 3.3990893433255565e-10
is O 0 7.443591298894603e-10
not O 0 1.6233531185960715e-10
associated O 0 2.266162146824513e-09
with O 0 8.93164486814868e-10
any O 0 2.037183088887673e-09
obvious O 0 3.3935128840312245e-07
phenotype O 0 2.946042877738364e-05
in O 0 4.947547083133941e-08
homozygous O 0 9.559703357808758e-06
individuals O 0 7.35617646796527e-08
. O 0 2.975417885409115e-07

Founder O 0 0.0005939987022429705
BRCA1 O 0 0.08611850440502167
and O 0 1.8680977973417612e-06
BRCA2 O 0 0.01948004961013794
mutations O 0 0.00014353360165841877
in O 0 1.670354663474427e-07
French O 0 4.675989112001844e-05
Canadian O 0 0.01660068891942501
breast B-Disease 1 0.9999796152114868
and I-Disease 1 0.9841017127037048
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999911785125732
families O 0 9.549565584165975e-05
. O 0 5.694033006875543e-06

We O 0 6.272072141655372e-07
have O 0 3.968806439047512e-08
identified O 0 1.392380255538228e-07
four O 0 1.0844630082829099e-08
mutations O 0 6.01672411448817e-07
in O 0 8.452248345669489e-10
each O 0 2.414599076239199e-10
of O 0 4.9886699216017405e-09
the O 0 6.350561761792051e-06
breast B-Disease 1 0.9999604225158691
cancer I-Disease 1 0.9996578693389893
- O 0 0.02366771176457405
susceptibility O 0 0.00029259687289595604
genes O 0 4.4844838953395083e-07
, O 0 2.498911300108375e-08
BRCA1 O 0 0.00011317199096083641
and O 0 3.142321958193861e-08
BRCA2 O 0 6.416063115466386e-05
, O 0 6.805437546830717e-09
in O 0 2.5467256747901956e-08
French O 0 2.4075203327811323e-05
Canadian O 0 0.05138162896037102
breast B-Disease 1 0.9999860525131226
cancer I-Disease 1 0.9999736547470093
and O 0 0.49909508228302
breast B-Disease 1 0.9999984502792358
/ I-Disease 1 0.9999960660934448
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999951124191284
families O 0 2.179694638471119e-05
from O 0 2.345987013541162e-06
Quebec O 0 0.0021964649204164743
. O 0 1.3474223123921547e-06

To O 0 1.8386430156169808e-07
identify O 0 6.203466114129697e-07
founder O 0 3.383154080438544e-06
effects O 0 1.7912459497892996e-06
, O 0 1.1002053490472008e-08
we O 0 2.6263635710677136e-09
examined O 0 9.282084079131891e-08
independently O 0 2.626750550405177e-08
ascertained O 0 1.38320740461495e-06
French O 0 1.0913052392425016e-05
Canadian O 0 5.817171040689573e-05
cancer B-Disease 0 0.07912807911634445
families O 0 5.200670560867593e-09
for O 0 1.7463737400635893e-10
the O 0 1.8201545826102006e-10
distribution O 0 4.721446011934916e-10
of O 0 1.0864245614250478e-10
these O 0 5.853595941296419e-10
eight O 0 9.233806963493407e-08
mutations O 0 1.4022285540704615e-05
. O 0 1.99977023385145e-07

Mutations O 0 0.0033507165499031544
were O 0 1.4262874969972472e-07
found O 0 2.5433712025346722e-08
in O 0 4.2209040707064105e-09
41 O 0 2.3317394237665212e-08
of O 0 3.2163967045306663e-09
97 O 0 4.22311700276623e-07
families O 0 2.155273506332378e-07
. O 0 6.347070780066133e-07

Six O 0 2.74004321454413e-07
of O 0 2.390392950246678e-08
eight O 0 1.4441727103076119e-07
mutations O 0 1.8789304476740654e-06
were O 0 3.1842037895302155e-09
observed O 0 3.611654619817273e-08
at O 0 1.3072440907535565e-08
least O 0 1.7957216158492884e-08
twice O 0 6.727142363160965e-07
. O 0 2.1360916946377984e-07

The O 0 4.405001163831912e-06
BRCA1 O 0 0.11551640927791595
C4446T O 0 0.00175748229958117
mutation O 0 0.0003546678926795721
was O 0 2.8142030927824635e-08
the O 0 1.666132232180928e-09
most O 0 6.150883691269371e-10
common O 0 2.167177903800166e-08
mutation O 0 1.7826569091994315e-06
found O 0 7.172266780486325e-09
, O 0 1.2745935418223553e-09
followed O 0 4.272932230264814e-09
by O 0 2.604578330789309e-09
the O 0 7.776994692676453e-08
BRCA2 O 0 0.003975304774940014
8765delAG O 0 0.013477941043674946
mutation O 0 0.0006537301815114915
. O 0 8.525665293745988e-07

Together O 0 1.1796771559602348e-06
, O 0 3.495218336979633e-08
these O 0 3.0931903705067043e-09
mutations O 0 3.7644917938450817e-07
were O 0 8.252515892870349e-10
found O 0 7.719734296252057e-10
in O 0 3.5747729776325343e-10
28 O 0 1.51495449518535e-09
of O 0 2.5979385309682357e-10
41 O 0 2.832274681452418e-08
families O 0 4.336306869134887e-09
identified O 0 8.122655437148296e-09
to O 0 2.2816271094683316e-10
have O 0 1.9040207188680824e-09
a O 0 3.539726662893372e-07
mutation O 0 6.504255725303665e-05
. O 0 2.3551122296794347e-07

The O 0 8.810958433969063e-07
odds O 0 8.576284926675726e-06
of O 0 8.811948504217071e-09
detection O 0 6.607951377191057e-07
of O 0 3.733091058499838e-10
any O 0 1.4518126978391166e-10
of O 0 1.7472366609094792e-10
the O 0 3.5736018588750085e-09
four O 0 3.7703986777160026e-07
BRCA1 O 0 0.03554125875234604
mutations O 0 2.8605101761058904e-05
was O 0 7.773361687668512e-08
18 O 0 2.253545403618773e-07
. O 0 1.8313596683583455e-07

7x O 0 0.07421959191560745
greater O 0 4.8626229727233294e-06
if O 0 3.2865177246321764e-08
one O 0 2.0408039702601855e-09
or O 0 1.4207460763415725e-09
more O 0 1.7715058309164533e-09
cases O 0 7.769416470182477e-07
of O 0 0.00040814877138473094
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999947547912598
were O 0 8.910112825333272e-08
also O 0 3.264581049933213e-09
present O 0 4.186770929948125e-09
in O 0 5.22662535473728e-09
the O 0 2.2294898371910676e-08
family O 0 1.3504183016266325e-06
. O 0 7.184125365711225e-07

The O 0 6.608002536268032e-07
odds O 0 3.8092696286184946e-06
of O 0 5.740171893364732e-09
detection O 0 4.527265957676718e-07
of O 0 5.256735602365836e-10
any O 0 1.768851176642272e-10
of O 0 1.0901941849272845e-10
the O 0 2.1754553714004032e-09
four O 0 3.774888739371818e-07
BRCA2 O 0 0.02578730508685112
mutations O 0 9.724161645863205e-05
was O 0 2.2229598073408852e-07
5 O 0 3.470765363999817e-07
. O 0 2.9046304916846566e-07

3x O 0 0.00043336988892406225
greater O 0 3.705319613800384e-06
if O 0 3.747634025330626e-08
there O 0 1.5633484506949458e-09
were O 0 4.446416568271161e-10
at O 0 1.122923420915356e-09
least O 0 6.814409037048108e-10
five O 0 3.106540580333217e-09
cases O 0 5.9177693856327096e-08
of O 0 1.9485480606817873e-06
breast B-Disease 1 0.9999877214431763
cancer I-Disease 1 0.9975364208221436
in O 0 6.93586699185289e-08
the O 0 6.5599124354776e-08
family O 0 2.033689952440909e-06
. O 0 4.49337164809549e-07

Interestingly O 0 2.043321364908479e-05
, O 0 3.5151416000189784e-08
the O 0 4.810017717460369e-09
presence O 0 1.5367357164564055e-08
of O 0 3.1050731763571093e-08
a O 0 0.0005011360626667738
breast B-Disease 1 0.9999707937240601
cancer I-Disease 1 0.9972152709960938
case O 0 1.0186187182625872e-06
< O 0 1.5275093119271332e-06
36 O 0 8.255101491272399e-09
years O 0 6.014291842326713e-10
of O 0 1.817226785716386e-10
age O 0 2.0254910637618195e-08
was O 0 1.6771384281355495e-09
strongly O 0 5.748693188145637e-10
predictive O 0 4.516973461932139e-09
of O 0 8.934605832955356e-11
the O 0 1.5501464001310694e-10
presence O 0 4.303322698184786e-10
of O 0 5.1001539796979856e-11
any O 0 4.1438023151707526e-11
of O 0 1.6770480837369206e-10
the O 0 1.6138360647843797e-09
eight O 0 1.3620054062357667e-07
mutations O 0 1.2213776244607288e-05
screened O 0 3.5626035241875798e-06
. O 0 3.339139595937013e-07

Carriers O 0 1.210027312481543e-05
of O 0 2.5131456027338572e-08
the O 0 1.6786051659778423e-08
same O 0 3.744519005977054e-08
mutation O 0 3.4840979878936196e-06
, O 0 7.438552551697342e-10
from O 0 1.8273969837334647e-10
different O 0 1.327790793981265e-10
families O 0 1.7989089107217637e-09
, O 0 5.900102628686454e-10
shared O 0 2.917089458875921e-09
similar O 0 2.1766062729966507e-08
haplotypes O 0 1.9035370542042074e-06
, O 0 2.3785533542763915e-09
indicating O 0 1.0192892752058924e-08
that O 0 3.3031348489753753e-11
the O 0 1.216668293890777e-10
mutant O 0 3.31407647991e-08
alleles O 0 5.895786081566712e-09
were O 0 3.562656836209044e-10
likely O 0 6.8336464265073e-10
to O 0 4.201614056675851e-11
be O 0 9.791524535618379e-11
identical O 0 1.7348254388593887e-08
by O 0 4.520539498287235e-10
descent O 0 9.953110335914062e-09
for O 0 1.0721183940631818e-09
a O 0 1.4662886371752393e-07
mutation O 0 3.2001569252315676e-06
in O 0 4.5081600674734545e-09
the O 0 8.152425401419805e-09
founder O 0 1.4078117374083376e-06
population O 0 1.1716254277871485e-07
. O 0 1.6297433091949642e-07

The O 0 4.2014363543785294e-07
identification O 0 5.797434141641133e-07
of O 0 5.144016768099391e-08
common O 0 3.658318973975838e-06
BRCA1 O 0 0.37090548872947693
and O 0 4.938185156788677e-06
BRCA2 O 0 0.27924731373786926
mutations O 0 1.729950963635929e-05
will O 0 1.328771981334853e-09
facilitate O 0 1.4590873398390158e-08
carrier O 0 4.728457952296594e-06
detection O 0 1.3152042583897128e-06
in O 0 2.769780493849794e-08
French O 0 2.746535392361693e-05
Canadian O 0 0.01724288985133171
breast B-Disease 1 0.9999780654907227
cancer I-Disease 1 0.9999752044677734
and O 1 0.5070831179618835
breast B-Disease 1 0.9999983310699463
/ I-Disease 1 0.9999939203262329
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999942779541016
families O 0 6.914846744621173e-05
. O 0 3.290282847956405e-06

Are O 0 5.909997184971871e-07
Dp71 O 0 0.00013395848509389907
and O 0 3.138518991363526e-07
Dp140 O 0 0.0008734242874197662
brain O 0 0.00565770547837019
dystrophin O 0 0.0007795703131705523
isoforms O 0 1.0179330729442881e-06
related O 0 2.0052530658176693e-07
to O 0 4.1981039089478145e-08
cognitive B-Disease 0 0.0018542821053415537
impairment I-Disease 1 0.9793410897254944
in O 0 0.001258582342416048
Duchenne B-Disease 1 0.9999464750289917
muscular I-Disease 1 0.9999598264694214
dystrophy I-Disease 1 0.99989914894104
? O 0 0.007400547619909048

Molecular O 0 0.0004676591488532722
study O 0 1.7066959117073566e-06
and O 0 3.4022512807041494e-08
neuropsychological O 0 1.5700266885687597e-05
analysis O 0 2.4789301278360654e-08
were O 0 9.782213927778116e-10
performed O 0 2.4300781387154302e-09
concurrently O 0 5.827831550675455e-09
on O 0 2.5160618477571006e-08
49 O 0 1.572445034980774e-05
patients O 0 0.00011861886741826311
with O 0 7.347655628109351e-05
Duchenne B-Disease 1 0.9999911785125732
muscular I-Disease 1 0.9999920129776001
dystrophy I-Disease 1 0.9999810457229614
( O 0 4.0093429561238736e-05
DMD B-Disease 1 0.9998849630355835
) O 0 1.8394704426327735e-08
in O 0 3.168415974030836e-09
order O 0 6.527380858045717e-10
to O 0 6.434802690691299e-11
find O 0 8.338892354409211e-10
a O 0 3.691783101444912e-09
molecular O 0 3.012860076978541e-07
explanation O 0 4.570514633428502e-09
for O 0 8.38493663390949e-10
the O 0 1.4203485498853752e-08
cognitive B-Disease 0 7.761748565826565e-05
impairment I-Disease 0 0.013446497730910778
observed O 0 6.243951133910741e-07
in O 0 8.299848985870995e-08
most O 0 1.3119696404828574e-06
DMD B-Disease 1 0.9999130964279175
patients O 0 0.02621081843972206
. O 0 1.5569238485113601e-06

Complete O 0 1.4294497532318928e-06
analysis O 0 8.52815560392628e-08
of O 0 1.7200704194308969e-09
the O 0 4.045253021445205e-09
dystrophin O 0 2.921812847489491e-05
gene O 0 3.481048054254643e-07
was O 0 7.648057298581534e-09
performed O 0 3.052667008063281e-09
to O 0 5.256653098917319e-11
define O 0 9.901035546988624e-10
the O 0 1.4944451232068445e-10
localization O 0 6.019643006283104e-09
of O 0 2.7027274862589934e-10
deletions O 0 1.1342470429553941e-07
and O 0 1.3308112389864846e-09
duplications O 0 9.086884915632254e-07
in O 0 4.636260264589964e-09
relation O 0 1.195223298111614e-08
to O 0 5.046201789760119e-10
the O 0 5.372814637638612e-09
different O 0 8.242267313107732e-08
DMD B-Disease 1 0.99875807762146
promoters O 0 0.0002476657973602414
. O 0 1.0151595688512316e-06

Qualitative O 0 5.552475613512797e-06
analysis O 0 1.3728514147715032e-07
of O 0 4.2704879632537995e-09
the O 0 5.622375898184373e-09
Dp71 O 0 1.9081619029748254e-05
transcript O 0 1.6346104985132115e-06
and O 0 4.310340528945744e-09
testing O 0 5.4675744820542604e-08
for O 0 1.5839617117929805e-10
the O 0 1.6439523353728447e-10
specific O 0 1.602788873844574e-10
first O 0 4.349234861145135e-10
exon O 0 1.3841413704085426e-07
of O 0 1.3552949873485431e-09
Dp140 O 0 3.5767041026701918e-06
were O 0 1.8946704205546894e-09
also O 0 2.3930786241521673e-09
carried O 0 3.309212814883722e-08
out O 0 2.2572121949337998e-08
. O 0 1.2947110406003048e-07

Neuropsychological O 0 0.004853086080402136
analysis O 0 4.618479124474106e-06
assessed O 0 1.7853551526059164e-06
verbal O 0 7.754286457384296e-07
and O 0 1.8432670501056236e-08
visuospatial O 0 9.37871154746972e-05
intelligence O 0 5.301223154674517e-06
, O 0 1.3958658229284993e-08
verbal O 0 1.8084327848555404e-06
memory O 0 4.23103483626619e-05
, O 0 2.725965408956199e-08
and O 0 1.1119052345520686e-08
reading O 0 2.3888301825536473e-07
skills O 0 1.8442326563672395e-06
. O 0 8.446452284260886e-07

Comparison O 0 4.518743480730336e-06
of O 0 7.0557689468842e-08
molecular O 0 1.105367027776083e-05
and O 0 6.502435212496493e-08
psychometric O 0 0.00043938070302829146
findings O 0 2.1244761683192337e-06
demonstrated O 0 2.643503478338971e-07
that O 0 5.217081211483787e-10
deletions O 0 5.8988256057546096e-08
and O 0 1.9771249082367603e-09
duplications O 0 1.2821500376958284e-06
that O 0 9.885072760340563e-10
were O 0 7.452271577612635e-10
localized O 0 2.235417753126967e-07
in O 0 1.5744984205312562e-09
the O 0 8.742735424505099e-10
distal O 0 3.225565023967647e-07
part O 0 4.657789709483495e-09
of O 0 4.3480902212067463e-10
the O 0 1.4600637365802527e-09
gene O 0 4.915425577678434e-08
seemed O 0 7.818755420885282e-09
to O 0 1.1934771226851382e-10
be O 0 2.818933142467728e-10
preferentially O 0 3.8365651988669924e-08
associated O 0 6.006020214499586e-08
with O 0 1.5271568543084868e-07
cognitive B-Disease 0 0.0031639239750802517
impairment I-Disease 1 0.656774640083313
. O 0 3.4012505238933954e-06

Two O 0 3.6890895671604085e-07
altered O 0 2.0521617898339173e-06
Dp71 O 0 1.3554732504417188e-05
transcripts O 0 1.9691083252837416e-07
and O 0 1.9233550307973246e-09
two O 0 5.553490445286968e-10
deleted O 0 3.23584288253187e-08
Dp140 O 0 6.670666721220186e-07
DNA O 0 1.1213962380907105e-07
sequences O 0 8.3563937991471e-09
were O 0 7.482137687198076e-10
found O 0 1.415112693692322e-09
in O 0 2.2015904654892893e-09
four O 0 1.0281348750140751e-07
patients O 0 0.00014487386215478182
with O 0 2.032829615927767e-05
severe O 1 0.9991270899772644
cerebral B-Disease 1 0.9998416900634766
dysfunction I-Disease 1 0.9995844960212708
. O 0 2.464677527314052e-05

These O 0 2.745960330230446e-07
findings O 0 3.500957461710641e-07
suggest O 0 1.0705129227517318e-08
that O 0 1.6085741072480175e-10
some O 0 6.31635091452587e-11
sequences O 0 2.2322801385143975e-09
located O 0 5.036627115373449e-09
in O 0 4.5467407616683886e-10
the O 0 2.031455004214422e-10
distal O 0 9.622704766343304e-08
part O 0 9.798721833931268e-10
of O 0 1.2793056891613475e-10
the O 0 6.55402843108277e-10
gene O 0 1.4389508251611005e-08
and O 0 9.492031605162765e-10
, O 0 8.144463436998706e-10
in O 0 8.054538702673142e-10
particular O 0 1.1339885697125851e-09
, O 0 6.090318249718507e-10
some O 0 5.282345116874865e-10
DMD B-Disease 0 0.18828028440475464
isoforms O 0 2.0950672308117646e-08
expressed O 0 3.104408285992122e-09
in O 0 3.0250195681702507e-09
the O 0 2.5462496111572364e-08
brain O 0 0.0021494319662451744
may O 0 7.136435442589573e-08
be O 0 1.6246572143163718e-10
related O 0 9.255433641719435e-10
to O 0 2.301338702936917e-10
the O 0 3.8448725092621316e-08
cognitive B-Disease 0 0.0033624807838350534
impairment I-Disease 1 0.5756300091743469
associated O 0 9.61539444688242e-06
with O 0 7.529627055191668e-06
DMD B-Disease 1 0.9999077320098877
. O 0 2.3645733904231747e-07
. O 0 9.020694733408163e-07

I1307K O 0 0.0026445789262652397
APC O 0 0.0005829133442603052
and O 0 5.143271550878126e-07
hMLH1 O 0 0.0005451575852930546
mutations O 0 7.366836507571861e-05
in O 0 1.2481259581420545e-08
a O 0 1.8219001418628977e-08
non O 0 4.180636636874624e-08
- O 0 1.707465912659245e-06
Jewish O 0 2.494140005637746e-08
family O 0 5.0025075637449845e-08
with O 0 1.4701755901569413e-07
hereditary B-Disease 1 0.9582231044769287
non I-Disease 1 0.8601842522621155
- I-Disease 1 0.9999780654907227
polyposis I-Disease 1 0.9999971389770508
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999899864196777
. O 0 8.172448724508286e-05

We O 0 2.3502657597873622e-07
describe O 0 2.2524174880800274e-07
a O 0 9.061859884695878e-08
French O 0 2.232653059763834e-06
Canadian O 0 1.8710661606746726e-05
hereditary B-Disease 1 0.9793869853019714
non I-Disease 1 0.978175938129425
- I-Disease 1 0.9999943971633911
polyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 0.0003157121827825904
HNPCC B-Disease 1 0.9994426369667053
) O 0 1.1254631715473806e-07
kindred O 0 7.830032700439915e-06
which O 0 5.742580633238958e-09
carries O 0 6.537478469681446e-08
a O 0 4.547803200694034e-08
novel O 0 4.310474253088614e-07
truncating O 0 0.00022565526887774467
mutation O 0 5.244556086836383e-05
in O 0 1.4916395230102353e-07
hMLH1 O 0 0.00010439354809932411
. O 0 1.0251754929413437e-06

Interestingly O 0 3.396260945009999e-05
, O 0 1.4403488535208453e-07
the O 0 3.1097556529857684e-08
I1307K O 0 9.698529538582079e-06
APC O 0 1.4096646737016272e-05
polymorphism O 0 3.7954532672301866e-06
, O 0 2.262042331224734e-09
associated O 0 3.5597580438917475e-09
with O 0 4.666759756410954e-10
an O 0 3.747303356504972e-09
increased O 0 4.941497081745183e-06
risk O 0 0.02251119539141655
of O 0 0.022009272128343582
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
, O 0 1.6429578408860834e-06
is O 0 2.1489432455723545e-08
also O 0 2.5435251682637272e-09
present O 0 3.435736140033896e-09
in O 0 7.239805643877162e-09
this O 0 4.7813148995601296e-09
family O 0 5.872735187040234e-07
. O 0 4.059539548961766e-07

The O 0 3.635035170646006e-07
I1307K O 0 3.067632860620506e-05
polymorphism O 0 1.5773895938764326e-05
has O 0 1.9447957910756486e-08
previously O 0 4.507833217815005e-09
only O 0 1.7386166117905333e-10
been O 0 8.187872602150037e-10
identified O 0 1.4879155685321166e-09
in O 0 2.814286026442403e-10
individuals O 0 3.166831519241242e-10
of O 0 1.7307595356896854e-09
self O 0 1.631902159715537e-05
- O 0 0.002866883296519518
reported O 0 3.883025328832446e-06
Ashkenazi O 0 1.6236965166172013e-05
Jewish O 0 3.7796726815031434e-07
origins O 0 1.4747635077583254e-06
. O 0 5.655817858496448e-07

In O 0 6.046491876077198e-07
addition O 0 1.8029429327270918e-07
, O 0 1.1694102575177112e-08
in O 0 2.215330807686655e-09
this O 0 4.928751851096536e-10
family O 0 2.247288932721858e-08
, O 0 2.486747474605977e-09
there O 0 9.185474048045705e-10
appears O 0 1.0865333521792309e-08
to O 0 1.210797295758681e-10
be O 0 2.1561341601028516e-10
no O 0 4.4702436197141537e-10
relationship O 0 2.247831920598742e-09
between O 0 5.050717621912781e-10
the O 0 8.116952110448494e-10
I1307K O 0 4.87394231640792e-07
polymorphism O 0 1.0019512330927682e-07
and O 0 2.717324421031009e-10
the O 0 5.01232055860612e-10
presence O 0 4.799021624535271e-09
or O 0 8.722418343154459e-09
absence O 0 3.1278216283681104e-07
of O 0 5.399943461270595e-07
cancer B-Disease 1 0.9498992562294006
. O 0 8.255545935753617e-08
. O 0 3.0841374609735794e-07

Identification O 0 1.4413400322155212e-06
of O 0 3.996890995949798e-08
a O 0 9.747301277229781e-08
novel O 0 8.995731803906892e-08
mutation O 0 1.9355155700395699e-07
of O 0 8.521042205167362e-10
the O 0 1.085571743608682e-09
CPO O 0 1.5837343880775734e-07
gene O 0 3.611585697171904e-08
in O 0 3.2121540982643637e-09
a O 0 2.6627981597471262e-08
Japanese O 0 1.2921309462399222e-06
hereditary B-Disease 0 0.1380235254764557
coproporphyria I-Disease 0 0.3563494086265564
family O 0 6.450258661061525e-05
. O 0 2.155023821615032e-06

Hereditary B-Disease 1 0.9957969188690186
coproporphyria I-Disease 1 0.9751449227333069
( O 0 1.7605680113774724e-05
HCP B-Disease 1 0.863171398639679
) O 0 1.4227988742732123e-07
is O 0 4.1143227491602374e-08
an O 0 4.923641085952113e-07
autosomal B-Disease 1 0.9731695055961609
dominant I-Disease 1 0.9769940972328186
disease I-Disease 1 0.998572587966919
characterized O 0 0.0003830151108559221
by O 0 1.922674215393272e-07
a O 0 3.0706058169016615e-05
deficiency B-Disease 0 0.207248255610466
of I-Disease 0 6.8219425664040045e-09
coproporphyrinogen I-Disease 0 0.0006640295032411814
oxidase I-Disease 0 1.022087690216722e-05
( O 0 1.393043902453428e-08
CPO O 0 4.669792019740271e-07
) O 0 1.913179836776635e-09
caused O 0 1.5804987540946058e-08
by O 0 4.833872746523582e-10
a O 0 1.6658152190984765e-08
mutation O 0 2.073358729148822e-07
in O 0 7.212897501496229e-10
the O 0 5.553874693475791e-09
CPO O 0 3.9224223655764945e-06
gene O 0 1.9450612853688654e-06
. O 0 2.2161228230288543e-07

Only O 0 9.701155079255841e-08
11 O 0 1.268674196808206e-07
mutations O 0 3.584738408335397e-07
of O 0 1.0319827214999577e-09
the O 0 3.0111406701394117e-09
gene O 0 1.0942810035885486e-07
have O 0 4.1117784732591645e-09
been O 0 2.2096097396229197e-08
reported O 0 2.2206427274795715e-06
in O 0 1.373510372104647e-06
HCP B-Disease 1 0.9988328814506531
patients O 0 0.04920504242181778
. O 0 2.5027088668139186e-06

We O 0 1.1798910009019892e-06
report O 0 3.7136683772587276e-07
another O 0 1.0417631557402274e-07
mutation O 0 3.509529278744594e-06
in O 0 7.124409950876043e-09
a O 0 4.185958246694099e-08
Japanese O 0 2.6580894996186544e-07
family O 0 1.0336083278161823e-06
. O 0 5.018869728701247e-07

Polymerase O 0 0.0007556427735835314
chain O 0 0.0008901372202672064
reaction O 0 7.954391548992135e-06
- O 0 6.06218918619561e-06
single O 0 5.86210440189916e-08
strand O 0 9.079228107111703e-07
conformational O 0 7.376146982096543e-07
polymorphism O 0 3.183480430379859e-07
and O 0 8.100125570287275e-10
direct O 0 2.244567420817134e-09
sequence O 0 1.628527712682626e-08
analyses O 0 2.2077475847481765e-08
demonstrated O 0 1.3750692140490628e-08
a O 0 5.718371109963982e-09
C O 0 3.844007068209976e-08
to O 0 2.185531616794023e-10
T O 0 7.717407584095781e-07
substitution O 0 4.899984862305473e-10
in O 0 2.9333016571264636e-10
exon O 0 4.3523677106804826e-08
1 O 0 3.950856863887964e-10
of O 0 3.784903640502435e-11
the O 0 3.40204031612501e-10
CPO O 0 2.994869419126189e-08
gene O 0 3.5081271221315546e-09
at O 0 6.59347410003619e-10
nucleotide O 0 1.3614775973280757e-08
position O 0 4.579799650628047e-09
85 O 0 1.1703541247243265e-08
, O 0 7.4360845259136e-10
which O 0 2.608131488557319e-10
lies O 0 3.99500654779672e-09
in O 0 4.2273071154674824e-10
the O 0 9.325979988261679e-10
putative O 0 3.952391693928803e-07
presequence O 0 1.411713242305268e-06
for O 0 7.143728386616033e-10
targeting O 0 1.9685314711637147e-08
to O 0 6.361321247538854e-09
mitochondria O 0 1.0137615390704013e-05
. O 0 4.648676963370235e-07

This O 0 2.7915660893995664e-07
mutation O 0 1.4333635590446647e-05
changes O 0 4.669604791729398e-08
the O 0 2.2673209976176167e-09
codon O 0 4.30910951365604e-08
for O 0 9.279720880606135e-10
glutamine O 0 3.8406728464224216e-08
to O 0 3.6780689605109274e-10
a O 0 6.69797417529594e-09
termination O 0 1.7800831528802519e-06
codon O 0 1.35567617576271e-07
at O 0 1.1803503952023675e-08
amino O 0 6.194520807412118e-08
acid O 0 7.136202953006432e-07
position O 0 5.15758458163873e-08
29 O 0 5.742703592659382e-07
. O 0 1.4567382322638878e-07

MaeI O 0 0.000640226062387228
restriction O 0 3.3216058454854647e-06
analysis O 0 2.070154181410544e-07
showed O 0 1.2790501102699636e-07
two O 0 8.849807553445999e-10
other O 0 4.732391145623183e-10
carriers O 0 1.7169598720556678e-07
in O 0 2.8440854116240644e-09
the O 0 6.461004620206268e-09
family O 0 3.9415132846443157e-07
. O 0 3.7607961189678463e-07

The O 0 1.2612213140528183e-05
C O 0 0.0028250485192984343
- O 0 0.49344947934150696
T O 1 0.7325513958930969
mutation O 0 2.832355494319927e-05
is O 0 3.8342515829015156e-09
located O 0 6.233916938214179e-09
within O 0 2.950552024927333e-09
a O 0 2.0988828453027963e-08
recently O 0 2.475144071922841e-07
proposed O 0 2.4556921829343992e-08
putative O 0 2.2815387978880608e-07
alternative O 0 5.672907033016372e-09
translation O 0 1.4814477422575578e-09
initiation O 0 1.5162070710061926e-08
codon O 0 1.0762641977635212e-07
( O 0 4.854720181413086e-09
TIC O 0 1.748065733409021e-05
- O 0 8.271368869827711e-07
1 O 0 2.5098296774217488e-09
) O 0 2.44425507611723e-10
, O 0 1.8274387558747662e-10
supporting O 0 4.599917335923465e-09
that O 0 1.3541141541395518e-09
TIC O 0 4.084854663233273e-05
- O 0 2.9447933229675982e-06
1 O 0 7.358418319114435e-09
is O 0 4.978610301797914e-10
the O 0 7.992299599912656e-10
real O 0 5.969109651005056e-08
TIC O 0 1.173317195934942e-05
rather O 0 6.418236608851657e-09
than O 0 2.1184131782092663e-08
TIC O 0 0.000741290336009115
- O 0 1.4282246411312371e-05
2 O 0 6.694808973861655e-08
. O 0 1.2198620780168312e-08
. O 0 1.0126102267804526e-07

Human B-Disease 0 3.874011599691585e-05
complement I-Disease 0 0.0005940211121924222
factor I-Disease 0 0.46135562658309937
H I-Disease 1 0.9999592304229736
deficiency I-Disease 1 0.9999192953109741
associated O 0 0.018536394461989403
with O 0 0.458922803401947
hemolytic B-Disease 1 0.9999889135360718
uremic I-Disease 1 0.9999967813491821
syndrome I-Disease 1 0.9999903440475464
. O 0 0.0002315327146789059

This O 0 3.4193814713034953e-07
study O 0 1.0261540950295966e-07
reports O 0 1.3678964627672485e-08
on O 0 3.3420108902504353e-09
six O 0 1.702478513720962e-08
cases O 0 1.1468863903019155e-07
of O 0 2.7531794444257685e-07
deficiency B-Disease 1 0.6641554832458496
in I-Disease 0 2.3635300383517688e-09
the I-Disease 0 4.931827168874747e-10
human I-Disease 0 1.3994986280962962e-09
complement I-Disease 0 1.2268949411975427e-08
regulatory I-Disease 0 2.314906396350125e-06
protein I-Disease 0 5.207751314628695e-07
Factor I-Disease 0 3.6689294802272343e-07
H I-Disease 0 0.13947393000125885
( O 0 3.0692081764982504e-08
FH O 0 0.0003408927586860955
) O 0 6.488478643262852e-10
in O 0 2.2404175736845389e-10
the O 0 2.0017272561734245e-10
context O 0 2.042630287135694e-09
of O 0 1.328301379999175e-08
an O 0 1.6481491911690682e-05
acute B-Disease 1 0.9999595880508423
renal I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999909400939941
. O 0 0.00021963818289805204

Five O 0 1.5931310315409064e-07
of O 0 9.111042587051088e-09
the O 0 4.136099462925813e-09
cases O 0 1.2914525449048142e-08
were O 0 1.0860149446401124e-09
observed O 0 1.1373227692956789e-08
in O 0 3.4025744444221573e-09
children O 0 3.9822275255119166e-08
presenting O 0 1.1299406651232857e-05
with O 0 0.1018250584602356
idiopathic O 1 0.9999978542327881
hemolytic B-Disease 1 0.9999995231628418
uremic I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999988079071045
( O 0 0.008182242512702942
HUS B-Disease 1 0.9997314810752869
) O 0 4.8030074140115175e-06
. O 0 2.4754726837272756e-06

Two O 0 1.4393162928172387e-07
of O 0 1.0803834271655433e-08
the O 0 1.2963834450374634e-08
children O 0 9.833517822244175e-08
exhibited O 0 3.742516582860844e-06
a O 0 0.000186050237971358
homozygous O 1 0.9594183564186096
deficiency O 1 0.9973763227462769
characterized O 0 6.955712706258055e-06
by O 0 1.7628096760091694e-09
the O 0 4.796923414041032e-10
absence O 0 4.24442125890323e-09
of O 0 9.509368292803799e-11
the O 0 4.010265453047168e-10
150 O 0 6.657725037939599e-09
- O 0 1.8400726276013302e-06
kD O 0 9.926928896675236e-07
form O 0 7.694920256540172e-10
of O 0 3.849843777103956e-10
Factor O 0 1.815247152592292e-08
H O 0 0.0005385397234931588
and O 0 7.103591603829784e-10
the O 0 2.720166036862537e-10
presence O 0 1.650500847105718e-09
, O 0 1.2033700425018168e-10
upon O 0 2.173467794630568e-10
immunoblotting O 0 3.06449408071785e-07
, O 0 6.203285801698044e-11
of O 0 3.2144370498699004e-11
the O 0 2.772097829062403e-10
42 O 0 3.18540820387625e-08
- O 0 1.5126763628359186e-06
kD O 0 8.843538125802297e-06
Factor O 0 6.771568195063082e-08
H O 0 0.0007505434914492071
- O 0 9.984788675865275e-07
like O 0 1.970423602060123e-09
protein O 0 6.347879999424322e-09
1 O 0 2.919349206820243e-09
( O 0 1.92603466508956e-09
FHL O 0 7.370251842075959e-05
- O 0 1.1374885389159317e-06
1 O 0 2.6354058935140756e-09
) O 0 2.8447458277902626e-10
and O 0 1.5103748807199224e-10
other O 0 1.0167975350583447e-09
FH O 0 0.014215989038348198
- O 0 3.8396596210077405e-05
related O 0 9.753215124419512e-08
protein O 0 3.6233504374649783e-07
( O 0 2.8685919417625882e-08
FHR O 0 7.360629388131201e-05
) O 0 2.185988101643943e-08
bands O 0 4.436645042460441e-07
. O 0 2.91839967303531e-07

Southern O 0 1.4963632565923035e-05
blot O 0 3.474577533779666e-05
and O 0 2.6304004308030926e-08
PCR O 0 3.773089360947779e-07
analysis O 0 7.666693058183682e-09
of O 0 9.448174465020998e-10
DNA O 0 7.080305408635468e-08
of O 0 1.3228496076322926e-09
one O 0 2.407574584140093e-08
patient O 0 6.363338616210967e-05
with O 0 6.534464318974642e-06
homozygous O 1 0.9283764362335205
deficiency O 1 0.9446303248405457
ruled O 0 2.877044664728601e-07
out O 0 2.4717419777608995e-10
the O 0 1.0361675406578286e-10
presence O 0 5.631979327347381e-10
of O 0 6.788240802801937e-11
a O 0 8.746270374615506e-10
large O 0 1.436388896713936e-09
deletion O 0 7.774947619054728e-08
of O 0 5.202592801012429e-10
the O 0 4.9896118348158325e-09
FH O 0 0.0003196771431248635
gene O 0 2.650717512153733e-08
as O 0 5.688528537106663e-10
the O 0 1.0810554229578884e-08
underlying O 0 7.236492365336744e-06
defect O 0 0.00024694640887901187
for O 0 1.0314148823908909e-07
the O 0 1.1373658708180301e-05
deficiency O 1 0.991644561290741
. O 0 1.5189834812190384e-06

The O 0 1.506089404301747e-07
other O 0 5.709793970964938e-09
four O 0 1.1302211611052826e-08
children O 0 2.2476788430481065e-08
presented O 0 1.204920749842131e-07
with O 0 6.949201178940712e-07
heterozygous O 0 0.005269235465675592
deficiency O 1 0.6432619690895081
and O 0 7.920341715816903e-09
exhibited O 0 1.0520045634621056e-07
a O 0 3.847447516136526e-08
normal O 0 2.4194611114580766e-07
immunoblotting O 0 9.022414815262891e-06
pattern O 0 4.402269482284282e-08
of O 0 1.6251128220901023e-10
proteins O 0 7.234722820825823e-10
of O 0 5.611820452777749e-10
the O 0 4.364829564451611e-08
FH O 0 0.09238813817501068
family O 0 4.798539066541707e-06
. O 0 6.478875889115443e-07

Factor B-Disease 1 0.9424445033073425
H I-Disease 1 0.9999661445617676
deficiency I-Disease 1 0.9996411800384521
is O 0 8.697369935362076e-08
the O 0 2.4495125927614936e-08
only O 0 1.9747557189475629e-07
complement B-Disease 1 0.8616054654121399
deficiency I-Disease 1 0.9999693632125854
associated O 0 1.0657420716597699e-05
with O 0 3.7145468922972213e-06
HUS B-Disease 1 0.9982624650001526
. O 0 1.0798253242683131e-05

These O 0 7.217307995688316e-08
observations O 0 1.5983829371180036e-07
suggest O 0 3.863493347466829e-08
a O 0 8.161198827849603e-09
role O 0 2.093469397834724e-08
for O 0 7.0441217303596204e-09
FH O 0 0.00513477623462677
and O 0 3.833397954622342e-08
/ O 0 8.207045539165847e-06
or O 0 6.021206644390986e-08
FH O 0 0.001154995639808476
receptors O 0 4.6887353732927295e-07
in O 0 6.7193686170696765e-09
the O 0 2.824269351719977e-08
pathogenesis O 0 0.006805945187807083
of O 0 5.832309398101643e-06
idiopathic O 1 0.9999120235443115
HUS B-Disease 1 0.9998451471328735
. O 0 1.971371830222779e-06
. O 0 3.0695443911099574e-06

Further O 0 5.281942776491633e-07
evidence O 0 1.04354313634758e-07
for O 0 7.86872433877761e-09
a O 0 5.519893520045116e-08
major O 0 2.4580123181294766e-07
ancient O 0 5.101054739498068e-06
mutation O 0 0.38583314418792725
underlying O 0 0.1079184040427208
myotonic B-Disease 1 0.9999780654907227
dystrophy I-Disease 1 0.9999481439590454
from O 0 1.7345682579161803e-07
linkage O 0 1.053472442436032e-05
disequilibrium O 0 9.902564488584176e-05
studies O 0 7.627738085602687e-08
in O 0 5.993841867280025e-09
the O 0 4.435246392375802e-09
Japanese O 0 1.3796974940305518e-07
population O 0 1.2108013436318288e-07
. O 0 3.2927113124969765e-07

The O 0 0.003587607527151704
myotonic B-Disease 1 0.9999486207962036
dystrophy I-Disease 1 0.9999756813049316
( O 0 0.0006169021362438798
DM B-Disease 1 0.9999412298202515
) O 0 2.6271973183611408e-06
mutation O 0 0.00010695903620216995
is O 0 2.3893672818076084e-08
an O 0 1.1053628234947155e-08
unstable O 0 0.00010081238724524155
( O 0 6.509458216896746e-08
CTG O 0 0.00019393004185985774
) O 0 7.4186066179038335e-09
n O 0 6.481020591309061e-07
repeat O 0 2.5899024080899835e-07
, O 0 4.656916519074628e-10
present O 0 3.123794001247404e-10
at O 0 7.591546835605811e-10
a O 0 5.690460325169511e-10
copy O 0 6.11941664008242e-10
number O 0 2.993831224595844e-11
of O 0 7.741818991435778e-11
5 O 0 1.2406068172765572e-08
- O 0 1.675234443609952e-06
37 O 0 2.2369951224732176e-08
repeats O 0 1.7508813954236757e-08
on O 0 1.2519544290157114e-09
normal O 0 1.2254122161436953e-08
chromosomes O 0 1.4314038843110666e-08
but O 0 1.6281097303671999e-10
amplified O 0 1.6982421024991368e-09
to O 0 6.616588527075251e-11
50 O 0 1.3449121816222487e-09
- O 0 1.7549805164662757e-08
3000 O 0 1.4943468684691652e-08
copies O 0 8.644559734705126e-09
on O 0 5.561955163102539e-08
DM B-Disease 1 0.9085181355476379
chromosomes O 0 3.0474693630822003e-05
. O 0 6.49504102057108e-07

Previous O 0 1.4520666809403338e-05
findings O 0 2.076371629300411e-06
in O 0 9.165985659365106e-08
Caucasian O 0 6.166428192955209e-06
populations O 0 8.39137612729246e-08
of O 0 1.3266657106214552e-08
a O 0 7.517759058828233e-06
DM B-Disease 1 0.9999327659606934
founder O 0 8.180137956514955e-05
chromosome O 0 0.00021020752319600433
raise O 0 1.0761513635770825e-07
a O 0 6.259258888974273e-09
question O 0 9.749356877364335e-10
about O 0 1.1682298184378936e-10
the O 0 1.9561480213425853e-10
molecular O 0 4.025167044119371e-08
events O 0 5.792653579028695e-10
involved O 0 1.2984812114424926e-09
in O 0 1.4834751205228258e-09
the O 0 6.203315638941831e-09
expansion O 0 1.2274411346879788e-05
mutation O 0 8.689681271789595e-05
. O 0 4.127575436996267e-07

To O 0 1.8160390879984334e-07
investigate O 0 9.88894385045569e-07
whether O 0 4.0460342631831736e-08
a O 0 7.693430603694651e-08
founder O 0 4.466506595690589e-07
chromosome O 0 2.620146460685646e-06
for O 0 6.024984067209971e-09
the O 0 1.9368745540759846e-07
DM B-Disease 1 0.9999217987060547
mutation O 0 7.737095438642427e-05
exists O 0 1.643866198719479e-08
in O 0 1.4259775582559087e-09
the O 0 1.1030456548155598e-09
Japanese O 0 1.6883342723872374e-08
population O 0 1.4347898424915684e-09
, O 0 1.0110653425599025e-09
we O 0 4.3358830414952365e-10
genotyped O 0 1.6586649280725396e-06
families O 0 1.8626441500302349e-09
using O 0 3.2714126962929413e-09
polymorphic O 0 3.4496567877795314e-06
markers O 0 4.6415539145527873e-07
near O 0 7.305197868845426e-08
the O 0 3.245879787172612e-09
( O 0 4.090455085759004e-09
CTG O 0 1.2310519196034875e-05
) O 0 4.468728054263238e-09
n O 0 4.680278493651713e-07
repeat O 0 6.779476393603545e-07
region O 0 3.8313732630967934e-08
and O 0 6.4994321036238034e-09
constructed O 0 9.407430297869723e-06
haplotypes O 0 0.0002612022799439728
. O 0 1.006765160127543e-06

Six O 0 5.143006660546234e-07
different O 0 2.316963154669338e-08
haplotypes O 0 2.045504515990615e-06
were O 0 1.2129019566486932e-08
found O 0 1.8307654059412926e-08
and O 0 3.4018750483255644e-08
DM B-Disease 1 0.997505247592926
alleles O 0 1.1043028962376411e-06
were O 0 1.8308107030406973e-08
always O 0 6.328889412543504e-08
haplotype O 0 3.4328804758843035e-05
A O 0 1.7490208392700879e-06
. O 0 5.230558031144028e-07

To O 0 8.500564518953979e-08
find O 0 2.3676415494833236e-08
an O 0 1.0371526970587297e-09
origin O 0 6.780777606074651e-10
of O 0 2.769777740496693e-10
the O 0 1.589506859467349e-09
( O 0 7.264746137991551e-09
CTG O 0 1.3134646906109992e-05
) O 0 5.1496393815853025e-09
n O 0 9.422283824278566e-07
repeat O 0 2.4405317162745632e-06
mutation O 0 7.476551786567143e-07
and O 0 2.9579319549277727e-10
to O 0 9.345436924323991e-11
investigate O 0 2.790272901620483e-09
the O 0 2.552212885476024e-10
mechanism O 0 2.4409527732416336e-09
of O 0 2.347901595367574e-10
the O 0 1.3645029550701793e-09
expansion O 0 1.3315589342255407e-07
mutation O 0 2.3423893935614615e-07
in O 0 3.9298808651722084e-10
the O 0 4.819088461616161e-10
Japanese O 0 7.0968511067803774e-09
population O 0 4.0069397799769035e-10
we O 0 7.356249637213708e-11
have O 0 5.0291725645079666e-11
studied O 0 1.6239268818551977e-09
90 O 0 6.061789292743924e-09
Japanese O 0 1.3340500970571156e-07
DM B-Disease 1 0.7820833921432495
families O 0 4.965942768109244e-09
comprising O 0 5.930070656745556e-09
190 O 0 6.52168496984018e-09
affected O 0 4.463259539733144e-09
and O 0 1.1112686326697485e-09
130 O 0 6.910817518246404e-08
unaffected O 0 5.163183686818229e-06
members O 0 5.09631057354909e-08
. O 0 2.51779795235052e-07

The O 0 1.8532383592173574e-06
results O 0 4.276703293726314e-06
suggest O 0 1.4838741435596603e-07
that O 0 1.0179229681384072e-09
a O 0 5.180563533713212e-09
few O 0 2.3273130089762617e-09
common O 0 1.6310487183091027e-08
ancestral O 0 9.153492328550783e-07
mutations O 0 3.3211747449968243e-06
in O 0 2.2940911392765884e-09
both O 0 1.6673179503712277e-09
Caucasian O 0 2.090474254146102e-06
and O 0 5.4884377043151744e-09
Japanese O 0 6.491146820053473e-08
populations O 0 8.600648193635152e-09
have O 0 1.169255248179013e-10
originated O 0 5.178594775223644e-10
by O 0 9.194742883744667e-11
expansion O 0 2.2550592504444467e-09
of O 0 6.983619932343643e-11
an O 0 2.2718650571906807e-10
ancestral O 0 6.018244391725602e-08
n O 0 1.3208632481109817e-06
= O 0 3.086791764417285e-07
5 O 0 3.732993469895973e-09
repeat O 0 1.96626483983664e-08
to O 0 3.352991495564339e-10
n O 0 4.574275749291701e-07
= O 0 5.360636237128347e-07
19 O 0 4.156346733452665e-08
- O 0 9.730301826493815e-07
37 O 0 4.671751696605497e-08
copies O 0 4.611787929320599e-08
. O 0 1.470925923285904e-07

These O 0 8.939698403764851e-08
data O 0 4.3335393939969435e-08
support O 0 1.4614213839081458e-08
multistep O 0 1.3333675497051445e-06
models O 0 4.071161896490594e-08
of O 0 3.847159035785808e-09
triplet O 0 0.0025386225897818804
repeat O 0 6.473246230598306e-06
expansion O 0 6.796884122195479e-07
that O 0 5.70373914765554e-10
have O 0 4.1056327781952007e-10
been O 0 5.32031363409402e-10
proposed O 0 3.8720120443258566e-09
for O 0 9.63636170858706e-10
both O 0 2.549179889399511e-08
DM B-Disease 1 0.9997701048851013
and O 0 9.146135653281817e-07
Friedreichs B-Disease 0 0.28166118264198303
ataxia I-Disease 1 0.9886077046394348
. O 0 2.5437941530981334e-07
. O 0 6.409944717233884e-07

The O 0 4.0362419895245694e-07
molecular O 0 1.2701557352556847e-05
basis O 0 3.6925706581314444e-07
of O 0 8.892665391613264e-06
C6 B-Disease 1 0.9999902248382568
deficiency I-Disease 1 0.9999828338623047
in O 0 9.115008481330733e-08
the O 0 1.7364676807574142e-08
western O 0 2.8867495416307065e-07
Cape O 0 4.747485036205035e-06
, O 0 1.1060968141407557e-08
South O 0 3.116845448403183e-08
Africa O 0 1.0744427925146738e-07
. O 0 1.6632712629416346e-07

Deficiency B-Disease 1 0.9855235815048218
of I-Disease 0 6.65479547024006e-08
the I-Disease 0 2.8561876419530563e-08
sixth I-Disease 0 2.970793389067694e-07
component I-Disease 0 5.405473046948828e-08
of I-Disease 0 9.70301616831648e-10
human I-Disease 0 1.1174585701212436e-08
complement I-Disease 0 9.701395953243264e-08
( O 0 2.7126356272333396e-08
C6 O 0 0.0029283897019922733
) O 0 7.37575822640224e-09
has O 0 4.4010750599454695e-09
been O 0 3.043707508254556e-09
reported O 0 3.3054465831128255e-08
in O 0 2.626296957686236e-10
a O 0 6.975529598385322e-10
number O 0 1.1145328410178124e-10
of O 0 1.2191142539919042e-10
families O 0 4.677899734240043e-10
from O 0 2.2444680836120057e-10
the O 0 8.093886116888882e-10
western O 0 3.043761509502474e-08
Cape O 0 1.0894718798226677e-06
, O 0 5.827353266596447e-09
South O 0 4.1588922528035255e-08
Africa O 0 9.844458048746674e-08
. O 0 2.287543168222328e-07

Meningococcal B-Disease 1 0.9995602965354919
disease I-Disease 1 0.9996833801269531
is O 0 1.2429666639945935e-05
endemic O 0 5.6918495829449967e-05
in O 0 1.568028729082016e-08
the O 0 5.9669451601962464e-09
Cape O 0 3.400461707769864e-07
and O 0 2.8259369844185755e-10
almost O 0 4.4887840666696377e-10
all O 0 7.013400277200432e-11
pedigrees O 0 7.377266797448101e-08
of O 0 1.9413343821383933e-08
total O 0 7.91565325926058e-05
C6 B-Disease 1 0.9999961853027344
deficiency I-Disease 1 0.9999933242797852
( O 0 5.896091579415952e-07
C6Q0 O 0 0.0063704634085297585
) O 0 6.448422240623586e-09
have O 0 1.0680832884801816e-09
been O 0 2.905079510284736e-09
ascertained O 0 2.3440831853349664e-07
because O 0 1.8752784214370877e-08
of O 0 2.029134122949472e-07
recurrent O 1 0.9931160807609558
disease O 1 0.9640241265296936
. O 0 2.9131210794730578e-06

We O 0 2.2211034433894383e-07
have O 0 1.853141107233114e-08
sequenced O 0 1.528834019381975e-07
the O 0 2.6943698383519177e-09
expressed O 0 3.1043609904912728e-09
exons O 0 6.04244405622012e-08
of O 0 1.3579110058614674e-09
the O 0 7.661109968637447e-09
C6 O 0 0.00041879861964844167
gene O 0 6.087745418881241e-08
from O 0 1.433542506923402e-09
selected O 0 1.240984981443205e-09
cases O 0 5.113210299612092e-09
and O 0 9.244988663503761e-10
have O 0 5.63660007557587e-10
found O 0 2.011871336193849e-09
three O 0 7.46079376057196e-09
molecular O 0 8.331033313879743e-05
defects O 0 0.06085566431283951
leading O 0 3.939543944397883e-07
to O 0 6.440690647480096e-09
total O 0 4.1458788473391905e-06
deficiency O 1 0.929226279258728
879delG O 0 0.00042409816524013877
, O 0 1.1916995390492957e-08
which O 0 1.941578009478917e-09
is O 0 1.954213457722176e-09
the O 0 4.5231294265590805e-09
common O 0 1.1739764715912315e-07
defect O 0 5.170928125153296e-05
in O 0 4.514200124816625e-09
the O 0 7.347507491317629e-09
Cape O 0 4.7548800807817315e-07
and O 0 1.5430379196601507e-09
hitherto O 0 1.4122113611847453e-07
unreported O 0 8.616628122126713e-08
, O 0 7.415193459259228e-10
and O 0 4.968573885655303e-10
1195delC O 0 5.052610049460782e-06
and O 0 6.827266307851687e-09
1936delG O 0 1.491425427957438e-05
, O 0 2.7296371829521604e-09
which O 0 5.208332098938229e-10
have O 0 2.1039148201396074e-10
been O 0 3.972702444787757e-10
previously O 0 4.223674299197455e-09
reported O 0 1.3495922601691746e-08
in O 0 1.2718566200220494e-09
African O 0 1.1994619519839489e-08
- O 0 2.1617654056171887e-05
Americans O 0 1.5360932081875944e-07
. O 0 1.8448238847668108e-07

We O 0 3.776411858780193e-07
also O 0 1.946387939710803e-08
show O 0 7.975217819478075e-09
that O 0 5.992969454027275e-10
the O 0 3.640069579091687e-09
879delG O 0 1.4216775525710545e-05
and O 0 2.1720076404108113e-07
1195delC O 1 0.5740865468978882
defects O 1 0.95361328125
are O 0 1.2278078997951525e-08
associated O 0 4.7200643393807695e-08
with O 0 5.4879372157756734e-08
characteristic O 0 0.00010583721450529993
C6 O 1 0.9894677996635437
/ O 0 0.02134677954018116
C7 O 1 0.6240993738174438
region O 0 7.929964340291917e-06
DNA O 0 4.1419996705371886e-05
marker O 0 5.901942131458782e-06
haplotypes O 0 5.765246896771714e-06
, O 0 4.597970004738272e-09
although O 0 3.438469509120523e-09
small O 0 7.321096173740216e-09
variations O 0 7.53534976638548e-08
were O 0 8.537901052818597e-09
observed O 0 4.5757505517940444e-07
. O 0 1.5288952681657975e-07

The O 0 3.224849933758378e-06
1936delG O 0 0.058669574558734894
defect O 0 0.035982195287942886
was O 0 1.3589342984232644e-07
observed O 0 3.1332490380009403e-08
only O 0 5.079207054947688e-10
once O 0 2.0961252733542324e-09
in O 0 7.723107153800868e-10
the O 0 1.4914844914670766e-09
Cape O 0 2.2694449341997824e-07
, O 0 5.741920827695424e-10
but O 0 3.67794961153578e-10
its O 0 2.049096003986506e-09
associated O 0 7.208791430457495e-08
haplotype O 0 1.7321464838460088e-05
could O 0 7.456369743863434e-09
be O 0 3.0319859956051687e-09
deduced O 0 2.477404166256747e-07
. O 0 1.5969141031746403e-07

The O 0 1.155314990342049e-07
data O 0 4.334068393063717e-08
from O 0 4.7703476724336724e-09
the O 0 3.4816036720286547e-09
haplotypes O 0 2.1841310626768973e-06
indicate O 0 2.56179415458746e-08
that O 0 1.236313690311519e-10
these O 0 1.2175781216594572e-10
three O 0 5.3172022340675085e-09
molecular O 0 0.00011187763448106125
defects O 0 0.005917640402913094
account O 0 6.96184265791544e-09
for O 0 2.897017514769118e-09
the O 0 5.800332303351752e-08
defects O 0 0.0017199344001710415
in O 0 1.213882550032963e-09
all O 0 6.989696321735295e-11
the O 0 1.260383353240968e-09
38 O 0 1.3863792958090926e-07
unrelated O 0 2.1679175006283913e-06
C6Q0 O 0 0.0026824281085282564
individuals O 0 7.07922120923854e-09
we O 0 5.862501040176937e-10
have O 0 2.549916389149587e-10
studied O 0 5.014809900671935e-09
from O 0 1.7496620818846509e-09
the O 0 2.609841054379558e-08
Cape O 0 9.997375855164137e-06
. O 0 3.99714338072954e-07

We O 0 5.171089014766039e-07
have O 0 1.660109205658955e-08
also O 0 2.101934404308281e-09
observed O 0 8.100746740069553e-09
the O 0 3.933422476620763e-09
879delG O 0 4.020346386823803e-05
defect O 0 1.7535907318233512e-05
in O 0 6.669138574721956e-09
two O 0 3.6859169938452396e-08
Dutch O 0 0.00489700585603714
C6 B-Disease 1 0.999983549118042
- I-Disease 1 0.9993234872817993
deficient I-Disease 1 0.9998038411140442
kindreds O 0 0.0030865666922181845
, O 0 7.789342504338492e-09
but O 0 7.956647007922868e-10
the O 0 2.936146659138217e-09
879delG O 0 7.527168054366484e-05
defect O 0 4.628739407053217e-05
in O 0 6.658131823655822e-09
the O 0 9.670872103129113e-09
Cape O 0 3.1900467547529843e-06
probably O 0 1.363156254541309e-08
did O 0 4.5281592364609935e-10
not O 0 2.2676473546145992e-11
come O 0 9.675474310633092e-11
from O 0 1.528770582348571e-10
The O 0 7.363581411290454e-10
Netherlands O 0 1.5891779980847787e-07
. O 0 9.423828828403202e-09
. O 0 8.099545567574751e-08

Complement B-Disease 1 0.9869816899299622
C7 I-Disease 1 0.9999737739562988
deficiency I-Disease 1 0.9999750852584839
: O 0 1.123560195992468e-06
seven O 0 9.345663443127705e-08
further O 0 1.0608805922629472e-07
molecular O 0 0.0070820157416164875
defects O 0 0.28818589448928833
and O 0 1.1903796170997794e-08
their O 0 1.8135445145617268e-08
associated O 0 1.3395350606515422e-06
marker O 0 4.3072250264231116e-05
haplotypes O 0 0.00025651807663962245
. O 0 7.598397928632039e-07

Seven O 0 5.648475962516386e-07
further O 0 1.0743342215846496e-07
molecular O 0 7.247404482768616e-06
bases O 0 3.0455375963356346e-06
of O 0 2.9975246434332803e-05
C7 B-Disease 1 0.9999920129776001
deficiency I-Disease 1 0.9999910593032837
are O 0 4.418362209435145e-07
described O 0 1.6284757293760777e-05
. O 0 8.217416507250164e-07

All O 0 5.97182037154198e-08
these O 0 1.244111480502852e-08
new O 0 1.2366454882339895e-07
molecular O 0 0.0010243195574730635
defects O 0 0.031441830098629
involve O 0 1.2081413558462373e-07
single O 0 1.3734367598772224e-07
- O 0 5.983466053294251e-06
nucleotide O 0 1.358120726990819e-07
events O 0 1.571312302495187e-09
, O 0 9.552001412060918e-10
deletions O 0 3.356539579613127e-08
and O 0 4.2753917073312664e-10
substitutions O 0 7.014732350540953e-09
, O 0 2.157269640701287e-10
some O 0 4.2421021556604543e-11
of O 0 1.343081201810037e-10
which O 0 2.9335925355589154e-10
alter O 0 3.531788195232366e-08
splice O 0 3.1851718063080625e-07
sites O 0 1.3689430033991812e-08
, O 0 1.2853231812215427e-09
and O 0 1.90703364211231e-09
others O 0 3.404367632242611e-08
codons O 0 5.503899501491105e-06
. O 0 3.330362119413621e-07

They O 0 1.321295002298939e-07
are O 0 3.39240702196264e-09
distributed O 0 3.788424685069458e-09
along O 0 1.7129919704927943e-09
the O 0 1.3264069842477966e-09
C7 O 0 5.552777656703256e-05
gene O 0 1.2447873132259701e-07
, O 0 7.634659016098055e-10
but O 0 1.401587040872343e-10
predominantly O 0 4.5272094406634267e-10
towards O 0 8.402354922942834e-10
the O 0 1.136103766619101e-09
3 O 0 2.8334202539781472e-08
end O 0 1.489413392619099e-07
. O 0 1.3147536037649843e-07

All O 0 7.97300074850682e-08
were O 0 2.8840629440196608e-08
found O 0 2.3911772117912733e-08
in O 0 1.1412951472777877e-08
compound O 0 2.0362924715300323e-06
heterozygous O 0 9.378461072628852e-06
individuals O 0 1.15560808922055e-07
. O 0 3.287471486146387e-07

The O 0 1.8005226593231782e-05
C6 O 1 0.9898922443389893
/ O 0 0.005234330892562866
C7 O 1 0.6914653778076172
marker O 0 0.0003393132647033781
haplotypes O 0 0.0004368706722743809
associated O 0 7.938112958072452e-07
with O 0 1.5265118236129638e-07
most O 0 1.423309299752873e-06
C7 B-Disease 1 0.9995444416999817
defects I-Disease 1 0.9979478716850281
are O 0 1.7522820883186796e-07
tabulated O 0 4.4790838728658855e-05
. O 0 1.2092341705738363e-07
. O 0 4.894525886811607e-07

A O 0 3.0258688639150932e-05
genome O 0 4.635462391888723e-05
- O 0 3.067931857003714e-06
wide O 0 8.183711486253742e-08
search O 0 3.134659465331424e-08
for O 0 6.894055104567087e-09
chromosomal O 0 0.0024329626467078924
loci O 0 5.095684537081979e-05
linked O 0 0.0002685153449419886
to O 0 3.188624475569668e-07
mental O 1 0.927310049533844
health O 0 0.02149171754717827
wellness O 0 0.04855568706989288
in O 0 1.1700979030138114e-07
relatives O 0 1.414413873135345e-06
at O 0 1.0194009973929496e-06
high O 0 0.00012810330372303724
risk O 0 0.0003559168253559619
for O 0 5.154618065716932e-06
bipolar B-Disease 1 0.9999865293502808
affective I-Disease 1 0.9999513626098633
disorder I-Disease 1 0.9968811273574829
among O 0 7.238331534153986e-08
the O 0 2.095474727070723e-08
Old O 0 2.941512093457277e-06
Order O 0 1.3951236610409978e-07
Amish O 0 1.2027711818518583e-05
. O 0 8.197167744583567e-07

Bipolar B-Disease 1 0.9997982382774353
affective I-Disease 1 0.9997517466545105
disorder I-Disease 1 0.9999109506607056
( O 0 0.0021396034862846136
BPAD B-Disease 1 0.9999139308929443
; O 0 0.0043077790178358555
manic B-Disease 1 0.9999663829803467
- I-Disease 1 0.9999626874923706
depressive I-Disease 1 0.9999918937683105
illness I-Disease 1 0.9946234226226807
) O 0 1.3759316175310232e-07
is O 0 1.8618706576489785e-08
characterized O 0 2.0773725850631308e-07
by O 0 8.404919538129718e-10
episodes O 0 7.233939669504252e-09
of O 0 6.341333236292712e-09
mania B-Disease 0 0.02306175045669079
and O 0 4.166204448097233e-08
/ O 0 3.692731843329966e-05
or O 0 1.24897425735071e-07
hypomania B-Disease 0 0.08168179541826248
interspersed O 0 2.8752560865541454e-06
with O 0 3.461429898266033e-08
periods O 0 1.8349976471654372e-06
of O 0 2.0877020290299697e-07
depression B-Disease 0 0.10199414193630219
. O 0 1.3696386531591997e-06

Compelling O 0 7.533246844104724e-06
evidence O 0 5.285697284307389e-07
supports O 0 3.819400546944962e-07
a O 0 7.281882119514194e-08
significant O 0 3.88488530234099e-08
genetic O 0 1.6235735529335216e-06
component O 0 1.4197721043274214e-07
in O 0 2.755951244992616e-09
the O 0 8.5924494186429e-09
susceptibility O 0 2.7936728656641208e-05
to O 0 2.523838560364311e-08
develop O 0 8.504793368047103e-05
BPAD B-Disease 1 0.9989286065101624
. O 0 4.097183591511566e-06

To O 0 1.3949347987818328e-07
date O 0 2.8702072540909285e-07
, O 0 8.596924949699769e-09
however O 0 1.607979860374087e-09
, O 0 7.060259044067152e-10
linkage O 0 1.9024756170438195e-07
studies O 0 1.0134987071808155e-08
have O 0 2.387506303769271e-10
attempted O 0 5.024729077263146e-09
only O 0 1.379228536935173e-10
to O 0 1.9753974844771705e-10
identify O 0 6.47352749183483e-08
chromosomal O 0 0.0006470102234743536
loci O 0 6.116661552368896e-06
that O 0 2.1179122455805555e-08
cause O 0 1.0593533943392686e-06
or O 0 1.1823670043042966e-08
increase O 0 4.9896240028601824e-08
the O 0 2.686673639118453e-08
risk O 0 3.4957165553350933e-06
of O 0 1.679206995675031e-08
developing O 0 1.8553055269876495e-05
BPAD B-Disease 1 0.9980632662773132
. O 0 2.7653627512336243e-06

To O 0 1.986356750194318e-07
determine O 0 4.1631273006714764e-07
whether O 0 2.5784713031384854e-08
there O 0 3.58280871637362e-09
could O 0 2.650655472891117e-09
be O 0 7.370157262265309e-10
protective O 0 2.9025168259977363e-06
alleles O 0 4.3993988896318115e-08
that O 0 1.2745765554100785e-09
prevent O 0 1.0891024970760554e-07
or O 0 7.481399499909003e-09
reduce O 0 1.7630736692808568e-07
the O 0 1.7193956480809902e-08
risk O 0 4.278308551874943e-07
of O 0 3.0842004505871046e-09
developing O 0 1.5448373460458242e-06
BPAD B-Disease 1 0.9876875281333923
, O 0 1.4068056941596296e-08
similar O 0 6.909984140435199e-09
to O 0 2.093155787585843e-10
what O 0 6.518572348568341e-10
is O 0 1.128958038165706e-09
observed O 0 7.788852229850818e-09
in O 0 4.6008388210339035e-09
other O 0 5.761761912026486e-08
genetic B-Disease 1 0.9923753142356873
disorders I-Disease 1 0.9998865127563477
, O 0 1.095795241212727e-07
we O 0 1.404666161164414e-08
used O 0 2.752580883225164e-07
mental O 1 0.583899199962616
health O 0 0.04862860217690468
wellness O 0 0.22418436408042908
( O 0 1.794246600184124e-07
absence O 0 5.178432616048667e-07
of O 0 2.9458412598160066e-08
any O 0 1.3842155794918654e-06
psychiatric B-Disease 1 0.9975927472114563
disorder I-Disease 1 0.817290723323822
) O 0 8.177341470627653e-09
as O 0 1.9328836309284725e-09
the O 0 6.350325598702966e-09
phenotype O 0 1.989421434700489e-06
in O 0 1.981995456645791e-09
our O 0 4.405341869073709e-09
genome O 0 1.2525239867500204e-07
- O 0 5.822928415000206e-07
wide O 0 8.255763184195075e-09
linkage O 0 7.591510353677222e-08
scan O 0 2.0617450502413703e-07
of O 0 2.53600557220679e-10
several O 0 3.564532835564904e-10
large O 0 4.324850699788385e-09
multigeneration O 0 3.0595053885917878e-06
Old O 0 3.376431578772099e-08
Order O 0 8.832202746944517e-10
Amish O 0 6.09099828352555e-08
pedigrees O 0 5.280124923956464e-07
exhibiting O 0 1.4992150454418152e-07
an O 0 5.293240512571629e-09
extremely O 0 8.828739055388724e-07
high O 0 1.4113193174125627e-05
incidence O 0 0.013650772161781788
of O 0 1.0092105640069349e-06
BPAD B-Disease 1 0.9990002512931824
. O 0 4.1863204387482256e-06

We O 0 4.496878318605013e-07
have O 0 2.13741166987802e-08
found O 0 1.211676448065191e-08
strong O 0 7.243051936001166e-09
evidence O 0 1.45832423914527e-09
for O 0 3.5041261559065617e-10
a O 0 9.339548689979438e-09
locus O 0 6.530475502586341e-07
on O 0 3.34126042389471e-08
chromosome O 0 5.589984721154906e-05
4p O 0 0.039010751992464066
at O 0 5.7707143952256956e-08
D4S2949 O 0 2.257360165458522e-06
( O 0 4.266539121999813e-09
maximum O 0 5.880043829620263e-08
GENEHUNTER O 0 7.198845560196787e-05
- O 0 9.357843282487011e-07
PLUS O 0 2.5487373989108164e-08
nonparametric O 0 2.0248660348443082e-07
linkage O 0 8.80904451605602e-08
score O 0 4.342497916809407e-09
= O 0 3.0308427767522517e-08
4 O 0 1.838305063728285e-09
. O 0 3.015604987943732e-10
05 O 0 1.1639759804893401e-06
, O 0 1.758599488255186e-08
P O 0 1.9103541490039788e-05
= O 0 1.845181145654351e-07
5 O 0 3.299272188783675e-09
. O 0 3.165454565134951e-10
22 O 0 3.961717620626359e-09
x O 0 1.1829516211037117e-07
10 O 0 2.690384803827328e-09
( O 0 1.817019756877869e-09
- O 0 6.744293159499648e-07
4 O 0 1.0266314021123435e-08
) O 0 4.5033621276502345e-10
; O 0 8.092681524907164e-10
SIBPAL O 0 5.83544760957011e-06
Pempirical O 0 4.2614442463673186e-06
value O 0 3.909219170594724e-09
< O 0 3.069126819355006e-07
3 O 0 5.991464213650488e-09
x O 0 1.809871719160583e-07
10 O 0 5.428852478672752e-09
( O 0 4.154173005588291e-09
- O 0 1.0961125553876627e-06
5 O 0 3.840663342913331e-09
) O 0 3.160615935637878e-10
) O 0 1.8440493576576955e-10
and O 0 2.7048210893276803e-10
suggestive O 0 2.865693460307739e-08
evidence O 0 5.628434940341265e-10
for O 0 2.5550769833238007e-10
a O 0 1.2378013281022504e-08
locus O 0 1.847387238740339e-06
on O 0 1.2907302959774825e-07
chromosome O 0 0.0010557194473221898
4q O 1 0.8200955390930176
at O 0 1.1946619338232267e-07
D4S397 O 0 2.5379085855092853e-06
( O 0 3.0005056217419224e-09
maximum O 0 5.622711540809178e-08
GENEHUNTER O 0 0.00034357537515461445
- O 0 4.0218624235421885e-06
PLUS O 0 7.788781886119978e-08
nonparametric O 0 3.08593826048309e-07
linkage O 0 1.6193476426451525e-07
score O 0 5.39153877099352e-09
= O 0 5.999494590014365e-08
3 O 0 2.443445001887312e-09
. O 0 5.903659783257353e-10
29 O 0 2.5480714427317253e-08
, O 0 3.5378204810143643e-09
P O 0 1.237170636159135e-05
= O 0 1.0037148712171984e-07
2 O 0 1.556778372879819e-09
. O 0 2.323227027423158e-10
57 O 0 1.4417997462601306e-08
x O 0 2.399122251972585e-07
10 O 0 3.515850499624662e-09
( O 0 2.6118514018236283e-09
- O 0 9.55670884650317e-07
3 O 0 5.88163384662721e-09
) O 0 8.606780843578576e-10
; O 0 1.5200718461727547e-09
SIBPAL O 0 5.990351837681374e-06
Pempirical O 0 3.501325409160927e-06
value O 0 2.0541794931716595e-09
< O 0 2.1902206981394556e-07
1 O 0 3.2362732493851354e-09
x O 0 1.3510697272067773e-07
10 O 0 3.5041880508401846e-09
( O 0 2.432972268096023e-09
- O 0 6.258974849515653e-07
3 O 0 9.292230096491494e-09
) O 0 6.353909065559549e-10
) O 0 3.607134868577333e-10
that O 0 1.9782554760983118e-10
are O 0 9.75923564183745e-10
linked O 0 3.4018019050563453e-06
to O 0 6.198457214168229e-08
mental O 1 0.5285853743553162
health O 0 0.11461872607469559
wellness O 1 0.7968323826789856
. O 0 7.817087862349581e-06

These O 0 2.9932252232356404e-07
findings O 0 5.072038788966893e-07
are O 0 4.644739703962841e-09
consistent O 0 1.456412501710247e-08
with O 0 1.5148216014893023e-09
the O 0 2.817832411849963e-09
hypothesis O 0 3.968299111534179e-08
that O 0 2.0965001956696483e-10
certain O 0 3.9002057139470026e-10
alleles O 0 1.595235943341322e-08
could O 0 2.3636199664167634e-09
prevent O 0 3.1248696075181215e-08
or O 0 2.810430776989392e-09
modify O 0 8.488316183274947e-08
the O 0 9.28000876143642e-09
clinical O 0 2.1042114894953556e-06
manifestations O 0 3.75861588963744e-07
of O 0 2.9584091620904474e-08
BPAD B-Disease 1 0.9921592473983765
and O 0 4.5482718036282677e-08
perhaps O 0 8.108479931934198e-08
other O 0 2.4711079404937664e-08
related O 0 8.833660831442103e-05
affective B-Disease 1 0.9986037611961365
disorders I-Disease 1 0.9997202754020691
. O 0 1.7732698324834928e-05

Segregation O 0 0.01230565458536148
distortion O 0 0.09647027403116226
in O 0 0.003446475602686405
myotonic B-Disease 1 0.9994669556617737
dystrophy I-Disease 1 0.9997647404670715
. O 0 0.00032204296439886093

Myotonic B-Disease 1 0.999909520149231
dystrophy I-Disease 1 0.9999649524688721
( O 0 0.0016663490096107125
DM B-Disease 1 0.9998668432235718
) O 0 3.880161614233657e-07
is O 0 5.0274344687295525e-08
an O 0 1.2771570823133516e-07
autosomal B-Disease 1 0.8086695075035095
dominant I-Disease 1 0.520113468170166
disease I-Disease 1 0.7100299000740051
which O 0 1.930699511376588e-08
, O 0 2.221461903317845e-09
in O 0 5.476241682345062e-10
the O 0 7.292020876015215e-10
typical O 0 2.386890116667928e-07
pedigree O 0 3.4656657135201385e-06
, O 0 4.0224767960950203e-10
shows O 0 1.0356819846180088e-09
a O 0 1.883342592989834e-09
three O 0 3.570413298348285e-09
generation O 0 1.0735390105764964e-06
anticipation O 0 1.4715893485117704e-05
cascade O 0 0.0005396917695179582
. O 0 4.0005832602219016e-07

This O 0 1.2463225402825628e-06
results O 0 2.4072633095784113e-05
in O 0 6.198142273206031e-06
infertility B-Disease 1 0.9996663331985474
and O 1 0.6289048790931702
congenital B-Disease 1 0.9999994039535522
myotonic I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.999998927116394
( O 0 3.196278339601122e-05
CDM B-Disease 0 0.0005427736323326826
) O 0 4.025211275404672e-09
with O 0 8.002137841245371e-10
the O 0 2.4161206368944477e-09
disappearance O 0 6.895076580804016e-07
of O 0 9.265015421533462e-08
DM B-Disease 1 0.9997555613517761
in O 0 7.497687448676515e-08
that O 0 2.1747057488141763e-08
pedigree O 0 5.1112627261318266e-05
. O 0 5.315795306159998e-07

The O 0 1.6716629147595086e-07
concept O 0 7.709486027351886e-08
of O 0 6.727010948281986e-09
segregation O 0 3.895403096976224e-06
distortion O 0 3.7593290471704677e-06
, O 0 8.021656228152096e-09
where O 0 1.651354164522445e-09
there O 0 2.6308993872348196e-10
is O 0 1.3797836484474857e-10
preferential O 0 2.898332907008694e-09
transmission O 0 1.0106266756793048e-07
of O 0 1.3258953657224737e-10
the O 0 3.0219499125294647e-10
larger O 0 3.502771628305368e-09
allele O 0 1.0717305265472987e-08
at O 0 4.1935961370143104e-09
the O 0 9.78206937674031e-09
DM B-Disease 1 0.9885185360908508
locus O 0 1.664840237936005e-05
, O 0 8.06456501578623e-09
has O 0 1.46649137278132e-09
been O 0 4.678461507090503e-10
put O 0 1.0066742994752076e-09
forward O 0 6.629312654382602e-10
to O 0 7.499421916801197e-11
explain O 0 4.387831875618531e-09
partially O 0 1.6128205970744602e-07
the O 0 3.601684950282902e-09
maintenance O 0 1.9842524125124328e-05
of O 0 6.611324465666257e-08
DM B-Disease 1 0.9997894167900085
in O 0 4.968180888909046e-08
the O 0 2.111092101131362e-08
population O 0 1.1969279967161128e-07
. O 0 3.092861788900336e-07

In O 0 4.4975470814279106e-07
a O 0 3.157944377107924e-07
survey O 0 2.3797349513188237e-07
of O 0 1.6628439070132117e-08
DM B-Disease 1 0.9356454610824585
in O 0 1.9670714834774117e-08
Northern O 0 1.0357065605148819e-07
Ireland O 0 6.079854841800625e-08
, O 0 5.2255986204841065e-09
59 O 0 2.0456282356917654e-07
pedigrees O 0 2.513889739930164e-06
were O 0 4.407343823231713e-08
ascertained O 0 6.000844223308377e-06
. O 0 4.929753458782216e-07

Sibships O 0 0.0004462706856429577
where O 0 2.0255457400253363e-07
the O 0 1.136247362865106e-08
status O 0 6.251563267056781e-09
of O 0 2.437876289729246e-10
all O 0 4.9935389156985366e-11
the O 0 2.0411999868130692e-10
members O 0 2.045916214221677e-10
had O 0 1.69872149680117e-09
been O 0 9.75413749770837e-10
identified O 0 4.238628559249946e-09
were O 0 4.3563500029542013e-10
examined O 0 1.763308432600752e-08
to O 0 3.722537555983507e-11
determine O 0 5.859795426665926e-10
the O 0 4.5239037516076053e-10
transmission O 0 1.452172000426799e-07
of O 0 2.593671943884601e-09
the O 0 7.327525253231215e-08
DM B-Disease 1 0.9990113973617554
expansion O 0 2.7838161713589216e-06
from O 0 1.2044597319516015e-08
affected O 0 2.109904784219907e-08
parents O 0 5.104908051833945e-09
to O 0 2.730020931540622e-10
their O 0 5.825630644551438e-09
offspring O 0 4.160954176768428e-06
. O 0 3.7834664112779137e-07

Where O 0 6.481026844085136e-07
the O 0 8.600208900588768e-08
transmitting O 0 3.3586733479751274e-05
parent O 0 2.0490741007961333e-05
was O 0 1.046580777597228e-07
male O 0 7.291937436093576e-07
, O 0 5.939831737578061e-08
58 O 0 2.41159750657971e-06
. O 0 3.795153418195696e-07

3 O 0 8.215488946916594e-07
% O 0 2.9628475672893728e-08
of O 0 1.462206911106989e-09
the O 0 2.441739699321488e-09
offspring O 0 1.7317087497303874e-07
were O 0 3.7235923233680523e-09
affected O 0 1.6360838017703827e-08
, O 0 4.111298246289863e-10
and O 0 1.8236155641115914e-10
in O 0 4.106540940629344e-10
the O 0 4.904622818990845e-10
case O 0 4.85986184628473e-09
of O 0 2.0598084349288115e-10
a O 0 6.9106169675592355e-09
female O 0 3.3960574796765286e-07
transmitting O 0 9.774998034117743e-05
parent O 0 3.0407811209443025e-05
, O 0 6.965975529737989e-08
68 O 0 3.429738626437029e-06
. O 0 4.058184401856124e-07

7 O 0 1.4956613995309453e-05
% O 0 4.721919424355292e-07
were O 0 9.597958694484987e-08
affected O 0 1.7118975392804714e-06
. O 0 1.2136028999520931e-06

Studies O 0 3.0497724310407648e-06
on O 0 7.899073040107396e-08
meiotic O 0 4.9917241994990036e-05
drive O 0 1.2317390201133094e-06
in O 0 1.572628605117643e-07
DM B-Disease 1 0.9940336346626282
have O 0 4.022647548396208e-09
shown O 0 6.310023614730653e-09
increased O 0 6.6590715164238645e-09
transmission O 0 6.03852754466061e-08
of O 0 1.687450457144024e-10
the O 0 4.001128039998747e-10
larger O 0 5.120393886670627e-09
allele O 0 1.6770849597946835e-08
at O 0 2.741272098205627e-09
the O 0 5.602432739948426e-09
DM B-Disease 0 0.41956350207328796
locus O 0 1.6824919839564245e-06
in O 0 2.4632681672187573e-08
non O 0 2.7006101390725235e-06
- O 0 0.06861104816198349
DM O 1 0.9994619488716125
heterozygotes O 0 0.0002769035054370761
for O 0 1.4030226225258957e-07
CTGn O 0 0.000887740112375468
. O 0 1.0300637995896977e-06

This O 0 2.2935635968224233e-07
study O 0 1.020741038360029e-07
provides O 0 2.405421817286424e-08
further O 0 4.667982000938764e-09
evidence O 0 4.8962873755442615e-09
that O 0 1.0574392472761929e-09
the O 0 2.9490232478224243e-08
DM B-Disease 1 0.9986357092857361
expansion O 0 2.9494647151295794e-06
tends O 0 3.795015146579317e-08
to O 0 5.476429865147736e-10
be O 0 1.7945772645688862e-09
transmitted O 0 2.7599671170719375e-07
preferentially O 0 9.704178864922142e-07
. O 0 1.4287013527791714e-07

Diagnosis O 1 0.9871799349784851
of O 0 0.00020911841420456767
hemochromatosis B-Disease 1 0.999512791633606
. O 0 0.0001641760754864663

If O 0 0.0002817594213411212
untreated O 1 0.8953906893730164
, O 0 4.177153095952235e-05
hemochromatosis B-Disease 1 0.9999723434448242
can O 0 2.8089587431168184e-05
cause O 0 0.04039507359266281
serious O 0 0.10176564007997513
illness O 0 0.12673893570899963
and O 0 6.769541016637959e-08
early B-Disease 0 3.855800798646669e-07
death I-Disease 0 1.7141815078502987e-06
, O 0 1.5795706076460192e-08
but O 0 1.1114642539666875e-08
the O 0 2.9333503448469855e-07
disease O 0 0.0013633156195282936
is O 0 1.8427925851938198e-08
still O 0 7.272804225522123e-08
substantially O 0 9.077912181965075e-06
under O 0 7.441336947522359e-06
- O 1 0.8391852378845215
diagnosed O 1 0.9900304079055786
. O 0 1.1091939313701005e-06

The O 0 2.43298330815378e-07
cornerstone O 0 4.151663233642466e-06
of O 0 1.3762342376821834e-08
screening O 0 1.1843609399875277e-06
and O 0 7.0348034064693366e-09
case O 0 2.19469882267731e-08
detection O 0 5.933886200182314e-07
is O 0 4.5324019537495985e-10
the O 0 1.7596443746548118e-10
measurement O 0 1.5073949199972958e-08
of O 0 7.88333676116082e-10
serum O 0 2.373833240199019e-06
transferrin O 0 6.7594774009194225e-06
saturation O 0 5.058141141489614e-07
and O 0 1.2205036981072226e-09
the O 0 4.781496976136168e-09
serum O 0 4.624279426934663e-06
ferritin O 0 4.7655277739977464e-05
level O 0 4.464573066798039e-07
. O 0 2.1494193447324506e-07

Once O 0 1.2330517165537458e-05
the O 0 7.855334160922212e-07
diagnosis O 0 0.08367468416690826
is O 0 3.057461697153485e-07
suspected O 0 7.552164788648952e-06
, O 0 2.4168132384261298e-08
physicians O 0 6.627743687204202e-07
must O 0 2.5101263290139286e-09
use O 0 3.292244477037798e-09
serum O 0 1.8630184058565646e-05
ferritin O 0 0.0002824791881721467
levels O 0 5.271450618238305e-07
and O 0 1.6116221246420537e-08
hepatic O 0 0.006626450922340155
iron O 0 0.0005285781808197498
stores O 0 8.190987159650831e-07
on O 0 5.02592968132376e-07
liver O 0 0.4849667549133301
biopsy O 0 0.19821037352085114
specimens O 0 1.0056788823931129e-06
to O 0 3.7098040195360227e-09
assess O 0 1.9084445739281364e-06
patients O 0 1.053503979164816e-06
for O 0 3.3418692813036444e-10
the O 0 9.488158037029848e-10
presence O 0 2.1604916966566634e-08
of O 0 1.7006675179231934e-08
iron B-Disease 0 0.0026760990731418133
overload I-Disease 0 0.003038498107343912
. O 0 8.885857596396818e-07

Liver O 1 0.9996262788772583
biopsy O 1 0.9829036593437195
is O 0 3.3382988817720616e-07
also O 0 4.884329829479839e-09
used O 0 8.579426058474837e-10
to O 0 1.7612292180224642e-10
establish O 0 2.296704826321161e-09
the O 0 1.0064092892392296e-09
presence O 0 8.016547425881981e-09
or O 0 3.1690989832355854e-09
absence O 0 3.465994780071924e-08
of O 0 1.4662320246827676e-08
cirrhosis B-Disease 0 0.4252905547618866
, O 0 2.4750608673684837e-08
which O 0 6.941105468172282e-09
can O 0 2.5164649031239605e-08
affect O 0 3.822304279310629e-06
prognosis O 1 0.5224260091781616
and O 0 2.3322293429828278e-07
management O 0 5.345013050828129e-05
. O 0 6.576643158950901e-07

A O 0 2.3470531232305802e-05
DNA O 0 0.00015330959286075085
- O 0 2.1708781787310727e-05
based O 0 1.5812466003239933e-08
test O 0 5.9549614128684425e-09
for O 0 2.5782767587578803e-10
the O 0 1.7290403553360534e-09
HFE O 0 0.00021268244017846882
gene O 0 1.0987587728550352e-07
is O 0 6.719147460643171e-10
commercially O 0 1.411942007756295e-09
available O 0 2.843291990739516e-10
, O 0 1.5654960661137807e-10
but O 0 4.151990556922058e-11
its O 0 5.414400525149965e-11
place O 0 2.700022150303738e-10
in O 0 7.58565599223715e-10
the O 0 1.2298329465920688e-08
diagnosis O 0 0.0009587852982804179
of O 0 4.4143862965029257e-07
hemochromatosis B-Disease 1 0.9999898672103882
is O 0 4.1343989209963183e-07
still O 0 8.787933580833851e-08
being O 0 8.20949139779259e-08
evaluated O 0 4.54340488431626e-06
. O 0 3.8057220308473916e-07

Currently O 0 1.0837680974873365e-06
, O 0 1.3343066207482934e-08
the O 0 8.622407232650176e-10
most O 0 1.6932634461230833e-10
useful O 0 2.6509172634803235e-10
role O 0 1.5850867285394088e-09
for O 0 4.328850888857261e-10
this O 0 3.336213805216204e-10
test O 0 7.870750273752947e-09
is O 0 3.663701564349253e-10
in O 0 2.860873760113236e-10
the O 0 1.0044225451366628e-09
detection O 0 5.828400730933936e-07
of O 0 1.6707026873064024e-08
hemochromatosis B-Disease 1 0.9995606541633606
in O 0 8.468905576819452e-09
the O 0 1.5090541038986771e-09
family O 0 1.5871570724357298e-08
members O 0 1.0415734941204846e-09
of O 0 8.147264196622928e-09
patients O 0 3.5390889934205916e-06
with O 0 5.961052540470746e-09
a O 0 3.090170253017277e-07
proven O 0 2.4179259980883216e-06
case O 0 7.675095048398362e-08
of O 0 8.30085866709851e-09
the O 0 2.473745098541258e-06
disease O 0 0.020343191921710968
. O 0 7.850960628275061e-07

It O 0 4.1115069393526937e-07
is O 0 4.677065845726247e-08
crucial O 0 2.7508750122251513e-07
to O 0 2.2432254809245933e-07
diagnose O 1 0.9989802241325378
hemochromatosis B-Disease 1 0.9999903440475464
before O 0 0.03452809154987335
hepatic B-Disease 1 0.9999536275863647
cirrhosis I-Disease 1 0.9999421834945679
develops O 0 0.12282563745975494
because O 0 8.530450031685177e-06
phlebotomy O 1 0.8242522478103638
therapy O 0 0.2558991312980652
can O 0 6.134456270956434e-06
avert O 1 0.9920421242713928
serious O 1 0.9997215867042542
chronic O 1 0.9999979734420776
disease O 1 0.9980742931365967
and O 0 1.9258361305674043e-07
can O 0 1.028540452807647e-08
even O 0 9.358360308908686e-09
lead O 0 4.7711413486695164e-08
to O 0 7.083783559735934e-10
normal O 0 1.6402213987021241e-07
life O 0 1.6298444904805365e-07
expectancy O 0 9.215855243382975e-06
. O 0 1.970627572234207e-08
. O 0 9.633833997213515e-08

Prevalence O 0 0.0008820333168841898
of O 0 1.5992961266420025e-07
the O 0 7.35694740683357e-08
I1307K O 0 2.9143968276912346e-05
APC B-Disease 0 3.2121439289767295e-05
gene O 0 7.287480912054889e-07
variant O 0 1.2015751735816593e-06
in O 0 1.2074031774389482e-09
Israeli O 0 7.4337060951279454e-09
Jews O 0 1.2475611654849672e-09
of O 0 1.6595851082268354e-10
differing O 0 2.0434836045524207e-09
ethnic O 0 3.319901686893445e-09
origin O 0 1.0486465029657666e-08
and O 0 2.8395942308634403e-07
risk O 0 0.1811087727546692
for O 0 0.4258553683757782
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999948740005493
. O 0 5.578822674578987e-05

BACKGROUND O 0 3.095177817158401e-05
& O 0 3.672356797324028e-06
AIMS O 0 7.308387921511894e-07
Israeli O 0 1.8913863186753588e-07
Jews O 0 1.073657873718048e-08
of O 0 3.529113001832229e-09
European O 0 7.178277172670278e-08
birth O 0 1.4088475836615544e-05
, O 0 1.4716198037945105e-08
i O 0 1.269879312815192e-08
. O 0 5.991392937332307e-10
e O 0 9.507038711831228e-09
. O 0 8.180890687103926e-11
, O 0 1.609402749958022e-10
Ashkenazim O 0 2.4139476195728093e-08
, O 0 3.802148040854547e-10
have O 0 1.3400880405356475e-09
the O 0 3.679848532556207e-07
highest O 1 0.9862806797027588
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
incidence O 1 0.5278178453445435
of O 0 9.19284026679179e-09
any O 0 3.0400639783323413e-09
Israeli O 0 4.590458502207184e-07
ethnic O 0 4.932095407639281e-07
group O 0 3.994988674094202e-06
. O 0 6.243944881134667e-07

The O 0 5.548138233280042e-07
I1307K O 0 8.604675531387329e-05
APC B-Disease 0 0.00015335313219111413
gene O 0 8.550584425393026e-06
variant O 0 2.0681878595496528e-05
was O 0 6.568777166648943e-08
found O 0 2.2691175161071442e-08
in O 0 3.193651565425171e-08
6 O 0 1.2247484164618072e-06
. O 0 5.484536131916684e-07

1 O 0 5.664849140885053e-07
% O 0 1.4537538284287166e-08
of O 0 7.445564720320874e-10
American O 0 2.0678634360393744e-09
Jews O 0 3.126275016640534e-09
, O 0 2.372948060269664e-09
28 O 0 1.4650215263145583e-08
% O 0 1.3527304831839615e-09
of O 0 4.438614809032515e-09
their O 0 6.100437167333439e-05
familial O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
cases O 0 4.10964603361208e-05
, O 0 3.4412401817007776e-08
but O 0 1.306383445864867e-09
not O 0 1.8374488042205428e-10
in O 0 1.4632950406934242e-09
non O 0 4.896804028931001e-08
- O 0 1.7527949239593e-05
Jews O 0 2.329335302420077e-07
. O 0 4.365071220036043e-07

We O 0 1.170998189081729e-06
assessed O 0 1.7092645521188388e-06
the O 0 4.082335891553157e-08
I1307K O 0 2.789136669889558e-05
prevalence O 0 1.1697665286192205e-05
in O 0 2.47561660060569e-09
Israeli O 0 9.859544292112332e-09
Jews O 0 8.616816704609676e-10
of O 0 1.56036267240367e-10
differing O 0 1.2257505010992986e-09
ethnic O 0 1.6756869225531545e-09
origin O 0 6.717702394354319e-09
and O 0 2.871765047984809e-07
risk O 0 0.041495900601148605
for O 0 0.08280765265226364
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999943971633911
. O 0 6.634094461333007e-05

METHODS O 0 1.1619614269875456e-05
DNA O 0 1.5303339750971645e-05
samples O 0 9.834380421125388e-08
from O 0 5.967206284651638e-09
500 O 0 1.2659857162589105e-08
unrelated O 0 1.9567135467468688e-08
Jews O 0 1.1708491953754674e-09
of O 0 4.005434595111268e-10
European O 0 3.888857236233889e-09
or O 0 5.4323638920550366e-09
non O 0 4.9079684316666317e-08
- O 0 2.5683093554107472e-06
European O 0 3.187333286192029e-09
origin O 0 7.471955276727726e-10
, O 0 3.552939331630256e-10
with O 0 4.5287207317556977e-10
or O 0 8.332564083168847e-10
without O 0 1.1862562043774005e-09
a O 0 4.158977606749659e-09
personal O 0 3.3542100652539375e-08
and O 0 1.2168596796868769e-08
/ O 0 2.4556650259910384e-06
or O 0 4.4164973900251425e-09
family O 0 1.7616006431353526e-08
history O 0 5.821565451924471e-09
of O 0 7.290383852165405e-09
neoplasia B-Disease 1 0.5490692257881165
, O 0 4.6194008618272164e-09
were O 0 1.077117506298464e-09
examined O 0 5.4726452702880124e-08
for O 0 2.943064125737749e-10
the O 0 1.5139897113769507e-09
I1307K O 0 1.5402769122374593e-06
variant O 0 1.2398220405884786e-07
by O 0 4.105601136838999e-10
the O 0 7.396604440046417e-10
allele O 0 6.66292336859442e-08
- O 0 1.0535492265262292e-06
specific O 0 6.976916377965381e-09
oligonucleotide O 0 9.799899271456525e-05
( O 0 1.0730236255085401e-07
ASO O 0 0.0001977070642169565
) O 0 1.4086986688255365e-08
method O 0 1.2660453307944408e-07
. O 0 1.6001246194718988e-07

RESULTS O 0 1.850515400292352e-05
In O 0 7.969169502075601e-08
persons O 0 2.396044074259862e-08
at O 0 1.6016574022614805e-07
average O 0 2.0252406102372333e-05
risk O 0 0.07229460030794144
for O 0 0.01671997644007206
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999969005584717
, O 0 8.494444614370877e-07
I1307K O 0 0.00025627214927226305
was O 0 1.1999841831311642e-07
found O 0 2.5825663385603548e-08
in O 0 1.4019172489554421e-08
5 O 0 2.1389334392551973e-07
. O 0 3.1047892434798996e-07

0 O 0 1.8099527778758784e-06
% O 0 4.32792255367076e-08
of O 0 2.1213959477961453e-09
120 O 0 1.540427341240047e-08
European O 0 1.833592477851198e-08
and O 0 1.501349267130081e-08
1 O 0 4.962139428243972e-07
. O 0 3.933297421099269e-07

6 O 0 4.0658806028659455e-06
% O 0 4.3471160893204797e-08
of O 0 4.316148327632163e-09
188 O 0 7.526128342760785e-08
non O 0 5.303005323753496e-08
- O 0 4.905919013253879e-07
European O 0 5.3127622301474275e-09
Jews O 0 1.12592219991825e-08
( O 0 3.585100571967814e-08
P O 0 0.00011819049541372806
= O 0 1.219046680489555e-06
0 O 0 3.59030138952221e-08
. O 0 2.5799162806094955e-09
08 O 0 1.9385747407341114e-07
) O 0 1.94118996432735e-08
. O 0 9.03722963130349e-08

It O 0 5.474586828313477e-07
occurred O 0 4.429805812833365e-06
in O 0 1.3441632518151891e-07
15 O 0 8.086369120974268e-07
. O 0 6.14012890309823e-07

4 O 0 1.2536489748526947e-06
% O 0 5.8071510267154736e-08
of O 0 5.5736553150609325e-09
52 O 0 9.96249696072482e-08
Ashkenazi O 0 9.613634574634489e-06
Israelis O 0 1.4990379213486449e-06
with O 0 9.143893294094596e-06
familial O 1 0.9998712539672852
cancer B-Disease 1 0.999771773815155
( O 0 9.953870403478504e-07
P O 0 0.0024609880056232214
= O 0 1.5709197214164305e-06
0 O 0 2.4831939171576778e-08
. O 0 1.4259939895566731e-09
02 O 0 6.237130492081633e-07
) O 0 3.1200245165230456e-10
and O 0 2.93160135056425e-10
was O 0 1.5868110159189541e-09
not O 0 1.2642446811650387e-10
detected O 0 2.1500502711546687e-08
in O 0 3.764336620193376e-10
51 O 0 1.3373641749581111e-08
non O 0 3.3907767704732805e-09
- O 0 7.966631443423466e-08
European O 0 1.6730935525899326e-09
Jews O 0 8.224925629463087e-09
at O 0 7.127082426450215e-07
increased O 0 0.0019374912371858954
cancer B-Disease 1 0.9992637038230896
risk O 0 0.0008117793477140367
. O 0 5.193477363718557e-07

Colorectal B-Disease 1 0.9999128580093384
neoplasia I-Disease 1 0.9996582269668579
occurred O 0 0.001663725357502699
personally O 0 1.4309733160189353e-05
or O 0 3.964244399412564e-08
in O 0 3.3582410186028255e-09
the O 0 7.805787682890752e-10
families O 0 6.904117832995382e-10
of O 0 2.637320362097739e-10
13 O 0 2.1985522291601e-09
of O 0 2.1352540569008482e-10
20 O 0 4.8187969170498945e-09
Ashkenazi O 0 1.4071673604121315e-06
I1307K O 0 1.0812947948579676e-05
carriers O 0 5.401684575190302e-07
, O 0 7.038410410054041e-10
8 O 0 1.862203724556366e-09
of O 0 3.424873440405207e-10
whom O 0 4.11016332080294e-09
also O 0 1.0671363792624788e-09
had O 0 1.63630775595891e-09
a O 0 1.4567340667070994e-09
personal O 0 1.947765682075442e-08
or O 0 1.1247203168807118e-08
family O 0 3.320992547628521e-08
history O 0 2.0497344266345863e-08
of O 0 4.724135038713939e-08
noncolonic O 1 0.5841602087020874
neoplasia B-Disease 1 0.9975718855857849
. O 0 2.2789995455241296e-06

CONCLUSIONS O 0 1.611715561011806e-05
The O 0 4.403773061767424e-07
I1307K O 0 0.00017965778533834964
APC O 0 0.0005094031221233308
variant O 0 7.113286119420081e-05
may O 0 4.480816073737515e-08
represent O 0 2.463097725780017e-09
a O 0 8.527977257699604e-08
susceptibility O 0 8.229758532252163e-05
gene O 0 8.192469067580532e-06
for O 0 1.9684505332406843e-06
colorectal B-Disease 1 0.9999972581863403
, I-Disease 0 9.79417151825146e-08
or I-Disease 0 2.998264747589019e-08
other I-Disease 0 4.375029227787763e-09
, I-Disease 0 1.5778309148117842e-07
cancers I-Disease 0 0.011091552674770355
in O 0 1.459237708445471e-08
Ashkenazi O 0 1.4915007341187447e-05
Jews O 0 4.8342464253892103e-08
, O 0 4.56729054576499e-09
and O 0 5.044279660637585e-09
partially O 0 2.1953242139716167e-06
explains O 0 6.242652972332507e-08
the O 0 1.8933347334382233e-08
higher O 0 8.188345418602694e-06
incidence O 1 0.8764435052871704
of O 0 0.04560059309005737
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999949932098389
in O 0 2.3298817097838764e-07
European O 0 2.6800464070220187e-07
Israelis O 0 3.547993628671975e-06
. O 0 1.1072229426645208e-06

Systematic O 0 9.407878678757697e-06
analysis O 0 1.0641580274750595e-06
of O 0 1.223019410190318e-07
coproporphyrinogen O 0 0.013067139312624931
oxidase O 0 0.0019690589979290962
gene O 0 0.0023661430459469557
defects O 1 0.9602792859077454
in O 0 6.072154405956098e-07
hereditary B-Disease 1 0.5313783884048462
coproporphyria I-Disease 0 0.4493183195590973
and O 0 3.1423664950125385e-06
mutation O 0 0.002868262818083167
update O 0 5.1546416216297075e-05
. O 0 1.0856767858058447e-06

Hereditary B-Disease 1 0.9953438639640808
coproporphyria I-Disease 1 0.9916171431541443
( O 0 5.7801269576884806e-05
HC B-Disease 1 0.9948541522026062
) O 0 3.006643112257734e-07
is O 0 1.1572601721354658e-07
an O 0 4.5589243313770567e-07
acute O 1 0.9850842356681824
hepatic B-Disease 1 0.99992835521698
porphyria I-Disease 1 0.9998750686645508
with O 0 0.00016805542691145092
autosomal O 1 0.9968683123588562
dominant O 0 0.08463825285434723
inheritance O 0 0.07990563660860062
caused O 0 9.56053554546088e-05
by O 0 1.0560977869999988e-07
deficient B-Disease 0 0.00014501812984235585
activity I-Disease 0 1.3223104389226137e-08
of I-Disease 0 3.1963616198282807e-09
coproporphyrinogen I-Disease 0 0.0008905873401090503
III I-Disease 0 0.008699032478034496
oxidase I-Disease 0 3.9400256355293095e-05
( O 0 8.761306702353977e-08
CPO O 0 3.900942374457372e-06
) O 0 7.289442294222681e-08
. O 0 2.5380026613675e-07

Clinical O 0 0.002241940936073661
manifestations O 0 0.00014515260409098119
of O 0 8.922746133066539e-07
the O 0 1.1436131899245083e-05
disease O 0 0.39966484904289246
are O 0 5.730133167958229e-08
characterized O 0 1.561181852594018e-05
by O 0 2.6975857281286153e-07
acute O 0 0.14961636066436768
attacks O 0 0.00040095995063893497
of O 0 3.272500543971546e-05
neurological B-Disease 1 0.9999903440475464
dysfunction I-Disease 1 0.9989008903503418
often O 0 3.861706773022888e-06
precipitated O 0 0.00038401392521336675
by O 0 2.8350743974669967e-08
drugs O 0 1.8784399458127155e-07
, O 0 5.111552958680932e-09
fasting O 0 4.093697327789414e-07
, O 0 2.781183283673272e-08
cyclical O 0 0.00012972470722161233
hormonal O 0 0.004231080878525972
changes O 0 7.733822258160217e-07
, O 0 1.3264612164221035e-07
or O 0 7.803383596183266e-06
infectious B-Disease 1 0.9797011613845825
diseases I-Disease 1 0.9052321314811707
. O 0 3.1058871172717772e-06

Skin O 1 0.9979719519615173
photosensitivity O 1 0.9979458451271057
may O 0 3.572861533029936e-05
also O 0 4.2666144395298033e-08
be O 0 6.905662708334148e-09
present O 0 7.932727186243937e-08
. O 0 3.6444416195990925e-07

The O 0 2.581010960511776e-07
seven O 0 1.0929043270380134e-07
exons O 0 9.8429723038862e-07
, O 0 6.658207762910706e-09
the O 0 2.2779842456799315e-09
exon O 0 3.6847018236585427e-06
/ O 0 9.77600961959979e-07
intron O 0 9.072260581888258e-06
boundaries O 0 7.4102630698291705e-09
and O 0 3.434535433832764e-10
part O 0 7.330118179105227e-10
of O 0 2.9046293148482505e-10
3 O 0 6.893608350821978e-09
noncoding O 0 2.862137762349448e-06
sequence O 0 1.3519180219745408e-09
of O 0 8.097525427963603e-11
the O 0 3.270025916712882e-10
CPO O 0 2.933830423046402e-08
gene O 0 5.159943139432244e-09
were O 0 2.0230296604584197e-10
systematically O 0 8.134748874510933e-09
analyzed O 0 2.9719358085600334e-09
by O 0 2.382879449314146e-10
an O 0 5.554295912091334e-10
exon O 0 5.084808435640298e-06
- O 0 1.0114622455148492e-05
by O 0 9.963727620743157e-09
- O 0 7.853028364479542e-06
exon O 0 5.488765236805193e-05
denaturing O 0 0.0010199808748438954
gradient O 0 0.00026073696790263057
gel O 0 0.002149782609194517
electrophoresis O 0 0.00016412269906140864
( O 0 1.7561859522174927e-08
DGGE O 0 1.1030399036826566e-05
) O 0 1.1800503907366533e-09
strategy O 0 5.6571316520148685e-09
followed O 0 7.040329985663618e-10
by O 0 6.980849925897203e-11
direct O 0 1.8748545771440916e-10
sequencing O 0 7.80990205839771e-09
in O 0 2.7871029928405733e-09
seven O 0 2.815878374917702e-08
unrelated O 0 9.057141141965985e-06
heterozygous O 0 0.0002489432517904788
HC B-Disease 1 0.9988969564437866
patients O 0 0.00015690842701587826
from O 0 1.324794585144673e-08
France O 0 2.791813642488705e-07
, O 0 1.0070281497576161e-08
Holland O 0 1.5954784657878918e-06
, O 0 8.111941340871454e-09
and O 0 1.4018397109794023e-08
Czech O 0 0.00012199462071293965
Republic O 0 1.3097196642775089e-05
. O 0 1.1012634786311537e-06

Seven O 0 4.825711130251875e-06
novel O 0 6.167704214021796e-06
mutations O 0 3.561241101124324e-05
and O 0 1.0494549229633776e-08
two O 0 6.662857821027046e-09
new O 0 7.173555616191152e-08
polymorphisms O 0 3.599794581532478e-05
were O 0 5.143251868844345e-08
detected O 0 1.5578785678371787e-05
. O 0 4.956771135766758e-07

Among O 0 8.769478654357954e-07
these O 0 5.331991914658829e-08
mutations O 0 4.158232968620723e-06
two O 0 1.222587453497681e-08
are O 0 4.670893893887751e-09
missense O 0 1.919440910569392e-05
( O 0 1.121109161061895e-08
G197W O 0 6.855937954242108e-06
, O 0 6.222204085304384e-09
W427R O 0 2.926445176854031e-06
) O 0 1.247565939443973e-09
, O 0 3.4916836089138314e-10
two O 0 5.597367014331667e-10
are O 0 4.2144424061696384e-10
nonsense O 0 2.0018481450279069e-07
( O 0 1.2378195135553938e-09
Q306X O 0 9.123338031713502e-07
, O 0 2.5647066692613407e-09
Q385X O 0 1.2321784197411034e-06
) O 0 9.49366030233989e-10
, O 0 2.3947760441345167e-10
two O 0 1.986384390306739e-10
are O 0 1.4227656552900925e-10
small O 0 3.1454985283119186e-09
deletions O 0 2.796764988488576e-07
( O 0 7.183301509172679e-09
662de14bp O 0 5.220409093453782e-06
; O 0 7.49239514874489e-09
1168del3bp O 0 5.907939794269623e-06
removing O 0 1.8823278935542476e-07
a O 0 3.120605285289457e-08
glycine O 0 7.223821398838481e-07
at O 0 8.097657655525836e-09
position O 0 2.265634790887816e-09
390 O 0 8.07812838843347e-09
) O 0 1.998259613333886e-10
, O 0 1.2885650879645993e-10
and O 0 8.780330629232225e-11
one O 0 2.450042668744601e-10
is O 0 3.2398289606661024e-10
a O 0 4.533225794745022e-09
splicing O 0 2.1042396838311106e-06
mutation O 0 7.802766049280763e-06
( O 0 9.675078516124813e-09
IVS1 O 0 8.347637776751071e-05
- O 0 3.2868789276108146e-05
15c O 0 6.706370913889259e-05
- O 0 4.4203228753758594e-05
- O 0 2.1838935936102644e-05
> O 0 1.5792895737831714e-06
g O 0 5.031305363445426e-07
) O 0 2.3522764291961096e-10
which O 0 7.91033835656485e-11
creates O 0 1.6479119180345947e-09
a O 0 6.391004392369837e-10
new O 0 3.572566242837638e-09
acceptor O 0 4.659151215946622e-07
splice O 0 6.733632471878082e-05
site O 0 4.7767007345100865e-06
. O 0 6.400281336027547e-07

The O 0 9.949866353053949e-07
pathological O 0 3.890969674102962e-05
significance O 0 1.734505303829792e-07
of O 0 5.465913499591579e-09
the O 0 6.584529810282902e-09
point O 0 4.33520916942598e-08
mutations O 0 1.0733025419540354e-06
G197W O 0 2.32936258726113e-06
, O 0 3.359202027652941e-09
W427R O 0 1.2101495485694613e-06
, O 0 1.216492462319252e-09
and O 0 3.3795083398402426e-10
the O 0 6.244219030726583e-10
in O 0 2.4161066480843374e-09
- O 0 1.5215917983368854e-06
frame O 0 1.1371892014722107e-06
deletion O 0 4.074625849170843e-06
390delGly O 0 4.8676292863092385e-06
were O 0 1.2461389697904224e-09
assessed O 0 3.134215775801863e-09
by O 0 1.3011333677148684e-10
their O 0 6.882801273366823e-11
respective O 0 1.12257869666621e-09
expression O 0 2.470776694352139e-09
in O 0 3.3817196265495397e-10
a O 0 2.3818766958783044e-09
prokaryotic O 0 3.4639196400121364e-08
system O 0 1.7127838702890585e-08
using O 0 4.02702360347007e-09
site O 0 1.741006769861997e-07
- O 0 7.705597454332747e-06
directed O 0 1.8001391310917825e-07
mutagenesis O 0 1.216907003254164e-05
. O 0 2.8384192773955874e-07

These O 0 1.045453132064722e-06
mutations O 0 0.00027748808497563004
resulted O 0 1.8204153775513987e-06
in O 0 1.3928579178923428e-08
the O 0 4.3644607927717516e-09
absence O 0 5.508849199031829e-08
or O 0 3.679586413340985e-09
a O 0 1.7348785519288867e-08
dramatic O 0 6.742929485881177e-07
decrease O 0 3.5648292850964935e-07
of O 0 7.651544287057277e-09
CPO O 0 5.3188805395620875e-06
activity O 0 5.57716703042388e-07
. O 0 2.851132308023807e-07

The O 0 2.5566694716872007e-07
two O 0 4.8848725953121175e-08
polymorphisms O 0 6.468309493357083e-06
were O 0 8.769460713153876e-09
localized O 0 7.88022987308068e-07
in O 0 9.700540815060776e-09
noncoding O 0 3.210878048776067e-06
part O 0 1.1740045602337545e-09
of O 0 2.1862654742133003e-10
the O 0 9.206135853645492e-10
gene O 0 1.870591681552014e-08
1 O 0 3.92981558405836e-09
) O 0 6.370023397650471e-10
a O 0 2.593633752212554e-08
C O 0 1.1527807828315417e-06
/ O 0 4.371042450657114e-06
G O 0 1.4174537682265509e-05
polymorphism O 0 4.3135912619618466e-07
in O 0 3.51366513662299e-09
the O 0 4.259278263418764e-09
promotor O 0 5.242550832917914e-05
region O 0 6.43640731823325e-08
, O 0 1.3118067743178585e-09
142 O 0 1.7399552021402087e-08
bp O 0 1.4804577119775786e-07
upstream O 0 5.124770829922909e-09
from O 0 1.0078207018926477e-10
the O 0 7.244826960572937e-11
transcriptional O 0 8.240125914937835e-09
initiation O 0 2.8179522715277017e-08
site O 0 6.150090570145039e-08
( O 0 4.512065387984876e-09
- O 0 3.0337341740960255e-06
142C O 0 9.22931303648511e-06
/ O 0 3.3501166853966424e-06
G O 0 3.801024604399572e-06
) O 0 4.0184583438573895e-10
, O 0 1.3056902781194424e-10
and O 0 1.1584953829579803e-10
2 O 0 1.8724970463068757e-09
) O 0 4.371457085206032e-10
a O 0 3.970705098055305e-09
6 O 0 4.811240827962138e-08
bp O 0 9.022105587064289e-07
deletion O 0 5.71788291381381e-07
polymorphism O 0 2.4825695277286286e-07
in O 0 5.793957535971117e-10
the O 0 2.3796503656470236e-10
3 O 0 6.670435759303928e-09
noncoding O 0 2.9352186174946837e-06
part O 0 7.623600084549764e-10
of O 0 2.411322252982018e-10
the O 0 6.859320333951757e-10
CPO O 0 1.310992558956059e-07
gene O 0 2.333999837844658e-08
, O 0 1.7575690902660313e-09
574 O 0 2.3207785204704123e-07
bp O 0 3.1229157571033284e-07
downstream O 0 5.627579735545396e-09
of O 0 1.2092694900989187e-10
the O 0 1.7081688841180664e-10
last O 0 1.3616846539221683e-09
base O 0 1.4312637741653589e-09
of O 0 8.943608353906285e-11
the O 0 4.725788649295737e-10
normal O 0 4.2633118368939904e-08
termination O 0 1.0660870657375199e-06
codon O 0 1.984732023174729e-07
( O 0 1.126609650015098e-08
+ O 0 6.162585464153381e-07
574 O 0 4.987567990610842e-06
delATTCTT O 0 4.404635546961799e-05
) O 0 1.1348940631705773e-07
. O 0 2.409481680842873e-07

Five O 0 4.591645392792998e-06
intragenic O 0 0.0006573331193067133
dimorphisms O 0 0.0005113963270559907
are O 0 1.6041269645938883e-08
now O 0 8.646818372426424e-09
well O 0 2.2320161274791417e-09
characterized O 0 1.2195113185953232e-07
and O 0 4.4116627018198074e-10
the O 0 5.741044861728994e-10
high O 0 2.5200192155239165e-08
degree O 0 7.758265141433185e-09
of O 0 1.0391406624066235e-09
allelic O 0 3.1196912459563464e-05
heterogeneity O 0 0.0002565190370660275
in O 0 5.655553536598745e-07
HC B-Disease 1 0.9689693450927734
is O 0 4.650432927633119e-08
demonstrated O 0 7.219303910233066e-08
with O 0 1.6296081151168096e-09
seven O 0 3.715107776969262e-09
new O 0 2.207843463608583e-09
different O 0 2.52526138888598e-10
mutations O 0 1.963611495625628e-08
making O 0 2.1029199215316652e-10
a O 0 3.2537686434075397e-10
total O 0 1.0578986991971462e-10
of O 0 1.873817906394848e-10
nineteen O 0 1.4898992617418116e-07
CPO O 0 5.727060488425195e-05
gene B-Disease 0 0.00045504578156396747
defects I-Disease 1 0.8908619284629822
reported O 0 2.9569871458079433e-06
so O 0 7.808799828978863e-09
far O 0 2.3230521506434343e-08
. O 0 1.902090573935311e-08
. O 0 1.839506040823835e-07

Coincidence O 0 8.4437660916592e-06
of O 0 3.1972657410506145e-08
two O 0 1.822476924928651e-08
novel O 0 1.0238277070584445e-07
arylsulfatase O 0 5.504665750777349e-06
A O 0 4.943792930589552e-08
alleles O 0 8.623599256907255e-08
and O 0 1.2810016158937287e-08
mutation O 0 4.215550234221155e-06
459 O 0 4.014887508674292e-06
+ O 0 1.6569336366956122e-05
1G O 0 0.0057335481978952885
> O 0 2.6254790554958163e-06
A O 0 2.5549431015292612e-08
within O 0 2.968026935334933e-09
a O 0 1.3007153576438668e-08
family O 0 1.533911984097358e-07
with O 0 6.441283062486036e-07
metachromatic B-Disease 1 0.9990979433059692
leukodystrophy I-Disease 1 0.9998127818107605
: O 0 5.0793282468930556e-08
molecular O 0 2.806693828460993e-07
basis O 0 3.915682000865672e-09
of O 0 7.174715488389438e-09
phenotypic O 0 3.096382351941429e-05
heterogeneity O 0 0.0010604028357192874
. O 0 2.2076480945543153e-06

In O 0 4.93426853154233e-07
a O 0 2.3344369992628344e-07
family O 0 8.711449339671162e-08
with O 0 7.838645288416046e-09
three O 0 1.5998796953908823e-08
siblings O 0 1.3477474567480385e-06
, O 0 2.9965592229785898e-09
one O 0 9.166205017230311e-10
developed O 0 5.159454019576515e-08
classical O 0 7.524348006882065e-07
late O 0 1.866500315372832e-05
infantile O 1 0.9957315325737
metachromatic B-Disease 1 0.9999469518661499
leukodystrophy I-Disease 1 0.9999774694442749
( O 0 3.260265293647535e-05
MLD B-Disease 1 0.999512791633606
) O 0 1.9032832199172844e-07
, O 0 7.504311838602007e-08
fatal O 0 0.00041719083674252033
at O 0 9.325292893436199e-08
age O 0 1.7291971232680226e-07
5 O 0 4.3440159913643583e-08
years O 0 1.4441638995776884e-08
, O 0 2.4177062574182173e-09
with O 0 6.2858575233804e-08
deficient O 0 0.017412982881069183
arylsulfatase O 0 0.0009537370642647147
A O 0 1.4966067283239681e-06
( O 0 2.743114535519453e-08
ARSA O 0 0.0007603883277624846
) O 0 1.3730085957064375e-09
activity O 0 1.4484307087059278e-09
and O 0 5.588918217114269e-10
increased O 0 1.0923103843651916e-07
galactosylsulfatide O 0 0.0047730132937431335
( O 0 1.0508248351470684e-06
GS O 1 0.993614912033081
) O 0 1.0224031399275191e-07
excretion O 0 7.959407412272412e-06
. O 0 4.213128477204009e-07

The O 0 4.278096241705498e-07
two O 0 6.214295922291058e-08
other O 0 6.5010312688684735e-09
siblings O 0 3.858555373881245e-06
, O 0 4.84515787491091e-08
apparently O 0 7.03824127867847e-07
healthy O 0 6.95739799994044e-07
at O 0 1.6055043516871592e-08
12 O 0 9.238154241586471e-09
( O 0 1.283549377895099e-09
1 O 0 6.486601922262025e-09
/ O 0 1.5014758503184567e-07
2 O 0 2.8533548857012647e-09
) O 0 1.8447775251839715e-10
and O 0 2.110852465042612e-10
15 O 0 2.5753439381048793e-09
years O 0 2.2933823728976677e-09
, O 0 3.475378318462674e-10
respectively O 0 3.868630749082058e-09
, O 0 2.6521054796724286e-10
and O 0 1.6437924632572987e-10
their O 0 1.0191196775366507e-09
father O 0 9.196035222203136e-08
, O 0 8.13878386907163e-09
apparently O 0 2.0813902779082127e-07
healthy O 0 1.1805737187842169e-07
as O 0 2.648253838444248e-10
well O 0 9.560933156294027e-10
, O 0 2.03246752761288e-09
presented O 0 1.3961312106403057e-07
ARSA O 0 0.06754244118928909
and O 0 1.1142707734279611e-07
GS O 0 0.3627680540084839
values O 0 4.861818059254119e-09
within O 0 1.135438632005048e-09
the O 0 1.1646928976816184e-09
range O 0 3.4868019582745546e-08
of O 0 1.702597813846296e-07
MLD B-Disease 1 0.9995238780975342
patients O 0 0.006540665403008461
. O 0 1.5997583204807597e-06

Mutation O 0 0.002216304186731577
screening O 0 1.9909964976250194e-05
and O 0 2.8577026967013808e-08
sequence O 0 1.6701777383332228e-07
analysis O 0 6.391827156448926e-08
disclosed O 0 2.0452323212794e-07
the O 0 8.39947111863637e-10
involvement O 0 1.5216041759913423e-08
of O 0 3.6071692854910964e-10
three O 0 3.879663257322363e-09
different O 0 6.9705583527479575e-09
ARSA O 1 0.5058955550193787
mutations O 0 5.901024906052044e-06
being O 0 1.182226538887221e-09
the O 0 3.073211962689726e-10
molecular O 0 1.1162912372242317e-08
basis O 0 6.882542313846329e-10
of O 0 2.1799204663608407e-09
intrafamilial O 0 4.862231435254216e-05
phenotypic O 0 0.00016343695460818708
heterogeneity O 0 0.002464474178850651
. O 0 1.5483092283830047e-06

The O 0 6.950500392122194e-06
late O 0 0.0002983348094858229
infantile O 1 0.998894989490509
patient O 1 0.6342189311981201
inherited O 0 0.025716861709952354
from O 0 4.166713196696037e-08
his O 0 3.1840112768577455e-08
mother O 0 4.9089567255578e-07
the O 0 2.478404148575919e-09
frequent O 0 1.1234557462103112e-07
0 O 0 2.5421255145374744e-07
- O 0 2.4718898202991113e-05
type O 0 1.6218402834056178e-06
mutation O 0 2.1241073682176648e-06
459 O 0 5.218703904574795e-07
+ O 0 1.8255319673698978e-06
1G O 0 0.0005759939667768776
> O 0 1.5892098872427596e-06
A O 0 2.1981088949019068e-08
, O 0 4.2433992430979117e-10
and O 0 1.5779189066478239e-10
from O 0 3.3102193208733866e-10
his O 0 2.6252966467410488e-09
father O 0 2.948955746262527e-08
a O 0 9.947833667922623e-09
novel O 0 5.8615423625951735e-09
, O 0 3.9889286318484096e-10
single O 0 3.1256728316719773e-09
basepair O 0 2.616106485220371e-06
microdeletion O 0 9.861763601293205e-07
of O 0 5.271032499365447e-10
guanine O 0 1.2303661378609831e-07
at O 0 4.336588421693932e-09
nucleotide O 0 3.560343841968461e-08
7 O 0 1.2302224128291073e-08
in O 0 5.2415805029681906e-09
exon O 0 1.3115370165905915e-05
1 O 0 2.542663821714086e-07
( O 0 8.108882099122638e-08
7delG O 0 0.00012276294000912458
) O 0 1.579714421495737e-07
. O 0 3.188782500274101e-07

The O 0 8.18563762550184e-07
two O 0 5.210598033045244e-07
clinically O 0 0.00015957423602230847
unaffected O 0 4.512650048127398e-05
siblings O 0 5.928302925894968e-06
carried O 0 1.892255880875382e-07
the O 0 1.2886991029859018e-08
maternal O 0 3.694352199090645e-05
mutation O 0 3.1069543183548376e-05
459 O 0 3.284623971921974e-06
+ O 0 7.458167146978667e-06
1G O 0 0.010324088856577873
> O 0 5.907815648242831e-06
A O 0 4.014027155108124e-08
and O 0 1.2665308801729225e-09
, O 0 2.720223213348305e-10
on O 0 1.6850060235995556e-10
their O 0 1.906283464414571e-10
paternal O 0 1.3044076752066758e-07
allele O 0 3.1610657202918446e-08
, O 0 9.401222023086575e-10
a O 0 2.123209608129173e-09
novel O 0 3.595535202904898e-09
cytosine O 0 2.3476710353520502e-08
to O 0 1.5409548637101977e-10
thymidine O 0 1.2513646652223542e-07
transition O 0 3.6268552605633886e-08
at O 0 7.634459286975925e-09
nucleotide O 0 1.3346050309337443e-07
2435 O 0 1.899142807815224e-05
in O 0 5.542847514306004e-09
exon O 0 1.7780556618163246e-06
8 O 0 3.617915211862055e-08
, O 0 9.815331880602685e-10
resulting O 0 3.461157360717948e-09
in O 0 1.6467957553167878e-10
substitution O 0 5.545678916085706e-10
of O 0 6.674276131768409e-10
alanine O 0 1.5423522654600674e-06
464 O 0 1.045195858750958e-06
by O 0 3.160703698767975e-08
valine O 0 0.00015291014278773218
( O 0 1.5888507221006876e-07
A464V O 0 5.384384348872118e-05
) O 0 1.1036232194783224e-07
. O 0 2.314132814262848e-07

The O 0 1.1511746151882107e-06
fathers O 0 8.419273399340454e-06
genotype O 0 7.427415403071791e-05
thus O 0 6.21836250047636e-07
was O 0 6.68675568249455e-07
7delG O 0 0.0006824176525697112
/ O 0 0.0001157783844973892
A464V O 0 0.0002191507664974779
. O 0 9.252402719539532e-07

Mutation O 0 0.041175756603479385
A464V O 0 0.001285845530219376
was O 0 8.401270861213561e-07
not O 0 6.68064759068443e-09
found O 0 9.998127659116562e-09
in O 0 1.6869693197918423e-08
18 O 0 1.3677995411853772e-06
unrelated O 0 0.0009832826908677816
MLD B-Disease 1 0.9999216794967651
patients O 0 0.0003581386408768594
and O 0 1.528728432731441e-08
50 O 0 1.4020153571436822e-07
controls O 0 4.505670403887052e-06
. O 0 6.612768288505322e-07

A464V O 0 0.003532499074935913
, O 0 1.022545006890141e-06
although O 0 1.6863492646734812e-07
clearly O 0 1.816525809772429e-07
modifying O 0 7.582605121569941e-06
ARSA O 1 0.5061133503913879
and O 0 2.597540515125729e-06
GS O 1 0.9977127313613892
levels O 0 3.7983356833137805e-06
, O 0 8.818740404592518e-09
apparently O 0 9.063830930244876e-08
bears O 0 1.2690783535163064e-07
little O 0 6.844764310898199e-09
significance O 0 6.634514715386786e-09
for O 0 3.833593886781728e-09
clinical O 0 3.0426638204517076e-06
manifestation O 0 1.8204777916253079e-06
of O 0 6.285017661866732e-08
MLD B-Disease 1 0.9868882298469543
, O 0 3.571491546949801e-08
mimicking O 0 6.700814992655069e-06
the O 0 7.173363769652497e-08
frequent O 0 1.304061424889369e-05
ARSA O 1 0.6337023377418518
pseudodeficiency O 0 0.01346595585346222
allele O 0 4.626259033102542e-05
. O 0 2.8740632842527702e-06

Our O 0 2.3843106191634433e-06
results O 0 2.5774320420168806e-06
demonstrate O 0 2.1917395542914164e-07
that O 0 2.147819477826829e-09
in O 0 2.2166917190702407e-09
certain O 0 1.2557551443137527e-08
genetic O 0 3.764287248486653e-05
conditions O 0 9.297049837186933e-05
MLD B-Disease 1 0.9992662072181702
- O 0 0.002956451615318656
like O 0 6.649770512012765e-07
ARSA O 0 0.11473014205694199
and O 0 1.0156412599826581e-07
GS O 1 0.6418656706809998
values O 0 2.4685547828084964e-08
need O 0 1.564129825659677e-09
not O 0 1.3851285396437873e-10
be O 0 2.176172297918555e-10
paralleled O 0 1.5716435086687852e-07
by O 0 6.80949128195607e-08
clinical O 0 0.00354558858089149
disease O 0 0.0017736946465447545
, O 0 3.4726235220716717e-09
a O 0 1.5945484932444742e-08
finding O 0 6.007211794667455e-08
with O 0 7.205231611351337e-08
serious O 0 2.9686470952583477e-05
diagnostic O 0 0.0005669357487931848
and O 0 7.098504966052133e-07
prognostic O 0 0.15680241584777832
implications O 0 0.0005851249443367124
. O 0 2.5299075332441134e-06

Moreover O 0 3.574790389393456e-05
, O 0 1.723724238900104e-07
further O 0 7.205932206488797e-08
ARSA O 0 0.016730310395359993
alleles O 0 3.6756537156179547e-06
functionally O 0 1.3828691407979932e-05
similar O 0 6.942670438547793e-08
to O 0 2.6897180038787383e-09
A464V O 0 1.1615469702519476e-05
might O 0 8.769293735610972e-09
exist O 0 7.622407705021317e-10
which O 0 1.0399967692586998e-10
, O 0 5.4079192512990204e-11
together O 0 1.2456964626483824e-10
with O 0 1.991408149493168e-09
0 O 0 1.6601144352534902e-06
- O 0 0.003410455770790577
type O 0 7.036658644210547e-05
mutations O 0 0.00012183999206172302
, O 0 4.045579160560919e-08
may O 0 1.4062791819924314e-07
cause O 0 8.648543143863208e-07
pathological O 0 0.0003665923431981355
ARSA O 1 0.965589165687561
and O 0 1.7912493603944313e-06
GS O 1 0.9992316961288452
levels O 0 2.012910726989503e-06
, O 0 4.1204772927017075e-09
but O 0 1.075436295572274e-09
not O 0 8.043775645560913e-10
clinical O 0 2.9196071409387514e-06
outbreak O 0 1.1943470781261567e-05
of O 0 9.891149232998941e-09
the O 0 1.403690589540929e-06
disease O 0 0.01569432206451893
. O 0 3.5667802933403436e-08
. O 0 2.1397657690158667e-07

Human O 0 0.023644287139177322
MLH1 O 1 0.9990772008895874
deficiency O 1 0.9997848868370056
predisposes O 0 0.36097171902656555
to O 0 2.247108750452753e-05
hematological B-Disease 1 0.9996894598007202
malignancy I-Disease 1 0.9998946189880371
and O 0 0.00022278459800872952
neurofibromatosis B-Disease 1 0.9998975992202759
type I-Disease 0 0.00401352858170867
1 I-Disease 0 9.336475159216207e-06
. O 0 2.3459308522433275e-06

Heterozygous O 0 0.0018100955057889223
germ O 0 0.29491493105888367
- O 0 0.001208352274261415
line O 0 7.053305580484448e-06
mutations O 0 4.373352567199618e-06
in O 0 4.0832293102255335e-09
the O 0 4.202564074518023e-09
DNA O 0 3.4682479963521473e-06
mismatch O 0 0.0005998396663926542
repair O 0 0.0005411072634160519
genes O 0 2.659809013039194e-07
lead O 0 5.307057904246903e-07
to O 0 2.548137842950382e-07
hereditary B-Disease 1 0.9997386336326599
nonpolyposis I-Disease 1 0.9999831914901733
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999994158744812
. O 0 9.255007171304896e-05

The O 0 8.998592238640413e-05
disease O 1 0.7344893217086792
susceptibility O 0 0.0006657653721049428
of O 0 3.509567747528308e-08
individuals O 0 4.948982024188808e-08
who O 0 4.101801209799305e-08
constitutionally O 0 1.3150499853509245e-06
lack O 0 1.7856706335805939e-07
both O 0 1.38904541202578e-08
wild O 0 3.153008265144308e-06
- O 0 0.000832406512927264
type O 0 6.42250324744964e-06
alleles O 0 1.6178795476662344e-06
is O 0 4.0956095403998916e-08
unknown O 0 4.014552530406945e-07
. O 0 2.122935853776653e-07

We O 0 3.692542520639108e-07
have O 0 1.770905377895815e-08
identified O 0 4.5388951264158095e-08
three O 0 7.645766686437128e-09
offspring O 0 2.0813070022995817e-07
in O 0 1.9068309597969346e-08
a O 0 8.191399501811247e-06
hereditary B-Disease 1 0.9997814297676086
nonpolyposis I-Disease 1 0.9999938011169434
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
family O 0 0.0016059100162237883
who O 0 5.324752692104084e-06
developed O 0 4.0459155570715666e-05
hematological B-Disease 1 0.9973129630088806
malignancy I-Disease 1 0.9850715398788452
at O 0 2.509075045509235e-07
a O 0 3.491167532843065e-08
very O 0 2.925625741667659e-09
early O 0 1.328230414543441e-08
age O 0 1.4786029289837188e-08
, O 0 2.9021315905986e-10
and O 0 1.939855498456211e-10
at O 0 8.024345632406948e-10
least O 0 1.2458580000984654e-10
two O 0 2.949401139984431e-11
of O 0 5.7006361436906516e-11
them O 0 1.1737173732928596e-10
displayed O 0 5.292546845225843e-08
signs O 0 5.186112730370951e-07
of O 0 6.258151330484907e-08
neurofibromatosis B-Disease 1 0.9998366832733154
type I-Disease 0 0.000278158753644675
1 I-Disease 0 3.821473455900559e-06
( O 0 9.607755373508553e-07
NF1 B-Disease 0 0.05383981764316559
) O 0 5.639100209009484e-07
. O 0 6.912082426424604e-07

DNA O 0 2.273808786412701e-05
sequence O 0 6.659378755102807e-07
analysis O 0 8.108711568866056e-08
and O 0 4.6263490816045305e-09
allele O 0 1.0480570722393168e-07
- O 0 7.36667800538271e-07
specific O 0 1.3464316328537507e-09
amplification O 0 1.246672667321036e-07
in O 0 1.4783005930496529e-09
two O 0 1.1745443506683273e-09
siblings O 0 5.116003194416407e-07
revealed O 0 4.828984287996718e-07
a O 0 3.3592749559829826e-07
homozygous O 0 0.00022021376935299486
MLH1 O 1 0.6269752383232117
mutation O 0 0.00010820307943504304
( O 0 7.167400895013998e-08
C676T O 0 8.708370296517387e-05
- O 0 0.001610860344953835
- O 0 0.0002385669358773157
> O 0 3.870570071740076e-05
Arg226Stop O 0 0.0001152555996668525
) O 0 1.5064814817833394e-07
. O 0 2.8041895916430803e-07

Thus O 0 2.886765287257731e-06
, O 0 9.105799136932546e-08
a O 0 1.8749250330074574e-07
homozygous O 0 2.209610647696536e-05
germ O 0 0.0013111132429912686
- O 0 5.159697320777923e-05
line O 0 1.7246562720174552e-06
MLH1 O 0 0.02292936109006405
mutation O 0 7.806284702382982e-05
and O 0 1.8916712463123986e-07
consequent O 0 0.39254748821258545
mismatch O 1 0.999923825263977
repair O 1 0.9999830722808838
deficiency O 1 0.9999761581420898
results O 0 3.612466753111221e-05
in O 0 1.0857777255068868e-07
a O 0 3.407705207791878e-06
mutator O 1 0.9622087478637695
phenotype O 0 0.07692087441682816
characterized O 0 0.00015698984498158097
by O 0 9.991665592679055e-07
leukemia B-Disease 1 0.9996709823608398
and O 0 4.78488482258399e-06
/ O 0 0.4498736262321472
or O 0 0.017524385824799538
lymphoma B-Disease 1 0.9999995231628418
associated O 0 0.0003438119310885668
with O 0 4.7764970076968893e-05
neurofibromatosis B-Disease 1 0.9999773502349854
type I-Disease 0 0.00045988333295099437
1 I-Disease 0 7.179796739364974e-07
. O 0 4.517544383020322e-08
. O 0 2.883700744860107e-07

Missense O 1 0.8558430075645447
mutations O 0 0.019731152802705765
in O 0 1.2956250827755866e-07
the O 0 3.5549474475260467e-09
most O 0 4.382117724244239e-10
ancient O 0 1.0001288686112275e-09
residues O 0 2.492940298637336e-09
of O 0 3.2280600414935634e-10
the O 0 2.366281393051395e-09
PAX6 O 0 6.660413055215031e-05
paired O 0 1.681218861904199e-07
domain O 0 2.0965542191220266e-08
underlie O 0 2.703359882616496e-07
a O 0 3.570081474890685e-08
spectrum O 0 1.053156438501901e-06
of O 0 5.714906023968069e-07
human O 0 0.00975845381617546
congenital B-Disease 1 0.9999902248382568
eye I-Disease 1 0.9998294115066528
malformations I-Disease 1 0.9999042749404907
. O 0 4.6046530769672245e-05

Mutations O 0 0.0009427349432371557
of O 0 2.2135500898912142e-07
the O 0 1.0642185088727274e-07
human O 0 2.2006022390996804e-06
PAX6 O 1 0.8658901453018188
gene O 0 0.005148336756974459
underlie O 1 0.9195725917816162
aniridia B-Disease 1 0.9999784231185913
( O 0 0.0004445406957529485
congenital B-Disease 1 0.9999562501907349
absence I-Disease 0 7.834365533199161e-06
of I-Disease 0 1.684230177545487e-08
the I-Disease 0 1.2973858076748002e-07
iris I-Disease 0 0.08189653605222702
) O 0 2.5823002403058126e-08
, O 0 8.826885000701168e-09
a O 0 2.655115451943857e-07
rare O 0 5.243020495981909e-06
dominant O 0 0.0008321626228280365
malformation B-Disease 1 0.9995237588882446
of I-Disease 0 1.3218632943789999e-07
the I-Disease 0 8.69025427618908e-07
eye I-Disease 0 0.010357603430747986
. O 0 1.225648134095536e-06

The O 0 1.8962627734708803e-07
spectrum O 0 2.0181080344627844e-06
of O 0 9.864024974604035e-08
PAX6 O 0 0.21681812405586243
mutations O 0 0.025034043937921524
in O 0 9.56363419390982e-06
aniridia B-Disease 1 0.9999066591262817
patients O 0 0.0042039924301207066
is O 0 1.06419779655198e-08
highly O 0 9.837303416304621e-09
biased O 0 8.51795967093949e-09
, O 0 2.8297447718372837e-10
with O 0 2.4392995956468155e-10
92 O 0 1.252860393208266e-08
% O 0 3.4760413991641315e-10
of O 0 1.2242686031616046e-10
all O 0 5.381128875825425e-10
reported O 0 6.686564688607177e-07
mutations O 0 8.247014875450986e-07
leading O 0 2.7710381544920892e-08
to O 0 3.858842412274299e-10
premature O 0 3.1470850103687553e-07
truncation O 0 1.2340123589638097e-07
of O 0 4.5513914859185434e-10
the O 0 1.0809724226845674e-09
protein O 0 3.3526109888271094e-08
( O 0 1.1781476905170507e-09
nonsense O 0 2.4524950958948466e-08
, O 0 1.1518039993996254e-10
splicing O 0 6.27834229049995e-09
, O 0 2.928136622060151e-10
insertions O 0 3.588884212035737e-08
and O 0 7.850805561204766e-10
deletions O 0 5.315319029364218e-08
) O 0 3.0863994693319796e-10
and O 0 1.2076144251249588e-10
just O 0 2.7392846324580944e-10
2 O 0 1.1696885682255243e-09
% O 0 3.964572836689939e-10
leading O 0 8.096726622497386e-10
to O 0 1.7333509627626142e-11
substitution O 0 2.520026409769116e-10
of O 0 5.265653885144772e-11
one O 0 4.461163660707257e-10
amino O 0 4.3349257516922535e-09
acid O 0 9.156096325568797e-08
by O 0 5.159113691810546e-10
another O 0 1.571633845287579e-08
( O 0 6.358570203701674e-08
missense O 0 0.00012759228411596268
) O 0 7.028462079006204e-08
. O 0 1.6853765316682257e-07

The O 0 3.478924384126003e-07
extraordinary O 0 6.273992880778678e-07
conservation O 0 1.2778004077063088e-07
of O 0 1.1393826993000289e-09
the O 0 1.6304009253786944e-09
PAX6 O 0 1.8666354662855156e-05
protein O 0 5.6265090364604475e-08
at O 0 2.180843727828119e-09
the O 0 5.44985834238787e-10
amino O 0 3.4985250252361766e-09
acid O 0 2.5273793724522875e-08
level O 0 3.0688378505061564e-09
amongst O 0 2.5648436707825795e-09
vertebrates O 0 2.2755325801426807e-07
predicts O 0 1.6492324448336149e-06
that O 0 3.749169419364762e-09
pathological O 0 0.00018881149298977107
missense O 0 0.11242660135030746
mutations O 0 0.0001170286486740224
should O 0 3.6815872572759645e-09
in O 0 1.7185324274748837e-09
fact O 0 2.099186158233124e-09
be O 0 3.834417783288302e-10
common O 0 4.0888950003648006e-09
even O 0 2.192179104909542e-09
though O 0 1.175804009712067e-09
they O 0 1.165977037143051e-10
are O 0 9.394655886563186e-11
hardly O 0 9.98753080239112e-09
ever O 0 6.385110218332102e-09
seen O 0 1.0971462671705012e-07
in O 0 3.9995913425627805e-07
aniridia B-Disease 1 0.9984416365623474
patients O 0 0.002469877479597926
. O 0 1.302485088672256e-06

This O 0 6.012966764501471e-07
indicates O 0 3.59937985194847e-07
that O 0 9.63171209455993e-10
there O 0 4.0802455858468534e-10
is O 0 4.418483634527348e-10
a O 0 7.370807963980042e-09
heavy O 0 2.8083375127607724e-06
ascertainment O 0 0.0004616007790900767
bias O 0 6.670208563264168e-07
in O 0 1.0758096635754555e-09
the O 0 2.46034498330161e-10
selection O 0 1.4178306306789068e-09
of O 0 5.8769913380274375e-09
patients O 0 1.7051064560291707e-06
for O 0 1.0536989947240727e-08
PAX6 O 0 0.057709984481334686
mutation O 0 1.139235155278584e-05
analysis O 0 7.512371169582366e-09
and O 0 4.087006011399552e-10
that O 0 1.6278768610877847e-10
the O 0 1.5749699322498145e-09
missing O 0 7.508728003813303e-07
PAX6 O 0 0.05571737512946129
missense O 0 0.08321516960859299
mutations O 0 0.00036858697421848774
frequently O 0 2.033240775745071e-07
may O 0 1.552770498847167e-07
underlie O 0 1.824437640607357e-05
phenotypes O 0 5.721895649912767e-05
distinct O 0 2.4436519652226707e-07
from O 0 1.1872407412738539e-07
textbook O 0 0.00015661933866795152
aniridia B-Disease 1 0.975288450717926
. O 0 3.6225389976607403e-06

Here O 0 8.882435054147209e-07
we O 0 1.8989766203958425e-08
present O 0 8.89967921580137e-09
four O 0 2.1383984361023067e-08
novel O 0 4.973462068846857e-07
PAX6 O 0 0.0980185940861702
missense O 0 0.05870310217142105
mutations O 0 0.00018919211288448423
, O 0 6.139399655324951e-09
two O 0 2.212307448345996e-09
in O 0 8.98752983147233e-09
association O 0 9.050684468547843e-08
with O 0 1.1754777062833455e-07
atypical O 0 0.010904142633080482
phenotypes O 0 0.13288667798042297
ectopia B-Disease 0 0.1980661302804947
pupillae I-Disease 0 0.01590115949511528
( O 0 5.158745608468962e-08
displaced B-Disease 0 2.07667156360003e-07
pupils I-Disease 0 7.938892849779222e-07
) O 0 2.520164059660601e-07
and O 0 2.6158918444707524e-06
congenital B-Disease 1 0.9999456405639648
nystagmus I-Disease 0 0.3990964889526367
( O 0 3.566399797705344e-08
searching B-Disease 0 1.3552005384553922e-07
gaze I-Disease 0 3.687194066515076e-06
) O 0 2.900340412281821e-09
, O 0 4.869388225969828e-10
and O 0 2.2955694289894524e-10
two O 0 4.698932354330054e-10
in O 0 2.6394906260662765e-09
association O 0 7.799631163152299e-09
with O 0 1.260183846163443e-09
more O 0 6.01704863711916e-09
recognizable O 0 6.371735798893496e-05
aniridia B-Disease 1 0.9949113726615906
phenotypes O 0 0.013631775043904781
. O 0 1.4068064047023654e-06

Strikingly O 0 0.00041285669431090355
, O 0 1.42529088975607e-07
all O 0 5.114107803905199e-09
four O 0 2.8074587987703126e-08
mutations O 0 1.067342395799642e-06
are O 0 4.973029765764636e-10
located O 0 4.526166996754455e-09
within O 0 1.608145505649361e-09
the O 0 2.533579790409135e-09
PAX6 O 0 2.4609831598354504e-05
paired O 0 9.505482978511282e-08
domain O 0 7.411323110773083e-09
and O 0 8.053938627128332e-10
affect O 0 2.332815052241699e-09
amino O 0 2.7511457556528285e-09
acids O 0 1.5999643832032007e-09
which O 0 7.091512793655497e-11
are O 0 1.930004420169773e-11
highly O 0 2.983310265491923e-10
conserved O 0 1.0383858217721809e-09
in O 0 9.931216266023668e-11
all O 0 6.337855934512859e-11
known O 0 1.4158632044569686e-09
paired O 0 5.009687953361208e-08
domain O 0 4.672117270843046e-08
proteins O 0 1.3109011831602402e-07
. O 0 1.8829186387847585e-07

Our O 0 2.3867587515269406e-06
results O 0 7.32148237148067e-07
support O 0 2.1114264114885373e-08
the O 0 4.894420424506052e-09
hypothesis O 0 2.8534435259075508e-08
that O 0 8.956273916949087e-11
the O 0 1.1098001684306524e-10
under O 0 9.462458594455825e-10
- O 0 2.7912911093608272e-08
representation O 0 1.9468806566891317e-09
of O 0 1.3307636770321096e-08
missense O 0 0.027287909761071205
mutations O 0 0.00012471376976463944
is O 0 9.783301280208434e-09
caused O 0 9.562400293816609e-08
by O 0 4.489685068165272e-09
ascertainment O 0 0.0003730817697942257
bias O 0 4.652527422877029e-06
and O 0 9.352293162123715e-09
suggest O 0 9.321288629848823e-09
that O 0 3.1760258312196754e-10
a O 0 5.3727631232902695e-09
substantial O 0 7.724631956307348e-08
burden O 0 4.357162197266007e-06
of O 0 8.597978506941217e-08
PAX6 B-Disease 1 0.9932278990745544
- I-Disease 1 0.9158164858818054
related I-Disease 0 0.0003449385112617165
disease I-Disease 0 0.293425589799881
remains O 0 2.6306193490199803e-07
to O 0 8.109554694435417e-10
be O 0 2.5288098282061355e-09
uncovered O 0 3.351612349433708e-06
. O 0 1.7535686680503204e-08
. O 0 1.2661310222483735e-07

The O 0 5.2587068921639e-07
chromosomal O 0 0.00010038034088211134
order O 0 3.4938988591193265e-08
of O 0 3.0430167274886344e-09
genes O 0 1.52443874412711e-07
controlling O 0 2.5120252757915296e-06
the O 0 1.1485780326836448e-08
major O 0 2.2473237493159104e-07
histocompatibility O 0 0.2316756546497345
complex O 0 5.630917257803958e-06
, O 0 2.1245231351940674e-08
properdin O 0 4.6248562284745276e-05
factor O 0 1.7557565001879993e-07
B O 0 1.4832942270004423e-06
, O 0 1.1494371676690207e-08
and O 0 5.841867789513344e-08
deficiency B-Disease 0 0.0019087808905169368
of I-Disease 0 3.730841746651947e-10
the I-Disease 0 3.297748185637772e-10
second I-Disease 0 3.2983409337106195e-09
component I-Disease 0 2.0113775534014167e-08
of I-Disease 0 2.413154565061859e-09
complement I-Disease 0 7.764868996673613e-07
. O 0 3.5833917877425847e-07

The O 0 1.560865143801493e-07
relationship O 0 1.5946707776492985e-07
of O 0 3.7638936412065505e-09
the O 0 1.1732568250266695e-09
genes O 0 1.39646774144353e-08
coding O 0 3.1066258543432923e-07
for O 0 2.0932926503292038e-09
HLA O 0 3.770132252611802e-06
to O 0 1.0663952360046025e-10
those O 0 1.2433511165088618e-10
coding O 0 3.016948113554463e-08
for O 0 1.1246724662683505e-09
properdin O 0 1.5376996088889427e-05
Factor O 0 8.542254192889231e-08
B O 0 8.215128559641016e-07
allotypes O 0 2.207765464845579e-05
and O 0 7.953190994669512e-09
for O 0 1.683973138710826e-08
deficiency B-Disease 0 0.00028662336990237236
of I-Disease 0 1.1442975733633176e-10
the I-Disease 0 1.8168802573548248e-10
second I-Disease 0 9.373325449146819e-10
component I-Disease 0 4.8151216347491754e-09
of I-Disease 0 4.841734235760953e-10
complement I-Disease 0 3.6673196035508226e-08
( O 0 9.252402399795301e-09
C2 O 0 3.244116669520736e-05
) O 0 6.39107711197795e-10
was O 0 1.0606631128950994e-09
studied O 0 2.1725488075219346e-09
in O 0 7.667654289278403e-10
families O 0 3.534839310148641e-09
of O 0 1.6220393916910325e-08
patients O 0 0.0002046163281193003
with O 0 2.638779733388219e-05
connective O 1 0.999843955039978
tissue O 1 0.9994663596153259
disorders O 1 0.9997431635856628
. O 0 1.3364992810238618e-05

Patients O 0 0.0017547747120261192
were O 0 6.094018800695267e-08
selected O 0 1.2603840637837038e-08
because O 0 1.67719615973283e-09
they O 0 1.577542679820354e-10
were O 0 3.8236311339368e-10
heterozygous O 0 1.8791334355228173e-07
or O 0 6.299588051206229e-08
homozygous O 0 0.00028540007770061493
for O 0 5.469192183227278e-05
C2 B-Disease 1 0.9999758005142212
deficiency I-Disease 1 0.9999301433563232
. O 0 6.25878737992025e-06

12 O 0 1.347527586403885e-06
families O 0 1.1741220617977888e-07
with O 0 1.418794326468742e-08
15 O 0 5.744161413190341e-08
matings O 0 1.813206654333044e-05
informative O 0 5.621291620627744e-06
for O 0 9.894947288557887e-05
C2 B-Disease 1 0.9999890327453613
deficiency I-Disease 1 0.9999743700027466
were O 0 2.568149852777424e-07
found O 0 7.574753340122697e-07
. O 0 6.853675813545124e-07

Of O 0 1.1654282872086696e-07
57 O 0 5.218002456786053e-07
informative O 0 2.373302834257629e-07
meioses O 0 1.3067927284282632e-05
, O 0 1.4042395024560506e-09
two O 0 3.916546253979192e-10
crossovers O 0 2.6054742363612604e-08
were O 0 7.920730737964732e-10
noted O 0 3.0149853724736886e-09
between O 0 1.2514751013270597e-08
the O 0 9.43468876357656e-06
C2 B-Disease 1 0.9999908208847046
deficiency I-Disease 1 0.9999544620513916
gene O 0 1.5294976947188843e-06
and O 0 2.1566821661878066e-09
the O 0 1.3063218951003819e-08
HLA O 0 0.0013889041729271412
- O 0 6.170482811285183e-05
B O 0 2.200001034680099e-07
gene O 0 1.0119475923886512e-08
, O 0 1.5385438756343461e-10
with O 0 8.446216642754578e-11
a O 0 1.2942382721092827e-09
recombinant O 0 1.9281126029113693e-08
fraction O 0 7.419937109176544e-09
of O 0 2.634616969032777e-09
0 O 0 3.971305773120548e-07
. O 0 1.9055117661537224e-07

035 O 1 0.7419153451919556
. O 0 0.00041936355410143733

A O 0 5.142107511346694e-06
lod O 0 0.00013228622265160084
score O 0 4.30664428563432e-08
of O 0 4.20929469058251e-09
13 O 0 1.8463072848362572e-08
was O 0 2.7279922765188758e-09
calculated O 0 4.9883084329849225e-09
for O 0 1.0471590261573738e-09
linkage O 0 9.407663128513377e-06
between O 0 6.791024497942999e-05
C2 B-Disease 1 0.9999916553497314
deficiency I-Disease 1 0.9999657869338989
and O 0 3.0031583264644723e-07
HLA O 0 0.07944849878549576
- O 0 0.00010539036884438246
B O 0 1.30673470266629e-07
at O 0 1.2481062849900582e-09
a O 0 1.0947872608468856e-09
maximum O 0 4.612920712077084e-09
likelihood O 0 3.5760565619824547e-09
value O 0 5.740669398179854e-11
of O 0 4.067825937204006e-11
the O 0 2.0356945296118312e-10
recombinant O 0 2.616360106344473e-08
fraction O 0 1.1051098702807849e-08
of O 0 4.9722643780114595e-09
0 O 0 4.096356747140817e-07
. O 0 2.317956102615426e-07

04 O 0 0.027911731973290443
. O 0 0.00018445518799126148

18 O 0 3.78997378902568e-06
families O 0 1.6518990264557942e-07
with O 0 1.4659748082124224e-08
21 O 0 1.3846967128472443e-08
informative O 0 6.598333879281881e-09
matings O 0 2.424071112727688e-07
for O 0 8.242683757764269e-10
both O 0 8.324668732129226e-10
properdin O 0 5.704353952751262e-06
Factor O 0 2.6934465324757184e-08
B O 0 3.197937132881634e-07
allotype O 0 2.6603784135659225e-05
and O 0 8.938742723785253e-08
HLA O 0 0.04765627533197403
- O 0 0.0007129227742552757
B O 0 1.8337135543333716e-06
were O 0 8.262600381669927e-09
found O 0 9.679142465301993e-08
. O 0 2.0498366382071254e-07

Of O 0 2.1840591557520384e-07
72 O 0 8.920074492380081e-07
informative O 0 1.7522836515126983e-07
meioses O 0 5.299238546285778e-05
, O 0 6.470105784472935e-09
three O 0 6.9359971099913764e-09
recombinants O 0 1.6702106222510338e-05
were O 0 2.9159268333245336e-09
found O 0 3.92863119813569e-09
, O 0 2.488805550537876e-10
giving O 0 6.307204203359618e-10
a O 0 2.2361665852344004e-09
recombinant O 0 5.6561418659839546e-08
fraction O 0 3.551546967628383e-08
of O 0 7.550236880149441e-09
0 O 0 9.640135658628424e-07
. O 0 3.419244762881135e-07

042 O 0 0.03893649950623512
. O 0 0.00019628032168839127

A O 0 4.18764602727606e-06
lod O 0 4.53983448096551e-05
score O 0 2.3883147903802637e-08
of O 0 1.9317667465656996e-09
16 O 0 5.854458251519645e-09
between O 0 5.512104550575714e-09
HLA O 0 0.00011579935380723327
- O 0 3.619652261477313e-06
B O 0 4.750356552563062e-08
and O 0 5.93801341430833e-10
Factor O 0 3.853665830888531e-09
B O 0 2.6689406240620883e-08
allotypes O 0 1.439125867364055e-06
was O 0 2.133122123382236e-09
calculated O 0 1.372961411227891e-09
at O 0 2.424299372361105e-10
a O 0 5.559308569047516e-10
maximum O 0 2.318429670467026e-09
likelihood O 0 2.2359702978036466e-09
value O 0 3.576714965869421e-11
of O 0 3.8938706425906133e-11
the O 0 2.397001486187378e-10
recombinant O 0 1.5590552848721018e-08
fraction O 0 1.066676968974889e-08
of O 0 5.110071477076872e-09
0 O 0 4.859651312472124e-07
. O 0 1.736721770839722e-07

04 O 0 0.019008226692676544
. O 0 0.00010471997666172683

A O 0 9.370756970383809e-07
crossover O 0 1.0611553307171562e-06
was O 0 6.931899321216406e-08
shown O 0 5.00339236708669e-09
to O 0 1.3261508557960155e-10
have O 0 1.0718234633166901e-10
occurred O 0 1.3188866665458931e-09
between O 0 1.431962187714575e-10
genes O 0 8.614253199645816e-10
for O 0 1.0368634423274514e-10
Factor O 0 3.1294726809960594e-09
B O 0 1.6227642163357814e-07
and O 0 2.5219232924200696e-08
HLA O 0 0.18425415456295013
- O 0 0.007208958733826876
D O 0 0.0026883382815867662
, O 0 1.100269875209392e-09
in O 0 9.923988297799724e-10
which O 0 8.607393020554355e-09
HLA O 0 0.0070773703046143055
- O 0 0.0014044269919395447
D O 0 0.008558003231883049
segregared O 0 3.0720293580088764e-05
with O 0 8.395794992566152e-08
HLA O 0 0.010506446473300457
- O 0 2.179237526434008e-05
A O 0 1.1414828549050071e-07
and O 0 2.8564711485046246e-08
B O 0 5.102197974338196e-06
. O 0 3.4936329029733315e-07

These O 0 2.1909224301452923e-07
studies O 0 1.4675741510927764e-07
suggest O 0 1.5437098710435748e-08
that O 0 1.1085372203512023e-10
the O 0 1.9529979022880894e-10
genes O 0 1.2142670202663908e-09
for O 0 7.463381024308546e-10
Factor O 0 1.6307305372720293e-07
B O 0 5.994729508529417e-05
and O 0 7.482738146791235e-05
C2 B-Disease 1 0.9999961853027344
deficiency I-Disease 1 0.9999639987945557
are O 0 1.8750916375154247e-09
located O 0 1.0488766299943109e-08
outside O 0 6.146922526539811e-09
those O 0 4.781002260756395e-10
for O 0 1.071460253854184e-09
HLA O 0 3.209874557796866e-05
, O 0 6.739901969865514e-10
that O 0 3.097142681207643e-11
the O 0 4.715557805345938e-11
order O 0 1.2125629667014692e-10
of O 0 2.0641897913176166e-10
genese O 0 8.948285540100187e-06
is O 0 9.31013044436213e-09
HLA O 0 8.189713844330981e-05
- O 0 2.9218017516541295e-06
A O 0 2.952794275756787e-08
, O 0 2.768643314610131e-09
- O 0 1.9288390831206925e-06
B O 0 1.813953218743336e-07
, O 0 5.40637756785145e-09
- O 0 1.552019784867298e-05
D O 0 8.661297033540905e-05
, O 0 8.251287986205114e-10
Factor O 0 1.518925074606159e-08
B O 0 3.469320063231862e-06
allotype O 0 0.031206164509058
, O 0 7.564268162241206e-05
C2 B-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9999523162841797
, O 0 2.035586810222867e-09
that O 0 1.313010117298674e-10
the O 0 8.441228271927059e-10
genes O 0 3.528852232648205e-08
coding O 0 1.488400357629871e-05
for O 0 5.868184416613076e-06
C2 B-Disease 1 0.9999886751174927
deficiency I-Disease 1 0.9998456239700317
and O 0 1.7298823706823896e-08
Factor O 0 4.227625893804543e-08
B O 0 3.500262835132162e-07
allotypes O 0 3.2976840884657577e-06
are O 0 1.3031650758499325e-10
approximately O 0 9.86093096067009e-10
3 O 0 2.1974045694150846e-08
- O 0 2.937968474725494e-06
- O 0 6.328642143671459e-07
5 O 0 6.3131295746643445e-09
centimorgans O 0 1.1482646868898883e-06
from O 0 7.484935449220131e-10
the O 0 1.288349427142066e-09
HLA O 0 3.6032219213666394e-05
- O 0 1.6427557056886144e-06
A O 0 3.4544058280516765e-08
and O 0 8.047309485448295e-09
HLA O 0 0.002532778074964881
- O 0 2.7140875317854807e-05
B O 0 2.2568725910332432e-07
loci O 0 3.90172765207808e-08
, O 0 6.709146016525835e-10
and O 0 2.779154684162677e-10
that O 0 7.508295374325513e-11
the O 0 4.4299938717351495e-10
apparent O 0 1.5361034400029894e-07
lack O 0 1.2126382564758842e-08
of O 0 3.2168367969376277e-10
recombinants O 0 5.453034646052402e-07
between O 0 6.572480892863553e-10
the O 0 7.913632527056791e-10
Factor O 0 1.784965064643984e-08
B O 0 1.2720266795440693e-06
gene O 0 3.0847957077639876e-06
and O 0 1.8300293959327973e-05
C2 B-Disease 1 0.9999949932098389
deficiency I-Disease 1 0.9999909400939941
gene O 0 1.0978095815517008e-05
suggests O 0 9.996339400686338e-08
that O 0 1.266766969099109e-10
these O 0 5.457636773065211e-11
two O 0 2.77620898492259e-10
genes O 0 4.516043095037503e-09
lie O 0 1.917261194250841e-08
in O 0 2.762781392551261e-10
close O 0 1.7723575940209457e-09
proximity O 0 9.855369853539742e-09
to O 0 4.4595810377856537e-10
one O 0 1.76028314147203e-09
another O 0 4.7566665273279796e-08
. O 0 1.2133153859394952e-07

Distribution O 0 1.1054956985390163e-06
of O 0 7.802386647881576e-08
emerin O 0 0.00015480352158192545
and O 0 8.083186742169346e-08
lamins O 0 0.0006684449035674334
in O 0 5.246884526854956e-08
the O 0 7.185194306202902e-08
heart O 0 0.00020180073624942452
and O 0 2.3983943719940726e-08
implications O 0 1.608519596629776e-06
for O 0 1.4195271091921313e-07
Emery B-Disease 0 0.013034523464739323
- I-Disease 1 0.9859097003936768
Dreifuss I-Disease 1 0.9996916055679321
muscular I-Disease 1 0.9998377561569214
dystrophy I-Disease 1 0.9997404217720032
. O 0 1.9221226466470398e-05

Emerin O 0 0.0027321837842464447
is O 0 1.3928304554156057e-07
a O 0 5.247354906146029e-08
nuclear O 0 2.3643569591058622e-07
membrane O 0 2.553311730935093e-07
protein O 0 7.351070507866098e-08
which O 0 9.40455713305255e-10
is O 0 1.450681352821448e-09
missing O 0 2.0244211640374488e-08
or O 0 9.224789820905244e-09
defective O 0 1.255207371286815e-05
in O 0 2.9246240274005686e-07
Emery B-Disease 0 0.014209353365004063
- I-Disease 1 0.9968971014022827
Dreifuss I-Disease 1 0.9999178647994995
muscular I-Disease 1 0.9999712705612183
dystrophy I-Disease 1 0.9999653100967407
( O 0 7.654821092728525e-05
EDMD B-Disease 1 0.9987313151359558
) O 0 7.985569254742586e-07
. O 0 8.291571589325031e-07

It O 0 1.8422518621719064e-07
is O 0 8.933250583709196e-09
one O 0 8.225486958224337e-10
member O 0 5.262112967585608e-10
of O 0 1.820050360423764e-10
a O 0 4.488563298821191e-09
family O 0 2.6925937035571224e-08
of O 0 1.1821144951795759e-08
lamina O 0 0.4658597409725189
- O 0 0.0004240544803906232
associated O 0 1.8325925665862997e-08
proteins O 0 1.0983114417939532e-09
which O 0 2.512663688225558e-10
includes O 0 4.179653956271068e-09
LAP1 O 0 3.689753793878481e-05
, O 0 6.119910800350681e-09
LAP2 O 0 7.329459913307801e-05
and O 0 7.048021188893472e-08
lamin O 0 0.027377193793654442
B O 0 0.0008246093057096004
receptor O 0 0.0011251089163124561
( O 0 2.6179532142123207e-06
LBR O 0 0.4081467390060425
) O 0 4.450205324246781e-07
. O 0 5.712317943107337e-07

A O 0 2.6019438337243628e-06
panel O 0 5.543557790588238e-07
of O 0 8.536793494329231e-09
16 O 0 1.0364911418037082e-07
monoclonal O 0 3.8050502553232946e-06
antibodies O 0 1.8897216023106012e-06
( O 0 5.470753627889735e-09
mAbs O 0 1.5811718867553282e-06
) O 0 1.8269030732653846e-09
has O 0 5.397915447957757e-10
been O 0 1.8634463416766778e-10
mapped O 0 3.6982952256181534e-09
to O 0 2.5144556575762422e-11
six O 0 1.9812687601650225e-10
specific O 0 6.899928545189837e-11
sites O 0 2.7773319755119985e-10
throughout O 0 2.1745086287161541e-10
the O 0 2.7401833579965285e-10
emerin O 0 5.694917035725666e-07
molecule O 0 2.4623663108513938e-08
using O 0 2.690672129546101e-09
phage O 0 7.299249773495831e-07
- O 0 3.003424637881835e-07
displayed O 0 5.199877417538801e-09
peptide O 0 1.3944368326690437e-08
libraries O 0 1.0348170098595233e-09
and O 0 1.9328198763712834e-10
has O 0 2.828935419252332e-10
been O 0 8.125622397159304e-11
used O 0 1.1781516040532125e-10
to O 0 1.3559718625710815e-10
localize O 0 6.252936941564258e-07
emerin O 0 2.78698826150503e-05
in O 0 7.968162130111978e-09
human O 0 5.584831797023071e-08
and O 0 1.625846834940603e-07
rabbit O 0 0.006122944410890341
heart O 0 0.026057034730911255
. O 0 2.2436113340518204e-06

Several O 0 9.694678055893746e-07
mAbs O 0 0.00010149820445803925
against O 0 2.1053786269931152e-07
different O 0 3.017863292598122e-08
emerin O 0 0.001685497583821416
epitopes O 0 0.0020255742128938437
did O 0 4.728868319148205e-08
not O 0 6.417535391989304e-10
recognize O 0 1.0742149392228839e-08
intercalated O 0 2.157252765755402e-06
discs O 0 2.1831012020356866e-07
in O 0 4.955515553461964e-09
the O 0 2.6443446543567006e-08
heart O 0 3.27232301060576e-05
, O 0 2.6484772153168024e-09
though O 0 1.0951172191298042e-09
they O 0 1.4333284559242543e-10
recognized O 0 2.6528303997963576e-09
cardiomyocyte O 0 4.586385784932645e-06
nuclei O 0 4.641018165330024e-07
strongly O 0 1.8623678599283267e-08
, O 0 4.01948585526668e-10
both O 0 2.1573517972051093e-10
at O 0 2.532178910996663e-09
the O 0 6.953876363624545e-10
rim O 0 1.0468124145290858e-07
and O 0 7.425567938312838e-10
in O 0 3.2516178638530846e-09
intranuclear O 0 1.781059108907357e-05
spots O 0 2.0274687528853974e-07
or O 0 1.0731665334162699e-08
channels O 0 3.637053396232659e-07
. O 0 2.4403752263424394e-07

A O 0 1.82568564923713e-05
polyclonal O 0 0.0006447499617934227
rabbit O 0 0.0002793584717437625
antiserum O 0 0.0005324977682903409
against O 0 2.607527903819573e-06
emerin O 0 0.002344409003853798
did O 0 3.7702758248769896e-08
recognize O 0 1.3473572479938412e-08
both O 0 6.674505392822994e-10
nuclear O 0 9.98905917981574e-08
membrane O 0 3.61719045827158e-08
and O 0 8.319399613654355e-10
intercalated O 0 8.500838362124341e-07
discs O 0 8.905814041781923e-08
but O 0 3.9758257797117835e-10
, O 0 1.3686231314924413e-10
after O 0 3.133210080275006e-10
affinity O 0 2.4033890433372562e-09
purification O 0 8.460158795742245e-08
against O 0 2.68586286544803e-09
a O 0 7.84624365479658e-09
pure O 0 5.3379345388293586e-08
- O 0 2.7202654564462136e-06
emerin O 0 3.4327588309679413e-06
band O 0 9.98406424201903e-09
on O 0 2.958101541494784e-10
a O 0 1.7998699197718793e-09
western O 0 9.280893387142441e-09
blot O 0 5.091470939078135e-06
, O 0 1.3131510323560747e-09
it O 0 3.292255079667683e-10
stained O 0 1.4342290342028718e-06
only O 0 4.660284380619828e-10
the O 0 4.543544207535888e-09
nuclear O 0 1.0801546750371926e-06
membrane O 0 3.1947413390298607e-06
. O 0 2.788867732306244e-07

These O 0 6.283909215198946e-07
results O 0 1.1041006473533344e-06
would O 0 5.642217804080474e-09
not O 0 2.9000457590910855e-10
be O 0 1.3401435516868787e-10
expected O 0 6.868615676225431e-10
if O 0 2.4095475614771544e-10
immunostaining O 0 4.841231771024468e-07
at O 0 6.4792442522332294e-09
intercalated O 0 2.8232298063812777e-06
discs O 0 1.1358957152651783e-07
were O 0 2.581529434664276e-10
due O 0 3.392579828176423e-10
to O 0 1.490982164120691e-11
a O 0 3.4921895930573044e-10
product O 0 5.80684611506399e-10
of O 0 8.792011563230062e-11
the O 0 6.486041148612287e-10
emerin O 0 5.663542651745956e-06
gene O 0 4.3539699845496216e-08
and O 0 1.1014730239011783e-09
, O 0 6.383024664380343e-10
therefore O 0 4.14193151998532e-10
, O 0 1.1410458689020686e-10
cast O 0 7.949471081403203e-10
some O 0 7.325977324779132e-11
doubt O 0 7.891626241374183e-10
upon O 0 2.2234318552971644e-10
the O 0 2.9875824036906806e-09
hypothesis O 0 5.67716313071287e-07
that O 0 8.368121484636504e-08
cardiac B-Disease 1 0.97988361120224
defects I-Disease 1 0.9233753085136414
in O 0 3.271064088039566e-06
EDMD B-Disease 1 0.9998657703399658
are O 0 3.213136068325184e-08
caused O 0 6.471749429692863e-07
by O 0 2.4738890935793734e-09
absence O 0 3.733692821583645e-08
of O 0 4.259074870560653e-09
emerin O 0 0.0002995477698277682
from O 0 7.619856745577636e-08
intercalated O 0 0.0002584675676189363
discs O 0 2.324686101928819e-05
. O 0 7.093659633028437e-07

Although O 0 1.023772597363859e-06
emerin O 0 0.00018952232494484633
was O 0 5.581467021897879e-08
abundant O 0 1.0039634013025989e-08
in O 0 6.148326292532147e-10
the O 0 3.841020279615748e-10
membranes O 0 5.1406921386387694e-08
of O 0 1.5453883728255846e-09
cardiomyocyte O 0 9.164496441371739e-05
nuclei O 0 2.2137830910651246e-06
, O 0 2.955711675411976e-09
it O 0 1.7417997599800117e-10
was O 0 8.271804352588674e-10
absent O 0 3.0731022171437417e-09
from O 0 1.7343738945019282e-10
many O 0 1.570005514484052e-10
non O 0 3.3292245404936693e-08
- O 0 0.00020427966956049204
myocyte O 0 0.045078177005052567
cells O 0 2.98785721497552e-06
in O 0 1.9418083141431453e-08
the O 0 7.668290891160723e-08
heart O 0 0.0001590346946613863
. O 0 2.2701179602790944e-07

This O 0 4.057007529922885e-08
distribution O 0 3.91212289230225e-08
of O 0 6.353645609635805e-09
emerin O 0 4.4533204345498234e-05
was O 0 1.670760241267999e-08
similar O 0 1.7773440497137472e-09
to O 0 5.85887657833517e-11
that O 0 4.8576143107936787e-11
of O 0 1.9761738079271396e-10
lamin O 0 1.2379307008814067e-05
A O 0 1.89018720675449e-07
, O 0 1.8280951197269246e-09
a O 0 1.6725392626426583e-08
candidate O 0 4.623175797746626e-08
gene O 0 2.0750276163994386e-08
for O 0 6.612819736240283e-10
an O 0 1.3939288834308172e-08
autosomal O 0 0.00027739020879380405
form O 0 1.7916201500156603e-07
of O 0 3.145062805742782e-07
EDMD B-Disease 1 0.9988723397254944
. O 0 3.095124384344672e-06

In O 0 1.3340976465769927e-06
contrast O 0 3.7253598748065997e-06
, O 0 2.8097201720811427e-07
lamin O 0 0.035830866545438766
B1 O 1 0.5746528506278992
was O 0 1.9280211915884138e-07
absent O 0 7.547533442675558e-08
from O 0 2.1722670329182847e-09
cardiomyocyte O 0 4.283560883777682e-06
nuclei O 0 1.029023110277194e-06
, O 0 4.4000594279225425e-09
showing O 0 1.9386486371786305e-07
that O 0 6.4083409689885684e-09
lamin O 0 0.005242254585027695
B1 O 0 0.06795546412467957
is O 0 3.3301630342208455e-09
not O 0 6.606361291350282e-11
essential O 0 1.3333639747870052e-10
for O 0 5.782373538321117e-11
localization O 0 9.179173865447865e-09
of O 0 1.2194566467726986e-09
emerin O 0 8.991990398499183e-06
to O 0 1.1444684089312318e-09
the O 0 2.6937751584910075e-08
nuclear O 0 4.6372577344300225e-05
lamina O 0 0.028388258069753647
. O 0 5.985378948025755e-07

Lamin O 1 0.987046480178833
B1 O 1 0.9774836301803589
is O 0 4.656166652239335e-07
also O 0 1.8618493413669057e-08
almost O 0 1.4981111462475383e-08
completely O 0 1.197820864717869e-07
absent O 0 8.166027782863239e-07
from O 0 7.553985881258996e-08
skeletal O 0 0.020852744579315186
muscle O 0 0.021508818492293358
nuclei O 0 0.0002864146663341671
. O 0 1.8702260149439098e-06

In O 0 5.3816397667105775e-06
EDMD B-Disease 1 0.6353734135627747
, O 0 1.4937569403628004e-08
the O 0 2.0095474173587036e-09
additional O 0 4.166869960187114e-09
absence O 0 4.459985447624604e-08
of O 0 8.987101729474034e-09
lamin O 0 0.31130796670913696
B1 O 1 0.945910632610321
from O 0 6.502162364085962e-07
heart O 0 0.001192293013446033
and O 0 8.584950705881056e-08
skeletal O 0 0.06672876328229904
muscle O 0 0.0035674446262419224
nuclei O 0 1.5096387869562022e-05
which O 0 2.8226644133155787e-08
already O 0 7.887525299565823e-08
lack O 0 1.2720869335680618e-07
emerin O 0 0.0006829974008724093
may O 0 2.0400575451162695e-08
offer O 0 1.162158702605609e-09
an O 0 2.480417815586833e-10
alternative O 0 8.64617533125056e-09
explanation O 0 6.749167891229035e-09
of O 0 7.168324267503579e-10
why O 0 2.6327280355786797e-09
these O 0 1.616472372623079e-10
tissues O 0 1.2740756005769072e-07
are O 0 9.015374002885324e-10
particularly O 0 1.5458725854955446e-08
affected O 0 5.0808299789650846e-08
. O 0 9.657342481261821e-09
. O 0 1.5313015921947226e-07

Genetic O 0 0.00012824803707189858
mapping O 0 8.332623110618442e-06
of O 0 4.180580503998499e-08
the O 0 2.391018369962694e-07
copper B-Disease 0 0.00024366135767195374
toxicosis I-Disease 0 0.06659366935491562
locus O 0 2.251746627734974e-05
in O 0 1.2658860271130834e-07
Bedlington O 0 0.00023767493257764727
terriers O 0 4.6528675738954917e-05
to O 0 5.605896191696047e-09
dog O 0 4.675264790421352e-06
chromosome O 0 2.108236685671727e-06
10 O 0 5.424122484498639e-09
, O 0 1.0184841858773552e-09
in O 0 1.4440474371824052e-09
a O 0 2.839967017109757e-08
region O 0 1.1142707734279611e-07
syntenic O 0 9.742774636833929e-06
to O 0 1.4317116381334927e-09
human O 0 3.96916206568676e-08
chromosome O 0 6.146893611003179e-06
region O 0 7.74422233007499e-07
2p13 O 0 0.0004478651680983603
- O 0 0.0019637630321085453
p16 O 0 0.0001325111952610314
. O 0 3.69815296608067e-07

Abnormal O 1 0.996292233467102
hepatic B-Disease 1 0.9995344877243042
copper I-Disease 1 0.8141834139823914
accumulation I-Disease 0 0.0024606019724160433
is O 0 9.191143135467428e-08
recognized O 0 4.2652068543702626e-08
as O 0 2.045223901347981e-08
an O 0 1.4129362853054772e-06
inherited B-Disease 1 0.9999828338623047
disorder I-Disease 1 0.9999854564666748
in O 0 3.886030299327103e-06
man O 0 1.1972939319093712e-05
, O 0 4.364379790899875e-08
mouse O 0 7.597124749736395e-06
, O 0 3.6160180627575755e-08
rat O 0 0.00010892339196288958
and O 0 5.950082382355504e-08
dog O 0 4.632925265468657e-05
. O 0 7.19185777597886e-07

The O 0 1.920388740472845e-06
major O 0 5.1191350394219626e-06
cause O 0 9.348993444291409e-06
of O 0 2.1221950419203495e-07
hepatic B-Disease 1 0.9943525791168213
copper I-Disease 0 0.022365719079971313
accumulation I-Disease 0 0.00012560264440253377
in O 0 8.429539377630135e-08
man O 0 8.375831725970784e-07
is O 0 6.0860019246433694e-09
a O 0 8.053547162489849e-08
dysfunctional O 0 0.0006123468047007918
ATP7B O 0 0.10131330043077469
gene O 0 3.74832161469385e-05
, O 0 1.1254132914473303e-06
causing O 0 0.014053660444915295
Wilson B-Disease 0 0.2437630295753479
disease I-Disease 1 0.9649742245674133
( O 0 7.81861581344856e-06
WD B-Disease 1 0.999270498752594
) O 0 6.144662734186568e-07
. O 0 5.345494855646393e-07

Mutations O 0 0.0022490527480840683
in O 0 3.578184077923652e-07
the O 0 3.7057674262541695e-08
ATP7B O 0 0.00011458057997515425
genes O 0 3.7317209944376373e-07
have O 0 1.888659229010159e-09
also O 0 8.960499564558688e-10
been O 0 1.0566871821993118e-09
demonstrated O 0 3.2607491817771006e-08
in O 0 1.2015044070778913e-08
mouse O 0 2.4241505798272556e-06
and O 0 8.91701432692571e-08
rat O 0 0.0009204206289723516
. O 0 7.509938768635038e-07

The O 0 1.9846554550895235e-06
ATP7B O 0 0.004319882020354271
gene O 0 1.7540089174872264e-05
has O 0 5.093064814332138e-08
been O 0 2.960462319734347e-09
excluded O 0 6.5305725271969095e-09
in O 0 5.872819452967803e-10
the O 0 8.652159544375593e-10
much O 0 3.803811043923133e-09
rarer O 0 3.58814281753439e-06
human O 0 8.800795967545127e-07
copper B-Disease 0 0.0062023913487792015
overload I-Disease 1 0.6175039410591125
disease O 0 0.031669411808252335
non B-Disease 0 1.2065655710102874e-06
- I-Disease 0 0.0002444103010930121
Indian I-Disease 0 1.4845877558400389e-06
childhood I-Disease 0 0.011771073564887047
cirrhosis I-Disease 1 0.994358241558075
, O 0 1.747937545815148e-07
indicating O 0 9.036710252985358e-06
genetic O 0 0.00012223076191730797
heterogeneity O 0 0.001910661463625729
. O 0 2.9413101856334833e-06

By O 0 1.2461217693271465e-06
investigating O 0 2.3314174541155808e-05
the O 0 5.992632736706582e-07
common O 0 9.800197585718706e-05
autosomal O 1 0.999347984790802
recessive O 1 0.9997738003730774
copper B-Disease 1 0.9969366788864136
toxicosis I-Disease 1 0.999703586101532
( O 0 8.650911240692949e-07
CT B-Disease 0 0.012933067046105862
) O 0 6.04643135559968e-09
in O 0 1.2021553530416895e-08
Bedlington O 0 0.00019049522234126925
terriers O 0 0.00014181280857883394
, O 0 3.3984235425776887e-09
we O 0 3.7864583690705444e-10
have O 0 2.679036159580761e-10
identified O 0 1.7863298618081558e-09
a O 0 1.0428655716765434e-09
new O 0 2.4060218262178523e-09
locus O 0 2.1113876300660195e-06
involved O 0 3.9414231878254213e-07
in O 0 2.5122164515778422e-05
progressive O 1 0.9997034668922424
liver B-Disease 1 0.9999970197677612
disease I-Disease 1 0.9999523162841797
. O 0 2.445324935251847e-05

We O 0 1.3574244803749025e-06
examined O 0 4.78463834951981e-06
whether O 0 4.632718031416516e-08
the O 0 5.7281003051912194e-08
WD B-Disease 1 0.6723201870918274
gene O 0 7.5511566137720365e-06
ATP7B O 0 0.0021263204980641603
was O 0 4.442657086656254e-08
also O 0 2.2007211608610078e-09
causative O 0 5.285767770146776e-07
for O 0 4.407291420704951e-09
CT B-Disease 0 0.0018504381878301501
by O 0 4.7567731975561856e-09
investigating O 0 1.7265836049773498e-07
the O 0 1.0767668534583663e-08
chromosomal O 0 0.0007823861669749022
co O 0 1.3584367479779758e-05
- O 0 1.7993924075199175e-06
localization O 0 5.558879578870801e-08
of O 0 1.4709174989135931e-09
ATP7B O 0 1.8036593246506527e-05
and O 0 1.3476854077154599e-09
C04107 O 0 2.1580829923095735e-07
, O 0 2.463514670036915e-10
using O 0 5.150285198318727e-10
fluorescence O 0 9.727187233465884e-08
in O 0 5.258633528626433e-09
situ O 0 3.4938268527184846e-06
hybridization O 0 4.80465644159267e-07
( O 0 2.1383700143928763e-08
FISH O 0 3.888228761184109e-08
) O 0 4.385407947893327e-08
. O 0 1.8930627732061112e-07

C04107 O 0 0.0008617155835963786
is O 0 1.6907486610762135e-07
an O 0 1.1996723614515759e-08
anonymous O 0 1.795725523834335e-07
microsatellite O 0 0.0001291233056690544
marker O 0 7.89999194239499e-06
closely O 0 5.782183052360779e-07
linked O 0 8.337734470842406e-06
to O 0 8.807347740003024e-08
CT B-Disease 0 0.27703094482421875
. O 0 2.8074107376596658e-06

However O 0 3.8024022614990827e-06
, O 0 2.638098521856591e-07
BAC O 0 7.926409307401627e-05
clones O 0 2.548383690736955e-06
containing O 0 5.9324722911924255e-08
ATP7B O 0 0.00017716307775117457
and O 0 1.7651322181677642e-08
C04107 O 0 1.1486422408779617e-05
mapped O 0 3.8909891486582637e-07
to O 0 2.9877916807308225e-10
the O 0 2.4740494097841292e-09
canine O 0 7.185430877143517e-05
chromosome O 0 7.4003605732286815e-06
regions O 0 8.550095031978344e-08
CFA22q11 O 0 1.4937141713744495e-05
and O 0 6.483311665306246e-09
CFA10q26 O 0 1.7427209968445823e-05
, O 0 5.172023254118585e-09
respectively O 0 1.4653792845820135e-08
, O 0 1.2201267773903623e-09
demonstrating O 0 1.325682177366616e-07
that O 0 1.3268782517172895e-08
WD B-Disease 1 0.8306660056114197
cannot O 0 1.4998322583892332e-08
be O 0 8.567668241532544e-10
homologous O 0 2.0754201557338092e-07
to O 0 3.1805516442773296e-08
CT B-Disease 0 0.027629828080534935
. O 0 6.154433549454552e-07

The O 0 6.881648459966527e-07
copper O 0 1.030284784064861e-05
transport O 0 6.96711765613145e-07
genes O 0 3.60806808430425e-07
CTR1 O 0 0.00010811778338393196
and O 0 1.1243685094086686e-08
CTR2 O 0 4.8414109187433496e-05
were O 0 2.7267543778464187e-09
also O 0 6.026647514367767e-10
excluded O 0 3.79108522352567e-09
as O 0 4.006397158473618e-10
candidate O 0 1.2680567706979673e-08
genes O 0 7.284323810807791e-09
for O 0 2.3969617402030963e-09
CT B-Disease 0 0.0028659566305577755
since O 0 2.1889714929557158e-08
they O 0 1.5575349343599498e-10
both O 0 3.273158410976862e-10
mapped O 0 1.511077414306783e-07
to O 0 6.426309262508312e-09
canine O 0 0.0022399346344172955
chromosome O 0 0.0008664547349326313
region O 0 1.0377397302363534e-05
CFA11q22 O 0 0.0014625813346356153
. O 0 3.3920966870937264e-06

2 O 0 6.576353189302608e-05
- O 0 0.0003567406383808702
22 O 0 6.046588168828748e-06
. O 0 2.699783408388612e-06

5 O 0 0.00020840145589318126
. O 0 3.0362401957972907e-05

A O 0 2.7093628887087107e-06
transcribed O 0 1.2805578535335371e-06
sequence O 0 5.599454198090825e-07
identified O 0 9.557696500905877e-08
from O 0 1.5423377019985196e-09
the O 0 1.8808945512205355e-09
C04107 O 0 3.3915339372470044e-06
- O 0 3.0585483727918472e-06
containing O 0 6.660699369831491e-08
BAC O 0 5.720433546230197e-05
was O 0 6.786292860994081e-09
found O 0 4.88785012464632e-10
to O 0 4.168312570107524e-11
be O 0 3.400942374942595e-11
homologous O 0 2.0934762812174768e-09
to O 0 9.545604584548784e-11
a O 0 4.036605272261795e-09
gene O 0 2.6135072772603962e-08
expressed O 0 1.4598826592049363e-09
from O 0 7.921274747246798e-10
human O 0 8.26486967753226e-09
chromosome O 0 4.249990979587892e-06
2p13 O 0 2.026210495387204e-05
- O 0 2.1274940081639215e-05
p16 O 0 1.1561916153368657e-06
, O 0 1.0152665375073866e-09
a O 0 2.8918500927233026e-09
region O 0 8.317498689791591e-09
devoid O 0 6.740805691407559e-09
of O 0 4.174393331002335e-10
any O 0 9.104575426910344e-10
positional O 0 5.496768267221341e-07
candidate O 0 2.9583216019091196e-06
genes O 0 1.8044135003947304e-06
. O 0 3.470728984211746e-07

Molecular O 0 4.2563846363918856e-05
analysis O 0 1.7389574225035176e-07
of O 0 5.268462555108044e-09
the O 0 1.2331166310275421e-08
APC B-Disease 0 6.58207909509656e-06
gene O 0 1.428581413165375e-07
in O 0 2.950670374701758e-09
205 O 0 3.1670520428406235e-08
families O 0 5.008978565257394e-09
: O 0 2.1046662190826737e-09
extended O 0 7.925785183715561e-08
genotype O 0 3.212765295756981e-05
- O 0 0.00011455042840680107
phenotype O 0 1.3279438462632243e-05
correlations O 0 7.113549145287834e-07
in O 0 1.462762710957577e-08
FAP B-Disease 0 3.104614370386116e-05
and O 0 1.9518331395573796e-09
evidence O 0 1.436514907027231e-09
for O 0 1.0454401927484369e-10
the O 0 2.8134272689328554e-10
role O 0 1.559750550939043e-09
of O 0 1.5975980538485146e-09
APC B-Disease 0 3.832411493931431e-06
amino O 0 2.647014696322003e-07
acid O 0 2.5704466679599136e-05
changes O 0 8.076472113316413e-06
in O 0 0.007855160161852837
colorectal B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.999994158744812
predisposition O 1 0.9964168071746826
. O 0 1.0310534889867995e-05

BACKGROUND O 0 0.0001763700565788895
/ O 0 2.0375247913761996e-05
AIMS O 0 1.486520204707631e-06
The O 0 3.0856256216793554e-08
development O 0 1.0241669770039152e-06
of O 0 0.0013295377139002085
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999954700469971
and O 0 1.0351654822216005e-07
a O 0 7.966053772179293e-08
variable O 0 2.483161551936064e-07
range O 0 2.1175244668825144e-08
of O 0 1.1738909400094144e-08
extracolonic O 0 0.007387923542410135
manifestations O 0 0.0032139932736754417
in O 0 0.0015203992370516062
familial B-Disease 1 0.999995231628418
adenomatous I-Disease 1 0.9999978542327881
polyposis I-Disease 1 0.9999983310699463
( O 0 6.768486491637304e-05
FAP B-Disease 0 0.16341198980808258
) O 0 1.220881618024805e-08
is O 0 1.1813835465446232e-09
the O 0 3.963219474822921e-10
result O 0 1.498064561289425e-09
of O 0 2.6752880466496265e-10
the O 0 4.102488126989101e-09
dominant O 0 3.690578296300373e-06
inheritance O 0 0.00038926248089410365
of O 0 0.000276982958894223
adenomatous B-Disease 1 0.999995231628418
polyposis I-Disease 1 0.999994158744812
coli I-Disease 1 0.9999086856842041
( O 0 4.283520411263453e-06
APC B-Disease 0 0.0005207068752497435
) O 0 6.923838782313396e-07
gene O 0 5.112242797622457e-05
mutations O 0 0.00022695203369949013
. O 0 1.307120214733004e-06

In O 0 6.39225959275791e-07
this O 0 1.3872265114400761e-08
study O 0 6.718599454558216e-09
, O 0 3.5828412459082415e-10
direct O 0 9.982841220335104e-10
mutation O 0 7.923411970978123e-08
analysis O 0 6.483827363901185e-10
of O 0 1.0486295165534898e-10
the O 0 9.525474853333549e-10
APC B-Disease 0 9.831113629843458e-07
gene O 0 2.5236651879367855e-08
was O 0 1.949853611904473e-09
performed O 0 1.4546461812869893e-09
to O 0 1.1184639325811929e-10
determine O 0 1.099961988160203e-08
genotype O 0 1.8976101046064286e-06
- O 0 1.0824050150404219e-05
phenotype O 0 1.301977135881316e-06
correlations O 0 4.935727915267307e-08
for O 0 1.0120647653266701e-09
nine O 0 2.055661951771981e-08
extracolonic O 0 2.395894262008369e-05
manifestations O 0 6.543129984493135e-07
and O 0 2.109457053478536e-09
to O 0 4.947731113702503e-10
investigate O 0 5.603985542279588e-08
the O 0 1.0024747254533395e-08
incidence O 0 1.60655181389302e-05
of O 0 1.1491412266195766e-08
APC B-Disease 0 9.97688330244273e-05
mutations O 0 2.12449740502052e-05
in O 0 2.9896506248405785e-07
non O 0 0.0006447391933761537
- O 1 0.9998972415924072
FAP O 1 0.9999755620956421
colorectal B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.999988317489624
. O 0 4.130489469389431e-05

METHODS O 0 4.138803433306748e-06
The O 0 1.0214422019316771e-07
APC B-Disease 0 1.583943776495289e-05
gene O 0 7.715456717960478e-07
was O 0 2.1347471346189195e-08
analysed O 0 2.8950083219569933e-08
in O 0 3.191281239267596e-09
190 O 0 4.4386251119021836e-08
unrelated O 0 1.4127475651548593e-06
FAP B-Disease 0 0.0001553304900880903
and O 0 1.8179429517317658e-08
15 O 0 1.0341723282181192e-06
non O 0 0.0005263671046122909
- O 1 0.999955415725708
FAP O 1 0.9999924898147583
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
patients O 0 0.0035707789938896894
using O 0 9.925398103405314e-08
denaturing O 0 0.00065921142231673
gradient O 0 0.00010292255319654942
gel O 0 0.00012102943583158776
electrophoresis O 0 8.189727850549389e-06
, O 0 6.083015757774035e-10
the O 0 2.1057937338309074e-10
protein O 0 5.071232767051015e-09
truncation O 0 1.0833697672296694e-07
test O 0 5.73345326770891e-09
, O 0 2.4306423540565447e-10
and O 0 1.7391439677272302e-10
direct O 0 4.959420429884176e-09
sequencing O 0 7.075950065882353e-07
. O 0 2.0356505103791278e-07

RESULTS O 0 0.00017056349315680563
Chain O 0 2.384174513281323e-05
terminating O 0 3.1002321065898286e-06
signals O 0 2.150231068753783e-07
were O 0 4.632989103470209e-09
only O 0 1.0965595098610947e-09
identified O 0 4.931587227474665e-08
in O 0 1.3091953299237957e-08
patients O 0 1.5286984762497013e-06
belonging O 0 1.800509430438524e-08
to O 0 6.046693146188886e-10
the O 0 2.0563954095109693e-08
FAP B-Disease 0 0.06844041496515274
group O 0 1.0852461400645552e-06
( O 0 7.544381475099726e-08
105 O 0 2.0179927560093347e-06
patients O 0 3.960239337175153e-05
) O 0 7.092956622045676e-08
. O 0 2.386512392149598e-07

Amino O 0 1.664737101236824e-05
acid O 0 4.6345958253368735e-05
changes O 0 1.0456271581915644e-07
were O 0 3.648862989535928e-09
identified O 0 1.537773641757667e-08
in O 0 2.310166280494741e-09
four O 0 3.122974945313217e-08
patients O 0 8.458382581011392e-07
, O 0 4.674340914334607e-10
three O 0 3.9668873741405264e-10
of O 0 3.047127272726158e-10
whom O 0 5.965442806399324e-09
belonged O 0 1.2568238894061778e-08
to O 0 1.5458061219941754e-10
the O 0 2.4360367056885934e-09
non O 0 2.71724530875872e-07
- O 0 0.0005134993116371334
FAP O 0 0.04723576083779335
group O 0 3.6704728699987754e-05
of O 0 0.0035895530600100756
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
patients O 1 0.9650218486785889
. O 0 9.256689736503176e-06

Genotype O 1 0.5908411145210266
- O 0 0.16372022032737732
phenotype O 0 0.0077364640310406685
correlations O 0 0.00010246191231999546
identified O 0 1.2798826674043084e-06
significant O 0 2.4416666022375466e-08
differences O 0 3.870692211194182e-08
in O 0 2.5219895061212583e-09
the O 0 1.3320429204100037e-09
nature O 0 3.3835476642707363e-09
of O 0 6.253933482192053e-10
certain O 0 4.41520064953238e-09
extracolonic O 0 0.00013882556231692433
manifestations O 0 7.903435289335903e-06
in O 0 7.469937486348499e-07
FAP B-Disease 1 0.824783205986023
patients O 0 6.47057022433728e-05
belonging O 0 1.0974539321750854e-07
to O 0 1.6509668077091533e-09
three O 0 1.82728427944312e-07
mutation O 0 8.736851305002347e-05
subgroups O 0 3.489403388812207e-05
. O 0 8.323373208440898e-07

CONCLUSIONS O 0 1.0942327207885683e-05
Extended O 0 3.003828169312328e-06
genotype O 0 0.0007237537647597492
- O 0 0.0006323281559161842
phenotype O 0 7.483466470148414e-05
correlations O 0 8.066151053753856e-07
made O 0 4.8804742469599205e-09
in O 0 5.375458744794059e-09
this O 0 9.833995839869658e-10
study O 0 7.5709740698926e-09
may O 0 2.9480209384757927e-09
have O 0 1.422711393139764e-10
the O 0 1.455894432789151e-10
potential O 0 1.3747118998708174e-09
to O 0 5.255369750489791e-11
determine O 0 8.559647990402652e-10
the O 0 1.8471435492273258e-10
most O 0 7.808553803556606e-11
appropriate O 0 1.1098240104701063e-09
surveillance O 0 3.546910534169001e-07
and O 0 1.0885621293255099e-08
prophylactic O 0 0.0008290222031064332
treatment O 0 0.0003704930713865906
regimens O 0 0.0006335717625916004
for O 0 5.7684665932811185e-09
those O 0 1.6124308999110326e-08
patients O 0 8.392419658775907e-06
with O 0 1.6159243898528075e-07
mutations O 0 0.00011143610026920214
associated O 0 4.546207605926611e-07
with O 0 1.363338810733694e-07
life O 0 1.3878048775950447e-05
threatening O 0 0.00192369450815022
conditions O 0 5.1717914175242186e-05
. O 0 9.249138770428544e-07

This O 0 1.5790396901138593e-07
study O 0 1.1606865513158482e-07
also O 0 2.670721421793587e-09
provided O 0 2.108258234656546e-09
evidence O 0 1.0235260416990855e-09
for O 0 4.291077493334683e-10
the O 0 1.5137645581475567e-09
pathological O 0 1.2046340316373971e-06
nature O 0 5.447304829431232e-09
of O 0 7.872773544193024e-10
amino O 0 3.5478638693575704e-08
acid O 0 4.365271024653339e-07
changes O 0 1.0967358576863262e-08
in O 0 3.73919295526548e-09
APC O 0 1.2408148677423014e-06
associated O 0 3.961188710377428e-09
with O 0 7.776498334166604e-10
both O 0 3.4310665419923225e-09
FAP B-Disease 0 0.0002703796199057251
and O 0 1.867668686372781e-07
non O 0 0.0009891522349789739
- O 1 0.9999370574951172
FAP O 1 0.9999892711639404
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
patients O 1 0.9653945565223694
. O 0 7.102419203874888e-07
. O 0 9.312208817391365e-07

Inherited B-Disease 1 0.999734103679657
colorectal I-Disease 1 0.9999957084655762
polyposis I-Disease 1 0.9999786615371704
and O 1 0.601498007774353
cancer B-Disease 1 0.999889612197876
risk O 0 8.048197923926637e-05
of O 0 8.417244679037594e-09
the O 0 7.104993215989452e-08
APC O 0 0.0004614039498846978
I1307K O 0 0.0006289092707447708
polymorphism O 0 0.00018625397933647037
. O 0 1.4504877299259533e-06

Germ O 0 0.04203725606203079
- O 0 0.00011543983418960124
line O 0 4.4929814180250105e-07
and O 0 4.90876184144895e-09
somatic O 0 5.589221814261691e-07
truncating O 0 4.172219996689819e-05
mutations O 0 1.42251008128369e-06
of O 0 1.0765404123702638e-09
the O 0 4.167124423304358e-09
APC B-Disease 0 2.123990043401136e-06
gene O 0 5.199394337296326e-08
are O 0 3.628962408352976e-10
thought O 0 1.7046059008762882e-09
to O 0 2.0875032813449934e-09
initiate O 0 0.00016508526459801942
colorectal B-Disease 1 0.9999957084655762
tumor I-Disease 1 0.9996335506439209
formation O 0 0.05321364477276802
in O 0 0.0013587368885055184
familial B-Disease 1 0.9999954700469971
adenomatous I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999949932098389
and O 0 0.000304020824842155
sporadic O 1 0.9830179214477539
colorectal O 1 0.9999979734420776
carcinogenesis O 1 0.999494194984436
, O 0 4.341682597441832e-06
respectively O 0 4.865726168645779e-06
. O 0 9.763896287040552e-07

Recently O 0 1.3432573723548558e-05
, O 0 8.680829921559052e-08
an O 0 2.362170015146603e-08
isoleucine O 0 0.00014091374760027975
- O 0 0.0001301610900554806
- O 0 1.4179918252921198e-05
> O 0 4.710980192612624e-07
lysine O 0 1.4113737734078313e-07
polymorphism O 0 2.8542717700474896e-07
at O 0 6.082473635871111e-09
codon O 0 7.646164590369153e-08
1307 O 0 9.132356240115769e-07
( O 0 1.3422546407682034e-09
I1307K O 0 9.665656364177266e-08
) O 0 1.2579451369454375e-10
of O 0 3.717982172135592e-11
the O 0 3.063935216651714e-10
APC B-Disease 0 3.931377250410151e-07
gene O 0 2.3269322468877363e-08
has O 0 1.0737269962035612e-09
been O 0 2.4488838734626484e-10
identified O 0 9.222744790093884e-10
in O 0 2.4441990098544863e-10
6 O 0 7.070369623107808e-09
% O 0 2.5795423574948018e-09
- O 0 4.475085120247968e-07
7 O 0 9.198803496701657e-09
% O 0 3.886008181908096e-10
of O 0 2.661576792295506e-10
the O 0 3.816856608551689e-09
Ashkenazi O 0 7.0890869210415985e-06
Jewish O 0 4.447345816060988e-07
population O 0 1.8972974658026942e-07
. O 0 3.389466485259618e-07

To O 0 3.493026667911181e-07
assess O 0 3.940347141906386e-06
the O 0 6.94696282721452e-08
risk O 0 1.688610154815251e-06
of O 0 1.4659684577367216e-09
this O 0 8.681865226733976e-10
common O 0 1.7479917957530233e-08
APC B-Disease 0 1.2119721759518143e-05
allelic O 0 0.0003918773727491498
variant O 0 0.0026662545278668404
in O 0 3.648988058557734e-05
colorectal O 1 0.9999970197677612
carcinogenesis O 1 0.9830812811851501
, O 0 1.4485203791991808e-07
we O 0 1.5277802356550296e-09
have O 0 2.572058677152711e-10
analyzed O 0 4.466018665993943e-09
a O 0 2.237779295199971e-09
large O 0 5.830266047723853e-09
cohort O 0 5.423664219961211e-07
of O 0 9.079793583666174e-10
unselected O 0 1.280300784856081e-05
Ashkenazi O 0 1.0554173059063032e-05
Jewish O 0 9.61151584988329e-08
subjects O 0 1.3661083642091398e-07
with O 0 1.1662782526400406e-06
adenomatous B-Disease 1 0.9998276233673096
polyps I-Disease 1 0.9136502742767334
and O 0 5.499421149579575e-07
. O 0 3.0352853173098993e-06
or O 0 0.18764850497245789
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999958276748657
, I-Disease 0 5.895192600746668e-08
for O 0 4.550855692286859e-09
the O 0 3.8595455720269456e-08
APC O 0 0.00011966725287493318
I1307K O 0 0.00031074348953552544
polymorphism O 0 9.516358841210604e-05
. O 0 4.662965409352182e-07

The O 0 2.369113190070493e-06
APC O 0 0.00012092859105905518
I1307K O 0 3.787450987147167e-05
allele O 0 2.4185947040678e-06
was O 0 4.499468886365321e-08
identified O 0 2.8635627202788783e-08
in O 0 2.804984466919791e-09
48 O 0 2.2361078322319372e-08
( O 0 1.021388640332077e-09
10 O 0 1.0174338038737574e-09
. O 0 1.4624125521667253e-10
1 O 0 2.58954435672365e-09
% O 0 1.89725968269272e-09
) O 0 1.6982809603049986e-09
of O 0 7.2018213614910565e-09
476 O 0 7.438813190674409e-05
patients O 0 0.0002806339180096984
. O 0 7.158737957979611e-07

Compared O 0 1.751812078509829e-06
with O 0 1.3340852866861042e-08
the O 0 2.3816131289322584e-09
frequency O 0 5.9945963748475606e-09
in O 0 5.353488208292845e-10
two O 0 1.7413015473977111e-10
separate O 0 2.267139143086183e-09
population O 0 1.3346828087179574e-09
control O 0 1.6095516031100487e-08
groups O 0 7.8120881985555e-10
, O 0 3.7020619902961016e-10
the O 0 9.615798157724953e-10
APC O 0 1.0080947276946972e-06
I1307K O 0 5.861528279638151e-06
allele O 0 1.4342329279770638e-07
is O 0 2.0634822739395986e-09
associated O 0 1.8463026663084747e-09
with O 0 3.419266536575094e-10
an O 0 4.977148138074483e-10
estimated O 0 3.6157008054260587e-08
relative O 0 4.039003158595733e-07
risk O 0 1.790426154002489e-06
of O 0 5.738113539877077e-09
1 O 0 4.449220796232112e-07
. O 0 3.817208380496595e-07

5 O 0 6.881797889946029e-05
- O 0 0.00020532439521048218
1 O 0 2.9397481284831883e-06
. O 0 1.8499786165193655e-06

7 O 0 0.00029889936558902264
for O 0 0.00015450947103090584
colorectal B-Disease 1 0.9999908208847046
neoplasia I-Disease 1 0.9995101690292358
( O 0 6.415804136850056e-07
both O 0 3.190781114881247e-07
P O 0 0.16731508076190948
= O 0 3.279420707258396e-05
. O 0 3.1247743947915296e-08
01 O 0 0.0001424834772478789
) O 0 8.942033247194558e-08
. O 0 1.5174025236319721e-07

Furthermore O 0 1.795418211258948e-05
, O 0 1.7569540489148494e-07
compared O 0 2.179884859287995e-07
with O 0 2.9762485809214922e-08
noncarriers O 0 9.6049094281625e-05
, O 0 2.8998382362033226e-08
APC O 0 5.943326868873555e-06
I1307K O 0 7.901091521489434e-06
carriers O 0 3.5975128298559866e-07
had O 0 1.9716868138175414e-09
increased O 0 4.675957399058461e-09
numbers O 0 3.104882129179032e-09
of O 0 1.6294970706098866e-08
adenomas B-Disease 1 0.7586113810539246
and O 0 0.0013248859904706478
colorectal B-Disease 1 0.9999996423721313
cancers I-Disease 1 0.9999587535858154
per O 0 1.3948106243333314e-05
patient O 0 0.001067525357939303
( O 0 3.4056932918247185e-07
P O 0 0.001234730938449502
= O 0 9.800522775549325e-07
. O 0 6.586159395638447e-10
03 O 0 6.143116024759365e-07
) O 0 4.722130464429597e-10
, O 0 1.0050372339920344e-10
as O 0 6.285656717341936e-11
well O 0 1.6335688357571598e-10
as O 0 2.3937257731532213e-10
a O 0 6.8018821686166575e-09
younger O 0 1.9099982750958588e-07
age O 0 6.14640953244816e-07
at O 0 1.1765738463509479e-06
diagnosis O 0 0.02226393111050129
. O 0 1.5828464938749676e-06

We O 0 3.7789371276630845e-07
conclude O 0 5.061939418737893e-07
that O 0 6.175196354263335e-09
the O 0 9.670355183288848e-09
APC O 0 7.255191121657845e-06
I1307K O 0 1.3280299754114822e-05
variant O 0 6.07393667451106e-06
leads O 0 2.1298752983511804e-07
to O 0 5.865769647783736e-09
increased O 0 1.2490005246945657e-05
adenoma B-Disease 1 0.999869704246521
formation O 0 2.182785829063505e-05
and O 0 2.9377824617426995e-09
directly O 0 1.3271813648074726e-09
contributes O 0 5.218616649926844e-09
to O 0 1.1566517188477121e-10
3 O 0 3.966224237927918e-09
% O 0 2.078524241611035e-09
- O 0 2.0717655502267007e-07
4 O 0 4.364977268522807e-09
% O 0 5.412142400906816e-10
of O 0 5.320791029994609e-10
all O 0 1.0293391916604833e-08
Ashkenazi O 0 0.1311216652393341
Jewish O 1 0.9755812883377075
colorectal B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.999988317489624
. O 0 4.620227628038265e-05

The O 0 6.597014703402238e-07
estimated O 0 5.500947963810177e-07
relative O 0 6.849299097666517e-06
risk O 0 2.741762000368908e-05
for O 0 2.111080199540538e-08
carriers O 0 5.2119025895080995e-06
may O 0 6.281386788486998e-08
justify O 0 1.1991627957286255e-07
specific O 0 4.05033295791668e-09
clinical O 0 6.709535682603018e-07
screening O 0 1.0401272021454133e-07
for O 0 1.498292462320805e-10
the O 0 1.3287053401978e-10
360 O 0 2.2422139700495336e-09
, O 0 2.769767193377959e-10
000 O 0 1.98655980554463e-09
Americans O 0 8.364969827923119e-10
expected O 0 9.500181752386538e-10
to O 0 1.3277579036241605e-10
harbor O 0 1.1560898371953954e-07
this O 0 1.3937095921789933e-10
allele O 0 3.4171556695383742e-09
, O 0 3.3595079496073765e-10
and O 0 5.35655242384081e-10
genetic O 0 1.808760430321854e-07
testing O 0 2.6793149032755537e-08
in O 0 2.3083990274841426e-10
the O 0 1.0813842876711277e-10
setting O 0 5.885909537539646e-09
of O 0 8.600036238703979e-10
long O 0 5.838242032041308e-07
- O 0 2.4135295461746864e-05
term O 0 5.842591690452537e-07
- O 0 9.168866199615877e-06
outcome O 0 5.091433052939465e-08
studies O 0 1.81298425161458e-08
may O 0 9.550184643103421e-09
impact O 0 8.508545334962037e-08
significantly O 0 3.318899325677194e-05
on O 0 0.02759188786149025
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
prevention O 1 0.8019139170646667
in O 0 2.3593587172854313e-07
this O 0 1.5831055577564257e-08
population O 0 1.4474488807536545e-07
. O 0 4.238687836277677e-07

Localization O 0 2.2952115614316426e-05
of O 0 2.0672776201990928e-07
human O 0 1.9697124571393942e-06
BRCA1 O 0 0.001996875973418355
and O 0 4.197871561473221e-08
its O 0 8.624093084108608e-08
loss O 0 9.272134775528684e-06
in O 0 1.8814549918033663e-08
high O 0 3.135520273644943e-06
- O 0 9.529061935609207e-05
grade O 0 8.230474122683518e-06
, O 0 6.932111773494398e-08
non B-Disease 0 2.4730596123845316e-05
- I-Disease 1 0.9549531936645508
inherited I-Disease 1 0.9996620416641235
breast I-Disease 1 0.9999557733535767
carcinomas I-Disease 1 0.9999390840530396
. O 0 8.871869795257226e-06

Although O 0 4.066940562097443e-07
the O 0 3.558687211580036e-08
link O 0 2.2727260784449754e-07
between O 0 3.027895445484319e-08
the O 0 3.640572003860143e-07
BRCA1 O 1 0.5363669991493225
tumour B-Disease 1 0.9996669292449951
- O 0 5.016510476707481e-05
suppressor O 0 1.9781062292167917e-05
gene O 0 1.8871139673137804e-06
and O 0 7.983879299899854e-07
hereditary B-Disease 1 0.9998482465744019
breast I-Disease 1 0.9999979734420776
and I-Disease 1 0.9965320825576782
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
is O 0 1.25249655980042e-07
established O 0 2.5043698670401682e-08
, O 0 5.544430470294515e-10
the O 0 3.2951200101827283e-10
role O 0 6.948868147560461e-09
, O 0 1.8313406346948113e-09
if O 0 2.758347994458177e-10
any O 0 9.119204003038561e-11
, O 0 1.419364070720519e-10
of O 0 8.157273745368343e-10
BRCA1 O 0 2.05835749511607e-05
in O 0 6.129457119641302e-08
non B-Disease 0 2.5332938093924895e-05
- I-Disease 1 0.9913173913955688
familial I-Disease 1 0.9998539686203003
cancers I-Disease 1 0.9998834133148193
is O 0 1.1793914609370404e-06
unclear O 0 2.4851092348399106e-06
. O 0 7.724439115008863e-07

BRCA1 O 1 0.9979504942893982
mutations O 0 0.22070647776126862
are O 0 2.586594689546473e-07
rare O 0 2.172903577957186e-06
in O 0 2.0745297035773547e-07
sporadic B-Disease 0 0.0016990603180602193
cancers I-Disease 1 0.9897353649139404
, O 0 6.934531171509661e-08
but O 0 1.8743630647577447e-08
loss O 0 3.0325481930049136e-06
of O 0 1.1509728281566822e-08
BRCA1 O 0 0.0015522778267040849
resulting O 0 4.543347245089535e-07
from O 0 6.6827632316801555e-09
reduced O 0 2.1055352306120767e-07
expression O 0 1.3211356453268763e-08
or O 0 1.9551269492268375e-09
incorrect O 0 1.966872531511399e-08
subcellular O 0 6.023820446898753e-07
localization O 0 8.915379794416367e-07
is O 0 2.850004454657551e-09
postulated O 0 2.1255203819237067e-08
to O 0 8.63556864905135e-11
be O 0 4.8868221969033954e-11
important O 0 1.372039287739213e-10
in O 0 1.7918273531591922e-09
non B-Disease 0 7.085668016770796e-07
- I-Disease 1 0.5102270841598511
familial I-Disease 1 0.9998196959495544
breast I-Disease 1 0.9999866485595703
and I-Disease 1 0.7964910864830017
ovarian I-Disease 1 0.999998927116394
cancers I-Disease 1 0.9999862909317017
. O 0 1.789616362657398e-05

Epigenetic O 0 0.1731197088956833
loss O 0 0.06961813569068909
, O 0 3.110512238890806e-07
however O 0 3.1129957278608344e-08
, O 0 4.882839022002372e-09
has O 0 1.949749695029368e-09
not O 0 1.1137168270947129e-10
received O 0 1.1036223046545501e-09
general O 0 3.0126283689924094e-09
acceptance O 0 1.325243630390105e-07
due O 0 2.7500821175863166e-08
to O 0 1.9517205906982582e-10
controversy O 0 5.8227422883305735e-09
regarding O 0 3.702909368019647e-10
the O 0 2.135013693616017e-10
subcellular O 0 4.121438479387507e-08
localization O 0 6.206726510527005e-08
of O 0 3.5722460545173362e-09
BRCA1 O 0 2.073084942821879e-05
proteins O 0 6.8053207513685265e-09
, O 0 1.1144525302597685e-09
reports O 0 4.718780921564303e-10
of O 0 1.4890731703243176e-10
which O 0 2.556061751146643e-10
have O 0 1.4675875792402593e-10
ranged O 0 9.507437503941674e-09
from O 0 3.544647353415087e-10
exclusively O 0 1.6081516118759964e-09
nuclear O 0 7.36905363396545e-08
, O 0 2.4563126532761714e-10
to O 0 1.8695481274200176e-10
conditionally O 0 8.958598982644617e-07
nuclear O 0 1.9518422789133183e-07
, O 0 3.539742665648049e-10
to O 0 1.1602002691901703e-10
the O 0 3.3506466490251796e-09
ER O 0 0.0002789320715237409
/ O 0 2.6972409159498056e-06
golgi O 0 1.7808009943109937e-05
, O 0 6.330586055369736e-10
to O 0 7.859656675490712e-11
cytoplasmic O 0 3.3911081942505916e-08
invaginations O 0 6.672601671198208e-07
into O 0 1.9084309688111034e-09
the O 0 8.54301607233765e-09
nucleus O 0 1.659832719269616e-06
. O 0 3.32586438389626e-07

In O 0 2.1538350836181053e-07
an O 0 9.84545067694853e-09
attempt O 0 3.974593809630278e-08
to O 0 1.5693892851942337e-09
resolve O 0 9.826973723647825e-08
this O 0 5.826460980351555e-10
issue O 0 2.5609721010511066e-09
, O 0 5.192025698264047e-10
we O 0 1.4154952210354566e-10
have O 0 3.610693688482769e-10
comprehensively O 0 6.82120287365251e-07
characterized O 0 3.5344612570042955e-06
19 O 0 2.168221499232459e-06
anti O 0 0.000510396552272141
- O 0 0.049255531281232834
BRCA1 O 0 0.03619597852230072
antibodies O 0 2.962301005027257e-05
. O 0 5.832615670442465e-07

These O 0 8.946690854827466e-08
reagents O 0 1.3268576140035293e-06
detect O 0 3.3717485621309606e-06
a O 0 2.3696971496178776e-08
220 O 0 4.201804770787021e-08
- O 0 2.564072929089889e-06
kD O 0 4.953362349624513e-06
protein O 0 1.2299784302172156e-08
localized O 0 3.872161258300366e-08
in O 0 4.843526135722698e-10
discrete O 0 1.2489309142438287e-08
nuclear O 0 2.433507688692771e-07
foci O 0 3.427726937843545e-07
in O 0 1.372647218111922e-09
all O 0 3.034628381914928e-10
epithelial O 0 4.817140506929718e-06
cell O 0 1.5314100892283022e-05
lines O 0 9.637608400225872e-07
, O 0 9.181568283445074e-10
including O 0 1.5939334296888319e-09
those O 0 1.8555168512790488e-09
derived O 0 9.553850333077207e-08
from O 0 1.7758119383870508e-06
breast B-Disease 1 0.9966158270835876
malignancies I-Disease 1 0.7161396145820618
. O 0 1.914880385811557e-06

Immunohistochemical O 0 0.0039607444778084755
staining O 0 0.0008359118946827948
of O 0 2.47215325543948e-06
human O 0 9.815835801418871e-05
breast O 1 0.9951139092445374
specimens O 0 2.6482965040486306e-05
also O 0 3.042888181425951e-07
revealed O 0 2.3630462237633765e-05
BRCA1 O 0 0.028566308319568634
nuclear O 0 3.979785833507776e-05
foci O 0 0.0002576875558588654
in O 0 6.42839222564362e-06
benign O 1 0.9785516858100891
breast O 1 0.9997480511665344
, O 0 1.5923584214760922e-05
invasive B-Disease 1 0.9884888529777527
lobular I-Disease 1 0.9999854564666748
cancers I-Disease 1 0.9997542500495911
and O 0 1.8219665207652724e-06
low B-Disease 0 0.03810018673539162
- I-Disease 1 0.9779161810874939
grade I-Disease 1 0.887444019317627
ductal I-Disease 1 0.9999344348907471
carcinomas I-Disease 1 0.9999425411224365
. O 0 1.5222103684209287e-05

Conversely O 0 0.0002232123661087826
, O 0 7.33285162368702e-07
BRCA1 O 0 0.0005000216187909245
expression O 0 8.331186904797505e-07
was O 0 1.9798660844116966e-07
reduced O 0 3.009379838658788e-07
or O 0 8.83294859477246e-09
undetectable O 0 2.041612560788053e-06
in O 0 5.043786499570047e-10
the O 0 3.2921171344568734e-10
majority O 0 1.1572259817071995e-09
of O 0 6.822498677117039e-10
high O 0 1.7879144706967054e-06
- O 0 0.0004684973100665957
grade O 0 0.0001388731034239754
, O 0 2.743570348684443e-06
ductal B-Disease 1 0.9999070167541504
carcinomas I-Disease 1 0.9999769926071167
, O 0 1.21312453416067e-07
suggesting O 0 1.3862550929388817e-07
that O 0 5.725811491608113e-10
absence O 0 2.7965455728917732e-08
of O 0 7.257779710556633e-09
BRCA1 O 0 0.0007445019437000155
may O 0 2.0371725639733995e-08
contribute O 0 1.748380995536536e-09
to O 0 1.0026725977274609e-10
the O 0 8.769573400790875e-10
pathogenesis O 0 7.528058745265298e-07
of O 0 2.1176393971700236e-10
a O 0 1.981572239628804e-09
significant O 0 3.3967708645832317e-09
percentage O 0 2.1406434314030776e-07
of O 0 3.972221662706943e-08
sporadic B-Disease 1 0.5646902322769165
breast I-Disease 1 0.9999830722808838
cancers I-Disease 1 0.9996817111968994
. O 0 3.6483956478150503e-07
. O 0 5.055300675849139e-07

